% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
%
\documentclass[
]{article}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\hypersetup{
  hidelinks,
  pdfcreator={LaTeX via pandoc}}
\urlstyle{same} % disable monospaced font for URLs
\usepackage[margin=1in]{geometry}
\usepackage{longtable,booktabs}
% Correct order of tables after \paragraph or \subparagraph
\usepackage{etoolbox}
\makeatletter
\patchcmd\longtable{\par}{\if@noskipsec\mbox{}\fi\par}{}{}
\makeatother
% Allow footnotes in longtable head/foot
\IfFileExists{footnotehyper.sty}{\usepackage{footnotehyper}}{\usepackage{footnote}}
\makesavenoteenv{longtable}
\usepackage{graphicx,grffile}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{5}
\usepackage[]{natbib}
\bibliographystyle{plainnat}

\author{}
\date{\vspace{-2.5em}}

\begin{document}

{
\setcounter{tocdepth}{2}
\tableofcontents
}
\hypertarget{preface}{%
\section{Preface}\label{preface}}

\hypertarget{rapid-reference}{%
\section{Rapid Reference}\label{rapid-reference}}

\hypertarget{calling-for-help}{%
\subsection{Calling for Help}\label{calling-for-help}}

\hypertarget{bch}{%
\subsubsection{BCH}\label{bch}}

!\href{images/xyz.png}{}

\hypertarget{bmc}{%
\subsubsection{BMC}\label{bmc}}

!\href{images/xyz.png}{}

\hypertarget{pals}{%
\subsection{PALS}\label{pals}}

\hypertarget{pals-quick-references}{%
\subsubsection{PALS Quick References}\label{pals-quick-references}}

\hypertarget{vital-signs-in-children}{%
\paragraph{Vital Signs in Children}\label{vital-signs-in-children}}

\includegraphics{images/rapid-reference_pals-vital-signs.png}

\hypertarget{pediatric-color-coded-length-based-resuscitation-tape}{%
\paragraph{Pediatric Color-Coded Length-Based Resuscitation Tape}\label{pediatric-color-coded-length-based-resuscitation-tape}}

\includegraphics{images/rapid-reference_pals-color-coded-tape.png}

\hypertarget{pals-algorithms}{%
\subsubsection{PALS Algorithms}\label{pals-algorithms}}

\hypertarget{pals-systematic-approach-algorithm}{%
\paragraph{PALS Systematic Approach Algorithm}\label{pals-systematic-approach-algorithm}}

\includegraphics{images/rapid-reference_pals-systematic-approach.png}

\hypertarget{bradycardia-with-a-pulse-and-poor-perfusion-algorithm}{%
\paragraph{Bradycardia with a Pulse and Poor Perfusion Algorithm}\label{bradycardia-with-a-pulse-and-poor-perfusion-algorithm}}

\includegraphics{images/rapid-reference_pals-bradycardia-pulse-poor-perfusion.png}

\hypertarget{tachycardia-with-a-pulse-and-poor-perfusion-algorithm}{%
\paragraph{Tachycardia with a Pulse and Poor Perfusion Algorithm}\label{tachycardia-with-a-pulse-and-poor-perfusion-algorithm}}

\includegraphics{images/rapid-reference_pals-tachycardia-pulse-poor-perfusion.png}

\hypertarget{cardiac-arrest}{%
\paragraph{Cardiac Arrest}\label{cardiac-arrest}}

\includegraphics{images/rapid-reference_pals-cardiac-arrest-algorithm.png}
\includegraphics{images/rapid-reference_pals-cardiac-arrest-doses-details.png}

\hypertarget{management-of-shock-after-rosc-algorithm}{%
\paragraph{Management of Shock After ROSC Algorithm}\label{management-of-shock-after-rosc-algorithm}}

!\href{images/rapid-reference_pals-post-rosc.png}{}

\hypertarget{drugs-used-in-pals}{%
\paragraph{Drugs Used in PALS}\label{drugs-used-in-pals}}

\includegraphics{images/rapid-reference_pals-drugs-1.png}
\includegraphics{images/rapid-reference_pals-drugs-2.png}

\hypertarget{shock}{%
\subsubsection{Shock}\label{shock}}

\hypertarget{recognition-of-shock}{%
\paragraph{Recognition of Shock}\label{recognition-of-shock}}

!\href{images/rapid-reference_shock-recognition.png}{}

\hypertarget{management-of-shock}{%
\paragraph{Management of Shock}\label{management-of-shock}}

\begin{itemize}
\tightlist
\item
  Oxygen
\item
  Pulse oximetry
\item
  ECG monitor
\item
  IV/IO access
\item
  BLS as indicated
\item
  POCT glucose
\end{itemize}

\hypertarget{hypovolemic-shock}{%
\subparagraph{Hypovolemic Shock}\label{hypovolemic-shock}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.53\columnwidth}\raggedright
Non-hemorrhagic\strut
\end{minipage} & \begin{minipage}[b]{0.41\columnwidth}\raggedright
Hemorrhagic\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.53\columnwidth}\raggedright
- 20 mL/kg NS/LR bolus, repeat PRN\textless br- Consider colloid\strut
\end{minipage} & \begin{minipage}[t]{0.41\columnwidth}\raggedright
- Control external bleeding- 20 mL/kg NS/LR bolus, repeat 2 or 3x PRN- Transfuse pRBCs PRN\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{distributive-shock}{%
\subparagraph{Distributive Shock}\label{distributive-shock}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.21\columnwidth}\raggedright
Septic\strut
\end{minipage} & \begin{minipage}[b]{0.38\columnwidth}\raggedright
Anaphylactic\strut
\end{minipage} & \begin{minipage}[b]{0.32\columnwidth}\raggedright
Neurogenic\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.21\columnwidth}\raggedright
Management Algorithm:- Septic Shock\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
- IM epinephrine (or autoinjector)- Fluid boluses (20mL/kg NS/LR)- Albuterol- Antihistamines, corticosteroids- Epinephrine infusion\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
- 20mL/kg NS/LR bolus, repeat PRN- Vasopressor\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{cardiogenic-shock}{%
\subparagraph{Cardiogenic Shock}\label{cardiogenic-shock}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.33\columnwidth}\raggedright
Bradyarrhythmia/Tachyarrhythmia\strut
\end{minipage} & \begin{minipage}[b]{0.61\columnwidth}\raggedright
Other(e.g.~CHD, myocarditis, cardiomyopathy, poisoning)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.33\columnwidth}\raggedright
Management Algorithm:- Bradycardia- Tachycardia w/ poor perfusion\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\raggedright
- 5 to 10 mL/kg NS/LR bolus, repeat PRN- Vasoactive infusion- Consider expert consultation\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{obstructive-shock}{%
\subparagraph{Obstructive Shock}\label{obstructive-shock}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.38\columnwidth}\raggedright
Ductal-Dependent(LV outflow obstruction)\strut
\end{minipage} & \begin{minipage}[b]{0.18\columnwidth}\raggedright
Tension Pneumothorax\strut
\end{minipage} & \begin{minipage}[b]{0.16\columnwidth}\raggedright
Cardiac Tamponade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Pulmonary Embolism\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.38\columnwidth}\raggedright
- Prostaglandin E1- Expert consultation\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
- Needle decompression- Tube thoracostomy\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
- Pericardiocentesis0 20 mL/kg NS/LR bolus\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- 20 mL/kg NS/LR bolus, repeat PRN- Consider thrombolytics, anticoagulants- Expert consultation\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{hemodynamic-parameters-in-shock}{%
\paragraph{Hemodynamic Parameters in Shock}\label{hemodynamic-parameters-in-shock}}

\begin{longtable}[]{@{}lllllll@{}}
\toprule
\begin{minipage}[b]{0.04\columnwidth}\raggedright
Type\strut
\end{minipage} & \begin{minipage}[b]{0.07\columnwidth}\raggedright
Examples\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Preload(CVP, PCWP)\strut
\end{minipage} & \begin{minipage}[b]{0.15\columnwidth}\raggedright
Afterload(SVR)\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
CO(SV*HR)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Mixed Venous O2 (MVO2)\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Distributive}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
- Sepsis- Anaphylaxis- Severe neurologic injury (loss of α-1 activity)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↓\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
↓\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
↑ then ↓\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
- \textbf{Sepsis:} Crystalloid (20 cc/kg NS, repeat PRN) + abx- \textbf{Anaphylaxis:} Epi + crystalloid- \textbf{Neurogenic:} Crystalloid + α-active pressors, (norepi @ 0.05-2 mcg/kg/min)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Hypovolemic}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
- Blood loss- GI or Renal losses- ↓ intake\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↓\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
- \textbf{Crystalloid replacement:} 20 cc/kg, repeat PRN- For blood loss: Consider pRBCs\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Cardiogenic}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
- Myocarditis- MI- Dysrhythmia\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↓\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Targeted at etiology: \textbf{Inotropes,} revascularization, \textbf{anti-arrhythmics,} cardiovert\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Obstructive}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
- Tamponade- PE\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
↓\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Fix obstruction} (pericardiocentesis, thrombectomy/lysis for PE)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{respiratory-emergencies}{%
\subsubsection{Respiratory Emergencies}\label{respiratory-emergencies}}

\hypertarget{medications-to-avoid-in-children-w-neuromuscular-disease}{%
\paragraph{Medications to Avoid in Children w/ Neuromuscular Disease}\label{medications-to-avoid-in-children-w-neuromuscular-disease}}

Recall that the use of succinylcholine for intubation of children w/ neuromuscular diseases may trigger life-threatening conditions, such as hyperkalemia or malignant hyperthermia. Several commonly used drugs, such as aminoglycosides, have intrinsic neuromuscular blocking activity that can worsen respiratory muscle weakness.

\hypertarget{management-of-respiratory-emergencies-flowchart}{%
\paragraph{Management of Respiratory Emergencies Flowchart}\label{management-of-respiratory-emergencies-flowchart}}

Summarizes general management of respiratory emergencies and specific management by etiology. Note that this chart does not include all respiratory emergencies; it provides key management strategies for a limited number of diseases.

\includegraphics{images/rapid-reference_pals-resp-emergencies.png}

\hypertarget{infectious-disease}{%
\subsection{Infectious Disease}\label{infectious-disease}}

\hypertarget{sepsis-huddle}{%
\subsubsection{Sepsis Huddle}\label{sepsis-huddle}}

\hypertarget{huddle-steps-resident-responsibilities}{%
\paragraph{Huddle Steps (Resident Responsibilities)}\label{huddle-steps-resident-responsibilities}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{Review vital sign trend}
\item
  \textbf{Examine patient} (especially respiratory, mental status, perfusion)
\item
  \textbf{Discuss IV access}
\item
  \textbf{Review antibiotic plan:} New agent(s) needed, delivery priority, need for ID consult
\item
  \textbf{Consider fluid bolus}
\item
  Discuss plan for repeat assessment
\end{enumerate}

\textbf{\emph{USE SEPSIS POWERPLAN TO ENSURE STAT IV ANTIBIOTICS AND FLUIDS!}}

\includegraphics{images/rapid-reference_sepsis-huddle.png}

\hypertarget{csf-analysis}{%
\subsubsection{CSF Analysis}\label{csf-analysis}}

\hypertarget{age-based-ranges-for-csf-studies}{%
\paragraph{Age-Based Ranges for CSF Studies}\label{age-based-ranges-for-csf-studies}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.04\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.25\columnwidth}\raggedright
WBC (mm\^{}3)Mean (Range)\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Glucose (mg/dL)Mean (Range)\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Protein (mg/dL)Mean (Range)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Premature}\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
9\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
50 (24-63)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
115 (65-150)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Term newborn}\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
8.2 (0-22)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
52 (34-119)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
90 (20-170)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{0-4 wks}\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
11 (0-35)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
46 (36-61)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
84 (35-189)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{4-8 wks}\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
7.1 (0-25)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
46 (29-62)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
59 (19-121)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{\textgreater8 wks}\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
2.3 (0-5)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
61 (45-65)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
28 (20-45)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{genenral-heuristics-for-csf-interpretation}{%
\paragraph{Genenral Heuristics for CSF Interpretation}\label{genenral-heuristics-for-csf-interpretation}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.16\columnwidth}\raggedright
Diagnosis\strut
\end{minipage} & \begin{minipage}[b]{0.07\columnwidth}\raggedright
WBC\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Glucose\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Protein\strut
\end{minipage} & \begin{minipage}[b]{0.25\columnwidth}\raggedright
Opening Pressure\strut
\end{minipage} & \begin{minipage}[b]{0.10\columnwidth}\raggedright
Other\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{Bacterial meningitis}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
↑, mostly PMNs\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↓ (\textless60\% serum glucose)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↑↑\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
+CSF Cx / gram stain, often +BCx\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{Viral meningitis}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Slightly ↑, mostly lymphocytes\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Normal to slightly ↑\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
HSV may have RBCs in CSF\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{TB meningitis}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
↑ (PMNs → lymphocytes)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↓ (\textless60\% serum glucose)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Variable\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
+AFB\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{Fungal meningitis}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
↑, lymphocytes\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↓ (\textless60\% serum glucose)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Variable\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Fungal Cx\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{GBS}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
NNormal\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↑↑\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
So-called ``albumino-cytologic dissociation''\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{SAH}\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Normal (accounting for peripheral ratio of RBC to WBC)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
↑\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Normal to ↑\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Xanthochromia = yellow appearance of CSF, suggests long-term presence of RBCs (to distinguish from traumatic tap)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{respiratory}{%
\subsection{Respiratory}\label{respiratory}}

\hypertarget{status-asthmaticus}{%
\subsubsection{Status Asthmaticus}\label{status-asthmaticus}}

\hypertarget{a-b-c}{%
\paragraph{A-B-C}\label{a-b-c}}

\textbf{Epinephrine} 0.01 mg/kg IM PRN extremis

\hypertarget{initial-treatment}{%
\paragraph{Initial treatment}\label{initial-treatment}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} ED Asthma Status Plan
\item
  \textbf{``Unineb''} = Albuterol + ipratropium combination nebs

  \begin{itemize}
  \tightlist
  \item
    \emph{NOTE:} 1x Unineb = 3x Combineb
  \end{itemize}
\item
  \textbf{Steroids} (if no improvement after first neb or if patient on home steroids)

  \begin{itemize}
  \tightlist
  \item
    Dexamethasone = dosed q24-48h, 0.6 mg/kg
  \item
    Prednisone/Prednisolone = dosed q12h, 2mg/kg
  \item
    Methylprednisolone 2mg/kg
  \end{itemize}
\end{itemize}

\hypertarget{if-poor-response-add}{%
\paragraph{If poor response, add}\label{if-poor-response-add}}

\begin{itemize}
\tightlist
\item
  \textbf{Magnesium sulfate} 40mg/kg (2mg max)

  \begin{itemize}
  \tightlist
  \item
    Monitor for hypotension, consider NS bolus
  \end{itemize}
\item
  \textbf{Continuous nebulized albuterol}

  \begin{itemize}
  \tightlist
  \item
    Titrate to HR
  \end{itemize}
\end{itemize}

\hypertarget{if-poor-response-continues-add}{%
\paragraph{If poor response continues, add}\label{if-poor-response-continues-add}}

\begin{itemize}
\tightlist
\item
  \textbf{Terbutaline:} Loading dose 5-10 mCg/kg IV/SC over 10m. Infusion 0.4 mCg/kg/min IV.

  \begin{itemize}
  \tightlist
  \item
    EKG, troponin, CK q12h
  \end{itemize}
\item
  Consider \textbf{Heliox} 70:30 helium:oxygen mixture
\end{itemize}

\hypertarget{if-impending-respiratory-failure}{%
\paragraph{If impending respiratory failure}\label{if-impending-respiratory-failure}}

\begin{itemize}
\tightlist
\item
  \textbf{Rapid sequence intubation}
\item
  \textbf{Mechanical ventilation:} Minimize PEEP, maximize E time. Permissive hypercapnia. Anticipate air leak, pneumothorax, bronchospasm, PEA.
\end{itemize}

\hypertarget{as-patient-improves}{%
\paragraph{As patient improves}\label{as-patient-improves}}

``Last on, first off'' to peel off therapy

\hypertarget{abgs-vbgs}{%
\subsubsection{ABGs \& VBGs}\label{abgs-vbgs}}

\begin{itemize}
\tightlist
\item
  Presented as: \textbf{pH / pCO2 / pO2 / HCO3}
\item
  \textbf{Venous pH + 0.035 = Arterial pH}
\item
  Look at past VBGs for baseline pCO2 (e.g.~chronically elevated in ex-preemies w/ CLD)
\item
  VBGs sufficient to assess acid-base status \& clinical response to treatments (in general). \textbf{ABG preferred over VBG:}

  \begin{itemize}
  \tightlist
  \item
    to accurately determine \textbf{PaCO2 in severe shock}
  \item
    to accurately determine PaCO2 if hypercapnic (i.e.~PaCO2 \textgreater45 mmHg)
  \end{itemize}
\end{itemize}

\hypertarget{stepwise-approach-to-abgvbg-interpretation}{%
\paragraph{Stepwise Approach to ABG/VBG Interpretation}\label{stepwise-approach-to-abgvbg-interpretation}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{Compare pH} to normal range
\item
  Identify the \textbf{primary process} that led to the change in pH (using PCO2/HCO3)
\item
  Calculate the \textbf{serum anion gap (SAG)}

  \begin{itemize}
  \tightlist
  \item
    \textbf{SAG = Na+ - (Cl- + HCO3-).} If \textbf{\textgreater12,} there is a primary AG metabolic acidosis
  \end{itemize}
\item
  Identify the \textbf{compensatory process} (if one is present)
\item
  Identify if any other disorders are present or there is a \textbf{mixed acid-base process using delta/delta = (AG - 12) / (24 - Bicarb)}

  \begin{itemize}
  \item
    \textless{} 0.4 → pure Non-AG Metabolic Acidosis (NAGMA)
  \item
    0.4 - 0.8 → mixed NAGMA + High-AG Metabolic Acidosis (HAGMA)
  \item
    0.8 - 2.0 → a pure HAGMA
  \item
    \begin{quote}
    2.0 → mixed HAGMA + metabolic alkalosis
    \end{quote}
  \end{itemize}
\end{enumerate}

\hypertarget{normal-blood-gas-values}{%
\paragraph{Normal Blood Gas Values}\label{normal-blood-gas-values}}

\begin{longtable}[]{@{}lll@{}}
\toprule
& Arterial & Venous\tabularnewline
\midrule
\endhead
\textbf{pH} & 7.35 - 7.45 & 7.31 - 7.41\tabularnewline
\textbf{pCO2} (mmHg) & 35 - 45 & 40 - 50\tabularnewline
\textbf{pO2} (mmHg) & 75 - 100 & 36 - 42\tabularnewline
\textbf{HCO3} (meQ/L) & 22 - 26 & Same\tabularnewline
\textbf{BE} & -2 to +2 & Same\tabularnewline
\textbf{O2 Saturation} & \textgreater95\% & 60-80\%\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{compensation}{%
\paragraph{Compensation}\label{compensation}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.42\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Defect\strut
\end{minipage} & \begin{minipage}[b]{0.37\columnwidth}\raggedright
Compensatory Response**\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.42\columnwidth}\raggedright
\textbf{Respiratory Acidosis}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
↑ pCO2\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
\textbf{↑ HCO3}- \emph{Acute} = \textbf{+1} MeQ/L HCO3 for +10 mm Hg PaCO2- \emph{Chronic} = \textbf{+4} MeQ/L HCO3- for +10 mm Hg PaCO2\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.42\columnwidth}\raggedright
\textbf{Respiratory Alkalosis}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
↓ pCO2\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
\textbf{↓ HCO3}- \emph{Acute} = \textbf{-2} MeQ/L HCO3 for -10 mm Hg PaCO2- \emph{Chronic} = \textbf{-5} MeQ/L HCO3- for -10 mm Hg PaCO2\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.42\columnwidth}\raggedright
\textbf{Metabolic Acidosis}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
↓ HCO3\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
\textbf{↓ pCO2}- pCO2 = 1.5 x HCO3 + 8 +/- 2 (\textbf{Winter's Formula})\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.42\columnwidth}\raggedright
\textbf{Metabolic Alkalosis}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
↑ HCO3\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
\textbf{↑ pCO2}- pCO2 \textbf{+ 0.6} for + 1.0 mEq/L HCO3\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

** HCO3 = kidneys (\textbf{days}). CO2 = lungs (\textbf{minutes}).
*** \textbf{Limits of compensation:} HCO3 = 15-38. CO2 = 10.

\includegraphics{images/rapid-reference_gas-interpretation-ddx.png}

\hypertarget{respiratory-support-for-spontaneously-breathing-patients}{%
\subsubsection{Respiratory Support for Spontaneously Breathing Patients}\label{respiratory-support-for-spontaneously-breathing-patients}}

\begin{longtable}[]{@{}lllllll@{}}
\toprule
\begin{minipage}[b]{0.09\columnwidth}\raggedright
Type\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
O2 Delivery\strut
\end{minipage} & \begin{minipage}[b]{0.15\columnwidth}\raggedright
CO2 Exit\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
FiO2\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Rate\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Pros\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Cons\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{``Blow By'' Oxygen (BBO2)}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
O2 tubing or simple mask held by a child's face\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Mouth\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{\textless30\%} (limited evidence)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
At least 10L/min through a reservoir (such as mask)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Can be used in children who can't tolerate other methods\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Limited and variable O2 delivery\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Low Flow Nasal Cannula (LFNC)}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Through nasal prongs attached to tubing\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Mouth\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{25-40\%} (100\% O2 delivers variable FiO2 based on placement of nares, patient's inspiratory effort and minute ventilation)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{1-4L/min} (Rates \textgreater2L/min can create Positive airway pressure in newborns/infants)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Mobile, infants can feed w/ low-flow in place, may be better tolerated than a mask\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
- Cannot reliably deliver high concentrations of FiO2- Prongs can be difficult to keep in position\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{High Flow Nasal Cannula (HFNC)}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Up to \textbf{8L/min} in infants, up to \textbf{60L/min} in children/adults\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Simple Mask}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
O2 enters mask through a tube\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Holes in the side of the mask\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{35-50\%} (Room air can enter through exit holes, mixing w/ delivered O2)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{6-10L/min}\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Can deliver higher concentrations of FiO2 than NC\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Cannot reliably deliver precise concentrations of O2 because of mixing w/ room air\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Partial Rebreather}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
O2 enters the mask through a tube as well as from an \textbf{attached reservoir}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Holes in the sides of the mask. Room air can still enter, but not as much as w/ the simple mask.\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
50-60\% O2\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
10-12L/min\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Non-Rebreather Mask}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
O2 enters the mask through a tube as well as from an \textbf{attached reservoir w/ a one-way valve}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Two exhalation ports; one is fitted w/ a one-way valve and one allows mixing (fail-safe so that if the O2 delivery port blocked, patient doesn't suffocate)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Up to \textbf{95\% O2}\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{10-15L/min}\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Max FiO2 administered to a spontaneously breathing patient\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Stored in the code cart at BCH\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{CPAP/BiPAP}\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
\emph{See Critical Care/ICP chapter}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{trach-troubleshooting}{%
\subsubsection{Trach Troubleshooting}\label{trach-troubleshooting}}

\hypertarget{tracheostomy-basics}{%
\paragraph{Tracheostomy Basics}\label{tracheostomy-basics}}

\begin{itemize}
\tightlist
\item
  \textbf{Major types:} Shiley or Bivona (more flexible, better for active children)
\item
  \textbf{Sizes:} A ``3.0'' trach has an inner diameter of 3.0 mm, sizes vary by age
\item
  \textbf{Cuffed vs.~uncuffed:} C\textbf{uffs improve air seal and prevent aspiration,} but uncuffed allows spontaneous breathing, improved vocalization, may be appropriate for infants and small children
\item
  \textbf{Outer vs.~inner cannula:} Outer cannula holds stoma open, inner cannula can be removed for cleaning
\item
  \textbf{Fenestration:} Improves vocalization
\item
  \textbf{Trach ties:} The part that wraps around the neck to keep trach in place
\end{itemize}

\hypertarget{trach-complications}{%
\paragraph{Trach Complications}\label{trach-complications}}

\begin{itemize}
\tightlist
\item
  \textbf{Plan ahead!}

  \begin{itemize}
  \tightlist
  \item
    Differentiate new (\textless{} 7 days) vs.~mature stoma (\textgreater{} 7 days)
  \item
    Know if your patient can be ventilated ``from above'' in event of trach malfunction
  \item
    Know your patient's trach brand, size, features and have replacement trach at bedside, including one size smaller
  \end{itemize}
\item
  \textbf{Decannulation:}

  \begin{itemize}
  \tightlist
  \item
    Staff assist, call RT urgently
  \item
    If new stoma, do \textbf{NOT} blindly replace trach, call ORL instead
  \end{itemize}
\item
  \textbf{Obstruction:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Mucous plugging} → suction, replace inner cannula, etc.
  \item
    \textbf{Back-walling} = Distal end of trach obstructs against posterior tracheal wall → call RT, reposition trach, may need longer trach
  \item
    \textbf{Tracheal stenosis or granulation tissue} → call ORL, may need to be addressed surgically
  \item
    Consider deflating cuff and ventilating ``from above'' if possible
  \end{itemize}
\item
  \textbf{Bleeding:}

  \begin{itemize}
  \tightlist
  \item
    Although rare, have high index of suspicion for tracheo-arterial fistula, call ORL
  \item
    Differentiate blood from trach vs.~from stoma/trach site
  \end{itemize}
\end{itemize}

\hypertarget{status-epilepticus-se}{%
\subsection{Status Epilepticus (SE)}\label{status-epilepticus-se}}

\hypertarget{powerplans-order-sets}{%
\subsubsection{PowerPlans \& Order Sets}\label{powerplans-order-sets}}

Neuro Seizure Admit Plan

\hypertarget{definition}{%
\subsubsection{Definition}\label{definition}}

\begin{itemize}
\tightlist
\item
  \textbf{Neurologic emergency!}
\item
  Seizure lasting \textgreater{} 30 min or 2 sequential seizures w/o return to baseline
\item
  \textbf{Refractory SE} is \textgreater{} 60 min
\end{itemize}

\hypertarget{presentation}{%
\subsubsection{Presentation}\label{presentation}}

Generalized SE, focal SE, hemi-convulsive status w/ hemiparesis

\hypertarget{differential}{%
\subsubsection{Differential}\label{differential}}

Sepsis, hypoglycemia, meningitis/encephalitis, skull fracture/trauma, HTN, mass, herniation

\hypertarget{management}{%
\subsubsection{Management}\label{management}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{Step 1} (0-5 min):

  \begin{itemize}
  \tightlist
  \item
    \textbf{Monitors, O2, IV access, STAT labs} (glucose, CBC, chem10, LFTs, UA/blood/urine cultures if febrile, urine tox screen, AED levels if relevant)
  \item
    \textbf{Lorazepam IV} (0.1 mg/kg/dose. Max 4mg.)
  \item
    If no access: \textbf{Diazepam PR} (0.5 mg/kg if \textless5yo; 0.3 mg/kg if 6-11yo; 0.2 mg/kg if \textgreater11yo)

    \begin{itemize}
    \tightlist
    \item
      \emph{NOTE:} Rapid redistribution → increased risk of seizure recurrence
    \end{itemize}
  \end{itemize}
\item
  \textbf{Step 2} (10-15 min):

  \begin{itemize}
  \tightlist
  \item
    \textbf{REPEAT Lorazepam IV} (0.1 mg/kg/dose. Max 4mg.)
  \item
    \emph{+} \textbf{Fosphenytoin IV} (20mg/kg infused over 7 min)

    \begin{itemize}
    \tightlist
    \item
      \emph{NOTE:} Will decrease BP
    \end{itemize}
  \item
    \emph{or} \textbf{Keppra IV} (60 mg/kg IV. Max dose 4500 mg.)
  \end{itemize}
\item
  \textbf{Step 3} (20-30 min):

  \begin{itemize}
  \tightlist
  \item
    Consult Neurology. Consider LP, EKG.
  \item
    \textbf{Phenobarbital IV} (20mg/kg infused over 15-20 min)

    \begin{itemize}
    \tightlist
    \item
      \emph{NOTE:} Will decrease RR, be prepared to intubate/bag
    \end{itemize}
  \end{itemize}
\end{enumerate}

\hypertarget{psychiatric}{%
\subsection{Psychiatric}\label{psychiatric}}

\hypertarget{anxiety-agitation-delirium}{%
\subsubsection{Anxiety, Agitation \& Delirium}\label{anxiety-agitation-delirium}}

\hypertarget{definition-1}{%
\paragraph{Definition}\label{definition-1}}

Anxiety, agitation, and delirium can often present together and can be difficult to differentiate in the seriously ill child. Management is often similar.

\hypertarget{anxiety}{%
\paragraph{Anxiety}\label{anxiety}}

Common among children with chronic or life-threatening illnesses. Difficult to separate from physical symptoms; \textbf{may exacerbate physical symptoms (pain, dyspnea, etc).}

\hypertarget{agitation}{%
\paragraph{Agitation}\label{agitation}}

Unpleasant state of arousal → loud speech, crying, ↑ motor activity/autonomic arousal

\hypertarget{delirium}{%
\paragraph{Delirium}\label{delirium}}

An acute-onset \textbf{disturbance of consciousness that fluctuates throughout the day}

\hypertarget{management-1}{%
\paragraph{Management}\label{management-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Non-pharmacologic:} Treat underlying cause, meditation, diaphragmatic breathing, massage, biofeedback therapy, \textbf{regulate sleep/wake cycle,} frequent \textbf{reorientation to time and place,} frequent reassurance, \textbf{minimize use of restraints}
\item
  Pharmacologic

  \begin{itemize}
  \tightlist
  \item
    Ask Psych team when to use PO vs.~IV/IM
  \item
    Onset of action:

    \begin{itemize}
    \tightlist
    \item
      \textbf{PO/enteral:} Usually 30-60 min for beginning of peak effects
    \item
      \textbf{IM:} Usually 15-30 min
    \item
      \textbf{IV:} Usually 5-15 min
    \end{itemize}
  \end{itemize}
\end{itemize}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.29\columnwidth}\raggedright
Drug\strut
\end{minipage} & \begin{minipage}[b]{0.29\columnwidth}\raggedright
Dose\strut
\end{minipage} & \begin{minipage}[b]{0.34\columnwidth}\raggedright
Notes\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Diphenhydramine} (Benadryl)\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
1 mg/kg per dose PO/IM/IV- \emph{Limits per 24h}: **\_\textless\_7yo:** 50-75mg; \textbf{8-12yo:} 75-100mg; \textbf{Adolescents:} 100-150mg\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
- Anticholinergic- Avoid if dehydrated, CF, asthma, previous paradoxical rxn\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Lorazepam} (Ativan)\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{0.02-0.05 mg/kg q6h PO/SL/IV/SC}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
(\textbf{8-12yo:} \textasciitilde0.5mg. \textbf{13yo+:} 1mg.)- \emph{Limits per 24h}: \textbf{8-12yo:} 2mg; \textbf{Adolescents:} 3mg\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
- Avoid in delirium- Avoid in pts \textless7yo\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Clonidine}\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
- **\_\textless\_7yo:** 0.025-0.05mg first dose- \textbf{\emph{8-12yo}:} 0.05mg first dose \textbf{\emph{13yo+}:} 0.1mg first dose\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
Useful w/ hx of ADHD, PTSD, younger children\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Clonazepam}\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{0.005-0.01 mg/kg PO q8-12h}- Can increase every 3 days up to 0.05-0.1 mg/kg PO q8-12h (max 0.2 mg/kg/day)\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
Avoid in delirium\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Haloperidol} (Haldol)\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{0.01-0.02 mg/kg PO q8h} (max 0.5-1 mg)- \textbf{Acute agitation:} 0.025 mg/kg PO \& can repeat 0.025 mg/kg in 1 hr as needed\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
IM form for acute agitation, \textbf{delirium,} psychosis/mania\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Risperidone}\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{0.25-0.5 mg PO qPM or divided} (max 3 mg/day)\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
Order only w/ Psych input\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Quetiapine} (Seroquel)\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{25 mg q12h PO,} can increase daily by 25mg/dose, to max 100-200 mg q12h)\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
Order only w/ Psych input\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Olanzapine} (Zyprexa)\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{1.2-2.5 mg PO daily} (max 5 mg/day)\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
Order only w/ Psych input\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{overnight-behavioral-plan}{%
\subsubsection{Overnight Behavioral Plan}\label{overnight-behavioral-plan}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} Agitation (mild), agitation (moderate), agitation (severe), behavioral health safety plan, behavioral restraints
\item
  \textbf{Err on the side of more restrictive:} When in doubt, put on a 1:1, order suicide precautions including finger foods, ``arms length'' if any significant concern for active attempts to hurt self, security at door for elopement risk, security in room if needs hands-on (care companion cannot put arms on/only observe and alert RN and team of concerns)
\item
  \textbf{Behavioral Rapid Response (BRR), Call 5-5555:} For active unsafe behaviors. Summons BRT psych RN, on-call psychiatrist (if in-house), ER psych SW (if in-house).
\item
  Never allow patient to get between you and the exit. Always ask for escort (including BRT clinician or PCS clinician). Put lanyards, long-hair, loose clothing away as able, etc.
\item
  \textbf{PGY-2s and above are the only people allowed to order physical or chemical IM restraints} (must be 1-time orders, cannot write PRN IM psychotropic meds or PRN physical restraints)
\end{itemize}

\hypertarget{adolescent-medicine}{%
\section{Adolescent Medicine}\label{adolescent-medicine}}

\hypertarget{bch-wards-tips}{%
\subsection{BCH Wards Tips}\label{bch-wards-tips}}

\hypertarget{primary-diagnoses}{%
\paragraph{Primary diagnoses}\label{primary-diagnoses}}

\begin{itemize}
\tightlist
\item
  Eating disorders
\item
  Anovulatory uterine bleeding
\item
  Some primary care patients admitted for Gen Peds issues
\end{itemize}

\hypertarget{format}{%
\paragraph{Format}\label{format}}

\begin{itemize}
\tightlist
\item
  Table rounds. Intern fills out and presents Eating Disorder worksheet (will be reviewed on the first day)
\item
  Do NOT write notes daily, but expected to examine patients daily, present thoughtful plans, and write an event note should something significant happen in a given 24hr period
\end{itemize}

\hypertarget{adolescent-clinic-tips}{%
\subsection{Adolescent Clinic Tips}\label{adolescent-clinic-tips}}

\hypertarget{overview}{%
\subsubsection{Overview}\label{overview}}

\begin{itemize}
\tightlist
\item
  Goal skills

  \begin{itemize}
  \tightlist
  \item
    Taking an effective social history
  \item
    Addressing confidentiality
  \item
    Discussing topics such as sex, contraception, substance use, and weight
  \item
    Performing respectful genital exams
  \item
    Strength-based approaches to management
  \end{itemize}
\item
  Format

  \begin{itemize}
  \tightlist
  \item
    Scheduled w/ same preceptor multiple times at BCH and BMC
  \item
    Try to schedule patients for return visits w/ you for continuity
  \end{itemize}
\end{itemize}

\hypertarget{bch-adolescent-clinic-specifics}{%
\subsubsection{BCH Adolescent Clinic Specifics}\label{bch-adolescent-clinic-specifics}}

\begin{itemize}
\tightlist
\item
  Population

  \begin{itemize}
  \tightlist
  \item
    11-25 yo
  \item
    Primarily from the Greater Boston Area and surrounding suburbs
  \item
    Primary and Subspecialty care for patients with eating disorders, reproductive endocrine concerns, and chronic fatigue
  \item
    Primary languages spoken: English and Spanish
  \end{itemize}
\item
  Resources available:

  \begin{itemize}
  \tightlist
  \item
    Mental health
  \item
    Psychopharm support
  \item
    Nutrition
  \item
    Resource specialist for social needs
  \item
    On-site sexual health counselling and STD testing (including HIV)
  \end{itemize}
\end{itemize}

\hypertarget{bmc-adolescent-clinic-specifics}{%
\subsubsection{BMC Adolescent Clinic Specifics}\label{bmc-adolescent-clinic-specifics}}

\begin{itemize}
\tightlist
\item
  Population

  \begin{itemize}
  \tightlist
  \item
    12-22 yo
  \item
    Primarily from Dorchester, Roxbury, Hyde Park, South Boston, and the South End
  \item
    Primary care, first point of medical contact for adolescents new to the United States, and subspecialty care for teen parents, adolescents with substance use disorders, gender diversity, individuals s/p sexual assault, and menstrual disorders
  \item
    Primary languages spoken: English, Haitian Creole, Spanish, and Cape Verdean Creole
  \end{itemize}
\item
  Subspecialty programs \& Resources available

  \begin{itemize}
  \tightlist
  \item
    CATALYST (for adolescents and young adults w/ substance use)
  \item
    Teen and Tot programs (to serve young parents and their children)
  \item
    CATCH (providing gender affirming care to youth of all ages)
  \item
    Sexual assault follow-up clinic
  \item
    Menstrual Disorders Clinic
  \item
    Integrated behavioral health social workers, patient navigators, and a family planner
  \end{itemize}
\end{itemize}

\hypertarget{heeadsss-assessment1}{%
\subsection[HEEADSSS Assessment]{\texorpdfstring{HEEADSSS Assessment\footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{HEEADSSS Assessment}}\label{heeadsss-assessment1}}

Parents, family members, or other involved adults should \textbf{NOT} be present during the HEEADSSS interview. Addressing this and the need for confidentiality at the beginning of the visit is important. Before asking adults to leave the room, always ask whether they have any concerns to express or questions to ask and assure them of further interaction once the confidential interview is over. Sometimes having a confidential moment with the adult can also be very informative to the patient's care.

Consider starting your HEEADSSS assessment by asking about the patient's \textbf{strengths}. A simple question such as ``What are your greatest strengths'' can go a long way in rapport building and eliciting motivations to engage in healthy behavior change.

\textbf{Bold} (green) = essential questions
\emph{Italics} (blue) = as time permits
Plain text (red) = optional or when the situation requires

\hypertarget{home}{%
\subsubsection{Home}\label{home}}

\begin{itemize}
\tightlist
\item
  \textbf{Where do you live? Who lives w/ you?}
\item
  \textbf{What are your relationships like at home? Who can you talk to at home?}
\item
  \emph{Is there anyone new at home? Has someone left recently?}
\item
  \emph{Have you moved recently?}
\item
  \emph{Have you ever had to live away from home? (Why?)}
\item
  \emph{Have you ever run away? (Why?)}
\end{itemize}

\hypertarget{education-andor-employment}{%
\subsubsection{Education and/or Employment}\label{education-andor-employment}}

\begin{itemize}
\tightlist
\item
  \textbf{Do you go to school? Do you work? Or both?}
\item
  \textbf{What are your favorite subjects at school? Your least favorite subjects?}
\item
  \textbf{How are your grades? Any recent changes? Any dramatic changes in the past?}
\item
  \textbf{What are your future education/employment plans/goals?}
\item
  \textbf{Are you working? Where? How many hours per week?}
\item
  \textbf{Tell me about your friends at school.}
\item
  \textbf{Have you ever had to repeat a class? Have you ever had to repeat a grade?}
\item
  \emph{Have you changed schools in the past few years?}
\item
  \emph{Have you ever been suspended? Expelled? Have you ever considered dropping out?}
\item
  \emph{How well do you get along w/ the people at school? Work?}
\item
  Do you feel connected to your school? Do you feel as if you belong?
\item
  Are there adults at school you feel you could talk to about something important? (Who?)
\end{itemize}

\hypertarget{eating}{%
\subsubsection{Eating}\label{eating}}

\begin{itemize}
\tightlist
\item
  \textbf{Do you have any concerns about your body shape, weight, or size?}
\item
  \textbf{Have you ever done anything to try to change your weight or body shape such as dieting, vomiting or taking diet pills/laxatives/supplements?}
\item
  \textbf{Have there been any recent changes in your weight?}
\item
  \textbf{How many meals/snacks do you eat each day?}
\item
  \textbf{What do you think would be a healthy diet? How does that compare to your current eating patterns?}
\item
  \emph{Do you eat in front of the TV? Computer?}
\item
  \emph{Does it ever seem as though your eating is out of control?}
\end{itemize}

\hypertarget{activities}{%
\subsubsection{Activities}\label{activities}}

\begin{itemize}
\tightlist
\item
  \textbf{What do you and your friends do for fun? (w/ whom, where, and when?)}
\item
  \textbf{What do you and your family do for fun? (w/ whom, where, and when?)}
\item
  \textbf{Do you participate in any sports or other physical activities that are heart healthy?}
\item
  \emph{How much time do you spend looking at a screen each day (other than doing your homework)?}
\end{itemize}

\hypertarget{drugs}{%
\subsubsection{Drugs}\label{drugs}}

\begin{itemize}
\tightlist
\item
  \textbf{In the past year, how often have you smoked tobacco or MJ, vaped, or had alcohol?}

  \begin{itemize}
  \tightlist
  \item
    If any use disclosed, \textbf{ask about other substances and do CRAFFT screen}
  \item
    If no use disclosed, \textbf{ask the following questions:}

    \begin{itemize}
    \tightlist
    \item
      \textbf{Do any of your friends drink, smoke, vape, or use drugs? Have you ever ridden in a CAR driven by someone (including yourself) who was ``high'' or had been using alcohol or drugs?}
    \end{itemize}
  \end{itemize}
\item
  \emph{Is there any history of alcohol or drug problems in your family? Does anyone smoke at home?}
\item
  \emph{Do you ever drink or use drugs when you're alone?}
\item
  \emph{(Assess frequency, intensity, patterns of use or abuse, and how youth obtains or pays for drugs, alcohol, or tobacco)}
\end{itemize}

\hypertarget{sexuality}{%
\subsubsection{Sexuality}\label{sexuality}}

\begin{itemize}
\tightlist
\item
  \textbf{Do you see yourself as a boy, a girl, something different, or you're not sure?}
\item
  \textbf{Are you attracted to other people? If so: boys, girls, both?}
\item
  \textbf{Have you ever had sex with anyone? If so, what kinds of sex? How many people have you had sex with?}
\item
  \textbf{Unfortunately some young people are forced to have sex. Has anyone ever forced you to have sex?}
\item
  \textbf{What are you doing to prevent pregnancy?}
\item
  \textbf{What are you doing to protect yourself from STDs and HIV?}
\item
  \textbf{Have you or your partners ever had an STD?}
\item
  \emph{How many sexual partners have you had altogether?}
\item
  \emph{Females: Have you ever been pregnant or worried that you may be pregnant? Males: Have you ever gotten someone pregnant or worried that that might have happened?}
\item
  \emph{What percentage of the time do you use condoms during intercourse?}
\item
  \emph{Does anything ever get in the way of always using a condom?}
\item
  \emph{When you and your partner get into fights, what sort of things happen?}
\end{itemize}

\hypertarget{suicide-depressionmood}{%
\subsubsection{Suicide \& Depression/Mood}\label{suicide-depressionmood}}

\begin{itemize}
\tightlist
\item
  \textbf{PHQ2: Over the past two weeks have you felt down, depressed, or hopeless? Over the past two weeks have you had little interest or pleasure in doing things?}
\item
  \textbf{Have you thought about hurting or killing yourself or someone else?}
\item
  IF ANY OF THE ABOVE ARE POSITIVE, \textbf{perform full PHQ9}
\item
  \emph{Do you have problems with anxiety?}
\item
  \emph{Some young people have had bad things happen to them, and then they have nightmares, flashbacks or feel on-edge/ hyper-alert. Do you have these symptoms?}
\end{itemize}

\hypertarget{safety}{%
\subsubsection{Safety}\label{safety}}

\begin{itemize}
\tightlist
\item
  \textbf{Do you feel safe at home? At school? In your community? With your friends? In your relationships?}
\item
  \textbf{Have you ever been bullied? Have you ever bullied someone else?}
\item
  \textbf{Have you ever been seriously injured? (How?) How about anyone else you know?}
\item
  \textbf{What percent of the time do you wear a seatbelt in the car?}
\item
  \textbf{Do you use safety equipment for sports and or other physical activities (for example, helmets for biking or skateboarding)?}
\item
  \textbf{Has anyone ever forced you to have sex with them, or hit, punched, kicked, slapped, or physically or sexually hurt you in any other way?}
\item
  \textbf{Is there a gun in your home/ do you have access to a gun?}
\item
  \emph{Have you ever been in a car or motorcycle accident? If so, what happened?}
\item
  \emph{Have you gotten into physical fights in school or your neighborhood? Are you still getting into fights?}
\item
  \emph{Have you ever felt that you had to carry a knife, gun, or other weapon to protect yourself? Do you still feel that way?}
\end{itemize}

\hypertarget{adolescent-screening-tools}{%
\subsection{Adolescent Screening Tools}\label{adolescent-screening-tools}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.36\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.25\columnwidth}\raggedright
Screeners\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
When to use\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.36\columnwidth}\raggedright
Depression\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
\href{https://www.hiv.uw.edu/page/mental-health-screening/phq-2}{PHQ-2}, \href{https://www.aacap.org/App_Themes/AACAP/docs/member_resources/toolbox_for_clinical_practice_and_outcomes/symptoms/GLAD-PC_PHQ-9.pdf}{PHQ-A} = PHQ-9 modified for adolescents, \href{https://depts.washington.edu/hcsats/FCAP/resources/PSC-17\%20English.pdf}{PSC-17} (up to age 15)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- Routine Child Health Maintenance visits - Visits for mood follow-up - When you're concerned about depression and/or suicidality in your patient\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.36\columnwidth}\raggedright
Anxiety\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
\href{https://www.aacap.org/App_Themes/AACAP/docs/member_resources/toolbox_for_clinical_practice_and_outcomes/symptoms/GLAD-PC_PHQ-9.pdf}{PSC-17} (up to age 15), \href{https://www.integration.samhsa.gov/clinical-practice/gad708.19.08cartwright.pdf}{GAD-7}, \href{https://www.pediatricbipolar.pitt.edu/sites/default/files/SCAREDChildVersion_1.19.18.pdf}{SCARED}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- Routine Child Health Maintenance visits - Visits for mood follow-up - When you're concerned that anxiety is a problem for your patient\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.36\columnwidth}\raggedright
Substance Use\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
\href{https://www.drugabuse.gov/ast/s2bi/\#/}{S2BI}, \href{https://www.integration.samhsa.gov/clinical-practice/sbirt/CRAFFT_Screening_interview.pdf}{CRAFFT}, \href{https://www.drugabuse.gov/ast/bstad/\#/}{BSTAD}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- Routine Child Health Maintenance visits - F/u after visits in the ED for acute intoxication - When you're concerned that substance use is a problem for your patient\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{contraception2}{%
\subsection[Contraception]{\texorpdfstring{Contraception\footnote{Jones, H. Guillain-Barre Syndrome: Perspectives w/ Infants and Children. Seminars in Pediatric Neurology June 2000.}}{Contraception}}\label{contraception2}}

\hypertarget{emergency-contraception-ec}{%
\subsubsection{Emergency Contraception (EC)}\label{emergency-contraception-ec}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.67\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
Notes\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Access\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.67\columnwidth}\raggedright
Ella (ulipristal acetate)\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- \textbf{Most effective EC pill} to prevent pregnancy \textbf{up to 5 days after} unprotected sex - Do NOT give if starting any form of hormonal contraception (ulipristal binds the progesterone receptors and blocks the hormone's effects)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
- \textbf{Rx ONLY} - Safe to call in a prescription w/o pregnancy test or seeing patient\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.67\columnwidth}\raggedright
Plan B One-Step (levonorgestrel 1.5mg)\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Works to prevent pregnancy for the \textbf{first 3 days after} unprotected sex - Works less well in patients who are overweight or obese - Discuss with your preceptor if you should recommend a double dose for your overweight patients\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
- Sold (at cost \$\$, w/o Rx) to anyone of any age at most pharmacies, though access is still difficult for adolescents. \textbf{Much cheaper w/ Rx.} - Safe to call in a prescription w/o pregnancy test or seeing patient\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.67\columnwidth}\raggedright
Copper IUD (Paragard)\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- \textbf{Most effective form of EC} (\textgreater99\%), effective \textbf{up to 7 days after} unprotected sex - Can provide up to 12 years of highly effective contraception after placement\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Must be placed in a clinic setting by a trained provider\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{For more information} on emergency contraception (EC), please see the following resources: \href{https://www.bedsider.org/methods/emergency_contraception}{Bedsider}, \href{https://www.reproductiveaccess.org/wp-content/uploads/2014/12/emergency-contraception.pdf}{reproductiveaccess.org}, \href{https://www.mass.gov/info-details/emergency-contraception-get-the-facts}{Mass.gov EC site}

\hypertarget{shared-decision-making-sdm}{%
\subsubsection{Shared Decision Making (SDM)}\label{shared-decision-making-sdm}}

\begin{itemize}
\tightlist
\item
  Collaborative process, allows patients and their providers to make healthcare decisions together, taking into account the best scientific evidence available, as well as the patient's values and preferences
\item
  Provider role: knowledge of the medical information
\item
  Patient role: expert regarding their own values and preferences
\end{itemize}

\hypertarget{applying-sdm-principles-to-contraceptive-counseling-visits}{%
\subsubsection{Applying SDM Principles to Contraceptive Counseling Visits}\label{applying-sdm-principles-to-contraceptive-counseling-visits}}

\hypertarget{establish-rapport}{%
\paragraph{Establish rapport}\label{establish-rapport}}

\begin{itemize}
\tightlist
\item
  ``What brings you in today? What's happening with your birth control?''
\item
  ``Why did you decide to choose \_\_\_\_?''
\item
  Ask interactive open-ended questions. The HEEADSSS assessment is a great way to establish rapport for new patients.
\end{itemize}

\hypertarget{assess-patient-readiness}{%
\paragraph{Assess patient readiness}\label{assess-patient-readiness}}

\begin{itemize}
\tightlist
\item
  ``What are important features that your birth control should have?''
\item
  ``What did you like/dislike about the birth control methods you used in the past?''
\item
  ``Different types of birth control affect your period differently. Some make your period a bit heavier, lighter, sporadic, or may take your period away. Which do you think will be best for you?''
\end{itemize}

\hypertarget{tailor-information-and-discussion-to-patient-preferencesneeds}{%
\paragraph{Tailor information and discussion to patient preferences/needs}\label{tailor-information-and-discussion-to-patient-preferencesneeds}}

\begin{itemize}
\tightlist
\item
  Your patient says they want a method where they will still have a regular period. Counsel them on the contraceptive ring, patch, pill, and copper IUD and NOT on the shot, implant, or LNG IUDs.
\item
  Your patient says they want a method that is easy to keep private. Counsel them on the contraceptive implant, shot, IUD, and ring and NOT on the pill or patch.
\item
  Your patient has heavy periods and doesn't want them to be any heavier. Provide information on any method other than the copper IUD.
\item
  Your patient says they absolutely want to have a period every month. Provide more information on the LNG 15 and 19.5mg IUDs, and Copper IUD, and NOT the LNG 52mg IUD (Mirena).
\item
  Use patient's identified preferences for discussing particular methods. Being knowledgeable of contraceptive mechanisms of action, side effects, and delivery routes is important to provide this tailored information.
\end{itemize}

\hypertarget{discuss-contraception-side-effects}{%
\paragraph{Discuss contraception side effects}\label{discuss-contraception-side-effects}}

\begin{itemize}
\tightlist
\item
  ``Patients who begin the birth control pill may have breast tenderness or a mild headache during the first month. These usually go away.''
\item
  ``With the LNG 52mg IUD, you may have spotting for about 4 months after placement, then your period will become lighter. After a year with the IUD, some patients stop getting their period.''
\item
  Many patients feel they do not receive adequate information about side effects, and that providers often overlook possible side effects in counseling discussions. It is important to discuss the specific side effects that patients should expect with the contraception type that is aligned with their preferences.
\end{itemize}

\hypertarget{identify-misconceptions-about-specific-contraception-methods}{%
\paragraph{Identify misconceptions about specific contraception methods}\label{identify-misconceptions-about-specific-contraception-methods}}

\begin{itemize}
\tightlist
\item
  ``I'm sorry that your friend had a bad experience with the vaginal contraceptive ring and weight gain. This isn't typical with most ring users. I support you in using this method because it aligns with your preferences. If you experience weight gain, you can absolutely choose a different option.''
\item
  ``I hear your concern that your friend had worsening acne with her IUD. We usually don't see this in the majority of patients, so it's not likely that it will happen to you.''
\item
  Respectfully addressing myths or misconceptions about IUD types helps to keep conversations open, while providing patients with accurate information.
\end{itemize}

\hypertarget{ensure-access-to-method-discontinuation-at-any-time}{%
\paragraph{Ensure access to method discontinuation at any time}\label{ensure-access-to-method-discontinuation-at-any-time}}

\begin{itemize}
\tightlist
\item
  ``If you decide you don't like this birth control, you can switch to something else at any time.''
\item
  ``If you decide that you want to stop your birth control, I'm always here to talk about it and to support you.''
\item
  ``If for whatever reason you decide that you don't want the IUD anymore, I will remove it.''
\item
  Patients should be informed at the time of insertion that they can have their IUD removed at any time, and for any reason.
\item
  IUD removal should be provided with the immediacy as ``same-day'' IUD placement is provided.
\end{itemize}

\textbf{For more information} on contraceptive methods, minor consent laws, as well as medical eligibility criteria and selected practice recommendations, please see the following resources: \href{https://youngwomenshealth.org/2009/01/28/pros-and-cons-contraceptive-methods/}{Center for Young Women's Health}, \href{https://www.bedsider.org/}{Bedsider}, \href{https://www.reproductiveaccess.org}{Reproductive Access}, \href{https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html}{CDC MEC}, \href{https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/summary.html}{CDC SPR}, \href{http://www.guttmacher.org/state-policy/explore/minors-access-contraceptive-services}{Guttmacher Institute}

\hypertarget{tanner-staging3}{%
\subsection[Tanner Staging]{\texorpdfstring{Tanner Staging\footnote{Shahrizaila, N, and Yuki, N. Bickerstaff brainstem encephalitis and Fisher Syndrome: anti-GQ1B antibody syndrome. Journal of Neurology, Neurosurgery and Psychiatry 84(5). 2013.}}{Tanner Staging}}\label{tanner-staging3}}

\begin{figure}
\centering
\includegraphics{images/adolescent_tanner-staging.png}
\caption{Tanner Stages}
\end{figure}

\hypertarget{vaginal-discharge-and-infections}{%
\subsection{Vaginal Discharge and Infections}\label{vaginal-discharge-and-infections}}

****NOTE: Treatments change frequently! Check the \href{https://www.cdc.gov/std/treatment/default.htm}{CDC Treatment Guidelines} or download the ``CDC STD Tx Guide'' app.**

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.46\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
Signs \& Symptoms\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
Diagnosis\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Physiologic (leukorrhea)\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- Clear, white, or grey discharge; no offensive odor - No burning or itching\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- pH \emph{\textless{}} 4.5 - Wet mount: epithelial cells w/ no or few leukocytes\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Reassurance\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Candida vaginitis (``yeast infection'')\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- Odorless curd-like white clumpy discharge - Intense burning and pruritus\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- pH \textless{} 4.5 - KOH: No fish odor, +budding yeast and pseudohyphae, +WBC - Vaginitis Panel via vaginal swab (tests for BV, Candida Vaginitis, Trich)\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Fluconazole 150 mg PO (single dose) - Miconazole or clotrimazole intravaginal cream\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Trichomoniasis\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- Malodorous, frothy, yellow-green or cream colored discharge - Pruritus, dysuria\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- pH \textgreater{} 4.5 - KOH: Fish odor may be present - Wet mount: WBC and pear shaped organism w/ motile flagella - Vaginitis Panel via vaginal swab (tests for BV, Candida Vaginitis, Trich) - NAAT dirty urine collection\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Metronidazole 2g PO (single dose) or 500mg PO BID for 7 days \textbf{Partner:} treat and refrain from intercourse for 7 days\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Bacterial vaginosis (BV)\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- Malodorous, increased mild grey-white discharge - Mild or absent pruritis or burning\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- pH \textgreater{} 4.5 - KOH: +Fish odor - Wet mount: \textgreater20\% clue cells-epithelial cells covered w/ gram negative rods - Vaginitis Panel via vaginal swab (tests for BV, Candida Vaginitis, Trich)\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Metronidazole 500mg PO BID for 7 days, OR - Metronidazole gel 0.75\% one applicator (5g) intravaginally daily for 5 days \textbf{Partner:} treat if recurrent infection\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Gonorrhea (GC)\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- Majority asymptomatic - Grey-white cervical discharge\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
GC/CT NAAT vaginal swab or dirty urine\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Ceftriaxone 250mg IM + azithromycin 1g PO (co-tx chlamydia and covers resistant gonorrhea) - Refrain from intercourse x7 days \textbf{Partner:} Evaluate and treat contacts w/i prior 60 days\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Chlamydia (CT)\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- Majority asymptomatic - Yellowish vaginal discharge\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
GC/CT NAAT vaginal swab or dirty urine\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Azithromycin 1g PO x1 - If allergic to azithro, can do doxycycline 100mg PO BID x7 days - Refrain from intercourse x7 days \textbf{Partner:} Evaluate and treat contacts w/i prior 60 days\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Retained tampon\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Malodorous discharge\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
History and PE\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Remove tampon\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.46\columnwidth}\raggedright
Allergic vaginitis\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Local pain, vaginal erythema\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
History of exposure to deodorant spray, scented tampons, etc.\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Cessation of sensitizing agent\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{hiv}{%
\subsection{HIV}\label{hiv}}

\hypertarget{signs-symptoms}{%
\subsubsection{Signs \& Symptoms}\label{signs-symptoms}}

\begin{itemize}
\tightlist
\item
  \textbf{Acute HIV infection:} mono-like illness w/ nonspecific sxs (fever, lymphadenopathy, sore throat, rash, myalgia/arthralgia, diarrhea, mucocutaneous ulcers, weight loss, headache) usually \textasciitilde2-4 weeks after exposure, sometimes up to 10 months after exposure
\item
  Early infection is asymptomatic in 10-60\% of cases
\end{itemize}

\hypertarget{diagnosis}{%
\subsubsection{Diagnosis}\label{diagnosis}}

\begin{itemize}
\tightlist
\item
  \textbf{Suspected case:} HIV-1/2 Combo Ag/Ab + RT-PCR HIV viral load test

  \begin{itemize}
  \tightlist
  \item
    If testing is negative, but very-high risk exposure was recent, repeat test in 1-2 weeks
  \item
    For cases of presumed sexual assault, repeat HIV testing in 6 wks, 3mo and 6mo
  \end{itemize}
\item
  \textbf{Routine screening:} Fourth gen HIV-1/2 Combo Ag/Ab reflex to confirmatory subtyping HIV1/HIV2 differentiation immunoassay, followed by viral load testing only if there is a discrepancy
\end{itemize}

\hypertarget{pep-vs.-prep}{%
\subsubsection{PEP vs.~PrEP}\label{pep-vs.-prep}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.38\columnwidth}\raggedright
PEP = Post-Exposure Prophylaxis\strut
\end{minipage} & \begin{minipage}[b]{0.38\columnwidth}\raggedright
PrEP = Pre-Exposure Prophylaxis\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.16\columnwidth}\raggedright
EBG\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
Sexual Assault EBG\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
PrEP EBG\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
What is it?\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
Always a 3 drug regimen: - \textbf{Preferred regimen} (tablets only): Truvada (tenofovir and emtricitabine) + Raltegravir - \textbf{Alternative regimen} (if unable to swallow pills): Zidovudine + Lamivudine, + Raltegravir (chewtab) OR Lopinavir/Ritonavir (liquid)\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
Daily Truvada (tenofovir-emtricitabine)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
Who's it for?\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
Consider PEP if the following three statements apply to the patient: - Isolated anal, vaginal, percutaneous or oral exposure to possibly or definitely HIV infected blood or semen - Exposure occurred within 72 hours of presentation - Patient/family will consent to treatment and agree to follow-up\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
HIV neg Adolescents/Adults weighing \textgreater35 kg and meeting one of the following indications: - Men who have sex with men - Person who injects drugs - Heterosexual men and women at substantial risk of acquiring HIV infection (any sex partner w/ HIV or HIV risk factors, hx of bacterial STI, hx injecting drugs, used non-occupational PEP, survival/transactional sex, been in drug tx program, interest in trying to conceive w/ a discordant partner)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{genital-ulcers-and-warts}{%
\subsection{Genital Ulcers and Warts}\label{genital-ulcers-and-warts}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.26\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Signs \& Symptoms\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Diagnosis\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.26\columnwidth}\raggedright
Genital herpes\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Grouped vesicles, painful shallow ulcers, tender inguinal adenopathy\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Tzanck smear and viral culture - Antigen testing to determine HSV1 vs.~HSV2 can give more information about recurrence prognosis\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{First episode:} - Acyclovir 400mg TID x5-10 days, OR - Valacyclovir 1g BID x7-10 days \textbf{Recurrent episodes:} - Acyclovir 400mg TID x5 days, OR - Valacyclovir 500 mg BID x3 days \textbf{Daily suppressive (maintenance) therapy:} - Acyclovir 400 PO BID - Valacyclovir 500mg-1g PO daily\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.26\columnwidth}\raggedright
Genital warts\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- Single or multiple soft fleshy papillary or sessile painless growths around genitals - No inguinal lymphadenopathy\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- \textbf{Initial:} clinical presentation - \textbf{Final:} Pap test revealing typical cytologic changes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Goal:} remove exophytic warts; exclude cervical dysplasia before treatment \textbf{Medication} (not in preg): - Podophylin 0.5\% gel BID x3 days then off x4 days, and repeat up to 4 times; OR - Imiquimod 5\% cream 3x/wk on alternate days until resolution (\textless16 wks) \textbf{Prevention:} Gardasil 9-valent vaccine (HPV(6, 11, + 7 others)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.26\columnwidth}\raggedright
Syphilis\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- \textbf{Primary:} Indurated, well defined, usually single painless ulcer ``chancre'' - \textbf{Secondary:} weeks to months later; systemic infection w/ rash, fever, HA, malaise, anorexia, adenopathy - \textbf{Latent} → Leads to \textbf{Tertiary} in 25\%: CNS, cardiac manifestations; gummatous lesions\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- \textbf{Initial:} FTA-ABS, MHA-TP, dark-field microscopy or DFA test of exudate or tissue - \textbf{Final:} VDRL, RPR (reverse sequence screening @ BCH) - False seronegatives seen in first 3 months; presumptive tx recommended\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Primary} and \textbf{Secondary:} - Benzathine Penicillin G: 2.4 mil U IM x1 dose - Doxycycline 100mg BID x14 days for allergy/preg \textbf{Latent:} infected but no sx - Benzathine Penicillin G: 2.4 mil U IM qweekly x3 wks \textbf{Partner:} evaluate if contact w/i 3 mo for primary, 6 mo for secondary, 1 year for latent\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.26\columnwidth}\raggedright
Chancroid\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- Multiple, ragged, painful, non-indurated ulcers - Painful suppurative inguinal adenopathy\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- \textbf{Initial:} clinical presentation, neg syphilis and HSV - \textbf{Final:} culture of \emph{haemophilus ducreyi}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Azithromycin 1g PO x1 dose - Ceftriaxone 250 mg IM x1 dose - Ciprofloxacin 500 mg BID x3 days - Erythromycin 500 mg TID x7 days \textbf{Partner:} evaluate and treat contacts w/i 10 days of symptoms\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{pelvic-inflammatory-disease-pid}{%
\subsection{Pelvic Inflammatory Disease (PID)}\label{pelvic-inflammatory-disease-pid}}

****NOTE: Epididymitis is the male equivalant of female PID!**

\hypertarget{powerplans-order-sets-ebgs}{%
\subsubsection{PowerPlans / Order Sets / EBGs}\label{powerplans-order-sets-ebgs}}

Pelvic Inflammatory Disease EBG

\hypertarget{pathophysiology}{%
\subsubsection{Pathophysiology}\label{pathophysiology}}

Infection of upper genital tract (cervix, uterus, fallopian tubes, ovaries)

\hypertarget{etiology}{%
\subsubsection{Etiology}\label{etiology}}

N. gonorrhea, C. trachomatis or other anaerobic organisms

\hypertarget{clinical-manifestations}{%
\subsubsection{Clinical Manifestations}\label{clinical-manifestations}}

Pelvic pain, dyspareunia, vaginal discharge, fever, menstrual irregularities associated w/ lower abdominal tenderness, adnexal tenderness, and/or cervical motion tenderness

\hypertarget{physical-exam}{%
\subsubsection{Physical Exam}\label{physical-exam}}

Uterine, adnexal, or cervical motion tenderness +/- LQ or RUQ tenderness

\hypertarget{evaluation}{%
\subsubsection{Evaluation}\label{evaluation}}

\begin{itemize}
\tightlist
\item
  STI testing (GC/CT, trich, BV, RPR, HIV)
\item
  Consider CBCd, ESR, urine hCG, UA, UCx
\end{itemize}

\hypertarget{management-2}{%
\subsubsection{Management}\label{management-2}}

\hypertarget{outpatient}{%
\paragraph{Outpatient}\label{outpatient}}

\begin{itemize}
\tightlist
\item
  Ceftriaxone 250 mg IM in a single dose PLUS doxycycline 100 mg PO BID for 14 days w/ or w/o metronidazole 500mg PO BID for 14 days
\end{itemize}

\hypertarget{inpatient}{%
\paragraph{Inpatient}\label{inpatient}}

\begin{itemize}
\tightlist
\item
  IV regimen A: cefoxitin 2g IV q6h plus doxycycline 100mg PO BID
\item
  IV regimen B: clindamycin 900 mg IV every 8 hours plus gentamicin 3 mg/kg IV q24h
\item
  Following A, B: doxycycline 100mg PO BID for 14 days. If with pelvic abscess, BV, trich, or recent instrumentation also give 14 days of metronidazole.
\item
  Alternative regimens: Levofloxacin +/- Metronidazole; Ofloxacin +/- Metronidazole; Amp/Sulbactam + Doxy
\end{itemize}

\textbf{Partner:} Evaluation and treatment of contacts w/i prior 60 days recommended. Refrain from intercourse in the meantime

\hypertarget{heavy-or-irregular-menstrual-bleeding}{%
\subsection{Heavy or Irregular Menstrual Bleeding}\label{heavy-or-irregular-menstrual-bleeding}}

\hypertarget{powerplans-order-sets-ebgs-1}{%
\subsubsection{PowerPlans / Order Sets / EBGs}\label{powerplans-order-sets-ebgs-1}}

Heavy/Irregular Menstrual Bleeding EBG

\hypertarget{definition-2}{%
\subsubsection{Definition}\label{definition-2}}

Abnormalities in the frequency, duration, volume, and/or timing of menstrual bleeding

\hypertarget{differential-diagnosis}{%
\subsubsection{Differential Diagnosis}\label{differential-diagnosis}}

Anovulatory bleeding (most common cause in adolescents), pregnancy (\textbf{must rule out} even w/o report of sexual activity), coagulopathy, recent start/stop of contraception

\hypertarget{clinical-manifestations-1}{%
\subsubsection{Clinical Manifestations}\label{clinical-manifestations-1}}

\begin{itemize}
\tightlist
\item
  Menses prolonged or cycle shortened w/ frequent menses (normal menses happen every 21-45 days)
\item
  Flow moderate to heavy
\item
  May present w/ anemia leading to orthostasis, fatigue, tachycardia, syncope/ presyncope or exercise intolerance
\item
  Other changes may include: weight change, visual changes, headache, heat or cold intolerance, skin changes (hirsutism or acne), palpitations, cyclic abdominal pain
\end{itemize}

\hypertarget{evaluation-1}{%
\subsubsection{Evaluation}\label{evaluation-1}}

\begin{itemize}
\tightlist
\item
  Labs: CBC w/ diff, urine hCG, gonorrhea and chlamydia testing, coagulation studies, von Willebrand panel, TSH, LH, FSH, prolactin, free/total testosterone, DHEAS
\item
  Imaging: Pelvic ultrasound if mass palpable, uterine abnormality suspected, or patient is not responding to typical therapies
\item
  Exam: External GU exam to evaluate for active bleeding, masses, signs of trauma, virilization
\item
  Ask about personal and family history of bleeding
\end{itemize}

\hypertarget{management-3}{%
\subsubsection{Management}\label{management-3}}

\begin{itemize}
\tightlist
\item
  Consider NSAID trial (ibuprofen or naproxen), OCPs (screen for estrogen contraindications to determine type of OCP) continuously (occasionally BID-QID) until bleeding stops, daily iron supplements for anemia.
\item
  Send to ED if vital signs unstable or with severe anemia (for further workup for surgical cause of bleed, possible transfusion, and possible tranexamic acid or aminocaproic acid)
\item
  Antiemetic PRN nausea associated w/ hormone therapy
\end{itemize}

\hypertarget{amenorrhea4}{%
\subsection[Amenorrhea]{\texorpdfstring{Amenorrhea\footnote{Peragallo, J. Pediatric Myasthenia Gravis. Seminars in Pediatric Neurology. May 2017.}}{Amenorrhea}}\label{amenorrhea4}}

\hypertarget{definition-3}{%
\subsubsection{Definition}\label{definition-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Primary:} Absence of menses by age 15 or absence of menses 3 years following thelarche
\item
  \textbf{Secondary:} Absence of menses for three cycles or for three-six months w/ prior normal menses
\end{itemize}

\hypertarget{pathophysiology-1}{%
\subsubsection{Pathophysiology}\label{pathophysiology-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Primary w/o secondary sex characteristics (no breast development) but normal genitalia (uterus and vagina):} Turner syndrome, abnormal X chromosome, mosaicism, pure gonadal dysgenesis, 17 a-hydroxylase deficiency, hypothalamic failure secondary to inadequate gonadotropin- releasing hormone (GnRH) release, constitutional delay of puberty
\item
  \textbf{Primary w/ normal breast development but absent uterus:} Androgen insensitivity, congenital absence of uterus (MRKH)
\item
  \textbf{Primary w/ no breast development and no uterus:} 17,20 desmolase deficiency, agonadism, 17 -hydroxylase deficiency w/ 46 XY karyotype
\item
  \textbf{Primary and secondary w/ normal secondary sex characteristics:} Hypothalamic causes (idiopathic, phenothiazines, heroin, stress, exercise, weight loss, chronic illness, craniopharyngioma, tuberculous granuloma, meningoencephalitis, polycystic ovary syndrome), pituitary causes (Sheehan's syndrome, aneurysm, empty sella, tumors), ovarian causes (premature ovarian insufficiency), uterine causes (Asherman syndrome), pregnancy
\end{itemize}

\hypertarget{clinical-manifestations-2}{%
\subsubsection{Clinical Manifestations}\label{clinical-manifestations-2}}

\begin{itemize}
\tightlist
\item
  May see absence of secondary sex characteristics in conjunction w/ amenorrhea
\end{itemize}

\hypertarget{physical-exam-1}{%
\subsubsection{Physical Exam}\label{physical-exam-1}}

\begin{itemize}
\tightlist
\item
  Height, weight
\item
  Signs of malnutrition, androgen excess, thyroid dysfunction
\item
  Tanner stage, breast exam and pelvic exam
\item
  Webbed neck, low set ears, broad shield-like chest in Turner's syndrome
\end{itemize}

\hypertarget{evaluation-2}{%
\subsubsection{Evaluation}\label{evaluation-2}}

\begin{itemize}
\tightlist
\item
  Pregnancy test, TSH, FSH, prolactin, ultrasound to evaluate for presence of uterus
\item
  \textbf{Primary w/o secondary sex characteristics or absent uterus:} Karyotype, FSH, Testosterone level.
\item
  \textbf{Primary and secondary w/ normal secondary sex characteristics:} Urine pregnancy; FSH; Testosterone level; prolactin level -- if elevated, need MRI of head to evaluate for prolactinoma; Progestin withdrawal test: Positive response indicates the production of estrogen w/o normal cycling such as in PCOS (if evidence of hyperandrogenism or elevated testosterone). Negative test w/ low FSH suggests low estrogen state as is seen in hypothalamic amenorrhea from nutritional deficiency. Negative test w/ high FSH indicates ovarian insufficiency.
\end{itemize}

\hypertarget{management-4}{%
\subsubsection{Management}\label{management-4}}

\begin{itemize}
\tightlist
\item
  \textbf{PCOS:} hormonal contraception or cyclical provera 10mg/day x 10d to induce bleeding
\item
  \textbf{Irreversible hypopituitarism or ovarian insufficiency:} Premarin 0.625-2.5 mg/day or transdermal estrogen and Provera 10mg/day medroxyprogesterone 10-14 days per month.
\item
  \textbf{Hypothalamic amenorrhea related to nutritional deficiency:} energy re-balance/weight restoration
\end{itemize}

\hypertarget{gender-affirming-care}{%
\subsection{Gender Affirming Care}\label{gender-affirming-care}}

\hypertarget{why}{%
\subsubsection{Why}\label{why}}

One of our roles as providers of gender diverse youth is to combat the adverse experiences and risk factors for developing mental health disorders \textbf{by building safe communities for our patients and adopting a gender affirming approach to care.}

\hypertarget{how}{%
\subsubsection{How}\label{how}}

\begin{itemize}
\tightlist
\item
  Call patients by the name and pronouns that they tell you best describe them in all clinical settings.
\item
  Build our lexicon to help lead our co-workers by example in using appropriate and non-stigmatizing language to affirm the child's or adolescent's authentic self and gender identity (see gender-bread person below for review of terminology).
\item
  Ask about gender identity at routine healthcare visits.
\item
  Individuals who identify as transgender have \textbf{higher rates} of depression, anxiety, eating disorders, self-harm, and suicide compared to their cis-gendered peers. \textbf{Screen} for these when the opportunity arises and provide appropriate referrals/supports PRN.
\end{itemize}

\hypertarget{gender-affirming-care-clinics}{%
\subsubsection{Gender Affirming Care Clinics}\label{gender-affirming-care-clinics}}

\begin{itemize}
\tightlist
\item
  At BMC: CATCH
\item
  At BCH: GeMs
\end{itemize}

\hypertarget{the-genderbread-person}{%
\subsubsection{\texorpdfstring{\href{https://www.genderbread.org/}{The Genderbread Person}}{The Genderbread Person}}\label{the-genderbread-person}}

\begin{figure}
\centering
\includegraphics{images/adolescent_genderbread-person.png}
\caption{Genderbread Person}
\end{figure}

\hypertarget{eating-disorders-ed}{%
\subsection{Eating Disorders (ED)}\label{eating-disorders-ed}}

\hypertarget{anorexia-nervosa-an}{%
\subsubsection{Anorexia Nervosa (AN)}\label{anorexia-nervosa-an}}

\hypertarget{powerplans-order-sets-ebgs-2}{%
\paragraph{PowerPlans / Order Sets / EBGs}\label{powerplans-order-sets-ebgs-2}}

\begin{itemize}
\tightlist
\item
  Restrictive Eating Power Plan and Admission Orderset
\item
  Restrictive Eating EBG
\end{itemize}

\hypertarget{definition-4}{%
\paragraph{Definition}\label{definition-4}}

\begin{itemize}
\tightlist
\item
  Restriction of energy intake relative to requirements, leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health
\item
  Significantly low weight is defined as a weight that is less than minimally normal or, for children and adolescents, less than minimally expected
\item
  Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes w/ weight gain, even though at a significantly low weight
\item
  Disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight
\end{itemize}

\hypertarget{clinical-manifestations-3}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-3}}

Weight loss, abdominal pain, bloating, constipation, cold intolerance, lanugo, fatigue, weakness, delayed puberty

\hypertarget{physical-exam-2}{%
\paragraph{Physical Exam}\label{physical-exam-2}}

Low body temp, bradycardia, low blood pressure, orthostasis, lanugo, dry skin and hair, scalp hair thinning, scaphoid abdomen, palpable stool, breast atrophy, hypoestrogenized vaginal mucosa

\hypertarget{evaluation-3}{%
\paragraph{Evaluation}\label{evaluation-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} CBCd, UA, urine pregnancy, chem 10, LFTs, TFTs, and EKG
\item
  \textbf{Weight:} Compared to prior growth charts; calculate IBW based off of 50\% BMI for age (unless previously tracking on different percentile)
\end{itemize}

\hypertarget{inpatient-management}{%
\paragraph{Inpatient Management}\label{inpatient-management}}

\begin{itemize}
\tightlist
\item
  Restrictive Eating protocol

  \begin{itemize}
  \tightlist
  \item
    If 18yo+, then must sign contract in ED agreeing to protocol
  \end{itemize}
\item
  Goal is to medically stabilize (weight \textgreater80\% of IBW), VSS (HR \textgreater50, no longer orthostatic), electrolytes stable (monitor potassium, phos and mag)
\item
  Refeed gradually to target meal plan while monitoring for refeeding syndrome (watch for edema, low phos)
\item
  Weight increase of 0.2kg/day, supplement if not gaining weight; 1750-2000kcal diet to be increased by 250 kcal per day until goal calories met, meals per EBG (set time for meal, replace w/ 120\% ensure if \textless75\% complete (either PO or via NG))
\item
  Check electrolytes daily and supplement w/ PhosNaK and/or MVI if abnormal (at BCH the protocol is to start both supplements on admission)
\item
  Activity: Bed rest while orthostatic. No physical activity while inpatient; can earn wheelchair rides, bathroom privileges, etc.
\item
  Consults: Psychiatry, Nutrition
\item
  Supervision: Sitter if active SI, Security if elopement risk
\end{itemize}

\hypertarget{bulimia-nervosa-bn}{%
\subsubsection{Bulimia Nervosa (BN)}\label{bulimia-nervosa-bn}}

\hypertarget{definition-5}{%
\paragraph{Definition}\label{definition-5}}

\begin{itemize}
\tightlist
\item
  Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:

  \begin{itemize}
  \tightlist
  \item
    Eating, in a discrete period of time (eg, w/i any two-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances
  \item
    A sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating)
  \end{itemize}
\item
  Recurrent inappropriate compensatory behavior to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications; fasting; or excessive exercise
\item
  The binge eating and inappropriate compensatory behaviors both occur, on average, at least once a week for three months
\item
  Self-evaluation is unduly influenced by body shape and weight
\item
  The disturbance does not occur exclusively during episodes of anorexia nervosa
\end{itemize}

\hypertarget{clinical-manifestations-4}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-4}}

See AN, PLUS: Esophagitis and cavities

\hypertarget{physical-exam-3}{%
\paragraph{Physical Exam}\label{physical-exam-3}}

See AN, PLUS: Calluses on fingers, cavities, and tooth decay

\hypertarget{evaluation-4}{%
\paragraph{Evaluation}\label{evaluation-4}}

See AN

\hypertarget{inpatient-management-1}{%
\paragraph{Inpatient Management}\label{inpatient-management-1}}

See AN, PLUS: Purge precautions (no bathroom privileges (use bedside commode), room searches)

\hypertarget{acute-refusal-of-food-intake-disorder-arfid}{%
\subsubsection{Acute Refusal of Food Intake Disorder (ARFID)}\label{acute-refusal-of-food-intake-disorder-arfid}}

\hypertarget{powerplans-order-sets-ebgs-3}{%
\paragraph{PowerPlans / Order Sets / EBGs}\label{powerplans-order-sets-ebgs-3}}

ARFID protocol and PowerPlan

\hypertarget{definition-6}{%
\paragraph{Definition}\label{definition-6}}

\begin{itemize}
\tightlist
\item
  Persistent failure to meet appropriate nutritional and/or energy needs associated w/ one (or more) of the following:

  \begin{itemize}
  \tightlist
  \item
    Significant weight loss\\
  \item
    Significant nutritional deficiency
  \item
    Dependence on eneteral feeding or oral nutritional supplements
  \item
    Marked interference w/ psychosocial functioning
  \end{itemize}
\item
  Disturbance not better explained by lack of available food
\item
  \textbf{No evidence of a disturbance in body image}
\end{itemize}

\hypertarget{pathophysiology-2}{%
\paragraph{Pathophysiology}\label{pathophysiology-2}}

\begin{itemize}
\tightlist
\item
  Patients w/ autism, ADHD, and intellectual disabilities are more likely to develop ARFID
\item
  Often have co-occurring anxiety disorder; high risk for other psychiatric disorders
\end{itemize}

\hypertarget{clinical-manifestations-5}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-5}}

See AN, PLUS: Fear of choking or vomiting, limited range of preferred foods becomes narrower over time, will only eat certain textures of food, etc.

\hypertarget{evaluation-5}{%
\paragraph{Evaluation}\label{evaluation-5}}

See AN

\hypertarget{inpatient-management-2}{%
\paragraph{Inpatient Management}\label{inpatient-management-2}}

\begin{itemize}
\tightlist
\item
  ARFID protocol
\item
  Often requires enteral nutrition (many patients will go home on enteral feeds)
\end{itemize}

\hypertarget{references}{%
\subsection{References}\label{references}}

\textbf{Additional Resources:}

\href{https://www.adolescenthealth.org/Training-and-CME/Adolescent-Medicine-Resident-Curriculum.aspx}{Society for Adolescent Health \& Medicine Resident Curriculum}

\hypertarget{allergy-and-immunology}{%
\section{Allergy and Immunology}\label{allergy-and-immunology}}

\hypertarget{adverse-drug-reactions}{%
\subsection{Adverse Drug Reactions}\label{adverse-drug-reactions}}

\hypertarget{type-a-vs-b-adrs}{%
\subsubsection{Type A vs B ADRs}\label{type-a-vs-b-adrs}}

\hypertarget{type-a}{%
\paragraph{Type A}\label{type-a}}

\begin{itemize}
\tightlist
\item
  Predictable, dose dependent (ex overdose, SEs, drug interactions. 85-95\%
\end{itemize}

\hypertarget{type-b}{%
\paragraph{Type B}\label{type-b}}

Unpredictable hypersensitivity reactions (intolerance, idiosyncracy, immunologic). 10-15\%.
I - Immediate (mins-hrs) - IgE mediated
- Anaphylaxis, angioedema, hives, hypotension, N/V/D
II - Delayed (variable) - Cytotoxic
- Hemolysis, thrombocytopenia, neutropenia
III - Delayed (weeks) - Immune-complex
- Serum sickness, arthus reaction, vasculitis
IV - Delayed (days to weeks) - Cell-mediated
- Contact dermatitis, SJS/TEN, DRESS

\#\#\# Organ-specific ADRs
\textbar{} Exanthems \textbar{} Diffuse fine macules/papules days after drug initiation \textbar{} Allopurinol, aminopenicillins, cephalosporins, AEDs, sulfonamides \textbar{}
\textbar------------------------\textbar------------------------------------------------------------------------------------------------------------\textbar-------------------------------------------------------------------\textbar{}
\textbar{} Urticaria / Angioedema \textbar{} W/in minutes of drug initiation \textbar{} B-lactam antibiotics, ACEi \textbar{}
\textbar{} Fixed Eruption \textbar{} Hyperpigmented plaques that recur in same site \textbar{} Tetracyclines, NSAIDs, carbamazepine \textbar{}
\textbar{} Pustules \textbar{} Acneiform, Acute generalized eczematous pustulosis \textbar{} Steroids, sirolimus, antibiotics, CCBs \textbar{}
\textbar{} Bullous \textbar{} Tense or flaccid blisters \textbar{} Furosemide/vanco, capropril/penicillamine \textbar{}
\textbar{} SJS \textbar{} Fever, erosive stomatitis, ocular involvement, purpuric macules (face, trunk) w/ \textless10\% epidermal detachment \textbar{} Sulfa antibiotics, AEDs, oxicam NSAIDs, and allopurinol \textbar{}
\textbar{} TEN \textbar{} Similar to SJS but w/ \textgreater{} 50\% epidermal detachment \textbar{} Same as SJS, mortality as high as 50\% \textbar{}
\textbar{} Lupus (skin) \textbar{} Erythematous / scaly plaques in photodistribution \textbar{} Hydrochlorothiazide, CCB, ACEis \textbar{}
\textbar{} Hematologic \textbar{} Hemolytic anemia, thrombocyto/granulocytopenia \textbar{} Penicillin, quinine, sulfonamides \textbar{}
\textbar{} Hepatic \textbar{} Hepatitis, cholestatic jaundice \textbar{} acetaminophen, sulfonamides \textbar{}
\textbar{} Pulmonary \textbar{} Pneumonitis, fibrosis \textbar{} Bleomycin, Nitrofurantoin, MTX \textbar{}
\textbar{} Renal \textbar{} Interstitial nephritis, MGN \textbar{} Penicillin, sulfonamides, allopurinol \textbar{}

\#\#\# Multiorgan ADRs
\textbar{} Anaphylaxis \textbar{} Urticaria/angioedema, bronchospasm, GI sx, hypoTN \textbar{} B-lactam antibiotics, monoclonal Abs \textbar{}
\textbar----------------\textbar-------------------------------------------------------------\textbar----------------------------------------------\textbar{}
\textbar{} DRESS \textbar{} Cutan. eruption, fever, eosinophilia, hep. dysfunction, LAD \textbar{} AEDs, sulfonamides, minocyc., allopurinol \textbar{}
\textbar{} Serum Sickness \textbar{} Urticaria, morbiliform rash, arthralgias, fever \textbar{} Heterologous abs, infliximab, bactrim, PCN \textbar{}
\textbar{} SLE \textbar{} Arthralgias, myalgias, fever, malaise \textbar{} Hydralazine, Procainamide, Isoniazid \textbar{}
\textbar{} Vasculitis \textbar{} Cutaneous or visceral vasculitis \textbar{} Hydralazine, penicillamine, propylthiouracil \textbar{}

\#\#\# Desensitization
\textbf{Definition}: give increasing doses over hours -\textgreater{} mast cells/basophils unreactive to Ag activation (only for Type I HSRs)
\textbf{Result}: Temporary tolerance -\textgreater{} patient can receive the drug at usual intervals. When drug is stopped, desensitization ends (d-wk)

\#\# Anaphylaxis

\#\#\# Definition
Acute, life threatening systemic HSR (min-hrs) w/ \textgreater= 1/3 of the following criteria:
- \textbf{Hives plus another system}: acute onset illness (mins-hrs) involving skin/mucosa, or both, and \textgreater= 1 of the following: respiratory compromise, reduced BP or symptoms of end-organ dysfunction
- \textbf{Two systems involved}: \textgreater= 2 of the following must occur rapidly after exposure to a likely allergen (mins-hrs): skin-mucosal involvement, respiratory compromise, reduced BP or associated symptoms of end-organ dysfunction, persistent GI symptoms
- \textbf{Hypotension}: reduced BP after exposure to known allergen (mins-hrs)

\#\#\# Allergens
-Meds (B-lactams, ASA/NSAIDs), food, insects, cold/heat, exercise, latex

\#\#\# Clinical
-Skin involvement in 90\%, respiratory in 70\%, CV (hypotension) in 45\%, GI in 45\%
-Monitor for biphasic reaction (4-25\% occurrence)- sx recur w/in 10h (but up to 72h)

\#\#\# Severe Reaction
-Hypotension w/ wide PP, AMS/confusion, syncope, cyanosis, dyspnea, hypoxia

\#\#\# Management
\textbf{Emergent}
\includegraphics{images/Allergy_Immunology_flowsheet_1.png}

\textbf{Inpatient}
\includegraphics{images/allergy_immunology_flowsheet_2.png}

\#\#\# Med Dosing
- Epinephrine IM (1 mg/mL) - 0.01 mg/kg (\textless10 kg), 0.15 mg/kg (10-25kg), 0.3 (\textgreater25 kg)
- Cetirizine - 2.5 mg (6mo-2 yrs), 5 mg (2-5 yrs), 10 mg (≥6 yrs)
- Diphenhydramine - 1 mg/kg IV/PO (max 50 mg)
- Dexamethasone 0.6 mg/kg (max 16 mg) OR methylprednisolone 1 mg/kg (max 60)
- Ranitidine - 2 mg/kg PO (max 150 mg) OR 1 mg/kg IV (max 60 mg)

\#\#\# ED Discharge Criteria
No hypotension, resolved wheezing, ≤ 2 doses of Epi

\#\#\# Post-discharge Treatment
3 days of Cetirizine daily, consider ranitidine, f/u with PCP/Allergy

\#\# Primary Immunodeficiencies

\#\#\# Pathophysiology
- Genetic defects in the adaptive (B- or T-cell) or innate (phagocytes, complement) immune systems lead to recurrent infections
- Over 200 distinct disorders: B cell defects (65\%), combined B and T cell deficiencies (15\%), phagocytic disorders (10\%), T cell deficiencies (5\%), and complement deficiencies/others (5\%)

\#\#\# Epidemiology
The overall incidence is 1:10000, and overall prevalence is 1:2000.

\#\#\# Clinical
- Can be nonspecific and broad
\textbf{Constitutional}: Poor growth, failure to thrive
\textbf{GI}: chronic diarrhea.
\textbf{Derm}: Atopic and non-atopic dermatitis, severe diaper rash, neonatal rash, anhydrosis, as well as delayed separation of the umbilical cord (LAD)
\textbf{Immuno}: Recurrent infections, autoimmunity
Family history of consanguinity or family history of immunodeficiency or unexplained childhood deaths puts a child at higher risk of having or developing a primary immunodeficiency

\#\#\# Physical Exam
\textbf{Vital signs}: Growth parameters
\textbf{General exam}: Note dysmorphisms, including teeth and hair (abnormal in NEMO). Look for infectious sources (sinusitis, otitis, pneumonia, thrush, diaper rash)
\textbf{HEENT exam}: Note tonsils (absent in XLA) and examine for thrush and other signs of infection such as sinusitis or recurrent otitis media
\textbf{CV exam}: Note any cardiac anomalies including heart sounds, pulses, perfusion, and overall volume status as cardiac anomalies can be a part of certain syndromes associated w/ immunodeficiency syndromes (e.g.: DiGeorge Syndrome)
\textbf{Respiratory}: Note symmetry of lung exam, quality of air entry, and lung sounds as pulmonary anomalies may be a manifestation of immunodeficiency syndromes
\textbf{GI}: A thorough GI exam including abdominal exam for elements like hepatosplenomegaly and rectal exam for possible anal atresia is important
\textbf{GU}: Primary immunodeficiencies can also lead to GU anomalies; assess for absence/presence of appropriate male/female organs in the correct number
\textbf{Derm exam}: Skin exam for eczema/dermatitis (i.e.~WAS, SCID, hyper IgE syndrome) as well as erythroderma (Omenn Syndrome). Note telangiectasia (AT), warts, granulomas, poor wound healing or ulcers
\textbf{Neuro}: A thorough neuro exam may also hint at the etiology of an immunodeficiency (ataxia-telangiectasia), an infection such as meningitis, or may help elucidate an alternate cause of symptoms

\#\#\# Diagnosis
\textbf{Initial labs}: CBC w/ differential (note especially lymphopenia), chem7, albumin, urinalysis, ESR, CRP, quantitative immunoglobulins (IgG, IgA, IgM, IgE), specific vaccine antibody studies (tetanus, HiB, pneumococcal).
\textbf{Follow-up labs}: HIV testing. B- and T-cell subset, complement screening (C3, C4, AH50, CH50), vaccine challenge (administer pneumococcal or other vaccine and measure titers 4-6 weeks later), Dihydrorhodamine (DHR) assay (CGD). Leukocyte adhesion defect testing (LAD).
\textbf{Advanced lab analysis}: T cell proliferation studies (mitogen, antigen), T and B cell memory panels, NK cell function assays, Toll-like receptor assays. Immunodeficiency genetic panel. Whole exome or whole genome sequencing.

\#\#\# Treatment
Varies widely based upon the deficiency. Common therapies include prophylactic antibiotics, IVIG, bone marrow transplant.

\#\# Indications for a Primary Immunodeficiency Evaluation
- ≥8 ear infections w/i one year
- \textgreater2 serious sinus infections w/i one year
- \textgreater2 pneumonias w/i one year
- FTT, poor weight gain, or abnormal growth parameters
- Abnormal physical exam suggestive of syndrome
- Recurrent skin or organ abscesses
- Persistent thrush (mouth/skin), at \textgreater12 months of age
- Severe or overwhelming infection

\begin{itemize}
\tightlist
\item
  Infection w/ unusual organisms
\item
  Need for intravenous antibiotics to clear infections
\item
  Infections w/ opportunistic organisms (Aspergillus, Pneumocystis)
\item
  Severe forms of viral infections (HSV, VZV, EBV)
\item
  Complications from a live vaccine
\item
  A family history of primary immunodeficiency
\item
  Abn. TRECs on newborn screen x2
\item
  Abn. screening CBC (profound leukopenia, lymphopenia, eosinophilia)
\end{itemize}

\#\# Diagnostic Approach to Primary Immunodeficiencies

\#\#\# Initial Labs (most cases)
- CBC w/ differential
- Quantitative immunolgobulins (IgG, IgA, IgM, IgE)
- Specific antibody studies (tetanus, HiB (PRP), pneumococcal)

\#\#\# Next Step
(include w/ initial labs if suspicious of specific disorder)
- B- and T-cell subsets
- T cell proliferation studies (mitogen, antigen)
- Complement screening (CH50, AH50, C3, C4)
- DHR (dihydrorhodamine assay for CGD)

\#\#\# Advanced
(Depending on specific history)
- T and B cell memory panels
- NK cell function assay
- Toll-like receptor studies
- Specific genetic testing

\#\# Classification of Primary Immunodeficiencies

\#\#\# B-cell (Humoral): decreased B-cell numbers and/or impaired antibody production

\#\#\#\# Diseases
- X-linked agammaglobulinemia
- Transient hypogammaglobulinemia of infancy
- IgA or IgG selective Ig deficiency

\#\#\#\# Clinical Manifestations
- Presents \textless12 mo old (3-6 mo, due to loss of maternal antibody)
- Bacterial infxn (sinusitis, otitis, pneumonia)
- Chronic diarrhea, FTT
- Bronchiectasis
- Enteroviral meningoencephalitis (chronic)

\#\#\#\# Organisms
-Encapsulated: S. pneumo, HiB, N. meningitidis, S. typhi
-GI: Giardia, Campylobacter
-Also: S. Aureus, Pseudomonas, Enteroviral meningoencephalitis

\#\#\#\# Vaccine Issues
Do not give live vaccines for severe defects. Vaccination is not necessary if on IgG replacement. Effectiveness of other vaccines is uncertain

\#\#\# T-cell Defects (Cellular): lack of or decreased number of T-cells

\#\#\#\# Diseases
DiGeorge Syndrome, SCID (T-/B+)

\#\#\#\# Clinical Manifestations
- Presents at birth/early infancy
- Mucocutaneous candidiasis
- Severe viral infections
- Bacterial, fungal, opportunistic infections
- Warts or severe eczema
- Chronic diarrhea, FTT

\#\#\#\# Organisms
- Candida, PJP, Mycobacterium, S. typhi
- VZV, HSV, CMV

\#\#\#\# Vaccine Issues
Do not give live virus vaccines if substantial T cell defect

\#\#\# Combined B/T Cell Defect

\#\#\#\# Diseases
- SCID (T-/B-)
- CVID
- Wiskott-Aldrich syndrome
- Ataxia-telangiectasia
- X-linked lymphoproliferative disease (XLP)
- Hyper IgE syndrome
- DOCK8 deficiency
- ZAP70 deficiency

\#\#\#\# Clinical Manifestations
- Presents during 1st year of life. XLP/CVID can present as teens/adults
- Infections (sinusitis, otitis, pneumonia)
- Abscesses (recurrent)
- Chronic diarrhea, gastroenteritis, FTT
- Mucocutaneous candidiasis
- Viral/opportunistic/fungal infections
- Increased cancer risk

\#\#\#\# Organisms
- Candida, PJP, Mycobacterium, encapsulated bacteria
- VZV, HSV, CMV infections

\#\#\#\# Vaccine Issues
Do not give live vaccines (OPV, BCG, smallpox, YF, live influenza, MMR, MMRV, rotavirus). Effectiveness of other vaccines is uncertain.

\#\#\# Phagocytic Defects

\#\#\#\# Diseases
- Chronic granulomatous disease (CGD), Leukocyte adhesion deficiency (LAD)
- Chediak-Higashi syndrome (CHS)

\#\#\#\# Clinical Manifestations
- Typically presents in infancy
- Poor wound healing
- Delayed separation of the umbilical cord (LAD)
- Lymphadenitis/abscesses
- Catalase (+) bacterial infections (CGD)
- Candidiasis
- Chronic gingivitis, oral disease
- Hepatosplenomegaly

\#\#\#\# Organisms
- Catalase (+) bacteria:
-- S aureus
-- Pseudomonas
-- Burkholderia cepacia
-- Nocardia
-- Enterobacteria erratia and Klebsiella
- Fungal infections:
-- Aspergillus
-- Candida albicans

\#\#\#\# Vaccine Issues
- Live viral vaccines contraindicated in CH \& LAD, but OK in CGD
- Live bacterial vaccines are contraindicated. Other vaccines are safe/ effective

\#\#\# Complement Defects

\#\#\#\# Diseases
Classical pathway:
- C1q, Cqr, C1s, C2, C4
- Hereditary angioedema (C1-est)
- C2: most common in Causasians

Lectin pathway:
- MBL, M-/L-/H-ficolin, CL-11, MASPs

Alternative pathway:
- Factors D, B, and properdin

\#\#\#\# Clinical Manifestations
- Can present at any age
- Angioedema of the face, lips, hands, feet, GI tract, throat (C1-inh)
- Recurrent sinopulmonary infections
- Bacteremia/pyogenic bacterial infections
- Meningitis
- Autoimmune disease (lupus-like)
- Often autosomal dominant inheritance
- Associated w/ atypical HUS

\#\#\#\# Organisms
Encapsulated bacteria, Neisseria

\#\#\#\# Vaccine Issues
- No vaccine contraindications
- Refer to CDC guidelines re: additional vaccinations for protection against encapsulated bacteria

\#\# Selected Primary Immunodeficiencies
\textbar{} Disorder \textbar{} Cell \textbar{} Gene \textbar{} Age \textbar{} Presentation \textbar{} Labs \textbar{}
\textbar-----------------------------------------\textbar---------------------------------------------\textbar-----------------------------------------------------\textbar--------------------------\textbar-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\textbar----------------------------------------------------------------------------------------------------------------------------------------------------------------\textbar{}
\textbar{} Chediak-Higashi Syndrome (CHS) \textbar{} Phagocyte \textbar{} CHS1, AR \textbar{} Infancy \textbar{} -Oculocutaneous albinism, recurrent pyogenic infections (S. aureus) -May present with accelerated phase or HLH: fever, jaundice, hepatosplenomeglay, lymphadenopathy, bleeding, neurologic changes -Lysosomes unable to fuse with phagosomes to lyse bacteria \textbar{} -Neutropenia -Giant lysosomal granules in neutrophils -Impaired T/NK cell function \textbar{}
\textbar{} Chronic Granulomatous Disease (CGD) \textbar{} Phagocyte \textbar{} Multiple phagocyte oxidases (gp91phox), X-linked/AR \textbar{} Infancy-adult, most \textless5yo \textbar{} -Recurrent bacterial/fungal infections, often w/ encapsulated and catalase-positive organisms -Granulomas and cold abscesses, both superficial and deep -Inability of neutrophils to generate oxidative burst, but chemotaxis and phagocytic function intact \textbar{} -Normal neutrophil count -Reduced superoxide production when stimulated in vitro -DHR assay \textbar{}
\textbar{} Selective IgA Deficiency \textbar{} B-cell \textbar{} - \textbar{} \textgreater4yo \textbar{} -Most patients (85-90\%) are asymptomatic -Recurrent sinopulmonary infection (H. influenzae, S. pneumo), Giardia lamblia infections, autoimmune disease -Increased risk of anaphylaxis to blood products \textbar{} -Low IgA, normal IgG/M \textbar{}
\textbar{} X-linked Agammaglobulinemia (XLA) \textbar{} Complete absence of mature B-cells \textbar{} BTK, X-linked recessive \textbar{} 3-18mo \textbar{} -Recurrent bacterial infections: sinuses, ear, lung (S. pneumo, HIB, S. pyogenes, Pseudomonas) -Exam: absent tonsils and adenoids \textbar{} -Low levels of IgG, IgM, IgA -Reduced/absent CD19/20 B-cells \textbar{}
\textbar{} DiGeorge Syndrome \textbar{} Normal to severe T-cell immunodef \textbar{} Del. 22q11.2 \& 10p13-14 \textbar{} Infancy \textbar{} -Triad: hypoplastic thymus, conotruncal cardiac/aortic arch defects, hypoparathyroidism -Characteristic faces: low set ears, ocular hypertelorism, bulbous nasal tip \textbar{} -Hypocalcemia -Reduced CD3+ T cells -Abnormal cardiac echo \textbar{}
\textbar{} Ataxia Telangiectasia (AT) \textbar{} B- and T-cell \textbar{} ATM, AR \textbar{} \textgreater1yo \textbar{} -Progressive cerebellar ataxia, oculocutaneous telangiectasia, diminished/absent deep tendon reflexes -Recurrent sinopulmonary infections -Increased risk of malignancy \textbar{} -Selective IgA deficiency -Low T-cell numbers -Elevated serum AFP \textbar{}
\textbar{} Common Variable Immunodeficiency (CVID) \textbar{} Impaired T-cell function, B-cell maturation \textbar{} - \textbar{} Childhood-Adolescence \textbar{} -Recurrent sinopulmonary infections, autoimmunity, chronic lung disease -Poor response to protein, polysaccharide vaccines (tetanus, PCV) \textbar{} -Significantly reduced IgG -Reduced IgA and/or IgM \textbar{}
\textbar{} Hyper IgE Syndrome \textbar{} B- and T-cell \textbar{} STAT3, AD \textbar{} First wks of life \textbar{} -Papulopustular rash, skin abscesses (S. aureus), eczema, retained primary teeth -Coarse/thickened facial features, frontal bossing, wide alar base of nose \textbar{} -Eosinophilia -Elevated IgE \textbar{}
\textbar{} Severe Combined Immunodeficiency (SCID) \textbar{} B- and T-cell, depending on the type \textbar{} Multiple (RAG1, RAG2, ADA, Artemis, IL2RG) \textbar{} Part of newborn screen \textbar{} -Persistent mucocutaneous candidiasis, FTT, recurrent fevers, chronic diarrhea -Infections with adenovirus/CMV/EBV/RSV can be fatal -Live-attenuated vaccines can be fatal -Immunologic emergency: positive pressure room, urgent work-up and evaluation for bone marrow transplant \textbar{} -NBS: low TRECs -CXR: absence of thymic shadow -Absolute T-cell count \textless300, abnormal T-cell proliferation studies, presence of maternal T-cells in circulation \textbar{}

\#\# Selected Immunodeficiencies
\textbar{} Wiskott-Aldrich Syndrome \textbar{} B- and T-cell \textbar{} WAS X-linked \textbar{} Infancy \textbar{} -Triad: thrombocytopenia (small platelets), eczema, immunoglobulin abnormalities -Chronic otitis media/sinusitis, infection with encapsulated organisms \textbar{} -IgG nml, IgM low, IgA/E elevated -Decreased number of T cells -Thrombocytopenia \textbar{}
\textbar--------------------------------------------\textbar---------------\textbar-------------------------\textbar-----------\textbar---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\textbar--------------------------------------------------------------------------------------------------------\textbar{}
\textbar{} X-linked Lymphoproliferative Disease (XLP) \textbar{} T- and B-cell \textbar{} XLP/SH2D 1A, X-linked R \textbar{} Childhood \textbar{} -Fulminant EBV infection (often w/ hepatitis, hepatosplenomegaly, liver failure), often causing secondary hemophagocytic lymphohistiocytosis or aplastic anemia -Inc risk of malignancy, especially lymphoma \textbar{} -B/T cell numbers normal; function is abnormal -IgG is low, IgM is increased -Anemia, thrombocytopenia \textbar{}

\#\# Specific Antibody Deficiencies
\textbar{} \textbar{} Presentation \textbar{} IgG \textbar{} IgA \textbar{} IgM \textbar{} IgG subclass \textbar{} Vaccine response \textbar{} B cells \textbar{}
\textbar------------------------------\textbar-----------------------------------------------------------------------------\textbar-----\textbar-----------\textbar------------\textbar-------------------\textbar------------------\textbar---------\textbar{}
\textbar{} Subclass deficiency \textbar{} Recurrent severe infections (controversial) \textbar{} NL \textbar{} NL \textbar{} NL \textbar{} At least 1 is low \textbar{} LOW \textbar{} NL \textbar{}
\textbar{} Selective IgA Deficiency \textbar{} Asymptomatic or associated w/ autoimmune, GI, atopic disorders \textbar{} NL \textbar{} LOW \textbar{} NL \textbar{} NL \textbar{} NL OR LOW \textbar{} NL \textbar{}
\textbar{} Hyper IgM Syndrome \textbar{} Severe infections, including PJP \textbar{} LOW \textbar{} LOW \textbar{} NL OR HIGH \textbar{} LOW \textbar{} LOW \textbar{} NL \textbar{}
\textbar{} Specific Antibody Deficiency \textbar{} Often asymptomatic, inadequate antibody response to polysaccharide antigen \textbar{} NL \textbar{} NL \textbar{} NL \textbar{} NL \textbar{} LOW \textbar{} NL \textbar{}
\textbar{} CVID \textbar{} Recurrent infections \textbar{} LOW \textbar{} NL OR LOW \textbar{} NL OR LOW \textbar{} LOW \textbar{} LOW \textbar{} NL \textbar{}

\#\# Characteristics of Selected SCID disorders

\#\#\# T-, B+, SCID

\#\#\#\# Gene defects
- IL2RG (most common form, X-linked)
- JAK3
- IL7RA
- IL2RA
- CD3D/E/Z
- PTPRC
- CORO1A
- ZAP70

\#\#\#\# Treatment
Bone marrow transplant or gene therapy (IL2RG)

\#\#\# T-, B-, SCID

\#\#\#\# Gene defects
- RAG1/RAG2 (common)
- Artemis (common)
- Adenosine deaminase (ADA, common)
- PRKDC
- AK2
- LIG4
- Cernunnos (NHEJ1)

\#\#\#\# Treatment
- Bone marrow transplant or gene therapy (ADA)
- ADA can be treated w/ gene therapy or enzyme replacement

\#\# General Approach to the Immunodeficient Patient

Approaching the immunodeficient patient in clinic:
- See indications for testing/tests above.
- Is antibiotic prophylaxis indicated?
- Can they receive immunizations? If they can, have they mounted a sufficient immune response to vaccines (ie. do they need vaccine titers)?
- Low threshold for antibiotic use in the event that infection is suspected.

Managing a sick immunodeficient patient:
- Obtain blood culture and labs.
- Give antibiotics/antivirals promptly.
- Determine whether imaging/surgery is indicated (ie. drain an abscess).
- Be aware of blood products given. Blood may need to be from CMV- donors, filtered to remove WBCs, and irradiated.
- Replace missing immune components (ie. IVIG)

\hypertarget{cardiology}{%
\section{Cardiology}\label{cardiology}}

\hypertarget{cardiology-rotation-tips}{%
\subsection{Cardiology Rotation Tips}\label{cardiology-rotation-tips}}

\hypertarget{team-structure}{%
\paragraph{Team Structure}\label{team-structure}}

\begin{itemize}
\tightlist
\item
  \textbf{1 Fellow:} Should be your first stop for everything. \textbf{Trust them!} They are fantastic and want to teach.
\item
  \textbf{4 Residents:} One will be on outpatient, one post-call (but will round), two there all morning
\item
  \textbf{Attendings} (usually 4-5 of them):

  \begin{itemize}
  \tightlist
  \item
    \textbf{General Cardiology:} Most patients are usually on this team.
  \item
    \textbf{Heart Failure/Transplant:} You will always round w/ the attending on this team, sometimes there will be a fellow too.
  \item
    \textbf{BACH:} Adult congenital. You will round w/ the BACH attending and fellow.
  \item
    \textbf{Electrophysiology (EP):} You should see the fellow every day.
  \item
    \textbf{Pulmonary Hypertension:} You will occasionally have patients on this service and will round w/ the attending.
  \item
    \textbf{Primary Attending:} Cardiology is a team sport, meaning there are multiple physicians on the care team. This is the patient's longitudinal cardiologist who will check in periodically.
  \end{itemize}
\item
  Of note, there is also an \textbf{NP team.} This team is separate from the MD team during the day, but \textbf{you will cross-cover them overnight and on weekends/holidays} (which means when you are overnight, you will need to signout to the NP team in the morning).
\end{itemize}

\hypertarget{admissions}{%
\paragraph{Admissions}\label{admissions}}

You will have a few types of admissions. The main ones will be from the CICU, from the ED, and post-cath:

\begin{itemize}
\tightlist
\item
  \textbf{CICU admission:} Go with fellow to 8S (bring a COW) to get sign-out directly from the team caring for the patient. Write transfer note, enter transfer accept order, and perform transfer med rec.
\item
  \textbf{ED admission:} Just like any other admission, except the cardiology fellow sees them in the ED and there is a consult note
\item
  \textbf{Post-cath:} Usually you won't get signout on this patient. The fellow will get some signout from the patient's primary cardiologist. Ask them for more information and do some chart review for more information.
\end{itemize}

\hypertarget{resources}{%
\paragraph{Resources}\label{resources}}

\begin{itemize}
\tightlist
\item
  \textbf{Medical Team Coordinator:} Should be your first stop for questions on basically everything non-medical. This includes scheduling a procedure, getting prior authorization for medications, discharge planning, how to put in a specific order, where the food is - really, anything and everything. They are AMAZING.

  \begin{itemize}
  \tightlist
  \item
    Will also send you a welcome email before the rotation w/ excellent resources. Try to read them!
  \end{itemize}
\item
  \textbf{Fellow:} Cardiology is a great time to learn and the fellows are excited about the heart and want to teach. Don't be afraid to ask them questions about the physiology and pathophysiology.
\item
  \textbf{Attendings:} Similarly excited to teach. Many of them will bring a whiteboard on rounds and draw out the physiology of the patient. Feel free to ask them to do so if you want to learn more!
\end{itemize}

\hypertarget{disaster-planning}{%
\subsection{Disaster Planning}\label{disaster-planning}}

\hypertarget{know-and-use-your-resources}{%
\paragraph{Know and use your resources!!!}\label{know-and-use-your-resources}}

\begin{itemize}
\tightlist
\item
  \textbf{Fellow:} Should always be your first call. Run the list w/ them multiple times a day and at night. Before they go lie down, ``disaster round'' w/ them and ask all the questions you have about what to do if X happens to Y patient.
\item
  \textbf{Nurses:} They have been doing this for longer than we have and know these patients incredibly well. Ask them for tips as well. On midnight rounds, always say hello and ask them what they are worried about for each patient.
\item
  \textbf{Code cards:} Carry them w/ you. They have lots of great information on them!
\item
  \textbf{CICU:} They are right next door and can get over to the general cardiology floor very quickly. Don't be afraid to call them. Always better to over call than under call them.
\end{itemize}

\hypertarget{ekg-approach}{%
\subsection{EKG Approach}\label{ekg-approach}}

\begin{itemize}
\tightlist
\item
  \textbf{Paper speed:} Standard 25mm/s → Small box = 0.04s, Big box = 0.2s
\item
  \textbf{Standardization marker:}

  \begin{itemize}
  \tightlist
  \item
    2 big boxes tall = ``full standard'' and 10 mm = 1 mV
  \item
    1 big box tall = ``half standard'' and 5 mm = 1 mV
  \item
    Limb leads can be in full standard while the precordial are in half standard
  \end{itemize}
\end{itemize}

\includegraphics{images/cardiology_standardization-marker.png}

\hypertarget{ventricular-rate}{%
\subsubsection{Ventricular Rate}\label{ventricular-rate}}

\begin{itemize}
\tightlist
\item
  300-150-100-75-60-50 rules if the rhythm is regular, OR
\item
  Count the number of QRS complexes in the rhythm strip (10 seconds) and multiply by 6 (works even if the rhythm is irregular)
\end{itemize}

\hypertarget{rhythm}{%
\subsubsection{Rhythm}\label{rhythm}}

\begin{itemize}
\tightlist
\item
  \textbf{Sinus rhythm} = (1) P before every QRS, (2) QRS after every P, and (3) Normal P axis (0-90°, upright P waves in I and aVF)
\end{itemize}

\hypertarget{qrs-axis}{%
\subsubsection{QRS Axis}\label{qrs-axis}}

\begin{itemize}
\tightlist
\item
  \textbf{Determine axis} by looking at leads I and aVF:

  \begin{itemize}
  \tightlist
  \item
    ↑ in I, ↑ in aVF = axis between 0 and +90°
  \item
    ↑ in I, ↓ in aVF = axis between -90 and 0°
  \item
    ↓ in I, ↓ in aVF = axis between -90 and 180°
  \item
    ↓ in I, ↑ in aVF = axis between +90 and 180°
  \end{itemize}
\item
  Once you've identified axis quadrant, \textbf{find the most isoelectric limb lead:}

  \begin{itemize}
  \tightlist
  \item
    The QRS axis is 90° away from the most isolelectric lead
  \item
    Normal axis varies w/ age (newborn = rightward b/c RV dominance in utero, childhood = leftward b/c LV becomes dominant)
  \item
    Superior axis = AV canal defects, tricuspid atresia and large VSD or left anterior hemiblock
  \item
    Leftward axis in a cyanotic newborn is highly suggestive of tricuspid atresia
  \end{itemize}
\end{itemize}

\hypertarget{intervals-segments}{%
\subsubsection{Intervals \& Segments}\label{intervals-segments}}

\hypertarget{pr-interval}{%
\paragraph{PR interval}\label{pr-interval}}

Atrial depolarization (P wave) and delay at AV node (PQ segment)

\begin{itemize}
\tightlist
\item
  The normal PR interval increases w/ age
\item
  Prolonged PR intervals are seen in AV nodal block (heart block)
\item
  Short PR intervals are seen in pre-excitatory conditions such as WPW
\item
  Variable PR interval can be seen in wandering atrial pacemaker, multifocal atrial tachycardia and Wenkebach-type 2nd degree heart block
\item
  Depressed PR segment may be seen in pericarditis
\end{itemize}

\hypertarget{qrs-interval}{%
\paragraph{QRS interval}\label{qrs-interval}}

Ventricular depolarization

\begin{itemize}
\tightlist
\item
  The upper limit of normal increases w/ age (0.07 s in newborns to 0.12 s in adults)
\item
  A wide (prolonged) QRS is indicative of depolarization which proceeds independent of the His-Purkinje system or in which depolarization via the His-Purkinje system is aberrant
\item
  This is seen in ventricular arrhythmias, pre-excitation, IV conduction delays and BBB
\end{itemize}

\hypertarget{qt-interval}{%
\paragraph{QT interval}\label{qt-interval}}

Ventricular depolarization (QRS) and repolarization

\begin{itemize}
\tightlist
\item
  QTc normalizes QT interval accounting for HR, calculated w/ Bazett formula: QT (sec) / √RR(sec)
\item
  A normal QTc in the newborn = 0.47 s, it shortens in older children to 0.44, and then elongates to the normal adult values of approximately 0.45 s in men and 0.46 s in women
\item
  Prolonged QTc is seen in congenital long QT syndrome, electrolyte derangements (hypokalemia, hypomagnesemia and hypocalcemia), hypothermia and is caused or worsened by many medications
\end{itemize}

\hypertarget{q-wave}{%
\paragraph{Q wave}\label{q-wave}}

Ventricular septal depolarization, which proceeds from left-to-right and inferior-to-superior

\begin{itemize}
\tightlist
\item
  Small q waves should be seen in the inferior and left-facing leads (I,II,V5,V6 and III and aVF).
\item
  Duration should not exceed 0.04 sec and amplitude should not exceed 25\% of QRS wave in height
\item
  Abnormally tall or long Q-waves may represent ischemia
\item
  Q waves in V1 and V2 are \textbf{always abnormal}
\end{itemize}

\hypertarget{u-wave}{%
\paragraph{U wave}\label{u-wave}}

Small deflection often seen closely following the T wave, which may represent repolarization of the Purkinje fibers or after depolarizations w/i the ventricle

\begin{itemize}
\tightlist
\item
  A U wave is a normal finding if it is small (\textless25\% the amplitude of the T wave), there is an isoelectric segment between the T wave and U wave, and if the U wave is upright
\item
  If any of these features are not met, the U wave may be pathologic
\item
  Prominent U waves are seen most often seen in hypokalemia, but can also be seen in other electrolyte derangements, ventricular hypertrophy, LQTS and w/ antiarrhythmic therapy
\item
  Inverted U waves are concerning for ischemia, ventricular hypertrophy or cardiomyopathy
\item
  U waves are often more prominent at slow heart rates (\textless65 bpm)
\item
  If U waves are large (\textgreater25\% of the T wave amplitude) and there is no isoelectric segment between the T wave and U wave, they should be included in the QTc calculation (which becomes the QTUc)
\end{itemize}

\hypertarget{st-segment}{%
\paragraph{ST segment}\label{st-segment}}

Ventricular repolarization

\begin{itemize}
\tightlist
\item
  Elevation or depression \textgreater1mm in limb leads or \textgreater2mm in precordial leads is abnormal and is concerning for ischemia if seen in a territorial distribution (especially w/ reciprocal changes in other territories) or pericarditis if diffuse
\item
  Concave ``smiling'' ST-elevation is often normal, as seen in benign early repolarization, however convex ``frowning'' ST-elevation is ominous
\end{itemize}

\hypertarget{rs-progression}{%
\paragraph{R/S progression}\label{rs-progression}}

R/S ratio represents the ratio of left to right ventricular forces. R waves in the right precordial leads represent depolarization of the right ventricle, and S waves in these leads represent depolarization of the left ventricle. Pattern reversed in left precordial leads.

\begin{itemize}
\tightlist
\item
  In newborn period of a FT infant, the RV is dominant and as such the R wave in lead V1 should be greater than the S wave
\item
  As a child ages, the LV becomes progressively more dominant until late adolescence when an adult-type R/S progression is seen w/ small R waves and large S waves in V1 w/ large R waves and small S waves in V6
\end{itemize}

\hypertarget{t-waves}{%
\paragraph{T waves}\label{t-waves}}

\begin{itemize}
\tightlist
\item
  Normal T wave pattern varies w/ age

  \begin{itemize}
  \tightlist
  \item
    At birth, all T waves should be upright
  \item
    Over the first days of life, leads V1-V3 invert (V1 first, V3 last) and after 7-10 days of life it is pathologic for there to be upright T waves in lead V1 and represent RV strain if present
  \end{itemize}
\item
  It is normal for the T waves in leads V1-V3 to be inverted in children, and between the ages of \textasciitilde8-20yo these T waves start to become upright (V3 first, V1 last)

  \begin{itemize}
  \tightlist
  \item
    However, it is not abnormal for T wave inversion to persist into an individual's 20s, and this is called a persistent juvenile T wave
  \end{itemize}
\item
  It is \textbf{always abnormal} to see an inverted T waves in leads V5 + V6 (ischemia or ventricular strain)
\item
  Peaked T-waves are seen in hyperkalemia and elevated ICP and abnormally flat in hypokalemia
\end{itemize}

\hypertarget{chamber-size}{%
\subsubsection{Chamber Size}\label{chamber-size}}

\hypertarget{r-atrial-enlargement-rae}{%
\paragraph{R atrial enlargement (RAE)}\label{r-atrial-enlargement-rae}}

P wave height \textgreater2.5 mm (2.5 small boxes) in lead II or tall initial positive portion in V1

\hypertarget{l-atrial-enlargement-lae}{%
\paragraph{L atrial enlargement (LAE)}\label{l-atrial-enlargement-lae}}

P wave duration \textgreater2.5 small boxes (100 msec) in lead II. Notched in lead II or deep/wide terminal negative portion of p-wave in V1.

\hypertarget{l-ventricular-hypertrophy-lvh}{%
\paragraph{L ventricular hypertrophy (LVH)}\label{l-ventricular-hypertrophy-lvh}}

\begin{itemize}
\tightlist
\item
  R wave \textgreater{} 98th\% in I, II, aVL, V5, V6
\item
  S-wave \textgreater{} 98th\% in V1
\item
  Supported by:

  \begin{itemize}
  \tightlist
  \item
    Inverted T in V5 or V6 (strain pattern)
  \item
    Left axis deviation
  \item
    Left atrial enlargement
  \end{itemize}
\end{itemize}

\hypertarget{r-ventricular-hypertrophy-rvh}{%
\paragraph{R ventricular hypertrophy (RVH)}\label{r-ventricular-hypertrophy-rvh}}

\begin{itemize}
\tightlist
\item
  R wave \textgreater98th\% in aVR, V1, V2, V4R (or pure R wave \textgreater{} 10 mm)
\item
  S wave \textgreater98th\% in I, V5, V6
\item
  qR pattern in V1
\item
  Upright T in V1 (pre-adol.) suggests RV strain
\item
  Right axis deviation
\end{itemize}

\hypertarget{strain}{%
\paragraph{Strain}\label{strain}}

QRS-T angle \textgreater{} 90° (diff. between QRS / T axes)

\hypertarget{normal-ekg-values-by-age1}{%
\subsubsection[Normal EKG values by age]{\texorpdfstring{Normal EKG values by age\footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{Normal EKG values by age}}\label{normal-ekg-values-by-age1}}

\begin{figure}
\centering
\includegraphics{images/cardiology_normal-ekg-values-by-age.png}
\caption{Values are 2nd -- 98th percentile (mean)}
\end{figure}

\hypertarget{other-cardiac-work-up}{%
\subsection{Other Cardiac Work-Up}\label{other-cardiac-work-up}}

\hypertarget{chest-x-ray-cxr}{%
\subsubsection{Chest X-Ray (CXR)}\label{chest-x-ray-cxr}}

\begin{itemize}
\tightlist
\item
  \textbf{Heart size:} \textgreater50-60\% of thorax is abnormal on PA film (confounded by: poor inspiration, AP technique, thymic shadow)
\item
  \textbf{Lung fields:} increased pulmonary blood flow (increased pulm. vasc. markings, engorged vessels) = sign of overcirculation

  \begin{itemize}
  \tightlist
  \item
    Decreased vascular markings indicate decreased pulmonary blood flow
  \item
    Pulmonary edema and effusions may indicate CHF or left-sided obstructive disease
  \end{itemize}
\item
  \textbf{Thymic shadow:} lack of a thymic shadow in neonates should raise suspicion for 22q11 del. and associated cardiac defects
\item
  \textbf{Aortic arch:} sidedness (left-sided aortic arch is normal)
\item
  \textbf{Heart border:} Left or right atrial enlargement
\item
  \textbf{Rib notching:} suggests the presence of collateral vessels, as can be seen in coarctation
\end{itemize}

\hypertarget{what-to-do-next}{%
\subsubsection{What to do next\ldots{}}\label{what-to-do-next}}

\begin{itemize}
\tightlist
\item
  4-extremity BP: Upper \textgreater{} Lower (or less commonly R arm \textgreater{} L arm) suggests obstruction of the aorta (e.g.~interrupted arch, coarctation)

  \begin{itemize}
  \tightlist
  \item
    Exception to the rule: L arm \textgreater{} R suggests aortic obstruction w/ aberrant right subclavian
  \end{itemize}
\item
  Pre- and post-ductal O2 sats (measure on R arm and either foot)
\item
  Hyperoxia Test:

  \begin{itemize}
  \tightlist
  \item
    PaO2 \textless{} 100 mm Hg on 100\% RA suggests cyanotic congenital heart disease, \textgreater200 suggests pulmonary etiology
  \item
    Pulse oximetry can be used as approximation if unable to obtain ABG.
  \end{itemize}
\item
  Consult Cardiology!
\end{itemize}

\hypertarget{when-to-start-prostaglandins}{%
\subsubsection{When to start prostaglandins}\label{when-to-start-prostaglandins}}

\begin{itemize}
\tightlist
\item
  After work-up, if high suspicion for cyanotic heart disease, start PGE1 (alprostadil) 0.01 mcg/kg/min as soon as possible
\item
  Monitor for apnea and hypotension
\item
  Consider securing airway if patient requires transport
\end{itemize}

\hypertarget{common-cardiology-concerns}{%
\subsection{Common Cardiology Concerns}\label{common-cardiology-concerns}}

\hypertarget{hyperlipidemia-hld}{%
\subsubsection{Hyperlipidemia (HLD)}\label{hyperlipidemia-hld}}

\emph{\textbf{See }Weight Management EBG}**

\hypertarget{screening}{%
\paragraph{Screening}\label{screening}}

\begin{itemize}
\tightlist
\item
  When?

  \begin{itemize}
  \tightlist
  \item
    Screen all kids once at ages 9-11 and again from age 17-21
  \item
    If pt has \emph{\textgreater{}} 1 CVD risk factor, screen every 1-3 years

    \begin{itemize}
    \tightlist
    \item
      \textbf{CVD risk factors:} Dyslipidemia, obesity, HTN, DM, FH of premature CVD, smoking exposure
    \end{itemize}
  \end{itemize}
\item
  How?

  \begin{itemize}
  \tightlist
  \item
    Fasting lipid panel: Total cholesterol, TG, HDL, LDL-c (not reliable if TG \textgreater400)
  \end{itemize}
\end{itemize}

\hypertarget{diagnosis-1}{%
\paragraph{Diagnosis}\label{diagnosis-1}}

\begin{itemize}
\tightlist
\item
  TC \emph{\textgreater{}} 200 (borderline is 170-199)
\item
  LDL \emph{\textgreater{}} 130 (borderline is 110-129)
\item
  TG \emph{\textgreater{}} 100 (age 0-9), TG \emph{\textgreater{}} 130 (age 10-19)
\item
  HDL \textless{} 45
\end{itemize}

\hypertarget{management-5}{%
\paragraph{Management}\label{management-5}}

\begin{itemize}
\tightlist
\item
  Repeat and confirm abnormal value in 2 weeks to 3 months (including borderline values)
\item
  Lifestyle changes: Diet changes (+/- nutrition consult, preventative cardiology referral), weight loss, increase exercise
\item
  Consider statin therapy if no response in 6 months (referral to preventative cardiology clinic)
\item
  If high risk for CVD (genetic familial hypercholesterolemia, DM, ESRD, KD, solid-organ transplant recipient, childhood cancer survivor or moderate risk with add'l risk factors), start statin with goal LDL \textless100
\end{itemize}

\hypertarget{hypertension-htn}{%
\subsubsection{Hypertension (HTN)}\label{hypertension-htn}}

\emph{\textbf{See }Hypertension EBG}**
\emph{\textbf{See }Nephrology chapter\textbf{ for further details, including BP percentiles, discussion of causes of secondary HTN, and treatment*
}}See \textbf{Critical Care/ICP chapter} for discussion of Hypertensive Emergency*

\hypertarget{screening-1}{%
\paragraph{Screening}\label{screening-1}}

\begin{itemize}
\tightlist
\item
  All Well-Child Visits \textgreater{} 3yo
\item
  All Well Child Visits \textless{} 3yo with HTN risk factors (see EBG)
\item
  All Visits for \textgreater3yo with risk factors:

  \begin{itemize}
  \tightlist
  \item
    BMI \textgreater95\%ile, renal disease, diabetes, coarctation, hx arch obstruction, known HTN, taking meds known to increase BP
  \end{itemize}
\end{itemize}

\hypertarget{diagnosis-2}{%
\paragraph{Diagnosis}\label{diagnosis-2}}

\begin{itemize}
\tightlist
\item
  Children \textless{} 13yo: Automatic BP \emph{\textgreater{}} 90\%ile for age. Repeat manually. If persistently abnormal, follow EBG.
\item
  Children \emph{\textgreater{}} 13yo: Automatic BP \emph{\textgreater{}} 120/80 mmHg. Repeat manually. If persistently abnormal, follow EBG.
\end{itemize}

\hypertarget{management-6}{%
\paragraph{Management}\label{management-6}}

\begin{itemize}
\tightlist
\item
  \textbf{Elevated BP:} Repeat 6mo → 6mo → further work-up (see below), referral, and/or treatment if abnormal
\item
  \textbf{Stage I HTN:} Repeat 1-2wks → 3mo → further work-up, referral, and/or treatment if abnormal
\item
  \textbf{Stage II HTN:} Referral (Renal or Cards) and work-up

  \begin{itemize}
  \tightlist
  \item
    Send to ED if symptomatic (headache, visual changes)
  \end{itemize}
\end{itemize}

\hypertarget{work-up}{%
\paragraph{Work-up}\label{work-up}}

\begin{itemize}
\tightlist
\item
  Additional history, chem10, UA, fasting/non-fasting cholesterol (total/HDL)
\item
  If \textless6yo or evidence of abnormal UA or renal function → renal US with doppler
\item
  If Obese, HbA1c and ALT
\item
  Optional: Glucose, fasting lipids, TSH, drug screen, sleep study, CBC
\end{itemize}

\hypertarget{evaluating-murmurs-including-in-a-newborn}{%
\subsubsection{Evaluating Murmurs (including in a newborn)}\label{evaluating-murmurs-including-in-a-newborn}}

\hypertarget{history}{%
\paragraph{History}\label{history}}

Complete history, family history of murmur/CHD. Symptoms include respiratory difficulty, diaphoresis with exertion or feeds, poor growth. Evaluate if murmur was previously documented.

\hypertarget{physical-exam-4}{%
\paragraph{Physical Exam}\label{physical-exam-4}}

Pulses, palpation of chest, and auscultation- describe position that is loudest, quality of sound, radiation, presence of thrill. Grades:

\begin{itemize}
\tightlist
\item
  Grade 1: barely audible
\item
  Grade 2: soft, but audible in a busy room
\item
  Grade 3: loud, but without thrill
\item
  Grade 4: loud and thrill present
\item
  Grade 5: very loud, heard with stethoscope partially of of the chest
\item
  Grade 6: very loud, heard with stethoscope off of the chest
\end{itemize}

\hypertarget{is-it-innocent-or-pathologic}{%
\paragraph{Is it innocent or pathologic?}\label{is-it-innocent-or-pathologic}}

\begin{itemize}
\tightlist
\item
  \textbf{Features of innocent murmurs:} Grade \emph{\textless{}} 2, softer when sitting than supine, short and systolic, minimal radiation, musical or vibratory quality
\item
  \textbf{Features of pathologic murmurs:} Grade \emph{\textgreater{}} 3, holosystolic (septal defects, MR, TR), harsh or blowing quality, abnormal S2 (wide splitting, fixed splitting, paradoxical splitting, single S2, loud S2), systolic click (MVP), diastolic murmur (always pathologic), louder in seated/upright position, gallop rhythm, friction rub
\end{itemize}

\hypertarget{work-up-1}{%
\paragraph{Work-up}\label{work-up-1}}

If concerned for pathologic murmur based on above criteria, then obtain: EKG, four-extremity BPs, Cardiology consult for echo

\hypertarget{common-innocent-murmurs}{%
\paragraph{Common Innocent Murmurs}\label{common-innocent-murmurs}}

\begin{itemize}
\tightlist
\item
  \textbf{Vibratory/Still's murmur:} LLSB/LMSB, musical; age 3-6 most commonly (infant to adolescent)
\item
  \textbf{Pulmonary ejection murmur:} LMSB/LUSB, crescendo-decrescendo; all ages
\item
  \textbf{Peripheral pulmonary stenosis (PPS):} \textless1yo, heard at LUSB with radiation to back/axilla
\item
  \textbf{Venous hum:} continuous murmur, loudest over the lower neck, age 3-8 yo, disappears when supine
\end{itemize}

\hypertarget{arrhythmias-pacemakers}{%
\subsection{Arrhythmias \& Pacemakers}\label{arrhythmias-pacemakers}}

\hypertarget{causes-of-palpitations}{%
\subsubsection{Causes of Palpitations}\label{causes-of-palpitations}}

\hypertarget{cardiac}{%
\paragraph{Cardiac}\label{cardiac}}

PACs, PVCs, sustained or non-sustained tachyarrhythmias

\hypertarget{non-cardiac}{%
\paragraph{Non-cardiac}\label{non-cardiac}}

Hypoglycemia, toxic exposures, pheochromocytoma, increased metabolic demand (fever, anemia), catecholamine response (anxiety, emotional arousal), hyperventilation, POTS, hyperthyroidism

\hypertarget{premature-ventricular-contractions-pvcs}{%
\subsubsection{Premature Ventricular Contractions (PVCs)}\label{premature-ventricular-contractions-pvcs}}

\hypertarget{presentation-1}{%
\paragraph{Presentation}\label{presentation-1}}

Ranges from asymptomatic → \textbf{palpitations, lightheadedness.} Irregular pulse on exam.

\hypertarget{presentation-2}{%
\paragraph{Presentation}\label{presentation-2}}

Ranges from asymptomatic → \textbf{palpitations, lightheadedness.} Irregular pulse on exam.

\hypertarget{pathophysiology-3}{%
\paragraph{Pathophysiology}\label{pathophysiology-3}}

Enhanced automaticity, triggered activity

\hypertarget{work-up-2}{%
\paragraph{Work-up}\label{work-up-2}}

\begin{itemize}
\tightlist
\item
  EKG, 24-48hr Holter, chem10, TFTs
\item
  May require echo or exercise testing (dependent upon severity)
\item
  PVCs not coming from the RVOT (which should have a LBBB pattern with an inferior and leftward axis) should raise concern for underlying pathology)
\end{itemize}

\hypertarget{treatment}{%
\paragraph{Treatment}\label{treatment}}

Usually none

\begin{itemize}
\tightlist
\item
  Treat underlying cause (if one exists, e.g.~a drug)
\item
  Beta blockers or CCBs if symptomatic
\item
  If refractory and associated with depressed cardiac function, radiofrequency catheter ablation
\end{itemize}

\hypertarget{premature-atrial-contractions-pacs}{%
\subsubsection{Premature Atrial Contractions (PACs)}\label{premature-atrial-contractions-pacs}}

\hypertarget{presentation-3}{%
\paragraph{Presentation}\label{presentation-3}}

Range: asymptomatic → \textbf{palpitations, lightheadedness.} Irregular pulse on exam.

\hypertarget{pathophysiology-4}{%
\paragraph{Pathophysiology}\label{pathophysiology-4}}

Enhanced automaticity, triggered activity

\hypertarget{work-up-3}{%
\paragraph{Work-up}\label{work-up-3}}

Similar to work up for PVCs

\hypertarget{treatment-1}{%
\paragraph{Treatment}\label{treatment-1}}

Rarely required. Beta-blockade can be considered for symptomatic PACs.

\hypertarget{sinus-bradycardia}{%
\subsubsection{Sinus Bradycardia}\label{sinus-bradycardia}}

\hypertarget{presentation-4}{%
\paragraph{Presentation}\label{presentation-4}}

Usually asymptomatic; lightheadedness, SOB, exercise intolerance or syncope and cardiovascular collapse; poor feeding, irritability and/or respiratory abnormalities in infants. By age:

\begin{itemize}
\tightlist
\item
  Newborn to 3 years: \textless{} 90-100 bpm
\item
  3-9 years: \textless{} 60 bpm
\item
  9-16 years: \textless{} 50 bpm
\item
  Well trained adult athletes: \textless{} 40 bpm
\end{itemize}

\hypertarget{pathophysiology-5}{%
\paragraph{Pathophysiology}\label{pathophysiology-5}}

Conditioning (athletes), increased ICP, medications (beta blockers, digoxin, CCBs, steroids, analgesics and sedatives as well as alpha 2 blockers), structural CHD with sinus node dysfunction, anorexia

\hypertarget{work-up-4}{%
\paragraph{Work-up}\label{work-up-4}}

Assess for \textbf{perfusion,} history for causes including meds; \textbf{EKG.}

\hypertarget{treatment-2}{%
\paragraph{Treatment}\label{treatment-2}}

\begin{itemize}
\tightlist
\item
  Observation if asymptomatic
\item
  Treat underlying causes
\item
  Consider pacemaker if symptomatic
\end{itemize}

\hypertarget{av-block}{%
\subsubsection{AV Block}\label{av-block}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Degree\strut
\end{minipage} & \begin{minipage}[b]{0.31\columnwidth}\raggedright
PR Interval\strut
\end{minipage} & \begin{minipage}[b]{0.43\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
1st degree AV block\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
\textbf{Prolonged PR interval} Birth - 4 wks: 0.08-0.12 1-3 mos: 0.08-0.13 3-12 mos: 0.08-0.14 1-3 yrs: 0.08-0.15 3-5 yrs: 0.1-0.15 5-8 yrs: 0.09-0.16 8-12 yrs: 0.1-0.17 12-16 yrs: 0.1-0.18 Adult: 0.12-0.20\strut
\end{minipage} & \begin{minipage}[t]{0.43\columnwidth}\raggedright
Increased vagal tone, idiopathic, acute rheumatic fever (ARF), Lyme dz, hypothermia, cardiomyopathy, electrolyte disturbances (hyperkalemia)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
2nd degree AV block, Mobitz I (Wenkebach)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
Progressive lengthening of PR → non-conducted P wave\strut
\end{minipage} & \begin{minipage}[t]{0.43\columnwidth}\raggedright
- Usually AT the level of the AV node (does not progress to complete heart block) - Healthy individuals during sleep\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
2nd degree AV block, Mobitz II\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
No lengthening of PR interval followed by sudden non-conducted P-wave\strut
\end{minipage} & \begin{minipage}[t]{0.43\columnwidth}\raggedright
Usually BELOW level of AV node (e.g., His bundle pathology)→ may progress to complete heart block\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
3rd degree AV block (Complete)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
Complete AV dissociation\strut
\end{minipage} & \begin{minipage}[t]{0.43\columnwidth}\raggedright
- Narrow QRS (junctional beats) vs.~wide QRS (ventricular beats) → may cause hemodynamic collapse - Congenital heart block in infants of mothers w/ SLE (anti-Ro/anti-La Ab), L-TGA, heterotaxy - Acquired heart block: myocarditis, Lyme dz, ARF, MI\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{supraventricular-tachycardia-svt}{%
\subsubsection{Supraventricular Tachycardia (SVT)}\label{supraventricular-tachycardia-svt}}

\hypertarget{presentation-5}{%
\paragraph{Presentation}\label{presentation-5}}

Paroxysmal palpitations, chest pain, shortness of breath, dizziness or syncope w/ sudden onset and sudden resolution. HR characteristically invariable and is generally \textgreater{} 220 bpm in infants and \textgreater{} 180 bpm in children

\hypertarget{work-up-5}{%
\paragraph{Work-up}\label{work-up-5}}

EKG in SVT shows a (usually) narrow complex QRS, regular rate, +/- retrograde P-waves. SVT with abberancy or antidromic AVRT can be wide complex.

\hypertarget{treatment-3}{%
\paragraph{Treatment}\label{treatment-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Vagal maneuvers} (ice to face for babies, Valsalva maneuvers, blowing through a straw)
\item
  Give \textbf{adenosine} 0.1 mg/kg (max dose 6-12 mg) as a rapid IV push through an IV as close to the heart as possible, followed by very rapid NS flush (this may be repeated at 0.2 mg/kg)

  \begin{itemize}
  \tightlist
  \item
    Do \textbf{NOT} give adenosine if rate is \textbf{irregular} at all!
  \end{itemize}
\item
  Immediate \textbf{synchronized cardioversion} is indicated if the patient is unstable
\end{itemize}

\hypertarget{wolff-parkinson-white-syndrome}{%
\subsubsection{Wolff-Parkinson-White Syndrome}\label{wolff-parkinson-white-syndrome}}

\hypertarget{presentation-6}{%
\paragraph{Presentation}\label{presentation-6}}

Episodes of paroxysmal supraventricular tachycardia or asymptomatic/incidental finding on EKG

\hypertarget{pathophysiology-6}{%
\paragraph{Pathophysiology}\label{pathophysiology-6}}

Early conduction of atrial impulses to the ventricle defined by short PR interval, wide QRS, delta wave. Creates risk for SVT as well as pre-excited atrial tachycardias which can be life-threatening.

\hypertarget{work-up-6}{%
\paragraph{Work-up}\label{work-up-6}}

Echo to r/o structural heart disease (i.e.~Ebstein's anomaly); exercise testing

\hypertarget{treatment-4}{%
\paragraph{Treatment}\label{treatment-4}}

Catheter ablation is curative; antiarrhythmic medications prior to ablation

\hypertarget{ventricular-tachycardia-vtvtach-and-ventricular-fibrillation-vfvfib}{%
\subsubsection{Ventricular Tachycardia (VT/VTach) and Ventricular Fibrillation (VF/VFib)}\label{ventricular-tachycardia-vtvtach-and-ventricular-fibrillation-vfvfib}}

\hypertarget{presentation-7}{%
\paragraph{Presentation}\label{presentation-7}}

Range: asymptomatic → palpitations, chest pain, dizziness or syncope → hemodynamic collapse and rapid death

\hypertarget{pathophysiology-7}{%
\paragraph{Pathophysiology}\label{pathophysiology-7}}

Drugs, electrolyte abnormalities that prolong QT, underlying cardiac disease, inherited arrhythmia syndromes including LQTS, Brugada syndrome, CPVT and ACM can also predispose to these rhythms. Atrial tachycardias in patients with WPW can degenerate into VF. There are also \textbf{``benign''} varieties which can occur in young people with structurally normal hearts.

\hypertarget{work-up-7}{%
\paragraph{Work-up}\label{work-up-7}}

EKG, electrolytes, blood gas, and tox screen

\hypertarget{treatment-5}{%
\paragraph{Treatment}\label{treatment-5}}

\begin{itemize}
\tightlist
\item
  \textbf{VTach w/ a pulse:}

  \begin{itemize}
  \tightlist
  \item
    Consult Cardiology, follow \textbf{PALS} algorithm (consider antiarrhythmic medications)
  \item
    \textbf{Synchronized cardioversion} 0.5-1 J/kg initially, repeat w/ up to 2 J/kg. May be used w/ or instead of medical therapy
  \end{itemize}
\item
  \textbf{VFib or pulseless VTach:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{CPR} immediately
  \item
    \textbf{Defibrillate} initially w/ 2 J/kg, repeat at 4 J/kg w/ a maximum of 10 J/kg every 2 mins
  \item
    If not converted, use \textbf{epinephrine} (0.01 mg/kg = 0.1 ml/kg of 1:10,000 IV), may repeat every 3-5 mins
  \item
    Consider lidocaine, amiodarone and magnesium sulfate in consultation with Cardiology
  \end{itemize}
\end{itemize}

\hypertarget{long-qt-syndrome}{%
\subsubsection{Long QT Syndrome}\label{long-qt-syndrome}}

\hypertarget{presentation-8}{%
\paragraph{Presentation}\label{presentation-8}}

Range: incidental findings, family history → syncope, palpitations, arrhythmia, seizures, or sudden death. Often provoked by exercise, strong emotions or diving into cold water.

\hypertarget{pathophysiology-8}{%
\paragraph{Pathophysiology}\label{pathophysiology-8}}

\begin{itemize}
\tightlist
\item
  \textbf{Congenital:} Ion channelopathies (most common are LQTS1, 2 and 3; autosomal recessive version is called Jervell and Lange-Nielsen syndrome and is associated with sensorineural hearing loss)
\item
  \textbf{Acquired:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Electrolyte abnormalities:} Hypokalemia, hypomagnesemia and hypocalcemia)
  \item
    \textbf{\href{www.crediblemeds.org}{Meds}:} Macrolides, quinolones, metronidazole, multiple antifungals, most anti-emetics, SSRIs and TCAs, many antipsychotics, multiple antiarrhythmics, methadone and diphenhydramine)
  \end{itemize}
\end{itemize}

\hypertarget{work-up-8}{%
\paragraph{Work-up}\label{work-up-8}}

\begin{itemize}
\tightlist
\item
  EKG w/ prolonged QTc (upper limit of normal 450-460 ms), T-wave alternans, notched T-waves or low resting HR; electrolytes
\item
  Genetic testing may be indicated
\end{itemize}

\hypertarget{treatment-6}{%
\paragraph{Treatment}\label{treatment-6}}

\begin{itemize}
\tightlist
\item
  Adequate magnesium, potassium and calcium level
\item
  Avoid any \href{www.crediblemeds.org}{medications that may prolong QTc} and activities known or suspected to provoke it
\item
  Beta blockers, ICD placement and left thoracic sympathectomy are options for high-risk patients
\end{itemize}

\hypertarget{pacemakers}{%
\subsubsection{Pacemakers}\label{pacemakers}}

\hypertarget{positions}{%
\paragraph{Positions}\label{positions}}

Describe how the pacemaker functions and is programmed:

\begin{itemize}
\tightlist
\item
  \textbf{Position 1:} The chamber being paced (A = atrium, V = ventricle, D = dual
\item
  \textbf{Position 2:} The chamber being sensed (A, V, D or O = no sensing)
\item
  \textbf{Position 3:} Response to a particular sensed event

  \begin{itemize}
  \tightlist
  \item
    I = a sensed event inhibits pacemaker output
  \item
    T = a sensed event triggers pacemaker output
  \item
    D = dual modes of response (i.e.~a sensed event in the atrium inhibits pacemaker output in the atrium, but triggers ventricular pacemaker output w/ a programmed delay to mimic intrinsic AV delay)
  \item
    O = no response to sensed events)
  \end{itemize}
\end{itemize}

\hypertarget{settings}{%
\paragraph{Settings}\label{settings}}

\begin{itemize}
\tightlist
\item
  \textbf{AAI:} Atrial demand pacing and is an appropriate mode for patients w/ sinus node dysfunction, but should not be used for patients w/ AV node dysfunction
\item
  \textbf{VVI:} Ventricular demand pacing and is used quite uncommonly -- results in loss of AV synchrony and can result in a type of cardiomyopathy called pacemaker syndrome (signs and symptoms similar to heart failure)
\item
  \textbf{DDD:} Dual chamber pacing- provides more physiologic pacing w/ preserved AV synchrony and may be used in patients w/ both sinus node and AV node dysfunction. This mode of pacing can result in four different rhythms:

  \begin{itemize}
  \tightlist
  \item
    Normal sinus rhythm (pacemaker does not fire)
  \item
    Atrial pacing w/ a native QRS (pacemaker provides atrial impulse only)
  \item
    AV sequential pacing (pacemaker provides atrial impulse w/ a programmed PR interval mimicking AV node function followed by ventricular impulse)
  \item
    Atrial sensing and ventricular pacing (pacemaker provides ventricular impulse only at intervals mimicking AV node function)
  \end{itemize}
\end{itemize}

\hypertarget{acyanotic-congenital-heart-disease-chd}{%
\subsection{Acyanotic Congenital Heart Disease (CHD)}\label{acyanotic-congenital-heart-disease-chd}}

\hypertarget{atrial-septal-defect-asd}{%
\subsubsection{Atrial Septal Defect (ASD)}\label{atrial-septal-defect-asd}}

\hypertarget{lesion}{%
\paragraph{Lesion}\label{lesion}}

\includegraphics{images/cardiology_asd.png}

\hypertarget{basics}{%
\paragraph{Basics}\label{basics}}

\begin{itemize}
\tightlist
\item
  \textbf{Volume} overload
\item
  4 types based on location and embryologic origin:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Ostium primum: low in septum; can involve AV valve
  \item
    Ostium secundum: most common; near foramen ovale
  \item
    Sinus venosus: may involve connection w/ SVC, IVC, often associated PAPVC
  \item
    Coronary sinus (defect between CS and LA, not truly in atrial septum)
  \end{enumerate}
\item
  Amount of L → R shunt depends on side of defect, SVR relative to PVR, relative LV and RV compliance
\item
  PAPVC has similar hemodynamic consequences as ASDs
\end{itemize}

\hypertarget{presentation-9}{%
\paragraph{Presentation}\label{presentation-9}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Often asymptomatic, may result in poor growth. When causing significant overcirculation, causes fatigue, dyspnea, CHF and can lead to pulmonary vascular disease (Eisenmenger syndrome). Paradoxical emboli.
\item
  \textbf{PE:} Fixed and widely split S2. SEM caused by increased flow across PV, not flow through septal defect. Diastolic rumble if significantly increased volume of flow across the tricuspid valve.
\end{itemize}

\hypertarget{studies}{%
\paragraph{Studies}\label{studies}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Enlargement of right-sided chambers, RBBB, RAD. Superior axis in primum ASD.
\item
  \textbf{CXR:} Often normal. Overcirculation (increased pulmonary vascular markings). Cardiomegaly.
\end{itemize}

\hypertarget{treatment-7}{%
\paragraph{Treatment}\label{treatment-7}}

\begin{itemize}
\tightlist
\item
  Secundum defects may close spontaneously
\item
  Surgery indicated if symptomatic or is Qp:Qs \textgreater{} 1.5:1. Surgical or transcatheter closure.
\item
  \textbf{Surgical goal:} Close the defect and avoid development of irreversible pHTN/Eisenmenger's syndrome
\end{itemize}

\hypertarget{ventricular-septal-defect-vsd}{%
\subsubsection{Ventricular Septal Defect (VSD)}\label{ventricular-septal-defect-vsd}}

\hypertarget{lesion-1}{%
\paragraph{Lesion}\label{lesion-1}}

\includegraphics{images/cardiology_vsd.png}

\hypertarget{basics-1}{%
\paragraph{Basics}\label{basics-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Volume} overload and possible \textbf{pressure} overload
\item
  Opening in ventricular septum occurs in 1 of 4 locations:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    AV canal septum
  \item
    Conal septum
  \item
    Membranous septum
  \item
    Muscular septum
  \end{enumerate}
\item
  Degree of shunting determined by size of defect and relative SVR/PVR:

  \begin{itemize}
  \tightlist
  \item
    If small in size (and pressure restrictive) may not be hemodynamically significant
  \item
    If moderate in size, can cause pulmonary overcirculation and left-sided volume overload
  \item
    If large can expose RV to systemic pressure in addition to volume overload
  \end{itemize}
\end{itemize}

\hypertarget{presentation-10}{%
\paragraph{Presentation}\label{presentation-10}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Depends on size. Symptoms occur as PVR decreases during first weeks of life and flow across the defect increases. Sx of CHF include, tachypnea, poor growth, sweating, feed fatigue, dyspnea.
\item
  \textbf{PE:} Early or holosystolic regurgitant-type murmur. Smaller defects are louder because of higher pressure gradient across lesion. Large defects may cause very quiet murmurs (may only heard a loud S2). Volume overload can produce a left-sided heave.
\end{itemize}

\hypertarget{studies-1}{%
\paragraph{Studies}\label{studies-1}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Normal or LAE, LVH, sometimes RVH if defect is large and RV is exposed to systemic pressure OR if pulmonary vascular disease has developed due to chronic overcirculation
\item
  \textbf{CXR:} Can be normal, +/- mild cardiomegaly or increased pulmonary blood flow
\end{itemize}

\hypertarget{treatment-8}{%
\paragraph{Treatment}\label{treatment-8}}

\begin{itemize}
\tightlist
\item
  May spontaneously close on its own, especially small muscular types
\item
  Surgery if symptomatic or persistently elevated PVR; otherwise, may observe
\item
  Repair is surgical patch closure or cath device closure
\item
  \textbf{Surgical/cath goal:} Close the defect
\end{itemize}

\hypertarget{patent-ductus-arteriosis-pda}{%
\subsubsection{Patent Ductus Arteriosis (PDA)}\label{patent-ductus-arteriosis-pda}}

\hypertarget{lesion-2}{%
\paragraph{Lesion}\label{lesion-2}}

\includegraphics{images/cardiology_pda.png}

\hypertarget{basics-2}{%
\paragraph{Basics}\label{basics-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Volume} overload
\item
  Common in premature newborns
\item
  Can be asymptomatic, or can cause pulmonary overcirculation, CHF and systemic hypoperfusion
\end{itemize}

\hypertarget{presentation-11}{%
\paragraph{Presentation}\label{presentation-11}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Respiratory distress, feeding fatigue, poor growth, CHF
\item
  \textbf{PE:} Continuous ``machine-like'' murmur at LUSB (though murmur can also be systolic only), wide pulse pressure, bounding or palmar pulses
\end{itemize}

\hypertarget{studies-2}{%
\paragraph{Studies}\label{studies-2}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Often normal, can have LVH or RVH
\item
  \textbf{CXR:} Normal, +/- increased vascular markings, +/- cardiomegaly
\end{itemize}

\hypertarget{treatment-9}{%
\paragraph{Treatment}\label{treatment-9}}

\begin{itemize}
\tightlist
\item
  Indomethacin, ibuprofen or acetaminophen in preemies. Less likely to be successful in non-preemies.
\item
  Surgical ligation or cath device occlusion
\item
  \textbf{Surgical/cath goal:} Close the duct
\end{itemize}

\hypertarget{av-canal-defects-avcd}{%
\subsubsection{AV Canal Defects (AVCD)}\label{av-canal-defects-avcd}}

\hypertarget{lesion-3}{%
\paragraph{Lesion}\label{lesion-3}}

\includegraphics{images/cardiology_avcd.png}

\hypertarget{basics-3}{%
\paragraph{Basics}\label{basics-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Volume} overload
\item
  Components:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Primum ASD
  \item
    AV-canal type VSD
  \item
    AV valve defects
  \end{enumerate}
\item
  Occurs on a spectrum:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Partial AV canal (ASD, cleft MV)
  \item
    Transitional AV canal (Cleft MV, ASD and small VSD)
  \item
    Complete AV canal (ASD, VSD, common AV valve)
  \end{enumerate}
\item
  Common in T21
\item
  Can be balanced (equal sized ventricles) or unbalanced (unequal sized ventricles)
\end{itemize}

\hypertarget{presentation-12}{%
\paragraph{Presentation}\label{presentation-12}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Presentation similar to that of VSD w/ CHF: poor growth, sweating, feed fatigue, dyspnea. Severity depends on type of defect.
\item
  \textbf{PE:} Murmurs of ASD, VSD, MR +/- gallop
\end{itemize}

\hypertarget{studies-3}{%
\paragraph{Studies}\label{studies-3}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Superior axis; +/- RVH, LVH
\item
  \textbf{CXR:} cardiomegaly +/- increased vascular markings
\end{itemize}

\hypertarget{treatment-10}{%
\paragraph{Treatment}\label{treatment-10}}

\begin{itemize}
\tightlist
\item
  Surgery often required before in 1st year of life
\item
  Patch closure of septal defects, often involves valvuloplasty
\item
  \textbf{Surgical goal:} Closing defects and achieving AV valve competency
\item
  \textbf{Complications:} AV valve regurgitation and stenosis after repair
\item
  Single ventricle palliation may be required for severely unbalanced defects
\end{itemize}

\hypertarget{congenital-corrected-tga}{%
\subsubsection{Congenital Corrected TGA}\label{congenital-corrected-tga}}

\hypertarget{lesion-4}{%
\paragraph{Lesion}\label{lesion-4}}

\includegraphics{images/cardiology_corrected-tga.png}

\hypertarget{basics-4}{%
\paragraph{Basics}\label{basics-4}}

\begin{itemize}
\item
  Transposed great arteries (PA off LV, Ao off RV)
\item
  Segmental anatomy is \{S,L,L\} or, less commonly, \{I,D,D\}
\item
  \textbf{Blood flow:} LA → RV → aorta → body → IVC/SVC → RA → LV → PA → lungs → pulmonary veins → LA
\item
  \begin{quote}
  90\% associated w/ other cardiac defects (often a VSD, LVOT obstruction, Ebstein-like TV)
  \end{quote}
\item
  Can have coronary anomalies
\item
  High risk for spontaneous or post-surgical AV block
\end{itemize}

\hypertarget{presentation-13}{%
\paragraph{Presentation}\label{presentation-13}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} No cyanosis unless other cyanotic defects present. Can present w/ R heart failure in early adulthood as RV cannot tolerate work load as systemic ventricle.
\item
  \textbf{PE:} Dependent on associated defects. May have stigmata of right heart failure. May have loud S2 due to anterior position of AoV.
\end{itemize}

\hypertarget{studies-4}{%
\paragraph{Studies}\label{studies-4}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Q waves in right precordial leads, no Q waves in left-sided leads. Often have conduction system abnormalities including bradycardia and AV block.
\item
  \textbf{CXR:} Dextrocardia or mesocardia may be present
\end{itemize}

\hypertarget{treatment-11}{%
\paragraph{Treatment}\label{treatment-11}}

\begin{itemize}
\tightlist
\item
  Conventionally, only associated defects were repaired
\item
  The newer anatomic approach involves the ``double switch'' operation, which involves an arterial and atrial level switch via baffling or a Mustard-Rastelli procedure if significant PS is present
\item
  Often ``training'' of the LV w/ PA banding before the LV is made the systemic ventricle is required, unless significant PS or a large VSD is present
\item
  Timing of surgery is a major challenge
\end{itemize}

\hypertarget{valvar-pulmonary-stenosis}{%
\subsubsection{Valvar Pulmonary Stenosis}\label{valvar-pulmonary-stenosis}}

\hypertarget{lesion-5}{%
\paragraph{Lesion}\label{lesion-5}}

\includegraphics{images/cardiology_pulm-stenosis.png}

\hypertarget{basics-5}{%
\paragraph{Basics}\label{basics-5}}

\begin{itemize}
\tightlist
\item
  \textbf{Pressure} overload
\item
  Stenotic pulmonary valve, causing increased pressure on RV, TR, may be transmitted to RA
\item
  \textbf{Critical} if ductal patency is required for pulmonary blood flow (these children require prostaglandins and early intervention)
\end{itemize}

\hypertarget{presentation-14}{%
\paragraph{Presentation}\label{presentation-14}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} If mild/moderate, asymptomatic. If severe, RV dysfunction and TR, hepatomegaly. If critical, can present w/ cyanosis.
\item
  \textbf{PE:} SEM at LUSB, ejection click, +/-TR murmur. Often worsens in first few months of life, then stabilizes.
\end{itemize}

\hypertarget{studies-5}{%
\paragraph{Studies}\label{studies-5}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Normal to RAD, RVH. +/- RV strain pattern.
\item
  \textbf{CXR:} +/- ↓ vasc markings
\end{itemize}

\hypertarget{treatment-12}{%
\paragraph{Treatment}\label{treatment-12}}

\begin{itemize}
\tightlist
\item
  \textbf{If critical,} start PGE
\item
  Repair is balloon valvuloplasty in cath lab. Surgical repair if severely thickened valve, or muscular subpulmonary stenosis.
\item
  \textbf{Surgical/cath goal:} Relieve obstruction, will often have some degree of PR afterward
\end{itemize}

\hypertarget{valvar-aortic-stenosis}{%
\subsubsection{Valvar Aortic Stenosis}\label{valvar-aortic-stenosis}}

\hypertarget{lesion-6}{%
\paragraph{Lesion}\label{lesion-6}}

\includegraphics{images/cardiology_aortic-stenosis.png}

\hypertarget{basics-6}{%
\paragraph{Basics}\label{basics-6}}

\begin{itemize}
\tightlist
\item
  \textbf{Pressure} overload
\item
  LVOT obstruction LVH, systolic and diastolic dysfunction, CHF, MR. Severe LVOTO causes decreased CO.
\item
  \textbf{Critical} if ductal patency is required for systemic blood flow
\item
  Supravalvar stenosis common in William's Syndrome
\end{itemize}

\hypertarget{presentation-15}{%
\paragraph{Presentation}\label{presentation-15}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Infants often asymptomatic. Stenosis worsens w/ age, causing CHF or even cardiogenic shock.
\item
  \textbf{PE:} Harsh SEM at base radiating to neck, ejection click w/ valvar stenosis, LV heave or tap
\end{itemize}

\hypertarget{studies-6}{%
\paragraph{Studies}\label{studies-6}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} LVH +/- strain pattern
\item
  \textbf{CXR:} Normal to cardiomegaly; pulmonary edema possible
\end{itemize}

\hypertarget{treatment-13}{%
\paragraph{Treatment}\label{treatment-13}}

\begin{itemize}
\tightlist
\item
  \textbf{If critical,} start PGE to maintain CO
\item
  Repair is cath balloon valvuloplasty or surgical aortic valvuloplasty or valve replacement
\item
  \textbf{Surgical goal:} Relieve obstruction, avoid AR
\end{itemize}

\hypertarget{coarctation-of-the-aorta}{%
\subsubsection{Coarctation of the Aorta}\label{coarctation-of-the-aorta}}

\hypertarget{lesion-7}{%
\paragraph{Lesion}\label{lesion-7}}

\includegraphics{images/cardiology_coarct.png}

\hypertarget{basics-7}{%
\paragraph{Basics}\label{basics-7}}

\begin{itemize}
\tightlist
\item
  \textbf{Pressure} overload
\item
  Narrowing of the aorta near the aortic isthmus (juxta-ductal)
\item
  If \textbf{critical,} requires PGE for systemic blood flow
\item
  Common in Turner Syndrome
\end{itemize}

\hypertarget{presentation-16}{%
\paragraph{Presentation}\label{presentation-16}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} In infants, often presents as PDA closes: poor growth, sweating, feed fatigue, dyspnea and can present as cardiogenic shock
\item
  \textbf{PE:} Upper extremity HTN, w/ drop in lower extremity BPs. SEM at LUSB radiating to back, BP gradient between R arm and legs, brachiofemoral delay and/or decreased/absent femoral pulses.
\end{itemize}

\hypertarget{studies-7}{%
\paragraph{Studies}\label{studies-7}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RVH in infancy, LVH in children
\item
  \textbf{CXR:} Cardiomegaly ``3 sign,'' rib notching in older children (collateral vessels eroding bone)
\end{itemize}

\hypertarget{treatment-14}{%
\paragraph{Treatment}\label{treatment-14}}

\begin{itemize}
\tightlist
\item
  \textbf{Infants:} PGE if signs of shock to maintain CO
\item
  Repair is surgical coarct excision and anastomosis or cath balloon dilation and possibly stenting in older children
\item
  \textbf{Surgical goal:} Relief of obstruction
\item
  \textbf{Complications:} Re-coarctation
\end{itemize}

\hypertarget{cyanotic-congenital-heart-disease-chd}{%
\subsection{Cyanotic Congenital Heart Disease (CHD)}\label{cyanotic-congenital-heart-disease-chd}}

\hypertarget{tetralogy-of-fallot-tof}{%
\subsubsection{Tetralogy of Fallot (ToF)}\label{tetralogy-of-fallot-tof}}

\hypertarget{lesion-8}{%
\paragraph{Lesion}\label{lesion-8}}

\includegraphics{images/cardiology_tof.png}

\hypertarget{basics-8}{%
\paragraph{Basics}\label{basics-8}}

\begin{itemize}
\tightlist
\item
  Anterior malalignment of the conal septum, causing:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Large anterior malalignment VSD
  \item
    RV outflow obstruction
  \item
    Overriding aorta
  \item
    RV hypertrophy
  \end{enumerate}
\item
  Degree of cyanosis depends on amount of RVOT obstruction:

  \begin{itemize}
  \tightlist
  \item
    ``Pink Tets'' have minimal RVOT obstruction (VSD-like physiology)
  \item
    ``Blue Tets'' have significant RVOT obstruction
  \end{itemize}
\item
  Pulmonary Atresia and Major Aorto-Pulmonary Collateral Arteries (TOF/PA/MAPCAs) is the most severe variant
\item
  \textbf{Hypercyanotic episode (``Tet Spell'')} occurs due to: (1) dynamic worsening of RVOT obstruction, (2) increased PVR, and (3) decreased SVR. Results in cyanosis and, if persistent, acidosis 2/2 right-to-left shunting.
\end{itemize}

\hypertarget{presentation-17}{%
\paragraph{Presentation}\label{presentation-17}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} May have \textbf{``Tet Spells''}

  \begin{itemize}
  \tightlist
  \item
    Symptoms can range from severe cyanosis to predominantly pulmonary over circulation and volume overload resulting in heart failure depending on degree of RVOTO
  \item
    \textbf{``Balanced'' tets} (moderate PS, Qp:Qs close to 1) may present only w/ a murmur
  \end{itemize}
\item
  \textbf{PE:} SEM at LUSB (2/2 RVOT obstruction, VSD does not cause murmur), absent or soft P2
\end{itemize}

\hypertarget{studies-8}{%
\paragraph{Studies}\label{studies-8}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RAD, RVH, RAE, RBBB
\item
  \textbf{CXR:} ``Boot-shaped'' heart. Decreased pulmonary markings. +/- right-sided aortic arch. Look for absent thymic shadow (seen in patients w/ 22q11 deletion).
\item
  Coronary artery anomalies are common, may have absent ductus arteriosus
\end{itemize}

\hypertarget{treatment-15}{%
\paragraph{Treatment}\label{treatment-15}}

\begin{itemize}
\tightlist
\item
  PGE if neonatal cyanosis to preserve ductal patency and pulmonary blood flow
\item
  \textbf{Acute hypercyanotic episode:}

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Decrease PVR: Supplemental O2, morphine, bicarb
  \item
    Increase SVR: Knees to chest, alpha-1 agonists
  \item
    Increase systemic venous return
  \end{enumerate}
\item
  Beta blockers may be used to prevent infundibular spasm
\item
  \textbf{Surgical repair:} Patch closure of VSD and relieve RVOT obstruction (may require muscle bundle resection, patch augmentation of RVOT which may be valve-sparing or a transannular patch). Unifocalization for TOF/PA/MAPCAs. Will often have PR after repair.
\item
  \textbf{Surgical goal:} Close VSD, relieve RVOT obstruction
\end{itemize}

\hypertarget{transposition-of-the-great-arteries-tga}{%
\subsubsection{Transposition of the Great Arteries (TGA)}\label{transposition-of-the-great-arteries-tga}}

\hypertarget{lesion-9}{%
\paragraph{Lesion}\label{lesion-9}}

\includegraphics{images/cardiology_tga.png}

\hypertarget{basics-9}{%
\paragraph{Basics}\label{basics-9}}

\begin{itemize}
\tightlist
\item
  Aorta arises from RV, pulmonary artery arises from LV w/ D-looped ventricles. May also have a VSD.
\item
  Results in two parallel circulations and severe cyanosis unless \textbf{mixing} occurs at the atrial or ventricular level (PDA alone is not sufficient)
\end{itemize}

\hypertarget{presentation-18}{%
\paragraph{Presentation}\label{presentation-18}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Profound cyanosis and tachypnea at birth. If large VSD, can have comfortable dyspnea.
\item
  \textbf{PE:} Often no murmur if no VSD. +/- single S2.
\end{itemize}

\hypertarget{studies-9}{%
\paragraph{Studies}\label{studies-9}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} May be normal
\item
  \textbf{CXR:} ``Egg on a string'' heart, increased pulmonary vascular markings
\end{itemize}

\hypertarget{treatment-16}{%
\paragraph{Treatment}\label{treatment-16}}

\begin{itemize}
\tightlist
\item
  PGE in newborns
\item
  Often emergent balloon atrial septostomy to ensure mixing of the two parallel circulations
\item
  \textbf{Surgical repair:} Arterial switch w/ transfer of the coronary buttons. Older surgeries involved atrial switch (i.e.~Mustard, Senning)
\item
  \textbf{Surgical goal:} Restore normal connections between ventricles and great vessels
\end{itemize}

\hypertarget{total-anomalous-pulmonary-venous-return-tapvr}{%
\subsubsection{Total Anomalous Pulmonary Venous Return (TAPVR)}\label{total-anomalous-pulmonary-venous-return-tapvr}}

\hypertarget{lesion-10}{%
\paragraph{Lesion}\label{lesion-10}}

\includegraphics{images/cardiology_tapvr.png}

\hypertarget{basics-10}{%
\paragraph{Basics}\label{basics-10}}

\begin{itemize}
\tightlist
\item
  Pulmonary veins do not return to LA
\item
  Four types:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Supracardiac
  \item
    Intracardiac
  \item
    Infradiaphragmatic
  \item
    Mixed
  \end{enumerate}
\item
  Cyanosis is due to \textbf{mixing} of oxygenated and deoxygenated blood or pulmonary edema if veins are obstructed (common in infradiaphragmatic type)

  \begin{itemize}
  \tightlist
  \item
    \textbf{Must} have mixing lesion to survive (i.e.~ASD)
  \item
    Anomalous connection causes L → R shunt and there is shunting of mixed blood R → L at the atrial or ventricular level, causing cyanosis
  \end{itemize}
\end{itemize}

\hypertarget{presentation-19}{%
\paragraph{Presentation}\label{presentation-19}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Can mimic RDS if pulmonary venous obstruction is present. Can present w/ signs of RV volume overload if obstruction is not significant (similar to other left-to-right shunt lesions).
\item
  \textbf{PE:} If vein obstruction, single loud S2. If no obstruction, increased RV impulse, SEM at LUSB, diastolic TV rumble. +/- fixed split S2.
\item
  Cyanosis may be mild if Qp:Qs is high and there is no obstruction
\end{itemize}

\hypertarget{studies-10}{%
\paragraph{Studies}\label{studies-10}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RAD, RVH, +/-RAE
\item
  \textbf{CXR:} If pulm vein obstruction, pulm edema (similar to RDS). ``Snowman sign'' in supracardiac type.
\end{itemize}

\hypertarget{treatment-17}{%
\paragraph{Treatment}\label{treatment-17}}

\begin{itemize}
\tightlist
\item
  Emergent surgery if severe vein obstruction: anastomose pulm venous confluence to LA and close ASD
\item
  Supportive care including O2, inotropes, mechanical ventilation, ECMO as needed
\item
  PGE may worsen cyanosis if there is pulmonary venous obstruction
\item
  \textbf{Surgical goal:} Connect pulm veins to LA and close mixing lesion
\end{itemize}

\hypertarget{tricuspid-atresia}{%
\subsubsection{Tricuspid Atresia}\label{tricuspid-atresia}}

\hypertarget{lesion-11}{%
\paragraph{Lesion}\label{lesion-11}}

\includegraphics{images/cardiology_tricuspid-atresia.png}

\hypertarget{basics-11}{%
\paragraph{Basics}\label{basics-11}}

\begin{itemize}
\tightlist
\item
  No outlet from RA → RV. Supply to LA via PFO or ASD.
\item
  Classified based upon great arterial relationship (d-TGA in type II), presence of VSD and degree of PS

  \begin{itemize}
  \tightlist
  \item
    If no VSD, will have hypoplastic RV and pulmonary atresia
  \item
    If + VSD, variable severity of RV and PA hypoplasia
  \end{itemize}
\item
  Pulmonary blood flow may be PDA dependent
\end{itemize}

\hypertarget{presentation-20}{%
\paragraph{Presentation}\label{presentation-20}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Variable timing depending on size of VSD and degree of PS. Usually cyanotic by 2 months w/ cyanosis, tachypnea.
\item
  \textbf{PE:} +/- VSD murmur. Single S2.
\end{itemize}

\hypertarget{studies-11}{%
\paragraph{Studies}\label{studies-11}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RAE, LVH, LAD w/ left/superior axis (distinguishes TA from most other forms of cyanotic disease)
\item
  \textbf{CXR:} Usually decreased pulmonary vascular markings. Can have increased if TGA.
\end{itemize}

\hypertarget{treatment-18}{%
\paragraph{Treatment}\label{treatment-18}}

\begin{itemize}
\tightlist
\item
  PGE if cyanotic, to maintain pulm flow
\item
  Some neonates require atrial septostomy
\item
  Manage CHF if present
\item
  \textbf{Surgical repair:} Staged palliation: BT shunt → bidirectional Glenn → Fontan
\item
  \textbf{Surgical goal:} Make two separate circulations w/ passive blood flow to the lungs and LV-driven systemic flow
\end{itemize}

\hypertarget{ebsteins-anomaly}{%
\subsubsection{Ebstein's Anomaly}\label{ebsteins-anomaly}}

\hypertarget{lesion-12}{%
\paragraph{Lesion}\label{lesion-12}}

\includegraphics{images/cardiology_ebsteins-anomaly.png}

\hypertarget{basics-12}{%
\paragraph{Basics}\label{basics-12}}

\begin{itemize}
\tightlist
\item
  Tricuspid valve is apically displaced into RV w/ leaflets adherent to RV wall, ASD present. Causes atrialization of the RV and RA enlargement.
\item
  Impaired RV output 2/2 TR, RV dysfunction, possible RVOTO from redundant valve tissue
\item
  Can cause a ``circular shunt'' in utero (Ao → ductus → retrograde PA → RA → PFO → LA → LV → Ao) and hydrops
\item
  Frequently associated w/ WPW
\end{itemize}

\hypertarget{presentation-21}{%
\paragraph{Presentation}\label{presentation-21}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Variable presentation from cyanosis in delivery room and early right heart failure to adults w/ murmurs, arrhythmia or incidental EKG findings based upon degree of TV displacement
\item
  \textbf{PE:} Systolic murmur 2/2 TR. Often has gallop.
\end{itemize}

\hypertarget{studies-12}{%
\paragraph{Studies}\label{studies-12}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RAE, RBBB. May have WPW and may present in AVRT.
\item
  \textbf{CXR:} Cardiomegaly, which can be massive and box-like 2/2 RAE. Decreased pulmonary vascular markings can be normal.
\end{itemize}

\hypertarget{treatment-19}{%
\paragraph{Treatment}\label{treatment-19}}

\begin{itemize}
\tightlist
\item
  Consider PGE in neonates w/ severe cyanosis
\item
  Improves as PVR falls
\item
  \textbf{Surgical repair:} Variable depending on severity, but may include TVplasty (Cone procedure) or replacement, reduction atrioplasty and ventricular plication. If severe, may require palliation down single ventricle pathway.
\item
  \textbf{Surgical goal:} Improve RV function, reduce TR
\end{itemize}

\hypertarget{hypoplastic-left-heart-syndrome-hlhs}{%
\subsubsection{Hypoplastic Left Heart Syndrome (HLHS)}\label{hypoplastic-left-heart-syndrome-hlhs}}

\hypertarget{lesion-13}{%
\paragraph{Lesion}\label{lesion-13}}

\includegraphics{images/cardiology_hlhs.png}

\hypertarget{basics-13}{%
\paragraph{Basics}\label{basics-13}}

\begin{itemize}
\tightlist
\item
  Group of left-sided obstructive anomalies characterized by underdevelopment of the left heart thought to be secondary to reduced in utero blood flow
\item
  Requires PDA and ASD for survival
\item
  Three types:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    MS/AS
  \item
    MS/AA
  \item
    MA/AA
  \end{enumerate}
\item
  Further classified based upon presence or absence of unrestrictive atrial septal defect

  \begin{itemize}
  \tightlist
  \item
    If atrial septum is intact (IAS) or restrictive, outcome is poor
  \end{itemize}
\end{itemize}

\hypertarget{presentation-22}{%
\paragraph{Presentation}\label{presentation-22}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Presents w/ cyanosis secondary to left atrial hypertension and pulmonary edema if atrial septum intact or restrictive. Presents w/ cardiogenic shock and CHF if atrial septum unrestrictive as PDA closes.
\item
  \textbf{PE:} Increased RV impulse, single S2, often no murmur, poor pulses, cool extremities
\end{itemize}

\hypertarget{studies-13}{%
\paragraph{Studies}\label{studies-13}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RVH, reduced left-sided forces
\item
  \textbf{CXR:} Cardiomegaly, ↑ pulm markings
\end{itemize}

\hypertarget{treatment-20}{%
\paragraph{Treatment}\label{treatment-20}}

\begin{itemize}
\tightlist
\item
  PGE to preserve ductal patency and systemic perfusion
\item
  Balloon atrial septostomy if IAS
\item
  \textbf{Surgical repair:} Three-stage univentricular palliation:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Atrial septectomy, creation of neoaorta, modified BT-shunt or Sano shunt v. Hybrid procedure
  \item
    Bidirectional Glenn (superior cavopulmonary anastomosis)
  \item
    Fontan (total cavopulmonary shunt)
  \end{enumerate}
\item
  \textbf{Surgical goal:} Separation of pulmonary and systemic circulation w/ passive pulm return and RV-generated systemic flow
\end{itemize}

\hypertarget{double-outlet-right-ventricle-dorv}{%
\subsubsection{Double Outlet Right Ventricle (DORV)}\label{double-outlet-right-ventricle-dorv}}

\hypertarget{lesion-14}{%
\paragraph{Lesion}\label{lesion-14}}

\includegraphics{images/cardiology_dorv.png}

\hypertarget{basics-14}{%
\paragraph{Basics}\label{basics-14}}

\begin{itemize}
\tightlist
\item
  Family of lesions where both great vessels arise from RV
\item
  VSD always present
\item
  Multiple ``types'' (dependent on relationship of VSD to great arteries):

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    TOF-type: Sub-aortic VSD with PS (blood from LV goes predominately into LV)
  \item
    VSD-type: Sub-aortic VSD with no PS
  \item
    D-TGA type: Sub-pulmonary VSD
  \item
    Can also have a ``doubly-committed'' or ``non-committed'' VSD
  \end{enumerate}
\end{itemize}

\hypertarget{presentation-23}{%
\paragraph{Presentation}\label{presentation-23}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:}

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    TOF presents like TOF
  \item
    TGA-type presents like TGA, but usually w/ better mixing
  \item
    VSD type like VSD
  \end{enumerate}
\item
  \textbf{PE:} Variable, based on type of DORV
\end{itemize}

\hypertarget{studies-14}{%
\paragraph{Studies}\label{studies-14}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} No hallmark EKG, because of variety of physiology types
\item
  \textbf{CXR:} Cardiomegaly and pulm flow depend on degree of PS present
\end{itemize}

\hypertarget{treatment-21}{%
\paragraph{Treatment}\label{treatment-21}}

\begin{itemize}
\tightlist
\item
  Medical management determined by Qp:Qs
\item
  Treat CHF if present
\item
  \textbf{Surgical repair:} Depends on physiology
\item
  \textbf{Surgical goal:} Separation of pulmonary and systemic circulations versus single ventricle repair
\end{itemize}

\hypertarget{truncus-arteriosus}{%
\subsubsection{Truncus arteriosus}\label{truncus-arteriosus}}

\hypertarget{lesion-15}{%
\paragraph{Lesion}\label{lesion-15}}

\includegraphics{images/cardiology_truncus-arteriosus.png}

\hypertarget{basics-15}{%
\paragraph{Basics}\label{basics-15}}

\begin{itemize}
\tightlist
\item
  Failure of embryonic truncus arteriosus to septate
\item
  Associated w/ a VSD, aortic arch and coronary anomalies
\item
  Several subtypes depending on how PAs come off the truncus
\item
  Cyanosis is secondary to \textbf{mixing}
\item
  Both ventricles feed both arteries, pulmonary overcirculation worsens as PVR falls
\item
  Associated w/ 22q11 syndrome
\end{itemize}

\hypertarget{presentation-24}{%
\paragraph{Presentation}\label{presentation-24}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} CHF over first few weeks as PVR falls and dependent on degree of truncal valve regurgitation
\item
  \textbf{PE:} loud single S2, ejection click. SEM at LUSB. Diastolic decrescendo murmur from truncal regurgitation. Bounding pulses from diastolic runoff.
\end{itemize}

\hypertarget{studies-15}{%
\paragraph{Studies}\label{studies-15}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} LVH, RVH
\item
  \textbf{CXR:} Cardiomegaly. Increased pulmonary vascular markings. +/- right-sided aortic arch.
\end{itemize}

\hypertarget{treatment-22}{%
\paragraph{Treatment}\label{treatment-22}}

\begin{itemize}
\tightlist
\item
  Treat CHF if present
\item
  \textbf{Surgical repair:} Division of pulmonary arteries from truncus and placement of RV-PA conduit. Closure of VSD (i.e.~Rastelli operation).
\item
  \textbf{Surgical goal:} Establishing separated pulmonary and systemic circulations
\end{itemize}

\hypertarget{pulmonary-atresia-with-ivs}{%
\subsubsection{Pulmonary atresia with IVS}\label{pulmonary-atresia-with-ivs}}

\hypertarget{lesion-16}{%
\paragraph{Lesion}\label{lesion-16}}

\includegraphics{images/cardiology_pulm-atresia-ivs.png}

\hypertarget{basics-16}{%
\paragraph{Basics}\label{basics-16}}

\begin{itemize}
\tightlist
\item
  Either membranous (valve leaflets are fused) or muscular (no valve tissue)
\item
  Pulm flow depends on PDA
\item
  R → L shunt via atrial
\item
  Results in varying degrees of RV hypoplasia
\item
  Can result in RV-dependent coronary circulation wherein large portions of coronaries are supplied by high-pressure RV cavity instead of from aorta
\end{itemize}

\hypertarget{presentation-25}{%
\paragraph{Presentation}\label{presentation-25}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Cyanosis at birth that worsens as PDA closes
\item
  \textbf{PE:} PDA murmur
\end{itemize}

\hypertarget{studies-16}{%
\paragraph{Studies}\label{studies-16}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} Mild LAD from weak right side, RAE
\item
  \textbf{CXR:} ↓ pulm markings
\end{itemize}

\hypertarget{treatment-23}{%
\paragraph{Treatment}\label{treatment-23}}

\begin{itemize}
\tightlist
\item
  PGE in newborns
\item
  Cannot decompress RV if RVDCC → single ventricle palliation
\item
  If non-RVDCC, can establish RV-PA continuity in cath lab or OR, some get ``1.5 V'' repair if RV hypoplastic
\end{itemize}

\hypertarget{surgical-repair-of-chd}{%
\subsection{Surgical Repair of CHD}\label{surgical-repair-of-chd}}

\hypertarget{stage-1-operation-aka-norwood-operation}{%
\subsubsection{Stage 1 Operation (aka Norwood Operation)}\label{stage-1-operation-aka-norwood-operation}}

\hypertarget{indications}{%
\paragraph{Indications}\label{indications}}

Single ventricle heart disease with obstruction to systemic blood flow and hypoplastic aortic arch (prototype HLHS)

\hypertarget{goals}{%
\paragraph{Goals}\label{goals}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Establish systemic blood flow (DKS anastomosis creates neo-aortic valve from pulmonary valve, AscAo anastomosed end-to-side to provide coronary blood flow), aortic arch repair
\item
  Provide pulmonary blood flow:

  \begin{enumerate}
  \def\labelenumii{\arabic{enumii}.}
  \setcounter{enumii}{2}
  \tightlist
  \item
    mBTS (continuous flow, results in diastolic hypotension)
  \item
    Sano shunt (RV-PA conduit, less diastolic run off, but requires right ventriculotomy
  \end{enumerate}
\item
  Provide adequate mixing at atrial level/left atrial decompression (atrial septectomy)
\end{enumerate}

\hypertarget{post-op-sats}{%
\paragraph{Post-op Sats}\label{post-op-sats}}

75-85\%

\includegraphics{images/cardiology_norwood.png}

\hypertarget{bidirectional-glenn}{%
\subsubsection{Bidirectional Glenn}\label{bidirectional-glenn}}

\hypertarget{indications-1}{%
\paragraph{Indications}\label{indications-1}}

Intermediate step in single ventricle palliation (may be second operation for some (i.e.~HLHS)), or first operation for others (i.e.~some types of tricuspid atresia)

\hypertarget{goals-1}{%
\paragraph{Goals}\label{goals-1}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Provide passive pulmonary blood flow (anastomose SVC to RPA)
\item
  Volume-unload systemic ventricle (takedown mBTS or Sano)
\end{enumerate}

\hypertarget{post-op-sats-1}{%
\paragraph{Post-op Sats}\label{post-op-sats-1}}

80s

\hypertarget{complications}{%
\paragraph{Complications}\label{complications}}

Results in no hepatic blood reaching the lungs and can lead to pulmonary AVMs

\includegraphics{images/cardiology_bidirectional-glenn.png}

\hypertarget{fontan}{%
\subsubsection{Fontan}\label{fontan}}

\hypertarget{description}{%
\paragraph{Description}\label{description}}

Can be ``lateral tunnel'' (Fontan pathway within lateral atrium) or extra-cardiac. Usually ``fenestrated'' (small hole connecting Fontan pathway to systemic atrium: obligate right-to-left shunt).

\hypertarget{indications-2}{%
\paragraph{Indications}\label{indications-2}}

Last stage of single ventricle palliation (common pathway for heterogenous group of conditions)

\hypertarget{goals-2}{%
\paragraph{Goals}\label{goals-2}}

Increase pulmonary blood flow and provide ``hepatic factor'' to the lungs to prevent AVMs (IVC connected to PAs via Fontan pathway)

\hypertarget{post-op-sats-2}{%
\paragraph{Post-op Sats}\label{post-op-sats-2}}

\begin{quote}
90\%
\end{quote}

\hypertarget{complications-1}{%
\paragraph{Complications}\label{complications-1}}

Results in elevated CVP and chronic low CO, leads to a host of end organ problems including Fontan-associated liver disease, plastic bronchitis and PLE

\includegraphics{images/cardiology_fontan.png}

\hypertarget{arterial-switch-operation}{%
\subsubsection{Arterial Switch Operation}\label{arterial-switch-operation}}

\hypertarget{indications-3}{%
\paragraph{Indications}\label{indications-3}}

May be used as one component of the ``double switch operation'' for congenitally corrected TGA, or in some types of DORV

\hypertarget{goals-3}{%
\paragraph{Goals}\label{goals-3}}

Create circulation that is ``in series'' rather than ``parallel'' by connecting translocating aorta and MPA above the valves (coronaries are moved as ``buttons'' with the aorta)

\hypertarget{complications-2}{%
\paragraph{Complications}\label{complications-2}}

Post-op issues can include coronary obstruction and supravalvar PS/AS

\includegraphics{images/cardiology_arterial-switch1.png} \includegraphics{images/cardiology_arterial-switch2.png}

\hypertarget{catheterization-caring-for-the-post-cath-child}{%
\subsection{Catheterization \& Caring for the Post-Cath Child}\label{catheterization-caring-for-the-post-cath-child}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Inspect access site (usually femoral or neck) for bleeding or hematoma formation
\item
  Assess distal pulses and ensure they are intact and equal bilaterally
\item
  Compare lower extremity warmth, edema and skin color:

  \begin{enumerate}
  \def\labelenumii{\arabic{enumii}.}
  \setcounter{enumii}{3}
  \tightlist
  \item
    Signs of venous thrombus include edema, increased warmth and erythema
  \item
    Signs of arterial thrombus include pain, pallor, paresthesia/numbness, poor pulses and cool extremities
  \end{enumerate}
\item
  Listen to heart and lung sounds and think about what you should be hearing given what procedures were performed
\item
  Most patients will require at least one hemoglobin/hematocrit check to ensure they are not bleeding
\item
  Some patients will require a chest x-ray to ensure they have not developed a pneumothorax and to ensure their device has not migrated
\end{enumerate}

\hypertarget{complications-3}{%
\paragraph{Complications}\label{complications-3}}

Hematoma, pulseless limb, pulmonary hemorrhage, PTX, bowel ischemia, stroke

\begin{figure}
\centering
\includegraphics{images/cardiology_post-cath-presssures-sats.png}
\caption{Normal post-cath pressures \& sats}
\end{figure}

\hypertarget{cardiomyopathy}{%
\subsection{Cardiomyopathy}\label{cardiomyopathy}}

\hypertarget{hypertrophic-cardiomyopathy-hcm}{%
\subsubsection{Hypertrophic Cardiomyopathy (HCM)}\label{hypertrophic-cardiomyopathy-hcm}}

\hypertarget{presentation-26}{%
\paragraph{Presentation}\label{presentation-26}}

Often discovered incidentally on EKG (LVH, T-wave abnormalities) or as part of familial screening. If symptomatic: Dyspnea, exertional chest pain, fatigue, presyncope, syncope, palpitations, ventricular arrhythmias and sudden death

\hypertarget{physical-exam-5}{%
\paragraph{Physical Exam}\label{physical-exam-5}}

Left-sided heave and lateral displacement of the PMI; audible S4 and a harsh mid to late systolic murmur at the mid to lower left sternal border that is louder while standing as well as w/ the Valsalva maneuver (as decreased LV volume worsens the obstruction)

\hypertarget{pathophysiology-9}{%
\paragraph{Pathophysiology}\label{pathophysiology-9}}

Autosomal dominant inheritance of mutation in sarcomeric proteins. Myofibrillar disarray and hypertrophy of the LV, most commonly the interventricular septum → LVOT obstruction and diastolic dysfunction (though other patterns of hypertrophy are seen). Associated with some syndromes (i.e.~Noonan syndrome).

\hypertarget{work-up-9}{%
\paragraph{Work-up}\label{work-up-9}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG} may show left axis deviation, LVH w/ or w/o strain, and pathologic septal Q waves in the inferior and lateral leads +/- LA enlargement
\item
  \textbf{Echo} w/ diagnostic LV and septal hypertrophy
\item
  +/- Cardiac MRI (to assess tissue characteristics and risk stratify), catheterization, EP studies, genetic testing
\end{itemize}

\hypertarget{treatment-24}{%
\paragraph{Treatment}\label{treatment-24}}

\begin{itemize}
\tightlist
\item
  ICD if high-risk features of history of arrhythmia
\item
  Beta-blockers or calcium channel blockers reduce obstruction and have antiarrhythmic properties
\item
  Septal or left ventricular myomectomy and septal alcohol ablation are sometimes utilized
\item
  Severe cases may require heart transplant
\end{itemize}

\hypertarget{dilated-cardiomyopathy}{%
\subsubsection{Dilated Cardiomyopathy}\label{dilated-cardiomyopathy}}

\hypertarget{presentation-27}{%
\paragraph{Presentation}\label{presentation-27}}

Signs of right-sided heart failure (peripheral edema, hepatomegaly, JVD) and left-sided heart failure (pulmonary crackles, cold extremities and weak pulses); often tachycardic, tachypneic, DOE

\hypertarget{physical-exam-6}{%
\paragraph{Physical Exam}\label{physical-exam-6}}

Systolic murmur (representing AV valve regurgitation) may be present w/ an audible S3 or S4

\hypertarget{pathophysiology-10}{%
\paragraph{Pathophysiology}\label{pathophysiology-10}}

Systolic dysfunction w/ enlargement of ventricles. Often idiopathic but can be secondary to myocarditis, thyroid disease, metabolic disease, nutrient deficiencies (selenium, carnitine, thiamine), drugs (especially anthracyclines), toxins, radiation, infiltrative processes, muscular dystrophies, familial DCM syndromes.

\hypertarget{work-up-10}{%
\paragraph{Work-up}\label{work-up-10}}

\begin{itemize}
\tightlist
\item
  \textbf{CXR} w/ cardiomegaly, pulmonary vascular congestion/edema
\item
  \textbf{EKG} w/ sinus tachycardia and may show LVH and non-specific ST-T changes; may be low voltages and atrial enlargement; arrhythmias may be present
\item
  \textbf{Echo} w/ LV chamber dilation and poor contractility
\end{itemize}

\hypertarget{treatment-25}{%
\paragraph{Treatment}\label{treatment-25}}

Diuretics, ACE inhibitors, digoxin. May require mechanical support (VAD, ECMO) or heart transplant.

\hypertarget{arrhythmogenic-cardiomyopathy}{%
\subsubsection{Arrhythmogenic Cardiomyopathy}\label{arrhythmogenic-cardiomyopathy}}

\hypertarget{presentation-28}{%
\paragraph{Presentation}\label{presentation-28}}

Predominately symptoms attributable to ventricular tachyarrhythmia (syncope, SCD, presyncope, palpitations), or less commonly signs of heart failure

\hypertarget{pathophysiology-11}{%
\paragraph{Pathophysiology}\label{pathophysiology-11}}

Fibrofatty replacement of the ventricular myocardium leading to dangerous ventricular dysrhythmias (and less often SVT) and ventricular dysfunction. Both ventricles can be involved (RV-dominant, LV-dominant, and biventricluar phenotypes)

\hypertarget{work-up-11}{%
\paragraph{Work-up}\label{work-up-11}}

EKG, echocardiogram, EP studies, MRI and genetic testing

\hypertarget{treatment-26}{%
\paragraph{Treatment}\label{treatment-26}}

\begin{itemize}
\tightlist
\item
  Beta-blockers, restriction from sports
\item
  If history of VT or VF or have certain high-risk features, should have an ICD placed
\end{itemize}

\hypertarget{restrictive-cardiomyopathy}{%
\subsubsection{Restrictive Cardiomyopathy}\label{restrictive-cardiomyopathy}}

\hypertarget{presentation-29}{%
\paragraph{Presentation}\label{presentation-29}}

Signs and symptoms of heart failure (see CHF section below)

\hypertarget{pathophysiology-12}{%
\paragraph{Pathophysiology}\label{pathophysiology-12}}

Non-compliant ventricular tissue → \textbf{diastolic} dysfunction and atrial enlargement w/ relatively normal ventricular dimensions

\hypertarget{work-up-12}{%
\paragraph{Work-up}\label{work-up-12}}

Echo, cardiac cath, +/- cardiac MRI, consider genetic testing

\hypertarget{treatment-27}{%
\paragraph{Treatment}\label{treatment-27}}

Heart failure management (see CHF section below). May require heart transplant.

\hypertarget{left-ventricular-non-compaction-cardiomyopathy-lvnc}{%
\subsubsection{Left Ventricular Non-Compaction Cardiomyopathy (LVNC)}\label{left-ventricular-non-compaction-cardiomyopathy-lvnc}}

\hypertarget{presentation-30}{%
\paragraph{Presentation}\label{presentation-30}}

Signs and symptoms of heart failure (see CHF section below)

\hypertarget{pathophysiology-13}{%
\paragraph{Pathophysiology}\label{pathophysiology-13}}

During fetal cardiac development, the ventricular myocardium begins as a spongy, highly-trabeculated tissue that should become ``compacted'' ventricular cavity becomes relatively smooth, especially w/i the LV, which doesn't happen in patients w/ this In patients w/ LVNC

\begin{itemize}
\tightlist
\item
  Can have predominately dilated, predominately restrictive or mixed phenotypes
\end{itemize}

\hypertarget{work-up-13}{%
\paragraph{Work-up}\label{work-up-13}}

Echo, cardiac MRI, cardiac cath, consider genetic testing

\hypertarget{treatment-28}{%
\paragraph{Treatment}\label{treatment-28}}

Heart failure management (see CHF section below)

\hypertarget{congestive-heart-failure-chf}{%
\subsection{Congestive Heart Failure (CHF)}\label{congestive-heart-failure-chf}}

\hypertarget{presentation-31}{%
\paragraph{Presentation}\label{presentation-31}}

\begin{itemize}
\tightlist
\item
  \textbf{Infants:} Tachycardia, tachypnea, feeding difficulty, diaphoresis (particularly w/ feeding) and poor growth
\item
  \textbf{Children and adolescents:} Shortness of breath, orthopnea, cough, peripheral edema
\end{itemize}

\hypertarget{physical-exam-7}{%
\paragraph{Physical Exam}\label{physical-exam-7}}

Gallops, murmurs (MR/TR), hepatomegaly, edema of ankles or eyelids, tachypnea, tachycardia, crackles, cool extremities, delayed cap refill, weak pulses

\hypertarget{pathophysiology-14}{%
\paragraph{Pathophysiology}\label{pathophysiology-14}}

Multiple etiologies, including structural heart disease, arrhythmia, ischemia, cardiomyopathies, myocarditis, severe hypertension, and systemic issues (including severe anemia and severe thyroid disease)

\hypertarget{work-up-14}{%
\paragraph{Work-up}\label{work-up-14}}

\begin{itemize}
\tightlist
\item
  \textbf{CXR:} Cardiomegaly and pulmonary edema, Kerley B lines
\item
  \textbf{EKG:} Atrial or ventricular enlargement, ischemia, arrhythmia
\item
  \textbf{Echo:} Depressed systolic function, +/- ventricular dilation and/or hypertrophy
\item
  \textbf{Labs:} If severely depressed cardiac output, may have acidosis, elevated lactate, elevated BNP, abnormal electrolytes, and elevated CK and troponin (if myocardial injury is present). If right sided, may have abnormal liver studies.
\end{itemize}

\hypertarget{treatment-29}{%
\paragraph{Treatment}\label{treatment-29}}

\begin{itemize}
\tightlist
\item
  \textbf{Diuresis:} Furosemide or other loop diuretic are first-line. Thiazide diuretics and spironolactone also may be used, usually in chronic CHF.
\item
  \textbf{Inotropes:} Digoxin increases contractility. Dopamine or epinephrine may be used in sicker ICU patients.
\item
  \textbf{Afterload reduction:} ACE inhibitors decreased SVR and may positively impact cardiac remodeling. Milrinone infusion has a similar effect and may be used in sicker patients.
\item
  \textbf{Other measures:} O2 and correction of anemia aid O2 delivery. Salt restriction aids diuresis. Treating underlying illness (e.g.~infection, arrhythmia, acidosis) can improve contractility. Sedation and mechanical ventilation can decrease demand on the heart.
\end{itemize}

\hypertarget{coronary-artery-anomalies}{%
\subsection{Coronary Artery Anomalies}\label{coronary-artery-anomalies}}

\hypertarget{anomalous-left-coronary-artery-off-the-pulmonary-artery-alcapa}{%
\subsubsection{Anomalous Left Coronary Artery off the Pulmonary Artery (ALCAPA)}\label{anomalous-left-coronary-artery-off-the-pulmonary-artery-alcapa}}

\hypertarget{presentation-32}{%
\paragraph{Presentation}\label{presentation-32}}

Recurrent episodes of irritability and emesis, as well as \textbf{signs of congestive heart failure in infants} (diaphoresis, tachycardia, tachypnea, respiratory distress, weak peripheral pulses and cool extremities +/- gallop or MR murmur)

\hypertarget{pathophysiology-15}{%
\paragraph{Pathophysiology}\label{pathophysiology-15}}

Left coronary artery arises from the pulmonary artery rather than left coronary cusp of aortic valve → massive ischemia once PVR falls (reversal of flow from coronaries into PA)

\includegraphics{images/cardiology_alcapa.png}

\hypertarget{work-up-15}{%
\paragraph{Work-up}\label{work-up-15}}

\begin{itemize}
\tightlist
\item
  \textbf{CXR:} Cardiomegaly, pulmonary edema
\item
  \textbf{EKG:} Signs of anterolateral ischemia manifest as pathologic Q waves (often very deep, but fairly narrow), inverted T waves and ST-segment elevation in leads I, aVL and V4-V6. Prolonged QTc may also be seen
\item
  \textbf{Echo} is definitive, may confirm w/ MR/CT/angiography
\end{itemize}

\hypertarget{treatment-30}{%
\paragraph{Treatment}\label{treatment-30}}

Surgery to reimplant LCA to aorta and patch pulmonary artery

\hypertarget{anomalous-aortic-origin-of-a-coronary-artery-aaoca}{%
\subsubsection{Anomalous Aortic Origin of a Coronary Artery (AAOCA)}\label{anomalous-aortic-origin-of-a-coronary-artery-aaoca}}

\hypertarget{presentation-33}{%
\paragraph{Presentation}\label{presentation-33}}

Range: asymptomatic → massive ischemia and sudden death

\hypertarget{pathophysiology-16}{%
\paragraph{Pathophysiology}\label{pathophysiology-16}}

Variation in the number, shape or location of the ostia (origin) of the coronary arteries, usually non pathologic. LCA or LAD arising from the right coronary cusp leads the anomalous vessel to course anteriorly around the aortic valve, placing the vessel between the aorta and pulmonary artery and at risk for compression during times of peak cardiac output.

\includegraphics{images/cardiology_aaoca.png}

\hypertarget{treatment-31}{%
\paragraph{Treatment}\label{treatment-31}}

\begin{itemize}
\tightlist
\item
  Anomalous LCA from the right coronary cusp (picture on L) is always treated w/surgery, even if asymptomatic, due to high risk of sudden death
\item
  Anomalous RCA from the left coronary cusp (picture on R) is also associated w/ increased frequency of sudden death, though to a lesser extent; treatment is controversial
\end{itemize}

\hypertarget{pulmonary-hypertension-phtn}{%
\subsection{Pulmonary Hypertension (pHTN)}\label{pulmonary-hypertension-phtn}}

\hypertarget{presentation-34}{%
\paragraph{Presentation}\label{presentation-34}}

\textbf{Acute} → sx of R heart failure. \textbf{Chronic} → dyspnea w/ exertion and fatigue.

\begin{itemize}
\tightlist
\item
  Can lead to hemoptysis and sudden death from acute R heart failure from pulmonary hypertensive crisis
\item
  May become cyanotic with acute increases in PVR if ASD present (which can preserve CO)
\end{itemize}

\hypertarget{physical-exam-8}{%
\paragraph{Physical Exam}\label{physical-exam-8}}

RV heave, +/- TR murmur, cyanosis, clubbing, RHF signs such as JVD, hepatomegaly, peripheral edema

\hypertarget{pathophysiology-17}{%
\paragraph{Pathophysiology}\label{pathophysiology-17}}

Mean pulmonary atrial pressure \textgreater20 mmHg. Causes are:

\begin{itemize}
\tightlist
\item
  Pulmonary arterial HTN
\item
  Left heart dysfunction/obstruction
\item
  Lung pathology or hypoxemia
\item
  Chronic thromboembolism
\item
  Multifactorial
\end{itemize}

\hypertarget{work-up-16}{%
\paragraph{Work-up}\label{work-up-16}}

\begin{itemize}
\tightlist
\item
  \textbf{EKG:} RV hypertrophy often w/ accompanying strain (excessive right-sided forces for age w/ QRS-T angle \textgreater{} 90 degrees). In children, upright T-waves in V1 after 7-10 days of life suggests this diagnosis as can a qR pattern in V1.
\item
  \textbf{CXR:} May show mildly enlarged cardiac chambers, underlying lung disease, and prominent proximal pulmonary arteries w/ diminished distal pulmonary vasculature
\item
  \textbf{Echo:} May show enlarged or hypertrophied right-sided chambers. Position of the interventricular septum (which should bow into the usually low pressure RV) may flatten or bow into the LV. If present, the TR jet can estimate systolic RV pressure using the Bernoulli equation (upper limit of normal is \textasciitilde25mmHg). Septal defects may also be used in this manner.
\item
  \textbf{Cardiac catheterization} is definitive diagnosis. Mean PA pressures \textgreater20 mmHg are diagnostic. Often performed w/ pulmonary vasodilator testing to assess response to potential therapies.
\end{itemize}

\hypertarget{treatment-32}{%
\paragraph{Treatment}\label{treatment-32}}

\begin{itemize}
\tightlist
\item
  Correct underlying cause!
\item
  Counseling to avoid strenuous activity (esp.~isometric exertion), avoid alpha adrenergic meds
\item
  \textbf{Pulmonary vasodilators} can be used: Remodulin (IV infusion of trepostinil), Bosentan (endothelin receptor antagonist), Sildenafil (phosphodiesterase inhibitor), nifedipine (calcium channel blocker), iNO, supplemental oxygen
\end{itemize}

\hypertarget{cardiac-infections}{%
\subsection{Cardiac Infections}\label{cardiac-infections}}

\hypertarget{myocarditis}{%
\subsubsection{Myocarditis}\label{myocarditis}}

\hypertarget{presentation-35}{%
\paragraph{Presentation}\label{presentation-35}}

Range: asymptomatic → chest pain, palpitations, syncope, CHF w/ DOE and fatigue

\hypertarget{physical-exam-9}{%
\paragraph{Physical Exam}\label{physical-exam-9}}

Fever, tachycardia, ventricular arrhythmias, new murmur or cardiogenic shock (poor pulses, hypotension, cool extremities)

\hypertarget{pathophysiology-18}{%
\paragraph{Pathophysiology}\label{pathophysiology-18}}

Usually due to \textbf{viruses} (coxsackie B, adenovirus and enterovirus, and more recently HHV6 virus and parvovirus B19, measles, mumps, rubella, CMV, HIV, arboviruses, parvovirus, and influenza) or \textbf{inflammatory conditions} (Kawasaki disease, ARF)

\hypertarget{work-up-17}{%
\paragraph{Work-up}\label{work-up-17}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} CBC, inflammatory markers, cardiac enzymes, viral serologies, +/- rheumatologic screening if a systemic inflammatory process is suspected
\item
  \textbf{CXR:} May show cardiomegaly and pulmonary vascular congestion/edema
\item
  \textbf{EKG:} Non-specific. May show sinus tachycardia, arrhythmia, heart block, prolonged QT-interval, bundle branch blocks, abnormal QRS axis, diffusely low voltage QRS complexes (\textless5 mm in full standard across the limb leads), non-specific ST-T changes, and diffuse ST elevations w/ PR depression if there is coincident pericarditis
\item
  \textbf{Echo:} Useful for evaluating cardiac function and ruling out other causes of cardiac dysfunction, but cannot definitively diagnosis myocarditis
\item
  \textbf{Gadolinium-enhanced cardiac MRI} that shows late gadolinium enhancement is suggestive of myocarditis, though is somewhat non-specific
\item
  \textbf{Endomyocardial biopsy} via right heart cath may be diagnostic, but has low sensitivity due to sampling error
\end{itemize}

\hypertarget{treatment-33}{%
\paragraph{Treatment}\label{treatment-33}}

Largely supportive:

\begin{itemize}
\tightlist
\item
  Tx CHF w/ diuretics, ACE inhibitors, +/- milrinone (can worsen hypotension), inotropes, +/- antiarrhythmics, anticoagulant
\item
  IVIG used but data is limited
\item
  Fulminant myocarditis may require mechanical support with ECMO or VAD
\end{itemize}

\hypertarget{endocarditis}{%
\subsubsection{Endocarditis}\label{endocarditis}}

\hypertarget{presentation-36}{%
\paragraph{Presentation}\label{presentation-36}}

\begin{itemize}
\tightlist
\item
  \textbf{Subacute:} Low-grade fevers, myalgias, fatigue, weight loss, exercise intolerance
\item
  \textbf{Acute:} Rapid, fulminant, high fevers, toxic appearance (usually \emph{S. aureus})
\end{itemize}

\hypertarget{physical-exam-10}{%
\paragraph{Physical Exam}\label{physical-exam-10}}

Tachycardia, new murmur, splenomegaly, \textbf{Roth spots} (retinal lesion), \textbf{Janeway lesions} (palms/soles), \textbf{Osler nodes} (painful fingers and toes), \textbf{splinter hemorrhages}

\hypertarget{pathophysiology-19}{%
\paragraph{Pathophysiology}\label{pathophysiology-19}}

Bacteria (usually \emph{S. aureus,} viridans strep, coag neg staph) that damage endothelium and set off clotting cascade leading to fibrin deposition over valve

\hypertarget{work-up-18}{%
\paragraph{Work-up}\label{work-up-18}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} BCx x3 initially, then daily if persistently febrile. CBC w/ elevated WBC, +/- anemia. Elevated ESR and CRP. Microscopic hematuria due to renal emboli.
\item
  \textbf{CXR:} May show evidence of CHF or septic emboli
\item
  \textbf{EKG:} May show AV conduction defects if vegetation involves conduction system
\item
  \textbf{Echo:} TTE is adequate in most kids; TEE indicated only if TTE inadequate. Absence of vegetations on echo does not exclude a clinical dx of endocarditis.
\end{itemize}

\hypertarget{diagnosis-3}{%
\paragraph{Diagnosis}\label{diagnosis-3}}

\begin{itemize}
\tightlist
\item
  Pathologic criteria: Pathologic lesions on histology (vegetation/abscess w/ active IE), OR microorganism identified on histology or culture of vegetation/abscess
\item
  Clinical criteria (\textbf{Modified Duke Criteria}): 2 major, OR 1 major + 3 minor, OR 5 minor:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Major Criteria:} (1) \emph{\textgreater{}} 2 blood cultures w/ typical organisms (or persistently positive); (2) Endocardial involvement (vegetation, abscess, new valvular regurgitation)
  \item
    \textbf{Minor Criteria:} (1) Predisposition; (2) Fever; (3) Vascular phenomena (septic emboli, mycotic aneurysm, ICH, Roth spots, Janeway lesion); (4) Immunologic phenomena (GN, RF+, Osler nodes)
  \end{itemize}
\end{itemize}

\hypertarget{treatment-34}{%
\paragraph{Treatment}\label{treatment-34}}

\begin{itemize}
\tightlist
\item
  \textbf{Antibiotics:} Empirically cover \emph{Staph, Strep, Enterococci} (e.g.~vanc) → tailor based on sensitivities; generally x4-6 wks
\item
  \textbf{Surgery:} If persistent bacteremia despite adequate abx therapy, heart failure, progressive valvular dysfunction, conduction tissue involvement, or large lesion at high risk of embolizing
\end{itemize}

\hypertarget{complications-4}{%
\paragraph{Complications}\label{complications-4}}

Heart failure (most common indication for surgery), perivalvular abscess (suspect if new conduction abnormality or persistent bacteremia), pericarditis, septic emboli, metastatic abscess, embolic stroke, renal infarction

\hypertarget{pericarditis}{%
\subsubsection{Pericarditis}\label{pericarditis}}

\hypertarget{presentation-37}{%
\paragraph{Presentation}\label{presentation-37}}

Chest pain (often relieved by leaning forward) +/- tachypnea and dyspnea

\hypertarget{physical-exam-11}{%
\paragraph{Physical Exam}\label{physical-exam-11}}

Friction rub, weak apical impulse, poor perfusion, hepatomegaly

\hypertarget{pathophysiology-20}{%
\paragraph{Pathophysiology}\label{pathophysiology-20}}

\textbf{Infectious} (bacterial, viral (Coxsackie), fungal, parasitic, TB), \textbf{inflammatory} (ARF, SLE, uremia, radition, drugs), traumatic, oncologic, chronic (constrictive pericarditis)

\hypertarget{work-up-19}{%
\paragraph{Work-up}\label{work-up-19}}

\textbf{EKG} w/ decreased precordial voltages indicate \textbf{effusion}; diffuse ST elevation w/ PR depression is seen in \textbf{pericarditis}. Electrical alternans may manifest as QRS of alternating amplitude or axis, and is seen in pericardial \textbf{effusion.} There may be diffusely low voltage (\textless{} 5mm in full standard) QRS complexes in the limb leads.

\hypertarget{treatment-35}{%
\paragraph{Treatment}\label{treatment-35}}

NSAIDs and colchicine, treat underlying cause

\hypertarget{references-1}{%
\subsection{References}\label{references-1}}

\hypertarget{cellular-therapy}{%
\section{Cellular Therapy}\label{cellular-therapy}}

\hypertarget{introduction}{%
\subsection{Introduction}\label{introduction}}

Hematopoietic Cell Transplantation (HCT) is a powerful intervention that has the potential to cure numerous malignant and non-malignant disorders. For cancer, HCT allows high dose chemotherapy to be used +/- a graft-vs-leukemia effect (if allogeneic). For non-malignant disorders (hemoglobinopathy, immunodeficiency, primary HLH), the HCT can replace genetically defective cells with those that do not have the mutation.

As you can imagine, whether you are treating a malignant or non-malignant disorder fundamentally affects how you approach a transplant. For malignant disease, it is more important to use myeloablative conditioning (MAC) to try to completely eliminate all cancer cells. By contrast, when treating a non-malignant disorder, a mixed chimerism may sometimes be sufficient to provide functional cure, and reduced intensity conditioning (RIC) is an option. It is less about eliminating all patient bone marrow cells and more about sneaking in enough that work (note: if too few sneak in, they might be kicked out by patient = ``graft failure'').

With MAC, there is higher potential for graft-vs-host disease (GvHD), given the high amounts of inflammation that occur, which is usually a precipitating factor for the GvH response. There are also more long-term sequelae of aggressive chemotherapy.

RIC is theoretically gentler with regards to GvHD and chemotoxicity. However, as mentioned, it increases the risk of graft failure, which is a scenario where the patient rejects the graft and can lead to disease recurrence with autologous recovery (bad) or pancytopenia (also bad).

The major risks of transplant are: chemotoxicity, veno-occlusive disease (VOD), transplant associated thrombotic microangiopathy (TA-TMA), infection, GvHD, and graft failure. We will try to outline the clinical and laboratory signs of these complications in the coming sections, along with the approximate time period after transplant one might expect them. Treatments shown reflect common practice at DFCI, but there is considerable variation across institutions.

Overall, transplant outcomes have significantly improved over the past few decades. While we see the sickest patients in our ICU, there are many we don't see that are now thriving at home.

The cell therapy field is also witnessing some exciting innovations. Using gene editing, there are gene-corrected autologous HCTs being tested for a variety of monogenic disorders. Cytotoxic T lymphocyte therapies are being refined for viremia that is refractory to standard treatment. And, of course, how could we fail to mention CAR T?

\hypertarget{hematopoietic-cell-transplantation-hct}{%
\subsection{Hematopoietic Cell Transplantation (HCT)}\label{hematopoietic-cell-transplantation-hct}}

\hypertarget{graft}{%
\subsubsection{Graft}\label{graft}}

\begin{itemize}
\item
  CD34+ cells: the hematopoietic stem cells (HSC) that help reconstitute blood cell lineages in a patient
\item
  T-cells: donor T-cells can recognize patient as foreign → GvHD (bad) or graft-vs-leukemia effect = GvL (good); meanwhile, residual host T cells can recognized donor as foreign → graft failure (bad)
\item
  Other mixed immune cells
\end{itemize}

\hypertarget{donor-types}{%
\subsubsection{Donor Types}\label{donor-types}}

\emph{Everyone has a donor; some are more ideal than others}

Autologous Donor - self

\begin{itemize}
\tightlist
\item
  To rescue a patient's hemopoietic system after high-dose chemotherapy for solid tumors (not appropriate for other indications)
\end{itemize}

Allogeneic -- Related Donor

\begin{itemize}
\tightlist
\item
  Matched Related Donor (MRD) - biological sibling

  \begin{itemize}
  \tightlist
  \item
    bone marrow aspirated from sibling shortly before planned transplant
  \item
    cord blood can be used if newly born sibling is known to be a match prior to birth
  \item
    best outcomes; preferable for HCT for non-malignant disorders to optimize risk:benefit ratio
  \end{itemize}
\item
  Haplo-identical Donor -- biological parent

  \begin{itemize}
  \tightlist
  \item
    not first choice but option that is available for most patients
  \item
    may have pre- or post-transplant T-cell depletion to reduce risk of GvHD (see below)
  \end{itemize}
\end{itemize}

Allogeneic -- Unrelated (Matched or Mismatched)

\begin{itemize}
\tightlist
\item
  Sources: peripheral blood stem cells (PBSCs), bone marrow, cord blood (marrow most common at DFCI)
\item
  Higher chance of GvHD and graft failure
\item
  Can T-cell deplete via positive or negative selection

  \begin{itemize}
  \tightlist
  \item
    Positive selection -- CD34+ HSCs isolated using magnetic beads and are used as product for transfusion (most common for PBSCs)
  \item
    Negative selection -- giving patients serotherapy like anti-thymocyte globulin (ATG) or alemtuzumab (Campath™) to kill the T-cells in the graft
  \end{itemize}
\end{itemize}

\hypertarget{conditioning-regimens}{%
\subsubsection{Conditioning Regimens}\label{conditioning-regimens}}

\begin{itemize}
\tightlist
\item
  Myeloablative (MAC)

  \begin{itemize}
  \tightlist
  \item
    Common regimens: busulfan-fludarabine ``Bu/Flu'' or Busulfan-Cyclophosphamide ``Bu/Cy''
  \end{itemize}
\item
  Reduced Intensity (RIC)

  \begin{itemize}
  \tightlist
  \item
    Common regimens: Fludarabine-Melphalan-Campath ``Flu/Mel/Campath''
  \end{itemize}
\end{itemize}

\emph{Considerations based on disease indication and any baseline organ damage}

\hypertarget{timeline}{%
\subsubsection{Timeline}\label{timeline}}

\begin{itemize}
\item
  Patients are admitted 1-2 weeks before stem cell infusion, during which they have central access placed and receive their conditioning regimen to deplete their hematopoietic cells (max effect delayed per below)
\item
  Stem cell infusion occurs on Day 0; the WBC nadir is usually Day +8-12
\item
  Engraftment (ANC \textgreater500 x3 days) generally occurs by Day +14-28 depending on the cell source and conditioning used
\item
  Criteria for discharge: neutrophil engraftment, no active infections, patient able to PO or tolerate NG (usually a 6-week admission at minimum)
\end{itemize}

\hypertarget{complications-5}{%
\subsubsection{Complications}\label{complications-5}}

\emph{All patients experience complications; some are inevitable (e.g.~mucositis) and we work through them; others we try hard to avoid (e.g.~graft failure)}

BEFORE STEM CELL INFUSION

\begin{itemize}
\tightlist
\item
  Anaphylactic/infusion reactions to agents (e.g.~DMSO, ATG, Campath™)
\end{itemize}

DURING STEM CELL INFUSION

\begin{itemize}
\tightlist
\item
  Generally uneventful, but watch blood pressure
\end{itemize}

AFTER STEM CELL INFUSION

\begin{itemize}
\item
  Mucositis

  \begin{itemize}
  \tightlist
  \item
    Chemotherapy kills the mucosal layer in the GI tract; extremely painful; patients can't eat and require TPN for a period of time
  \end{itemize}
\item
  Pancytopenia (before engraftment occurs)

  \begin{itemize}
  \tightlist
  \item
    Infection, anemia, and bleeding risks
  \item
    Handle with transfusions and infection prophylaxis
  \item
    Aid neutrophil recovery by giving Filgrastim
  \end{itemize}
\item
  Graft-vs-host Disease

  \begin{itemize}
  \tightlist
  \item
    Risk factors: HLA mismatch, MAC, non-CD34 selected PBSC graft
  \item
    Acute GvHD usually onsets within the first 100 days

    \begin{itemize}
    \tightlist
    \item
      Skin rash, diarrhea, liver toxicity (not necessarily all)
    \end{itemize}
  \item
    Chronic GvHD onsets after Day +100

    \begin{itemize}
    \tightlist
    \item
      More scleroderma like, lung disease (bronchiolitis obliterans), joint pain
    \end{itemize}
  \item
    Prophylaxis with: Calcineurin inhibitor (Cyclosporine \textgreater\textgreater{} tacrolimus) + methotrexate (MTX) or CellCept (MMF)
  \item
    Treatment with: steroids
  \end{itemize}
\item
  Veno-occlusive Disease (a.k.a. SOS)

  \begin{itemize}
  \tightlist
  \item
    Risk factors: MAC, busulfan, pre-existing liver dysfunction
  \item
    Usually onsets within first 28 days of transplant
  \item
    Warning signs: weight gain, ascites, painful hepatomegaly, rising LFTs, persistent thrombocytopenia
  \item
    May need PICU admission for hepatopulmonary or hepatorenal syndrome (respiratory failure, AKI)
  \item
    Prophylaxis with: ursodiol, Vit-E
  \item
    Treatment with: defibrotide
  \end{itemize}
\item
  Transplant-associated Thrombotic Microangiopathy (TA-TMA)

  \begin{itemize}
  \tightlist
  \item
    Systemic endothelial injury → Coombs negative hemolysis (schistocytes!), platelet aggregation with microvascular thrombi (possible organ damage), and subsequent thrombocytopenia
  \item
    Possible signs: \emph{de novo} anemia and thrombocytopenia, schistocytes, new hypertension, elevated LDH, proteinuria, and terminal complement activation (sC5b-C9)
  \item
    Treatment: eculizumab (terminal complement inhibitor)
  \end{itemize}
\item
  Graft Failure (GF)

  \begin{itemize}
  \tightlist
  \item
    If patient never achieves engraftment or if it is subsequently lost
  \item
    Risk factors: RIC, HLA mismatch, certain conditioning agents
  \item
    May require stem cell boost or second transplant to overcome pancytopenia
  \end{itemize}
\item
  CMV

  \begin{itemize}
  \tightlist
  \item
    Highest risk when there is a mismatch between donor/recipient status prior to transplant; monitor with weekly PCR
  \item
    Viremia may take off when engraftment occurs
  \item
    Challenge is that effective agents like valganciclovir are myelosuppressive, which can damage the graft
  \item
    Symptoms: diarrhea, pneumonia, ocular disease
  \end{itemize}
\item
  EBV

  \begin{itemize}
  \tightlist
  \item
    B-cells infected with EBV proliferate but T-cells usually keep them in check
  \item
    With GvHD prophylaxis, T-cells are inhibited and patient can develop post-transplant lymphoproliferative disorder (PTLD)
  \end{itemize}
\item
  Adenovirus, BK virus, HHV6, CLABSI
\item
  Posterior Reversible Encephalopathy Syndrome (PRES)

  \begin{itemize}
  \tightlist
  \item
    Associated with use of calcineurin inhibitors (e.g.~cyclosporine and tacrolimus) used for GvHD prophylaxis
  \item
    AMS/seizures; diagnosed on MRI
  \end{itemize}
\item
  Late effects of chemotherapy

  \begin{itemize}
  \tightlist
  \item
    Patients get echocardiogram, PFTs, LFTs, kidney function tests prior to transplant as baseline
  \item
    Women may be offered egg preservation
  \item
    Can develop endocrine and reproductive issues, lung damage
  \end{itemize}
\end{itemize}

\hypertarget{cytotoxic-t-lymphocytes-ctls}{%
\subsection{Cytotoxic T Lymphocytes (CTLs)}\label{cytotoxic-t-lymphocytes-ctls}}

\hypertarget{concept}{%
\subsubsection{Concept}\label{concept}}

\begin{itemize}
\item
  CMV, EBV, and ADV are common viruses that can have high morbidity/mortality in immunocompromised patients that are s/p HCT
\item
  Current antiviral therapies like cidofovir \& valganciclovir may tackle viremia, but they do not address the root cause, which is the lack of virus-specific T cells; this is where CTLs can help
\item
  Steps to making a CTL therapy

  \begin{itemize}
  \tightlist
  \item
    Matched donor or third party donor provides peripheral blood mononuclear cells (PBMCs)
  \item
    These are exposed to viral antigens in vitro
  \item
    Virally activated T-cells are isolated from the T-cell milieu, expanded, and infused into patient
  \end{itemize}
\item
  Because T-cells are mostly specific to virus, there is less GvHD than with an unselected donor lymphocyte infusion
\item
  To increase efficiency of manufacturing, tri-valent CTLs (specific to CMV, EBV, \& ADV) are under investigation
\end{itemize}

\hypertarget{chimeric-antigen-receptor-car-t-cells}{%
\subsection{Chimeric Antigen Receptor (CAR) T-cells}\label{chimeric-antigen-receptor-car-t-cells}}

\hypertarget{concept-1}{%
\subsubsection{Concept}\label{concept-1}}

\begin{itemize}
\item
  T-cells are genetically engineered to actively target cells that express tumor specific antigens
\item
  First FDA approvals came in 2017 with Kymriah™ and Yescarta™ for treatment of B-cell ALL and lymphoma (CD19-specific CAR)
\item
  Steps to making a CAR T therapy

  \begin{itemize}
  \tightlist
  \item
    Autologous T-cells isolated from a patient
  \item
    T-cells are genetically modified to express CARs
  \item
    CAR T-cells are expanded in vitro
  \item
    Patient undergoes lymphodepleting chemotherapy
  \item
    CAR T therapy is infused
  \end{itemize}
\item
  What is a CAR?

  \begin{itemize}
  \tightlist
  \item
    Synthetic protein construct
  \item
    Extra-cellularly, there is a single-chain variable fragment (scFv) that recognizes tumor cell surface antigens
  \item
    Intracellularly, there is a co-stimulatory domain (e.g.~CD28, 4-1BB, ICOS) that provides the necessary co-stimulation signal and a T-cell intracellular signaling domain (CD3z)
  \item
    The extra- and intra-cellular domains are connected by a transmembrane fragment
  \end{itemize}
\item
  Who gets it?

  \begin{itemize}
  \tightlist
  \item
    At DFCI, CAR T is used as a bridge to transplant; ideally a patient with leukemia will be ``minimal-residual-disease'' (MRD) negative and then get a HCT as consolidation therapy
  \item
    However, if they are MRD+, CAR T can be used to get them into full remission before HCT; other places may not proceed to HCT\ldots it is so new that we are still getting the data for what recommendations should be
  \end{itemize}
\end{itemize}

\hypertarget{complications-6}{%
\subsubsection{Complications}\label{complications-6}}

\begin{itemize}
\tightlist
\item
  Cytokine Release Syndrome (CRS)

  \begin{itemize}
  \tightlist
  \item
    CAR T-cells are engineered to be activated (intrinsic co-stimulation)
  \item
    Within days of administration, especially if high tumor burden, can have surge of pro-inflammatory cytokines
  \item
    At its worst, this can lead to multi-organ failure and death
  \item
    Prevention: lower disease burden, monitor closely
  \item
    Treatment: tocilizumab
  \end{itemize}
\item
  Neurotoxicity

  \begin{itemize}
  \tightlist
  \item
    Altered mental status, myoclonus, and seizures have been witnessed with CD19 CAR T
  \item
    Unknown pathophysiology; appears to be reversible
  \end{itemize}
\end{itemize}

\hypertarget{emerging-cellular-therapies}{%
\subsection{Emerging Cellular Therapies}\label{emerging-cellular-therapies}}

\hypertarget{currently-in-clinical-trials}{%
\subsubsection{Currently in Clinical Trials}\label{currently-in-clinical-trials}}

\begin{itemize}
\tightlist
\item
  Gene-edited autologous HCT

  \begin{itemize}
  \tightlist
  \item
    For monogenic disorders (sickle cell, HLH, IPEX)
  \item
    Still have to improve conditioning regimen to be less toxic
  \end{itemize}
\item
  Next Generation CAR T

  \begin{itemize}
  \tightlist
  \item
    Extension to solid tumors and additional liquid tumors
  \item
    Built in safety mechanisms to prevent CRS (suicide genes)
  \item
    Built in features to prevent T-cell exhaustion and to assist with solid tumor penetration
  \item
    Multivalency to respond to combinations of antigens
  \item
    Linkage of CAR to T-reg to apply same principal to autoimmunity
  \end{itemize}
\item
  Regulatory T-cells (T-reg) therapy

  \begin{itemize}
  \tightlist
  \item
    For GvHD and autoimmune disease
  \item
    Working on preventing phenotype switching in vivo
  \end{itemize}
\item
  Mesenchymal Stromal Cell therapy

  \begin{itemize}
  \tightlist
  \item
    For GvHD and autoimmune disease
  \item
    Working on improving efficacy
  \end{itemize}
\item
  Combined marrow and organ transplant

  \begin{itemize}
  \tightlist
  \item
    For inducing tolerance to solid organ transplantation
  \item
    Most evidence for combined marrow and kidney transplantation, with some evidence for lung
  \end{itemize}
\end{itemize}

\hypertarget{critical-care-icp}{%
\section{Critical Care \& ICP}\label{critical-care-icp}}

\hypertarget{vasopressors-inotropes}{%
\subsection{Vasopressors \& Inotropes}\label{vasopressors-inotropes}}

\begin{itemize}
\tightlist
\item
  Dopamine

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      1-20 mcg/kg/min (1-5 mostly affects DA; 6-10 β1; 11-20 α1)
    \end{itemize}
  \item
    Mechanism

    \begin{itemize}
    \tightlist
    \item
      DA, β1, α1
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Lower doses primarily cause inotropy \& chronotropy (β1); DA-mediated splanchnic vasodilation of uncertain clinical significance
    \item
      Higher doses will increase SVR and chronotropy, could decrease CO if afterload-sensitive
    \item
      Can be used w/ norepinephrine for distributive or hypovolemic shock as higher doses increase SVR
    \end{itemize}
  \end{itemize}
\item
  Epinephrine (EPI)

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      0.05-1 mcg/kg/min
    \end{itemize}
  \item
    Mechanism

    \begin{itemize}
    \tightlist
    \item
      β1, β2 \textgreater{} α1
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Increases CO, SVR w/ effects on CO \textgreater{} effects on SVR
    \item
      Due to strong inotropic effects, preferred agent for cardiogenic shock
    \end{itemize}
  \end{itemize}
\item
  Norepinephrine (NE)

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      0.01-1 mcg/kg/min
    \end{itemize}
  \item
    Mechanism

    \begin{itemize}
    \tightlist
    \item
      α1 \textgreater{} β1 \textgreater{} β2
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Primarily increases SVR, minimal change to HR
    \end{itemize}
  \end{itemize}
\item
  Milrinone

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      0.25-1 mcg/kg/min
    \end{itemize}
  \item
    Mechanism

    \begin{itemize}
    \tightlist
    \item
      Phospho-diesterase (PDE) inhibitor
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Positive inotrope and decreases SVR (SVR effect more prominent - BP likely to decrease even if CO increases)
    \end{itemize}
  \item
    Useful for cardiogenic shock (CHF) w/ normal or high BP to reduce afterload and increase CO
  \end{itemize}
\end{itemize}

\hypertarget{shock-1}{%
\subsection{Shock}\label{shock-1}}

\hypertarget{definition-7}{%
\paragraph{Definition}\label{definition-7}}

Metabolic demands of body \textgreater{} delivered oxygen to tissues

\begin{itemize}
\tightlist
\item
  Oxygen delivery (DO2) = content of arterial oxygen (CaO2) x cardiac output (CO)
\item
  CaO2 = (1.34 x Hgb x \% O2 Sat) + (0.003 x PaO2)
\item
  CO = SV x HR, SV determined by preload, afterload, and contractility
\end{itemize}

\hypertarget{labs}{%
\paragraph{Labs}\label{labs}}

\begin{itemize}
\tightlist
\item
  \textbf{Blood gas} w/ \textbf{lactate}

  \begin{itemize}
  \tightlist
  \item
    Assess pH and bicarb to determine degree of metabolic acidosis due to anaerobic metabolism - note, bicarb on blood gas is calculated based on the pH and pCO2 - obtain chemistry to measure directly
  \item
    Increased lactate associated w/ inadequate tissue O2 delivery in shock states (but can also be elevated if not cleared appropriately, for example in liver failure)
  \end{itemize}
\item
  \textbf{Mixed venous saturation (ScvO2) / arterial-venous O2 difference}

  \begin{itemize}
  \tightlist
  \item
    Normal is 70-75\%, normal AVO2d is 25-30\%. ScvO2 often low in shock (inadequate delivery for utilization), can be high with hyperdynamic circulation, or may suggest impaired o2 utilization by cells due to injury (usually a bad sign)
  \item
    Most useful from central line terminating in distal SVC, preferably RA; not useful from peripheral VBG
  \item
    True pulmonary arterial saturation (SvO2) no longer routinely utilized
  \end{itemize}
\item
  \textbf{CBC} and \textbf{blood culture}

  \begin{itemize}
  \tightlist
  \item
    WBC count to assess infection
  \item
    Hemoglobin to assess oxygen carrying capacity (see CaO2 above)
  \end{itemize}
\item
  \textbf{Chem 10} w/ \textbf{LFTs}

  \begin{itemize}
  \tightlist
  \item
    Chemistry to assess solutes (Na, K, Cl, gluc), bicarb, renal function (BUN/Cr), intravascular volume status (BUN:Cr ratio)
  \item
    LFTs to assess liver damage(transaminase/GGT/bilirubin elevations)
  \end{itemize}
\end{itemize}

\hypertarget{types-of-shock}{%
\subsubsection{Types of Shock}\label{types-of-shock}}

\begin{itemize}
\tightlist
\item
  Hypovolemic

  \begin{itemize}
  \tightlist
  \item
    Causes

    \begin{itemize}
    \tightlist
    \item
      Dehydration, hemorrhage, osmotic diuresis, third-spacing fluid, burns
    \end{itemize}
  \item
    Physiology

    \begin{itemize}
    \tightlist
    \item
      Not enough fluid in vasculature → decreased preload \& CVP → low CO → decr. O2 delivery
    \end{itemize}
  \item
    Findings

    \begin{itemize}
    \tightlist
    \item
      Dry mucous membranes, oliguria, weak pulses w/ delayed capillary refill
    \end{itemize}
  \item
    Management

    \begin{itemize}
    \tightlist
    \item
      Fluid resuscitation, stop fluid losses if possible (e.g.~treat bleeding)
    \item
      Rapid transfusion protocol if hemorrhage
    \item
      Rapid infuser in ICUs, ED, OR
    \end{itemize}
  \end{itemize}
\item
  Distributive (septic, anaphylactic, neurogenic)

  \begin{itemize}
  \tightlist
  \item
    Causes

    \begin{itemize}
    \tightlist
    \item
      \textbf{Septic \& anaphylactic:} Vasodilation \& increased capillary permeability)
    \item
      \textbf{Neurogenic:} Loss of sympathetic innervation to vascular tone)
    \end{itemize}
  \item
    Physiology

    \begin{itemize}
    \tightlist
    \item
      Poor tone and/or leaking of vasculature → low SVR → relative hypovolemia/ preload, low DBP. Contractility may be depressed later in sepsis presentation, CVP will vary.
    \end{itemize}
  \item
    Findings

    \begin{itemize}
    \tightlist
    \item
      Bounding pulses \& brisk capillary refill if capillaries are leaky → warm extremities (\textbf{NOT} always true in pediatric septic shock!)
    \item
      Low DBP (especially in neurogenic), widened pulse pressure
    \end{itemize}
  \item
    Management

    \begin{itemize}
    \tightlist
    \item
      \textbf{Vasopressors:} New guidelines are \textbf{EPI for ``cold''} and \textbf{NE for ``warm,''} may also see dopamine and vasopressin)

      \begin{itemize}
      \tightlist
      \item
        Anaphylactic → EPI
      \item
        Neurogenic → NE
      \end{itemize}
    \end{itemize}
  \end{itemize}
\item
  Cardiogenic

  \begin{itemize}
  \tightlist
  \item
    Causes

    \begin{itemize}
    \tightlist
    \item
      Arrhythmias, myocarditis, CHF, cardiomyopathy, trauma, \textbf{cardiac tamponade, pulmonary embolism}
    \end{itemize}
  \item
    Physiology

    \begin{itemize}
    \tightlist
    \item
      Poor contractility or ability to relax → ineffective systolic output → decreased CO w/ initial low CVP and high SVR
    \end{itemize}
  \item
    Findings

    \begin{itemize}
    \tightlist
    \item
      Weak pulses w/ narrow pulse pressure (due to low SBP), pallor, cold extremities, delayed capillary refill, \textbf{signs of heart failure} (respiratory distress, hepatomegaly, JVD)
    \end{itemize}
  \item
    Management

    \begin{itemize}
    \tightlist
    \item
      LIMIT fluid resuscitation (5-10cc/kg)
    \item
      Inotropic agents (low dose dopamine, or epinephrine, less commonly dobutamine)
    \item
      Can consider milrinone if BP normal to decrease afterload
    \end{itemize}
  \end{itemize}
\item
  Obstructive

  \begin{itemize}
  \tightlist
  \item
    Causes

    \begin{itemize}
    \tightlist
    \item
      Pulmonary embolism, cardiac tamponade
    \end{itemize}
  \item
    Physiology

    \begin{itemize}
    \tightlist
    \item
      Ability to produce adequate CO is impaired because of obstruction
    \end{itemize}
  \item
    Findings

    \begin{itemize}
    \tightlist
    \item
      Tamponade - Pulsus paradoxus or electrical alternans, narrow pulse pressure w/ increased diastolic
    \end{itemize}
  \item
    Management

    \begin{itemize}
    \tightlist
    \item
      Specific to the underlying cause
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{septic-shock-treatment-algorithm1}{%
\subsubsection[Septic Shock Treatment Algorithm]{\texorpdfstring{Septic Shock Treatment Algorithm\footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{Septic Shock Treatment Algorithm}}\label{septic-shock-treatment-algorithm1}}

\includegraphics{images/critical-care_surviving-sepsis-initial-resuscitation-algorithm.png}
\includegraphics{images/critical-care_fluid-vasoactive-inotrope-management.png}

\hypertarget{analgesia-sedation-paralysis}{%
\subsection{Analgesia, Sedation \& Paralysis}\label{analgesia-sedation-paralysis}}

\hypertarget{analgesics}{%
\subsubsection{Analgesics}\label{analgesics}}

\begin{itemize}
\tightlist
\item
  \textbf{Morphine}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 20 min
    \item
      Duration: 3-5 hrs
    \end{itemize}
  \item
    Bolus Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.05-0.1 mg/kg/dose q1-2h
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Can be associated w/ histamine release leading to hypotension, pruritus, flushing
    \end{itemize}
  \end{itemize}
\item
  \textbf{Hydromorphone (Dilaudid)}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 15 min
    \item
      Duration: 5 hrs
    \end{itemize}
  \item
    Bolus Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.015 mg/kg/dose q3h
    \end{itemize}
  \item
    Considerations
  \end{itemize}
\item
  \textbf{Fentanyl}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: Immediate
    \item
      Duration: 30-60 min
    \end{itemize}
  \item
    Bolus Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 1-2 mcg/kg/dose q1h
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Minimal hemodynamic instability w/ bolus doses
    \item
      Large/rapid bolus doses can lead to muscle rigidity, interfering w/ ventilation → administer NMB or naloxone, support breathing
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{sedatives}{%
\subsubsection{Sedatives}\label{sedatives}}

\begin{itemize}
\tightlist
\item
  \textbf{Dexmedetomidine}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 5 min
    \item
      Duration: 1-2 hrs
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      0.2-2 mcg/kg/hr
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Dose-dependent bradycardia is common
    \item
      Can also cause hypertension or hypotension
    \end{itemize}
  \end{itemize}
\item
  \textbf{Midazolam (Versed)}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 1-5 min
    \item
      Duration: 2-6 hrs
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.05-0.1 mg/kg/dose q1-2h
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Dose-dependent hypotension and respiratory depression
    \end{itemize}
  \end{itemize}
\item
  \textbf{Lorazepam (Ativan)}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 15-30 min
    \item
      Duration: 8-12 hrs
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.05 mg/kg/dose q4h-q12h
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Same adverse effects as midazolam, longer duration of action
    \end{itemize}
  \end{itemize}
\item
  \textbf{Ketamine}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 30 sec
    \item
      Duration: 5-10 min
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      \textbf{Intubation:} IV:1-2 mg/kg/dose (load) + 0.5 mg/kg/dose q5min PRN
    \item
      \textbf{Conscious sedation:} IV: 0.2 - 1 mg/kg (load) + 0.5 mg/kg q10min PRN
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Dissociative (causes trance-like state associated w/ amnesia, but patients still move). Mild analgesic.
    \item
      Myocardial depressant, but also increases catecholamine release
    \item
      Bronchodilator
    \end{itemize}
  \end{itemize}
\item
  \textbf{Propofol}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 60 sec
    \item
      Duration: 3-10 min
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      25-150 mcg/kg/min, bolus 1-2 mg/kg
    \item
      Only credentialed ICU/anesth in non-intubated patients. Attgs can bolus (or fellow under direct supervision). Infusion not to last longer than 12 hrs in children.
    \end{itemize}
  \item
    Considerations
  \item
    Dose-dependent hypotension (vasodilation and myocardial depression)
  \item
    Prolonged/high dose infusions increase risk of propofol infusion syndrome (cardiac failure, arrhythmias, rhabdo, lactic acidosis, among other problems). Children at higher risk.
  \end{itemize}
\end{itemize}

\hypertarget{paralytics}{%
\subsubsection{Paralytics}\label{paralytics}}

\begin{itemize}
\tightlist
\item
  \textbf{Rocuronium}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 60-90 sec (high dose); 2-3 min (low dose)
    \item
      Duration: 30-60 min
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.6-1.2mg/kg/dose
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      High dose (1.2mg/kg) has more rapid onset but also longer duration, can be used for rapid sequence intubation
    \end{itemize}
  \end{itemize}
\item
  \textbf{Vecuronium}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 1-2 min
    \item
      Duration: 20-60 min
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.1 mg/kg/dose, or infusion of 0.1mg/kg/hr
    \end{itemize}
  \item
    Considerations
  \end{itemize}
\item
  \textbf{Cisatracurium}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 1-3 min
    \item
      Duration: 25-44 min
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 0.2 mg/kg/dose, or infusion
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Undergoes non-enzymatic degradation in circulation, thus duration of action remains same in patients w/ liver/renal dysfxn
    \end{itemize}
  \end{itemize}
\item
  \textbf{Succinylcholine}

  \begin{itemize}
  \tightlist
  \item
    Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      Onset: 30-60 sec
    \item
      Duration: 5-10 min
    \end{itemize}
  \item
    Dose

    \begin{itemize}
    \tightlist
    \item
      IV: 1-2 mg/kg
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      See below
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{rapid-sequence-intubation-rsi}{%
\subsection{Rapid Sequence Intubation (RSI)}\label{rapid-sequence-intubation-rsi}}

*****NOTE:** Pre-oxygenate w/ 100\% O2 for 2-5 min whenever possible!*

\hypertarget{pre-med-appetizer}{%
\subsubsection{Pre-Med (``Appetizer'' 🥗)}\label{pre-med-appetizer}}

\begin{itemize}
\tightlist
\item
  \textbf{Atropine}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      0.02 mg/kg IV/IO (min 0.1mg, max 0.5mg)
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Prevents vagal response
    \item
      \textbf{\emph{Use if \textless1yo or \textless5yo if using succinylcholine!}}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Lidocaine 2\%}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      1 mg/kg IV
    \item
      Give 2-5 min prior to paralysis
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Likely ↓ ICP, RAD
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{induction-main-course}{%
\subsubsection{Induction (``Main Course'' 🍔)}\label{induction-main-course}}

\begin{itemize}
\tightlist
\item
  \textbf{Ketamine}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      1-2 mg/kg IV
    \item
      \textbf{Duration:} 30-60 min
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Bronchodilator, ↑ BP
    \item
      \textbf{CON:} ↑ ICP, dysphoria, sialogogue, cardiodepressant
    \item
      \textbf{\emph{Contraindications: ↑ ICP, globe injury, psychosis}}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Propofol}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      1-4 mg/kg IV
    \item
      \textbf{Onset time:} 60 sec
    \item
      \textbf{Duration:} 3-10 min
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} ↓ ICP, anti-emetic
    \item
      \textbf{CON:} ↓↓↓ BP, ↓ cardiac output
    \item
      \textbf{\emph{Contraindications: Shock, cardiac dysfunction, hypersensitivity}}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Midazolam}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      0.1 mg/kg IV/IO
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Short-acting
    \item
      \textbf{CON:} ↓ BP, respiratory depression
    \item
      \textbf{\emph{Contraindications: HD instability}}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Fentanyl}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      2-4 mcg/kg IV/IO
    \item
      \textbf{Onset time:} 90 sec
    \item
      \textbf{Duration:} 30-60 min
    \item
      \textbf{\emph{Give slowly!}}
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Short-acting opiate, hemodynamically neutral
    \item
      \textbf{CON:} Apnea, chest wall rigidity
    \item
      \textbf{\emph{Contraindications: Hypersensitivity}}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Etomidate}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      0.3 mg/kg IV
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Best agent for HD stability
    \item
      \textbf{CON:} Adrenal suppression, clonic movements
    \item
      \textbf{\emph{Contraindications: Septic shock}}
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{paralysis-dessert}{%
\subsubsection{Paralysis (``Dessert'' 🍰)}\label{paralysis-dessert}}

\begin{itemize}
\tightlist
\item
  \textbf{Succinylcholine}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      1-2 mg/kg IV
    \item
      \textbf{Onset:} 60 sec
    \item
      \textbf{Offset:} 5-10 min
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Depolarizing agent
    \item
      \textbf{PRO:} Good for laryngospasm
    \item
      \textbf{CON:} Not reversible, can provoke hyperkalemia or malignant hyperthermia in susceptible individuals ,
    \item
      \textbf{\emph{Contraindications:}}

      \begin{itemize}
      \tightlist
      \item
        \textbf{\emph{↑ K+: Renal failure, burns, crush injury, neuromusc. dz, paraplegia}}
      \item
        \textbf{\emph{Malignant hyperthermia (hx or risk)}}
      \item
        \textbf{\emph{Pseudocholinesterase deficiency (will prolong effect)}}
      \item
        \textbf{\emph{Known difficult intubation/upper airway obstruction (can't be reversed)}}
      \item
        \textbf{\emph{Globe injury, glaucoma}}
      \end{itemize}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Rocuronium}

  \begin{itemize}
  \tightlist
  \item
    Dosing \& Pharmacokinetics

    \begin{itemize}
    \tightlist
    \item
      1.2 mg/kg IV
    \item
      \textbf{Onset:} 2 min
    \item
      \textbf{Offset:} 30 min
    \item
      Hepatic \textgreater{} renal excretion
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      \textbf{PRO:} Safe alternative agent, reversible with neostigmine or sugammadex
    \item
      \textbf{CON:} Longer onset/offset, transient HTN, hypotension also possible
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{respiratory-support-ventilation-oxygenation}{%
\subsection{Respiratory Support: Ventilation \& Oxygenation}\label{respiratory-support-ventilation-oxygenation}}

\hypertarget{high-flow-nasal-cannula-hfnc}{%
\subsubsection{High-Flow Nasal Cannula (HFNC)}\label{high-flow-nasal-cannula-hfnc}}

\hypertarget{definition-8}{%
\paragraph{Definition}\label{definition-8}}

Delivery of heated and humidified air and oxygen at rates that exceed spontaneous inspiratory flow

\hypertarget{indications-contraindications}{%
\paragraph{Indications \& Contraindications}\label{indications-contraindications}}

\begin{itemize}
\tightlist
\item
  Indications

  \begin{itemize}
  \tightlist
  \item
    Respiratory distress/dyspnea to offload work of breathing
  \item
    Asthma
  \item
    Bronchiolitis
  \item
    Tracheomalacia
  \item
    Preoxygenation/apneic oxygenation prior to and during intubation
  \end{itemize}
\item
  Contraindications

  \begin{itemize}
  \tightlist
  \item
    Hypercarbic respiratory failure
  \item
    Inability to protect airway
  \item
    Impaired or absent spontaneous respiratory drive
  \item
    Facial anomalies or injuries that preclude nasal cannula fit
  \item
    Excessive oral or nasal secretions
  \item
    Active vomiting
  \item
    Bowel obstruction
  \item
    Existing air leak (pneumothorax/pneumomediastinum)
  \item
    Agitation or confusion predicting inability to tolerate
  \end{itemize}
\end{itemize}

\hypertarget{bronchiolitis-hfnc-pathway}{%
\paragraph{Bronchiolitis HFNC Pathway}\label{bronchiolitis-hfnc-pathway}}

\begin{itemize}
\tightlist
\item
  Inclusion criteria: Age \textless2yo w/ dx of bronchiolitis, hypoxia requiring \textgreater2L/min LFNC or 35\% FiO2, or persistent increased WOB
\item
  Initiate at 1 L/kg/min and adjust FiO2 to goal SpO2 \textgreater90\%
\item
  Reassess hourly to determine if can wean or need to escalate:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Weaning:} Wait until patient has achieved 8 hr period of stability on current flow rate and FiO2 has been weaned to 21\%-30\%

    \begin{itemize}
    \tightlist
    \item
      If current support 1L/kg/min, turn HFNC off and transition to LFNC if still requiring FiO2
    \item
      If not 1 L/kg/min, decrease flow to 1L/kg/min and then turn HFNC off after 8 hr period of stability
    \item
      Monitor patient in setting that can restart HFNC for 8-12 hrs after discontinuation
    \end{itemize}
  \item
    \textbf{Escalation:} If no clinical improvement or increased WOB, escalate to 2 L/kg/min and continue to reassess hourly

    \begin{itemize}
    \tightlist
    \item
      If clinical improvement, can advance to \textbf{weaning} pathway
    \item
      If no clinical improvement, consider transition to \textbf{NIPPV}
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{non-invasive-positive-pressure-ventilaion-nippv}{%
\subsubsection{Non-Invasive Positive Pressure Ventilaion (NIPPV)}\label{non-invasive-positive-pressure-ventilaion-nippv}}

\hypertarget{interface}{%
\paragraph{Interface}\label{interface}}

Nasal mask, facemask, RAM nasal cannula depending on patient

\begin{itemize}
\tightlist
\item
  Consult w/ RT at BCH or BMC to evaluate patient early for best interface for NIPPV
\end{itemize}

\hypertarget{continuous-positive-airway-pressure-cpap}{%
\paragraph{Continuous Positive Airway Pressure (CPAP)}\label{continuous-positive-airway-pressure-cpap}}

\begin{itemize}
\tightlist
\item
  Provides continuous airway pressure (\textbf{PEEP}). FiO2 can be adjusted to improve oxygenation as well.
\item
  \textbf{Mechanism:} Alveolar recruitment improved, which improves oxygenation through better V/Q matching
\item
  \textbf{Indications:} Hypoxic respiratory failure, obstructive sleep apnea, upper airway obstruction
\item
  \textbf{Considerations:} No ``breaths'' delivered, so patient \textbf{MUST} be spontaneously breathing
\end{itemize}

\hypertarget{bilevel-positive-airway-pressure-bipap}{%
\paragraph{Bilevel Positive Airway Pressure (BiPAP)}\label{bilevel-positive-airway-pressure-bipap}}

\begin{itemize}
\tightlist
\item
  Provides inspiratory pressure (\textbf{IPAP}) (compared to PIP), and expiratory pressure (\textbf{EPAP}) (compared to PEEP). Can also adjust FiO2 to improve oxygenation.
\item
  \textbf{Mechanism:} In addition to alveolar recruitment, delta pressure (IPAP - EPAP) influences tidal volume to improve ventilation (Minute Ventilation = Tidal Volume x Respiratory Rate). IPAP can also reduce work of breathing.
\item
  \textbf{Indications:} Hypoxic, hypercarbic or mixed respiratory failure
\item
  \textbf{Considerations:} Although you can set a mandatory breath rate in certain BiPAP modes, machine breaths that are not aligned w/ patient efforts do not result in good tidal volumes due to the noninvasive interface; therefore \textbf{not a good choice} for patients w/ inconsistent respiratory drive. \textbf{Relatively contraindicated} in patients w/ altered mental status or who cannot protect their airway (ie. no cough or gag) from aspiration.
\end{itemize}

\hypertarget{weaning-niv-support}{%
\paragraph{Weaning NIV Support}\label{weaning-niv-support}}

Refer to ICP SCAMP for pathway

\begin{itemize}
\tightlist
\item
  Criteria for \textbf{weaning} (must meet 4/5):

  \begin{itemize}
  \tightlist
  \item
    CV stability (HR and BP wnl for age or at patient baseline)
  \item
    Work of breathing none to mild
  \item
    FiO2 \emph{\textless{}} 40\%
  \item
    tcCO2 or pCO2 at baseline or wnl
  \item
    Afebrile
  \end{itemize}
\item
  Criteria for \textbf{sprinting} from NIV:

  \begin{itemize}
  \tightlist
  \item
    Clinical stability on goal setting for 4 hrs
  \item
    Tolerating airway clearance measures/suctioning
  \end{itemize}
\item
  Markers of \textbf{intolerance to sprinting} (if at any time 2 or more markers shown, resume NIV):

  \begin{itemize}
  \tightlist
  \item
    Tachypnea increased
  \item
    tcCO2, etCO2 or pCO2 increased by 10
  \item
    Work of breathing increased from none/mild to moderate or severe
  \item
    FiO2 increased to \emph{\textgreater{}} 50\% or NC \textgreater2 LPM from time of initiation of sprint
  \end{itemize}
\end{itemize}

\hypertarget{mechanical-ventilation-mv}{%
\subsubsection{Mechanical Ventilation (MV)}\label{mechanical-ventilation-mv}}

\hypertarget{glossary}{%
\paragraph{Glossary}\label{glossary}}

\begin{itemize}
\tightlist
\item
  \textbf{MBR} (mandatory breath rate): \# of breaths the ventilator will deliver to patient per minute (vent will ensure patient receives breaths if patient not spontaneously triggering the ventilator)
\item
  \textbf{RR:} MBR plus whatever spontaneous breaths the patient takes (breaths above MBR may or may not be supported depending on mode)
\item
  \textbf{PIP} (peak inspiratory pressure): Highest pressure the patient will see during the respiratory cycle
\item
  \textbf{PEEP} (positive end expiratory pressure): Pressure the lungs see during expiration (helps keep the alveoli open during expiration and prevent atelectasis)
\item
  \textbf{TV} (tidal volume): Max volume delivered to the patient during inspiration
\item
  \textbf{IT} (inspiratory time): Time over which tidal volume is delivered
\item
  \textbf{ET} (expiratory time): Time when inspiratory flow is not being delivered, generally longer than IT (basically what is left over after you have a certain number of breaths per minute w/ a certain Ti)
\item
  \textbf{MAP} (mean-airway pressure): (Ti x PIP) + (Te x PEEP) / (Ti + Te)
\end{itemize}

\hypertarget{general-principles-of-mechanical-ventilation}{%
\paragraph{General Principles of Mechanical Ventilation}\label{general-principles-of-mechanical-ventilation}}

\begin{itemize}
\tightlist
\item
  Improve \textbf{oxygenation} (increase \textbf{PaO2}) by recruiting alveoli and optimizing V/Q matching

  \begin{itemize}
  \tightlist
  \item
    Usually done by optimizing PEEP, MAP, I:E ratio. Can also increase inspired O2 concentration by increasing FiO2.
  \item
    Both atelectasis and overdistension must be avoided
  \end{itemize}
\item
  Improve \textbf{ventilation} (decrease \textbf{PaCO2}) by increasing alveolar ventilation

  \begin{itemize}
  \tightlist
  \item
    Adjust variables that influence RR, TV
  \item
    Remember: Lungs need to empty in order for new air from outside (pCO2 = 0) to enter (particularly in patients w/ obstructive physiology (asthma), which may require longer expiratory times)
  \end{itemize}
\end{itemize}

\hypertarget{modes-of-ventilation}{%
\paragraph{Modes of Ventilation}\label{modes-of-ventilation}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{AC (Assist-Control)}

  \begin{itemize}
  \tightlist
  \item
    Every breath is machine supported and has the same parameters (PIP, PEEP, Ti), whether patient-triggered or machine-triggered
  \item
    Breaths can be triggered by patient (assisted breaths) or elapsed time if patient not able to trigger (controlled breaths)
  \item
    Risk of overventilation if patient's spontaneous respiratory rate is high for other reasons (fever, agitation) or if ventilator is inappropriately triggering
  \item
    Can set to pressure control or volume control
  \end{itemize}
\item
  \textbf{SIMV (Synchronized Intermittent Mandatory Ventilation)}

  \begin{itemize}
  \tightlist
  \item
    Machine will synchronize breath delivery to align w/ patient's effort, but if patient is not triggering breaths frequently enough, machine provides mandatory breath rate to patient
  \item
    Often paired w/ pressure support ventilation (SIMV + PSV) to support breaths above mandatory breath rate
  \item
    Can set to pressure or volume control:

    \begin{itemize}
    \tightlist
    \item
      \textbf{Pressure Control:} Set pressure, tidal volume changes based on compliance (∆V/∆P)
    \item
      \textbf{Volume Control:} Set volume, pressure changes
    \end{itemize}
  \end{itemize}
\item
  \textbf{PRVC (Pressure-Regulated Volume Control)}

  \begin{itemize}
  \tightlist
  \item
    Ventilator adjusts pressure depending on exhaled tidal volume every 3rd breath
  \item
    Optimizes lowest pressure possible to achieve set tidal volume by constant automated adjustments
  \end{itemize}
\item
  \textbf{PS (Pressure Support)}

  \begin{itemize}
  \tightlist
  \item
    No mandatory breath rate, no set inspiratory time
  \item
    When patient triggers a breath, machine delivers a set level of pressure above PEEP
  \item
    Inspiratory time of breath determined by patient-driven inspiratory flow (flow cycling) - if patient is ``satisfied'' (inspiratory flow drops below a certain threshold from peak, because the patient stops actively inhaling), the ventilator will cycle into exhalation
  \end{itemize}
\end{enumerate}

\hypertarget{troubleshooting-desaturations-on-a-ventilator-dope}{%
\paragraph{Troubleshooting Desaturations on a Ventilator (``DOPE'')}\label{troubleshooting-desaturations-on-a-ventilator-dope}}

\begin{itemize}
\tightlist
\item
  \textbf{D}islodgement (of ETT): Mask ventilate, call staff assist
\item
  \textbf{O}bstruction (mucus plug): Suction, call nursing \& RT
\item
  \textbf{P}neumothorax: Obtain CXR, consider needle decompression if concern for tension physiology
\item
  \textbf{E}quipment failure: Bag-ETT to ventilate, call RT
\end{itemize}

\hypertarget{extracorporeal-membrane-oxygenation-ecmo}{%
\subsection{Extracorporeal Membrane Oxygenation (ECMO)}\label{extracorporeal-membrane-oxygenation-ecmo}}

\hypertarget{definition-9}{%
\paragraph{Definition}\label{definition-9}}

An extracorporeal circuit designed to provide prolonged pulmonary (\textbf{VV ECMO}) or cardiopulmonary (\textbf{VA ECMO}) support by removing blood from the native vascular system, performing gas and heat exchange and reinfusing the oxygenated blood into the body.

\begin{itemize}
\tightlist
\item
  \textbf{Venovenous (VV ECMO):} Drains systemic venous deoxygenated blood, oxygenates it and removes carbon dioxide, and returns oxygenated blood to the systemic venous system. Provides pulmonary support (blood still goes through native heart and lungs) and is effective in respiratory failure w/ \textbf{intact cardiac function}.
\item
  \textbf{Venoarterial (VA ECMO):} Drains systemic venous deoxygenated blood, oxygenates it and removes carbon dioxide, and returns oxygenated blood to systemic arterial system. Provides cardiopulmonary support (some blood bypasses native heart and lungs) and is effective in patients w/ \textbf{cardiopulmonary failure}.
\end{itemize}

\hypertarget{indications-contraindications-1}{%
\paragraph{Indications \& Contraindications}\label{indications-contraindications-1}}

\begin{itemize}
\tightlist
\item
  Indications

  \begin{itemize}
  \tightlist
  \item
    Hypoxemic respiratory failure w/ PaO2/FiO2 \textless{} 100 or Oxygenation Index (OI) \textgreater{} 40 despite optimized ventilator settings (PIP \textgreater{} 35 cm H20, PEEP \textgreater{} 10 cm H20, MAP \textgreater{} 18 cm H20; failure of high frequency ventilation) (OI = FiO2 * Mean Airway Pressure * 100/PaO2, note, multiply by 100 if (correctly) expressing FiO2 as a decimal; if using percent O2, don't multiply by 100))
  \item
    Persistent hypercapnic respiratory failure w/ arterial pH \textless{} 7.2 refractory to all ventilation modes.
  \item
    Refractory cardiogenic shock
  \item
    Cardiac arrest
  \item
    Failure to wean from intraoperative cardiopulmonary bypass
  \item
    VA ECMO or ventricular assist device (VAD) may be used as a bridge to cardiac transplant
  \item
    VV ECMO is potential bridge to lung transplant in certain circumstances
  \end{itemize}
\item
  Contraindications

  \begin{itemize}
  \tightlist
  \item
    Lack of reversible etiology of critical illness
  \item
    Irreversible, progresive, severe neurologic compromise
  \item
    Large intracranial hemorrhage prior to ECMO
  \item
    Severe bleeding
  \item
    Severe coagulopathy or refractory thrombocytopenia
  \item
    Unwitnessed out-of-hospital cardiac arrest
  \item
    Presence of Do Not Resuscitate (DNR) Order
  \item
    Pre-existing multiorgan failure
  \end{itemize}
\end{itemize}

\hypertarget{pre-ecmo-initiation}{%
\paragraph{Pre-ECMO Initiation}\label{pre-ecmo-initiation}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Type and cross, arterial blood gas, electrolytes, CBC, coags, lactic acid, LFTs, chem 10
\item
  Head US in neonates to rule out severe IVH
\item
  Echocardiogram to evaluate cardiac function and for structural CHD
\end{enumerate}

\hypertarget{titration}{%
\paragraph{Titration}\label{titration}}

\begin{itemize}
\tightlist
\item
  Titrate to achieve an \textbf{arterial O2 saturation} \textgreater90\% for VA ECMO and \textgreater80\% for VV ECMO (there is mixing of oxygenated and deoxygenated blood w/i the RA during VV ECMO), and \textbf{mixed venous O2 saturation} of \textgreater70\% for VA ECMO
\item
  Target normal lactates and arterial BP (measures of perfusion)
\end{itemize}

\hypertarget{complications-7}{%
\paragraph{Complications}\label{complications-7}}

\begin{itemize}
\tightlist
\item
  \textbf{Bleeding} is the most common complication (30-40\% by some estimates), can be life-threatening. May require immediate surgical intervention, brief cessation of heparin infusion or use of plasminogen inhibitors (i.e.~aminocaproic acid).
\item
  \textbf{Thromboembolism} is infrequent, but can be catastrophic, especially in VA ECMO where embolization is systemic
\item
  \textbf{Vessel perforation, dissection, or occlusion,} resulting in \textbf{distal ischemia} (latter can be seen in femoral arterial cannulation, treated w/ placement of a distal perfusion cannula)
\end{itemize}

\hypertarget{acute-respiratory-distress-syndrome-ards}{%
\subsection{Acute Respiratory Distress Syndrome (ARDS)}\label{acute-respiratory-distress-syndrome-ards}}

\hypertarget{definition-10}{%
\paragraph{Definition}\label{definition-10}}

\begin{itemize}
\tightlist
\item
  Acute respiratory failure not fully explained by cardiac etiology or fluid overload

  \begin{itemize}
  \tightlist
  \item
    Excludes patients w/ perinatal pulmonary disease
  \end{itemize}
\item
  CXR w/ pulmonary infiltrates (does not have to be bilateral)
\item
  Increased oxygenation index
\end{itemize}

\hypertarget{pathophysiology-21}{%
\paragraph{Pathophysiology}\label{pathophysiology-21}}

\begin{itemize}
\tightlist
\item
  No unifying pathophysiology for ARDS - can be direct injury (pneumonia, traumatic contusion) or indirect (systemic inflammation from sepsis)
\item
  Overall, insult causes alveolar cell damage filling of airspaces w/ exudate. Over \textasciitilde3 wks, granulation tissue formation occurs which leads to remodeling and fibrosis.
\item
  Alveolar collapse leads to V/Q mismatch
\end{itemize}

\hypertarget{clinical-manifestations-6}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-6}}

\begin{itemize}
\tightlist
\item
  Respiratory distress out of proportion to underlying disease
\item
  Hypoxemia
\item
  Decreased lung compliance
\end{itemize}

\hypertarget{diagnostic-studies}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies}}

\begin{itemize}
\tightlist
\item
  CXR: Commonly see bilateral infiltrates, although not required for diagnosis
\item
  ABG: High A-a gradient
\item
  PaO2 to FiO2 ratio is \textless{} 300
\end{itemize}

\hypertarget{management-7}{%
\paragraph{Management}\label{management-7}}

Lung protective ventilatory strategies to reduce ventilator-induced lung injury

\begin{itemize}
\tightlist
\item
  Maintain TV 4-6cc/kg, use PEEP to improve oxygenation (continue increasing PEEP if FiO2 \textgreater{} 0.6 and not hyperinflated). Target SpO2 88-94\% (wean if \textgreater98\%), goal FiO2 \textless{} 0.6.
\item
  Permissive hypercapnia (pH 7.15-7.30), PaCO2 60s
\end{itemize}

\hypertarget{hypertensive-crisis}{%
\subsection{Hypertensive Crisis}\label{hypertensive-crisis}}

\hypertarget{definitions}{%
\paragraph{Definitions}\label{definitions}}

\begin{itemize}
\tightlist
\item
  \textbf{Hypertensive Urgency:} Severe elevation in BP WITHOUT evidence of acute end-organ damage
\item
  \textbf{Hypertensive Emergency:} BP \textgreater Stage II HTN for age WITH evidence of \textbf{acute end-organ damage}
\end{itemize}

\hypertarget{etiology-1}{%
\paragraph{Etiology}\label{etiology-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Neonates:} Renovascular disease, congenital renal anomalies, BPD, coarctation
\item
  \textbf{Children:} Renovascular disease, glomerulonephritis, endocrine disease
\item
  \textbf{Adolescents:} Renovascular disease, drugs (cocaine, amphetamines, Serotonin Syndrome)
\end{itemize}

\hypertarget{clinical-manifestations-7}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-7}}

\begin{itemize}
\tightlist
\item
  \textbf{Hypertensive encephalopathy:} Headache, altered MS, vision changes, seizures, acute stroke
\item
  \textbf{Myocardial ischemia:} Acute chest pain, dyspnea, orthopnea, cough. Can hear diffuse, fine crackles at lung base, S3 gallop.
\item
  \textbf{Aortic dissection:} Chest \& abdominal pain, end-organ dysfunction
\item
  \textbf{Retinal hemorrhages} and exudates
\item
  \textbf{Malignant nephrosclerosis:} Leading to acute renal failure, hematuria, and proteinuria
\item
  \textbf{Posterior Reversible Encephalopathy Syndrome (PRES):} Encephalopathic or seizing patient in setting of acute hypertensive crisis w/ neuroimaging findings of reversible vasogenic subcortical edema w/o infarction. Edema usually seen in parietal and occipital lobes.
\end{itemize}

\hypertarget{diagnostic-studies-1}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-1}}

\begin{itemize}
\tightlist
\item
  4-extremity BPs
\item
  Fundoscopic exam
\item
  Chem 10 to evaluate for renal impairment
\item
  CBC +/- reticulocyte count and smear to look for microangiopathic anemia
\item
  UA to look for hematuria, proteinuria
\item
  EKG to look for evidence of LVH or myocardial ischemia
\item
  CXR if chest pain or SOB (look for cardiac enlargement, pulmonary edema)
\item
  Head CT or MRI if abnormal neurologic exam or mental status
\item
  Consider tox screen, pregnancy test, endocrine testing to look for underlying cause
\end{itemize}

\hypertarget{management-8}{%
\paragraph{Management}\label{management-8}}

\begin{itemize}
\tightlist
\item
  \textbf{Hypertensive Urgency:} Reduce BP slowly over 24-48 hrs

  \begin{itemize}
  \tightlist
  \item
    IV Hydralazine/Labetalol OR PO Isradipine/Clonidine
  \end{itemize}
\item
  \textbf{Hypertensive Emergency:} Reduce BP by 10-20\% over 1st hr, reduce by no more than 25\% in first 8 hrs

  \begin{itemize}
  \tightlist
  \item
    IV Hydralazine or Labetalol bolus, followed by Nicardipine or Labetalol infusion
  \end{itemize}
\end{itemize}

\hypertarget{medications-for-management-of-hypertensive-crisis}{%
\subparagraph{Medications for Management of Hypertensive Crisis}\label{medications-for-management-of-hypertensive-crisis}}

\begin{itemize}
\tightlist
\item
  \textbf{Hydralazine}

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      Start at 0.1-0.2 mg/kg/dose (max 20mg), max 0.5 mg/kg q4h
    \item
      Onset 10 min, duration 4-6 hrs
    \end{itemize}
  \item
    Indications

    \begin{itemize}
    \tightlist
    \item
      Short-term control of symptomatic hypertension
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Not for use in LV dysfunction
    \item
      Potential exists for prolonged hypotension
    \end{itemize}
  \end{itemize}
\item
  \textbf{Labetalol}

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      0.25-1 mg/kg/dose (max 40mg) as frequently as q5-10min, or continuous 0.25-1 mg/kg/hr
    \end{itemize}
  \item
    Indications

    \begin{itemize}
    \tightlist
    \item
      Short-term control of symptomatic hypertension
    \item
      For \textbf{pheochromocytoma}, use after initiation of an alpha blocker so as to not precipitate hypertensive crisis
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Not for use in myocardial dysfunction
    \end{itemize}
  \end{itemize}
\item
  \textbf{Nicardipine}

  \begin{itemize}
  \tightlist
  \item
    Dosing

    \begin{itemize}
    \tightlist
    \item
      Loading dose 5-10 mcg/kg, then 0.5-3.5 mcg/kg/min
    \item
      Peak effect at 30 min, lasting up to 4 hrs
    \end{itemize}
  \item
    Indications

    \begin{itemize}
    \tightlist
    \item
      Consider using w/ renal dysfunction
    \end{itemize}
  \item
    Considerations

    \begin{itemize}
    \tightlist
    \item
      Not for acute heart failure or coronary ischemia
    \item
      \textbf{Caution} in infants w/ calcium-dependent myocardium
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{diabetic-ketoacidosis-dka}{%
\subsection{Diabetic Ketoacidosis (DKA)}\label{diabetic-ketoacidosis-dka}}

\hypertarget{order-set}{%
\paragraph{Order Set}\label{order-set}}

\begin{itemize}
\tightlist
\item
  DKA ICP Order Set → Look for Excel calculator hyperlink for 2-Bag Method
\item
  Yellow DKA Card
\end{itemize}

\hypertarget{definition-11}{%
\paragraph{Definition}\label{definition-11}}

Plasma glucose \textgreater200 + Acidosis (pH \textless7.3 or venous HCO3 \textless15) + Ketonuria or ketonemia

\hypertarget{clinical-manifestations-8}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-8}}

\begin{itemize}
\tightlist
\item
  Hyperglycemia, vomiting, abdominal pain, dehydration, altered mental status
\item
  History of Type 1 Diabetes or weight loss, polyuria, polydipsia
\end{itemize}

\hypertarget{diagnostic-studies-2}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Initial:} Chem 10, beta-hydroxybutyrate, VBG, HgbA1c, consider pancreatic autoantibody panel, TFTs, c-peptide, insulin, urine ketones
\item
  While on \textbf{insulin infusion:}

  \begin{itemize}
  \tightlist
  \item
    Point of care glucose q1h
  \item
    Chem 10, beta-hydroxybutyrate, VBG q2h
  \end{itemize}
\item
  While on \textbf{subcutaneous insulin:}

  \begin{itemize}
  \tightlist
  \item
    Point of care glucose before meals/bed and q2am
  \item
    Chem 10, beta hydroxybutyrate, VBG only PRN
  \end{itemize}
\end{itemize}

\hypertarget{management-9}{%
\paragraph{Management}\label{management-9}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{FLUIDS:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{NS Bolus:} 10 cc/kg IV x1, may repeat with caution
  \item
    \textbf{2-Bag Method} for fluid management (defer if serum K \textgreater5 mEq/L)

    \begin{itemize}
    \tightlist
    \item
      1.5-2x maintenance rate - use excel calculator to titrate Bag \#1 and 2 rates
    \item
      Bag \#1 = NS + K Acetate 20 mEq/L + K Phos 20 mEq/L
    \item
      Bag \#2 = D12.5W + NS + K Acetate 20 mEq/L + K Phos 20 mEq/L
    \end{itemize}
  \item
    \textbf{Goal Dextrose Content} in infusion (based on blood glucose)

    \begin{itemize}
    \item
      \begin{quote}
      300 = 0\%
      \end{quote}
    \item
      276-300 = 5\%
    \item
      251-275 = 7.5\%
    \item
      201-250 = 10\%
    \item
      \textless200 = 12.5\%
    \end{itemize}
  \end{itemize}
\item
  \textbf{INSULIN INFUSION:} Start after 1hr of fluid administration)

  \begin{itemize}
  \tightlist
  \item
    Start infusion at 0.1 units/kg/hr (for mild DKA, can use 0.05 unit/kg/hr)
  \end{itemize}
\item
  \textbf{SUBCUTANEOUS (subQ) INSULIN:} Start when patient can tolerate PO, vpH \textgreater7.3, HCO2 \textgreater15, and/or anion gap 14)

  \begin{itemize}
  \tightlist
  \item
    Give the first rapid- and long-acting subQ insulin 15 min pre-meal. Stop IVF \& insulin drip 30 mins after subQ dose.
  \item
    Calculate \textbf{total daily dose (TDD)} based on chart in DKA card and per Endocrine consult
  \item
    \textbf{Basal-Bolus regimen} = ½ of TDD as Lantus or Tresiba once daily + ½ TDD as Humalog divided in meals
  \end{itemize}
\end{enumerate}

\hypertarget{complications-8}{%
\paragraph{Complications}\label{complications-8}}

\begin{itemize}
\tightlist
\item
  \textbf{CEREBRAL EDEMA:} Headache, emesis, increased BP, change in consciousness/responsiveness, delirium, confusion, unequal/dilated pupils, cranial nerve palsy, papilledema, incontinence, bradycardia, respiratory irregularity or arrest, sudden polyuria

  \begin{itemize}
  \tightlist
  \item
    Decrease IV rate, raise HOB to 30°
  \item
    Mannitol 1 g/kg IV over 15 min, follow UOP and VS
  \item
    Consider ETT placement for airway control \& hyperventilate to pCO2 patient had prior to intubation → slowly normalize over 12-24 hrs
  \item
    Consider STAT head CT once airway is stabilized
  \end{itemize}
\item
  \textbf{HYPOPHOSPHATEMIA:} Metabolic encephalopathy (irritability, paresthesias, confusion, seizure, coma), ileus, dysphagia, proximal myopathy, hemolysis
\item
  \textbf{HYPONATREMIA:} Presentation varies based on measured sodium (\textbf{Na 115-120} = seizure, coma, respiratory arrest. \textbf{Na 120-125} = lethargy, headache, obtundation. \textbf{Na 125-130} = nausea and malaise.)

  \begin{itemize}
  \tightlist
  \item
    If symptomatic, infuse 3\% hypertonic saline 5 mL/kg IV over 15 min, stop when symptoms resolve
  \end{itemize}
\item
  \textbf{HYPOGLYCEMIA:} If BG \textless200 and anion gap is near to normal, reduce insulin to 0.075 cc/kg/hr, then to 0.05 unit/kt/hr. Discuss with Endocrine prior to decreasing.
\item
  \textbf{HYPOKALEMIA:} If symptomatic, give 0.5-1 mEq/kg IV over 2 hrs with goal K=3.5 to 4.5
\item
  \textbf{HYPOCALCEMIA:} Decreased BP, tetany, laryngospasm. May result with excess phosphate administration.
\end{itemize}

\hypertarget{references-2}{%
\subsection{References}\label{references-2}}

\hypertarget{dermatology}{%
\section{Dermatology}\label{dermatology}}

\hypertarget{key-questions-for-taking-a-dermatologic-history}{%
\subsection{Key Questions for Taking a Dermatologic HIstory}\label{key-questions-for-taking-a-dermatologic-history}}

\begin{itemize}
\tightlist
\item
  When did it start? (ask for timepoints, i.e., ``before Christmas?'')
\item
  Does it itch, burn, or hurt?
\item
  When was the first episode?
\item
  Where on the body did it start? Was it present at birth?
\item
  How has it spread (pattern of spread)?
\item
  How have individual lesions changed? (Size, shape, color, itch, bleeding?)
\item
  Is there a family history? (eczema, acne, psoriasis, autoimmune disease)
\item
  What has made it worse or triggered it?
\item
  What have you tried for it? Did it help?
\item
  Hx of atopic triad (asthma, allergies, atopic dermatitis)?
\item
  New exposures: Medications? (Look at external med rec) Travel? Environmental?
\item
  Ask if they brought the medications they are using
\end{itemize}

\hypertarget{describing-dermatologic-lesions}{%
\subsection{Describing Dermatologic Lesions}\label{describing-dermatologic-lesions}}

\hypertarget{primary-lesion}{%
\subsubsection{Primary Lesion}\label{primary-lesion}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.68\columnwidth}\raggedright
Description of the ``family'' of a lesion\strut
\end{minipage} & \begin{minipage}[b]{0.18\columnwidth}\raggedright
Appearance\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Macule\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Flat, not palpable; color change; \textless1cm (e.g., freckle, labial macule)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-macule.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Patch\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Flat, not palpable; color change; \textgreater1cm (e.g., congenital nevus or large birthmark)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-patch.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Papule\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Raised; \textless1 cm (e.g.~mole, acne)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-papule.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Plaque\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Raised; \textgreater1 cm usual flat topped (e.g.~psoriasis)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-plaque.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Nodule\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Raised; round-topped lesion w/ depth; \textgreater0.5cm up to 1 cm (e.g.~acne)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-nodule.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Tumor\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Very large, round-topped lesion w/ depth, exophytic, endophytic or level w/ skin surface ; \textgreater1cm (e.g.~strawberry hemangioma of infancy)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-tumor.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Wheal\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Edematous, raised, hive-like\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\includegraphics{images/derm_lesions-wheal.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Vesicle\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Small fluid-containing blister \textless1cm (e.g.~chickenpox, shingles zoster)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Bulla\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Large fluid-containing blister \textgreater{} 1cm (e.g.~bullous pemphigoid)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Pustule\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Exudate filled; \textless1cm; can develop into furuncle, then abscess (e.g.~pustular psoriasis)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Telangiectasia\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Dilated superficial capillaries\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Verrucae\strut
\end{minipage} & \begin{minipage}[t]{0.68\columnwidth}\raggedright
Soft, tan-colored, cauliflower-like papules (e.g.~warts caused by HPV)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{secondary-changes}{%
\subsubsection{Secondary Changes}\label{secondary-changes}}

Describe the changes that occur superimposed upon the primary lesion

\begin{itemize}
\tightlist
\item
  \textbf{Scale:} Flakes of ``dead skin''; thickening of outermost layer (stratum corneum)
\item
  \textbf{Crust:} Adherent, dried serum, exudate or blood on the skin
\item
  \textbf{Desquamation:} Thicker scale that is shedding off
\item
  \textbf{Erosion:} Loss of superficial layers of skin (epidermis only involved, does not scar); erosions lead to ulcerations
\item
  \textbf{Ulceration:} Loss of deeper layers of skin (extends to dermis, scars)
\item
  \textbf{Fissure:} Deep linear cracks in skin
\item
  \textbf{Atrophy:} Thinning of skin; can be in the epidermis, dermis, or subcutaneous fat
\item
  \textbf{Excoriation:} Erosions due to scratching
\item
  \textbf{Lichenification:} Thickened, leather-like skin, normal skin lines accentuated
\item
  \textbf{Scar/keloid:} Permanent fibrotic changes that result from damage extending into the dermis, keloids extend beyond the borders of the original defect
\item
  \textbf{Umbilicated:} Centrally indented
\end{itemize}

\hypertarget{color-descriptor}{%
\subsubsection{Color Descriptor}\label{color-descriptor}}

\begin{itemize}
\tightlist
\item
  \textbf{Erythematous:} Blanchable red or pink hue in the skin, indicates vascular dilation; erythema is not a color per se
\item
  \textbf{Purpuric:} Violaceous color due to blood pigment
\item
  \textbf{Petechial:} Pinpoint, non-blanching bleeding into the skin from capillaries

  \begin{itemize}
  \tightlist
  \item
    \textbf{Purpura} = 1cm, \textbf{ecchymoses} \textgreater{} 1cm
  \end{itemize}
\item
  \textbf{Hyperpigmentation:} Darker than normal skin color
\item
  \textbf{Hypopigmentation:} Lighter than normal skin color
\end{itemize}

\hypertarget{lesion-shapes}{%
\subsubsection{Lesion Shapes}\label{lesion-shapes}}

\begin{itemize}
\tightlist
\item
  \textbf{Annular:} Ring-shaped lesion \includegraphics{images/derm_lesions-annular.png}
\item
  \textbf{Nummular/discoid/round:} Coin-shaped lesion \includegraphics{images/derm_lesions-nummular.png}
\item
  \textbf{Arcuate:} Arc-shaped lesion \includegraphics{images/derm_lesions-arcuate.png}
\item
  \textbf{Linear} Forming a line \includegraphics{images/derm_lesions-linear.png}
\item
  \textbf{Serpiginous:} Wavy like a snake \includegraphics{images/derm_lesions-serpiginous.png}
\item
  \textbf{Figurate/polycyclic:} Lots of different ring shapes, rings within rings \includegraphics{images/derm_lesions-figurate.png}
\item
  \textbf{Retiform/reticulate:} Web or net-like, following vasculature \includegraphics{images/derm_lesions-figurate.png}
\item
  \textbf{Targetoid:} Lesions with a bull's eye, or concentric rings or varying colors \includegraphics{images/derm_lesions-targetoid.png}
\end{itemize}

\hypertarget{distribution}{%
\subsubsection{Distribution}\label{distribution}}

\begin{itemize}
\tightlist
\item
  \textbf{Clustered (agminated):} Grouped together in a bunch but not running together
\item
  \textbf{Discrete/scattered:} Lesions are separate from one another
\item
  \textbf{Acral:} Over distal portions of limbs: finger tips, knuckles, elbows, knees, buttocks, toes, heels
\item
  \textbf{Generalized:} Throughout body
\item
  \textbf{Photodistributed:} Sun-exposed areas
\item
  \textbf{Coalescing:}
\end{itemize}

\hypertarget{newborn-derm}{%
\subsection{Newborn Derm}\label{newborn-derm}}

\hypertarget{neonatal-rashes}{%
\subsubsection{Neonatal Rashes}\label{neonatal-rashes}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.27\columnwidth}\raggedright
Condition\strut
\end{minipage} & \begin{minipage}[b]{0.33\columnwidth}\raggedright
Description\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Appearance\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Sebaceous hyperplasia\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Minute, profuse yellow-white papules frequently on forehead, nose, lip, and cheeks\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_sebaceous-hyperplasia.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Milia/miliaria\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
1-2 mm pearly, opalescent cysts\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_milia.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Neonatal acne (neonatal cephalic pustulosis)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Inflammatory papules and pustules usually w/o comedonal lesions\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_neonatal-acne.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Sucking blisters\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Solitary or scattered superficial bullae on upper limbs of infants at birth (presumed in utero sucking)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_sucking-blisters.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Cutis marmorata\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Evanescent, lacy, reticulated red and/or blue cutaneous pattern when exposed to low environmental temperatures\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_cutis-marmorata.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Harlequin color change\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
When infant (usually immediate newborn period and in low birth weight infants) is laying on side, dependent area is deep red and upper half (longitudinally) is pale\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_harlequin-color-change.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Nevus simplex (``salmon patch,'' ``stork bite,'' ``angel's kiss'')\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Small, pink, ill-defined vascular macule usually on glabella, eyelids, upper lip and nuchal area\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_nevus-simplex.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Erythema toxicum neonatorum (e tox)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Benign, self-limited evanescent eruption usually in term infants presenting w/ firm, yellow-white papules and pustules w/ a surrounding erythematous flare; palms and soles are almost never affected\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_etox.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Transient neonatal pustular melanosis (TNPM)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Superficial pustules, ruptured pustules w/ a fine scale, and hyperpigmented macules\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_tnpm.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Seborrheic dermatitis\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Erythema and greasy scales usually on the scalp (``cradle cap''), face, forehead, trunk, intertriginous and flexural areas including diaper\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_seborrheic-dermatitis.png}\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{neonatal-birthmarks}{%
\subsubsection{Neonatal Birthmarks}\label{neonatal-birthmarks}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.27\columnwidth}\raggedright
Condition\strut
\end{minipage} & \begin{minipage}[b]{0.33\columnwidth}\raggedright
Description\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Appearance\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Congenital melanocytic nevus (CNM, moles)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Often benign neoplasms composed of melanocytes- Small and medium sized CMN have less than 1\% risk of malignant transformation; large and giant lesions the risk is higher, ranging from 0-7.6\%\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_congenital-melanocytic-nevus.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Nevus sebaceous (organoid hamartoma)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Overgrown epidermis, sebaceous glands, hair follicles, apocrine glands and connective tissue that occurs primarily on scalp or face- Presents as solitary, smooth, yellow-orange hairless patch, often oval or linear. Often becomes more pronounced in adolescence, appearing bumpy, warty, scaly.\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_nevus-sebaceous.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Aplastic cutis congenita\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Absence of skin present at birth that can be localized or widespread- Can be an isolated finding or associated with other developmental anomalies- Large scalp defects should be imaged to r/o underlying bone, vascular, or soft tissue defects\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_aplastic-cutis-congenita.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Congenital dermal melanocytosis (CDM; slate gray patch, Mongolian spot)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Blue or slate-gray macular lesions- Important to always point out to parents and to counsel them to point out to caretakers / daycare, as they can be mistaken for bruises\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_congenital-dermal-melanocytosis.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Vascular tumors\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Infantile hemangioma, congenital hemangioma, pyogenic granuloma- Hemangioma red flags: Beard distribution (evaluate airway), periocular (ophtho), paraspinal midline, hemangiomatosis (multiple small hemangiomas → evaluate for parenchymal hemangiomas, especially hepatic and CNS), very large hemangioma, associated thrill or bruit, head tilting\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_pyogenic-granuloma.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.27\columnwidth}\raggedright
Vascular malformations\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Capillary malformation (nevus flammeus/Port wine stain), lymphatic malformations, cutis marmorata telangiectatica congenita (CMTC)\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/derm_nevus-flammeus.png}\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{diaper-dermatitis}{%
\subsubsection{Diaper Dermatitis}\label{diaper-dermatitis}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.06\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.51\columnwidth}\raggedright
Contact/Irritant Dermatitis\strut
\end{minipage} & \begin{minipage}[b]{0.34\columnwidth}\raggedright
Candida Dermatitis\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Epidemiology\strut
\end{minipage} & \begin{minipage}[t]{0.51\columnwidth}\raggedright
Most common cause\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
2nd most common cause\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Physical Exam\strut
\end{minipage} & \begin{minipage}[t]{0.51\columnwidth}\raggedright
Spares creases/skin folds \includegraphics{images/derm_diaper-dermatitis.png}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
``Beefy'' red rash involving skin folds w/ satellite lesions \includegraphics{images/derm_diaper-dermatitis-candida.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Management\strut
\end{minipage} & \begin{minipage}[t]{0.51\columnwidth}\raggedright
Topical barrier ointment/paste (petrolatum, zinc oxide)\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
Topical antifungal (nystatin)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{dermatologic-emergencies}{%
\subsection{Dermatologic Emergencies}\label{dermatologic-emergencies}}

\hypertarget{stevens-johnson-syndrome-sjs}{%
\subsubsection{Stevens Johnson Syndrome (SJS)}\label{stevens-johnson-syndrome-sjs}}

\hypertarget{definition-12}{%
\paragraph{Definition}\label{definition-12}}

Skin + 2 or more mucosa. 10-30\% BSA.

\hypertarget{etiology-2}{%
\paragraph{Etiology}\label{etiology-2}}

Infection \& meds (sulfonamides anticonvulsants, NSAIDs, allopurinol, dapsone)

\hypertarget{presentation-38}{%
\paragraph{Presentation}\label{presentation-38}}

Mucosal involvement, prodromal fever, sore throat, HA, malaise, erythematous target like lesions forming blisters that rupture

\hypertarget{management-10}{%
\paragraph{Management}\label{management-10}}

\begin{itemize}
\tightlist
\item
  Treat/discontinue underlying cause
\item
  Magic mouthwash for stomatitis, artificial tears for ocular involvement
\item
  Care to avoid scarring and adhesions
\item
  Hospitalize, treat like a burn patient (fluids, electrolytes, pain, prevent infection)
\end{itemize}

\hypertarget{toxic-epidermal-necrolysis-ten}{%
\subsubsection{Toxic Epidermal Necrolysis (TEN)}\label{toxic-epidermal-necrolysis-ten}}

\hypertarget{definition-13}{%
\paragraph{Definition}\label{definition-13}}

Skin + 2 or more mucosa. \textgreater30\% BSA.

\hypertarget{etiology-3}{%
\paragraph{Etiology}\label{etiology-3}}

As above in SJS

\hypertarget{presentation-39}{%
\paragraph{Presentation}\label{presentation-39}}

Extensive skin and mucosal involvement (conjunctival, oral, genital, pulmonary), large bullae that rupture and leave large erosions (Nikosky +)

\includegraphics{images/derm_ten.png}

\hypertarget{management-11}{%
\paragraph{Management}\label{management-11}}

\begin{itemize}
\tightlist
\item
  See SJS management above
\item
  Consider IVIG
\end{itemize}

\hypertarget{drug-reaction-with-eosinophilis-and-systemic-symptoms-dress}{%
\subsubsection{Drug Reaction with Eosinophilis and Systemic Symptoms (DRESS)}\label{drug-reaction-with-eosinophilis-and-systemic-symptoms-dress}}

\hypertarget{definition-14}{%
\paragraph{Definition}\label{definition-14}}

Potentially life-threatening adverse drug-induced reaction characterized by skin rash, hypereosinophilia, liver involvement, fever, and lymphadenopathy

\hypertarget{etiology-4}{%
\paragraph{Etiology}\label{etiology-4}}

Meds (carbamazepine, allopurinol, sulfasalazine, phenobarbital, lamotrigine, nevirapine, etc). Can also be associated w/ some viral infxns (HHV6, EBV, CMV).

\hypertarget{presentation-40}{%
\paragraph{Presentation}\label{presentation-40}}

\begin{itemize}
\tightlist
\item
  Onset is usually 2-6 wks after initiation of drug tx
\item
  Rash is often morbilliform or exfoliative and may be associated w/ facial edema
\item
  Systemic symptoms: Fever, lymphadenopathy
\item
  Lab abnormalities: Hypereosinophilia, liver involvement
\end{itemize}

\includegraphics{images/derm_dress.png}

\hypertarget{management-12}{%
\paragraph{Management}\label{management-12}}

\begin{itemize}
\tightlist
\item
  Discontinue offending medication
\item
  Coticosteroids and IVIG may improve sx but evidence is not definitive
\item
  Recovery is prolonged (6+ wks) and may have intermittent flare-ups, 10\% mortality rate
\end{itemize}

\hypertarget{staph-scalded-skin-syndrome-ssss}{%
\subsubsection{Staph Scalded Skin Syndrome (SSSS)}\label{staph-scalded-skin-syndrome-ssss}}

\hypertarget{definition-15}{%
\paragraph{Definition}\label{definition-15}}

Exfoliative toxin-producing S. aureus

\hypertarget{presentation-41}{%
\paragraph{Presentation}\label{presentation-41}}

Fever, irritability, skin tenderness → diffuse erythema and flaccid blisters → scaling and desquamation

\includegraphics{images/derm_ssss.png}

\hypertarget{management-13}{%
\paragraph{Management}\label{management-13}}

Case dependent: Oxacillin, Nafcillin, or Vancomycin

\hypertarget{common-dermatologic-conditions}{%
\subsection{Common Dermatologic Conditions}\label{common-dermatologic-conditions}}

\hypertarget{acne}{%
\subsubsection{Acne}\label{acne}}

\hypertarget{pathophysiology-22}{%
\paragraph{Pathophysiology}\label{pathophysiology-22}}

Obstruction of pilosebaceous unit by abn keratinization and sebum w/ bacterial proliferation (P. acnes) and inflammation

\hypertarget{management-14}{%
\paragraph{Management}\label{management-14}}

\begin{itemize}
\tightlist
\item
  Depends on type:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Comedonal:} (1) Topical retinoids, (2) benzoyl peroxide and topical abx
  \item
    \textbf{Papulopustular:} (1) Maximize topical tx, (2) oral antibiotics, (3) hormonal therapy
  \item
    \textbf{Nodulocystic:} Isotretinoin
  \end{itemize}
\item
  Antibiotics: Tetracycline, Doxycycline, Minocycline, Erythromycin
\item
  Tips:

  \begin{itemize}
  \tightlist
  \item
    Use topical abx in conjunction w/ benzoyl peroxide (to avoid P. acnes resistance)
  \item
    Benzoyl peroxide inactivates tretinoin, so apply benzoyl peroxide in AM and tretinoin in PM
  \item
    OCPs and spironolactone can be considered in female pts
  \item
    May take 6-8 weeks to see improvement
  \item
    Rx: 30-60 gm w/ refills
  \end{itemize}
\end{itemize}

\hypertarget{atopic-dermatitis-eczema}{%
\subsubsection{Atopic Dermatitis (Eczema)}\label{atopic-dermatitis-eczema}}

\hypertarget{definition-16}{%
\paragraph{Definition}\label{definition-16}}

Chronic inflammatory condition leading to pruritic, erythematous, and scaly lesions

\hypertarget{presentation-42}{%
\paragraph{Presentation}\label{presentation-42}}

\begin{itemize}
\tightlist
\item
  Usually presents before 2yo
\item
  Infants (scalp, face, extensor surfaces), children (flexural surfaces)
\item
  Often associated w/ \textbf{allergic triad} (w/ asthma + allergic rhinitis)
\item
  Also associated w/ \textbf{keratosis pilaris} (hyperkeratotic follicular papules, usually on back of arms but also frequently on lateral cheeks of infants and younger children) and \textbf{pityriasis alba} (hypopigmented, flat, indistinct border, usually face)
\end{itemize}

\hypertarget{complications-9}{%
\paragraph{Complications}\label{complications-9}}

Superinfection w/ staph and strep (weeping, crusting, pustules) or herpes simplex (vesicles)

\hypertarget{management-15}{%
\paragraph{Management}\label{management-15}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=45612\&algVersion=1.3\&accessCode=null}{Eczema}
\item
  \textbf{Lifestyle:} Eliminate allergens, short baths w/ warm water and mild soap
\item
  \textbf{Bleach baths} (decrease bacteria):

  \begin{itemize}
  \tightlist
  \item
    For a full bathtub of water, add 1/2 cup of bleach
  \item
    For a half-full tub of water, add 1/4 cup of bleach
  \item
    For a baby tub, add 1 teaspoon of bleach per gallon of water
  \end{itemize}
\item
  \textbf{Emollients:} Hydrolated Petrolatum, Vaseline™, Eucerin™, Cetaphil™
\item
  \textbf{Topical steroids:} (see chart below at end of chapter)
\item
  \textbf{Topical immunomodulators:} Calcineurin inhibitors (Tacrolimus ointment (Protopic) 0.03\%, 0.1\%; Pimecrolimus (Elidel) 1\%): used on facial lesions, less risk of tissue injury; approved for \textgreater2 years of age
\item
  \textbf{Anti-Staph antibiotics} (if bacterial infection): Cephalexin, Trimethoprim-sulfamethoxazole, Mupirocin
\item
  \textbf{Antipruritic medication:} Diphenhydramine or Hydroxyzine
\end{itemize}

\hypertarget{erythema-multiforme}{%
\subsubsection{Erythema Multiforme}\label{erythema-multiforme}}

\hypertarget{definition-17}{%
\paragraph{Definition}\label{definition-17}}

Usually skin only (minimal mucosa). \textless10\% BSA.

\hypertarget{etiology-5}{%
\paragraph{Etiology}\label{etiology-5}}

Infection (HSV, mycoplasma PNA), medications (Penicillins, sulfonamides, NSAIDs, barbiturates)

\hypertarget{presentation-43}{%
\paragraph{Presentation}\label{presentation-43}}

Erythematous papules expanding to target-like plaques w/ dusky violaceous centers, found symmetrically on distal extremities and progress proximally

\includegraphics{images/derm_erythema-multiforme.png}

\hypertarget{management-16}{%
\paragraph{Management}\label{management-16}}

Treat/discontinue underlying cause. Supportive care.

\hypertarget{impetigo}{%
\subsubsection{Impetigo}\label{impetigo}}

\hypertarget{definition-18}{%
\paragraph{Definition}\label{definition-18}}

\begin{itemize}
\tightlist
\item
  Contagious superficial skin infection
\item
  Can be primary (direct infection of previously normal skin) or secondary (infection of skin that has already been disrupted)
\end{itemize}

\hypertarget{presentation-44}{%
\paragraph{Presentation}\label{presentation-44}}

\begin{itemize}
\tightlist
\item
  Classified as bullous vs.~non-bullous (70\%)

  \begin{itemize}
  \tightlist
  \item
    \textbf{Non-bullous impetigo:} Usually occurs on traumatized skin, S aureus (coagulase+) and S pyogenes (GABHS), spread by contact, non-pruritic, no constitutional sx
  \item
    \textbf{Bullous impetigo:} More common in infants and young children, caused by S aureus (coagulase+ (same types as TSS and SSSS), bulla develop on intact skin
  \end{itemize}
\end{itemize}

\includegraphics{images/derm_impetigo-bullous.png} \includegraphics{images/derm_impetigo-nonbullous.png}

\hypertarget{management-17}{%
\paragraph{Management}\label{management-17}}

\begin{itemize}
\tightlist
\item
  Mupirocin (Bactroban) TID x 7-10 days
\item
  May need oral abx for widespread disease
\item
  If MRSA consideration, clindamycin should be used
\end{itemize}

\hypertarget{erysipelas}{%
\subsubsection{Erysipelas}\label{erysipelas}}

\hypertarget{definition-19}{%
\paragraph{Definition}\label{definition-19}}

Infection involving upper dermis and superficial lymphatics, usually from S. pyogenes

\hypertarget{presentation-45}{%
\paragraph{Presentation}\label{presentation-45}}

Well-defined demarcation between infected and normal skin

\includegraphics{images/derm_erysipelas.png}

\hypertarget{management-18}{%
\paragraph{Management}\label{management-18}}

\begin{itemize}
\tightlist
\item
  \textbf{Localized lesions:} Topical mupirocin 2\% ointment
\item
  \textbf{Extensive lesions:} Cephalexin, dicloxacillin, clindamycin or erythromycin if PCN-allergic
\end{itemize}

\hypertarget{molluscum-contagiosum}{%
\subsubsection{Molluscum Contagiosum}\label{molluscum-contagiosum}}

\hypertarget{definition-20}{%
\paragraph{Definition}\label{definition-20}}

Wart-like lesion caused by DNA poxvirus

\hypertarget{presentation-46}{%
\paragraph{Presentation}\label{presentation-46}}

\begin{itemize}
\tightlist
\item
  Small flesh-colored, dome shaped, umbilicated papules
\item
  Most common in school aged children. Immunocompromised patient may have extensive disease.
\item
  Transmitted by fomites/close contact. If molluscum in genital area of child, must consider possible sexual abuse.
\end{itemize}

\includegraphics{images/derm_molluscum-contagiosum.png}

\hypertarget{management-19}{%
\paragraph{Management}\label{management-19}}

Self-limited

\hypertarget{pityriasis-rosea}{%
\subsubsection{Pityriasis Rosea}\label{pityriasis-rosea}}

\hypertarget{presentation-47}{%
\paragraph{Presentation}\label{presentation-47}}

\begin{itemize}
\tightlist
\item
  Single erythematous herald patch followed by collection of smaller patches
\item
  Typically in pts ages 10-35
\item
  Usually lasting between 2-12 weeks
\end{itemize}

\includegraphics{images/derm_pityriasis-rosea.png}

\hypertarget{management-20}{%
\paragraph{Management}\label{management-20}}

\begin{itemize}
\tightlist
\item
  Self-limited
\item
  Counsel patient and family of long duration
\end{itemize}

\hypertarget{scabies}{%
\subsubsection{Scabies}\label{scabies}}

\hypertarget{definition-21}{%
\paragraph{Definition}\label{definition-21}}

Mite infection transmitted by contact

\hypertarget{presentation-48}{%
\paragraph{Presentation}\label{presentation-48}}

Rash and severe itching (delayed type IV hypersensitivity) w/ papules, nodules, scaling, and sometimes linear distribution

\includegraphics{images/derm_scabies.png}

\hypertarget{management-21}{%
\paragraph{Management}\label{management-21}}

\begin{itemize}
\tightlist
\item
  Permethrin (single application has 90-95\% cure rate, do not use \textless2 mos old, can reapply in 7 days)
\item
  Treat all family members and wash clothes and bed linens
\end{itemize}

\hypertarget{lice}{%
\subsubsection{Lice}\label{lice}}

\hypertarget{presentation-49}{%
\paragraph{Presentation}\label{presentation-49}}

Diagnosis usually made by nits (eggs) on hair shafts, adult lice may be difficult to see

\hypertarget{management-22}{%
\paragraph{Management}\label{management-22}}

\begin{itemize}
\tightlist
\item
  1\% Permethrin rinse (Nix) and Pyrtherin (Rid)
\item
  Do not use shampoo/conditioner prior to tx
\item
  Requires retreatment 7-10 days later (not ovicidal)
\item
  Additional methods: Wet combing. Butter, olive oil, mayo, petroleum jelly to suffocate lice.
\item
  Tx of family not usually indicated
\end{itemize}

\hypertarget{tinea-corporis}{%
\subsubsection{Tinea Corporis}\label{tinea-corporis}}

\hypertarget{definition-22}{%
\paragraph{Definition}\label{definition-22}}

Superficial dermatophytosis

\hypertarget{presentation-50}{%
\paragraph{Presentation}\label{presentation-50}}

Scaly erythematous pruritic patch w/ centrifugal spread and subsequent central clearing w/ raised annular border

\includegraphics{images/derm_tinea-corporis.png}

\hypertarget{management-23}{%
\paragraph{Management}\label{management-23}}

\begin{itemize}
\tightlist
\item
  \textbf{1st line/localized:} Topical antifungal (may take several weeks to clear)
\item
  \textbf{2nd line/extensive:} Oral antifungals (terbinafine, griseofulvin)
\end{itemize}

\hypertarget{tinea-capitis}{%
\subsubsection{Tinea Capitis}\label{tinea-capitis}}

\hypertarget{definition-23}{%
\paragraph{Definition}\label{definition-23}}

Superficial dermatophytosis

\hypertarget{presentation-51}{%
\paragraph{Presentation}\label{presentation-51}}

Scaly erythematous patch that can progress to alopecia w/ inflammation

\includegraphics{images/derm_tinea-capitis.png}

\hypertarget{management-24}{%
\paragraph{Management}\label{management-24}}

Oral griseofulvin or terbinafine

\hypertarget{cutaneous-signs-of-systemic-disease}{%
\subsection{Cutaneous Signs of Systemic Disease}\label{cutaneous-signs-of-systemic-disease}}

\begin{itemize}
\tightlist
\item
  \textbf{SLE:} Erythematous patches in photodistribution, ``malar'' face
\item
  \textbf{Discoid Lupus:} Annular, scaly plaques, atrophy, and dyspigmentation in photodistribution
\item
  \textbf{Juvenile Dermatomyositis:} Erythematous/violaceous scaly, macules, overlying knuckles, face and extensor surfaces
\item
  \textbf{HSP:} Purpuric papules and plaques on buttocks and lower extremities
\item
  \textbf{Kawasaki Disease:} Erythematous maculopapular to urticarial plaques, edema, desquamation
\item
  \textbf{IBD:} Aphthae; erythema nodosum; pyoderma gangrenosum, thrombophlebitis, perianal fissures
\item
  \textbf{Graft vs.~Host:} Acute onset erythema, papules, vesicles, bulla
\item
  \textbf{DRESS:} Diffuse erythema, urticarial macules and plaques
\end{itemize}

\hypertarget{drug-eruptions}{%
\subsection{Drug Eruptions}\label{drug-eruptions}}

\begin{itemize}
\tightlist
\item
  \textbf{Urticaria:} Penicillins, cephalosporins, sulfonamides, aspirin/NSAIDS, radiocontrast, TNF inhibitors
\item
  \textbf{Angioedema:} Aspirin/NSAIDS, ACEi
\item
  \textbf{Serum-Sickness Reaction:} Cephalosporins, penicillins, minocycline, bupropion, sulfonamides
\item
  \textbf{Exanthematous:} Any drug
\item
  \textbf{DRESS:} Phenytoin, phenobarbital, carbamazepine, lamotrigine, allopurinol, sulfonamides, dapsone, minocycline
\item
  \textbf{Pustular (acute generalized exanthematous pustulosis):} Beta-lactams, macrolides, clindamycin, terbinafine, calcium channel blockers, antimalarials
\item
  \textbf{Acneiform:} Corticosteroids, androgen, lithium, iodines, phenytoin, isoniazid, tetracycline, B vitamins, azathioprine
\item
  \textbf{Vasculitis:} Penicillins, NSAIDs, sulfonamides, cephalosporins
\item
  \textbf{SJS/TEN:} Sulfonamides anticonvulsants, NSAIDs, allopurinol, dapsone
\item
  \textbf{Drug-induced Lupus:} Minocycline, procainamide, hydralazine, isoniazid, penicillamine, carbamazepine, chlorpromazine, infliximab
\end{itemize}

\hypertarget{principles-of-dermatologic-therapy}{%
\subsection{Principles of Dermatologic Therapy}\label{principles-of-dermatologic-therapy}}

The efficacy of any topical medication is related to:

\begin{itemize}
\tightlist
\item
  Active ingredient (inherent strength)
\item
  Concentration of medication
\item
  Anatomic location
\item
  Vehicle (mode in which it is transported)

  \begin{itemize}
  \tightlist
  \item
    \textbf{Ointment:} (e.g.~Vaseline). Lubricating, semi-occlusive, greasy, does not sting. Useful for smooth, non-hairy skin, dry, thick or hyperkeratotic lesions.
  \item
    \textbf{Cream:} Less greasy, not occlusive, may sting, could cause irritation, vanish when rubbed in. Useful for acute exudative inflammation, intertriginous areas.
  \item
    \textbf{Lotion:} Less greasy, less occlusive, may sting, pourable liquid. Useful for acute exudative inflammation (e.g.~acute contact dermatitis) and on hairy areas.
  \item
    \textbf{Oil:} Less stinging, keratolytic (removes scale). Useful for the scalp, especially for people with coarse or very curly hair.
  \item
    \textbf{Gel:} May sting, greaseless, least occlusive, dries quickly. Useful for acne and on scalp/hairy areas without matting.
  \item
    \textbf{Foam:} Spreads readily, easier to apply, more expensive, cosmetically elegant. Useful for hairy areas and inflamed skin.
  \item
    \textbf{Spray:} Aerosols (rarely used), pump sprays
  \end{itemize}
\end{itemize}

\includegraphics{images/derm_vehicles.png}

\hypertarget{quantities-of-topicals-to-prescribe}{%
\subsubsection{Quantities of Topicals to Prescribe}\label{quantities-of-topicals-to-prescribe}}

\begin{itemize}
\tightlist
\item
  When deciding how much topical to prescribe, think in terms of lesion size and body surface area (BSA)

  \begin{itemize}
  \tightlist
  \item
    1 Finger Tip Unit (FTU) = 0.5 grams topical medication dispensed from a 5mm nozzle placed on pad of index finger from distal tip to DIP joint = 2 adult palms = 2\% BSA
    \includegraphics{images/derm_topicals-ftu.png}

    \begin{itemize}
    \tightlist
    \item
      \emph{Example:} How much topical medication should you Rx for 2\% BSA BID x30 days?

      \begin{itemize}
      \tightlist
      \item
        1 FTU = 0.5 grams = 2\% BSA
      \item
        0.5 grams x 2 times per day = 1 gram
      \item
        1 gram x 30 days = 30 grams
      \end{itemize}
    \end{itemize}
  \item
    Remember that children, especially infants, have a high BSA to volume ratio, which puts them at risk for systemic absorption of topically applied medications
  \end{itemize}
\end{itemize}

\hypertarget{topical-steroids}{%
\subsection{Topical Steroids}\label{topical-steroids}}

\hypertarget{classes-of-topical-steroids}{%
\subsubsection{Classes of Topical Steroids}\label{classes-of-topical-steroids}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.44\columnwidth}\raggedright
Potency Class\strut
\end{minipage} & \begin{minipage}[b]{0.50\columnwidth}\raggedright
Common Examples\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 1:} Superpotent\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Betamethasone 0.05\% G/O/L, Clobetasol 0.05\% C/O/G/S/F, Diflorasone 0.05\% O, Halobetasol 0.05\%\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 2:} Potent\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Betamethasone 0.05\% C, Desoximetasone 0.25\% C/ 0.05\% G, Fluocinonide 0.05\% C/O/G/S\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 3:} Upper Mid\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Betamethasone valerate 0.1\%/0.12\%F, Diflorasone 0.05\% C, Triamcinolone 0.1\% O\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 4:} Mid-Strength\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Fluocinolone 0.025\% O, Hydrocortisone 0.2\% O, Mometasone 0.1\% C/L, Triamcinolone 0.1\% C\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 5:} Lower Mid\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Desonide 0.05\% O, Fluocinolone 0.025\%, Hydrocortisone 0.2\% C, Triamcinolone 0.025\% O/L\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 6:} Mid\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Betamethasone 0.1\% C, Desonide 0.05\% C, Fluocinolone 0.01\% C/S, Triamcinolone 0.025\% C\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.44\columnwidth}\raggedright
\textbf{Class 7:} Least Potent\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Hydrocortisone 1\%-2.5\%\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

C = cream, G = gel, L = lotion, O = ointment, S = solution, F = foam

\begin{itemize}
\tightlist
\item
  \textbf{Potency:} Ointment (thickest, most potent) \textgreater{} Gel \textgreater{} Cream \textgreater{} Lotion (liquidy, easier to spread)

  \begin{itemize}
  \tightlist
  \item
    Look at the CLASS, not the percentage (e.g.~clobetasol 0.05\% is much stronger than HC 1\%)
  \end{itemize}
\item
  \textbf{Uses:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Class 1} uses: Severe dermatoses over non-facial/non-intertriginous areas, especially good for palms and soles
  \item
    \textbf{Class 2-4} uses: Mild-to-moderate non-facial/non-intertriginous dermatoses, okay to use on flexural surfaces for limited periods
  \item
    \textbf{Class 5-7} uses: Consider when treating large areas (given likelihood of systemic absorption), also for eyelid/genital dermatoses
  \end{itemize}
\end{itemize}

\hypertarget{side-effects-of-topical-steroids}{%
\subsubsection{Side Effects of Topical Steroids}\label{side-effects-of-topical-steroids}}

\begin{itemize}
\tightlist
\item
  \textbf{Local side effects} of topical steroids: Skin atrophy, telangiectasias, striae, acne or rosacea-like eruptions, allergic contact dermatitis, hypopigmentation
\item
  \textbf{Systemic side effects} of topical steroids (rare d/t low percutaneous absorption): Glaucoma, HPA suppression, Cushing's syndrome, hypertension, hyperglycemia

  \begin{itemize}
  \tightlist
  \item
    Exercise caution w/ widespread use and occlusive methods (e.g.~plastic wrap, bandages)
  \end{itemize}
\item
  For all steroids, \textbf{do not use for more than 14 days per month.} Instruct patients to use in pulse (a few days at a time) manner.
\end{itemize}

\hypertarget{sun-protection}{%
\subsection{Sun Protection}\label{sun-protection}}

\hypertarget{types-of-sunscreen}{%
\subsubsection{Types of Sunscreen}\label{types-of-sunscreen}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.44\columnwidth}\raggedright
Physical Blockers\strut
\end{minipage} & \begin{minipage}[b]{0.50\columnwidth}\raggedright
Chemical Sunscreens\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.44\columnwidth}\raggedright
- Blocks and scatters UV and visible light- Active ingredients include zinc oxide, titanium dioxide, iron oxide- Less irritating to sensitive skin and immediately effective\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
- Absorbs light and re-emits energy as insignificant quantities of heat- Active ingredients are benzophenone, avobenzone, oxybenzone- Not as messy, easier to apply, less apparent white sheen\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{choosing-sunscreen}{%
\subsubsection{Choosing Sunscreen}\label{choosing-sunscreen}}

\begin{itemize}
\tightlist
\item
  Sunscreens are best for protection against UVB and UVA rays
\item
  ``Broad spectrum'' sunscreens are the best
\item
  SPF 30 blocks 97\% of sun's rays
\item
  ``Water resistant'' sunscreens need to be re-applied q2h
\item
  Sun's rays are strongest between 10AM - 4PM
\item
  Good rule of thumb: ``If your shadow appears to be shorter than you are, seek shade''
\item
  Avoid sunscreen use in infants less than 6 months of age. Instead use protective clothing, such as long sleeve clothing and a hat w/ brim.
\end{itemize}

\hypertarget{references-3}{%
\subsection{References}\label{references-3}}

\hypertarget{additional-dermatology-resources}{%
\subsubsection{Additional Dermatology Resources}\label{additional-dermatology-resources}}

\begin{itemize}
\tightlist
\item
  \href{https://www.aad.org/education/basic-derm-curriculum}{American Academy of Dermatology Basic Dermatology Curriculum:} Three-Week Pediatrician Rotation for Pediatricians
\item
  \href{https://www.visualdx.com/learnderm}{LearnDerm by VisualDx}
\end{itemize}

\hypertarget{emergency-medicine}{%
\section{Emergency Medicine}\label{emergency-medicine}}

\hypertarget{acute-abdominal-pain}{%
\subsection{Acute Abdominal Pain}\label{acute-abdominal-pain}}

\hypertarget{differential-1}{%
\subsubsection{Differential}\label{differential-1}}

\hypertarget{gi}{%
\paragraph{GI}\label{gi}}

Appendicitis, trauma, pancreatitis, intussusception, malrotation ± volvulus, inflammatory bowel disease, gastritis, bowel obstruction, irritable bowel syndrome, abscess, hepatitis, perforated ulcer, Meckel diverticulum, cholecystitis, choledocholithiasis, constipation, gastroenteritis (particularly with associated mesenteric adenitis)

\hypertarget{renal}{%
\paragraph{Renal}\label{renal}}

Urinary tract infection, pyelonephritis, nephrolithiasis

\hypertarget{gu}{%
\paragraph{GU}\label{gu}}

Ectopic pregnancy, ovarian cyst/torsion, tubo-ovarian abscess, pelvic inflammatory disease, testicular torsion

\hypertarget{oncologic}{%
\paragraph{Oncologic}\label{oncologic}}

Wilms tumor, neuroblastoma, rhabdomyosarcoma, lymphoma

\hypertarget{other}{%
\paragraph{Other}\label{other}}

Henoch-Schonlein purpura, lower lobe pneumonia, sickle cell anemia, diabetic ketoacidosis, juvenile idiopathic arthritis, incarcerated hernia, Streptococcal pharyngitis

\hypertarget{workup}{%
\subsubsection{Workup}\label{workup}}

\hypertarget{history-1}{%
\paragraph{History}\label{history-1}}

Course and characterization, diarrhea, constipation, emesis, melena, hematochezia, fever, last oral intake, menstrual history, vaginal symptoms, urinary symptoms, respiratory symptoms, travel history, diet, pertinent family history

\hypertarget{pe}{%
\paragraph{PE}\label{pe}}

\begin{itemize}
\tightlist
\item
  Vital signs, toxic appearance, rashes, arthritis, jaundice
\item
  Thorough abdominal exam, not through clothes - need to visualize abdomen (if concern for appendicitis, check for psoas sign, obturator, Rovsing's)
\item
  Rectal exam with stool Hemoccult
\item
  Bimanual exam in sexually active females
\item
  Genital exam
\end{itemize}

\hypertarget{studies-17}{%
\paragraph{Studies}\label{studies-17}}

\begin{itemize}
\tightlist
\item
  KUB to assess for obstruction, free air; should be done in toxic patients
\item
  Abdominal/pelvic ultrasound
\item
  Consider abdominal CT
\item
  Pelvic MRI for appendicitis if institutionally available
\end{itemize}

\hypertarget{labs-1}{%
\paragraph{Labs}\label{labs-1}}

CBC with differential, chemistry, liver and kidney function, ESR, CRP, amylase, lipase, Gonorrhea/Chlamydia/Trichomonas, urine pregnancy

\hypertarget{treatment-36}{%
\paragraph{Treatment}\label{treatment-36}}

\begin{itemize}
\tightlist
\item
  NPO, fluids
\item
  ``GI cocktail'' - multiple antacids
\item
  Consider nasogastric decompression
\item
  Serial abdominal exams
\item
  Surgical/gynecologic/GI evaluation
\item
  Pain control and antibiotics as indicated
\end{itemize}

\hypertarget{altered-mental-status}{%
\subsection{Altered Mental Status}\label{altered-mental-status}}

\hypertarget{differential-2}{%
\subsubsection{Differential}\label{differential-2}}

Important to maintain a broad differential diagnosis and think systematically - Can use the mnemonic VITAMINS
\textbf{Vascular}: Stroke, cerebritis, migraine, vasculitis
\textbf{Infection}: Encephalitis, meningitis, brain abscess, sepsis
\textbf{Toxins/Trauma}: Environmental/Medication toxins, head trauma
\textbf{Accident/Abuse}: Epidural hematoma, large subdural, TBI (diffuse axonal injury)
\textbf{Metabolic}: Hypoglycemia, DKA, thyroid dysfxn, electrolyte abnormality, inborn error of metabolism, hypoxia, hypercarbia, renal, hepatic, endocrine
\textbf{Intussusception}: Somnolent variant
\textbf{Neoplasm}: Intracranial neoplasm, paraneoplastic syndrome
\textbf{Seizure}: Active seizure, subclinical status epilepticus, postictal state
Suspicion guided by age and history. Acute-onset altered mental status in an adolescent has a strong probability of being toxin-related.

\hypertarget{approach}{%
\subsubsection{Approach}\label{approach}}

Initial evaluation and stabilization:
- Place on monitors, consider access
- Primary Survey (ABCDE), POC glucose
- Secondary Survey (AMPLE History)
- Allergies, Medications, PMHx, Last meal, Events preceding presentation
- Acute vs chronic change? How quickly did this occur?
- Continue to obtain more detailed history (including exposures, recent travel, possible medications in home, drug use, recent illnesses, possible inciting events, etc) while stabilizing
- GCS \textless{} 8 often suggests the need for airway management and mechanical ventilation, but decision is case by case

\hypertarget{physical-exam-12}{%
\subsubsection{Physical Exam}\label{physical-exam-12}}

\begin{itemize}
\tightlist
\item
  Thorough head to toe examination (including ABCs as above)
\item
  Detailed neurologic exam including fundoscopic exam if possible, mental status
\item
  Cardiorespiratory exam
\item
  Abdominal exam
\item
  Skin exam looking for rashes, signs of trauma
\end{itemize}

\hypertarget{studies-18}{%
\subsubsection{Studies}\label{studies-18}}

\textbf{\emph{Broad initial workup can include the following, but is strongly guided by history or lack thereof}}:
- CBC/d
- BMP
- LFTs
- Ammonia
- Drug screening: Urine Tox (extended opioid), urine marijuana, serum tox, APAP/ASA/EtOH levels
- VBG
\textbf{\emph{Other workup can be tailored to H\&P and PE}}:
- Blood culture, LP if concerned for infection and/or fever (*see Neuro section for meningitis management)
- Abd US if concerned for intussusception
- Head CT if concerned for trauma, acute hemorrhage, stroke, increased ICP
- Consider coags and other tests for possible medication exposures
- Detailed metabolic workup if concerned for underlying inborn error
- EEG for seizure or subclinical status (though only useful in active seizure, manage ABCs are the priority)

\hypertarget{blunt-abdominal-trauma}{%
\subsection{Blunt Abdominal Trauma}\label{blunt-abdominal-trauma}}

Sources: \textbf{BCH EBG} (Trauma, abdominal), \textbf{CHOP Clinical Pathway}, Fleisher GR, Ludwig S, eds.~(2010) Textbook of Pediatric Emergency Medicine. 6th ed.~Philadelphia: Lippincott Williams \& Wilkins.

\hypertarget{assessment}{%
\subsubsection{Assessment}\label{assessment}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Abdominal wall abrasion, erythema, ecchymosis or seat belt sign
\item
  Any abdominal tenderness/pain
\item
  Evidence of thoracic wall trauma
\item
  Absent or decreased breath sounds
\item
  Vomiting
\end{enumerate}

\hypertarget{if-1-or-2-of-the-above-present}{%
\subsubsection{If \#1 or \textgreater2 of the above present}\label{if-1-or-2-of-the-above-present}}

\begin{itemize}
\tightlist
\item
  FAST sensitivity limited compared to adults but is specific (i.e.~positive is valuable)
\item
  Abdominal CT with IV contrast
\item
  Labs: CBC. Can consider LFTs, amylase/lipase, UA, type and screen
\item
  Surgical consult
\end{itemize}

\hypertarget{treatment-37}{%
\subsubsection{Treatment}\label{treatment-37}}

\begin{itemize}
\tightlist
\item
  Any traumatic findings: admit to trauma surgery service, as a normal CT does not rule out duodenal hematoma which can lead to perforation
\item
  No traumatic findings: observe 4 hrs after CT, reevaluate including: PO challenge, vital signs, repeat abdominal/thoracic exams
\item
  If symptoms worsening, consider imaging or trauma consult if not already obtained
\item
  If symptoms improved, discharge to home with return instructions
\end{itemize}

\hypertarget{appendicitis}{%
\subsection{Appendicitis}\label{appendicitis}}

Sources: \textbf{BCH EBG} (appendicitis), \textbf{CHOP Clinical Pathway}

\hypertarget{definition-24}{%
\subsubsection{Definition}\label{definition-24}}

Inflammation of the appendix caused by obstruction of the lumen

\hypertarget{pathophysiology-23}{%
\subsubsection{Pathophysiology}\label{pathophysiology-23}}

\begin{itemize}
\tightlist
\item
  The appendix is a blind pouch in the RLQ that can become obstructed with a fecalith or lymph tissue. Once it becomes obstructed, it becomes inflamed and edematous which eventually leads to necrosis and perforation.
\item
  Inflammation can also occur as a result of bacterial invasion without obstruction.
\end{itemize}

\hypertarget{clinical}{%
\subsubsection{Clinical}\label{clinical}}

\begin{itemize}
\tightlist
\item
  Pain begins in periumbilical region (referred pain) and then moves to RLQ
\item
  Anorexia, nausea, vomiting, and fever
\item
  Young children may not have classic signs and therefore many present with perforation
\item
  Perforation can occur between 24-72 hours after symptom onset if not diagnosed.

  \begin{itemize}
  \tightlist
  \item
    Perforation can present with high fevers, peritoneal signs, and/or sepsis
  \end{itemize}
\end{itemize}

\hypertarget{physical-exam-13}{%
\subsubsection{Physical Exam}\label{physical-exam-13}}

\begin{itemize}
\tightlist
\item
  Pain on palpation in periumbilical region that migrates to RLQ
\item
  Rovsing's sign: palpation of LLQ causes pain in RLQ
\item
  Psoas sign: increased abdominal pain when patient flexes right hip against resistance
\item
  Obturator sign: increased abdominal pain when patient's right leg is raised with knee flexed and then internally rotated at the hip.
\item
  Rectal exam: may have tenderness if appendix is retrocecal.
\item
  If perforated: guarding and/or rebound, or may paradoxically be quite benign
\end{itemize}

\hypertarget{studies-19}{%
\subsubsection{Studies}\label{studies-19}}

\begin{itemize}
\tightlist
\item
  If female, obtain urine HCG
\item
  CBC: poly-predominant leukocytosis (WBC\textgreater9, PMN\textgreater65\%) is strongly associated with appendicitis
\item
  UA may show mild pyuria
\item
  KUB: not indicated in most. may show fecalith, localized ileus, free air (if perforated), SBO in young child without prior surgical history is appendicitis unless proven otherwise
\item
  US recommended if moderate to high risk (based on PAS):

  \begin{itemize}
  \tightlist
  \item
    US: Positive if hyperemia, thickened wall, echogenic fat, fecalith. Interpretation heavily influenced by pre-test probability. Can be fooled into interpreting as positive if a blind end is not visualized
  \item
    CT with IV contrast or MRI: increased diameter, fat streaking
  \end{itemize}
\end{itemize}

\hypertarget{treatment-38}{%
\subsubsection{Treatment}\label{treatment-38}}

\begin{itemize}
\tightlist
\item
  Risk stratify based on WBC and U/S findings
\item
  NPO
\item
  Consult surgery
\item
  Antibiotics once confirmed: Cefoxitin 40mg/kg for uncomplicated, Zosyn 75mg/kg if abscess present
\item
  Urgent appendectomy
\item
  If perforated: antibiotics with interval appendectomy
\end{itemize}

\hypertarget{acute-chest-pain}{%
\subsection{Acute Chest Pain}\label{acute-chest-pain}}

Sources: BCH EBG (chest pain), CHOP Clinical Pathway, Uptodate

\hypertarget{differential-3}{%
\subsubsection{Differential}\label{differential-3}}

\hypertarget{cant-miss}{%
\paragraph{Can't miss}\label{cant-miss}}

Acute coronary syndrome, myocarditis, pneumothorax, pulmonary embolism, aneurysm

\hypertarget{msk}{%
\paragraph{MSK}\label{msk}}

Costochondritis, musculoskeletal strain/trauma, precordial catch (Texidor's twinge), rib fracture

\hypertarget{cardiac-1-of-children}{%
\paragraph{Cardiac (1\% of children)}\label{cardiac-1-of-children}}

\begin{itemize}
\tightlist
\item
  Ischemia: severe aortic and pulmonary stenosis, hypertrophic or dilated cardiomyopathy, history of Kawasaki disease and subsequent coronary thrombosis, anomalous coronary arteries, familial dyslipidemia, medication or drug induced vasospasm (i.e.~cocaine abuse)
\item
  Arrhythmia: SVT or ventricular tachyarrhythmias
\item
  Inflammatory: myocarditis, pericarditis
\item
  Mitral valve prolapse
\item
  Aortic dissection (consider in Marfan, Ehlers-Danlos, Turner, or Noonan)
\end{itemize}

\hypertarget{pulmonary}{%
\paragraph{Pulmonary}\label{pulmonary}}

Pneumonia, asthma, upper respiratory infection causing coughing, hyperventilation, pneumothorax, pleuritis, pulmonary embolism

\hypertarget{gi-1}{%
\paragraph{GI}\label{gi-1}}

GERD, esophagitis, esophageal spasm. Also consider foreign body ingestion, gastritis, pancreatitis, cholecystitis, peptic ulcer disease, Mallory-Weiss tears, Boerhaave syndrome and hiatal hernias

\hypertarget{psych}{%
\paragraph{Psych}\label{psych}}

Anxiety, panic attacks

\hypertarget{id}{%
\paragraph{ID}\label{id}}

Shingles (herpes zoster infection)

\hypertarget{heme}{%
\paragraph{Heme}\label{heme}}

Severe anemia, Sickle cell anemia-related VOE or acute chest syndrome

\hypertarget{history-2}{%
\subsubsection{History}\label{history-2}}

\begin{itemize}
\tightlist
\item
  Location, chronicity, duration, frequency, severity, quality, radiation of pain
\item
  Precipitating or alleviating factors
\item
  Association with exertion, syncope, or palpitations
\item
  History of inflammatory disorders, hypercoagulable states, connective tissue disease
\item
  Family history of early thromboembolic disease, sudden death, drowning, or congenital heart disease
\end{itemize}

\hypertarget{physical-exam-14}{%
\subsubsection{Physical Exam}\label{physical-exam-14}}

\begin{itemize}
\tightlist
\item
  Complete cardiorespiratory and abdominal exam
\item
  Examination of skin overlying area of pain
\item
  Palpation for reproducible pain
\item
  Concerning findings:

  \begin{itemize}
  \tightlist
  \item
    Non-innocent heart murmurs (\textgreater III/VI in intensity, diastolic, harsh quality, no positional change, louder standing than supine)
  \item
    Clicks, rubs or gallops
  \item
    Abnormal S2
  \item
    Stigmata of connective tissue disease
  \item
    Hepatomegaly
  \item
    Pallor, diaphoresis, or poor perfusion
  \end{itemize}
\end{itemize}

\hypertarget{studies-20}{%
\subsubsection{Studies}\label{studies-20}}

\begin{itemize}
\tightlist
\item
  EKG
\item
  CXR for suspected pulmonary or cardiac disease
\item
  CT w/PE protocol if high suspicion for PE
\item
  Consider CBC, inflammatory markers, D-dimer, troponin, BNP, tox screen as indicated
\item
  Cardiology consult in ED if high risk history, concerning exam findings, abnormal EKG
\end{itemize}

\hypertarget{acute-scrotal-pain}{%
\subsection{Acute Scrotal Pain}\label{acute-scrotal-pain}}

Sources: \textbf{BCH EBG} (Acute Scrotal Pain), \textbf{CHOP Clinical Pathway}, Brenner, JS, Ojo A. UpToDate: Causes of scrotal pain in children and adolescents

\hypertarget{history-3}{%
\subsubsection{History}\label{history-3}}

\begin{itemize}
\tightlist
\item
  Pain (Onset, Duration, Location, Migration, Severity)
\item
  Anorexia/Nausea (Last meal)
\item
  Vomiting (Time of onset, Last episode, Number of episodes)
\item
  Urine (Dysuria, Quantify urine output, Hesitancy, Urgency, Hematuria)
\item
  Sexual History (Sexually active?, History of STIs, Urethral discharge)
\item
  Fever
\item
  Trauma
\end{itemize}

\hypertarget{physical-exam-15}{%
\subsubsection{Physical Exam}\label{physical-exam-15}}

\begin{itemize}
\tightlist
\item
  Abdomen (Focal tenderness, Guarding/rebound, CVA tenderness)
\item
  Genital (Tanner stage, Inguinal canal abnormality, Scrotal tenderness, Lie of testicles, Tenderness of testicles, Abnormal color of scrotum, Differences in size, Presence/absence of cremasteric reflex)
\end{itemize}

\hypertarget{studies-21}{%
\subsubsection{Studies}\label{studies-21}}

\begin{itemize}
\tightlist
\item
  Imaging: Scrotal US with doppler
\item
  Labs: UA and UCx if fever, dysuria, or concern for epididymitis; GC/CT in sexually active patients.
\item
  Urgently consult urology if suspicion for torsion (TWIST score ≥2), without waiting for imaging results
\end{itemize}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.06\columnwidth}\raggedright
Condition\strut
\end{minipage} & \begin{minipage}[b]{0.27\columnwidth}\raggedright
Definition/Pathogenesis\strut
\end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright
Clinical Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.31\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Testicular Torsion\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Rotation of the spermatic cord of the testis → diminished blood flow → infarction -\textasciitilde30\% of acute scrotal pain is testicular torsion\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Acute, severe pain -Swollen, high-riding testis, diffusely tender, possibly w/ horizontal lie -Absent cremastmeric reflex -Overlying edema\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Surgical emergency: surgical exploration, detorsion, and fixation of the bilateral testes -Pain control\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Torsion of the testicular appendage\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Rotation of appendix testis (small vestigial structure on the anterosuperior aspect of the testis) → localized infarction\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Localized pain to upper pole of the testes only -Classic ``blue dot'' sign\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Pain medication, scrotal support, and rest -Pain should resolve in a few days, if not patient needs re-evaluation\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Epididymitis\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Inflammation of the epididymis\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Indolent pain and swelling of epididymis -Dysuria -Penile discharge -Fever -US: Increased blood flow\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Supportive care -Sexually active adolescents: treat like STD -In prepubertal children, may be bacterial or aseptic (traumatic, viral), refer to urology -Antibiotics if UCx positive\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Orchitis\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Inflammation of the testes - Viral (mumps, rubella, coxsackie, echovirus, lymphocytic choriomeningitis virus, parvovirus) and bacterial (brucellosis) infections\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Generalized scrotal swelling, pain, and tenderness -Erythema and shininess of the overlying skin -Increased blood flow on US\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Supportive care -Support of the inflamed testis -NSAIDs and ice packs -Mumps testing if unimmunized\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Trauma\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Blunt vs.~penetrating trauma → can cause hematocele, hematoma, testicular rupture, or traumatic epididymitis\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Swelling, pain, and tenderness -Bruising or abrasions -High index of suspicion for concomitant torsion\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Penetrating wounds, rupture, or large hematoceles require surgical repair (Urology) -Antibiotics for wounds -Otherwise, supportive care\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Vasculitis\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Occasionally occurs as part of IgA vasculitis or HSP\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Acute or insidious pain -Signs of systemic illness (fever, abd pain, rash) -US can distinguish from torsion\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Supportive care -NSAIDs and ice packs -Steroids helpful in severe HSP\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Incarcerated Inguinal Hernia\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Herniation of bowel or omentum into the scrotum\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
-Pain and scrotal mass -Audible bowel sounds -US shows herniated bowel\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
-Attempt manual reduction immediately -Surgical intervention -Pain control\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{atraumatic-limp}{%
\subsection{Atraumatic Limp}\label{atraumatic-limp}}

Sources: \textbf{BCH EBG} (limp/irritable hip), \textbf{CHOP Clinical Pathway} (septic arthritis), UpToDate: Approach to the child with a limp, UpToDate: Overview of the causes of limp in children, Kocher MS, Zurakowski D, Kasser JR. Differentiating between septic arthritis and transient synovitis of the hip in children: an evidence-based clinical prediction algorithm. J Bone Joint Surg Am 1999; 81:1662

\hypertarget{differential-diagnoses}{%
\subsubsection{Differential Diagnoses}\label{differential-diagnoses}}

\hypertarget{big-four-inflammatory-causes}{%
\paragraph{``Big Four'' inflammatory causes}\label{big-four-inflammatory-causes}}

Septic Arthritis, Transient Synovitis, Lyme Arthritis, Osteomyelitis

\hypertarget{other-inflammatory-causes}{%
\paragraph{Other inflammatory causes}\label{other-inflammatory-causes}}

Myositis, Oncologic, Abscess, Appendicitis, JIA

\hypertarget{non-inflammatory-causes}{%
\paragraph{Non-inflammatory causes}\label{non-inflammatory-causes}}

Toddler's fracture, Legg-Calvé-Perthes disease, Slipped capital femoral epiphysis (SCFE), Overuse injuries (Osgood-Schlatter, Sinding-Larsen-Johansson, Patellofemoral syndromes), Torsion of the testicle, Foot foreign body, Poor shoe fit

\hypertarget{red-flags}{%
\paragraph{Red flags}\label{red-flags}}

Pain at rest, non-weight bearing, pain at night, and pain away from joints; systemic symptoms such as weight loss, fevers; anemia or petechiae

\hypertarget{workup-1}{%
\subsubsection{Workup}\label{workup-1}}

\hypertarget{general-approach}{%
\paragraph{General approach}\label{general-approach}}

Exam → XR any suspected joint → if XR negative, consider labs and use Kocher Criteria to determine hip US or not

\hypertarget{physical-exam-16}{%
\paragraph{Physical Exam}\label{physical-exam-16}}

\begin{itemize}
\tightlist
\item
  Evaluate for swelling, erythema, fluctuance, point tenderness
\item
  Evaluate ROM or pain on ROM
\item
  Observe how the child naturally holds the leg
\item
  Observe gait
\item
  Rule out foreign body on the sole of the foot
\end{itemize}

\hypertarget{imaging}{%
\paragraph{Imaging}\label{imaging}}

\begin{itemize}
\tightlist
\item
  X-ray films
\item
  US if hip source suspected and 2+ of Kocher criteria + CRP\textgreater2
\end{itemize}

\hypertarget{labs-2}{%
\paragraph{Labs}\label{labs-2}}

(if fever, inability to weight bear, or clinical
concern for septic arthritis):
- CBC, ESR/CRP, BCx, Lyme Titers

\hypertarget{kocher-criteria}{%
\paragraph{Kocher Criteria}\label{kocher-criteria}}

\begin{itemize}
\tightlist
\item
  Fever \textgreater{} 38.5
\item
  Non-weight bearing
\item
  ESR \textgreater40
\item
  WBC \textgreater12K
\end{itemize}

\begin{figure}
\centering
\includegraphics{images/ED_kocher_criteria.png}
\caption{ED\_Kocher\_Criteria}
\end{figure}

\hypertarget{management-25}{%
\subsubsection{Management}\label{management-25}}

\textbf{Kocher scores 0-1 generally indicate transient synovitis}
\textbf{If Kocher criteria \textgreater1, consult ortho and consider tapping joint}
- Clinically apparent knee/ankle effusion -\textgreater{} tap joint
- Irritable hip -\textgreater{} hip ultrasound -\textgreater{} if effusion, tap joint
- If no effusion -\textgreater{} MRI to look for osteomyelitis

\textbf{Analyze Joint Fluid}
- Labs: WBC and differential, Gram Stain, Culture
- \textgreater50k WBC or gram stain positive → treat as septic arthritis
- 25k-50k WBC → possible septic joint, could also be Lyme arthritis, synovitis, other causes
- \textless25k WBC → transient synovitis

\hypertarget{discharge-criteria}{%
\subsubsection{Discharge Criteria}\label{discharge-criteria}}

\begin{itemize}
\tightlist
\item
  Non-toxic appearing
\item
  Weight bearing, with rare exception
\item
  Have discussed cases of diagnostic uncertainty with orthopedics
\item
  Reliable caretaker and ability to return if needed
\item
  Discharge with: NSAIDs, signs/symptoms warranting return, 24hr follow-up
\end{itemize}

\hypertarget{animal-bites}{%
\subsection{Animal Bites}\label{animal-bites}}

Sources: AAP Red Book, UpToDate

\hypertarget{bacteria}{%
\subsubsection{Bacteria}\label{bacteria}}

\begin{itemize}
\tightlist
\item
  \textbf{Cat/Dog}: Pasteurella, anaerobes
\item
  \textbf{Cat}: Bartonella henselae
\item
  \textbf{Human}: Strep, Staph, anaerobes, Eikenella
\end{itemize}

\hypertarget{clinical-presentation}{%
\subsubsection{Clinical Presentation}\label{clinical-presentation}}

\begin{itemize}
\tightlist
\item
  \textbf{Dog}: abrasions, lacerations, puncture wounds, tissue avulsion, or crush injuries
\item
  \textbf{Cat}: abrasions, scratches, lacerations, or deep puncture wounds
\item
  \textbf{Human}: bruising, abrasions, lacerations in pattern of human teeth; in adolescents, often occur with closed-fist injury
\item
  \textbf{Snake}: varies by species, fang marks with evidence of local envenomation (redness, swelling, oozing) or venom spreading (lymphadenopathy, remote swelling, systemic toxicity)
\item
  \textbf{Rodent}: similar to cat injuries
\end{itemize}

\hypertarget{workup-2}{%
\subsubsection{Workup}\label{workup-2}}

\begin{itemize}
\tightlist
\item
  Wound cultures are not indicated in clinically uninfected bite wounds
\item
  Gram stain, aerobic/anaerobic wound Cx from the depth of an infected puncture or laceration
\item
  Aerobic/anaerobic BCx in patients with an infected bite wound and evidence of systemic infection
\item
  Plain films to identify bone or joint disruption in deep bite wounds, or to identify subcutaneous gas and/or bony/soft tissue changes if wound is infected
\item
  Head CT for deep bite wounds to the scalp, especially in children \textless2 yrs of age
\item
  For snake bites, urgently consult Poison Control (1-800-222-1222) and toxicology
\end{itemize}

\hypertarget{management-and-treatment}{%
\subsubsection{Management and Treatment}\label{management-and-treatment}}

Wound care
- Control bleeding, assess neurovascular status
- Apply local anesthetics for cleaning and closure
- Clean with 1\% povidone iodine or 1\% benzalkonium chloride and irrigate with copious amounts of saline

Primary closure (laceration repair) if:
- Dog bite or other cosmetically important bite (face)
- Clinically uninfected
- \textless12 hours old on body, \textless24 hours old on face
- NOT located on hand or foot
- Sutures needed for hemostasis

Secondary closure (no repair) for all other bite wounds (i.e.~cat or human, puncture wounds, and wounds in immunocompromised hosts)
Do NOT use adhesive to close bite wounds
Antibiotic prophylaxis for all animal bites:
- PO: Augmentin,
- IV: Unasyn, Zosyn, TMP-SMX+clindamycin
- Human: 5-7 days\textbf{\emph{
- Cat/dog: 7-10 days}}
Assess tetanus status
- Give tetanus Ig+toxoid if \textless2 primary immunizations
- Give tetanus toxoid if completed primary series but no booster \textgreater5 years
Rabies prophylaxis for bites by wild animals or if high prevalence of rabies

\hypertarget{brief-resolved-unexplained-event-brue}{%
\subsection{Brief Resolved Unexplained Event (BRUE)}\label{brief-resolved-unexplained-event-brue}}

Sources: BCH EBG (BRUE), CHOP Clinical Pathway

\hypertarget{presentation-52}{%
\subsubsection{Presentation}\label{presentation-52}}

Report of 1 or more of the following symptoms that are now resolved:
- Cyanosis or pallor
- Absent, decreased, or irregular breathing
- Marked change in tone (hyper- or hypotonia)
- Altered level of responsiveness

\hypertarget{workup-3}{%
\subsubsection{Workup}\label{workup-3}}

\begin{itemize}
\tightlist
\item
  History of eye deviation, responsiveness, rhythmic movements → consider Neurology consult
\item
  New murmur → EKG, CXR → if abnormal, consult cardiology
\item
  Family history of long QT syndrome, sudden cardiac or unexplained death in 1st or 2nd degree relative before age 35, unexplained drowning or car accident, sibling with h/o SIDS, ALTE, or BRUE → EKG → if abnormal, consult cardiology
\item
  History of paroxysmal cough, pertussis exposure → CBC, pertussis PCR
\item
  Weight concern → further workup for FTT as indicated, consider checking NBS
\item
  NAT concern → see Suspected Child Abuse section
\end{itemize}

\hypertarget{management-and-treatment-1}{%
\subsubsection{Management and Treatment}\label{management-and-treatment-1}}

Determine if patient meets low risk criteria:
- Age \textgreater60 days
- Born \textgreater or= 32 weeks GA and corrected GA \textgreater or= 45 weeks
- No CPR by trained provider
- Event \textless1 min
- First event
- No concerning H\&P as above
\textbf{Low risk} → ED observation on continuous CV monitor and pulse ox for at least 1 hour including 2 observed feedings by RN or MD
\textbf{High risk} → Admit to inpatient, continuous CV monitor and pulse ox for at least 6 hours (no more than 24 hours) including 2 observed feedings by RN or MD and 2 sleep/awake cycles

Provide CPR training kit to parents/guardians on discharge

\hypertarget{burns}{%
\subsection{Burns}\label{burns}}

Sources: CHOP clinical pathway

\hypertarget{classification-1st-degree}{%
\subsubsection{Classification: 1st degree}\label{classification-1st-degree}}

Definition: superficial (epidermis)
Symptoms: Erythema, pain
Description/Treatment:
- Includes sunburn, minor scalds
- Does not require fluid replacement; not included in estimate of surface area burned
- Usually heals without scarring in 3-5 days

\hypertarget{classification-2nd-degree}{%
\subsubsection{Classification: 2nd degree}\label{classification-2nd-degree}}

\textbf{Superficial partial thickness}
Symptoms: Intesne pain, blisters, pink to cherry-red skin, moist, weepy
Description/Treatment:
-Nails, hair, sebaceous glands, nerves intact
-Can progress to deep partial or full-thickness burns
-Spontaneous re-epithelialization in 2-3 weeks

\textbf{Deep parital thickness}
Symptoms: Intense pain, dry and white in color
Description/Treatment: Disruption of nails, hair, sebaceous glands, nerves. Skin grafting may be required based on size

\hypertarget{classification-3rd-degree}{%
\subsubsection{Classification: 3rd Degree}\label{classification-3rd-degree}}

\textbf{Full Thickness}
Symptoms: Charred black color ± areas dry or white. Pain intense or absent, depending on nerve involvement
Treatment: Skin grafting required

\hypertarget{pathogenesis}{%
\subsubsection{Pathogenesis}\label{pathogenesis}}

Burn injury -\textgreater{} increased capillary permeability -\textgreater{} third spacing, edema, fluid loss

\hypertarget{estimating-burn-size}{%
\subsubsection{Estimating Burn Size}\label{estimating-burn-size}}

\begin{itemize}
\tightlist
\item
  Estimate proportion of total body surface area involved
\item
  Rule of 9's for adults and older adolescents:
  9\% for each arm
  18\% for each leg
  9\% for head
  18\% for front torso
  18\% for back torso
\item
  Rule of 9's does not apply to children due to differing body proportions, see modification for children below
\item
  Palm of child's hand = 0.5\% of total body surface area, can use to estimate burn size:
\end{itemize}

\textbf{Modified Lund and Browder Chart}
\includegraphics{images/ED_modified_Lund_Browder_chart.png}

\hypertarget{workup-4}{%
\subsubsection{Workup}\label{workup-4}}

\begin{itemize}
\tightlist
\item
  Mechanism of burns (flame, chemical, electrical)
\item
  Closed vs.~open space exposure
\item
  Condition of other victims, such as death at the scene
\item
  Duration of exposure
\item
  Associated trauma, such as falls
\item
  Tetanus immunization status
\item
  Always consider non-accidental trauma (See Suspected Child Abuse)
\end{itemize}

\hypertarget{treatment-39}{%
\subsubsection{Treatment}\label{treatment-39}}

Treatment is based on the depth of burn, proportion of TBSA involved, and if there is airway involvement or other injuries:

\textbf{Airway}
- Assess for signs of inhalation injury or respiratory distress, snoot in nares, carbonaceous sputum, stridor
- Consider intubation for \textgreater30\%TBSA burned

\textbf{Breathing}
- Assume carbon monoxide poisoning with severe/closed space burns
- Assess stability of the airway
- If airway injury, early intubation (use smaller cuffed ETT than necessary for age given continued swelling that will occur)

\textbf{Circulation}
- For burns \textgreater15\%BSA or any evidence of inhalation → Parkland formula
- Initial bolus of 20 cc/kg NS
- Parkland fluid resuscitation formula: good estimate for losses, but underestimates needs of young children \textless5yo. Provides fluid requirements to be added in addition to normal maintenance fluid requirements
- {[}TBSA burned (\%){]} x {[}wt (kg){]} x {[}4mL{]} = total mL resuscitation required over first 24 hrs → Give 1⁄2 in 1st 8 hours, remainder in next 16 hrs

\textbf{Assess urine output}:
- Urine output \textless1mL/kg/hr → 20 mL/kg bolus of crystalloid
- Urine output = 1-3 mL/kg/ht → continue parkland formula
- Urine output \textgreater3 mL/kg/hr →decrease rate to 2/3 Parkland formula

\textbf{Pain control}: IV narcotic therapy often necessary (can give IM morphine or IN fentanyl prior to placing IV)

\textbf{Wound care}:
Cleanse affected area with lukewarm sterile water.
Wipe away loose tissue with sterile gauze
Leave unruptured bullae intact (do not rupture)
Topical antibiotics (Silvadene, Bacitracin) applied directly to burns
Admit if: partial thickness burns of \textgreater10\% TBSA or \textgreater{} 2\% full-thickness burns, hands, joints

\hypertarget{deep-space-neck-infections}{%
\subsection{Deep Space Neck Infections}\label{deep-space-neck-infections}}

\hypertarget{peritonsillar-abscess}{%
\subsubsection{Peritonsillar Abscess}\label{peritonsillar-abscess}}

Sources: CHOP Clinical Pathway

\hypertarget{definition-25}{%
\paragraph{Definition}\label{definition-25}}

Suppurative collection in tonsils with extension into the peritonsillar space

\hypertarget{epidemiology}{%
\paragraph{Epidemiology}\label{epidemiology}}

Most common in adolescents

\hypertarget{etiology-6}{%
\paragraph{Etiology}\label{etiology-6}}

Polymicrobial, S. pyogenes is most common, less common -- anaerobes, S. aureus

\hypertarget{pathogenesis-1}{%
\paragraph{Pathogenesis}\label{pathogenesis-1}}

Pharyngitis → progresses to abscess

\hypertarget{clinical-1}{%
\paragraph{Clinical}\label{clinical-1}}

Fever, pharyngitis, unilateral pain, muffled (hot potato) voice, trismus, drooling

\hypertarget{workup-5}{%
\paragraph{Workup}\label{workup-5}}

\textbf{History}: Fever duration, neck ROM, PO intake, foreign body, trauma hx, recent ENT surgery, recent abx
\textbf{Exam}: Peritonsillar fullness. Drooling, displacement of uvula away from affected side, peritonsillar fluctuance, ipsilateral cervical lymphadenopathy
\textbf{Labs}: Not routinely indicated
\textbf{Imaging}: Not routinely indicated

\hypertarget{treatment-40}{%
\paragraph{Treatment}\label{treatment-40}}

Drainage by ORL:
- Bedside needle aspiration in older children may be appropriate
- Incision and drainage
Antibiotics: Clindamycin or Ampicillin-Sulbactam

\hypertarget{complications-10}{%
\paragraph{Complications}\label{complications-10}}

Airway obstruction, aspiration PNA, sepsis, jugular vein thrombosis or thrombophlebitis (Lemierre syndrome), carotid rupture, other deep neck space infections, mediastinitis

\hypertarget{parapharyngeal-abscess}{%
\subsubsection{Parapharyngeal Abscess}\label{parapharyngeal-abscess}}

\hypertarget{definition-26}{%
\paragraph{Definition}\label{definition-26}}

Suppurative collection in the area of the lateral neck from the skull to the hyoid bone.

\hypertarget{etiology-7}{%
\paragraph{Etiology}\label{etiology-7}}

Polymicrobial, S. pyogenes, S. aureus, anaerobes.

\hypertarget{pathogenesis-2}{%
\paragraph{Pathogenesis}\label{pathogenesis-2}}

Spread of infection into lateral aspect of neck from pharyngitis, tonsillitis, parotitis, otitis, mastoiditis and dental infections

\hypertarget{presentation-53}{%
\paragraph{Presentation}\label{presentation-53}}

Symptoms can be subtle. Fever, pharyngitis, neck stiffness, dysphagia/odynophagia, muffled (hot potato voice) trismus, drooling, respiratory distress or stridor.

\hypertarget{workup-6}{%
\paragraph{Workup}\label{workup-6}}

\textbf{History}: Fever duration, neck ROM, PO intake, foreign body, trauma hx, recent ENT surgery, recent abx, chest pain
\textbf{Exam}: Induration and swelling below the angle of the mandible, medial bulging of the pharyngeal wall, torticollis or difficulty with neck rotation
\textbf{Labs}: CBC w/diff, aerobic and anaerobic BCx, rapid strep and throat culture, chem if decreased PO, fluid culture if abscess drained
\textbf{Imaging}:
Low suspicion → XR lateral neck → If normal, does not rule out infection
High suspicion → Neck CT with contrast (only way to diagnose parapharyngeal abscess)

\hypertarget{treatment-41}{%
\paragraph{Treatment}\label{treatment-41}}

\begin{itemize}
\tightlist
\item
  Airway compromise → secure airway, emerg. surgical drainage, IV antibiotics
\item
  Mature abscess (\textgreater2.5 cm2) → surgical drainage + IV antibiotics
\item
  Phlegmon → IV antibiotics, re-image in 24-48 hours
\item
  Antibiotics: Ampicillin-sulbactam + vancomycin (severe) or clindamycin (non-severe)
\end{itemize}

\hypertarget{complications-11}{%
\paragraph{Complications}\label{complications-11}}

See ``Peritonsillar Abscess'' above

\hypertarget{retropharyngeal-abscess}{%
\subsubsection{Retropharyngeal Abscess}\label{retropharyngeal-abscess}}

Sources: \textbf{CHOP Clinical Pathway}, UpToDate: Retropharyngeal infections in children, UpToDate: Peritonsillar cellulitis and abscess

\hypertarget{definition-27}{%
\paragraph{Definition}\label{definition-27}}

Deep neck abscess in the potential space between the posterior pharyngeal wall and the deep cervical fascia
- Occurs in young children (\textless5 years)
- Retropharyngeal lymph nodes regress as children age, making RPA unlikely in older children

\hypertarget{etiology-8}{%
\paragraph{Etiology}\label{etiology-8}}

S. pyogenes, S. aureus, anaerobes

\hypertarget{pathogenesis-3}{%
\paragraph{Pathogenesis}\label{pathogenesis-3}}

Spread of infection from nasopharynx via lymph system to retropharyngeal lymph nodes → phlegmon → abscess formation

\hypertarget{presentation-54}{%
\paragraph{Presentation}\label{presentation-54}}

Fever, decreased PO, pharyngitis, drooling, dysphagia, neck stiffness (refusal to extend or pain with neck extension), torticollis, trismus

\hypertarget{workup-7}{%
\paragraph{Workup}\label{workup-7}}

History, Physical, Labs: See ``Parapharyngeal Abscess'' above
\textbf{Imaging}:
- Low suspicion → XR lateral neck
- Greater than 7 mm at C2 (roughly 1⁄2 the width of the vertebral body) or 14 mm at C6 in children
- Greater than 22 mm at C6 in adults
- High suspicion → Neck CT with contrast

\hypertarget{treatment-42}{%
\paragraph{Treatment}\label{treatment-42}}

\begin{itemize}
\tightlist
\item
  Airway compromise → secure airway (highly morbid, prepare for surgical airway concurrently), emergency surgical drainage, IV antibiotics
\item
  Mature abscess (\textgreater2.5 cm2) → surgical drainage + IV antibiotics
\item
  Phlegmon → IV antibiotics, re-image in 24-48 hours
\item
  Antibiotics: Ampicillin-sulbactam + vancomycin (severe) or clindamycin (non-severe)
\end{itemize}

\hypertarget{complications-12}{%
\paragraph{Complications}\label{complications-12}}

See ``Peritonsillar Abscess'' above

\hypertarget{dehydration}{%
\subsection{Dehydration}\label{dehydration}}

Sources: \textbf{BCH EBG} (Gastroenteritis), \textbf{CHOP Clinical Pathway}

\hypertarget{definition-28}{%
\subsubsection{Definition}\label{definition-28}}

\begin{itemize}
\tightlist
\item
  Dehydration = cellular water loss
\item
  Hypovolemia or volume depletion = reduced effective circulating volume
\end{itemize}

\hypertarget{presentation-55}{%
\subsubsection{Presentation}\label{presentation-55}}

Mottled cool extremities, sunken fontanelle in infants, receded eyes, hyperpnea; sensorium usually remains intact until moderate dehydration; weak cry or stupor suggests shock.
Symptoms of underlying etiology will be present (diarrhea, fever, etc.)
Regarding dehydration specifically, fussiness, thirst, and lethargy may be present
See table below for additional physical examination findings

\hypertarget{physical-findings-of-volume-depletion}{%
\subsubsection{Physical Findings of Volume Depletion}\label{physical-findings-of-volume-depletion}}

\begin{longtable}[]{@{}llll@{}}
\toprule
Findings & Mild (3-5\%) & Moderate (6-9\%) & Severe (\textgreater10\%)\tabularnewline
\midrule
\endhead
Pulse & Full, normal rate & Rapid & Rapid/weak/absent\tabularnewline
Systolic Press. & Normal & Normal to low & Low\tabularnewline
Respirations & Normal & Deep (rate ↑) & Deep, tachypnea\tabularnewline
Buccal mucosa & Tacky/slightly dry & Dry & Parched\tabularnewline
Ant. fontanelle & Normal & Sunken & Markedly sunken\tabularnewline
Eyes & Normal & Sunken & Markedly sunken\tabularnewline
Skin turgor & Normal & Reduced & Tenting\tabularnewline
Skin & Normal & Cool & Cool/mottled\tabularnewline
Urine output & Normal/mildly dec & Markedly reduced & Anuria\tabularnewline
Systemic signs & Increased thirst & Listlessness & Grunting, coma\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{differential-4}{%
\subsubsection{Differential}\label{differential-4}}

\begin{itemize}
\tightlist
\item
  ↑ output (gastroenteritis (most common), diabetes mellitus, diabetes insipidus)
\item
  ↓ intake (gingivostomatitis, viral or bacterial pharyngitis, nausea/vomiting)
\item
  ↑ insensible losses/metabolic demand (bacterial infections with fever such as PNA, meningitis, UTI)
\end{itemize}

\hypertarget{workup-8}{%
\subsubsection{Workup}\label{workup-8}}

Important to establish degree of dehydration: mild (3-5\%), moderate (6-9\%), or severe (\textgreater10\%) to guide therapy
BCH/CHOP guidelines provide an \textbf{Assessment Tool}
10-point (1 point each):
- Ill-appearing or decreased activity
- Tachycardia for age
- Tachypnea or abnormal respirations
- Decreased urine output
- Sunken eyes
- Decreased or absent tears
- Dry mucous membranes
- Abnormal pulses/perfusion
- Cap refill \textgreater2 sec
- Decreased skin turgor
Scoring: \textless3 = mild, 3-6 = moderate, \textgreater6 = severe

\textbf{Labs}
- Mild or moderate dehydration → may not require laboratory testing
- Moderate or severe dehydration → D-stick, chemistry, UA (for urine spec grav)
- Low serum bicarbonate useful for determining whether starvation ketosis is present (if anion gap elevated) or excessive diarrhea (if anion gap not present)

\hypertarget{treatment-43}{%
\subsubsection{Treatment}\label{treatment-43}}

\hypertarget{mild}{%
\paragraph{Mild}\label{mild}}

Initiate oral rehydration therapy (ORT)
- 5-10 mL every 3-5 minutes via bottle, cup, syringe

\hypertarget{moderate}{%
\paragraph{Moderate}\label{moderate}}

Initiate ORT, consider IVF
- Similar outcomes but fewer complications and higher satisfaction with ORT in RCTs comparing IV fluids and ORT groups
- If ORT fails → obtain D-stick* → 2x 20 mL/kg NS boluses -OR- 20 mL/kg D5NS bolus + 20 mL/kg NS bolus → start 1.5-2x mIVF → transition back to ORT as tolerated

\hypertarget{severe}{%
\paragraph{Severe}\label{severe}}

Initiate IVF
- Goal 40 mL/kg total within 1 hour: obtain D-stick* → 2x 20 mL/kg NS boluses -OR- 20 mL/kg D5NS bolus + 20 mL/kg NS bolus → start 2x mIVF of D5NS or D5 ½ NS after bolus
- Consider alternative diagnosis (septic shock) if persistent hemodynamic abnormalities after 60 mL/kg

\hypertarget{ort-failure}{%
\paragraph{ORT failure}\label{ort-failure}}

\begin{itemize}
\item
  \begin{quote}
  1 emesis despite ondansetron
  \end{quote}
\item
  Refusal to drink or not consistently drinking
\item
  Oral intake cannot match diarrheal losses
\item
  No improvement in Dehydration Score, VS despite child drinking
\end{itemize}

\hypertarget{ondansetron}{%
\paragraph{Ondansetron}\label{ondansetron}}

(available in liquid, oral-disintegrating, or tablet forms)
8-15 kg = 2 mg PO
15-30 kg = 4 mg PO
30 kg = 8 mg PO

\hypertarget{discahrge-criteria}{%
\paragraph{Discahrge Criteria}\label{discahrge-criteria}}

Clinical signs of dehydration improved/mild
Caregivers understand ORT instructions and able to perform at home
Caregivers understand reasons to return
***Best practice is to first obtain a D-stick, as DKA may present with moderate-severe dehydration, can mimic gastroenteritis, and may be worsened with administration of glucose

\hypertarget{dental-emergencies}{%
\subsection{Dental Emergencies}\label{dental-emergencies}}

\includegraphics{images/ED_dental_image_1.jpg}
\includegraphics{images/ED_dental_image_2.jpg}
\includegraphics{images/ED_dental_image_3.png}
\includegraphics{images/ED_dental_image_4.jpg}

Sources: McTigue DJ, Azadani E. Evaluation and management of dental injuries in children. In: UpToDate, Wiley, JF (Ed), UpToDate, Waltham, MA. (Accessed on February 22, 2020.)

\hypertarget{avulsion}{%
\subsubsection{Avulsion}\label{avulsion}}

The tooth is completely displaced from the alveolar ridge; the periodontal ligament is severed, and fracture of the alveolus may occur. Extra-oral dry time \textless{} 60 minutes has an increased prognosis of saving the tooth. Primary (``baby'') teeth should not be replaced. If child cooperative, the tooth should be placed into the socket immediately (by the parent before arrival to care if possible). Otherwise, may be placed in a solution with order of preference: save-a-tooth \textgreater{} milk \textgreater{} normal saline. Solution should be chilled but tooth should not be placed directly on ice

\hypertarget{fracture}{%
\subsubsection{Fracture}\label{fracture}}

\textbf{Infraction}: cracked tooth
\textbf{Enamel only (Ellis I - uncomplicated)}: tooth chipped, pain absent but may be elicited with manipulation.
\textbf{Enamel and dentin (Ellis II - uncomplicated)}: ``yellowish'', tooth chipped with exposed dentin, sensitive to touch and temperature. Cover exposed dentin with calcium hydroxide. Care within 48 hours
\textbf{Complicated crown fracture (Ellis III - complicated)}: ``reddish'', exposure of the pulp and central artery, increased risk of infection. Emergency dental evaluation
\textbf{Root fracture}: May not also involve the crown. If the crown is not involved, root fracture suggested by mobility of the crown
\textbf{Alveolar fracture}: causes dislocation of multiple teeth that move with palpation.

\hypertarget{luxation-injuries}{%
\subsubsection{Luxation Injuries}\label{luxation-injuries}}

Involve the supporting structures of the teeth, including the periodontal ligament and alveolar bone

\hypertarget{concussion}{%
\paragraph{Concussion}\label{concussion}}

The tooth is neither loose nor displaced; it may be tender with the pressure of biting because of inflammation of the periodontal ligament.

\hypertarget{subluxation}{%
\paragraph{Subluxation}\label{subluxation}}

The tooth is loose, but not displaced from its socket; the periodontal ligament fibers are damaged and inflamed.

\hypertarget{intrusion}{%
\paragraph{Intrusion}\label{intrusion}}

The tooth is driven into the socket, compressing the periodontal ligament and fracturing the alveolar socket.

\hypertarget{extrusion}{%
\paragraph{Extrusion}\label{extrusion}}

The tooth is centrally dislocated from its socket; the periodontal ligament is lacerated and inflamed.

\hypertarget{lateral-luxation}{%
\paragraph{Lateral luxation}\label{lateral-luxation}}

The tooth is displaced anteriorly, posteriorly, or laterally; the periodontal ligament is lacerated, and the supporting bone is fractured.

\hypertarget{workup-9}{%
\subsubsection{Workup}\label{workup-9}}

Determine if tooth is primary or permanent
Indication for urgent Dental consult
- Avulsed permanent tooth (after reimplantation whenever possible)
- Extrusion \textgreater3 mm or interfering with bite
- Laterally luxated (displaced) teeth that interfere with bite (if not interfering with bite, will often spontaneously revert)
- Intruded primary teeth
- Fractured teeth when dental pulp is exposed (bleeding from central core of tooth)
- Suspected dental root or alveolar fracture (e.g.~tooth mobility, pain out of proportion when tooth is wiggled)
- Suspected jaw fracture (posterior tooth fracture, jaw tenderness, and/or malocclusion) to obtain panoramic radiographs
\textbf{Imaging}: consider XR to search for swallowed or buried (in laceration) tooth. Teeth have also been discovered in the lungs.

\hypertarget{treatment-44}{%
\subsubsection{Treatment}\label{treatment-44}}

Reimplantation (while awaiting arrival of dental team\ldots)
- Avulsed permanent teeth should be reimplanted immediately, ideally within 15 minutes and up to one hour
- Store in save-a-tooth (preferred, available in BCH ED pharmacy), cold milk or saliva if unable to reimplant
- Handle the tooth carefully by the crown to prevent damage to the periodontal ligament
- Remove debris by gentle rinsing with saline or tap water; do not attempt to sterilize or scrub the tooth
- Reimplant manually
- Keep the tooth in place by having the child hold it or bite on a gauze pad or clean towel.
Uncomplicated fracture of permanent tooth:
- Store tooth fragments in tap water to prevent discoloration
- Dental follow-up within a few days to bond fracture piece or smooth a fracture
Other injuries (infraction, concussion, subluxation) warrant outpatient dental referral

\hypertarget{general-aftercare}{%
\paragraph{General aftercare}\label{general-aftercare}}

\begin{itemize}
\tightlist
\item
  Soft diet for up to 10 days and limit sucking (pacifier or digit)
\item
  Continue brushing with a soft-bristled toothbrush
\item
  Avoid flossing until healing has occurred
\item
  Chlorhexidine mouthrinse for luxation of permanent teeth
\item
  Tetanus prophylaxis, for dirty wounds, avulsed teeth, deep lacerations, or marked luxation injuries
\item
  Antibiotic therapy is indicated for permanent teeth avulsions (\textless8yrs: amox; \textgreater8yrs: doxy) and management of secondary infections
\end{itemize}

\hypertarget{epistaxis}{%
\subsection{Epistaxis}\label{epistaxis}}

Sources: Messner AH. Management of epistaxis in children. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 22, 2020.)
Acknowledgements: Ali Baker

\hypertarget{pathogenesis-4}{%
\subsubsection{Pathogenesis}\label{pathogenesis-4}}

The anterior nasal septum is highly vascularized (Kiesselbach's plexus) and is subject to exposure due to location. Any factors that cause congestion of nasal vessels, or drying or irritation of the nasal mucosa increases the likelihood of bleeding.

\hypertarget{etiology-9}{%
\subsubsection{Etiology}\label{etiology-9}}

\begin{itemize}
\tightlist
\item
  Trauma (including nose-picking, foreign body)
\item
  Mucosal irritation: allergic rhinitis, viral URI, dry environment
\item
  Anatomic: septal deviation, unilateral choanal atresia
\item
  Tumor: hemangioma, nasopharyngeal angiofibroma, pyogenic granuloma, papilloma
\item
  Vascular abnormality
\item
  Bleeding disorders (coagulation disorders, platelet disorders, blood vessel disorders)
\item
  Inflammatory: Granulomatosis with polyangiitis (GPA), formerly called Wegener's
\item
  Medications: ASA, ibuprofen, anticoagulants, valproic acid
\end{itemize}

\hypertarget{clinical-presentation-1}{%
\subsubsection{Clinical Presentation}\label{clinical-presentation-1}}

\begin{itemize}
\tightlist
\item
  Active bleeding or dried blood
\item
  Nasal mucosa: may be dry, cracked, pale, boggy, or have prominent vessels
\item
  If there is active bleeding, look for vessels involved
\item
  Exclude masses, polyps, foreign bodies
\item
  Exclude underlying bleeding disorder: ecchymosis, petechiae, cutaneous blood vessel disorders
\end{itemize}

\hypertarget{workup-10}{%
\subsubsection{Workup}\label{workup-10}}

No studies are routinely required
- Hematologic and coagulation studies if history suggests personal or family history of bleeding disorder
- CT or MRI if malignancy is suspected

\hypertarget{treatment-45}{%
\subsubsection{Treatment}\label{treatment-45}}

\begin{itemize}
\tightlist
\item
  Rapid assessment of general appearance, vital signs, airway stability, and mental status
\item
  Sustained pressure on nostrils/anterior plexus (apply for minimum 5-10 min); have child sit up and bend forward at the waist to prevent aspiration or swallowing of blood
\item
  Apply local vasoconstrictor: Oxymetazoline (0.05\%, Afrin) preferred to phenylephrine (0.25\%)
\item
  Anterior nasal packing (avoid in infants \textless1yr due to risk of aspiration and airway obstruction) -\textgreater{} evaluate oropharynx to confirm adequate hemostasis
\item
  Chemical cautery (silver nitrate) or electrocautery of actively bleeding vessel
\item
  Indications for ORL consultation: severe epistaxis, troublesome recurrent epistaxis, local abnormalities, need for nasal packing
\item
  Consider referral to Hematology: severe or recurrent bleeding, family history of bleeding disorders
\end{itemize}

\hypertarget{febrile-infant}{%
\subsection{Febrile Infant}\label{febrile-infant}}

Sources: \textbf{BCH EBG} (FUO, Fever 0-1 months, Fever 0-90 days, Fever 1-2 months, Fever/UTI 2-24 months), \textbf{CHOP clinical pathway}

\hypertarget{definition-29}{%
\subsubsection{Definition}\label{definition-29}}

Temperature ≥38.0 (100.4 C) in infant ≤90 days
Temperature ≥38.5 (101.3 C) in child \textgreater3 months

\hypertarget{etiology-10}{%
\subsubsection{Etiology}\label{etiology-10}}

\begin{itemize}
\tightlist
\item
  Rates of serious bacterial infection (SBI) in febrile infants/young children range from 7-38\% of infants aged 0-28 days seen in emergency department for fever.
\item
  UTI is the most common (5.9\%), followed by bacteremia (1\%), meningitis (0.3\%).
\end{itemize}

\hypertarget{pathogenesis-5}{%
\subsubsection{Pathogenesis}\label{pathogenesis-5}}

\textbf{Bacterial}: UTI, pneumonia, bacteremia, meningitis, cellulitis, enteritis, osteomyelitis
\textbf{Viral}: Enterovirus, HSV, influenza, RSV, rotavirus, aseptic meningitis
\textbf{Neonate}: (within first 7 days of life) often vertical transmission
\textbf{Less common}: recent immunizations, malignancy, medications (antibiotics, antineoplastic drugs, biologics), immunological (Kawasaki), immunodeficiency (HIV, SCID, humoral deficiency), hereditary autoinflammatory syndromes of periodic fever, other periodic fever syndromes

\hypertarget{most-common-pathogens-by-age}{%
\subsubsection{Most Common Pathogens by Age}\label{most-common-pathogens-by-age}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.38\columnwidth}\raggedright
Bacteremia/Meningitis\strut
\end{minipage} & \begin{minipage}[b]{0.48\columnwidth}\raggedright
Other pathogens\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
0-28 days\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
Group B Strep Gram negative enterics (E. coli, Klebsiella) Listeria/Enterococcus\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
HSV \emph{Conjunctivitis}: Gonorrhea, Chlamydia, S. aureus \emph{Pneumonia}: Chlamydia, S. aureus \emph{Diarrhea}: Salmonella\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
28-60 days\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
GBS (Late onset) Gram negative enterics Strep Pneumo N. meningitides Group A Strep Staph\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
\emph{Pneumonia}: Chlamydia, Staph aureus, Pertussis, RSV and other viruses \emph{Diarrhea}: Salmonella\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
3-36 mos\strut
\end{minipage} & \begin{minipage}[t]{0.38\columnwidth}\raggedright
Strep Pneumo N. meningitides Group A Strep Staph\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
\emph{UTI}: E. coli, other GNR, enterococcus\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{clinical-presentation-2}{%
\subsubsection{Clinical Presentation}\label{clinical-presentation-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Non-specific symptoms}: poor feeding, lethargy or irritability. They may have hypothermia instead of fever
\item
  Otitis media/URI symptoms, if present, do not preclude need for further eval.
\end{itemize}

\hypertarget{history-4}{%
\paragraph{History}\label{history-4}}

Full pre- and perinatal history including GBS status, need for intrapartum antibiotics, evidence of maternal HSV or other infections

\hypertarget{physical-exam-17}{%
\paragraph{Physical exam}\label{physical-exam-17}}

Bulging fontanelle (Meningeal signs unlikely in infants), respiratory distress or focal lung findings, conjunctivitis, oral lesions, vesicles, cellulitis, rash, vomiting, diarrhea, swelling of a joint or extremity

\hypertarget{workup-11}{%
\subsubsection{Workup}\label{workup-11}}

\hypertarget{age-0--1-month-well-appearing}{%
\paragraph{Age 0- \textless1 month (well-appearing)}\label{age-0--1-month-well-appearing}}

\begin{itemize}
\tightlist
\item
  Procalcitonin (PCT)
\item
  CBC w/ diff
\item
  Blood Cx
\item
  Cath or SPA UA w/ micro
\item
  Urine Cx
\item
  LP: CSF cell count, protein, glucose, culture, gram stain, HOLD
\item
  CXR if respiratory symptoms
\item
  Consider stool culture if heme+ diarrhea
\item
  Consider HSV testing
\end{itemize}

\hypertarget{age-1--2-months-well-appearing}{%
\paragraph{Age 1- \textless2 months (well-appearing)}\label{age-1--2-months-well-appearing}}

\begin{itemize}
\tightlist
\item
  Procalcitonin (PCT)
\item
  CBC w/ diff
\item
  Blood Cx
\item
  Cath or SPA UA w/ micro
\item
  Urine Cx
\item
  CXR if respiratory symptoms
\item
  Consider stool culture if heme+ diarrhea
\item
  If PCT \textgreater{} 0.2 or WBC \textless5K or \textgreater15K
\item
  LP: CSF cell count, protein, glucose, culture, gram stain, HOLD
\end{itemize}

\hypertarget{treatment-46}{%
\subsubsection{Treatment}\label{treatment-46}}

\begin{itemize}
\tightlist
\item
  Empiric therapy while awaiting culture results if \textless28 days, ill-appearing, or meets any high risk criteria (see below table)
\item
  In patients with positive UA or cultures, therapy should be tailored appropriately (empiric is cephalexin 25mg/kg/dose TID for 10 days)
\end{itemize}

\hypertarget{emperic-antibiotic-treatment-based-on-age}{%
\paragraph{Emperic Antibiotic Treatment Based on Age}\label{emperic-antibiotic-treatment-based-on-age}}

\textbf{Age \textless= 14 days}
Emperic treatment: Ampicillin and Ceftazidime
- Gentamicin can replace Ceftazidime
- Add acyclovir if CSF pleocytosis or ill-appearing
- Use Cefepime instead of Ceftazidime if CSF pleo

\textbf{Age 15-28 days}
Emperic treatment: Ceftriaxone (50mg/kg)
- Add ampicillin and acyclovir if CSF pleocytosis or ill-appearing
- Use Cefepime (50mg/kg) instead of CTX if CSF pleocytosis

\textbf{Age \textgreater29 days}
Emperic treatment: Ceftriaxone
- Meningitic dose if CSF pleocytosis
- Consider vancomycin if suspicion for pneumococcal meningitis

\hypertarget{foreign-body-aspiration}{%
\subsection{Foreign Body Aspiration}\label{foreign-body-aspiration}}

Sources: \textbf{No BCH EBG, No CHOP pathway}. Ruiz FE. Airway foreign bodies in children. In: UpToDate, Hoppin AG (Ed), UpToDate, Waltham, MA. (Accessed on February 22, 2020.)

\hypertarget{presentation-56}{%
\subsubsection{Presentation}\label{presentation-56}}

In acute period, children may have chest pain, wheezing, cough, tachypnea, stridor, resp distress
Classic triad is wheeze, cough, and diminished breath sounds (though only present in 57\% in one study)
In subacute/chronic period after aspiration, children may present with pneumonia (often in the RML as a result of right main-stem FB aspiration)\\
Signs and symptoms can vary according to location of FB:
- Laryngotracheal: acute respiratory distress, stridor, wheeze, hoarseness
- Large bronchi: coughing, wheeze, hemoptysis, choking (most FBs are located in bronchi)
- Lower airways: may have little acute distress after initial choking episode

\hypertarget{workup-12}{%
\subsubsection{Workup}\label{workup-12}}

\hypertarget{physical-exam-18}{%
\paragraph{Physical Exam}\label{physical-exam-18}}

\begin{itemize}
\tightlist
\item
  Stridor, hoarseness, inspiratory wheeze suggest upper airway location (wheeze may be monophonic and focal)
\item
  Asymmetric lung aeration and/or focal decreased breath sounds suggest lower airway location
\end{itemize}

\hypertarget{diagnostic-studies-3}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-3}}

\begin{itemize}
\tightlist
\item
  AP and Lateral CXR and soft tissue neck films
\item
  Expiratory film or lateral decubitus films if lower airway location is suspected (air trapping seen in obstructed lung
\end{itemize}

\hypertarget{management-26}{%
\subsubsection{Management}\label{management-26}}

\begin{itemize}
\tightlist
\item
  If complete upper airway obstruction present, perform back blows (child \textless1 yr of age) or Heimlich maneuver (child \textgreater1 yr of age) to dislodge object → PALS
  \emph{Blind/finger sweeping of the mouth should be avoided}
\item
  Consult Ear-Nose-Throat (ORL) or general surgery for flexible or rigid bronchoscopy in all cases of suspected foreign-body aspiration to visualize the trachea and bronchi and remove object if seen
\end{itemize}

\hypertarget{foreign-body-ingestion}{%
\subsection{Foreign Body Ingestion}\label{foreign-body-ingestion}}

Sources: \textbf{CHOP clinical pathway}

\hypertarget{pathogenesis-6}{%
\subsubsection{Pathogenesis}\label{pathogenesis-6}}

Average GI transit time is 3.6 days
\textbf{Anatomical narrowings}: cricopharyngeus muscle, aortic crossover of esophagus, lower esophageal sphincter, pylorus, duodenal sweep, ileocecal junction
- Objects \textgreater{} 25 mm diameter unlikely to pass pylorus
- Objects \textgreater{} 6 cm length unlikely to pass duodenal sweep
\textbf{Button batteries}: caustic injury from high pH → injury at anode (narrow portion) of batter → stricture formation (can happen within 2 hours) → aortoenteric fistula is feared complication
\textbf{Magnets}: Multiple in different bowel segments can adhere and erode through bowel wall causing perforation

\hypertarget{presentation-57}{%
\subsubsection{Presentation}\label{presentation-57}}

Depends on age, location, and nature of FB
- \textbf{Esophagus}: refusal to eat, dysphagia, drooling, respiratory symptoms
- \textbf{Stomach}: asymptomatic unless causing gastric outlet obstruction
- \textbf{Intestine}: asymptomatic unless retained/obstructing, dependent on location

\hypertarget{workup-13}{%
\subsubsection{Workup}\label{workup-13}}

Start with XR AP single view neck, chest, abdomen
XR lateral for coins, battery, magnet OR if esophageal or unknown location

\hypertarget{treatment-47}{%
\subsubsection{Treatment}\label{treatment-47}}

Depends on symptoms, location, and nature of FB. General principles:

\hypertarget{button-batteries}{%
\paragraph{Button batteries}\label{button-batteries}}

EMERGENT GI/ENT/surgery consult, urgent endoscopic removal if esophageal or gastric, otherwise admit and close observation with serial XRs. Sucralfate if esophageal.

\hypertarget{coinsblunt-objects}{%
\paragraph{Coins/Blunt objects}\label{coinsblunt-objects}}

GI/ENT/surgery consult if symptomatic, urgent endoscopic removal if esophageal, otherwise observation (consider admit vs.~outpatient f/u)

\hypertarget{sharp-objects}{%
\paragraph{Sharp objects}\label{sharp-objects}}

GI/ENT/surgery consult if symptomatic, urgent endoscopic removal if esophageal or gastric, otherwise admit and close observation with serial XRs

\hypertarget{magnets}{%
\paragraph{Magnets}\label{magnets}}

1 magnet? → treat like blunt object; 2 magnets? → remove if gastric or proximal, or symptomatic, otherwise admit and close observation with serial XRs

\hypertarget{food-impaction}{%
\paragraph{Food impaction}\label{food-impaction}}

GI/ENT/Surgery consult, urgent endoscopic removal with biopsies to evaluate for EOE

\hypertarget{suspected-child-abuse}{%
\subsection{Suspected Child Abuse}\label{suspected-child-abuse}}

Source: No BCH EBG; CHOP clinical pathway

\hypertarget{presentation-58}{%
\subsubsection{Presentation}\label{presentation-58}}

\hypertarget{skeletal-injuries}{%
\paragraph{Skeletal injuries}\label{skeletal-injuries}}

\begin{itemize}
\tightlist
\item
  \textbf{Long bones}: epiphyseal/metaphyseal fracture seen as ``bucket handle'' or ``corner fracture'' at the end of long bones, spiral fractures
\item
  \textbf{Ribs}: posterior nondisplaced rib fractures due to squeezing of the rib cage (may not be visible on plain film until callus formation)
\item
  \textbf{Skull}: fractures \textgreater3mm wide, complex fractures, bilateral fractures, non-parietal fractures. These suggest forces greater than those sustained from minor household trauma
\end{itemize}

\hypertarget{bruises}{%
\paragraph{Bruises}\label{bruises}}

Unusual/protected areas (chest, abdomen, back, buttocks)
Patterned
Multiple bruises or bruises in different stages of healing, do not fit the history and developmental stage
\textbf{TEN-4 Bruising Clinical Decision Rule}:
- Bruising present in TEN region (torso, ears, neck) \textless{} 4yrs of age \emph{OR}
- Bruising present in any region \textless{} 4mo of age \emph{AND}
- No confirmed accident in public setting that accounts for bruising

\hypertarget{burns-1}{%
\paragraph{Burns}\label{burns-1}}

\begin{itemize}
\tightlist
\item
  Multiple burn sites
\item
  Well-demarcated edges
\item
  Stocking/glove distributions
\item
  Absence of splash marks
\item
  Symmetrically burned buttocks or lower legs
\end{itemize}

\hypertarget{head-trauma}{%
\paragraph{Head trauma}\label{head-trauma}}

\begin{itemize}
\tightlist
\item
  Subdural hematomas
\item
  Retinal hemorrhages
\item
  Skull fractures (see above)
\end{itemize}

\hypertarget{workup-14}{%
\subsubsection{Workup}\label{workup-14}}

\begin{itemize}
\tightlist
\item
  Consult CPT, Social Work
\item
  Skeletal survey (\textless2yo)
\item
  Noncontrast head CT: good for intracranial hemorrhage and skull fractures
\item
  Brain MRI: If asymptomatic
\item
  Abd or pelvic CT: consider if symptomatic or suggested by physical exam/lab studies
\item
  Consider c-spine MRI if concerned for abusive head trauma
\item
  Dilated indirect ophthalmoscopy exam for retinal hemorrhages
\item
  CBC, CMP, Amylase, Lipase, UA (all patients \textless7yrs, \textgreater7yrs if clinically indicated)
\item
  Bone health labs (if fractures): Ca, Mg, Phos, Alk Phos, intact PTH, 25 Hydroxyvitamin D
\item
  Bleeding disorders labs (if bruising/bleeds): PT/PTT,consider vWF, Factor VIII, IX
\end{itemize}

\hypertarget{sexual-assault}{%
\subsection{Sexual Assault}\label{sexual-assault}}

Sources: BCH EBG, CHOP Clinical Pathway, UpToDate

\hypertarget{workup-12yo}{%
\subsubsection{Workup (\textless12yo)}\label{workup-12yo}}

Medically cleared?
- Consider trauma or GYN eval
- Work up altered medical status
Consult SW

\hypertarget{occurred-72-hours}{%
\paragraph{Occurred \textless72 hours:}\label{occurred-72-hours}}

\textbf{Do not interview the child → defer interview and GU exam}
- Document parent/guardian statements only (preferably with SW present if available)
- Child's spontaneous statements documented as quotes in evidence kit
Urgently consult CPT, Children's Advocacy Center
Forensic evidence collection by ED provider using pediatric kit if patient consents
Baseline testing (discuss with CPT): Urine NAAT for Gonorrhea/Chlamydia/Trichomonas, RPR, Hep B Core Ab, Hep B Surface Ab/Ag, Hep C Ab, HIV-1/2 Combo Ag/Ab, urine HCG for pubertal females
File 51A (with Social Work)

\hypertarget{occurred-72-hours-1}{%
\paragraph{Occurred \textgreater72 hours:}\label{occurred-72-hours-1}}

Complete history and physical exam, if patient/family consent
Baseline testing (see above)
File 51A (with Social Work)

\hypertarget{treatment-12yo}{%
\subsubsection{Treatment (\textless12yo)}\label{treatment-12yo}}

Urine NAATs require confirmation prior to treatment with antibiotics
Pre-pubertal children should NOT receive STI prophylaxis
Update Hep B, tetanus vaccines as needed
\textbf{Emergency contraception} (if urine HCG negative):
- 0-72 hours: Levonorgestrel (Plan B) 1.5 mg PO once
- 72-120 hours: Ulipristal (Ella) 30 mg PO once (if no hormonal birth control for 5 days after)
Determine need for HIV PEP (see Clinical Pathway)

\hypertarget{workup-12yo-1}{%
\subsubsection{Workup (\textgreater12yo)}\label{workup-12yo-1}}

Medically cleared?
- Consider trauma or GYN eval
- Work up altered medical status
Consult SW

\hypertarget{occurred-120-hours-5-days}{%
\paragraph{Occurred \textless120 hours (5 days):}\label{occurred-120-hours-5-days}}

\begin{itemize}
\tightlist
\item
  Ask for patient consent to receive SANE (Sexual Assault Nurse Examiner) services: 617-647-0710 (BARCC also paged simultaneously)
\item
  Forensic evidence collection by SANE or ED provider if patient consents
\item
  Urine HCG for all females
\item
  STI testing (if patient consents): Urine NAAT for Gonorrhea/Chlamydia/Trichomonas, RPR, - Hep B Core Ab, Hep B Surface Ab/Ag, Hep C Ab, HIV-1/2 Combo Ag/Ab
\end{itemize}

\hypertarget{occurred-120-hours-5-days-ago}{%
\paragraph{Occurred \textgreater120 hours (5 days) ago:}\label{occurred-120-hours-5-days-ago}}

\begin{itemize}
\tightlist
\item
  Call BARCC (Boston Area Rape Crisis Center): 617-492-7273
\end{itemize}

\hypertarget{treatment-12yo-1}{%
\subsubsection{Treatment (\textgreater12yo)}\label{treatment-12yo-1}}

\textbf{STI prophylaxis}:
- Gonorrhea + Chlamydia (ceftriaxone 250mg IM x1, azithromycin 1g PO x1)
- Trichomonas (metronidazole 2g PO x1)
\textbf{Emergency contraception} (if urine HCG negative):
- 0-72 hours: Levonorgestrel (Plan B) 1.5 mg PO once
- 72-120 hours: Ulipristal (Ella) 30 mg PO once (no hormonal birth control for 5 days after)
Determine need for HIV PEP (see Clinical Pathway)

\hypertarget{discharge-planning-12yo}{%
\subsubsection{Discharge planning (\textgreater12yo)}\label{discharge-planning-12yo}}

Contact PCP if patient consents, discuss need for CPT and Child Advocacy Center f/u, ensure appropriate HIV PEP meds/scripts and f/u plan if necessary, use BCH custom d/c instructions. SW will clear patient for d/c and provide resources.

\hypertarget{syncope}{%
\subsection{Syncope}\label{syncope}}

Sources: BCH EBG; Salerno JC. Causes of syncope in children and adolescents. In Uptodate: Wiley JF (Ed), UpToDate, Waltham, MA. (Accessed on February 22, 2020.)

\hypertarget{differential-5}{%
\subsubsection{Differential}\label{differential-5}}

\hypertarget{common-conditions}{%
\paragraph{Common conditions}\label{common-conditions}}

\begin{itemize}
\tightlist
\item
  Vasovagal
\item
  Breath holding spells (common in 6mo-24mo age range)
\item
  Orthostatic hypotension
\item
  Toxic exposure
\end{itemize}

\hypertarget{life-threatening}{%
\paragraph{Life-threatening}\label{life-threatening}}

\begin{itemize}
\tightlist
\item
  Arrhythmias: ventricular arrhythmias, long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), congenital short QT syndrome, pre-excitation syndromes such as WPW (which can lead to SVT with a rapid ventricular response)
\item
  Structural: hypertrophic cardiomyopathy, severe aortic stenosis, coronary artery anomalies, arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy
\item
  Acute myocarditis
\item
  Pulmonary hypertension
\item
  Vasovagal (neurocardiogenic)
\item
  Heat illness
\item
  Anaphylaxis
\end{itemize}

\hypertarget{other-1}{%
\paragraph{Other}\label{other-1}}

Hypoglycemia, SVT, bradycardia, POTS\\
Rule out mimics: seizure, stroke, TBI

\hypertarget{workup-15}{%
\subsubsection{Workup}\label{workup-15}}

\hypertarget{history-and-physical-exam}{%
\paragraph{History and Physical Exam}\label{history-and-physical-exam}}

\begin{itemize}
\tightlist
\item
  Precipitating factors: exercise, acute arousal, postural change, pain or emotion
\item
  Description of event
\item
  Past medical history
\item
  Family history of early cardiac death (\textless40 years), arrhythmias, cardiomyopathy, sudden drownings or unexplained car accidents, SIDS, LQTS, congenital deafness, HCM
\item
  Exam: including detailed cardiorespiratory and age-appropriate neurologic exam
\end{itemize}

\hypertarget{labs-and-imaging}{%
\paragraph{Labs and Imaging}\label{labs-and-imaging}}

\begin{itemize}
\tightlist
\item
  12-lead EKG
\item
  Urine hCG for post-pubertal females
\item
  Additional testing not indicated unless concerning H+P (i.e.~CBC in menstruating female with pallor, electrolytes if signs of dehydration, etc.)
\item
  Formal orthostatics NOT routinely recommended
\end{itemize}

Suspect neurologic etiology? → abnl neuro exam, severe headache → neurology consult/referral
Suspect cardiac etiology? → syncope w/ chest pain, exertion, palpitations; incr freq of events, non-innocent murmur, frequent PAC/PVC on monitor, abnl EKG → cardiology consult,
If FH of concerning cardiac history, otherwise reassuring exam and labs (none of the above), consider outpatient referral within 2 weeks

\hypertarget{trauma}{%
\subsection{Trauma}\label{trauma}}

\hypertarget{atls}{%
\subsubsection{ATLS}\label{atls}}

\hypertarget{primary-survey}{%
\paragraph{Primary Survey}\label{primary-survey}}

Assessment of \textbf{ABC}: \textbf{A}irway (with c-spine protection), \textbf{B}reathing, \textbf{C}irculation
\textbf{D}isability/neurologic assessment: AVPU (alert, verbal stimuli response, painful stimuli response, unresponsive; pupil size, symmetry, reactivity)
\textbf{E}xposure and environmental control: undress patient completely, take precautions to prevent hypothermia

\hypertarget{secondary-survey}{%
\paragraph{Secondary Survey}\label{secondary-survey}}

Head to toe assessment, including history and full physical exam
\textbf{AMPLE History}: Allergies, Medications, PMHx/Pregnancy, Last meal, Events/Environment leading to the injury

\hypertarget{head}{%
\subparagraph{Head}\label{head}}

Any scalp/skull injury, periorbital or post-auricular bruising, hemotympanum, nasal CSF drainage, loose teeth, concern for midface fracture (pass OGT rather than NGT)

\hypertarget{eye}{%
\subparagraph{Eye}\label{eye}}

\begin{itemize}
\tightlist
\item
  Pupillary size, hemorrhage, penetrating injury, entrapment
\item
  Corneal reflex
\item
  Contact lenses should be removed
\end{itemize}

\hypertarget{neck}{%
\subparagraph{Neck}\label{neck}}

\begin{itemize}
\tightlist
\item
  C-spine tenderness or deformity
\item
  Trachea midline
\item
  Hematoma
\item
  Bruit
\end{itemize}

\hypertarget{chest}{%
\subparagraph{Chest}\label{chest}}

\begin{itemize}
\tightlist
\item
  Clavicle deformity or tenderness
\item
  Breath sounds, heart sounds, crepitus
\item
  Chest wall symmetry, paradoxical movement, rib deformity, fracture
\end{itemize}

\hypertarget{abdomen}{%
\subparagraph{Abdomen}\label{abdomen}}

\begin{itemize}
\tightlist
\item
  Serial exams to evaluate tenderness, distension, ecchymosis
\item
  Shoulder pain suggests subdiaphragmatic process
\item
  Orogastric aspirates with blood or bile
\item
  Splenic laceration suggested by left upper quadrant rib tenderness, flank pain, flank ecchymoses, ``seatbelt sign'' (suggestive of GI injury)
\end{itemize}

\hypertarget{pelvis}{%
\subparagraph{Pelvis}\label{pelvis}}

Tenderness, symmetry, deformity, stability

\hypertarget{gu-1}{%
\subparagraph{GU}\label{gu-1}}

\begin{itemize}
\tightlist
\item
  Laceration, ecchymoses, hematoma, bleeding
\item
  Rectal tone, blood, displaced prostate
\item
  Blood at urinary meatus → don't catheterize, suggests urethral injury
\item
  Evaluate for pelvic fracture or instability
\end{itemize}

\hypertarget{back}{%
\subparagraph{Back}\label{back}}

Evaluate for step offs along spinal column, tenderness

\hypertarget{extremities}{%
\subparagraph{Extremities}\label{extremities}}

Neurovascular: pulse, perfusion, pallor, paresthesias, paralysis, pain

\hypertarget{neurologic}{%
\subparagraph{Neurologic}\label{neurologic}}

\begin{itemize}
\tightlist
\item
  Motor/sensory exam
\item
  Re-evaluation of level of consciousness
\item
  Pupillary response to light
\end{itemize}

\hypertarget{skin}{%
\subparagraph{Skin}\label{skin}}

Lacerations, abrasions, contusions

\hypertarget{mild-traumatic-brain-injury-contusion-and-concussion}{%
\subsection{Mild Traumatic Brain Injury (Contusion and Concussion)}\label{mild-traumatic-brain-injury-contusion-and-concussion}}

Sources: BCH Minor Head Trauma EBG

\hypertarget{definition-30}{%
\subsubsection{Definition}\label{definition-30}}

\begin{itemize}
\tightlist
\item
  Traumatic brain injury induced by biomechanical forces; may be caused by direct blow to head/face/neck or blow causing impulsive force transmitted to the head
\item
  Neuropathologic changes may result, but these reflect a functional disturbance (no changes on neuroimaging)
  Patient must present with history or physical exam signs of minor head injury \emph{AND}
\item
  In children \textless{} 2 years: be alert or awaken to voice or light touch
\item
  In children ≥ 2 years: have normal mental status, normal neurologic exam, and no evidence of skull fracture
\end{itemize}

\hypertarget{pathogenesis-7}{%
\subsubsection{Pathogenesis}\label{pathogenesis-7}}

\begin{itemize}
\tightlist
\item
  Linear forces: acceleration/deceleration injuries. Less likely to cause LOC, more commonly cause skull fractures, intracranial hematoma, cerebral contusion
\item
  Rotational forces: commonly cause LOC, associated with diffuse axonal injury and concussion
\end{itemize}

\hypertarget{presentation-59}{%
\subsubsection{Presentation}\label{presentation-59}}

Likely indicators of concussion (any/all of below)
- Disorientation or confusion immediately after the event
- Impaired balance within 1 day after injury
- Slower reaction time within 2 days after injury
- Impaired verbal learning and memory within 2 days after injury
\textbf{Signs/symptoms}: broad range, categorized within somatic, vestibular, oculomotor, cognitive, emotional/sleep
- Headache most common \textgreater{} dizziness \textgreater{} difficulty concentrating \textgreater{} confusion
Loss of consciousness NOT necessary for diagnosis of concussion

\hypertarget{workup-16}{%
\subsubsection{Workup}\label{workup-16}}

\hypertarget{history-5}{%
\paragraph{History}\label{history-5}}

Mechanism of injury, loss of consciousness, whether infant cried immediately, seizure activity, level of alertness after injury, headache, vision changes, and vomiting.
- Consider using a \textbf{post-concussion symptom checklist} at time of evaluation - both for facilitating history and tracking recovery (different checklists available based on age of patient)

\hypertarget{physical}{%
\paragraph{Physical}\label{physical}}

Full neurological exam, scalp abnormalities (hematoma, tenderness or depression), signs of basilar skull fracture (e.g.~periorbital ecchymosis, Battle's sign, hemotympanum, CSF otorrhea or rhinorrhea), bulging fontanelle in infants, c-spine examination

\hypertarget{pecarn-algorithm}{%
\paragraph{PECARN algorithm}\label{pecarn-algorithm}}

To determine need for imaging (Head CT)

\textbf{For children less than 2 years}:
Any altered mental status or palpable skull fracture
* Other considerations:
- Non-frontal scalp hematoma
- LOC ≥5 seconds
- ** Severe mechanism of injury
- Acting abnormally per parent

\textbf{For children 2 years and older}:
Any altered mental status or signs of a basilar skull fracture (retro-auricular or periorbital bruising, CSF otorrhea or rhinorrhea, hemotympanum)
* Other considerations:
- Any loss of consciousness
- History of vomiting
- ** Severe injury mechanism
- Severe headache

\begin{itemize}
\tightlist
\item
  If 1-2 of above is present, monitor 4-6 hours and obtain head CT if symptoms worsen or don't improve; If ≥3 above are present, head CT is recommended; If none is present, head CT not recommended
  ** Severe mechanism of injury: Motor vehicle crash with patient ejection, death of another passenger or rollover, pedestrian or bicyclist without helmet struck by motorized vehicle, falls (\textgreater3 feet children \textless{} 2 years or \textgreater{} 5 feet for children ≥ 2 years) or head struck by high impact object.
\end{itemize}

\hypertarget{treatment-48}{%
\subsubsection{Treatment}\label{treatment-48}}

\begin{itemize}
\tightlist
\item
  Intracranial injury or depressed, basilar, diastatic skull fx → NSGY consult \& admit
\item
  Simple skull fx (i.e \textless3 mm, non-depressed, single bone) → consider admit if young (\textless6 mo), consider SW evaluation (esp if \textless{} 2 yrs of age)
  \textbf{Discharge Criteria}: Normal mental status, non-focal neuro exam, able to PO, no social concerns, not \textless1 mo with isolated skull fracture
\end{itemize}

Dx of concussion with negative imaging:
- DO NOT return to play same day, risk of second-impact syndrome (2nd injury before full recovery → possible cerebral vascular congestion → diffuse cerebral edema)
- Physical rest: avoid strict ``bed rest,'' but limit activity to level that does not provoke/increase sx; sub-symptom threshold, aerobic exercise shown to decrease duration of sx
- Cognitive rest: academic adjustments as needed to reduce symptom exacerbation
- \textbf{Complete cognitive rest and avoidance of screen time NOT recommended}
- See Uptodate (``sample school note to guide academic accommodations for children and adolescents with concussion'') for template academic note
- PT for patients suffering from vestibular or oculomotor dysfunction
- No sports until asymptomatic and cleared by a physician, emphasize individualized course, warn of possible persistent symptoms beyond 1 month (\emph{See Graduated Return-to-Sport Program})
- Refer if: Symptoms \textgreater{} 4 weeks, lack of progression, confounding by coexisting conditions, multiple previous concussions

\textbf{Graduated Return-to-Sport Program}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.01\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Aim\strut
\end{minipage} & \begin{minipage}[b]{0.42\columnwidth}\raggedright
Activity\strut
\end{minipage} & \begin{minipage}[b]{0.32\columnwidth}\raggedright
Goal\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.01\columnwidth}\raggedright
1\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Symptom-limited activity\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Daily activities that do not provoke symptoms\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Gradual reintroduction of work and/or school activities\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.01\columnwidth}\raggedright
2\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Light aerobic exercise\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Walking or stationary cycling at slow-to-medium pace; no resistance training\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Increase heart rate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.01\columnwidth}\raggedright
3\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Sport-specific exercise\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Running or skating drills; no activities with risk of head impact\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Add movement\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.01\columnwidth}\raggedright
4\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Noncontact training drills\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Harder drills (eg, passing drills and team drills); may begin progressive resistance training\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Exercise, coordination, and increased thinking during sport\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.01\columnwidth}\raggedright
5\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Full-contact practice\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
After medical clearance, participate in full, normal training activities\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Restore confidence and allow coaching staff to assess functional skills\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.01\columnwidth}\raggedright
6\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Return to sport\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Normal game play\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Full clearance/participation\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

Recommend \textbf{48 hr of relative physical and cognitive rest before beginning the program}. No more than 1 step should be completed per day. If any symptoms worsen during exercise, the athlete should return to the previous step. Consider prolonging and/or altering the return-to-sport program for any pediatric and/or adolescent patient with symptoms over 4 wk.

\hypertarget{cervical-spine-injury}{%
\subsection{Cervical Spine Injury}\label{cervical-spine-injury}}

\hypertarget{workup-treatment}{%
\subsubsection{Workup \& Treatment}\label{workup-treatment}}

Place patient in C-collar prior to history and physical
Assess for (based on PECARN data; NEXUS and Canadian C-Spine Rule unclear sensitivity for \textless10yrs):
- Neck pain
- Midline posterior neck tenderness
- Decreased neck range of motion
- Torticollis
- AMS (GCS \textless{} 14)
- Focal neurologic finding
- Substantial co-existing injury (distracting injury, especially torso injuries)
- Predisposing conditions (Down syndrome, cervical arthritis, Ehlers-Danlos, etc)
- High risk mechanisms (MVC where patient partially/completely ejected from vehicle, passenger death, diving, hanging, clotheslining force, axial load force

If \textbf{any} of the above are present, recommend C-spine imaging (XR → cross-table lateral and AP, consider open-mouth odontoid if possible)
- Consider CT if concern for clinically significant injury, abnl XR, high risk injury mechanism
If \textbf{none} of the above are present, defer imaging and remove collar. If pain with active ROM, return patient to collar, obtain cervical spine films
- If imaging abnormal, consult orthopedics/neurosurgery
- If imaging normal, reassess patient, and if persistent midline neck tenderness,, assume cervical sprain and place in long-term C-collar (``Miami J'') → refer to spine clinic → usually able to discharge

\hypertarget{laceration-repair}{%
\subsection{Laceration Repair}\label{laceration-repair}}

\hypertarget{equipment}{%
\subsubsection{Equipment}\label{equipment}}

\begin{itemize}
\tightlist
\item
  \textbf{Basics}: light, mask, sterile gloves \& gown, betadine (or other cleansing solution)
\item
  \textbf{Irrigation}: sterile bowl, sterile water, 20-50 cc syringes with splash guard (all except water come in irrigation kit)
\item
  \textbf{Local anesthesia} or digital block
\item
  \textbf{Suture tray} (sterilized and packaged together): forceps, scissors, needle holder, hemostats, sterile gauze
\item
  \textbf{Suture material}: Nonabsorbable sutures (monofilament nylon, polypropylene) vs.~Absorbable sutures (Vicryl, fast absorbing gut -- use for deep wounds and in small children when suture removal would be just as traumatic as placement

  \begin{itemize}
  \tightlist
  \item
    Sole of foot or over large joints (knee): 4-0 or 3-0
  \item
    Scalp, trunk, extremity: 4-0; Face: 6-0 or 5-0
  \end{itemize}
\end{itemize}

\textbf{Alternatives to sutures}: Dermabond (tissue adhesive) +/- Steri-Strips: use for linear wounds with minimal tension. No removal needed.\\
Staples: Best for scalp wounds. Requires remover.\\
\includegraphics{images/ED_suture_selection.png}
\includegraphics{images/ED_suture_cartoon.png}

\hypertarget{general-technique}{%
\subsubsection{General Technique}\label{general-technique}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Set-up your equipment
\item
  Local anesthesia
\end{enumerate}

\begin{itemize}
\tightlist
\item
  LET gel (lidocaine, epinephrine, tetracaine) -- apply for 15-20 minutes (surrounding skin should be blanched)
\item
  1\% lidocaine (10mg/mL): onset 2-5 minutes, lasts 15-20 minutes. Toxic dose 5mg/kg (0.5cc/kg)
\item
  1\% lidocaine with epinephrine (1:200,000): onset 2-5 minutes, duration \textasciitilde60 minutes. Generally avoid use in digits, penis, pinna, tip of nose
\item
  Use buffered lidocaine if available (buffered with sodium bicarbonate)
\end{itemize}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\setcounter{enumi}{2}
\tightlist
\item
  Conscious sedation if needed
\item
  Wound preparation: Expose, explore (for foreign bodies), irrigate, clean periphery
\item
  Suture/Close:
\end{enumerate}

\begin{itemize}
\tightlist
\item
  \textbf{Simple interrupted} - most common stitch, closes superficial layer
\item
  \textbf{Deep subcutaneous} - reduces tension of deep wounds
\item
  \textbf{Buried horizontal dermal} - closes deep layer in shallow lacs
\item
  \textbf{Horizontal/vertical mattress}- reinforce SC tissue, relieves wound-edge tension
\item
  \textbf{Corner stitch} - repair flap-type, corner lacerations
\end{itemize}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\setcounter{enumi}{5}
\tightlist
\item
  Clean and dry: Apply topical antibiotic ointment and cover with dry sterile gauze
\end{enumerate}

\begin{itemize}
\tightlist
\item
  \textbf{Tetanus prophylaxis}: if have not received tetanus prophylaxis in preceding 10 years (if clean and minor wound) or 5 years (all other wounds) \emph{or} if they have not finished primary series.
\item
  \textbf{Antibiotic prophylaxis}: if wound is a bite wound, there is exposed cartilage/joint, or a contaminated wound (esp.~on plantar surface)
\end{itemize}

\begin{figure}
\centering
\includegraphics{images/ED_suture_removal_timing.png}
\caption{ED\_suture\_removal\_timing}
\end{figure}

\hypertarget{endocrinology}{%
\section{Endocrinology}\label{endocrinology}}

\hypertarget{adrenal-insufficiency}{%
\subsection{Adrenal Insufficiency}\label{adrenal-insufficiency}}

\hypertarget{powerplanorder-sets}{%
\subsubsection{PowerPlan/Order sets}\label{powerplanorder-sets}}

MICU adrenal stim testing, Endo AMB adrenal disorders

\hypertarget{definition-31}{%
\subsubsection{Definition}\label{definition-31}}

Impaired secretion of the adrenal glucocorticoid +/- mineralocorticoid hormones
- \textbf{Primary}: Failure to produce or secrete adrenal cortical hormones
\textgreater\textgreater{} - Most common causes: impaired adrenal steroidogenesis (CAH), adrenal destruction (autoimmune or infectious), adrenal dysgenesis
\textgreater\textgreater{} - Aldosterone deficiency leads to hypotension, hyponatremia, hyperkalemia
- \textbf{Central}: Impaired pituitary secretion of ACTH or hypothalamic secretion of CRH
\textgreater\textgreater{} - Most common cause: Exogenous corticosteroid administration
\textgreater\textgreater{} - Other: Hypothalamic defects (tumor, radiotherapy), hypopituitarism (surgery, infiltration)

\hypertarget{presentation-60}{%
\subsubsection{Presentation}\label{presentation-60}}

N/V, abdominal pain, orthostatic hypotension, lethargy, hypoglycemia
\textbf{ONLY IN PRIMARY}:
- Hyperpigmentation (↑ ACTH→ ↑ POMC→↑ melanocortin)
- Hyperkalemia (↓ Aldosterone)

\hypertarget{diagnostic-studies-4}{%
\subsubsection{Diagnostic Studies}\label{diagnostic-studies-4}}

\begin{itemize}
\tightlist
\item
  Suggestive: ↓ Na, ↑ K, ↓ Glu, metabolic acidosis
\item
  Confirmatory: AM cortisol \& ACTH levels
  \textgreater\textgreater{} - \textbf{Primary}: ↓ cortisol, ↑ ACTH
  \textgreater\textgreater{} - \textbf{Central}: ↓ cortisol, normal or ↓ ACTH
\item
  If not definitive: ACTH stimulation test
\end{itemize}

\hypertarget{acute-treatment}{%
\subsubsection{Acute Treatment}\label{acute-treatment}}

\textbf{Adrenal Crisis}:
- 20mL/kg NS bolus followed by 1.5-2x D5NS maintenance IVF
- Hydrocortisone 50-100 mg/m2
\textgreater\textgreater{} - \emph{Hydrocortisone also has some mineralocorticoid effect, so fludrocortisone is not required while a patient is on stress dose hydrocortisone}
- Monitor electrolytes \& fluid balance

\textbf{Stress Dose Steroids}:
- Minor (mild URI, T \textless38): None required
- Major (T \textgreater38, major surgery, vomiting): hydrocortisone 50 mg/m2 divided q6h

\hypertarget{maintenance-therapy}{%
\subsubsection{Maintenance Therapy}\label{maintenance-therapy}}

\begin{itemize}
\tightlist
\item
  Hydrocortisone 8-20 mg/m2/day divided into 3 doses (higher doses required for infants with CAH)
\item
  \textbf{Primary}: Fludrocortisone 0.1-0.2 mg daily
\item
  +/- salt supplementation in infants
\end{itemize}

\hypertarget{diabetic-ketoacidosis}{%
\subsection{Diabetic Ketoacidosis}\label{diabetic-ketoacidosis}}

\hypertarget{powerplanorder-sets-1}{%
\subsubsection{PowerPlan/Order sets}\label{powerplanorder-sets-1}}

DKA ICP order set, MICU DKA order set, NODM CPG order set

\hypertarget{definition-32}{%
\subsubsection{Definition}\label{definition-32}}

\begin{itemize}
\tightlist
\item
  Hyperglycemia: Blood glucose\textgreater{} 200 mg/dL
\item
  Metabolic Acidosis: pH\textless7.3 \textbf{\emph{OR}} HCO3\textless15 mmol/L
\item
  Ketosis: + Ketones in blood or urine
\end{itemize}

\hypertarget{pathophysiology-24}{%
\subsubsection{Pathophysiology}\label{pathophysiology-24}}

↓ Insulin→ Hyperglycemia → Osmotic diuresis → Dehydration
↓ Insulin→ ↑ lipolysis→ ↑ FFA → Ketoacidosis
↓ Insulin → Impaired K entry into cells → Total K deficit \textbf{\emph{even if plasma K is normal}}

\hypertarget{presentation-61}{%
\subsubsection{Presentation}\label{presentation-61}}

Hyperglycemia, vomiting, abd pain, dehydration, AMS
Hx: Wt loss, polyuria, polydipsia

\hypertarget{diagnostic-studies-5}{%
\subsubsection{Diagnostic Studies}\label{diagnostic-studies-5}}

\begin{itemize}
\tightlist
\item
  D-sticks q1h
\item
  Chem 10, beta-hydroxybutyrate, VBG q2h
\item
  Urine ketones
\item
  HbA1c
\item
  EKG
\item
  Consider pancreatic autoantibodies (refer to CPG for recommendations)
\end{itemize}

\hypertarget{treatment-49}{%
\subsubsection{Treatment}\label{treatment-49}}

\textbf{\emph{Please reference DKA card for detailed protocol}}
\textbf{1) FLUIDS}:
\textbf{NS Bolus}: Initially give \textbf{10-20 mL/kg NS bolus}; may repeat if persistent hypotension
- \textbf{Fluid Selection}: Fluids at \textbf{1.5-2x maintenance if corrected serum Na\textless135 mEq/L}; slow rate if signs of cerebral edema
- Use \textbf{2-Bag Method Calculator} (in reference text of DKA PowerPlans): Bag 1 NS plus electrolytes; Bag 2: D12.5 0.45\% NS plus electrolytes, hung together w/ insulin on a trifuse. Rates of each fluid are titrated to the \textbf{goal dextrose concentration}:

\begin{longtable}[]{@{}ll@{}}
\toprule
\textbf{Plasma K (mEq/L)} & \textbf{IV fluid K (mEq/L)}\tabularnewline
\midrule
\endhead
\textless= 4.5 & 40\tabularnewline
\textgreater4.5 & 0\tabularnewline
\bottomrule
\end{longtable}

\begin{itemize}
\tightlist
\item
  \textbf{Potassium Content}: Goal K = 3.5-4.5. Use K acetate and K phosphate, NOT KCl because of risk of hyperchloremia and non-gap metabolic acidosis. Max K that can be given is 80 mEq/L
\item
  DO NOT give HCO3 as increases the risk of cerebral edema
\end{itemize}

\textbf{2) INSULIN}:
- *\textbf{DO NOT give bolus of insulin!}
- After 1 hr of NS IVF, start infusion of regular insulin 0.05-0.1 units/kg/hr
- Continue insulin infusion until anion gap is closed and patient is ready to eat
- \textbf{Transitioning from IV to subQ}: Make sure patient has \textbf{meal in front of them before turning off drip}, give Humalog \& long-acting insulin 15 mins before meal, turn off insulin infusion and IV fluids 30 minutes after subQ injections

\textbf{Important Formulas}
- Corrected Na: serum Na + (1.6*{[}plasma glucose -- 100{]}/100)
- Anion Gap: serum Na -- (Cl + HCO3) **Note: use serum Na, NOT corrected Na
- Effective Osmolarity: 2{[}measured Na + glucose/18{]}

\hypertarget{subcutaneous-insulin-regimen}{%
\subsubsection{Subcutaneous Insulin Regimen}\label{subcutaneous-insulin-regimen}}

\textbf{How to order subcutaneous insulin at BCH}
1. Either type insulin into search tab (or get to this via the NODM admit plan)
2. If not going through NODM, click ``insulin .SC injection regimen orderset''\\
\textgreater\textgreater{} a. You will first be required to select frequency of POCT checks, parameters for RN to notify MD about glucose levels. Now for the insulin\ldots{}
3. You will most likely order scheduled glargine (Lantus). You will then most likely order lispro (Humalog) for the correction factors and carbohydrate ratios. \textbf{These are nested ordersets and can be confusing}
\textgreater\textgreater{} a. Scroll down to correction factor and select box ``insulin lispro 100 unit/mL correction factor Orderset''. Then scroll down to insulin: carbohydrate ratio and select box ``insulin lispro 100 unit/mL carbohydrate ratio orderset''
\textgreater\textgreater{} b. \textbf{make sure to click both before clicking ``OK'' in bottom right}
4. You will then be directed to the nested orderset where you can type in the times of day and doses that you want to give the correction factor and carb ratio
\textgreater\textgreater{} a. For correction factor you will have to decide if same CF for all times of day versus different times (ex, different for daytime meals vs at night). Click OK and then you will be prompted to carb ratio orderset
\textgreater\textgreater{} b. Again you will have to decide if same CR for all times of day versus different times

\hypertarget{hypoglycemia}{%
\subsection{Hypoglycemia}\label{hypoglycemia}}

\hypertarget{powerplanorder-sets-2}{%
\subsubsection{PowerPlan/Order sets}\label{powerplanorder-sets-2}}

ED hypoglycemia critical labs plan, ICP hypoglycemia fasting plan, NICU hypoglycemia plan, Metabolism hypoglycemia admit plan

\hypertarget{definition-33}{%
\subsubsection{Definition}\label{definition-33}}

Plasma glucose ≤ 60 mg/dL

\hypertarget{etiology-11}{%
\subsubsection{Etiology}\label{etiology-11}}

\textbf{Decreased Production of Glucose}
- Decreased release of glucose from liver: glycogen storage diseases, liver failure
- Impaired gluconeogenesis: fructose 1,6 diphosphatase deficiency, pyruvate carboxylase deficiency, maple syrup urine disease
- Galactosemia, hereditary fructose intolerance
- Disorders of fatty acid oxidation (↓FAO → ↓ATP and glycerol production → ↓gluconeogenesis)

\textbf{Increased Utilization/Impaired Conservation of Glucose}
- Disorders of fatty acid oxidation
- Ketotic hypoglycemia (accelerated starvation)
- Starvation

\textbf{Decreased Production and Increased Utilization of Glucose}
- Hyperinsulinemia
\textgreater\textgreater{} - Endogenous: congenital (transient or permanent), insulinoma
\textgreater\textgreater{} - Exogenous insulin
\textgreater\textgreater{} - Sulfonylureas
\textgreater\textgreater{} - Dumping syndrome, withdrawal of continuous enteral/parenteral nutrition
- Counter-regulatory hormone deficiency: growth hormone, cortisol/ACTH
- Beta Blockers

\hypertarget{presentation-62}{%
\subsubsection{Presentation}\label{presentation-62}}

\begin{itemize}
\tightlist
\item
  Early manifestations (blood sugar 40-70): sweating, tachycardia, tremor, hunger
\item
  Later manifestations (blood sugar \textless40): lethargy, irritability, confusion, seizure, coma
\item
  Ask about any medications in home (sulfonylureas, beta blockers, insulin)
\item
  Ask about temporal relationship to feeds
\end{itemize}

\hypertarget{diagnostic-approach}{%
\subsubsection{Diagnostic Approach}\label{diagnostic-approach}}

\hypertarget{diagnostic-studies-6}{%
\subsubsection{Diagnostic Studies}\label{diagnostic-studies-6}}

Critical Labs: \textbf{Must be obtained when BG \textless50}

\begin{itemize}
\tightlist
\item
  Plasma glucose
\item
  Beta-hydroxyburyrate (BOHB)
\item
  CMP
\item
  Insulin
\item
  C-peptide
\item
  Acylcarnitine profile
\item
  UA for ketones
\item
  Free Fatty Acids
\item
  Lactate
\item
  Ammonia
\item
  Cortisol
\item
  Growth Hormone
\item
  Free \& total carnitines
\end{itemize}

\hypertarget{treatment-50}{%
\subsubsection{Treatment}\label{treatment-50}}

\begin{itemize}
\tightlist
\item
  \textbf{Conscious}: 15 g of rapid-acting carbs by mouth (4oz juice = 1 tube glucose gel = 4 glucose tablets)
\item
  \textbf{Altered Mental Status}:\\
  \textgreater\textgreater{} - 2mL/kg D10 IVF bolus---\textgreater{} D10 IVF at GIR 4-6 (infants) or GIR 2-3 (older kids)
  \textgreater\textgreater\textgreater{} - Higher dextrose infusions NOT recommended: ↑ Insulin→ Worsening Hypoglycemia
  \textgreater\textgreater{} - If no IV access: Glucagon 1mg IM
  \textgreater\textgreater\textgreater{} - \textbf{\emph{ONLY effective in insulin-mediated hypoglycemia}}
\item
  \textbf{Monitoring}: q15-20 mins until BG \textgreater70, space to q1hr once stable
\end{itemize}

\hypertarget{diabetes-insipidus}{%
\subsection{Diabetes Insipidus}\label{diabetes-insipidus}}

\hypertarget{powerplanorder-sets-3}{%
\subsubsection{PowerPlan/Order sets}\label{powerplanorder-sets-3}}

MICU DI orderset, Endo AMB DI Plan

\hypertarget{definition-34}{%
\subsubsection{Definition}\label{definition-34}}

Failure to produce or respond to antidiuretic hormone (ADH), leading to excessive free water loss and subsequent hypernatremia

\hypertarget{etiology-12}{%
\subsubsection{Etiology}\label{etiology-12}}

\begin{itemize}
\tightlist
\item
  \textbf{Central}: Failure of posterior pituitary to secrete ADH
  \textgreater\textgreater{} - AVP mutation, hypothalamic/pituitary defect, trauma, neoplasm, infectious, infiltrative,
\item
  \textbf{Nephrogenic}: Failure of kidney to respond to ADH
  \textgreater\textgreater{} - Electrolyte disturbance (↑Ca, ↓K), congenital, medication-induced, tubulopathy
\end{itemize}

\hypertarget{presentation-63}{%
\subsubsection{Presentation}\label{presentation-63}}

Polyuria, nocturia, increased thirst, polydipsia

\hypertarget{diagnostic-studies-7}{%
\subsubsection{Diagnostic Studies}\label{diagnostic-studies-7}}

\begin{itemize}
\tightlist
\item
  Chem 10, serum osmolality
\item
  UA, urine SG, urine osm
\item
  Lab criteria
  \textgreater\textgreater{} - Serum osmolarity \textgreater{} 300 mosm/kg
  \textgreater\textgreater{} - Urine osmolarity \textless{} 300 mosm/kg
\item
  Urine output \textgreater{} 4 ml/kg/hr
\item
  Water deprivation test id diagnosis is uncertain
\item
  Vasopressin test to distinguish central vs nephrogenic DI
\end{itemize}

\hypertarget{treatment-51}{%
\subsubsection{Treatment}\label{treatment-51}}

\begin{itemize}
\tightlist
\item
  \textbf{Central Diabetes Insipidus}: vasopressin IV vs PO/intranasal/SC ddAVP
  \textgreater\textgreater{} - Low solute diet to reduce urinary excretion
  \textgreater\textgreater{} - PO/intranasal/SC ddAVP q8-12 hrs
  \textgreater\textgreater\textgreater{} - Oral preferred to intranasal due to fewer side effects
  \textgreater\textgreater\textgreater{} - SC used in infants due to more accurate dosing
  \textgreater\textgreater{} - Consider addition of thiazide diuretic ( induces volume depletion→ decreased UOP)
\item
  \textbf{Nephrogenic DI}:
  \textgreater\textgreater{} - Low solute diet
  \textgreater\textgreater{} - Thiazide diuretics +/- indomethacin to reduce urine output
\end{itemize}

\hypertarget{syndrome-of-inappropriate-adh-siadh}{%
\subsection{Syndrome of Inappropriate ADH (SIADH)}\label{syndrome-of-inappropriate-adh-siadh}}

\hypertarget{definition-35}{%
\subsubsection{Definition}\label{definition-35}}

Inappropriate antidiuretic hormone release → Hyponatremia, hypoosmolality, and inappropriately concentrated urine with no evidence of renal, hepatic, adrenal, or thyroid dysfunction

\hypertarget{etiology-13}{%
\subsubsection{Etiology}\label{etiology-13}}

\begin{itemize}
\tightlist
\item
  \textbf{CNS disease}: Meningitis/encephalitis, tumors, trauma, hydrocephalus, CVA, subdural hematoma, post-op
\item
  \textbf{Pulmonary disease}: PPV, bronchiolitis, pneumonia, asthma, CF
\item
  \textbf{Neoplastic}: Lymphoma, Ewing sarcoma, lung carcinoma
\item
  \textbf{Drugs}: carbamazepine, cyclophosphamide, desmopressin, SSRI's, etc
\item
  \textbf{Acute}: Stress, nausea, pain, general anesthesia
\end{itemize}

\hypertarget{pathophysiology-25}{%
\subsubsection{Pathophysiology}\label{pathophysiology-25}}

\begin{itemize}
\tightlist
\item
  ADH binds to V2R receptors in collecting tubules→ Insertion of aquaporin channels in apical membrane→ Increased water reabsorption→ Reduced urine output \& increased urine concentration→ Increased total body water→ Hyponatremia
\end{itemize}

\hypertarget{presentation-64}{%
\subsubsection{Presentation}\label{presentation-64}}

\begin{itemize}
\tightlist
\item
  Decreased UOP, hyponatremia, low serum osm and high urine osm
\item
  Patients typically have euvolemic hyponatremia and so do \textbf{\emph{NOT}} have peripheral edema/ascites
\item
  Headache, nausea, vomiting, muscle cramps, lethargy, confusion, seizures
\end{itemize}

\hypertarget{diagnostic-studies-8}{%
\subsubsection{Diagnostic Studies}\label{diagnostic-studies-8}}

Diagnostic Criteria:
- Plasma Osm \textless280
- Plasma Na \textless135
- Urine Osm \textgreater{} 100
- Urine Na \textgreater{} 20

\hypertarget{treatment-52}{%
\subsubsection{Treatment}\label{treatment-52}}

\textbf{Maintenance Therapy}:
- Fluid restriction +/- salt supplementation
- If ineffective: Consider addition of loop diuretics to impair urinary concentration

\textbf{If symptomatic} (seizure, AMS ):
- Rapid initial correction: 3-5mL/kg of 3\% saline over 10-15 mins
- Rate of Correction: Increase Na by \textbf{no more than 8-9 mEq/L in 24 hrs}
- \textbf{Risk of central pontine myelinolysis with rapid correction}

\hypertarget{calcium-homeostasis}{%
\subsection{Calcium Homeostasis}\label{calcium-homeostasis}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.30\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.08\columnwidth}\raggedright
\textbf{Calcium}\strut
\end{minipage} & \begin{minipage}[b]{0.21\columnwidth}\raggedright
*Serum PTH**\strut
\end{minipage} & \begin{minipage}[b]{0.08\columnwidth}\raggedright
*25-OHD**\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
\textbf{Alk Phos}\strut
\end{minipage} & \begin{minipage}[b]{0.08\columnwidth}\raggedright
\textbf{Phos}\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Hypoparathyroidism}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{PTH Resistance}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Vit D Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal/high\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal/low\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Vit D Resistance}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal/low\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Renal Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal/low\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal/high\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Hypomagnesemia}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal/low\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Metastatic Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Low PTH High PTHrP\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Familial Hypocalciuric Hypercalcemia (FHH)}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Normal/High\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Primary Hyperparathyroidism}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
High or inappropriately normal\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Normal/high\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
Low\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{hypocalcemia}{%
\subsection{Hypocalcemia}\label{hypocalcemia}}

\hypertarget{definition-36}{%
\subsubsection{Definition}\label{definition-36}}

\begin{itemize}
\tightlist
\item
  Normal values are age specific and vary between labs
\item
  Hypoalbuminemia will lower the serum calcium concentration by 0.8 mg/dL for every 1.0 g/dL reduction in serum albumin (below 4 g/dL)
\end{itemize}

\hypertarget{etiology-14}{%
\subsubsection{Etiology}\label{etiology-14}}

\hypertarget{low-pth-hypoparathyroidism}{%
\paragraph{Low PTH (Hypoparathyroidism)}\label{low-pth-hypoparathyroidism}}

\textbf{Congenital}
- Genetic Syndromes
\textgreater\textgreater{} - DiGeorge Syndrome
\textgreater\textgreater{} - Mitochondrial disorders (MELAS, etc.)
\textgreater\textgreater{} - HDR (hypoparathyroidism, deafness, renal anomaly)
\textgreater\textgreater{} - Sanjad-Sakati Syndrome (IUGR, hypocalcemia, dysmorphia)
\textgreater\textgreater{} - Kenny-Caffey Syndrome (dwarfism, cortical bone thickening, hypocalcemia)
- Mutations in production of PTH
- CaSR activating mutations (autosomal dominant hypocalcemia)
- Parathyroid aplasia/dysplasia

\textbf{Acquired}
- Hypomagnesemia or hypermagnesemia
- Autoimmune (APS1 or isolated)
- Infiltrative disease (copper/iron deposition)
- Acquired post-surgery

\hypertarget{high-pth}{%
\paragraph{High PTH}\label{high-pth}}

\textbf{Renal Failure}
- 1a-hydroxylase deficiency iso renal failure
- Pseudohypoparathyroidism (end organ resistance to PTH)
- Excess phosphate intake

\textbf{Low Vitamin D}
- Deficient vitamin D intake, intestinal absorption, or dermal synthesis
- Hereditary resistance to vitamin D (vit D-dependent rickets type 2)
- Defects in vit D metabolism: liver failure, renal failure, drugs that increase CYP450 activity
- Genetic disorders:
\textgreater\textgreater{} - 25-hydroxylase deficiency
\textgreater\textgreater{} - 1a-hydroxylase deficiency
\textgreater\textgreater{} - Increased catabolism of vit D mutations

\hypertarget{other-causes}{%
\paragraph{Other Causes}\label{other-causes}}

\textbf{Neonatal Hypocalcemia}
- \textbf{Early (0-3 DOL)}
\textgreater\textgreater{} - Exaggeration of normal decline in calcium concentration after birth
\textgreater\textgreater{} - Asymptomatic, requires nutritional support alone
- \textbf{Late (4-10 DOL)}
\textgreater\textgreater{} - Presents as severe neuromuscular irritability or seizure
\textgreater\textgreater{} - Most commonly from excess phosphate intake in cow's milk; mechanism unknown, thought that high phos may antagonize PTH secretion
- \textbf{Maternal Risk Factors}: Diabetes, Vit D deficiency, AED use, hyperparathyroidism, or eclampsia
- \textbf{Neonatal Factors}: low birth weight, prematurity, IUR, perinatal asphyxia
- \textbf{Hypocalcemia in setting of other illness}: sepsis, RDS, hyperbilirubinemia, renal failure

\textbf{Miscellaneous}
- \textbf{Hungry Bone Syndrome}: Avid bone mineralization after recovery from severe mineralization defect (e.g., vitamin D deficiency)
- \textbf{Osteopetrosis}: loss of osteoclast function
- \textbf{Citrate or Lactate administration} (e.g., from blood transfusion)
- \textbf{Hypomagnesemia}
- \textbf{Sepsis}/severe acute illness
- \textbf{Pancreatitis}: complex formation w/ fatty acids
- \textbf{Drugs}: bisphosphonates, cinacalcet, foscarnet, chemotherapy

\hypertarget{clinical-manifestations-9}{%
\subsubsection{Clinical Manifestations}\label{clinical-manifestations-9}}

\begin{itemize}
\tightlist
\item
  Acute hypocalcemia
  \textgreater\textgreater{} - Tremor, muscle spasms, paraesthesias, tetany (Chvostek, Trousseau signs)
  \textgreater\textgreater{} - Seizures
  \textgreater\textgreater{} - QT prolongation, impaired contractility
  \textgreater\textgreater{} - Psychiatric symptoms (anxiety, agitation, hallucinations)
\item
  Vitamin D deficiency: rickets, muscle weakness, hypotonia, growth retardation; in severe rickets, may see bowed legs or knocked-knees
\end{itemize}

\hypertarget{diagnostic-studies-9}{%
\subsubsection{Diagnostic Studies}\label{diagnostic-studies-9}}

\begin{itemize}
\tightlist
\item
  Albumin and/or ionized calcium to determine if true hypocalcemia
\item
  If hypocalcemia confirmed send PTH, magnesium, phosphate, BUN, creatinine, 25OH-vitamin D
\item
  XR for rickets: shows osteopenia, widening of the metaphysis, cupping/splaying of growth plate, formation of cortical spurs, fractures
\end{itemize}

\hypertarget{treatment-53}{%
\subsubsection{Treatment}\label{treatment-53}}

\begin{itemize}
\tightlist
\item
  Calcium salts PO for chronic hypocalcemia
\item
  Calcium salts IV for acute hypocalcemia
  \textgreater\textgreater{} - Ca gluconate 100 mg/kg ( = 1mL/kg of 10\% solution)
  \textgreater\textgreater{} - CaCl 20 mg/kg ( = 0.2 mL/kg of 10\% solution) for emergencies only (irritant, causes necrosis if extravasates)
\item
  Replenish magnesium stores or give vitamin D as appropriate
  \textgreater\textgreater{} - If initiating treatment for vitamin D deficiency, always give calcium along vitamin D to prevent hypocalcemia from hungry bone syndrome
\item
  In hypoparathyroidism, give 1,25 vitamin D (calcitriol) rather than ergocalciferol/cholecalciferol because of decreased 1a-hydroxylation in the kidney
\item
  If hyperphosphatemic, avoid {[}Ca+{]} X {[}PO4{]} \textgreater55 because of risk of metastatic calcification
\end{itemize}

\hypertarget{hypercalcemia}{%
\subsection{Hypercalcemia}\label{hypercalcemia}}

\hypertarget{definition-37}{%
\subsubsection{Definition}\label{definition-37}}

Normal values are age specific and vary between labs

\hypertarget{etiology-15}{%
\subsubsection{Etiology}\label{etiology-15}}

\hypertarget{parathyroid-related}{%
\paragraph{Parathyroid Related}\label{parathyroid-related}}

\begin{itemize}
\tightlist
\item
  Primary hyperparathyroidism (adenoma or hyperplasia)
\item
  Secondary hyperparathyroidism
\item
  Tertiary hyperparathyroidism (only in chronic renal failure with chronic secondary hyperpara autonomous overproduction of PTH develops iso parathyroid hyperplasia)
\item
  Familial hypocalciuric hypercalcemia (loss of function CaSR)
\end{itemize}

\hypertarget{increased-bone-reabsorption}{%
\paragraph{Increased Bone Reabsorption}\label{increased-bone-reabsorption}}

\begin{itemize}
\tightlist
\item
  Malignancy (metastatic or PTHrP secretion)
\item
  Hypervitaminosis D
  -Hypervitaminosis A
  -Immobilization
\end{itemize}

\hypertarget{increased-125-ohd-production}{%
\paragraph{Increased 1,25 OHD Production}\label{increased-125-ohd-production}}

\begin{itemize}
\tightlist
\item
  Granulomatous disease (sarcoid, tuberculosis)
\item
  Subcutaneous fat necrosis in neonates
\end{itemize}

\hypertarget{metabolic-disorders}{%
\paragraph{Metabolic Disorders}\label{metabolic-disorders}}

\begin{itemize}
\tightlist
\item
  Hypophosphatasia (defective alk phos)
\item
  Blue diaper syndrome (defect in tryptophan metabolism)
\item
  Congenital lactase deficiency
\end{itemize}

\hypertarget{medications}{%
\paragraph{Medications}\label{medications}}

\begin{itemize}
\tightlist
\item
  Thiazide diuretics
\item
  Lithium
  \#\#\#\# Other
  Adrenal insufficiency, Williams syndrome, thyrotoxicosis, milk alkali syndrome, excess calcium intake, ECMO (mechanism not well understood but thought to be secondary to incr PTH)
\end{itemize}

\hypertarget{clinical-manifestations-10}{%
\subsubsection{Clinical Manifestations}\label{clinical-manifestations-10}}

\textbf{``Stones, bones, moans, psychiatric overtones''}
- \textbf{Renal symptoms}: polyuria, renal stones, nephrocalcinosis
- \textbf{Musculoskeletal system}: Bone pain, joint aches
- \textbf{GI system}: paralytic ileus, abdominal cramping, constipation, anorexia, vomiting
- \textbf{Nervous system}: headache, personality change, proximal muscle weakness\\
- In infants, failure to thrive
- In severe hypercalcemia (\textgreater14 mg/dL) can have lethargy and coma

\hypertarget{diagnostic-algorithm}{%
\subsubsection{Diagnostic Algorithm}\label{diagnostic-algorithm}}

*subcutaneous fat necrosis often (not always) has incr 1,25 OHD

\hypertarget{treatment-54}{%
\subsubsection{Treatment}\label{treatment-54}}

\begin{itemize}
\tightlist
\item
  For mild/moderate hypercalcemia, if asymptomatic can monitor without immediate intervention
\item
  For severe hypercalcemia (\textgreater12 mg/dL) and/or symptomatic:
  \textgreater\textgreater{} - \textbf{Increase calcium excretion}: IV hydration w/ NS is first line; after hydration, may add, furosemide,
  \textgreater\textgreater{} - \textbf{Decrease bone resorption}:
  \textgreater\textgreater\textgreater{} - Calcitonin: inhibits osteoclast bone resorption, promotes Ca and phos excretion.
  \textgreater\textgreater\textgreater\textgreater{} - Initial dose IM/subq 2-4 units/kg every 12 hours, may increase to 8 units/kg every 12 hours to a max of every 6 hours. Most patients develop tachyphylaxis w/i 48 hours
  \textgreater\textgreater\textgreater{} - Bisphosphonates: inhibit osteoclast activity. Watch for hypocalcemia; also for hypophos and hypomag.
  \textgreater\textgreater\textgreater\textgreater{} - Pamidronate dose 0.5-1 mg/kg in children
\item
  Note: HD should be considered in patients who have serum Ca conc in range of 18-20 mg/dL and neurologic symptoms
\item
  Primary hyperparathyroidism - parathyroidectomy
\end{itemize}

\hypertarget{gastroenterology-hepatology-nutrition}{%
\section{Gastroenterology, Hepatology \& Nutrition}\label{gastroenterology-hepatology-nutrition}}

\hypertarget{constipation}{%
\subsection{Constipation}\label{constipation}}

\hypertarget{bristol-stool-chart1}{%
\subsubsection[Bristol Stool Chart]{\texorpdfstring{Bristol Stool Chart\footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{Bristol Stool Chart}}\label{bristol-stool-chart1}}

\includegraphics{images/gi_bristol-stool-chart.png}

\hypertarget{powerplans-order-sets-clinical-pathways}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=Constipation\&algVersion=1.4\&accessCode=null}{Constipation}
\item
  \textbf{PowerPlans \& Order Sets:} GI AMB Constipation Plan, GI Constipation Cleanout (GoLYTELY) Plan, Chocolate Bomb Plan, SMOG Enema Plan
\end{itemize}

\hypertarget{presentation-65}{%
\subsubsection{Presentation}\label{presentation-65}}

Two of the following for 2 weeks and ≥6 mos of age:

\begin{itemize}
\tightlist
\item
  \emph{\textless{}} 2 stools/week
\item
  Fecal/urinary incontinence (after toilet trained)
\item
  Painful/hard bowel movements
\item
  Rectal fecal mass
\item
  Large diameter stools that obstruct toilet/require multiple flushes
\end{itemize}

\hypertarget{differential-6}{%
\subsubsection{Differential}\label{differential-6}}

\begin{itemize}
\tightlist
\item
  \textbf{95\% functional:} Withholding (related to new stressor, anxiety, dev. delay, autism), exacerbated by excess dairy, low fiber, inadequate fluid, toilet training
\item
  \textbf{5\% organic:} Anatomic (e.g.~anal stenosis), hypothyroidism, CF, Celiac, lead poisoning (may see calcifications on KUB), opiates, anti-epileptics, neurologic (e.g.~Hirschsprung's, CP)
\end{itemize}

\hypertarget{red-flags-1}{%
\subsubsection{Red Flags}\label{red-flags-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Hx:} Onset \textless{} 1 month, passed meconium \textgreater48 HOL, breastfeeding w/ hard stools, FTT, motor delay, ribbon or bloody stools, bilious emesis, FHx Hirschsprung's.
\item
  \textbf{Exam:} Tight rectum gripping finger, explosive stool and air from rectum upon withdrawal of finger, no anal wink, perianal fistula, midline dimple, lower back hair tuft, lower limb weakness or abnormal tone, abnormal thyroid, severe abdominal distension, fever
\end{itemize}

\hypertarget{work-up-20}{%
\subsubsection{Work-up}\label{work-up-20}}

\begin{itemize}
\tightlist
\item
  If no red flags → KUB not routinely indicated
\item
  If red flags or signs of systemic illness → Refer to ED/admit, obtain chem10, KUB
\item
  If suspect Hirschsprung's → Consult GI \& Surgery for contrast enema, rectal bx
\end{itemize}

\hypertarget{management-27}{%
\subsubsection{Management}\label{management-27}}

See the \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=Constipation\&algVersion=1.4\&accessCode=null}{Constipation Clinical Pathway} for more even more options than below.

\hypertarget{clean-out-evidence-of-impaction}{%
\paragraph{Clean Out (evidence of impaction)}\label{clean-out-evidence-of-impaction}}

\begin{itemize}
\tightlist
\item
  \textbf{Inpatient}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Cleanout \& Bowel Prep:} MiraLax 34g q30min x4 hrs PO, OR Go-Lytely infusion via NG tube + IVF

    \begin{itemize}
    \tightlist
    \item
      Follow electrolytes and BUN/Cr if infusing for \textgreater12 hrs
    \item
      If Go-Lytely is complete and effluent is not clear, start NS enemas
    \end{itemize}
  \item
    \textbf{Chocolate bomb:} 4oz chocolate (or vanilla) ice cream + 15mL senna, + 30mL mineral oil* + 30mL milk of magnesia

    \begin{itemize}
    \tightlist
    \item
      \textbf{Contraindications} to PO mineral oil: Pt at risk for aspiration, age \emph{\textless{}} 12 mos, GERD
    \end{itemize}
  \item
    \textbf{SMOG enema:} 20 mL normal saline + 20 mL mineral oil + 20 mL glycerin
  \end{itemize}
\item
  \textbf{Outpatient} (\emph{\textgreater{}} 12 mos)

  \begin{itemize}
  \tightlist
  \item
    \textbf{Day 1-3:} MiraLax 0.5g/kg (2g in 1 oz fluid) TID + Ex-lax choc ½ square daily, OR fleet mineral oil enema BID (2-12yrs: 2oz, \textgreater12 yrs: 4oz)
  \item
    \textbf{Day 3 and disimpacted:} Begin maintenance (see below)
  \end{itemize}
\end{itemize}

\hypertarget{maintenance}{%
\paragraph{Maintenance}\label{maintenance}}

\begin{itemize}
\tightlist
\item
  Be sure to include constipation education, stool diary, diet review
\item
  \textbf{6-12 mo}

  \begin{itemize}
  \tightlist
  \item
    Maintenance therapy = clean out therapy for this age group
  \item
    \textbf{Start with osmotic:} Prune juice (2-6 oz/day in 2-4oz water), OR lactulose 1ml/kg/d BID, OR MiraLax 1g/k/d (mix in 4-8oz liquid, max dose 8.5g)
  \item
    If no relief, trial \textbf{glycerin suppository}
  \end{itemize}
\item
  \textbf{\emph{\textgreater{}} 12 mo}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Start with osmotic:} MiraLax (10-30kg: 8.5g/day, \textgreater30kg: 17g/day), OR lactulose 1g/kg BID
  \item
    If necessary, add \textbf{stimulant:} Senna (Ex-lax choc ½ square), OR bisacodyl (Dulcolax), OR milk of magnesia

    \begin{itemize}
    \tightlist
    \item
      Rx stimulant \textbf{\emph{\textless{}} 2 wks}
    \end{itemize}
  \item
    \textbf{AND} toilet-sitting TID or after meals, reward-based toilet training if age appropriate
  \end{itemize}
\item
  \textbf{Reassess after 2-4 wks}
\end{itemize}

\hypertarget{diarrhea}{%
\subsection{Diarrhea}\label{diarrhea}}

\hypertarget{powerplans-order-sets-clinical-pathways-1}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=DEHYGASTRO\&algVersion=1.9\&accessCode=null}{Gastroenteritis and Dehydration}
\item
  \textbf{PowerPlans \& Order Sets:} GI Chronic Diarrhea Labs Plan, SSYCE Plan, Stool Studies Plan
\end{itemize}

\hypertarget{differential-7}{%
\subsubsection{Differential}\label{differential-7}}

\hypertarget{acute-vs.-chronic}{%
\paragraph{Acute vs.~chronic}\label{acute-vs.-chronic}}

\begin{itemize}
\tightlist
\item
  \textbf{Acute (\textless{} 5 days):} Gastroenteritis (viral or bacterial), food poisoning, antibiotic-associated, organophosphate ingestion, hyperthyroidism, disaccharidase deficiency (infants), AOM
\item
  \textbf{Chronic (\textgreater{} 2 wks):} Postinfectious lactase deficiency, IBS, IBD, Celiac, CF, milk protein allergy (infants), lactose intolerance, laxative abuse, giardiasis or other parasite, primary immunodeficiency or HIV, SIBO, chemo-induced, secretory tumor (gastrinoma, VIPoma), lymphangiectasia, congenital villous atrophy
\end{itemize}

\hypertarget{most-common-vs.-cant-miss}{%
\paragraph{Most common vs.~can't miss}\label{most-common-vs.-cant-miss}}

\begin{itemize}
\tightlist
\item
  \textbf{Most common cause of\ldots{}}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Febrile, non-bloody:} Viral (noro, rotavirus), C. diff
  \item
    \textbf{Afebrile, non-bloody:} Viral enteritis, bacterial foodborne, recent abx use, excessive juice (sorbitol), postinfectious lactase deficiency
  \item
    \textbf{Febrile, bloody:} Bacterial enteritis (SSYCE)
  \item
    \textbf{Febrile, mucusy:} Bacterial enteritis
  \item
    \textbf{Afebrile, bloody:} Intussusception (+intermittent severe abd pain and age 6 mos-2 yrs)
  \end{itemize}
\item
  \textbf{Life-threatening}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Diarrhea associated w/ sepsis:} Commonly caused by Salmonella spp and toxigenic s.aureus, immunocompromised pts at incr. risk
  \item
    HUS: Bloody diarrhea w/ pallor, purpura, elevated serum BUN or Cr, or hematuria. Do not give antibiotics!
  \item
    \textbf{Toxic megacolon:} Severe diarrhea + abdominal distension/peritonitis (+hx Shigellosis, pseudomembranous colitis, Hirschsprung's, or IBD)
  \item
    \textbf{Non-classic presentation of appendicitis:} Age \textless{} 5yo w/ small volume mucusy stools
  \item
    \textbf{IBD:} Bloody diarrhea + weight loss, fever, fatigue, extraintestinal findings
  \end{itemize}
\end{itemize}

\hypertarget{work-up-21}{%
\subsubsection{Work-up}\label{work-up-21}}

\begin{itemize}
\tightlist
\item
  \textbf{Toxic appearing:} CBCd, retic, chem 10, BCx, stool cx (SSYCE), C. diff toxin, KUB, Abd US
\item
  \textbf{Non-toxic} but significant \textbf{dehydration:} Chem10
\item
  \textbf{Non-toxic} but \textbf{febrile + bloody} diarrhea: Stool cx (SSYCE)
\item
  \textbf{Recent immigration,} travel to underdeveloped country, significant farm exposure: Stool O+P
\item
  \textbf{Recent abx or hospitalization} AND age \emph{\textgreater{}} 12 mos: C. diff toxin
\item
  \textbf{Chronic watery:} Stool pH, stool electrolytes and osms, reducing substances, trial of fasting
\item
  \textbf{Chronic bloody (occult or gross):} FOBT, fecal calprotectin or lactoferrin, CBC, serum albumin, ESR/CRP
\item
  \textbf{Chronic fatty:} Fecal fat (quantitative is gold standard), fecal elastase-1, serum TTG IgA and total IgA
\end{itemize}

\hypertarget{interpretation}{%
\subsubsection{Interpretation}\label{interpretation}}

\hypertarget{stool-studies}{%
\paragraph{Stool Studies}\label{stool-studies}}

\begin{itemize}
\tightlist
\item
  Elevated \textbf{fecal calprotectin or lactoferrin:} Intestinal inflammation
\item
  Elevated \textbf{fecal fat:} Villous atrophy, pancreatic insufficiency
\item
  Elevated \textbf{stool Mg or Phos:} Laxative overuse/abuse
\end{itemize}

\hypertarget{differentiating-osmotic-vs.-secretory-diarrhea}{%
\paragraph{Differentiating osmotic vs.~secretory diarrhea}\label{differentiating-osmotic-vs.-secretory-diarrhea}}

\begin{itemize}
\tightlist
\item
  \textbf{Stool Osmolar Gap} = Stool Osm - (2 x {[}stool Na + stool K{]})
\item
  \textbf{Osmotic diarrhea} = osmolar gap \textgreater{} 100 mOsm/kg

  \begin{itemize}
  \tightlist
  \item
    Maldigested carbohydrates draw water into the intestinal lumen (e.g.~celiac, pancreatic disease, lactose intolerance)
  \item
    Stool volume \textbf{decreases with fasting}
  \item
    Presence of reducing substrates or stool pH\textless6 suggests carbohydrate malabsorption
  \end{itemize}
\item
  \textbf{Secretory diarrhea} = osmolar gap \textless{} 100 mOsm/kg

  \begin{itemize}
  \tightlist
  \item
    Secretion of water into intestine exceeds absorption (e.g.~cholera, ETEC, neuroendo tumor, hyperthyroidism, non-osmotic laxative use)
  \item
    Large volume stool that \textbf{does NOT} decrease with fasting
  \end{itemize}
\item
  \textbf{NOTE:} Many infectious diarrheas are \textbf{mixed} osmotic and secretory
\end{itemize}

\hypertarget{acute-management}{%
\subsubsection{Acute Management}\label{acute-management}}

\begin{itemize}
\tightlist
\item
  In a non-toxic child, start with appropriate re-hydration (see \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=DEHYGASTRO\&algVersion=1.9\&accessCode=null}{Gastroenteritis and Dehydration Clinical Pathway})
\item
  Generally avoid antidiarrheals
\item
  Antibiotics are not indicated for well-appearing child with acute bloody diarrhea
\end{itemize}

\hypertarget{acute-gastroenteritis}{%
\subsection{Acute Gastroenteritis}\label{acute-gastroenteritis}}

\hypertarget{powerplans-order-sets-clinical-pathways-2}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=DEHYGASTRO\&algVersion=1.9\&accessCode=null}{Gastroenteritis and Dehydration}
\end{itemize}

\hypertarget{presentation-66}{%
\subsubsection{Presentation}\label{presentation-66}}

Diarrhea (\textgreater2 loose/watery stools per day), +/- vomiting, fever, anorexia, cramping. Diarrhea usually lasts \textless1 wk and not more than 2 wks (diarrhea \textgreater14 days = ``chronic'').

\hypertarget{pathophysiology-26}{%
\subsubsection{Pathophysiology}\label{pathophysiology-26}}

\begin{itemize}
\tightlist
\item
  \textbf{Viruses} (\textbf{rotavirus}, \textbf{norovirus}, enteric adenovirus, calicivirus, astrovirus, enterovirus) are a major cause → Low-grade fever, vomiting, and \textbf{watery, non-bloody} diarrhea
\item
  \textbf{Bacteria} (SSYCE, C. diff) cause infiltration of mucosal lining → Fever, abdominal pain, \textbf{bloody} diarrhea, positive \textbf{stool leukocytes}
\item
  \textbf{Parasites} (Giardia, Cryptosoporidia, Cyclospora, E. histolytica)
\end{itemize}

\hypertarget{management-28}{%
\subsubsection{Management}\label{management-28}}

\begin{itemize}
\tightlist
\item
  \textbf{Dehydration score} determines management:

  \begin{itemize}
  \tightlist
  \item
    If severe, obtain POCT BG + lytes and start IVF
  \item
    Otherwise, oral rehydration solution (e.g.~Pedialyte or ½ strength apple juice)

    \begin{itemize}
    \tightlist
    \item
      \textbf{NOTE:} Theoretical risk that high osmolality fluids will worsen diarrhea and hypoNa fluids will lead to hypoNa, but one RCT demonstrated improved outcomes w/ ½ strength apple juice b/c Pedialyte = not tasty
    \end{itemize}
  \end{itemize}
\item
  No evidence for bowel rest or bland diet
\end{itemize}

\hypertarget{anticipatory-guidance}{%
\subsubsection{Anticipatory Guidance}\label{anticipatory-guidance}}

\begin{itemize}
\tightlist
\item
  Very common childhood illness (children \textless{} 5yo avg 2 episodes/year)
\item
  Fecal-oral transmission. Illness usually begins 12 hrs to 5 days after exposure, and generally lasts for 3-7 days.
\item
  Oral rehydration/breastfeeding must be continued at home. Return to normal diet as soon as can tolerate.
\item
  Do not give antidiarrheals
\item
  Fever is common, give antipyretics
\end{itemize}

\hypertarget{clostridium-difficile-c.-diff}{%
\subsection{Clostridium Difficile (C. diff)}\label{clostridium-difficile-c.-diff}}

\hypertarget{powerplans-order-sets-clinical-pathways-3}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-3}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} C. diff Treatment Plan
\end{itemize}

\hypertarget{presentation-67}{%
\subsubsection{Presentation}\label{presentation-67}}

\begin{itemize}
\tightlist
\item
  Ranges from \textbf{asymptomatic colonization} to \textbf{profuse watery diarrhea} to \textbf{fulminant colitis} w/ fever and severe illness

  \begin{itemize}
  \tightlist
  \item
    Asymptomatic colonization w/ toxigenic C. diff is common in neonates (\textless{} 28 days) and infants (\textless{} 12 mos)
  \item
    \textbf{Illness (but not colonization) is rare in children \textless{} 2 yo} because they lack cellular machinery to bind C. diff toxin
  \end{itemize}
\item
  \textbf{Complications:} Perforation, toxic megacolon
\end{itemize}

\hypertarget{pathophysiology-27}{%
\subsubsection{Pathophysiology}\label{pathophysiology-27}}

\begin{itemize}
\tightlist
\item
  Anaerobic, Gm+, toxin-producing bacillus. Spores extremely resistant. Toxins disrupt endothelial cytoskeleton → inflammation, necrosis.
\item
  Usually associated w/ antibiotic use (esp.~clindamycin, cephalosporins, penicillins), PPIs, immunosuppression, IBD (esp.~UC)
\end{itemize}

\hypertarget{work-up-22}{%
\subsubsection{Work-up}\label{work-up-22}}

\begin{itemize}
\tightlist
\item
  \textbf{Stool enzyme immunoassay (EIA)} = high sens/spec. Positives auto-reflex to PCR.
\item
  Stool culture is \textbf{NOT} helpful! Do not test if age \textless{} 12 mos.
\item
  Sample should be fresh (on ice if outpatient), and usually only one sample is needed to confirm infection
\item
  Place on contact + hand-wash precautions while awaiting stool result
\end{itemize}

\hypertarget{management-29}{%
\subsubsection{Management}\label{management-29}}

\begin{itemize}
\tightlist
\item
  \textbf{Initial, non-severe:} \textbf{Metronidazole} (Flagyl) IV or PO 30 mg/kg/day x10-14 days, OR Fidaxomycin PO
\item
  \textbf{Initial tx failure, underlying IBD, or severe disease:} \textbf{Vancomycin} PO 40 mg/kg/day (max 125 mg/dose) x10-14 days, OR Fidaxomicin PO
\item
  \textbf{Chronic-recurrent} (\textgreater3x): Fecal microbial transplantation
\end{itemize}

\hypertarget{inflammatory-bowel-disease-ibd}{%
\subsection{Inflammatory Bowel Disease (IBD)}\label{inflammatory-bowel-disease-ibd}}

\hypertarget{powerplans-order-sets-clinical-pathways-4}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-4}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} GI Inflammatory Bowel Disease Admit Plan, GI Inflammatory Bowel Disease Workup Plan, GI Inflammatory Bowel Disease Medications Plan
\end{itemize}

\hypertarget{crohns-disease-cd}{%
\subsubsection{Crohn's Disease (CD)}\label{crohns-disease-cd}}

\hypertarget{epidemiology-1}{%
\paragraph{Epidemiology}\label{epidemiology-1}}

Onset in teens-20s and 50s-60s. Unusual in \textless{} 5yo.

\hypertarget{risk-factors}{%
\paragraph{Risk Factors}\label{risk-factors}}

\begin{itemize}
\item
  \begin{quote}
  200 risk loci associated with both CD and UC, and associated w/ with other autoimmune diseases (ankylosing spondylitis, psoriasis, Celiac)
  \end{quote}
\item
  Family history, Ashkenazi Jewish heritage, European ancestry
\item
  NOD2/CARD15 mutations (CD). Turner's Syndrome (CD), smoking (CD), sedentary lifestyle (CD), poor diet (high animal fat intake, low vegetable/fruit intake, Vitamin D deficiency) (UC+CD).
\end{itemize}

\hypertarget{presentation-68}{%
\paragraph{Presentation}\label{presentation-68}}

\begin{itemize}
\tightlist
\item
  \textbf{Systemic:} Poor weight gain, stunted linear growth, anorexia, delayed puberty anemia, fatigue
\item
  \textbf{GI:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Early:} Abd pain, RLQ mass (ileal involvement), bloody stools, perianal skin tags, fistulas, and abscesses. Primary sclerosing cholangitis.
  \item
    \textbf{Late:} Stricture formation, intra-abd abscesses, colon cancer (8-10y after onset)
  \end{itemize}
\item
  \textbf{Extraintestinal:} Erythema nodosum, pyoderma gangrenosum, arthritis, uveitis/episcleritis, nephrolithiasis, osteoporosis, thrombosis
\end{itemize}

\hypertarget{work-up-23}{%
\paragraph{Work-up}\label{work-up-23}}

\begin{itemize}
\tightlist
\item
  High \textbf{ESR/CRP,} low albumin, low Hct, \textbf{low B12,} +fecal leukocytes, high fecal calprotectin/lactoferrin
\item
  p-ANCA -, \textbf{ANCA+} (80\% of patients)
\item
  Upper GI/SBFT/MRI/low dose CTE/WCE: \textbf{Skip lesions,} ``cobblestoning,'' aphthous ulcerations, narrowing or obstruction
\item
  \textbf{Endoscopy:} Inflammation can occur anywhere in the GI tract from mouth to anus (but most commonly is ileocecal), patchy involvement, colonic aphthous lesions, linear fissures, \textbf{rectal sparing,} pseudopolyps, perianal findings (skin tags, fissures fistulae)
\item
  \textbf{Biopsy:} Chronic inflammation, noncaseating granulomatous, transmural inflammation
\end{itemize}

\hypertarget{management-30}{%
\paragraph{Management}\label{management-30}}

\begin{itemize}
\tightlist
\item
  \textbf{Corticosteroids:} Systemic, topical (enteric-coated or rectal), or GI-focused (Budesonide, Uceris)
\item
  \textbf{Aminosalicylates (5-ASA):} Poor/minimal response in CD. Anti-inflammatory, not immune-suppressing. Timed release, enteric-coated, pH-release, rectal suppository or enema (only in mild disease).
\item
  \textbf{Immunomodulators:} Thiopurines (azathioprine, 6-MP -- check TPMT activity before starting), methotrexate. Take 2-3 mos to work so require a bridge (steroid or nutritional EEN) to manage acute inflammation.
\item
  \textbf{Biologics:} For \textbf{Infliximab} (IV) \& \textbf{adalimumab} (SC) (anti-TNFa), need HBsAg, VZV titer or 2 vaccines, TB within 6 mos to initiate. \textbf{Vedolizumab} (anti-integrin) used mainly for maintenance of CD colitis, approved in adults. \textbf{Ustekinumab} (nti-IL12/23) used mainly for maintenance, approved in adults.
\item
  \textbf{Antibiotics} (ciprofloxacin, metronidazole): Useful in mild active CD
\item
  \textbf{EEN:} Formula-based diet that can be used in place of steroids, which is as effective as steroids at inducing remission. Particularly good in growth failure and SI disease.
\item
  \textbf{Surgery:} For complications such as stricture, fistula, abscess formation and to remove isolated areas of bowel involvement
\item
  \textbf{Specific carbohydrate or anti-inflammatory diets:} As adjuvant
\item
  Use \textbf{Pediatric Crohn's Disease Activity Index (PCDAI)} to measure response
\end{itemize}

\hypertarget{ulcerative-colitis-uc}{%
\subsubsection{Ulcerative Colitis (UC)}\label{ulcerative-colitis-uc}}

\hypertarget{epidemiology-2}{%
\paragraph{Epidemiology}\label{epidemiology-2}}

Onset in teens and young adults

\hypertarget{risk-factors-1}{%
\paragraph{Risk Factors}\label{risk-factors-1}}

See CD

\hypertarget{presentation-69}{%
\paragraph{Presentation}\label{presentation-69}}

\begin{itemize}
\tightlist
\item
  \textbf{Systemic:} Similar to CD
\item
  \textbf{GI:} Frequent, bloody/mucousy diarrhea, tenesmus, overnight stools, abd pain similar to infectious colitis

  \begin{itemize}
  \tightlist
  \item
    \textbf{Toxic Megacolon:} Can be seen in both but more common in UC. Fever, tachycardia, dehydration, electrolyte disturbance, hypoTN/shock, abd distention, vomiting, severe pain, abrupt change from diarrhea to no/little stools. ↑ risk w/antimotility agents (loperamide or opiates). \textbf{STAT abd XR + Surgery consult.}
  \end{itemize}
\item
  \textbf{Extraintestinal:} Erythema nodosum, arthritis, thrombosis, PSC
\end{itemize}

\hypertarget{work-up-24}{%
\paragraph{Work-up}\label{work-up-24}}

\begin{itemize}
\tightlist
\item
  High \textbf{ESR/CRP,} low albumin, low Hct, +fecal leukocytes, high fecal calprotectin/lactoferrin
\item
  \textbf{p-ANCA+} (60\% of patients)
\item
  Endoscopy: Friable colonic mucosa w/ \textbf{continuous extension from rectum up to proximal colon,} pseudopolyps, ``backwash'' ileitis, +/- gastritis
  \textbf{Biopsy:} Chronic mucosal inflammation in lamina propria, crypt abscesses
\end{itemize}

\hypertarget{management-31}{%
\paragraph{Management}\label{management-31}}

\begin{itemize}
\tightlist
\item
  \textbf{Corticosteroids} and PO/PR \textbf{5-ASA,} as with CD
\item
  \textbf{Immunomodulators:} 6-MP (check TPMT activity before starting)
\item
  \textbf{Calcineurin inhibitors:} Racrolimus, cyclosporine as a bridge to colectomy
\item
  \textbf{Biologics:} \textbf{Infliximab} used for induction and maintenance. \textbf{Vedolizumab} used mainly for maintenance (UC \textgreater{} CD), approved in adults. \textbf{Tofacitinib (Xelganz)} approved for adults.
\item
  \textbf{Surgery:} Colectomy can be curative, but requires either ileostomy (undesirable) or ileal-rectal/ileal-anal anastamoses (complicated surgeries, prone to recurrence w/ any residual rectal mucosa)
\item
  \textbf{Specific carbohydrate or anti-inflammatory diets:} As adjuvant
\item
  \textbf{Probiotics} (VSL\#3): \textless ay be complimentary
\item
  Use \textbf{Pediatric Ulcerative Colitis Activity Index (PUCAI)} to measure response (Gastroenterology 2007;133:423-432)
\end{itemize}

\hypertarget{malabsorption}{%
\subsection{Malabsorption}\label{malabsorption}}

\hypertarget{carbohydrates}{%
\subsubsection{Carbohydrates}\label{carbohydrates}}

\hypertarget{presentation-70}{%
\paragraph{Presentation}\label{presentation-70}}

\textbf{Frequent, watery} stools

\hypertarget{pathophysiology-28}{%
\paragraph{Pathophysiology}\label{pathophysiology-28}}

Caused by: \textbf{Pancreatic insufficiency} (e.g.~CF) → inadequate amylase; \textbf{lactase deficiency} (postinfectious or permanent); \textbf{bacterial overgrowth}/alteration of bowel flora (e.g.~post-surgical, recent abx use); consumption of \textbf{excessive or non-absorbable sugars} (excessive juice consumption); \textbf{inadequate absorption} (e.g.~Celiac)

\hypertarget{work-up-25}{%
\paragraph{Work-up}\label{work-up-25}}

\begin{itemize}
\tightlist
\item
  Fecal pH \textless{} 6 (can also be seen transiently in viral enteritis)
\item
  Stool reducing substances \textgreater{} 0.5\%. Need fresh stool for this test!
\item
  Breath hydrogen test used to detect lactase and sucralase deficiency (rare); or strict elimination of lactase and reassess clinically
\end{itemize}

\hypertarget{fat}{%
\subsubsection{Fat}\label{fat}}

\hypertarget{presentation-71}{%
\paragraph{Presentation}\label{presentation-71}}

\textbf{Greasy, foul-smelling} stools (\textbf{steatorrhea})

\hypertarget{pathophysiology-29}{%
\paragraph{Pathophysiology}\label{pathophysiology-29}}

\begin{itemize}
\tightlist
\item
  Caused by: \textbf{Diseases affecting bile production/secretion}; \textbf{poor enterohepatic circulation of bile salts} (e.g.~ileal resection 2/2 short gut or Chron's); \textbf{pancreatic insufficiency} (e.g.~CF, Schwachman-Diamond) → inadequate lipase; \textbf{Giardia}
\item
  Critically affects absorption of the fat-soluble vitamins A, D, E, and K
\end{itemize}

\hypertarget{work-up-26}{%
\paragraph{Work-up}\label{work-up-26}}

\begin{itemize}
\tightlist
\item
  \textbf{Spot fecal fat} (Sudan III stain): Non-specific, but sample can be further tested for:

  \begin{itemize}
  \tightlist
  \item
    Split fats (fatty acids) = more suggestive of malabsorptive process, vs.
  \item
    Neutral fats = more suggestive of pancreatic dysfunction
  \end{itemize}
\item
  \textbf{72 hr fecal fat (Quantitative):} \textgreater{} 5g per 24 hrs suggests malabsorption (diet during these 24 hrs should be \textgreater35\% fat or \textasciitilde60g)
\end{itemize}

\hypertarget{protein}{%
\subsubsection{Protein}\label{protein}}

\hypertarget{presentation-72}{%
\paragraph{Presentation}\label{presentation-72}}

Edema, hypoalbuminemia

\hypertarget{pathophysiology-30}{%
\paragraph{Pathophysiology}\label{pathophysiology-30}}

\begin{itemize}
\tightlist
\item
  Most commonly caused by \textbf{pancreatic insufficiency } (e.g.~CF) → inadequate bicarb and peptidases
\item
  Differentiate from \textbf{protein losing gastroenteropathy (PLE),} which is excessive leakage of serum proteins into the gut
\end{itemize}

\hypertarget{work-up-27}{%
\paragraph{Work-up}\label{work-up-27}}

\begin{itemize}
\tightlist
\item
  Serum total protein, albumin
\item
  Stool alpha-1 antitrypsin (for PLE)
\end{itemize}

\hypertarget{celiac-disease}{%
\subsection{Celiac Disease}\label{celiac-disease}}

\hypertarget{powerplans-order-sets-clinical-pathways-5}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-5}}

\begin{itemize}
\tightlist
\item
  PowerPlans \& Order Sets: Celiac Disease Plan, Celiac Gene Assessment, GI AMB Celiac Disease (Future) Plan
\end{itemize}

\hypertarget{presentation-73}{%
\subsubsection{Presentation}\label{presentation-73}}

\begin{itemize}
\tightlist
\item
  \textbf{Classic:} Malabsorption (FTT/wt loss, steatorrhea), abd pain, gas, \textbf{bloating/distension, constipation or diarrhea,} anemia, non-erosive arthritis, dental enamel defects, aphthous ulcers, dermatitis herpetiformis (pruritic papules/vesicles), neuropsych (ADHD, depression, HA)

  \begin{itemize}
  \tightlist
  \item
    Can also be completely \textbf{asymptomatic}!
  \end{itemize}
\item
  \textbf{Infants:} Irritability, wasted extremities and buttocks, distended abdomen
\end{itemize}

\hypertarget{pathophysiology-31}{%
\subsubsection{Pathophysiology}\label{pathophysiology-31}}

\begin{itemize}
\tightlist
\item
  \textbf{HLA-DQ2 or -DQ8} (predisposition, \textbf{necessary for dz}) + environmental trigger → antibodies to gliadin (gluten byproduct), tissue transglutaminase (TTG; cross-links and deamidizes gliadin peptides) → \textbf{enterocyte destruction}
\item
  ↑ risk in T1DM, autoimmune thyroid dz, Turner and Down syndrome
\end{itemize}

\hypertarget{work-up-28}{%
\subsubsection{Work-up}\label{work-up-28}}

\begin{itemize}
\tightlist
\item
  \textbf{Serologies:} Anti-TTG IgA, anti-endomysial IgA. Always check IgA levels (IgA deficiency can yield false negatives)! Deamidated gliadin peptide (DGP) IgG if \textless{} 2 yo or if IgA deficient.
\item
  \textbf{Biopsy:} Intraepithelial lymphocytes, villous atrophy, crypt hyperplasia
\end{itemize}

\hypertarget{management-32}{%
\subsubsection{Management}\label{management-32}}

\begin{itemize}
\tightlist
\item
  \textbf{Gluten-free diet} is the only treatment currently available, but is hard to maintain as is \$\$ and requires very strict adherence

  \begin{itemize}
  \tightlist
  \item
    Wheat, rye, barley all contain gluten. Oats often cross-contaminated unless explicitly stated.
  \item
    Tends to be low-fiber, so watch for constipation
  \item
    Sx should start to improve 2-4 wks into GF diet
  \end{itemize}
\item
  Trend TTG until normalized (usually by 12 mos on GF diet); improves after 6 mos. Follow Vitamin D and B12 levels, iron/ferritin PRN, thyroid. Check if immune against Hep B.
\end{itemize}

\hypertarget{gastrointestinal-bleeding}{%
\subsection{Gastrointestinal Bleeding}\label{gastrointestinal-bleeding}}

\hypertarget{powerplans-order-sets-clinical-pathways-6}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-6}}

\begin{itemize}
\tightlist
\item
  PowerPlans \& Order Sets: ED Gastrointestinal Bleed Plan, ICU GI Bleed Admit Plan
\end{itemize}

\hypertarget{presentation-74}{%
\subsubsection{Presentation}\label{presentation-74}}

\begin{itemize}
\tightlist
\item
  \textbf{Upper GI bleed (UGIB):} \textbf{Hematemesis} (vomiting (or NGT/GT output) of red blood or coffee ground-like material), and/or \textbf{melena} (black, tarry stools). Hematochezia in brisk/massive UGIB, or sometimes in infants due to short intestinal transit time.
\item
  \textbf{Lower GI bleed (LGIB):} \textbf{Hematochezia} (bright red (BRBPR) or maroon-colored blood or fresh clots per rectum). \textbf{Melena} in proximal LGIB. \textbf{Painful vs.~non-painful} is an important distinction.
\end{itemize}

\hypertarget{anatomy}{%
\subsubsection{Anatomy}\label{anatomy}}

UGIB is proximal to \textbf{ligament of Treitz} (distal duodenum), LGIB is distal

\hypertarget{work-up-29}{%
\subsubsection{Work-up}\label{work-up-29}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} CBC, coags, chem10, LFTs, T\&S. +/- amylase/lipase. \textbf{Guaiac} to confirm it is blood.

  \begin{itemize}
  \tightlist
  \item
    ↑ BUN (in absence of renal dz) is consistent w/ UGIB, but normal or low doesn't r/o.
  \item
    Of note, some substances/methods can \textbf{interfere w/ stool guaiac tests}

    \begin{itemize}
    \tightlist
    \item
      \textbf{False positive:} Red meat (rare or well done, w/i 72hrs), ferrous sulfate (if stool pH \textless6), raw peroxidase-rich fruits \& vegetables (e.g.~broccoli, cauliflower, radishes, turnips), stool obtained during DRE (microtrauma)
    \item
      \textbf{False negative:} Vitamin C (\textgreater250 mg/day), storage of specimen \textgreater4 days, outdated reagent or card
    \end{itemize}
  \end{itemize}
\item
  \textbf{Imaging:} Consider XR (r/o foreign body or bowel obstruction/perforation) or abd US (evaluate for signs of portal HTN). Endoscopy and angiography may be diagnostic and therapeutic.
\end{itemize}

\hypertarget{differential-diagnosis-1}{%
\subsubsection{Differential Diagnosis}\label{differential-diagnosis-1}}

\hypertarget{upper-gi-bleed-ugib}{%
\paragraph{Upper GI Bleed (UGIB)}\label{upper-gi-bleed-ugib}}

Ddx for UGIB in an \textbf{infant:}

\begin{itemize}
\tightlist
\item
  Common

  \begin{itemize}
  \tightlist
  \item
    Swallowed maternal blood (from delivery or mother's nipples) → w/u: Apt test
  \item
    Esophagitis (from stress, hypoxia, indomethacin, dexamethasone)
  \end{itemize}
\item
  Uncommon

  \begin{itemize}
  \tightlist
  \item
    Gastric Ulcer
  \end{itemize}
\end{itemize}

Ddx for UGIB in a \textbf{child or adolescent:}

\begin{itemize}
\tightlist
\item
  Common

  \begin{itemize}
  \tightlist
  \item
    \textbf{Esophagus:} Esophagitis (reflux, pill-induced e.g.~NSAIDs or tetracycline); Mallory-Weiss tear
  \item
    \textbf{Stomach:} Gastritis (NSAIDs, H. pylori, binge drinking); stress ulcer
  \item
    \textbf{Duodenum:} Duodenitis (e.g.~Crohn's)
  \item
    \textbf{Other:} Swallowed blood from mouth/nasopharynx; facial trauma, tooth extraction, epistaxis; red-colored liquid meds (e.g.~tylenol)
  \end{itemize}
\item
  Uncommon

  \begin{itemize}
  \tightlist
  \item
    \textbf{Esophagus:} Esophagitis (viral, candidal, caustic, allergic/eosinophilic); foreign body; duplication cyst; varices (most common cause of severe acute UGIB in children; due to portal HTN)
  \item
    \textbf{Stomach:} Gastritis (Crohn's, portal HTN, CMV); ulcer (e.g.~Zollinger-Ellison); Cushing ulcer (↑ ICP); leiomyoma (uterine fibroid); vascular malformation (e.g.~Dieulafoy disease)
  \item
    \textbf{Duodenum:} Ulcer (e.g.~H. pylori, Curling ulcer in burn victims); foreign body; duplication cyst; vascular malformation; hemobilia (intrahepatic bleeding from biliary tree)
  \item
    \textbf{Other:} Swallowed blood (e.g.~Munchausen by proxy, pulmonary hemorrhage)
  \end{itemize}
\end{itemize}

\hypertarget{lower-gi-bleed-lgib}{%
\paragraph{Lower GI Bleed (LGIB)}\label{lower-gi-bleed-lgib}}

Ddx for LGIB in an infant:

\begin{itemize}
\tightlist
\item
  Common

  \begin{itemize}
  \tightlist
  \item
    Anal fissure (often w/constipation)
  \item
    Milk protein allergy (mucus in stool, diarrhea)
  \item
    Necrotizing enterocolitis
  \item
    Swallowed maternal blood or epistaxis (can present as hematochezia due to rapid transit; w/u: Apt test)
  \end{itemize}
\item
  Uncommon

  \begin{itemize}
  \tightlist
  \item
    Vascular lesions
  \item
    Hirschsprung enterocolitis
  \item
    Intussusception
  \item
    Intestinal duplication
  \item
    Meckel's diverticulum
  \item
    Infectious enterocolitis
  \item
    Infantile/very early onset IBD (VEO-IBD)
  \end{itemize}
\end{itemize}

Ddx for LGIB in a child or adolescent:

\begin{itemize}
\tightlist
\item
  Common

  \begin{itemize}
  \tightlist
  \item
    Anal fissure (constipation, r/o sexual abuse)
  \item
    Intussusception
  \item
    Infectious enterocolitis (salmonella, shigella campylobacter, E. coli 0157, Yersinia, C. diff)
  \item
    IBD
  \item
    Meckel's diverticulum (large-volume, painless bleeding)
  \item
    Perianal streptococcal cellulitis
  \item
    Juvenile/inflammatory polyp (painless)
  \end{itemize}
\item
  Uncommon

  \begin{itemize}
  \tightlist
  \item
    Nodular lymphoid hyperplasia
  \item
    Vascular malformations
  \item
    Intestinal duplication
  \item
    Henoch-Schonlein purpura (HSP)
  \item
    Infectious diarrhea (e.g.~CMV colitis. amebiasis)
  \item
    Hemorrhoids
  \item
    Colonic or rectal varices
  \item
    Neutropenic enterocolitis/typhlitis (immunosuppressed)
  \end{itemize}
\end{itemize}

\hypertarget{management-33}{%
\subsubsection{Management}\label{management-33}}

\begin{itemize}
\tightlist
\item
  \textbf{Initial:} Assess hemodynamic stability and determine need for fluid resuscitation and/or transfusion (establish IV access)
\item
  \textbf{In general:} NPO, high-dose PPI (or drip), fluids resuscitation +/- transfusion, correct coagulopathy
\item
  \textbf{UGIB:} Sometimes octreotide drip. Endoscopy/angiography.
\item
  \textbf{Avoid:} UGI barium contrast studies, sucralfate (Carafate) (can interfere w/ visualization on endoscopy)
\end{itemize}

\hypertarget{gastroesophageal-reflux-disease-gergerd}{%
\subsection{Gastroesophageal Reflux Disease (GER/GERD)}\label{gastroesophageal-reflux-disease-gergerd}}

\hypertarget{powerplans-order-sets-clinical-pathways-7}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-7}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=12345\&algVersion=1.2\&accessCode=null}{Gastroesophageal Reflux Disease (GERD)}
\item
  \textbf{PowerPlans \& Order Sets:} GI AMB Gastroesophageal Reflux Plan
\end{itemize}

\hypertarget{definitions-1}{%
\subsubsection{Definitions}\label{definitions-1}}

\begin{itemize}
\tightlist
\item
  \textbf{GER:} Reflux of gastric constants through LES into esophagus

  \begin{itemize}
  \tightlist
  \item
    \textbf{Physiologic in infants}; peaks around 4mo, typically improves significantly by 12mo
  \end{itemize}
\item
  \textbf{GERD} = GER + pathologic consequences (e.g.~esophagitis, FTT/ weight loss, aspiration)
\end{itemize}

\hypertarget{presentation-75}{%
\subsubsection{Presentation}\label{presentation-75}}

\begin{itemize}
\tightlist
\item
  \textbf{Infant:} Back arching, Sandifer syndrome, excessive crying (\textgreater{} 3 hrs/day), irritability after feeds
\item
  \textbf{Child:} Epigastric pain, heartburn, regurgitation, vomiting, exacerbated by supine position or acidic foods
\item
  \textbf{Moderate/severe symptoms:} \textgreater{} 3 days/wk, and/or interfere w/ function
\item
  \textbf{Red flags:} Weight loss/FTT, hematemesis, vomiting that is persistent, projectile, or bilious, feeding refusal, dysphagia, recurrent PNA. Should prompt further work-up or endoscopy.
\end{itemize}

\hypertarget{management-34}{%
\subsubsection{Management}\label{management-34}}

\begin{itemize}
\tightlist
\item
  \textbf{Approach to GERD in a child:} Goal is to differentiate between mucosal disease, abnormal esophageal acid exposure, reflux hypersensitivity and/or functional heartburn driving symptoms

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    \href{http://chbshare.chboston.org/TS/clinsvc/dom/domqp/Documents1/Forms\%20and\%20Templates/Rosen_GERD_NASPGHAN_Guidelines.pdf}{NASPHGAN \textbf{diet and lifestyle changes}}. If no improvement → \emph{Step 2:}
  \item
    2 wk trial of \textbf{H2RA} (e.g.~famotidine). If no improvement → 6-8 wk trial \textbf{PPI} (e.g.~omeprazole). If no improvement on PPI or if unable to wean acid suppression → \emph{Step 3:}
  \item
    \textbf{Refer to GI} (upper endoscopy +/- pH impedance testing)
  \end{enumerate}
\item
  \textbf{Approach to GERD in an infant:} Remember, GER is physiologic in infants! Impt to consider feeding difficulties/oropharyngeal dysphagia/aspiration in ddx.

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    \textbf{Reflux precautions:} Elevate HOB, paced feeding, hold upright for 30 min after feed, thicken feeds (Similac SpitUp/Enfamil AR or 1 tsp rice/oatmeal cereal per 1oz formula), avoid tobacco exposure. Specifically counsel that \textbf{all infants should continue back to sleep,} even with reflux. If no improvement → \emph{Step 2:}
  \item
    2-4 wk trial of \textbf{hydrolyzed or amino acid formula, or elimination trials} of cow's milk and soy from maternal diet if breastfeeding. If no improvement AND severe symptoms (poor weight gain, feeding refusal) → \emph{Step 3:}
  \item
    2-4 wk trial of \textbf{famotidine or omeprazole}. Counsel caregivers on limited evidence of efficacy and ↑ risk of CAP PNA, GI infections, vitamin deficiencies, and fractures. If severe symptoms persist beyond 12 mos age → \emph{Step 4:}
  \item
    \textbf{Refer to GI}
  \end{enumerate}
\end{itemize}

\hypertarget{pancreatitis}{%
\subsection{Pancreatitis}\label{pancreatitis}}

\hypertarget{powerplans-order-sets-clinical-pathways-8}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-8}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=PANCREATITIS_ACUTE\&algVersion=1.4\&accessCode=null}{Pancreatitis, Acute}
\item
  \textbf{PowerPlans \& Order Sets:} Acute Pancreatitis Plan, Acute Pancreatitis Critical Care Plan, ED Pancreatitis Plan, GI Pancreatitis Labs Plan
\end{itemize}

\hypertarget{presentation-76}{%
\subsubsection{Presentation}\label{presentation-76}}

\textbf{Epigastric abd pain} w/ band-like pain to back, fever, \textbf{N/V,} ileus, jaundice/clay-colored stools

\hypertarget{pathophysiology-32}{%
\subsubsection{Pathophysiology}\label{pathophysiology-32}}

\textbf{Gallstones or biliary disease} (30\% of pediatric cases), congenital anomalies (e.g.~\textbf{choledochal cyst,} pancreatic divisum), infectious (\textbf{mumps, mycoplasma,} coxsackie, influenza, salmonella, GNRs), drugs (\textbf{valproic acid,} L-asparaginase, steroids), systemic dz (\textbf{CF w/ pancreatic sufficiency,} Lupus, RA, HUS, Kawasaki, IBD), metabolic (\textbf{hyperlipoproteinemia,} hyperCa, DM), EtOH abuse, blunt abd trauma (e.g.~handlebar injury), genetic (SPINK1). 10\% will have recurrence of disease.

\hypertarget{diagnostic-criteria}{%
\subsubsection{Diagnostic Criteria}\label{diagnostic-criteria}}

At least \textbf{2 out of 3:} (1) Abdominal pain (see above), (2) Amylase or lipase \textgreater{} 3 ULN, (3) Imaging compatible w/ pancreatitis (US, EUS, MRI/MRCP)

\hypertarget{work-up-30}{%
\subsubsection{Work-up}\label{work-up-30}}

\begin{itemize}
\tightlist
\item
  Chem10, \textbf{amylase/lipase} (lipase rises earlier, elevated for longer, more specific), lipids, albumin, glucose, LFTs. ALT \textgreater{} 3x ULN has \textgreater95\% PPV for gallstone pancreatitis.
\item
  \textbf{Contrast-enhanced US} to confirm pancreatic inflammation and assess for gallstones or dilated CBD
\end{itemize}

\hypertarget{management-35}{%
\subsubsection{Management}\label{management-35}}

Refer to the \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=PANCREATITIS_ACUTE\&algVersion=1.4\&accessCode=null}{Acute Pancreatitis Clinical Pathway}. There are 4 components:

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{Pain control:} Ketorolac, acetaminophen +/- opiates
\item
  \textbf{Fluids:} NPO x24 hrs w/ NS or LR (if calcium wnl) bolus(es) followed by 2x MIVF
\item
  \textbf{Imaging:} Contrast-enhanced US
\item
  \textbf{Feeding:} Trial enteral feeds at 24 hrs if clinically stable. Interval increases in amylase and/or lipase or mild vomiting should not delay advancing introduction of enteral feeds.
\end{enumerate}

\hypertarget{complications-13}{%
\subsubsection{Complications}\label{complications-13}}

SIRS, ARDS, abscess, pleural effusion, pseudocyst (patients require f/u RUQ US in 4-6 wks to assess for pseudocyst)

\hypertarget{functional-gastrointestinal-disorders-fgid}{%
\subsection{Functional Gastrointestinal Disorders (FGID)}\label{functional-gastrointestinal-disorders-fgid}}

\hypertarget{pathophysiology-33}{%
\subsubsection{Pathophysiology}\label{pathophysiology-33}}

Hypersensitivity (visceral nervous system, CNS), motility disturbance, ?microbiome disturbance, psychological factors including caregiver stress, and abnormal responses to both normal and abnormal physiologic stimuli

\hypertarget{alarm-symptoms}{%
\subsubsection{Alarm Symptoms}\label{alarm-symptoms}}

Blood in stool, multiple episodes of diarrhea \textgreater{} daily, persistent fevers, weight loss, nighttime awakenings for pain or to have BM. \textbf{CANNOT} be FGID!

\hypertarget{management-36}{%
\subsubsection{Management}\label{management-36}}

Each diagnosis has its own specific management pearls (see below), but these general principles apply to all:

\begin{itemize}
\tightlist
\item
  Pt/family \textbf{education} about FGIDs. Thorough \textbf{understanding} of diagnosis and clear \textbf{motivation} to overcome it is critical for patient and family. \textbf{Language} is important: Can be helpful to describe broadly as ``hyperactive/overly sensitive gut nervous system'' that needs to be ``re-trained''; the word ``functional'' may be off-putting, so alternatives might be ``sensitive stomach'' or ``irritable bowel'' (as appropriate depending on specific diagnosis). Most important is \textbf{reassurance} (e.g.~have ruled out other concerning diagnoses). Many families are actually accepting and feel relieved to put a name to the symptoms.
\item
  \textbf{Judiciously} order labs/imaging \textbf{only if} alarm symptoms are present and after introducing possibility of FGID.
\item
  \textbf{CBT:} Relaxation training, cognitive restructuring, modifying family response. Also important to \textbf{address other psychological comorbidities.}
\item
  \textbf{Antispasmodics} (hyoscyamine, dicyclomine). \textbf{TCAs or SSRIs} if comorbid anxiety/depression.
\item
  Identify and avoid \textbf{food triggers} (e.g.~tomatoes/citrus, caffeine, carbonation, greasy, spicy foods).
\item
  \textbf{Inpatient:} Consider Magic Mouthwash (AIOH/diphenhydramine/lidocaine/MgOH/simethicone) or hyoscyamine if ``something'' necessary (e.g.~over a weekend)
\end{itemize}

\hypertarget{irritable-bowel-syndrome-ibs}{%
\subsubsection{Irritable Bowel Syndrome (IBS)}\label{irritable-bowel-syndrome-ibs}}

Subtype may be Constipation (\textbf{IBS-C}), Diarrhea (\textbf{IBS-D}), or mixed/alternating (\textbf{IBS-M} or \textbf{IBS-A})

\hypertarget{presentation-rome-iv-criteria}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria}}

Recurrent abd pain, at least 1 day/wk x3 mos, associated w/: Defecation, change in frequency/form of stool. Look for association w/ excitement or stress.

\hypertarget{specific-management}{%
\paragraph{Specific Management}\label{specific-management}}

\textbf{Probiotics} (lactobacillus or bifidobacteria). Bio-psycho-social approach. Medications to target symptoms, but educate that goal is to \textbf{improve rather than cure.} Return to \textbf{regular schedules/routines.}

\hypertarget{functional-dyspepsia-fd}{%
\subsubsection{Functional Dyspepsia (FD)}\label{functional-dyspepsia-fd}}

\hypertarget{presentation-rome-iv-criteria-1}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-1}}

\begin{quote}
1x/wk of: Bothersome postprandial fullness (uncomfortably full after regular-sized meal) w/early satiety, epigastric pain/burning
\end{quote}

\hypertarget{specific-management-1}{%
\paragraph{Specific Management}\label{specific-management-1}}

Small, frequent meals. Time-limited empiric trials of \textbf{acid suppression} or \textbf{prokinetics}. Peppermint oil (\textbf{IBguard}). Limit fructose, sorbitol. Consider \textbf{cyproheptadine} if weight loss. \textbf{Sulcralfate} helpful for burning, best to use single dose at night.

\hypertarget{abdominal-migraine}{%
\subsubsection{Abdominal Migraine}\label{abdominal-migraine}}

\hypertarget{presentation-rome-iv-criteria-2}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-2}}

Paradoxical episodes of acute periumbilical abd pain lasting \emph{\textgreater{}} 1 hr, often i/s/o family hx of migraine. Must be completely asymptomatic between attacks. Note: This is a controversial diagnosis.

\hypertarget{specific-management-2}{%
\paragraph{Specific Management}\label{specific-management-2}}

\textbf{Avoid caffeine.} \textbf{Ppx:} Cyprohepatdine, propranolol. \textbf{Abortive:} Triptan (IV, intranasal), dark/quiet room.

\hypertarget{functional-abdominal-pain-fap}{%
\subsubsection{Functional Abdominal Pain (FAP)}\label{functional-abdominal-pain-fap}}

\hypertarget{presentation-rome-iv-criteria-3}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-3}}

Often \textbf{vague, diffuse pain,} almost never focal. Often occurs at times of separation (bedtime or school) and is better over summer, weekends, or vacation.

\hypertarget{specific-management-3}{%
\paragraph{Specific Management}\label{specific-management-3}}

If severe, consider referral to Functional Abdominal Pain Clinic

\hypertarget{cyclic-vomiting-syndrome}{%
\subsubsection{Cyclic Vomiting Syndrome}\label{cyclic-vomiting-syndrome}}

\hypertarget{presentation-rome-iv-criteria-4}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-4}}

\begin{itemize}
\tightlist
\item
  Stereotypical episodes of intense vomiting separated by wks to mos, completely fine between attacks. Usually presents in 3-7yo, uncommon onset after puberty). Typically happens at night (e.g.~before bed), and parents can often tell it is coming (e.g.~child is pale). Often i/s/o maternal hx of migraine.
\item
  \textbf{Isolated vomiting should always raise concern,} so \textbf{need to r/o} malrotation, inborn error of metabolism, increased ICP, UPJ obstruction, pancreatitis, and cannabanoid hyperemesis syndrome (often responsive to hot showers, topical capsaicin cream)
\end{itemize}

\hypertarget{specific-management-4}{%
\paragraph{Specific Management}\label{specific-management-4}}

See abdominal migraine management above, plus IV hydration and ondansetron PRN

\hypertarget{functional-nausea}{%
\subsubsection{Functional Nausea}\label{functional-nausea}}

\hypertarget{presentation-rome-iv-criteria-5}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-5}}

Predominant symptom is nausea. At least 2 mos of all of the following: (1) Bothersome nausea at least 2x/wk generally not related to meals; (2) Not consistently associated w/ vomiting; (3) R/o other medical condition causing nausea.

\hypertarget{functional-vomiting}{%
\subsubsection{Functional Vomiting}\label{functional-vomiting}}

\hypertarget{presentation-rome-iv-criteria-6}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-6}}

At least 2 mos of all of the following: (1) Avg 1+ episodes of vomiting per week; (2) Absence of self-induced vomiting or criteria for eating disorder or rumination; (3) R/o other medical condition causing vomiting

\hypertarget{rumination-syndrome}{%
\subsubsection{Rumination Syndrome}\label{rumination-syndrome}}

\hypertarget{presentation-rome-iv-criteria-7}{%
\paragraph{Presentation (Rome IV Criteria)}\label{presentation-rome-iv-criteria-7}}

At least 2 mos of all of the following: (1) Repeated regurgitation and rechewing or expulsion of food, begins soon after ingestion of meal, does not occur during sleep; (2) Not preceded by retching; (3) R/o other medical conditions, including eating disorder

\hypertarget{specific-management-5}{%
\paragraph{Specific Management}\label{specific-management-5}}

Can use strategies similar to management of habit disorders. Education on diaphragmatic breathing.

\hypertarget{newborn-gi}{%
\subsection{Newborn GI}\label{newborn-gi}}

\hypertarget{pyloric-stenosis}{%
\subsubsection{Pyloric Stenosis}\label{pyloric-stenosis}}

\hypertarget{presentation-77}{%
\paragraph{Presentation}\label{presentation-77}}

\begin{itemize}
\tightlist
\item
  \textbf{Immediate postprandial projectile emesis,} ``hungry vomiter,'' palpable olive-like mass
\item
  4:1 M:F. Classically presents in \textbf{3-6wo infants, but can worsen by 2-3 mos} (rare by 12wo).
\end{itemize}

\hypertarget{pathophysiology-34}{%
\paragraph{Pathophysiology}\label{pathophysiology-34}}

Hypertrophy of pylorus. Risk factors = bottle feeding, maternal smoking.

\hypertarget{work-up-31}{%
\paragraph{Work-up}\label{work-up-31}}

BMP (\textbf{hyperchloremic metabolic alkalosis}), CBC (should be wnl), bili (unconjugated hyperbili), hemoccult stool (should be neg), \textbf{abd US}

\hypertarget{management-37}{%
\paragraph{Management}\label{management-37}}

\begin{itemize}
\tightlist
\item
  Address dehydration and correct alkalosis
\item
  Consult Surgery for pyloromyotomy (definitive treatment)
\item
  Post-op feeding can start within hours
\end{itemize}

\hypertarget{malrotationvolvulus}{%
\subsubsection{Malrotation/Volvulus}\label{malrotationvolvulus}}

\hypertarget{presentation-78}{%
\paragraph{Presentation}\label{presentation-78}}

Bilious emesis, third spacing, HD instability

\hypertarget{pathophysiology-35}{%
\paragraph{Pathophysiology}\label{pathophysiology-35}}

\begin{itemize}
\tightlist
\item
  \textbf{Malro:} Arrest in normal rotation in embryonic gut. Misplaced cecum is attached by peritoneal bands (Ladd bands) which cross the duodenum, leading to risk of volvulus. Mostly asymptomatic.
\item
  \textbf{Volvulus:} Small bowel twisting around SMA → vascular compromise, ischemia, necrosis
\end{itemize}

\includegraphics{images/gi_malro-volvulus.png}

\hypertarget{work-up-32}{%
\paragraph{Work-up}\label{work-up-32}}

Depends on clinical stability

\begin{itemize}
\tightlist
\item
  Bilious emesis + signs of sepsis/HD compromise + suspicion for volvulus → rapid resuscitation and surgical exploration
\item
  If HD stable → KUB, upper GI series (corkscrew appearance), abd US (whirlpool sign), CT in adults. Laproscopy if indeterminate.
\end{itemize}

\hypertarget{management-38}{%
\paragraph{Management}\label{management-38}}

\begin{itemize}
\tightlist
\item
  \textbf{Ladd procedure:} Division of Ladd bands, widening mesenteric base, explore duodenum with tube for patency, \textbf{appendectomy} (to avoid future confusion w/ abd pain), bowel resection PRN, replacement of bowels in nonrotation
\item
  Post-op, address \textbf{short gut syndrome} if relevant
\end{itemize}

\hypertarget{biliary-atresia-ba}{%
\subsubsection{Biliary Atresia (BA)}\label{biliary-atresia-ba}}

\hypertarget{presentation-79}{%
\paragraph{Presentation}\label{presentation-79}}

\textbf{Jaundice, acholic stools,} hepatomegaly

\hypertarget{pathophysiology-36}{%
\paragraph{Pathophysiology}\label{pathophysiology-36}}

\begin{itemize}
\tightlist
\item
  Most common cause of neonatal cholestasis; more common in premature infants
\item
  Grouped into 3 categories:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    \textbf{Nonsyndromic type:} Most common type (84\%). Perinatal and involves an inflammatory process involving intra- and extrahepatic fibro-obliteration → direct hyperbili → biliary cirrhosis, liver failure. Etiology unknown although possibly virus \& toxins.
  \item
    \textbf{Biliary Atresia Splenic Malformation} (10\% of cases) is associated w/ laterality malformations (e.g.~situs inversus, asplenia/polysplenia, malrotation, interrupted IVC, cardiac anomalies)
  \item
    \textbf{3rd type} (6\% of cases) is associated w/ other congenital anomalies (e.g.~intestinal atresia, imperforate anus, kidney and cardiac anomalies)
  \end{enumerate}
\end{itemize}

\hypertarget{work-up-33}{%
\paragraph{Work-up}\label{work-up-33}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} Bilirubin (conjugated hyperbili \textgreater1.0 mg/dl is always considered pathological and warrants workup), liver enzymes (transaminitis, elevated GGTP), obtain TSH/T4 for ddx
\item
  \textbf{Imaging:} Abd US (inability to visualize gallbladder or small gallbladder), HIDA scan (looks for excretion of bile from liver)
\item
  \textbf{Operative:} Liver biopsy, intra-op cholangiogram
\end{itemize}

\hypertarget{management-39}{%
\paragraph{Management}\label{management-39}}

\begin{itemize}
\tightlist
\item
  100\% mortality by 2yo if untreated. Early diagnosis (\textless{} 8wo) improves prognosis.
\item
  Kasai procedure (hepatoportoenterostomy): Best if done before 2mo. Removal of portal tract remnant followed by Roux-en-Y anastomosis of jejunal loop directly to liver capsule to allow bile drainage. 60-70\% of patients undergoing Kasai will eventually need liver transplant (BA = most common indication for pediatric liver transplant)
\end{itemize}

\includegraphics{images/gi_kasai.png}

\hypertarget{gi-imaging}{%
\subsection{GI Imaging}\label{gi-imaging}}

\hypertarget{abdominal-xr-kub}{%
\subsubsection{Abdominal XR (KUB)}\label{abdominal-xr-kub}}

\hypertarget{description-1}{%
\paragraph{Description}\label{description-1}}

Radiography. \textbf{Positions:} PA upright (most common), left lateral decubitus (for closer evaluation of peritoneal free air or to look for air trapping)

\hypertarget{used-to-evaluate}{%
\paragraph{Used to Evaluate}\label{used-to-evaluate}}

Abdominal pain or distension, constipation, emesis, concern for mass, concern for ingestion

\hypertarget{potential-pathology-visualized}{%
\paragraph{Potential Pathology Visualized}\label{potential-pathology-visualized}}

\begin{itemize}
\tightlist
\item
  Constipation (stool burden)
\item
  Ileus, bowel obstruction (dilated loops of bowel)
\item
  Foreign body
\item
  Necrotizing enterocolitis, bowel ischemia (pneumatosis, pneumoperitoneum, air in the biliary tree)
\item
  Bowel perforation (free air under diaphragm)
\end{itemize}

\hypertarget{patient-prep}{%
\paragraph{Patient Prep}\label{patient-prep}}

None

\hypertarget{modified-barium-swallow-mbs}{%
\subsubsection{Modified Barium Swallow (MBS)}\label{modified-barium-swallow-mbs}}

\hypertarget{description-2}{%
\paragraph{Description}\label{description-2}}

\textbf{Videofluorography} to evaluate the function of the phases of swallowing. Barium-impregnated foods of different consistencies are given to the patient and swallowing function is assessed.

\hypertarget{used-to-evaluate-1}{%
\paragraph{Used to Evaluate}\label{used-to-evaluate-1}}

Dysphagia; coughing, choking, drooling w/ swallowing; aspiration PNA, known or suspected; neurologic or anatomic disease that may affect swallowing function

\hypertarget{potential-pathology-visualized-1}{%
\paragraph{Potential Pathology Visualized}\label{potential-pathology-visualized-1}}

Swallowing dysfunction (e.g.~aspiration or laryngeal penetration), anatomic anomalies (note: esophagram, UGI series, or endoscopy may be better depending on the structural anomaly)

\hypertarget{patient-prep-1}{%
\paragraph{Patient Prep}\label{patient-prep-1}}

\begin{itemize}
\tightlist
\item
  NPO for several hours (check BCH/BMC policies and/or discuss w/ Feeding Team/SLP)
\item
  Pt needs to be able to cooperate w/ exam (i.e.~able to attempt swallowing when fed)
\end{itemize}

\hypertarget{upper-gi-ugi-series}{%
\subsubsection{Upper GI (UGI) Series}\label{upper-gi-ugi-series}}

\hypertarget{description-3}{%
\paragraph{Description}\label{description-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Single Contrast UGI:} Fluoroscopy of esophagus, stomach and duodenum, w/ PO barium as contrast agent
\item
  \textbf{Double Contrast UGI:} Fluoroscopy of esophagus, stomach and duodenum, w/ PO barium + sodium bicarbonate crystals (crystals release CO2, which distend the stomach and esophagus)
\item
  \textbf{UGI/SBFT} (small bowel follow-through): Single contrast UGI → drink additional contrast and wait 30 min → fluoroscopic evaluation q15 minutes until the enteric contrast reaches terminal ileum
\end{itemize}

\hypertarget{used-to-evaluate-2}{%
\paragraph{Used to Evaluate}\label{used-to-evaluate-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Single Contrast +/- SBFT:}

  \begin{itemize}
  \tightlist
  \item
    Severe or persistent abd pain, epigastric pain/discomfort
  \item
    Congenital syndromes associated w/ intestinal malrotation
  \item
    Weight loss or FTT
  \item
    Vomiting
  \item
    Esophageal strictures or foreign bodies
  \item
    Upper GI bleed
  \item
    Bowel dilation in short bowel syndrome
  \item
    Anastomotic stricture or abnormality in post-surgical short bowel syndrome patients
  \end{itemize}
\item
  \textbf{Double Contrast:} Evaluation of mucosal integrity
\end{itemize}

\hypertarget{potential-pathology-visualized-2}{%
\paragraph{Potential Pathology Visualized}\label{potential-pathology-visualized-2}}

Esophageal stricture/foreign body; malrotation; hiatal hernia; gastric outlet obstruction; delayed transit/delayed gastric emptying; gastritis, duodenitis, peptic ulcer disease; duodenal laceration or intramural hematoma; pyloric stenosis (although US is preferred); bowel dilatation post-surgery; anastomotic abnormality

\hypertarget{patient-prep-2}{%
\paragraph{Patient Prep}\label{patient-prep-2}}

\begin{itemize}
\tightlist
\item
  NPO \textgreater2 hrs or NPO \textgreater6 hrs is assessing for gallstones
\item
  Must be able to swallow contrast
\item
  Contrast may be placed through an enteral tube if small bowel follow through is desired
\item
  Counsel parents that barium may cause/worsen constipation
\end{itemize}

\hypertarget{considerations}{%
\paragraph{Considerations}\label{considerations}}

Barium is \textbf{contraindicated} i/s/o gastric perforation (use water soluble contrast), high aspiration risk, or colonic obstruction, T-E fistula, esophageal stricture, or in the immediate post-op period s/p GI surgery

\hypertarget{abdominal-ct}{%
\subsubsection{Abdominal CT}\label{abdominal-ct}}

\hypertarget{description-4}{%
\paragraph{Description}\label{description-4}}

Cross sectional imaging of abdominal structures. Both IV and oral contrast can be used.

\hypertarget{used-to-evaluate-3}{%
\paragraph{Used to Evaluate}\label{used-to-evaluate-3}}

Colicky pain; abd trauma (once HDS stable); cancer; liver disease; features of small intestinal Crohn's disease (fistula, stricture, abscess)

\hypertarget{potential-pathology-visualized-3}{%
\paragraph{Potential Pathology Visualized}\label{potential-pathology-visualized-3}}

Nephrolithiasis, urinary tract calculi (non-con); pelvic or abdo masses (contrast); IBD; SBO/LBO; diffuse liver disease (steatosis, iron deposition disease, cirrhosis); appendicitis; abd trauma

\hypertarget{patient-prep-3}{%
\paragraph{Patient Prep}\label{patient-prep-3}}

Oral or IV contrast as indicated

\hypertarget{contrast-enema}{%
\subsubsection{Contrast Enema}\label{contrast-enema}}

\hypertarget{description-5}{%
\paragraph{Description}\label{description-5}}

Contrast agent per rectum: \textbf{Water-soluble (gastrograffin)} if bowel perforation suspected, \textbf{air} if intussusception suspected

\hypertarget{used-to-evaluate-4}{%
\paragraph{Used to Evaluate}\label{used-to-evaluate-4}}

IBD; SBO/LBO; intussusception; anastomotic stricture or abnormality in post-surgical short bowel syndrome

\hypertarget{potential-pathology-visualized-4}{%
\paragraph{Potential Pathology Visualized}\label{potential-pathology-visualized-4}}

Lower abd obstruction in the neonate (Hirshprung's, meconium ileus, ileal atresia); intussusception (diagnostic and therapeutic); dnastomotic abnormality

\hypertarget{patient-prep-4}{%
\paragraph{Patient Prep}\label{patient-prep-4}}

None

\hypertarget{g-tubes-j-tubes}{%
\subsection{G-Tubes \& J-Tubes}\label{g-tubes-j-tubes}}

\hypertarget{powerplans-order-sets-clinical-pathways-9}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-9}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} Enteral Tube Obstruction Plan (can also find under Gastrostomy Tube Obstruction Plan)
\end{itemize}

\hypertarget{indications-4}{%
\subsubsection{Indications}\label{indications-4}}

\begin{itemize}
\tightlist
\item
  Inadequate intake (lower threshold in already malnourished, premature, oncologic kids)
\item
  NG/NJ = 1st line, short-term; GT/GJ/JT = if feedings indicated \textgreater{} 2 months
\end{itemize}

\hypertarget{tube-troubleshooting}{%
\subsubsection{Tube Troubleshooting}\label{tube-troubleshooting}}

\textbf{\emph{Before calling for help,}} need to know: \textbf{what kind of tube} (type, size), \textbf{who placed it} (Surgery, GI, IR), and \textbf{how old is the original tract}?

\hypertarget{tube-falls-out}{%
\paragraph{Tube Falls Out}\label{tube-falls-out}}

\begin{itemize}
\tightlist
\item
  \textbf{NEW T-type PEG tubes} placed by GI/Surgery \textless{} 6 months ago: \textbf{Do not attempt} replacement! Page GI fellow as tube will likely need replacement by IR.
\item
  \textbf{Surgically-placed G-tube:} If tract is \textless{} 12 wks old, page Gen Surg. If \textgreater{} 12 wks old, replace immediately with same-sized tube. If new tube is not immediately available, use Foley catheter in same French size (or 1 size larger to help dilate the tract). Do not force the tube in, as this can lead to false-tracking. Obtain G-tube study if any concerns for tube malposition.
\end{itemize}

\hypertarget{clogged-tube}{%
\paragraph{Clogged Tube}\label{clogged-tube}}

Crush 1 tab of sodium bicarb (324 mg) and 1 tab of Viokase 8 (Pancrelipase) in 5mL water. Instill slurry into feeding tube; wait 30-60 min, withdraw, and flush. See Enteral/Gastrostomy Tube Obstruction Order Set.

\hypertarget{granulation-tissue}{%
\paragraph{Granulation Tissue}\label{granulation-tissue}}

Stabilize tube. Consider silver nitrate vs.~triamcinolone cream vs.~salt in small amount of water.

\hypertarget{contact-dermatitis}{%
\paragraph{Contact Dermatitis}\label{contact-dermatitis}}

Absorbent topical powder, dressing. Consider Aveeno, Dombro, topical antifungal.

\hypertarget{cellulitis}{%
\paragraph{Cellulitis}\label{cellulitis}}

Outline erythema and start antibiotics

\hypertarget{devices}{%
\subsubsection{Devices}\label{devices}}

\hypertarget{percutaneous-endoscopic-gastrostomy-peg-tube}{%
\paragraph{Percutaneous Endoscopic Gastrostomy (PEG) Tube}\label{percutaneous-endoscopic-gastrostomy-peg-tube}}

\begin{itemize}
\tightlist
\item
  Usually T-type tube w/ cross-bar to hold internal balloon tight to abdominal wall
\item
  Needs 6 months before conversion to skin-level device. This is done endoscopically with sedation.
\end{itemize}

\includegraphics{images/gi_peg-tube.png}

\hypertarget{surgically-placed-g-tube}{%
\paragraph{Surgically Placed G-Tube}\label{surgically-placed-g-tube}}

\begin{itemize}
\tightlist
\item
  \textbf{MIC-G:} Non-skin level device w/ 3 ports (feeds, meds, balloon). Has round disk flange to hold it to abdominal wall.
\item
  \textbf{MIC-KEY:} Skin level button device w/ 2 ports. Tubing swivels, allowing patient to move comfortably. Now using AMT tubes instead of MIC-KEY.
\item
  \textbf{Bard button:} Skin level device, slightly smaller than MIC-KEY. Uses plastic bolster rather than balloon.
\item
  \textbf{MIC-GJ:} Non-skin level device placed by IR through existing gastrostomy site. Has separate ports for gastric and jejunal.
\item
  \textbf{MIC-KEY-GJ:} Skin level button device w/ separate ports for gastric and jejunal. Multiple jejunal exit holes allow for decreased clogging.
\end{itemize}

\hypertarget{jejunal-tube}{%
\paragraph{Jejunal Tube}\label{jejunal-tube}}

\begin{itemize}
\tightlist
\item
  No bolus feeds; continuous only, and requires slow advances
\item
  Needs large water flushes (15-30 mL) after medications and feeds to prevent clogging
\item
  Crushed medications can precipitate and should not be given through the J tube (e.g.~ciprofloxacin)
\item
  If vomiting, look for intussusception around tube with tube study
\end{itemize}

\hypertarget{infant-formulas}{%
\subsection{Infant Formulas}\label{infant-formulas}}

See the ``Pediatric Formula Guide'' on the \href{http://thebcrp.com/cards}{BCRP website's Virtual White Coat} for more detailed information

\hypertarget{helpful-math}{%
\subsubsection{Helpful Math}\label{helpful-math}}

\begin{itemize}
\tightlist
\item
  \textbf{1 oz = \textasciitilde30 mL}
\item
  Standard infant formula = 20 kcal/oz. Toddler/infant formula (1yo+) = 30kcal/oz
\end{itemize}

\hypertarget{types-of-formula}{%
\subsubsection{Types of Formula}\label{types-of-formula}}

\hypertarget{cows-milk}{%
\paragraph{Cow's Milk}\label{cows-milk}}

\begin{itemize}
\tightlist
\item
  \textbf{Common brands:} Enfamil (cheapest); Similac Advance (claims to have better calcium absorption); ``Step 2'' or ``next step'' versions (babies \textgreater{} 6mo) have more calcium, protein; Preemie versions (Enfacare, Neosure) have 22 kcal/oz, extra calcium, phosphorus
\end{itemize}

\hypertarget{partially-hydrolyzed}{%
\paragraph{Partially Hydrolyzed}\label{partially-hydrolyzed}}

\begin{itemize}
\tightlist
\item
  Whey = cow's milk-based
\item
  \textbf{Common brands:} Good Start (made by Nestle, covered by WIC)
\end{itemize}

\hypertarget{soy}{%
\paragraph{Soy}\label{soy}}

\begin{itemize}
\tightlist
\item
  Lactose-free, good for \textbf{lactose intolerance} or \textbf{galactosemia}
\item
  Can cause \textbf{constipation}
\item
  \textbf{Common brands:} Prosobee (made by Enfamil); Isomil (made by Similac); Goodstart Soy
\end{itemize}

\hypertarget{hydrolyzed-semi-elemental}{%
\paragraph{Hydrolyzed, Semi-Elemental}\label{hydrolyzed-semi-elemental}}

\begin{itemize}
\tightlist
\item
  \textbf{Common brands:} Nutramigen (cheapest, covered by WIC); Alimentum (sweeter taste); Pregestimil
\end{itemize}

\hypertarget{amino-acid-based-elemental}{%
\paragraph{Amino Acid-Based, Elemental}\label{amino-acid-based-elemental}}

\begin{itemize}
\tightlist
\item
  Very expensive \$\$\$\$
\item
  \textbf{Common brands:} Neocate (covered by WIC); Elecare (higher MCT oil content, less osms)
\end{itemize}

\hypertarget{caloric-supplements}{%
\subsubsection{Caloric Supplements}\label{caloric-supplements}}

\begin{itemize}
\tightlist
\item
  Formulas can be safely concentrated up to \textbf{28 kcal/oz}
\item
  If increased renal solute load is undesirable, use carb/lipid caloric supplements instead:

  \begin{itemize}
  \tightlist
  \item
    Polycose powder (carb-based)
  \item
    Corn oil, medium chain triglyceride (MCT) oil (lipid-based)
  \item
    Duocal (contains both carb and fats, only for infants \textgreater{} 1yo)
  \end{itemize}
\end{itemize}

\hypertarget{total-parenteral-nutrition-tpn}{%
\subsection{Total Parenteral Nutrition (TPN)}\label{total-parenteral-nutrition-tpn}}

\textbf{\emph{NOTE:}} \textbf{Enteral feeding is always the preferred route of nutrition support!} It ↓ gut atrophy, ↓ infections (boosts gut immune function), ↓ liver damage, and ↓ source of infection from central line.

\hypertarget{powerplans-order-sets-clinical-pathways-10}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-10}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} PN + lipid Orderset, PN Monitoring Plan, PN Profile
\item
  At BCH you write your own PN orders, but Nutrition will always walk you through it step by step!
\end{itemize}

\hypertarget{indications-5}{%
\subsubsection{Indications}\label{indications-5}}

Low birth weight. Abnormal nutritional status (z-score \textless{} -2 weight-for-age or weight-for-height, \textless{} 2500g). Dysfunctional GI tract. NPO \textgreater{} 4 days. \textbf{Always} in consultation with Nutrition Service and Dietitian.

\hypertarget{access}{%
\subsubsection{Access}\label{access}}

\begin{itemize}
\tightlist
\item
  If Osm \textgreater{} 900, need central access.
\item
  Calculate \% of daily maintenance fluids, consider heart or renal limitations
\end{itemize}

\hypertarget{monitoring}{%
\subsubsection{Monitoring}\label{monitoring}}

\begin{itemize}
\tightlist
\item
  Weight daily, length (\textless24 mos) weekly, height (\textgreater24 mos) periodically, head circumference (\textless24 mos) weekly
\item
  Fluid balance daily, chem10 daily until stable
\item
  Chem10, LFTs, and TG weekly
\item
  If on PN and minimal feeds for \textgreater{} 1 mo, nutritional labs checked periodically (Se, Cu, Zinc, Iron, Carnitine, CRP, vitamins A/D/E, INR, Manganese, Aluminum, iron studies, essential fatty acid profile)
\end{itemize}

\hypertarget{liver-enzymes}{%
\subsection{Liver Enzymes}\label{liver-enzymes}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.48\columnwidth}\raggedright
Pattern\strut
\end{minipage} & \begin{minipage}[b]{0.34\columnwidth}\raggedright
Lab Findings\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Ddx\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Hepatocellular\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
↑ ALT (specific), AST, LDH \textgreater\textgreater\textgreater{} ↑ GGTP, alk phos, bilirubin\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
- Viral (HepA, CMV, EBV, VSV, HSV, others)- Meds/toxins- Shock (highly elevated, LDH also high)- Autoimmune hepatitis- Steatosis (often subtle ALT elevation)- Celiac disease- Hemochromatosis (↑ ferritin/TIBC \textgreater45\%)- A1AT- Wilson's disease (AST\textgreater ALT, ↓ ceruloplasmin, ↓ alk phos)- EtOH (AST:ALT \textgreater2:1)- Non-hepatic: Adrenal insufficiency, thyroid disease, heart failure, NAT- \textbf{Isolated ↑ AST:} Myopathies, cardiomyopathies, hemolysis, strenuos exercise\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Cholestatic\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
↑ Alk phos, GGTP \& Direct Bili \textgreater\textgreater{} AST, ALT\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
- Bile duct obstruction/abnormalities (e.g.~gallstones)- Infectious hepatitis- Cirrhosis- Meds/toxins (anabolic steroids, amox/clav, erythromycin, bactrim, TPN)- PBC/PSC- A1AT- Alagille syndrome- Inborn errors of metabolism- CF\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Infiltrative\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
↑ Alk phos w/ nl bili (send GGT to determine if from liver or bone)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
- Granulomatous disease (e.g.~sarcoid, Tb)- Amyloidosis- HCC, liver mets\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Chronic/end-stage\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
↓ Alb, PT, PTT, factor VII, V \& serum lipids\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Progress of chronic liver disease\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{infectious-hepatitis}{%
\subsection{Infectious Hepatitis}\label{infectious-hepatitis}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.18\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Hepatitis A\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Hepatitis B\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Hepatitis C\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Hepatitis D\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.18\columnwidth}\raggedright
\textbf{Transmission}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Fecal-oral, blood\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Blood, sex, maternal-fetal (90\% vertical transmission rate, but \textbf{infants almost always become chronic carriers}; OK to breastfeed)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Blood, sex, maternal-fetal (\textless5\% vertical transmission rate; OK to breastfeed)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Blood, sex (less common). ONLY if \textbf{Hep B co-infection!}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
\textbf{Epidemiology}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
High in Mexico, S. America, Africa, Asia\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
1-2\% in US. Higher in Asia and South America. 10-20\% in China, sub-Saharan Africa\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Seroprevalence 0-1\% worldwide\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textless3\% of HBV+ patients\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
\textbf{Incubation}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
2-8 wks\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
1-4 mo\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
1-3 mo\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
3-7 wks\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
\textbf{Prophylaxis}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Hep A vaccine, pre-/post-exposure w/ polyclonal IgG\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Post-exposure w/ \textbf{HBIg \& HBV vaccine w/i 12 hrs} (newborns born to HBV+, needlesticks)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
None\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
None\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
\textbf{Management}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Supportive. Vit K for coagulopathy\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Entecavir, tenofovir, peginterferon alfa-2a, IFNa (20-50\% will seroconvert, but lots of systemic side effects), lamivudine (high rate of resistance)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Direct-acting antiretrovirals (DAA), specific treatment depends on genotype and age (ledipasvir/sofosbuvir, sofosbuvir/ribavirin or Glecaprevir/Piprentasvir). Treatment for patients \textless{} 3 yo should be deferred (until Ribavirin-free DAA available).\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
IFN-based. Lamivudine is not helpful.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
\textbf{Prognosis}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Usually self-limiting\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Self-limited or progression to chronic HBV/carrier status (esp.~neonates)- Cirrhosis in 3\%- Increased risk of hepatocellular cancer (yearly RUQ US, AFP level)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- 20-45\% spontaneous clearance- Remainder will have slow progression to cirrhosis/hepatocellular cancer if untreated\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Worse prognosis and faster progression than HBV alone\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{hep-b-serologies}{%
\subsubsection{Hep B Serologies}\label{hep-b-serologies}}

\begin{itemize}
\tightlist
\item
  \textbf{HBsAg} (surface antigen): Indicative of \textbf{acute} infection, disappears in 3-6 mos
\item
  \textbf{HBsAg} for \textgreater6 mos: \textbf{Carrier} state
\item
  \textbf{HBeAg} (secretory protein) and \textbf{HBV DNA} by PCR suggest \textbf{active viral replication}
\item
  \textbf{Anti-HBc IgM} (antibody to core protein): Secondary indicator of \textbf{acute} infection
\item
  \textbf{HBsAb} (antibody to surface protein): Neutralizing antibody, suggests \textbf{recovery or response to HBV vaccine}
\end{itemize}

\hypertarget{timeline-of-hep-b-serologies}{%
\paragraph{Timeline of Hep B Serologies}\label{timeline-of-hep-b-serologies}}

\includegraphics{images/gi_hep-b-serologies.png}

\hypertarget{interpretation-of-hep-b-serologies}{%
\paragraph{Interpretation of Hep B Serologies}\label{interpretation-of-hep-b-serologies}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
Anti-HBc IgM & Anti-HBc IgG & HBsAg & Anti-HBs & Interpretation\tabularnewline
\midrule
\endhead
\textbf{POS} & Neg & \textbf{POS} & Neg & Acute HBV infxn\tabularnewline
Neg & Neg & \textbf{POS} & Neg & Early acute HBV infxn\tabularnewline
Neg & \textbf{POS} & Neg & \textbf{POS} & Resolved acute HBV infxn\tabularnewline
Neg & Neg & Neg & \textbf{POS} & Prior vaccination for HBV (NOT infected)\tabularnewline
Neg & Neg & Neg & Neg & Not infected\tabularnewline
Neg & \textbf{POS} & \textbf{POS} & Neg & Chronic HBV infxn\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{autoimmune-hepatitis}{%
\subsection{Autoimmune Hepatitis}\label{autoimmune-hepatitis}}

\hypertarget{presentation-80}{%
\subsubsection{Presentation}\label{presentation-80}}

\begin{itemize}
\tightlist
\item
  Acute vs.~subacute. HSM, fatigue, amenorrhea.
\item
  Transaminitis \textgreater{} bilirubin elevation. Hypergammaglobulinemia.
\item
  Typically 10-20yo, affects mostly (75\%) females
\end{itemize}

\hypertarget{pathophysiology-37}{%
\subsubsection{Pathophysiology}\label{pathophysiology-37}}

\begin{itemize}
\tightlist
\item
  \textbf{Type 1} (classic, 80\% of cases): +ANA, anti-SM and/or anti-nuclear, anti-actin, rarely anti-ASGPR
\item
  \textbf{Type 2:} Anti-LKM and/or anti-liver cytosol. Recurrence and fulminant hepatitis more common in Type 2.
\item
  In AIH associated w/ Coombs-positive hemolytic anemia, none of the typical autoantibodies are present
\end{itemize}

\hypertarget{work-up-34}{%
\subsubsection{Work-up}\label{work-up-34}}

\begin{itemize}
\tightlist
\item
  LFTs, Ig levels, auto-antibodies, coags, consider liver biopsy. Sero-negative AIH exist but are rare.
\item
  Cholangiography if cholestatic w/ c/f ``Overlap Syndrome'' with PSC
\end{itemize}

\hypertarget{management-40}{%
\subsubsection{Management}\label{management-40}}

\begin{itemize}
\tightlist
\item
  Prednisone (18-24m) or azathioprine/6-MP (steroid-sparing; check TPMT enzyme activity first, as low TMPT levels = risk of myelosuppression)
\item
  Monitor LFTs for treatment success
\item
  Relapse more common if tx weaned in first 3 yrs of therapy or during puberty
\end{itemize}

\hypertarget{non-alcoholic-fatty-liver-disease-nafld}{%
\subsection{Non-Alcoholic Fatty Liver Disease (NAFLD)}\label{non-alcoholic-fatty-liver-disease-nafld}}

\hypertarget{presentation-81}{%
\subsubsection{Presentation}\label{presentation-81}}

\textbf{Often asymptomatic.} Fatigue, abdominal discomfort, acanthosis nigricans.

\hypertarget{pathophysiology-38}{%
\subsubsection{Pathophysiology}\label{pathophysiology-38}}

Incompletely understood, but insulin-resistance considered a key mechanism, +/- oxidative injury

\hypertarget{work-up-35}{%
\subsubsection{Work-up}\label{work-up-35}}

\begin{itemize}
\tightlist
\item
  Screen if \textgreater{} 9yo and BMI \textgreater94\%, or \textgreater85\% + risk factor (e.g.~signs of insulin resistance)
\item
  \textbf{ALT} \textgreater\textgreater\textgreater{} AST, alk phos, GGTP (although LFTs can be normal)
\item
  Abd US, Fibroscan (to assess degree of fibrosis)
\item
  Liver biopsy: If steatosis + hepatocellular injury present, then it is \textbf{Nonalcoholic Steatohepatitis (NASH)}
\end{itemize}

\hypertarget{management-41}{%
\subsubsection{Management}\label{management-41}}

Diet and exercise counseling, bariatric surgery, consider Vitamin E (limited evidence)

\hypertarget{references-4}{%
\subsection{References}\label{references-4}}

\hypertarget{hematology}{%
\section{Hematology}\label{hematology}}

\hypertarget{anemia-1}{%
\subsection[Anemia ]{\texorpdfstring{Anemia \footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{Anemia }}\label{anemia-1}}

\textbf{Table 447-1 Normal Mean and Lower Limits of Normal for Hemoglobin, Hematocrit, and Mean Corpuscular Volume}

\hypertarget{definition-38}{%
\subsubsection{Definition}\label{definition-38}}

Anemia is a reduction in hemoglobin concentration, hematocrit. The lower/upper limit of the normal range is set at two standard deviations below the mean for age and sex for the general population.

\textbf{Normal Mean and Lower Limits of Normal for Hgb, Hct \& MCV}

\begin{longtable}[]{@{}lllllll@{}}
\toprule
& Hemoglobin (g/dl) & & Hematocrit (\%) & & Mean Corpuscular volume (mM3) &\tabularnewline
\midrule
\endhead
\textbf{Age (yr)} & \textbf{Mean} & \textbf{Lower Limit} & \textbf{Mean} & \textbf{Lower Limit} & \textbf{Mean} & \textbf{Lower Limit}\tabularnewline
0.5-1.9 & 12.5 & 11.0 & 37 & 33 & 77 & 70\tabularnewline
2-4 & 12.5 & 11.0 & 38 & 34 & 79 & 73\tabularnewline
5-7 & 13.0 & 11.5 & 39 & 35 & 81 & 75\tabularnewline
8-11 & 13.5 & 12.0 & 40 & 36 & 83 & 76\tabularnewline
12-14 (F) & 13.5 & 12.0 & 41 & 36 & 85 & 78\tabularnewline
12-14 (M) & 14.0 & 12.5 & 43 & 37 & 84 & 77\tabularnewline
15-17 (F) & 14.0 & 12.0 & 41 & 36 & 87 & 79\tabularnewline
15-17 (M) & 15.0 & 13.0 & 46 & 38 & 86 & 78\tabularnewline
18-49 (F) & 14.0 & 12.0 & 42 & 37 & 90 & 80\tabularnewline
18-49 (M) & 16.0 & 14.0 & 47 & 40 & 90 & 80\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{approach-to-anemia-by-mcv-retics}{%
\subsubsection{Approach to Anemia (by MCV \& Retics)}\label{approach-to-anemia-by-mcv-retics}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.16\columnwidth}\raggedright
Reticulocyte count\strut
\end{minipage} & \begin{minipage}[b]{0.23\columnwidth}\raggedright
Microcytic anemia (MCV \textless80)\strut
\end{minipage} & \begin{minipage}[b]{0.26\columnwidth}\raggedright
Normocytic anemia (MCV 80-100)\strut
\end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright
Macrocytic anemia (MCV \textgreater100)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{LOW}(inappropriately low for the degree of anemia)\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
-\href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=IDA\&algVersion=1.4\&accessCode=null}{Iron deficiency} (see Clinical Pathway)- \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=Lead_Poisoning\&algVersion=1.9\&accessCode=null}{Lead poisoning} (see Clinical Pathway)- Chronic disease- Aluminum toxicity- Copper deficiency- Protein malnutrition\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Chronic disease- RBC aplasia (TEC, infection, drug induced)- Malignancy- JRA- Endocrinopathies- Renal failure\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- Folate deficiency, Vitamin B12 deficiency- Aplastic anemia- Congenital bone marrow dysfunction (Diamond-Blackfan or Fanconi syndromes, Diamond Blackfan anemia)- Drug-induced- Myelodysplasia- Trisomy 21- Hypothyroidism\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{NORMAL}\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
- Thalassemia trait- Sideroblastic anemia\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Very acute bleeding- Phlebotomy- Hypersplenism- Dyserythropoietic anemia II\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.16\columnwidth}\raggedright
\textbf{HIGH}\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
- Thalassemia syndromes- Hemoglobinopathies\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Antibody-mediated hemolysis- Hypersplenism- Microangiopathy (HUS, TTP, DIC, Kasabach-Merritt)- Membranopathies (spherocytosis)- Enzyme disorders (G6PD, PK)- Hemoglobinopathies- Acute/chronic bleeding\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- Dyserythropoietic anemia I, III- Active hemolysis\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\includegraphics{images/heme_approach-to-anemia-by-retic-vs-MCV_part1.jpg}

\includegraphics{images/heme_approach-to-anemia-by-retic-vs-MCV_part2.png}

\hypertarget{microcytic-anemias}{%
\subsubsection{Microcytic Anemias}\label{microcytic-anemias}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.04\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.15\columnwidth}\raggedright
Serum Iron\strut
\end{minipage} & \begin{minipage}[b]{0.07\columnwidth}\raggedright
TIBC\strut
\end{minipage} & \begin{minipage}[b]{0.36\columnwidth}\raggedright
\% Transferrin Sat (Fe/TIBC)\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Ferritin\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Smear\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Iron deficiency anemia}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright
Low (\textless12\%)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Hypochromic, microcytic\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Anemia of chronic disease/inflammation}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright
Normal (\textgreater18\%)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Normal/High\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Hypochromic, normocytic or microcytic\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Lead poisoning}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
High/normal\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Low/normal\strut
\end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High/Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Stippled, microcytic\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Sideroblastic}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright
High/Normal\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Ringed sideroblasts (BM)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Hemochromatosis}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Low\strut
\end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.04\columnwidth}\raggedright
\textbf{Alpha/Beta Thalassemia}\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
High\strut
\end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Microcytic RBCs, target cells (alpha), basophilic stippling (beta)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{thalassemias}{%
\paragraph{Thalassemias}\label{thalassemias}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Variant\strut
\end{minipage} & \begin{minipage}[b]{0.19\columnwidth}\raggedright
Defect\strut
\end{minipage} & \begin{minipage}[b]{0.31\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{α}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{α Thalassemia Minima}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
1 α-globin allele\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
\textbf{Asymptomatic} (no anemia)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{α Thalassemia Minor}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
2 α-globin alleles\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
- \textbf{Minimal anemia} (``α-thalassemia trait'')- Target cells\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Hemoglobin H disease}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
3 α-globin alleles\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
- \textbf{Hgb H} (4 β-globins)- Microcytic anemia, \textbf{chronic hemolytic anemia}- Pallor, splenomegaly, decreased lifespan\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Hydrops fetalis}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
4 α-globin alleles\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
- \textbf{Hgb Bart's} (4 γ-globins)- \textbf{Fetal edema} → intrauterine death\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{β}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{β Thalassemia Minor}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
1 β-globin allele\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
- \textbf{↓ β-globin, ↑ Hgb A2} (α2δ2)- \textbf{Minimal anemia} (``β-thalassemia trait'')\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{β Thalassemia Major}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
2 β-globin alleles\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
- \textbf{Absent β-globin, Hgb F} (α2γ2) \textbf{+ Hgb A2}- \textbf{Severe anemia}\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{sickle-cell-anemia}{%
\subsubsection{Sickle Cell Anemia}\label{sickle-cell-anemia}}

**** See full section below ****

\hypertarget{hemolytic-anemias}{%
\subsubsection{Hemolytic Anemias}\label{hemolytic-anemias}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.15\columnwidth}\raggedright
Smear\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
Coombs\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.15\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Drug-Induced}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Drug induces IgG → cross-reacts w RBCs\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Burr Cells- Schistocytes\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Direct (+)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Cephalosporins, PCNs, Quinidine, NSAIDs, Methyldopa\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Stop drug\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Autoimmune Hemolytic Anemia (AIHA)}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Warm-IgG:}- Primary- Secondary (HIV/EBV, SLE, Drugs (PCN), ALPs/immunodeficiencies, Evans, Transplant, Non-Hodgkin Lymphoma\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Microspherocytes\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
- Direct (+)- IgG +/- C3\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Asymptomatic vs.~life-threatening hemolytic anemia (mainly \textbf{extravascular})- Indirect hyperbilirubinemia, elevated LDH- Splenomegaly- Venous thromboemboli\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- \textbf{1st line:} RBC Transfusion, Prednisone (long taper over \textasciitilde3 mos)- \textbf{2nd line:} Rituximab- \textbf{3rd line:} Immunosuppressants, splenectomy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Cold-IgM:}- EBV (mono), mycoplasma\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Agglutination\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
C3+\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Hemolytic anemia (\textbf{intravascular})- Indirect hyperbilirubinemia, elevated LDH, low haptoglobin- Hemoglobinuria\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- RBC transfusion, once Hb is high enough, give IVF support to protect kidneys- Avoid cold (warmed IVF/blood)- \textbf{2nd line:} Rituximab, plasmapheresis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Paroxysmal Cold Hemoglobinuria (PCH):}- IgG (Donath-Landsteiner Ab)- EBV, mycoplasma\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Spherocytes or bland smear\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Must ask blood bank to look for \textbf{Donath-Landsteiner Ab}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Hemolytic anemia (\textbf{extra/intravascular})- Indirect hyperbilirubinemia, elevated LDH\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- RBC transfusion- Warmed IVF/blood- Keep warm\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Mechanical}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
- \textbf{Microangiopathic:} DIC, TTP,HUS- \textbf{Macroangiopathic:} Kasabach-Merritt Phenomenon, AS, prosthetic valves\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Schistocytes\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Hemolysis + thrombocytopenia- \textbf{DIC:} Fever, hypotension, prolonged PT/PTT, low fibrinogen- \textbf{TTP:} Hemolytic anemia, thrombocytopenia +/- fever, renal insult, and neurologic changes, normal PT/PTT/fibrinogen, low ADAMTS13 activity0 \textbf{HUS:} Hemolytic anemia, thrombocytopenia, fever, bloody diarrhea (E Coli)- \textbf{Atypical HUS:} Hemolytic anemia, thrombocytopenia, fever (stress trigger)\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- \textbf{TTP:} Plasmapheresis- \textbf{Sepsis:} Treat underlying cause\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Hereditary Spherocytosis}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Defect in RBC membrane (vertical interactions, ex/ band 3, ankyrin)\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Spherocytes- +Osm. frag\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- High MCHC- Jaundice/gallstones- Aplastic crisis\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Folic acid- Transfusions PRN- +/- splenectomy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Hereditary Elliptocytosis}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Defect in RBC membrane (horizontal interactions, ex/ spectrin)\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Elliptocytes\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- \textgreater50\% elliptocytes on blood smear- Ranges from clinically silent (no evidence of hemolysis) to chronic hemolytic anemia\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
None to folic acid +/- splenectomy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{G6PD Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
- Oxidants (fava, sulfa, dapsone, INH, quinine) → hemolysis- \textbf{Epidemiology:} Asian, African Am, Middle E.- \textbf{Genetics:} X-linked\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Bite cells- Heinz bodies\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Jaundice, dark urine, back pain\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Avoid oxidants- Transfuse\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Pyruvate Kinase Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
PK is required for RBC glycolysis\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Decreased PK activity\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Mild to severe chronic anemia- Gallstones- Iron overload\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Folic acid- Transfusion- +/- Splenectomy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Paroxysmal Nocturnal Hemoglobinuria}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Complement-mediated intravascular RBC lysis\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Absent CD55/59- Increased LDH\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
- Pancytopenia0 Venous thrombosis (abd/cerebral)- Hemoglobinuria\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
- Eculizumab- Iron/Folate\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\includegraphics{images/hemolytic_anemias_flowchart.png}

\hypertarget{other-normocytic-anemias}{%
\subsubsection{Other Normocytic Anemias}\label{other-normocytic-anemias}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.28\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Smear\strut
\end{minipage} & \begin{minipage}[b]{0.21\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{CKD-related anemia}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
ESRD → EPO deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Normochromic, normocytic\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Side effects of EPO: HTN, HA, flu-like sx\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
EPO/Fe\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Aplastic anemia}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
BM failure\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Pancytopenia\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Pallor/fatigue, infections, bruising\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Treat the underlying condition\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{macrocytic-anemias}{%
\subsubsection{Macrocytic Anemias}\label{macrocytic-anemias}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.28\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Smear\strut
\end{minipage} & \begin{minipage}[b]{0.21\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Folate deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
Alcoholism, AEDs, severe anorexia/dietary limitations\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Megaloblastic macrocytic\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Pallor/fatigue, atrophic glossitis\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
PO folate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{B12 deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
Pernicious, chronic gastritis, malabsorp, parasite (D. latum), severe anorexia/dietary limitations\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
-Megaloblastic macrocytic- Increased methylmalonic acid and homocysteine\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Pallor/fatigue, subacute combined degeneration, atrophic glossitis, dementia\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
- IM/IV B12- High dose PO B12- Anti-IF Abs\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{pediatric-specific-anemias}{%
\subsubsection{Pediatric-Specific Anemias}\label{pediatric-specific-anemias}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.28\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Smear\strut
\end{minipage} & \begin{minipage}[b]{0.21\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Anemia of prematurity}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
Preterm → decr EPO, decr RBC life, incr phlebotomy\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Asymptomatic vs.~tachycardia +/- apnea\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Fe, decreased phlebotomy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Erythro-blastosis}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
ABO set-up/Rh disease, minor blood group antigens\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Jaundice/hyperbili in 1st 24 HOL\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Transfusion, phototherapy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Fanconi}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
AR/XL mutation → aplastic\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Pancytopenia, aplastic\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Short, microcephaly, bent thumb, freckles, café-au-lait, ear abnormalities\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Transfusion +/- SCT\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Diamond-Blackfan}\strut
\end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright
Pure red cell aplasia\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Macrocytic, normal WBC\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Short, web neck, shield chest, cleft lip, triphalangeal thumbs\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Steroids, transfusion\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{newborn-anemia}{%
\paragraph{Newborn Anemia}\label{newborn-anemia}}

!\href{images/newborn_anemias_diagnostic_approach}{}

\hypertarget{sickle-cell-anemia-1}{%
\subsection{Sickle Cell Anemia}\label{sickle-cell-anemia-1}}

\hypertarget{pathophysiology-39}{%
\paragraph{Pathophysiology}\label{pathophysiology-39}}

Autosomal recessive missense mutation (Glu → Val) at position 6 of B-globin gene

\hypertarget{clinical-manifestations-11}{%
\paragraph{Clinical manifestations}\label{clinical-manifestations-11}}

\begin{itemize}
\tightlist
\item
  \textbf{Vaso-occlusive (pain) crisis:} Ischemia → pain

  \begin{itemize}
  \tightlist
  \item
    \emph{Triggers:} Cold weather (vasospasm), hypoxia, infection, dehydration, acidosis, alcohol intoxication, emotional stress, pregnancy, exertional stress
  \item
    \textbf{Bones:} Most commonly long bones like femur, tibia, humerus, and lumbar vertebrae (femoral head → avascular necrosis)
  \item
    \textbf{Joints \& soft tissue:} Dactylitis or hand and foot syndrome - painful and swollen hands/feet
  \item
    \textbf{Abdomen:} Can mimic an acute abdomen
  \item
    \textbf{Renal:} Papillary necrosis → hyposthenuria (inability to concentrate urine)
  \item
    \textbf{Lungs:} Acute chest syndrome
  \item
    \textbf{CNS:} Cerebral infarction, hemorrhage (young adults), seizures, transient ischemic attacks, cranial nerve palsies, meningitis, sensory deficits, and acute coma
  \item
    \textbf{Skin:} Ulceration, especially over bony prominences (malleoli)
  \item
    \textbf{Eye:} Retinal hemorrhages, proliferative retinopathy (more common in HbSC)
  \item
    \textbf{Penis:} Prevents drainage of blood from the corpus cavernosum leading to priapism
  \end{itemize}
\item
  \textbf{Acute chest syndrome (ACS):} Pulmonary infarction → fever, cough, chest pain, SOB, new pulmonary infiltrate on x-ray
\item
  \textbf{Fever:} Viral vs.~bacterial (including encapsulated organisms: H. flu, S. pneumoniae, N. meningitidis)

  \begin{itemize}
  \tightlist
  \item
    Children w/ sickle cell anemia also have lower serum IgM levels, impaired opsonization, and sluggish alternative complement pathway activation, so are susceptible to Mycoplasma pneumoniae, Salmonella, Staphylococcus aureus, and Escherichia coli
  \end{itemize}
\item
  \textbf{Sepsis:} Strep pneumo is most common cause
\item
  \textbf{Hyposplenia:} Splenic autoinfarction → susceptible to infections w/ encapsulated bacteria
\item
  \textbf{Osteomyelitis:} Staph \textgreater{} Salmonella, treat w/ CTX/Vanc
\item
  \textbf{Aplastic crisis:} Decreased retic/RBCs, parvo B19 infection, pallor, weakness, fatigue
\item
  \textbf{Splenic sequestration crisis:} Marked decrease in hemoglobin level despite persistent reticulocytosis, splenic vasoocclusion → rapid splenomegaly, prior to autosplenectomy
\end{itemize}

\hypertarget{diagnosis-4}{%
\paragraph{Diagnosis}\label{diagnosis-4}}

\begin{itemize}
\tightlist
\item
  \textbf{VOE:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Labs:} CBCd (compare to baseline Hb), retics, chem10, LFTs, amylase/lipase, T\&S
  \item
    \textbf{Imaging:} CXR PA \& lateral for fever, chest wall pain, hypoxia, or respiratory symptoms
  \end{itemize}
\item
  \textbf{Fever:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Labs:} CBCd (compare to baseline Hb), retics, chem10, LFTs, amylase/lipase, T\&S, BCx (for 1st temp \textgreater38.5C or 101.3F) and qdaily w/ temp spikes, ABG if hypoxic
  \item
    \textbf{Other studies:} UA/UCx (cath all M \textless6mo, F \textless2yo, or any child w/ urinary sx), viral panel, throat culture (if suggestive on exam), stool studies (if having diarrhea), LP (if neurologic s/sx)
  \item
    \textbf{Imaging:} CXR PA \& lateral (if fever, chest wall pain, hypoxia, respiratory symptoms)
  \end{itemize}
\end{itemize}

\hypertarget{management-42}{%
\paragraph{Management}\label{management-42}}

See sections below on \textbf{VOE, ACS,} and \textbf{fever}

\hypertarget{vaso-occlusive-episode-voe}{%
\subsubsection{Vaso-Occlusive Episode (VOE)}\label{vaso-occlusive-episode-voe}}

\textbf{\emph{\emph{BMC Sickle Cell Cards:}}} NOTE practices may vary at BCH. Should not replace clinical judgment or Pedi Heme consult (place consult order in EPIC and page on-call pager 5731); please page daily after rounds to discuss management as needed, and read daily consult note for detailed recommendations.

\includegraphics{images/heme_bmcvoecard_1.png}
\includegraphics{images/heme_bmcvoecard_2.png}

\textbf{\emph{\emph{THE INFORMATION BELOW IS APPLICABLE TO BOTH BMC \& BCH:}}}

\hypertarget{fluids-monitoring-labs}{%
\paragraph{Fluids, Monitoring, \& Labs}\label{fluids-monitoring-labs}}

\begin{itemize}
\tightlist
\item
  Hydration: D5 1/2NS or D5 NS @ 1.25x maintenance is crucial to lessen sickling
\item
  Continuous pulse oximetry
\item
  Routine labs are not needed for uncomplicated VOE
\item
  DVT prophylaxis should be addressed for all patients per inpatient protocol
\end{itemize}

\hypertarget{pain-management}{%
\subparagraph{Pain Management}\label{pain-management}}

\begin{itemize}
\tightlist
\item
  \textbf{Non-opioid analgesics:}

  \begin{itemize}
  \tightlist
  \item
    Standing NSAID: \textbf{Ketorolac} on admission if proven benefit; after 72 hrs switch to standing ibuprofen q6h
  \item
    Additional modalities: \textbf{Ketamine} (refer to Lexicomp for dosage), hot packs, lidocaine patch, distraction, Child Life, relaxation, acupuncture
  \end{itemize}
\item
  \textbf{Opioids:}

  \begin{itemize}
  \tightlist
  \item
    Management and prevention of opioid \textbf{side effects:}

    \begin{itemize}
    \tightlist
    \item
      \textbf{Constipation:} Standing stimulant laxative (senna) and daily Miralax w/ admit. Titrate for 1 soft formed stool q1-2d. Escalate PRN, may add Mg citrate, milk of magnnesia, lactulose, methylnaltrexone.
    \item
      \textbf{Pruritus and nausea:} Start w/ camphor-menthol lotion for mild itching. Next step is a naloxone drip at 0.5 mcg/kg/h, titrate up to 2 mcg/kg/h q3-4h for significant itching/nausea. Can then add Zofran. Avoid Benadryl given the sedating effect.
    \item
      \textbf{Prevent hypoventilation:} Crucially important in preventing atelectasis and ACS! Incentive spirometer 10x/hr while awake and q4h overnight. Bubbles or pinwheel in younger kids. HOB elevated to 30 degrees at all times. Have patient sit up in bed, out of bed to chair, and ambulation as tolerated. Standing albuterol q4-6h for pt w/ asthma, history of wheeze w/ prior VOE, chest or back pain, or any current wheezing or cough. Oxygen overnight PRN (goal O2 sat \textgreater{} 95\% or pt's known baseline; can provide NC O2 at 0.5-1L for mild desats while asleep; does not replace the need for incentive spirometry). Continue any home respiratory therapies (home O2, CPAP, etc).
    \end{itemize}
  \item
    \textbf{Titration of PCA/opioids:}

    \begin{itemize}
    \tightlist
    \item
      Use patient reported pain score (compare to baseline/chronic pain level) AND change in pain AND patient functional status to assess pain control
    \item
      Assess for VOE vs.~opioid side effects to help w/ dose adjustment
    \item
      Reassess pain control frequently, especially during first 24 hrs, and adjust PCA as needed w/ goal of providing 2/3 of total opioid dose as basal and 1/3 as demand
    \item
      Consider increasing basal rate by 20\% overnight early in the admission to avoid falling behind in pain control while asleep
    \item
      As pain is captured, wean PCA rate and then switch to orals
    \end{itemize}
  \item
    \textbf{Weaning to orals:} Please discuss patient specific plan w/ Pedi Heme; details will depend on length of admission, pain tolerance, and patient preference. In general, when pain is well-controlled, replace the basal PCA w/ SCHEDULED long- or short-acting oral medication (MS Contin, oxycodone, or hydromorphone), leaving the PCA demand button. If pain remains well-controlled after 12-24 hrs, then replace PCA demand w/ a standing short-acting medication (often oxycodone, tramadol, or hydromorphone). This step should be considered both a conversion and a wean.

    \begin{itemize}
    \tightlist
    \item
      \textbf{Quick conversion from IV to oral opiates} (meant as a guide, not a mandate):
    \end{itemize}
  \end{itemize}
\end{itemize}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.30\columnwidth}\raggedright
Total Basal IV morphine use over 24 hours\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Total Basal IV dilaudid use over 24 hours\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
MSContin dose\strut
\end{minipage} & \begin{minipage}[b]{0.18\columnwidth}\raggedright
If using ONLY oxycodone\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.30\columnwidth}\raggedright
10mg\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
2.5mg\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
15mg PO q12\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
5mg PO q6\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
15mg\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
4mg\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
15mg PO q8\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
5mg PO q4\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
20mg\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
5mg\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
30mg PO q12\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
10mg PO q6\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
30mg\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
8mg\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
30mg PO q8\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
10mg PO q4\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{discharge-planning}{%
\paragraph{Discharge planning}\label{discharge-planning}}

\begin{itemize}
\tightlist
\item
  Ready for discharge when pain is controlled on oral meds (pain may not be gone at this time)
\item
  Continue standing pain meds x48hrs at home before tapering to PRN
\item
  Anticipate home opioid needs; ask if opioids are available at home, and prescribe meds-in-hand early on day of discharge. If patient prefers to fill meds at home pharmacy, provide Rx early in hospital course (controlled substance prescriptions can now be faxed or sent electronically). Be aware of specific MA prescribing requirements for opioids.
\item
  Schedule follow-up in Heme clinic w/i 1 week (BMC clinic phone \# 617-414-4841), appointments are available everyday Mon-Fri
\end{itemize}

\hypertarget{acute-chest-syndrome-acs}{%
\subsubsection{Acute Chest Syndrome (ACS)}\label{acute-chest-syndrome-acs}}

ACS in SCD is multifactorial. Causes include \textbf{infection, bronchospasm, inflammation,} and \textbf{fat embolization.} It can be very serious and needs to be managed very closely.

\hypertarget{optimize-ventilation}{%
\paragraph{Optimize ventilation}\label{optimize-ventilation}}

to prevent serious sequelae from ACS:

\begin{itemize}
\tightlist
\item
  Incentive spirometry 10x per hour while awake and q4h overnight
\item
  Have patient sitting up in bed, out of bed to chair, and ambulation as tolerated
\item
  Examine patients for any drop in O2 saturation --- do NOT simply put on oxygen w/o evaluating
\item
  Standing albuterol neb q4-6h for those patients with known benefit, people with a history of reactive airway, asthma, wheeze on clinical exam. Add inhaled corticosteroid only if on one at home
\item
  Consult Pulm for any patient w/ wheezing, severe ACS, or as needed to help optimize respiratory status; please notify Pulm when of their patients are admitted w/ ACS
\item
  Consider high flow NC or BIPAP as appropriate (requires ICU transfer)
\end{itemize}

\hypertarget{fluid-balance}{%
\paragraph{Fluid balance}\label{fluid-balance}}

needs to be monitored carefully:

\begin{itemize}
\tightlist
\item
  Patients w/ SCD require increased IVF in cases of VOE or fever/dehydration. However, overhydration can worsen ACS.
\item
  In general, use IV + PO at 1x maintenance for patients w/ ACS
\item
  Must have strict I/O's ordered and reviewed regularly to adjust fluids as needed
\end{itemize}

\hypertarget{other-monitoring-labs}{%
\paragraph{Other monitoring \& labs}\label{other-monitoring-labs}}

\begin{itemize}
\tightlist
\item
  Continuous pulse oximetry
\item
  All patients w/ ACS should have an active \textbf{type \& screen}
\item
  \textbf{DVT prophylaxis} should be addressed for all patients per inpatient protocol
\end{itemize}

\hypertarget{antibiotics}{%
\paragraph{Antibiotics}\label{antibiotics}}

should include coverage for pneumococcus and atypicals (typically ceftriaxone and oral azithromycin):

\begin{itemize}
\tightlist
\item
  See Fever guidelines below for details
\end{itemize}

\hypertarget{transfusions}{%
\paragraph{Transfusions}\label{transfusions}}

must be approved by Heme:

\begin{itemize}
\tightlist
\item
  Need to balance need for immediate treatment w/ long term risks of alloimmunization
\item
  If the patient does not have an O2 requirement, we typically attempt medical management w/ abx and aggressive pulmonary toilet for 24hrs before transfusing
\item
  Potential indications for transfusion in ACS include a drop in Hb \textgreater{} 2g/dL below baseline w/o appropriate reticulocytosis, a significant oxygen requirement, or worsening work of breathing
\item
  See Blood Transfusions section below for details
\end{itemize}

\hypertarget{discharge-planning-1}{%
\paragraph{Discharge planning}\label{discharge-planning-1}}

\begin{itemize}
\tightlist
\item
  Stable for discharge when BCx are negative x48hrs and respiratory status is stable/improved
\item
  Should complete a full course of antibiotics to cover both pneumococcus and atypicals
\item
  Schedule follow-up w/ PCP w/o the week and in Heme clinic preferably w/i a week (BMC clinic phone \# 617-414-4841), appts at BMC are available every day Mon-Fri
\item
  At BMC, please refer to Pulm for outpatient follow-up (referral for ``SCD w/ ACS'')
\end{itemize}

\hypertarget{fever}{%
\subsubsection{Fever}\label{fever}}

\hypertarget{definition-39}{%
\paragraph{Definition}\label{definition-39}}

T \textgreater38.5C (101.3F) if \textgreater2mo

\hypertarget{work-up-36}{%
\paragraph{Work-up}\label{work-up-36}}

\begin{itemize}
\tightlist
\item
  Detailed history and physical exam to identify potential source
\item
  \textbf{Labs:} CBCd (compare to baseline Hb), retics, chem10, clot (hold for Blood Bank), BCx (for 1st temp \textgreater38.5C (101.3F) and qdaily w/ temp spikes), ABG (if hypoxic)
\item
  \textbf{Other studies:} UA/UCx (cath all M \textless6mo, F \textless2yo, or any child w/ urinary sx), viral panel, throat culture (if suggestive on exam), stool studies (if having diarrhea), LP (if neurologic s/sx)
\item
  \textbf{Imaging:} CXR PA \& lateral (if fever, chest wall pain, hypoxia, respiratory symptoms)
\end{itemize}

\hypertarget{management-43}{%
\paragraph{Management}\label{management-43}}

\begin{itemize}
\tightlist
\item
  \textbf{Inpatient} management:

  \begin{itemize}
  \tightlist
  \item
    IV bolus of 10 - 20 ml/kg if dehydrated→ IV fluids @ 1.25 Maint (+/- for fluid intolerance vs.~dehydration)
  \item
    \textbf{Antibiotics:} Goal administration w/i 30 min of arrival! Draw cultures first. Do not delay treatment while awaiting lab results and CXR. Needs empiric antibiotics even if a source of infection is identified.

    \begin{itemize}
    \tightlist
    \item
      \textbf{Ceftriaxone} 50 mg/kg IV/IM q24h (max dose 1g/day), q12h (max 2g/day) if suspect meningitis. If allergic to Ceftriaxone, consider Levofloxacin or Clindamycin if inpatient.
    \item
      Add \textbf{Vancomycin} 40-60 mg/kg/day divided q6h for CNS involvement (including meningitis), septic shock, central line/port, or hx of resistant infection
    \item
      For HD instability or meningitis; consider in pts w/ port or hx of resistant infection
    \item
      Add \textbf{Azithromycin} PO for pts w/ positive CXR or respiratory symptoms
    \end{itemize}
  \end{itemize}
\item
  \textbf{Outpatient} management and follow-up:

  \begin{itemize}
  \tightlist
  \item
    Observe in ED for 2 hrs after giving CTX. \textbf{Return if:} Temp \textgreater38.5C; poor PO intake; lethargy; respiratory symptoms; pain.
  \item
    Follow up in Hematology clinic, PCP's office, or ED in 24 hours for re-evaluation \& 2nd dose of CTX
  \item
    Follow up BCx at 24 and 48 hrs → call PCP regarding ED visit \& to assure follow up
  \end{itemize}
\end{itemize}

\hypertarget{blood-transfusions-in-scd}{%
\subsubsection{Blood Transfusions in SCD}\label{blood-transfusions-in-scd}}

Blood transfusions in SCD are used to increase RBC mass and oxygen carrying capacity and to decrease proportion of sickle cells. Acute benefits of transfusion must be weighed against the long-term risks, including alloimmunization. Phenotypically matched (ABO, Rh-D, Kell, C, E), sickle negative, leuko-depleted irradiated packed red blood cells are the blood product of choice. More extensive phenotyping needed for patients on chronic transfusion. It may take hours for the blood bank to find matched blood, and even longer in cases of alloimmunization so maintain an active type and screen if you anticipate needing to transfuse a patient.

\hypertarget{potential-indications-for-transfusion}{%
\paragraph{Potential indications for transfusion}\label{potential-indications-for-transfusion}}

\begin{itemize}
\tightlist
\item
  Aplastic crisis/acute anemia (drop in Hb \textgreater{} 2g/dL below baseline) w/o an appropriate reticulocytosis
\item
  Acute chest syndrome (ACS) not responsive to medical management or severe disease/ hypoxemia
\item
  Symptomatic anemia
\item
  Pre-procedure prophylaxis (goal Hb of 10 g/dL)
\item
  Splenic sequestration:
\item
  Hb drop \textgreater{} 2g/dl, drop in platelet count and WBC as well
\item
  Monitor spleen size and labs frequently
\end{itemize}

\hypertarget{amount-of-blood-to-transfuse}{%
\paragraph{Amount of blood to transfuse}\label{amount-of-blood-to-transfuse}}

based on goal Hb:

\begin{itemize}
\tightlist
\item
  mL of pRBC = (desired Hb - current Hb) x (wt (kg) x Blood Vol(ml/kg)) /(Hb of PRBC)
\item
  Blood volume = 80mL/kg for children
\item
  Hb of pRBCs = 18.5g/dL at BMC, avg HCT 60\% at BCH
\item
  1 unit pRBC = 250-350 mL; consider rounding down to a whole unit to avoid extra donor exposure
\end{itemize}

\hypertarget{other-considerations}{%
\paragraph{Other considerations}\label{other-considerations}}

\begin{itemize}
\tightlist
\item
  Premedicate only if history of transfusion reaction
\item
  Need for post-transfusions labs to be dictated by individual case
\end{itemize}

\hypertarget{transfusion-medicine}{%
\subsection{Transfusion Medicine}\label{transfusion-medicine}}

\hypertarget{consenting-a-patient-for-blood-products}{%
\subsubsection{Consenting a Patient for Blood Products}\label{consenting-a-patient-for-blood-products}}

\hypertarget{risks}{%
\paragraph{Risks}\label{risks}}

\begin{itemize}
\tightlist
\item
  Fever, chills, hives/itching, and shortness of breath (can be managed w/ medications)
\item
  Hemolytic transfusion reaction or transfusion-related lung injury (rare)
\item
  Bacterial or viral infection (hepatitis C, hepatitis B, HIV, malaria). Blood is extensively screened to prevent this.
\end{itemize}

\hypertarget{benefits}{%
\paragraph{Benefits}\label{benefits}}

Improve blood clotting or oxygen delivery

\hypertarget{alternatives-may-not-work-as-quickly}{%
\paragraph{Alternatives (may not work as quickly)}\label{alternatives-may-not-work-as-quickly}}

\begin{itemize}
\tightlist
\item
  Colony stimulating factor
\item
  Vitamin K
\item
  No treatment (note: parents may not refuse blood products in life-threatening situations)
\end{itemize}

\hypertarget{acute-transfusion-reactions}{%
\subsubsection{Acute Transfusion Reactions}\label{acute-transfusion-reactions}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.10\columnwidth}\raggedright
Time\strut
\end{minipage} & \begin{minipage}[b]{0.29\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Anaphylactic}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Sec-Mins\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
IgA def → anti-IgA/IgG Abs\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Shock, urticaria, angioedema, hypoTN\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
EPI, IVF, O2 Washed RBCs\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Within mins\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
IgE-mediated, bradykinin-med if ACEi\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
HoTN, wheeze, N/V/D\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
ABCs, Epi, Benadryl\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Urticarial}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Anytime\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
Type I HSR (IgE mediated)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Hives, erythema\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Benadryl, Wash\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Acute Hemolytic}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
First 15 mins\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
ABO/Kidd incomp.→ hemolysis/comp activ. Rh/Kell/Duffy incompatibility → hemolysis +Coombs, Pink plasma\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Fevere, chills, back or flank pain, bleeding/DIC\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
NS/Lasix Monitor for HoTN, AKI/DIC\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Febrile non-hemolytic}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
1-6 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
Donor WBCs → TNF-alpha, IL 1 / 6 RBC: anti-HLA Plt: donor WBC cytokines\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Low grade fever, chills, HA, flushing\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
APAP, meperidine Leukoreduction\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Delayed hemolytic}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
\textgreater3 days\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
Anamnestic IgG against exposed Ag (Kidd/Duffy/Kell) → extravasc. hemolysis\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Fever, anemia, jaundice, flu-like illness\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
R/O AIHA (+DAT)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Transfusion-related lung injury (TRALI)}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
1-6 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
Pre-Tx stress activates lung endothelial cells and primes PNMs Post-Tx donor anti-HLA Ab → primed PMNs\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Fever, SpO2 \textless90\%, PaO2/FiO2 \textless300 B/l pulm edema\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
ABCs, O2, mech vent. Dec.~in male donor\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Transfusion-Assoc. Circ Overload (TACO)}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
1-6 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
High risk in elderly, CHF, CKD, chronic anemias\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Cardiogenic edema → dyspnea, hypoxemia\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Stop, sit up , O2, diuretics, slower rate (1 cc/kg/hr)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Bacterial sepsis}\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
15-60 mins\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
Bacteria \textgreater\textgreater{} Viruses in donor blood RBC: Yersinia, PsA, Plt: Staph epi (GPCs)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Fever (\textgreater39), rigors, abd sxs, HoTN, shock\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Antibiotics Screen\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{specialized-rbcs}{%
\paragraph{Specialized RBCs}\label{specialized-rbcs}}

\begin{itemize}
\tightlist
\item
  \textbf{Irradiated:} BMT recipients, acquired congenital cellular immunodeficiency, blood from 1st/2nd degree relatives
\item
  \textbf{Leuko-reduced:} Chronic transfusion, CMV seronegative at-risk pts (AIDS, transplant), potential transplant candidates, previous febrile nonhemolytic transfusion reaction
\item
  \textbf{Saline Washed:} IgA deficiency, Complement-dependent AIHA, allergic reactions w/ RBC transfusion
\end{itemize}

\hypertarget{transfusion-products}{%
\subsubsection{Transfusion Products}\label{transfusion-products}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.12\columnwidth}\raggedright
Component\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
Contents\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
Volume\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
Indications\strut
\end{minipage} & \begin{minipage}[b]{0.21\columnwidth}\raggedright
Contraindications\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Considerations\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Red Blood Cells (RBC)}\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Concentrated RBCs\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
200-300 mL\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Symptomatic anemia (Hgb \textless7 g/dL); Acute hypovolemia due to hemorrhage\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Pharmacologically treatable anemia (eg. iron, folate, B12 deficiencies)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Must be ABO compatible, cross-match compatible Infuse w/in 4 hr or as patient tolerates\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Platelets (PLT)}\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
\textgreater5.5×10\^{}10 PLT per 50 ml\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
60 mL\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Bleeding related to thrombocytopenia or PLT dysfunction; Low PLT count\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Patients w/ TTP, HUS or HIT; Not as effective in ITP, DIC, sepsis, uremia, hypersplenism\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ABO and Rh compatible w/ patient's RBC if possible Infuse 5-10 mL/min or as tolerated, usually w/in 1 hour\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Leukocyte reduced RBC or PLT}\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
RBC or PLT w/ WBC: \textless5×10\^{}6\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Similar to original\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
RBC/PLT indications plus history of febrile transfusion reactions; At risk of CMV and alloimmunization\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
See RBC or PLT\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
See RBC or PLT\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Cryo-precipitate (Cryo)}\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
80-120 units Factor VIII; 150-250 mg Fibrinogen\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
25 mL 40-70\% orig. plasma VWF\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Fibrinogen deficiency or dysfunction\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Safer and more concentrated therapy available (ie, for specific clotting factors)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Consider alternative therapies for specific factor deficiencies Should be ABO compatible if possible\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Fresh frozen plasma (FFP)}\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
400 mg fibrinogen and 200 units of other clotting factors\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
200-250 mL\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Clotting factor def. (if specific factor conc. not avail.), lg volume required Severe liver disease Rapid warfarin reversal Vit K def w/ active bleed TTP/DIC: massive crystalloid + RBC transf. w/ ongoing bleeding C1 esterase inhib def.\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
Safer and more concentrated therapy available (ie, for specific clotting factors)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Should be ABO compatible Infuse 5-10 mL/min or as the patient tolerates Give 10-15 cc/kg\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{pancytopenia}{%
\subsection{Pancytopenia}\label{pancytopenia}}

\hypertarget{marrow}{%
\subsubsection{Marrow}\label{marrow}}

Decreased cellularity (aplastic, myelofibrosis, chemo), normal cellularity (MDS, PNH), increased cellularity (leukemia, lymphoma, MM, mets)

\hypertarget{systemic}{%
\subsubsection{Systemic}\label{systemic}}

Spleen (cirrhosis, myelofibrosis), toxin (EtOH, cocaine), nutrition (B12/folate def), rheum (SLE, RA), sepsis

\hypertarget{meds}{%
\subsubsection{Meds}\label{meds}}

NSAIDs, PPIs, sulfas, antihistamine, chemo, anticonvulsants, antiprotozoals, heavy metals

\hypertarget{infectious}{%
\subsubsection{Infectious}\label{infectious}}

Virus (HIV, HB/CV, CMV/EBV, Parvo), bacteria (Brucella, TB), fungi (Histo), parasites (Leishmania, Malaria, Schisto)

\hypertarget{thrombocytopenia}{%
\subsection{Thrombocytopenia}\label{thrombocytopenia}}

\hypertarget{definition-40}{%
\paragraph{Definition}\label{definition-40}}

Platelets \textless150,000 → increased risk of hemorrhage, mucosal bleeding, petechiae, purpura, ecchymoses

\hypertarget{pathogenesis-8}{%
\paragraph{Pathogenesis}\label{pathogenesis-8}}

\begin{itemize}
\tightlist
\item
  \textbf{Decreased platelet production:} Virus (EBV, Hep C, HIV, parvo), meds (chemo, thiazide, linezolid, chloramphenicol), leukemia, myelodysplasia, EtOH, BMF syndromes/aplastic anemia, Vit B12/Folate deficiency, congenital thrombocytopenias (WAS, TAR, MYH9)
\item
  \textbf{Increased platelet destruction:} Virus (HIV, HSV/VZV, EBV), meds (heparin), ITP, DIC, TTP, HUS, HIT, HELLP, antiphospholipid syndrome, vasculitis, vascular anomaly (Kasabach-Merritt)
\item
  \textbf{Hypersplenism:} Splenomegaly (cirrhosis, portal HTN) -Dilutional/pooling: massive transfusion, hypothermia/neonatal cooling
\end{itemize}

\hypertarget{labs-3}{%
\paragraph{Labs}\label{labs-3}}

\begin{itemize}
\tightlist
\item
  Plts \textless150,000, normal PT/PTT
\item
  \textbf{Blood smear:} Poor production (typically normal/small plts), increased destruction (large/giant platelets)
\end{itemize}

\hypertarget{causes}{%
\subsubsection{Causes}\label{causes}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.09\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.32\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.23\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{ITP (immune thrombocytopenic purpura)}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
\textbf{Autoimmune:} Primary or secondary (Evans, immunodeficiency (ALPs, others), infectious (HIV, Hep), rheum (SLE), transplant, medications/vaccines)\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- Plt \textless100,000- Antecedent viral infection- Diagnosis of exclusion\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
- Generally self-limited- Close observation- Steroids, IVIG, TPO-RA, immunosuppressants\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{HIT (heparin-induced thrombocytopenia)}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Heparin → forms complex w/ Plt F4-\textgreater{} immune complex formation → Plt activation/aggreg → thrombosis/thrombocytopenia\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Decision to screen based on 4T Score (if \textgreater4 poinnts, send ELISA/SRA):- Thrombocytopenia (\textgreater50\% fall but \textgreater20)- Timing of plt fall- Thrombosis or skin necrosis- Other causes\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
- Stop heparin- Lifelong avoidance. Use argatroban, fondaparinux instead.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{TTP (thrombotic thrombocytopenic purpura)}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
- Decreased ADAMTS 13 (uncleaved vWF multimers) → plt aggregation → thrombosis → plt consumption + microangiopathic hemolysis (schistocytes)- Primary or Secondary (pregnancy, HIV, rheumatologic dx, transplant)- Congenital TTP can present late\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Hemolytic Anemia and thrombocytopenia, +/- renal failure, and neuro\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
Plasmapheresis, +/- glucocorticoids, +/- Rituximab\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Classic HUS (hemolytic uremic syndrome)}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
E. coli O157:H7 → plt aggregation → thrombosis → plt consumption + microangiopathic hemolysis (schistocytes)\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Hemolysis, uremia, decreased plts, inc, fever, bloody diarrhea\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
Supportive, IVF, dialysis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Bernard-Soulier}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Decreased GpIb → dec. plt adhesion\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Large/decreased plt count\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
Supportive, perisurgical planning\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Glanzmann}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Decreased GpIIb/IIIa → dec. plt agg\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Normal plt count\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
Supportive, perisurgical planning\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Antiphospholipid syndrome (APLS)}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Persistent Antiphospholipid Abs w/ thrombosis (arterial or venous) or pregnancy complications → arterial/venous thrombosis (X2 \textgreater12 weeks apart)\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- +Antiphos. Abs (anticardiolipin Ab, B2 Glycoprotein Ab, Lupus Anticoagulant), thrombocytopenia- Primary or secondary (underlying rheumatologic dx)\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
- Anticoagulate: LMWH or warfarin for ATE or VTE treatment- Hydroxychloroquine\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{HELLP syndrome}\strut
\end{minipage} & \begin{minipage}[t]{0.32\columnwidth}\raggedright
Preeclampsia (HTN) + \textbf{\emph{H}}emolysis, \textbf{\emph{E}}levated \textbf{\emph{L}}iver enzymes, \textbf{\emph{L}}ow \textbf{\emph{P}}lts\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Schistocytes on smear\strut
\end{minipage} & \begin{minipage}[t]{0.23\columnwidth}\raggedright
Induce labor, deliver\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{hematologic-disorders-of-the-newbornchild}{%
\subsection{Hematologic Disorders of the Newborn/Child}\label{hematologic-disorders-of-the-newbornchild}}

\hypertarget{anemia-of-prematurity}{%
\subsubsection{Anemia of Prematurity}\label{anemia-of-prematurity}}

\hypertarget{pathogenesis-9}{%
\paragraph{Pathogenesis}\label{pathogenesis-9}}

Impaired EPO production; shortened RBC life; iatrogenic blood loss

\hypertarget{clinical-manifestations-12}{%
\paragraph{Clinical manifestations}\label{clinical-manifestations-12}}

Asymptomatic, apnea, poor weight gain, tachycardia

\hypertarget{diagnosis-5}{%
\paragraph{Diagnosis}\label{diagnosis-5}}

Hb/Hct, retic, smear

\hypertarget{management-44}{%
\paragraph{Management}\label{management-44}}

Decrease phlebotomy, iron supplementation, transfusions

\hypertarget{transient-erythroblastopenia-of-childhood}{%
\subsubsection{Transient Erythroblastopenia of Childhood}\label{transient-erythroblastopenia-of-childhood}}

\hypertarget{pathogenesis-10}{%
\paragraph{Pathogenesis}\label{pathogenesis-10}}

Acquired red cell aplasia (6mo - 5yr)

\hypertarget{clinical-manifestations-13}{%
\paragraph{Clinical manifestations}\label{clinical-manifestations-13}}

Gradual pallor, fatigue

\hypertarget{diagnosis-6}{%
\paragraph{Diagnosis}\label{diagnosis-6}}

Normocytic/normochromic anemia, Hb (3-8), retic

\hypertarget{management-45}{%
\paragraph{Management}\label{management-45}}

Self-resolving

\hypertarget{neonatal-polycythemia}{%
\subsubsection{Neonatal Polycythemia}\label{neonatal-polycythemia}}

\hypertarget{pathogenesis-11}{%
\paragraph{Pathogenesis}\label{pathogenesis-11}}

Erythropoiesis from intrauterine hypoxia. Risk factors: IUGR, maternal DM/HTN, smoking, delayed cord clamping, twin-twin transfusion.

\hypertarget{clinical-manifestations-14}{%
\paragraph{Clinical manifestations}\label{clinical-manifestations-14}}

Ruddy skin, hypoglycemia, resp distress, cyanosis, apnea

\hypertarget{diagnosis-7}{%
\paragraph{Diagnosis}\label{diagnosis-7}}

Hct \textgreater65\% in FT infant

\hypertarget{management-46}{%
\paragraph{Management}\label{management-46}}

If asymptomatic → hydration/feeding. If symptomatic → partial exchange transfusion.

\hypertarget{coagulation-disorders}{%
\subsection{Coagulation Disorders}\label{coagulation-disorders}}

\emph{Characterized by coagulopathy and/or hypercoagulability}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.06\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.33\columnwidth}\raggedright
Pathophysiology\strut
\end{minipage} & \begin{minipage}[b]{0.26\columnwidth}\raggedright
Clinical/Dx\strut
\end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{VWD (von nwillebrand deficiency)}\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
AD/AR def. of VWF → abnormal mucocutaneous bleeding\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Bruising, mucosal bleeding, menorrhagia- VWF Ag and Activity low, may have decreased FVIII activity and prolonged PTT\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- \textbf{Bleed:} DDAVP (if responder)- \textbf{Severe bleed:} VWF conc.- \textbf{Menorrhagia:} OCPs- Avoid aspirin use\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Hemophilia}\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- X-linked inheritance- \textbf{Hemophilia A:} Factor VIII deficiency- \textbf{Hemophilia B:} Factor IX deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Hemarthrosis, ICH, mucosal bleeding, epistaxis, occasional hematuria, GI bleed- Prolonged PTT, decreased FVIII or FIX activity; PT and plt wnl\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- \textbf{Hemophilia A:} FVIII concentrate (DDAVP for most mild pts)- \textbf{Hemophilia B:} FIX concentrate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Vitamin K deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Decreased synthesis of FX, IX,VII, II, Protein C, S- \textbf{Epidemiology:} Neonates, antibiotics, malabsorption (pancreatitis, celiac, IBD), warfarin use\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Easy bruising, mucosal bleeding, melena, hematuria, ICH (newborns)- Prolonged PT and PTT\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- Vit K (PO or IM)- \textbf{Acute bleed:} FFP or PCC\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{DIC (disseminnnated intravascular coagulation)}\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Widespread pathologic intravascular coagulation → plt/factor consumption, hemolysis- Causes: STOP Making Thrombi (\textbf{\emph{S}}epsis, \textbf{\emph{T}}rauma, \textbf{\emph{O}}B complications, \textbf{\emph{P}}ancreatitis, \textbf{\emph{M}}alignancy, \textbf{\emph{T}}ransfusion)\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
- Bleeding from wound/surgical site, hemoptysis, venous/arterial thrombosis → organ ischemia, hypoTN, jaundice, ext. cyanosis- Decreased Plts, fibrinogen, haptoglobin- Increased PT/PTT, D-Dimer, LDH\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
- Treat underlying cause- Aggressive support- Acute bleed: Plt transfusion + FFP +/- RBC transfusion\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Inherited hypercoagulable states}\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\textbf{Factor V Leiden}\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Reduced factor V inactivation by protein\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
Lifelong anticoagulation in the setting of homozygous inheritance and prior VTE\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\textbf{Prothrombinn 20210 mutation}\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Increased prothrombin levels\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\textbf{Antithrombin deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Reduced inactivation of factor 2 (thrombin)\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\textbf{Protein C or S deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Reduced factor 5 / 8 inactivation, purpura fulminans w/ homozygous protein C deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\includegraphics{images/bleeding_dx_coags.png}

\hypertarget{antiplatelet-anticoagulant-medications}{%
\subsection{Antiplatelet / Anticoagulant Medications}\label{antiplatelet-anticoagulant-medications}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.22\columnwidth}\raggedright
Medication\strut
\end{minipage} & \begin{minipage}[b]{0.09\columnwidth}\raggedright
MOA\strut
\end{minipage} & \begin{minipage}[b]{0.33\columnwidth}\raggedright
Monitor/Reversal\strut
\end{minipage} & \begin{minipage}[b]{0.25\columnwidth}\raggedright
Side Effects\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Aspirin (ASA)}\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Irreversibly inhibits COX → blocks production of Thromboxane A2 → blocks plt aggregation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
GI bleed, hyperventilation (resp alkalosis), tinnitus, Reye Syndrome\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Clopidogrel}\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Inhibits plt ADP receptors → blocks GPIIb/IIIa expression → blocks plt aggregation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
GI bleed\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Abciximab, Eptifatide}(GP IIb/IIIa inhibitors)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Binds plt GP IIb/IIIa → blocks plt aggregation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
GI bleed, N/V, back pain\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Aggrenox}\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Inhibits platelet cAMP phosphodiesterase → increases adenosine/cAMP → vasodilation \& decreases plt aggregation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Dizziness, headache, nausea\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Heparin}(continuous infusion)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Binds/activates antithrombin → inactivates thrombin/FXa → inhibits coagulation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- anti-Xa (goal 0.3-0.7)- Protamine sulfate (100\%)\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
HIT, hypersensitivity, narrow therapeutic window\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Enoxaparin, Dalteparin}(LMWH, SQ injection)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Binds antithrombin → inactivates FXa→ inhibits coagulation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- anti-Xa (goal: 0.5-1)- Protamine sulfate (60\%)\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
HIT (rare)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Fondaparinux}(direct factor Xa inhibitor, SQ injection)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Binds antithrombin → inactivates FXa → inhibits coagulation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Not routine, antiXa- No antidote\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
No risk of HIT (b/c does not bind PF4)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Rivaroxiban, Apixiban, Edoxaban}(direct factor Xa inhibitors, PO)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Binds FXa → inhibition activation of FII (prothrombin→ thrombin)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Not routine, Andexanet alfa (severe/life-threatening bleeding)\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Bleeding\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Dabigatran}(PO)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Direct thrombin (factor II) inhibitor\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Not routine, Idarucizumab (severe/life-threatening bleeding)\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Bleeding\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Argatroban, Bicalirudin}(continuous infusion)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Direct thrombin inhibitor. Binds thrombin → inhibits coagulation\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
- Check LFTs prior to starting- Check PTT 2 hrs after initiation and 2 hrs after any dose change (goal PTT 1.5-3x baseline)\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Hemorrhage, hypotension\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Warfarin}(PO)\strut
\end{minipage} & \begin{minipage}[t]{0.09\columnwidth}\raggedright
Inhibits epoxide reductase → inhibits Vit. K-dependent clotting factors: 2,7,9,10, protein C/S\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
INR / Start IV Vit K, FFP q4, Kcentra (if severe bleeding)\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Bleeding, teratogen, drug-induced interactions (cyt p450), skin necrosis\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{references-5}{%
\subsection{References}\label{references-5}}

\hypertarget{infectious-diseases}{%
\section{Infectious Diseases}\label{infectious-diseases}}

\hypertarget{antibiogram}{%
\subsection{\texorpdfstring{\href{https://bchfit.tch.harvard.edu/}{Antibiogram+}}{Antibiogram+}}\label{antibiogram}}

The \href{https://bchfit.tch.harvard.edu/}{Antibiogram+} website (also available as a phone app) is an excellent resource that contains \href{https://bchfit.tch.harvard.edu/susceptibilityMatrix}{Antibiotic Susceptibilities} matrices (typically referred to as ``the antibiogram(s)''), \href{https://bchfit.tch.harvard.edu/diagnoses}{Antibiotic Recommendations} for commonly encountered diagnoses, and \href{https://bchfit.tch.harvard.edu/dosingGuidelines}{Dosing Quick References} (although you can also always use Lexicomp for this purpose).

\hypertarget{antibiotic-susceptibilities-for-common-pathogens}{%
\subsection{\texorpdfstring{\href{https://bchfit.tch.harvard.edu/susceptibilityMatrix}{Antibiotic Susceptibilities} for Common Pathogens}{Antibiotic Susceptibilities for Common Pathogens}}\label{antibiotic-susceptibilities-for-common-pathogens}}

*****NOTE:*** The antibiograms are \textbf{updated annually} based on that year's susceptibility data, so the digital \href{https://bchfit.tch.harvard.edu/}{Antibiogram+} is always the most accurate resource. The following susceptibilities are based on the BCH Antibiogram+ at the time of publication.

*****ALSO NOTE:*** Sensitivities at \textbf{BMC} are \textbf{different}! (e.g.~higher rates of clindamycin-resistant MRSA)

\hypertarget{gram-negative-susceptibilities}{%
\subsubsection{Gram Negative Susceptibilities}\label{gram-negative-susceptibilities}}

\includegraphics{images/id_antibiogram-gn.png}

\hypertarget{gram-positive-susceptibilities}{%
\subsubsection{Gram Positive Susceptibilities}\label{gram-positive-susceptibilities}}

\includegraphics{images/id_antibiogram-gp.png}

\hypertarget{anaerobe-susceptibilities}{%
\subsubsection{Anaerobe Susceptibilities}\label{anaerobe-susceptibilities}}

\includegraphics{images/id_antibiogram-anaerobes.png}

\hypertarget{antibiotic-recommendations-dosing-duration-for-common-infections}{%
\subsection{\texorpdfstring{\href{https://bchfit.tch.harvard.edu/diagnoses}{Antibiotic Recommendations} (Dosing, Duration) for Common Infections}{Antibiotic Recommendations (Dosing, Duration) for Common Infections}}\label{antibiotic-recommendations-dosing-duration-for-common-infections}}

\emph{While these are often first line antibiotic choices, clinical decision-making on antibiotic prescribing should be based on the patient's entire clinical picture. Also make sure to review patient's allergy history prior to prescribing.}

\hypertarget{bone-joint}{%
\subsubsection{Bone \& Joint}\label{bone-joint}}

\begin{itemize}
\tightlist
\item
  \textbf{Osteomyelitis:} Cefazolin 50 mg/kg/dose IV q8h (2g) x 4wks
\item
  \textbf{Septic arthritis:} Cefazolin 50 mg/kg/dose IV q8h (2g) x 3wks
\end{itemize}

\hypertarget{head-neck}{%
\subsubsection{Head \& Neck}\label{head-neck}}

\begin{itemize}
\tightlist
\item
  \textbf{Acute otitis media (AOM):} Amoxicillin 45 mg/kg/dose BID (875 mg) x 5-10 days
\item
  \textbf{Acute sinusitis:} Amoxicillin-clavulanate 45 mg amox/kg/dose PO BID (1g) x 10 days
\item
  \textbf{Mastoiditis, peritonsillar abscess (PTA), and/or retropharyngeal abscess (RPA):} Ampicillin-sulbactam 50mg ampicillin/kg/dose IV q6h (2g) x 10-14 days
\item
  \textbf{Strep pharyngitis:} Amoxicillin 50 mg/kg daily (1g) x 10 days
\item
  \textbf{Suppurative cervical lymphadenitis:} Ampicillin-sulbactam 50 mg amp/kg/dose IV q6h (2g)
\end{itemize}

\hypertarget{gastrointestinal}{%
\subsubsection{Gastrointestinal}\label{gastrointestinal}}

\begin{itemize}
\tightlist
\item
  \textbf{C. diff:} Metronidazole 10 mg/kg/dose PO QID x 10 days
\item
  \textbf{Ruptured appendicitis:} Piperacillin-tazobactam 100 mg pip/kg/dose IV q8h (6g) x 7 days
\end{itemize}

\hypertarget{genitourinary}{%
\subsubsection{Genitourinary}\label{genitourinary}}

\begin{itemize}
\tightlist
\item
  \textbf{PID, outpatient:} Ceftriaxone 50 mg/kg/dose IM x1 (250mg) + Doxycycline 2.5 mg/kg/dose PO BID (100 mg) x 14 days + Metronidazole 10 mg/kg/dose PO BID (500 mg) x 14 days
\item
  \textbf{PID, inpatient:} Cefoxitin 40 mg/kg/dose IV q6h (2g) + Doxycycline IV/PO 2.5 mg/kg/dose PO BID (100 mg)
\item
  \textbf{Pyelonephritis:} Ceftriaxone 50 mg/kg/dose IV q24h (2g) x 10 days
\item
  \textbf{UTI 3-23 months, febrile, healthy, outpatient:} Cephalexin 25 mg/kg/dose TID (500 mg) x 10 days
\item
  \textbf{UTI \textgreater24 months, healthy, outpatient:} Cephalexin 25 mg/kg/dose PO TID (500 mg) x 3-5 days
\end{itemize}

\hypertarget{respiratory-1}{%
\subsubsection{Respiratory}\label{respiratory-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Community-acquired pneumonia (CAP), outpatient:} Amoxicillin 30 mg/kg/dose PO TID (500 mg-1g) x 7 days
\item
  \textbf{CAP, inpatient:} Ampicillin 50 mg/kg/dose IV q6h (2g) x 7 days
\item
  \textbf{CAP, complicated:} Ceftriaxone 50 mg/kg/dose IV q24h (2g) + Vancomycin 15-20 mg/kg/dose IV q6-8h (1g)
\item
  \textbf{Aspiration pneumonia:} Ampicillin-sulbactam 50 mg amp/kg/dose IV q6h (2g) x 7 days
\end{itemize}

\hypertarget{skin-soft-tissue}{%
\subsubsection{Skin \& Soft Tissue}\label{skin-soft-tissue}}

\begin{itemize}
\tightlist
\item
  \textbf{Cellulitis, non-purulent:} Cefazolin 25 mg/kg/dose IV q8h (1g) OR cephalexin 25 mg/kg/dose PO TID (1g) x 5-7 days
\item
  \textbf{Cellulitis, purulent or abscess:} TMP-SMX 6 mg TMP/kg/dose IV/PO q12h (160 mg) x 5-7 days
\end{itemize}

\hypertarget{cellulitis-abscess}{%
\subsection{Cellulitis \& Abscess}\label{cellulitis-abscess}}

\hypertarget{powerplans-order-sets-clinical-pathways-11}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-11}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=CELLULOABCCESS\&algVersion=1.6\&accessCode=null}{Cellulitis and Abscess}
\item
  \textbf{PowerPlans \& Order Sets:} Cellulitis and Abscess Pathway Plan
\end{itemize}

\hypertarget{etiology-16}{%
\subsubsection{Etiology}\label{etiology-16}}

Beta-hemolytic strep, S. Aureus \textgreater{} H. influenzae, Clostridia, S. Pneumo

\hypertarget{differential-8}{%
\subsubsection{Differential}\label{differential-8}}

\begin{itemize}
\tightlist
\item
  Erysipelas (upper dermis/superficial lymphatics, clear demarcated tissue)
\item
  Necrotizing fasciitis (pain out of proportion to exam, crepitus, toxic appearing)
\item
  Tenosynovitis (tenderness over flexor sheath, reduced motion)
\item
  Compartment syndrome (early → late: paresthesia, pain out of proportion/with stretch, pallor, pulseless)
\end{itemize}

\hypertarget{work-up-37}{%
\subsubsection{Work-up}\label{work-up-37}}

\begin{itemize}
\tightlist
\item
  Diagnosis is clinical, based on tenderness to palpation, warmth, erythema, induration, fluctuance, fever
\item
  Obtain US if concerned for abscess
\item
  Circle border of lesion with ink, upload photo to PowerChart w/ Cerner Camera Capture app
\item
  No need for labs (e.g.~CBC) or MRSA swab if hemodynamically stable
\end{itemize}

\hypertarget{managament}{%
\subsubsection{Managament}\label{managament}}

\begin{itemize}
\tightlist
\item
  Treatment duration typically 5-7 days
\item
  \textbf{Non-purulent:} Cephalexin/cefazolin, clindamycin
\item
  \textbf{Purulent:} 1st Line: TMP-SMX, 2nd Line: Clindamycin, 3rd Line: Doxycycline
\item
  Consider MRSA coverage (TMP-SMX, vanc, linezolid) if: no response to initial therapy, systemic illness, recurrent infection, prior history of MRSA, high prevalence of MRSA in community
\end{itemize}

\hypertarget{osteomyelitis}{%
\subsection{Osteomyelitis}\label{osteomyelitis}}

\hypertarget{powerplans-order-sets-clinical-pathways-12}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-12}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=OSTEOM\&algVersion=1.3\&accessCode=null}{Osteomyelitis}; \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=COMPLEX_OSTEO\&algVersion=1.3\&accessCode=null}{Osteomyelitis, Complex}
\item
  \textbf{PowerPlans \& Order Sets:} Osteomyelitis Admit Pathway Plan
\end{itemize}

\hypertarget{etiology-17}{%
\subsubsection{Etiology}\label{etiology-17}}

\begin{itemize}
\tightlist
\item
  Hematogenous seeding \textgreater{} direct inoculation vs.~contiguous spread
\item
  S. aureus, GAS, S. pneumo, H. flu type b, Salmonella (sickle cell), E. coli (neonates), Group B Strep (\textless3 mo), Kingella, Bartonella (vertebral), TB
\end{itemize}

\hypertarget{presentation-82}{%
\subsubsection{Presentation}\label{presentation-82}}

Fever, localized pain, swelling, warmth, reduced ROM/weight bearing

\hypertarget{differential-9}{%
\subsubsection{Differential}\label{differential-9}}

Cellulitis, septic joint, fracture, sickle cell crisis, rheumatic disease, bleed/joint effusion, malignancy

\hypertarget{work-up-38}{%
\subsubsection{Work-up}\label{work-up-38}}

CBC, CRP, ESR, BCx, plain film (only + after 10-14 days), MRI (sens 80-100\%, spec 70-100\%), technetium 99 bone scan

\hypertarget{treatment-55}{%
\subsubsection{Treatment}\label{treatment-55}}

\begin{itemize}
\tightlist
\item
  IV antibiotics +/- surgical debridement, full antibiotic course 4-6 weeks, ortho consult
\item
  1st line: Cefazolin (does not cover MRSA)
\item
  Clindamycin (recommended for use in staph infections if sensitivities are available or if Cephalosporin allergy)
\item
  Vancomycin if unstable/toxic-appearing
\item
  Ceftriaxone for sickle cell patients (for Salmonella)
\item
  Transition to PO antibiotics when no fever \textgreater24 hrs, improved pain/ROM, CRP downtrending, BCx negative x48 hrs
\end{itemize}

\hypertarget{septic-arthritis}{%
\subsection{Septic Arthritis}\label{septic-arthritis}}

\hypertarget{powerplans-order-sets-clinical-pathways-13}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-13}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=SEPTICARTHRITIS\&algVersion=1.9\&accessCode=null}{Septic Arthritis}
\item
  \textbf{PowerPlans \& Order Sets:} ED Septic Joint/Arthritis Plan
\end{itemize}

\hypertarget{etiology-18}{%
\subsubsection{Etiology}\label{etiology-18}}

MSSA, Strep pneumo, GAS, \textgreater{} MRSA, Kingella, gonorrhea, Lyme

\hypertarget{presentation-83}{%
\subsubsection{Presentation}\label{presentation-83}}

Fever, localized pain, reduced ROM/weight bearing

\hypertarget{differential-10}{%
\subsubsection{Differential}\label{differential-10}}

Crystal-induced arthritis, inflammatory arthritis (SLE, reactive, sarcoid), OA, malignancy, hemarthrosis

\hypertarget{work-up-39}{%
\subsubsection{Work-up}\label{work-up-39}}

\begin{itemize}
\tightlist
\item
  CBC, BCx, CRP, ESR, synovial fluid analysis, X-ray, US, consider Lyme Ab, ASLO, DNase-B Ab
\item
  \textbf{Kocher Criteria:} (1) ESR \textgreater40, (2) WBC \textgreater12, (3) Fever \textgreater38.5, (4) Non-weight bearing
\item
  Risk of septic arthritis with 0/4 (0.2\%), 1/4 (3\%), 2/4 (40\%), 4/4 (99.8\%)
\end{itemize}

\hypertarget{treatment-56}{%
\subsubsection{Treatment}\label{treatment-56}}

\begin{itemize}
\tightlist
\item
  1st line: Cefazolin x3 weeks, 2nd line: Clindamycin x3 weeks
\item
  Use ceftriaxone if concern for Lyme, gonorrhea, or GNR
\item
  Add vancomycin if clinically ill-appearing
\end{itemize}

\hypertarget{infectious-mononucleosis}{%
\subsection{Infectious Mononucleosis}\label{infectious-mononucleosis}}

\hypertarget{etiology-19}{%
\subsubsection{Etiology}\label{etiology-19}}

EBV (90\%) \textgreater{} CMV, acute HIV, HHV6/7, Hep B, Toxoplasma

\hypertarget{presentation-84}{%
\subsubsection{Presentation}\label{presentation-84}}

Fatigue, malaise, fever, dysphagia, LAD, splenomegaly (up to 65\%)

\hypertarget{differential-11}{%
\subsubsection{Differential}\label{differential-11}}

Viral syndrome, strep pharyngitis, malignancy

\hypertarget{work-up-40}{%
\subsubsection{Work-up}\label{work-up-40}}

\begin{itemize}
\tightlist
\item
  Monospot (poor sensitivity in first week - 75\%)
\item
  EBV IgG/IgM titers
\item
  Early Antigen IgG (EA-D IgG, rises in early infection)
\item
  EBNA IgG (negative EA-D and positive EBNA suggests past infection)
\item
  Lymphocytosis \textgreater50\%, atypical lymphocytes \textgreater10\%, +/- transaminitis
\end{itemize}

\hypertarget{treatment-57}{%
\subsubsection{Treatment}\label{treatment-57}}

\begin{itemize}
\tightlist
\item
  Supportive, no contact sports x 3 wks due to risk of splenic rupture
\item
  Avoid amoxicillin/other PCNs for treatment of concomitant strep pharyngitis given risk of associated rash
\end{itemize}

\hypertarget{acute-otitis-media-aom}{%
\subsection{Acute Otitis Media (AOM)}\label{acute-otitis-media-aom}}

\hypertarget{powerplans-order-sets-clinical-pathways-14}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-14}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=AcuteOtitisMedia\&algVersion=1.2\&accessCode=null}{Acute Otitis Media}
\item
  \textbf{PowerPlans \& Order Sets:} ED Otitis Plan
\end{itemize}

\hypertarget{etiology-20}{%
\subsubsection{Etiology}\label{etiology-20}}

Strep pneumo, Moraxella catarrhalis, H. flu

\hypertarget{differential-12}{%
\subsubsection{Differential}\label{differential-12}}

Otitis media externa, mastoiditis, serous effusion

\hypertarget{work-up-41}{%
\subsubsection{Work-up}\label{work-up-41}}

\begin{itemize}
\tightlist
\item
  Diagnostic criteria
\item
  Moderate-severe TM bulging
\item
  Mild TM bulging + ear pain/pulling
\item
  Intense TM erythema
\item
  Otorrhea not due to otitis externa
\item
  Acute symptoms + bulging TM + reduced TM mobility with pneumatic otoscopy
\end{itemize}

\hypertarget{treatment-58}{%
\subsubsection{Treatment}\label{treatment-58}}

\begin{itemize}
\tightlist
\item
  Amoxicillin (1st line), augmentin (2nd line)
\item
  Consider tubes if 3 episodes in 6 mos OR 4 episodes in 1 yr w/ 1 episode in the preceding 6 mos
\item
  If no severe symptoms (\textgreater39 C temp, ear pain 48+ hrs, severe ear pain), no bilateral symptoms in \textless24 mo pt, can defer antibiotic treatment
\end{itemize}

\hypertarget{influenza}{%
\subsection{Influenza}\label{influenza}}

\hypertarget{powerplans-order-sets-clinical-pathways-15}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-15}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=1012\&algVersion=1.7\&accessCode=null}{Influenza-Like Illness (ILI)}
\item
  \textbf{PowerPlans \& Order Sets:} ED Influenza Plan; Influenza, Respiratory Virus Microbiology Testing Plan; Influenza Immunization Plan
\end{itemize}

\hypertarget{etiology-21}{%
\subsubsection{Etiology}\label{etiology-21}}

Influenza A (including H1N1) or B

\hypertarget{presentation-85}{%
\subsubsection{Presentation}\label{presentation-85}}

Fever, cough, sore throat, rhinorrhea, myalgias, headaches, fatigue

\hypertarget{work-up-42}{%
\subsubsection{Work-up}\label{work-up-42}}

Clinical + rapid influenza diagnostic test which detects the viral antigen. \emph{At BCH we use PCR test (Influenza A/B, RSV PCR) since other rapid flu tests have low sensitivity.}

\hypertarget{treatment-59}{%
\subsubsection{Treatment}\label{treatment-59}}

\begin{itemize}
\tightlist
\item
  If diagnosis is identified within 48 hrs of symptom onset, antiviral therapy (Tamiflu) should be given for 5 days
\item
  Children at high risk should still be considered for antiviral therapy even after 48 hrs
\item
  \textbf{High risk} is defined by: \textless2 years old, presence of comorbidities (chronic pulmonary disease (asthma), cardiac disease, renal disease, hepatic disease, hematologic disease (sickle cell), neurodevelopmental disorders (CP, seizure disorder), moderate to severe developmental delay, pregnancy, metabolic disorders (including diabetes),chronic immunosuppression, hospitalized with high risk of influenza complication), pregnancy, morbid obesity
\item
  Tamiflu dosing for full-term children:

  \begin{itemize}
  \tightlist
  \item
    0-8 mo: 3 mg/kd/dose BID
  \item
    9-11 mo: 3.5 mg/kg/dose BID
  \item
    Children \textgreater12 mo:

    \begin{itemize}
    \tightlist
    \item
      (\textless)15 kg: 30 mg/kg BID
    \item
      15-23 kg: 45 mg/kg BID
    \item
      23-40 kg: 60 mg/kg BID
    \item
      (\textgreater)40 kg: 75 mg/kg BID
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{prophylaxis}{%
\subsubsection{Prophylaxis}\label{prophylaxis}}

\begin{itemize}
\tightlist
\item
  Annual flu vaccination is recommended for every child and adolescent, age 6 mos and older
\item
  Any child with an egg allergy of any severity can receive the influenza vaccine
\end{itemize}

\hypertarget{complications-14}{%
\subsubsection{Complications}\label{complications-14}}

Sinus or ear infections, pneumonia, myocarditis, sepsis

\hypertarget{fever-of-unknown-origin-fuo}{%
\subsection{Fever of Unknown Origin (FUO)}\label{fever-of-unknown-origin-fuo}}

\emph{See Rheumatology chapter for further discussion}

\hypertarget{powerplans-order-sets-clinical-pathways-16}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-16}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=FEVEROFUNKNOWNORIGIN(FUO)*\&algVersion=1.7\&accessCode=null}{Fever of Unknown Origin (FUO)} - includes H\&P template!
\item
  \textbf{PowerPlans \& Order Sets:} Fever of Unknown Origin (FUO) Pathway Plan
\end{itemize}

\hypertarget{definition-41}{%
\subsubsection{Definition}\label{definition-41}}

Fever without a source for \textgreater{} 7 days

\hypertarget{differential-13}{%
\subsubsection{Differential}\label{differential-13}}

\begin{itemize}
\tightlist
\item
  \textbf{Bacterial:} Endocarditis, mastoiditis, sub-diaphragmatic abscess, liver abscess, perinephric abscess, pyelonephritis, pelvic abscess, osteomyelitis, TB, salmonellosis (including typhoid), lymphogranuloma venereum, brucellosis, bartonella, leptospirosis, tularemia, psittacosis, tick-borne disease (e.g.~Anaplasma, Babesia), Q fever, RMSF
\item
  \textbf{Viral:} Adenovirus, arboviruses (e.g.~West Nile, dengue), primary HIV, CMV, EBV, HBV, HCV
\item
  \textbf{Fungal:} Blastomycosis, histoplasmosis
\item
  \textbf{Parasitic:} Malaria, toxoplasmosis, visceral larva migrans
\item
  \textbf{Granulomatous:} Sarcoidosis, granulomatous colitis
\item
  \textbf{Collagen vascular disease:} Systemic juvenile idiopathic arthritis (sJIA), polyarteritis nodosa, SLE
\item
  \textbf{Malignancy:} Leukemia, lymphoma, neuroblastoma, Langerhans cell histiocytosis
\item
  \textbf{Immunologic:} Primary or secondary immunodeficiency
\item
  \textbf{Miscellaneous:} Diabetes insipidus, drug fever, Kawasaki disease, familial dysautonomia (Riley-Day Syndrome), familial Mediterranean fever or other periodic fever syndromes, HLH, infantile cortical hyperostosis (Caffey Syndrome), pancreatitis, serum sickness, ulcerative colitis, thyrotoxicosis
\end{itemize}

\hypertarget{work-up-43}{%
\subsubsection{Work-up}\label{work-up-43}}

\begin{itemize}
\tightlist
\item
  \textbf{History} including thorough ROS, travel history, animal exposures, outdoor activities, insect bites, food exposures, sexual history, IV drug use
\item
  \textbf{Exam:} Skin exam, LN palpation, joint exam
\item
  \textbf{Labs:} CBCd, chem10, UA/UCx, BCx, HIV, LFTs, LDH, CPK, ESR/CRP, ANA, TST/IGRA, LDH/Uric acid, Procalcitonin, Ferritin, IgG, EBV, CMV, Viral respiratory testing
\item
  \textbf{Imaging:} CXR to start; may require abdominal axial imaging (MRI vs.~CT)
\item
  Additional work-up as indicated by history and physical, and decided upon with guidance from consulting teams and radiology
\end{itemize}

\hypertarget{treatment-60}{%
\subsubsection{Treatment}\label{treatment-60}}

\begin{itemize}
\tightlist
\item
  Unless patient is very ill, empiric antimicrobial therapy should be avoided as it often delays diagnosis
\item
  Can observe fever pattern for diagnostic purposes before treating fever
\item
  Glucocorticoids or other immunosuppressive therapy should be withheld until infectious etiology is adequately ruled out
\end{itemize}

\hypertarget{urinary-tract-infection-uti-first-febrile}{%
\subsection{Urinary Tract Infection (UTI), First Febrile}\label{urinary-tract-infection-uti-first-febrile}}

\hypertarget{powerplans-order-sets-clinical-pathways-17}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-17}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=uti2\&algVersion=1.4\&accessCode=null}{Urinary Tract Infection, First Febrile, Inpatient}. Also see: \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=URINARYTRACTINFECTION_2-24MONTHS_EMERGENT_URGENT\&algVersion=2.1\&accessCode=null}{Fever/UTI, 2-24 Months, Emergent/Urgent} and \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=URINARYTRACTINFECTION_2-18YEARSOLD_EMERGENT_URGENT\&algVersion=1.5\&accessCode=null}{Urinary Tract Infection, 2-18 Years Old, Emergent/Urgent}.
\item
  \textbf{PowerPlans \& Order Sets:} Urinary Tract Infection Pathway Plan
\end{itemize}

\hypertarget{etiology-22}{%
\subsubsection{Etiology}\label{etiology-22}}

E. coli, Klebsiella, Proteus, Enterobacter, Citrobacter, Enterococcus, Staph saprophyticus

\hypertarget{work-up-44}{%
\subsubsection{Work-up}\label{work-up-44}}

Inclusion Criteria: 0-24 mos, appropriate work-up for fever completed

\begin{itemize}
\tightlist
\item
  Send \textbf{UA and culture (UCx):}

  \begin{itemize}
  \tightlist
  \item
    Bagged UA if \textgreater6mo, cathed UA recommended if pyuria or bacteriuria present
  \item
    UA considered positive if: Trace or more Leuk Esterase OR ≥ 5 WBCs OR Trace or more nitrites
  \item
    UCx considered positive if: \textgreater{} 50,000 CFU of a uropathogen
  \end{itemize}
\item
  Start \textbf{IV antibiotics} if: \textless60 days old, ill-appearing, OR not tolerating PO
\item
  Obtain \textbf{renal US} if:

  \begin{itemize}
  \tightlist
  \item
    0-24 mos w/ a 1st time febrile UTI
  \item
    Any age w/ recurrent febrile UTIs
  \item
    Any age w/ UTI + family history of renal disease, poor growth, or HTN
  \item
    Failure to respond to appropriate antibiotic therapy
  \end{itemize}
\item
  Obtain \textbf{VCUG} if:

  \begin{itemize}
  \tightlist
  \item
    Any age w/ 2 or more febrile UTIs
  \item
    Any age w/ a 1st time febrile UTI w/ any of the following: (1) Abnormal renal US, (2) T \emph{\textgreater{}} 102.2 and pathogen other than E. coli, (3) Poor growth or HTN
  \end{itemize}
\end{itemize}

\hypertarget{treatment-61}{%
\subsubsection{Treatment}\label{treatment-61}}

\begin{itemize}
\tightlist
\item
  IV antibiotics if \textless60 days, ill-appearing, or poor PO
\item
  If \textless2mo, use Ceftazidime (IV) / Cefdinir (PO)
\item
  If \textgreater2 mo, Ceftriaxone (IV) / Cephalexin (PO) Upon discharge, use culture data to direct management
\end{itemize}

\hypertarget{bacterial-meningitis}{%
\subsection{Bacterial Meningitis}\label{bacterial-meningitis}}

\hypertarget{powerplans-order-sets-clinical-pathways-18}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-18}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} CSF Studies Plan
\end{itemize}

\hypertarget{presentation-86}{%
\subsubsection{Presentation}\label{presentation-86}}

\begin{itemize}
\tightlist
\item
  Fever, headache, vomiting, meningismus, seizures
\item
  \textbf{Kernig sign:} Stretching of hamstring w/ knee extension + back pain
\item
  \textbf{Brudzinski sign:} Passive neck flexion, involuntary hip/knee flexion
\item
  \textbf{Red flags:} Focal neurological deficits, seizures, papilledema, risk factors for TB (poor clinical outcomes), petechiae on exam (Neisseria)
\end{itemize}

\hypertarget{differential-14}{%
\subsubsection{Differential}\label{differential-14}}

Viral meningitis/encephalitis, brain abscess, increased ICP, neoplasm, ADEM

\hypertarget{work-up-45}{%
\subsubsection{Work-up}\label{work-up-45}}

\begin{itemize}
\tightlist
\item
  \textbf{LP:} CSF: WBC count often \textgreater{} 1,000, glucose often \textless{} 40 or \textless{} half of serum value, protein \textgreater{} 250, cell count w/ \textgreater{} 50\% PMNs
\item
  Obtain \textbf{imaging} on comatose patients or those w/ focal neurologic deficits \textbf{PRIOR to} LP
\item
  Pursue HSV testing (and coverage, see below) if: Maternal history of HSV, child unwell or toxic-appearing, presence of rash c/w HSV, lab abnormalities (pleocytosis, thrombocytopenia, transaminitis in pt \textless2wks), or pneumonia in pt \textless2 wks
\end{itemize}

\hypertarget{etiologymanagement}{%
\subsubsection{Etiology/Management}\label{etiologymanagement}}

\emph{Refer to NeoFax for dosing}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.14\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.37\columnwidth}\raggedright
Organism\strut
\end{minipage} & \begin{minipage}[b]{0.41\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.14\columnwidth}\raggedright
0-1 mo\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
GBS, E. coli, L. monocytogenes, S. pneumo\strut
\end{minipage} & \begin{minipage}[t]{0.41\columnwidth}\raggedright
Ampicillin 75-100 mg/kg/day (divided q6-q8h) AND Ceftriaxone (CTX) 50mg/kg/ dose q12h (if no contraindications to CTX). If contraindications to CTX (see below), ceftazidime/Cefepime 50 mg/kg/dose (refer to NeoFax for dosing)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
1-3 mos\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
S. pneumo, E. coli, Neisseria, GBS, L. monocytogenes, H. flu\strut
\end{minipage} & \begin{minipage}[t]{0.41\columnwidth}\raggedright
Ampicillin 50-100 mg/kg/day (divided q6-q8h) AND Ceftriaxone 50 mg/kg/dose q12h\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
3- 18 mos\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
N. meningitides, S. pneumo, H. influenzae\strut
\end{minipage} & \begin{minipage}[t]{0.41\columnwidth}\raggedright
Ceftriaxone 50mg/kg/dose q12h AND Vancomycin (dose to goal trough levels of 15-20 for meningitic dosing)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
Risk factors\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\raggedright
HSV\strut
\end{minipage} & \begin{minipage}[t]{0.41\columnwidth}\raggedright
Include HSV coverage (Acyclovir 20 mg/kg/dose q8h) if HSV risk factors above are present\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

Contraindications for ceftriaxone in neonates:
- Patients \textless{} 44 wks PMA w/ hyperbilirubinemia
- Patients \textless{} 44 wks PMA receiving calcium-containing intravenous fluids or parenteral nutrition), then amp + ceftazidime or cefepime

\hypertarget{complications-15}{%
\subsubsection{Complications}\label{complications-15}}

Seizure, stroke, elevated intracranial pressure

\hypertarget{covid-19}{%
\subsection{\texorpdfstring{\href{https://docs.google.com/presentation/d/13P51MYLSvwFDnY2127Lyh69S-WSXdUu4TAyy-H7wr68/edit\#slide=id.p}{COVID-19}}{COVID-19}}\label{covid-19}}

\emph{Click the link above or use the QR code below to navigate to our one-pager about SARS-CoV-2 and COVID-19.}

\includegraphics{images/id_covid-qr-code.png}

\hypertarget{powerplans-order-sets-clinical-pathways-19}{%
\subsubsection{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-19}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} COVID-19 (Novel Coronavirus) Evaluation Plan; COVID-19 (Novel Coronavirus) Evaluation Plan - PRE OP ONLY
\end{itemize}

\hypertarget{metabolism}{%
\section{Metabolism}\label{metabolism}}

\hypertarget{i-think-this-might-be-metabolic}{%
\subsection{I think this might be metabolic\ldots{}}\label{i-think-this-might-be-metabolic}}

\begin{itemize}
\tightlist
\item
  Page Metabolism!
\item
  \textbf{Patient is in a metabolic crisis:} \protect\hyperlink{metab-crisis}{see overviews} for specific crises (hyperammonemia, metabolic acidosis, etc.)
\item
  \textbf{Patient has a known diagnosis:}

  \begin{itemize}
  \tightlist
  \item
    Look for a \textbf{critical contingency plan} in Powerchart

    \begin{itemize}
    \tightlist
    \item
      Look for ``Critical Contingency'' on top blue bar
    \item
      Hover over this to see what date contingency note was created
    \item
      Find this note in documents
    \end{itemize}
  \item
    In the ED, find the relevant orderset in \textbf{ED Metabolism Plan}
  \item
    On admission, select the relevant \textbf{Admit Plan}
  \item
    Clinic notes or the family may have a ``sick day plan''
  \item
    Acute Illness Protocols \url{https://newenglandconsortium.org/for-professionals/acute-illness-protocols/}
  \end{itemize}
\item
  \textbf{Patient has no known diagnosis:} \protect\hyperlink{metab-ddx}{see ``Differential diagnosis by clinical manifestations''}
\item
  \textbf{Patient has an abnormal NBS result:}

  \begin{itemize}
  \tightlist
  \item
    \href{https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT_Sheets_and_Algorithms.aspx}{ACT sheets}
  \item
    Info for families: \url{https://www.newbornscreening.info/}, \url{https://nensp.umassmed.edu}
  \end{itemize}
\end{itemize}

\hypertarget{management-of-metabolic-crises}{%
\subsection{Management of Metabolic Crises}\label{management-of-metabolic-crises}}

\hypertarget{general-principles}{%
\subsubsection{General Principles}\label{general-principles}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\setcounter{enumi}{-1}
\tightlist
\item
  Consult metabolism!
\item
  ABCs: address any need for airway protection, intubation, mechanical ventilation, rehydration, inotropic support
\item
  Identify the trigger: underlying illness vs dehydration vs incorrect diet - will help metabolism guide management
\item
  Consider alternate dx: electrolyte imbalance, sepsis
\item
  Established dx: acute illness protocols above, family should have home / ED illness protocol
\end{enumerate}

\begin{quote}
\textbf{Bill's Pearls:} Think about the underlying metabolic \textbf{\emph{state}} of the patient!

The catabolic state precipitates most problems in decompensating metabolic diseases, anabolic support is focused on giving calories to stimulate insulin secretion and signaling. If someone is really sick and they are hyperglycemic (BG \textgreater{} 250 mg/dL), it would be better to give insulin than to cut the dextrose because the insulin will increase the anabolic support. If you have elevated beta-hydroxybutyrate (blood) or acetoacetate(urine) then you are in a catabolic state and at risk.

Similarly, don't be falsely reassured by correcting lab values. For instance, you can easily correct hypoglycemia, but the patient could still be catabolic and/or depleted of stores from their illness. They may still decompensate rapidly after therapy is weaned off.
\end{quote}

\hypertarget{acute-metabolic-encephalopathy}{%
\subsubsection{Acute Metabolic Encephalopathy}\label{acute-metabolic-encephalopathy}}

\hypertarget{definition-42}{%
\paragraph{Definition}\label{definition-42}}

Acute global cerebral dysfunction → altered mentation w/ or w/o seizures NOT due to primary structural brain disease (e.g., tumor or hemorrhage) or infection (though some IEMs may cause strokes)

\hypertarget{etiologies}{%
\paragraph{Etiologies}\label{etiologies}}

Hyperammonemia, metabolic acidosis-hyperlactatemia or ketosis, hypoglycemia, recurrent seizures (`excitotoxic' damage), specific toxins, e.g., copper deposition in Wilson's, electrolyte imbalances

\hypertarget{presentation-87}{%
\paragraph{Presentation}\label{presentation-87}}

\begin{itemize}
\tightlist
\item
  May be precipitated by high protein intake, catabolic state (fever/illness/GIB/fast)
\item
  Presents w/ lethargy, AMS, seizures, tachypnea 2/2 metabolic acidosis or central stimulation by inc NH3
\item
  Do NOT rule out IEMs even if: functional neuro disorder, presentation @ older age, sudden onset, no PMHx
\end{itemize}

\hypertarget{management-47}{%
\paragraph{Management}\label{management-47}}

\begin{itemize}
\tightlist
\item
  Reverse catabolism ASAP and prevent sequelae, do frequent neuro checks
\item
  \textbf{Hydration:} 10 mL/kg NS bolus if dehydrated, then D10 NS + 20 mEq/L of KCl (add after ruling out hyperkalemia or after voiding) @ 1-1.5x M, avoid hyponatremia (predisposes to cerebral edema; minimum of 4-5 meq/kg/day of sodium in fluids)
\item
  \textbf{Nutrition:} give calories via carbs + IL alone (unless FA ox d/o is on ddx, then no IL) to provide 1-1.5x TEE (120-150 kcal/kg/day), preferably enteral nutrition (enteral carbs → portal vein → maximize insulin release); can give TPN if enteral feeds are not tolerated, start protein w/in 48h
\item
  \textbf{Promote anabolism:} nutrition, ↓ counter-regulatory hormones → ensure adequate volume, ondansetron for vomiting if not at risk of long QT, treat infxn/fever/pain, correct hypoglycemia (bolus of 2 or 5 mL of 25 or 10\% Dextrose → rule of 50 (i.e., vol*\%dex = 50), then infusion to maintain a GIR of 8-12 mg/kg/min {[}GIR in mg/kg/min = dextrose\% x Vol (ml/kg/day) / 144{]}), maintain normoglycemia if needed with insulin @ 0.1mcg/kg/hr, titrating to maintain glucose between 100-120mg/dL (goal of high GIR = get glucose (i.e., calories), into the cells rather than add to Sosm by causing hyperglycemia), wean GIR slowly to prevent rebound hypoglycemia
\item
  \textbf{Cofactor therapy:} try the vitamins below even empirically, but esp if these disorders are on ddx
\end{itemize}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
\textbf{Suspected Enzyme Deficiency}\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
\textbf{Cofactor}\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Propionyl-CoA carboxylase, Beta-methylcrotonyl-CoA carboxylase, Holocarboxylase synthase, Pyruvate carboxylase, Biotinidase deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Biotin (dose depends on disorder)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Methylmalonyl-CoA mutase\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Hydroxycobalamin 1 mg/day IM\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
BCAA DH (MSUD), Pyruvate DH, Alpha-ketoglutarate DH\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Thiamine (B1) 100 mg/day\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
GAII (Multiple acyl-CoA DH)\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Riboflavin (B2) 200 mg/day\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\begin{itemize}
\tightlist
\item
  \textbf{L-carnitine:} inc urinary excretion of carnitine-bound organic acids → secondary deficiency; carnitine is neuroprotective and non-toxic, give 100mg/kg/day, max 6 g/d, 1st via IV bolus of daily dose, then divide q4-6h, IV or enteral; carnitine controversial in FAOD
\item
  \textbf{Toxin removal:} CVVH ideal; can consider PLEX or peritoneal dialysis in neonates (less effective); extracorporeal toxin removal if severe
\item
  \textbf{Specific rx:} Address underlying acidosis, hyperammonemia (scavengers), metabolic pathway block
\end{itemize}

\hypertarget{risks-of-therapy}{%
\paragraph{Risks of therapy}\label{risks-of-therapy}}

\begin{itemize}
\tightlist
\item
  \emph{Overhydration}
\item
  \emph{cerebral edema / herniation} (may need ventilation + other modes to control ICP while maintaining cerebral perfusion w/ mannitol, hypothermia)
\item
  protein malnutrition (if no protein \textgreater48h)
\end{itemize}

\hypertarget{hyperammonemia}{%
\subsubsection{Hyperammonemia}\label{hyperammonemia}}

\textbf{PowerPlan:} Metabolism Hyperammonemia Admit Orderset

\hypertarget{definition-43}{%
\paragraph{Definition}\label{definition-43}}

Normal ammonia levels vary w/ prematurity, age, and catabolic state; usu 15-35 μmol/L (up to 100 μmol/L in neonates), nl \textless50 μmol/L. Most IEMs \textgreater500, while ↑ NH3 in liver failure, sepsis usually \textless500

\hypertarget{underlying-differential-diagnosis}{%
\paragraph{Underlying differential diagnosis}\label{underlying-differential-diagnosis}}

UCDs (OTC most common), hyperammonemia-hyperornithine-hypercitrulline (HHH) syndrome, organic acidemias (PA, IVA, MMA), FAODs (MCAD, LCAD, LCHAD), systemic carnitine deficiency, PC deficiency, THAN (esp in preemies), liver failure from any cause, VPA toxicity, infection with urease-positive organism (e.g., Proteus, H pylori), post-transplant idiopathic HA, porto-systemic shunt

\hypertarget{pathophysiology-40}{%
\paragraph{Pathophysiology}\label{pathophysiology-40}}

Inc NH3 in brain → astrocytes turn NH3 into Gln → inc intracellular osmolality → cerebral edema.
NH3 inhibits α-KG DH → TCA cycle blocked → pyruvate ⇒ lactate, α-KG ⇒ Glu → excitotox/sz → cerebral edema, possible herniation. \textbf{Even brief periods of hyperammonemia in infants} may have chronic sequelae

\hypertarget{presentation-88}{%
\paragraph{Presentation}\label{presentation-88}}

Headaches, irritability, nausea/vomiting, Lethargy/delirium → coma, sz, opisthotonic posturing; central hyperventilation/resp alkalosis; cerebral edema → inc ICP → HTN + bradycardia, CN VI palsy, encephalopathy

\hypertarget{workup-17}{%
\paragraph{Workup}\label{workup-17}}

\textbf{free-flowing} sample in Na heparin tube w/o tourniquet, send to lab \textbf{on ice STAT} w/ chem 10, VBG, CBC/diff, plasma AAs, urine OAs, repeat NH3 at least q6-8h alongside daily chem and others PRN

\hypertarget{management-48}{%
\paragraph{Management}\label{management-48}}

\begin{itemize}
\tightlist
\item
  General measures/ABCs as above.
\item
  Stop protein intake: start hydration and nutrition as described above for goal GIR of 10-12 mg/kg/min, aiming to provide 120-150 kcal/kg/day
\item
  Give ammonia scavengers:

  \begin{itemize}
  \item
    Ammunol (sodium benzoate + sodium phenylacetate; ordered by metabolism)
  \item
    May also add Arginine HCl - avoid in Arginase deficiency, central access only
  \item
    Give one dose as bolus over 90 minutes, then second dose over 24 hours
  \end{itemize}
\item
  Consider dialysis for NH3 in critical cases (preferably ECMO-based, requiring NICU transfer)
  Reintroduce protein w/in 48h to prevent endogenous protein from breaking down
\end{itemize}

\hypertarget{approach-to-hyperammonemia-in-neonates}{%
\paragraph{Approach to hyperammonemia in neonates}\label{approach-to-hyperammonemia-in-neonates}}

\begin{figure}
\centering
\includegraphics{images/metab_hyperamm_neonates.png}
\caption{Approach to hyperammonemia workup in neonates.}
\end{figure}

\hypertarget{metabolic-acidosis-dt-suspected-iem}{%
\subsubsection{Metabolic Acidosis d/t suspected IEM}\label{metabolic-acidosis-dt-suspected-iem}}

\textbf{PowerPlan:} Metabolism Lactic or Metabolic Acidosis NOS Admit Plan

\hypertarget{definition-44}{%
\paragraph{Definition}\label{definition-44}}

Arterial blood gas with pH \textless{} 7.35, pCO2 \textless{} 35, bicarbonate \textless{} 22

\begin{figure}
\centering
\includegraphics{images/metab_acidosis.png}
\caption{Approach to metabolic acidosis workup.}
\end{figure}

\hypertarget{etiologies-1}{%
\paragraph{Etiologies}\label{etiologies-1}}

Inherited: organic acidurias, primary lactic acidemias, renal tubular acidosis; ANY metabolic crisis, if left untreated long enough, will progress to metabolic acidosis

\hypertarget{presentation-89}{%
\paragraph{Presentation}\label{presentation-89}}

Acute vomiting, dehydration, lethargy, and rapid, shallow breathing, often h/o protein load

\hypertarget{physical-exam-19}{%
\paragraph{Physical Exam}\label{physical-exam-19}}

\begin{itemize}
\tightlist
\item
  \textbf{Organic acidurias:} limb hypertonia/axial hypotonia, large amplitude tremor, myoclonic jerks, pedaling, sustained paraspinal contraction (opisthotonic posturing)
\item
  \textbf{RTA:} Failure to thrive, polyuria, and rachitic changes
\item
  \textbf{PDH deficiency:} blindness, hypotonia, DD, narrow forehead, frontal bossing, wide nasal bridge, long philtrum, and anteverted nostrils
\end{itemize}

\hypertarget{management-49}{%
\paragraph{Management}\label{management-49}}

\begin{itemize}
\tightlist
\item
  Work-up as per flow-chart above; also check ketones as a marker for catabolism
\item
  Hydration, caloric intake of 120-140kcal/kg/day, stop proteins initially (esp stop all BCAAs if MSUD is suspected), maintain glucose 100-150 (using high GIR +/- insulin), avoid hypoNa, cerebral edema
\item
  If serum bicarb \textless{} 14 meq/L and pH \textless{} 7.2, give IV bolus NaHCO3 as 2.5 meq/kg over 30 minutes, then 2.5 meq/kg/day until serum bicarbonate is 24-28 meq/L
\item
  HD = last resort but may be lifesaving in severe refractory cases (especially neonates)
\end{itemize}

\hypertarget{seizures-dt-suspected-iem}{%
\subsubsection{Seizures d/t suspected IEM}\label{seizures-dt-suspected-iem}}

\hypertarget{etiology-23}{%
\paragraph{Etiology}\label{etiology-23}}

Alteration of intracellular \textbf{osmolality}, depletion of substrates needed for \textbf{cellular metabolism} or membrane function, and/or intracellular accumulation of \textbf{toxic substances}

\hypertarget{underlying-differential-diagnosis-1}{%
\paragraph{Underlying differential diagnosis}\label{underlying-differential-diagnosis-1}}

DDx of `seizures in a newborn' is large, including many IEMs with poor prognosis. Rare but potentially treatable etiologies:

\begin{itemize}
\tightlist
\item
  \textbf{pyridoxine responsive seizures}
\item
  \textbf{folinic acid responsive seizures}
\item
  serine responsive 3-phosphoglycerate DH deficiency
\item
  sz from \textbf{hypoglycemia}
\item
  \textbf{biotin responsive} holocarboxylase synthetase deficiency
\item
  biotinidase deficiency
\end{itemize}

\hypertarget{management-50}{%
\paragraph{Management}\label{management-50}}

\begin{itemize}
\tightlist
\item
  \textbf{See neurology section for treatment of status epilepticus}
\item
  avoid AEDs that block mitochondrial fxn (VPA, chloral hydrate) - c/s fosphenytoin, BZDs, and/or levetiracetam
\item
  Correct fever, electrolyte issues, acidosis, hypoglycemia
\item
  If refractory, c/s empiric pyridoxine (100-200 mg IV x1), folinic acid (2.5-5 mg PO once daily), L-serine (200-600 mg/kg/d div 6x/day), or biotin (5-20 mg PO once daily)
\end{itemize}

\hypertarget{ketotic-hypoglycemia}{%
\subsubsection{Ketotic Hypoglycemia}\label{ketotic-hypoglycemia}}

\emph{For broader approach to Hypoglycemia, see the Endocrine chapter.}

\textbf{PowerPlan:} Metabolism Hypoglycemia Admit Plan

\hypertarget{definition-45}{%
\paragraph{Definition}\label{definition-45}}

BG \textless{} 60 mg/dL, elevated BOHB, likely acidosis\\
Gluconeogenic amino acid levels are low on plasma AA analysis

Distinguish from hypoglycemia with:

\begin{itemize}
\tightlist
\item
  lactic acidosis (possible carbohydrate metabolism defect)\\
\item
  no acidosis but elevated FFA (possible FAOD)
\item
  no acidosis or FFA (likely endocrine-mediated)
\end{itemize}

\hypertarget{etiology-24}{%
\paragraph{Etiology}\label{etiology-24}}

Failure of the catabolic state to maintain euglycemia, typically i/s/o trigger. Glycogen stores are typically depleted (no response from glucagon)

\hypertarget{presentation-90}{%
\paragraph{Presentation}\label{presentation-90}}

Very common in children 16 months to 3 years, usually gone by ages 10-12. Possibly related to factors that improve with age (increased muscle mass, decreasing GIR need, decreased head to body size).

\hypertarget{physical-exam-20}{%
\paragraph{Physical exam}\label{physical-exam-20}}

\begin{itemize}
\tightlist
\item
  Look for skin darkening or other signs of adrenocortical insufficiency
\item
  Enlarged liver (Hepatic glycogen storage disease)
\end{itemize}

\hypertarget{management-51}{%
\paragraph{Management}\label{management-51}}

\begin{itemize}
\tightlist
\item
  Promote anabolic state (not just correct the blood glucose)
\item
  Start children on D10 containing fluids at 1.5x maintenance rate until they demonstrate the ability to take substantial calories by mouth
\item
  Do not discharge catabolic state reversed (e.g.~taking very good PO, ketones clearing, hepatic stores repleting)
\end{itemize}

\hypertarget{access-in-a-metabolic-crisis}{%
\subsubsection{Access in a metabolic crisis}\label{access-in-a-metabolic-crisis}}

Pay attention to access because it determines your ability to provide anabolic support and give scavengers.

\textbf{PIV:} dextrose up to D12.5, continuous ammonul, intralipids\\
\textbf{G-Tube:} Metabolic formula to assist in detoxification, allows for highest calories/volume, avoid use if vomiting\\
\textbf{CVL/Port:} Ammonul w/ arginine bolus, high concentration dextrose

\textbf{Common caloric values for fluids:}

\begin{longtable}[]{@{}ll@{}}
\toprule
Fluid & Calories (kcal/mL)\tabularnewline
\midrule
\endhead
\textbf{D5} & 0.17\tabularnewline
\textbf{D10} & 0.34\tabularnewline
\textbf{D12.5} & 0.425\tabularnewline
\textbf{Intralipid} & 2.0\tabularnewline
\textbf{Metabolic formula} (30 kcal/oz) & 1.0\tabularnewline
\textbf{Pedialyte} & 0.105\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{differential-diagnosis-by-clinical-manifestations}{%
\subsection{Differential Diagnosis by Clinical Manifestations}\label{differential-diagnosis-by-clinical-manifestations}}

\hypertarget{presenting-in-neonatal-period-or-early-infancy}{%
\subsubsection{\texorpdfstring{Presenting in \emph{Neonatal period} or \emph{early infancy}}{Presenting in Neonatal period or early infancy}}\label{presenting-in-neonatal-period-or-early-infancy}}

\hypertarget{history-6}{%
\paragraph{History}\label{history-6}}

Consanguinity (increased inc of AR disorders), ethnicity (e.g., tyrosinemia in French-Canadians of Quebec), SIDS or intellectual disability in family (all from possible undiagnosed IEMs), relation of symptom to introduction of new food, NBS results

\hypertarget{presentation-91}{%
\paragraph{Presentation}\label{presentation-91}}

\begin{itemize}
\tightlist
\item
  Acute and severe, simulating sepsis (lethargy, vomiting, tachypnea, seizures, poor perfusion)

  \begin{itemize}
  \tightlist
  \item
    classically ex FT, prev healthy, deterioration despite support, usu neg sepsis workup
  \item
    d/t deficiency of a product or excess of toxic substrate, so called ``intoxications'' - organic acidemias, aminoacidopathies, and UCDs
  \item
    First presentation may be unmasked by a concurrent illness
  \end{itemize}
\item
  Indolent w/ early and persistent neurological deterioration

  \begin{itemize}
  \tightlist
  \item
    nl pregnancy, no interim healthy pd, d/t energy def: mitochondrial + peroxisomal disorders
  \end{itemize}
\end{itemize}

\hypertarget{encephalopathy}{%
\subparagraph{Encephalopathy}\label{encephalopathy}}

\begin{itemize}
\tightlist
\item
  MSUD
\item
  MMA
\item
  PA
\item
  IVA
\item
  MCD
\item
  UCD
\end{itemize}

\hypertarget{seizures}{%
\subparagraph{Seizures}\label{seizures}}

\begin{itemize}
\tightlist
\item
  B6 responsive seizures
\item
  MCD (biotin)
\item
  Folinic acid responsive
\item
  GLUT1
\item
  3PGD
\end{itemize}

\hypertarget{hepatic}{%
\subparagraph{Hepatic}\label{hepatic}}

\begin{itemize}
\tightlist
\item
  Galactosemia
\item
  Fructosemia
\item
  Tyrosinemia
\item
  Bile acid synthesis defects
\item
  Glycosylation defects Ib
\item
  LCHAD
\end{itemize}

\hypertarget{cardiomyopathy-1}{%
\subparagraph{Cardiomyopathy}\label{cardiomyopathy-1}}

\begin{itemize}
\tightlist
\item
  LC-FAOD
\item
  Pompes
\end{itemize}

\hypertarget{hypoglycemia-1}{%
\subparagraph{Hypoglycemia}\label{hypoglycemia-1}}

\begin{itemize}
\tightlist
\item
  GSD
\item
  FAOD
\item
  Primary hyperinsulinemia
\end{itemize}

\hypertarget{physical-exam-21}{%
\paragraph{Physical exam}\label{physical-exam-21}}

\begin{itemize}
\tightlist
\item
  Usually non-specific--hepatomegaly and HD instability may be only signs in a crisis
\item
  Dysmorphisms and other findings may be seen in specific cases:
\end{itemize}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.54\columnwidth}\raggedright
\textbf{Dysmorphisms}\strut
\end{minipage} & \begin{minipage}[b]{0.40\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Peroxisomal disorders (e.g.~Zellweger)\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Trisomy 21 like facies\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Pyruvate dehydrogenase deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
FAS like facies\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Lysosomal disorders (I cell disease)\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Hurler-like coarse facies\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Glycosylation defects\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Inverted nipples, fat pads/lipodystrophy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
\textbf{Hydrops}\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Storage disorders\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Mucopolysaccharidosis, Niemann-Pick\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Disorders affecting erythropoiesis\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
G6PD deficiency, pyruvate kinase deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Disorders affecting liver\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Neonatal hemochromatosis, galactosemia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
\textbf{Skin and hair manifestations}\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Acrodermatitis enteropathica (Zn def)\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Vesiculobullous/eczematoid lesions on perioral/perineal areas\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Hartnup\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Pellagra like features\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
PKU\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Blonde, fair, blue eyes\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Congenital Erythropoetic Porphyrias\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Photosensitivity with vesiculobullous lesions and scarring\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Biotinidase deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Rash and alopecia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
Menkes syndrome (Cu dysreg)\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Pilli torti (fragile, kinky hair), sagging skin\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
\textbf{Cataracts}\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Lowe, galactosemia, Zellweger and variants\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.54\columnwidth}\raggedright
\textbf{Hepatomegaly}\strut
\end{minipage} & \begin{minipage}[t]{0.40\columnwidth}\raggedright
Galactosemia, hereditary fructose intolerance, GSD type Ia \& III, LCHAD, Tyrosinemia, hemochromatosis, Zellweger, Lysosomal storage disease\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{initial-lab-workup}{%
\paragraph{Initial lab workup}\label{initial-lab-workup}}

Consider the following tests based on your above history and physical:

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
Lab test\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
Common associations\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
VBG + chem 10\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Acidosis and increased anion gap in organic acidemias\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Blood glucose\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Hypoglycemia in FAOD, glycogenolysis and glycosylation defects\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
LFTs and coags\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Jaundice/hepatitis in tyrosinemia, galactosemia, hemochromatosis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Plasma ammonia\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Increased in urea cycle defects and organic acidemias\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Plasma lactate (L), pyruvate (P), and ketoacids (3OHB, AcAc)\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Some IEMs have pathognomonic L/P or 3OHB/AcAc ratios\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
CBC w/diff\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Neutropenia and thrombocytopenia with IVA, MMA, PA; neutropenia in GSD Ib\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Blood Culture\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Galactosemia a/w increased incidence of E. coli sepsis.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Urine pH\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
\textgreater5 in setting of acidosis suggests distal RTA.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Urine (non-glucose) reducing substances\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Suggestive of galactosuria or fructosuria\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Urine ketones (if acidosis or hypoglycemia)\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
As with plasma ketoacids, although B-OHB may be easier to obtain from plasma in infants\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{secondary-workup}{%
\paragraph{Secondary workup}\label{secondary-workup}}

In discussion with metabolism:

\begin{itemize}
\tightlist
\item
  \textbf{Urine:} Organic acids, acylglycines, mucopolysaccharides, oligosaccharides
\item
  \textbf{Plasma:} AAs (quantitative), carnitine + acylcarnitine, Peroxisomal tests (VLCFA), bile acid analysis
\item
  \textbf{CSF:} for amino acids (glycine), lactate, pyruvate, and neurotransmitters, glucose (with corresponding serum glucose 30 min before LP)
\item
  \textbf{Imaging:} Brain MRI/MRS, HIDA scan for biliary atresia
\item
  \textbf{Auditory + ophthalmologic evaluations}
\item
  *In general pre-prandial samples should be sent for most tests (at least 2-4 hours after last feed)
\end{itemize}

\begin{quote}
\textbf{Bill's Pearls:} Plasma AAs

A plasma amino acid panel can tell you if you need to give protein or not, if you see deficiency in multiple amino acids. You can only restrict protein for 24-48 hours before an amino acid deficiency develops. When there is an AA deficiency, the catabolic state is less responsive to dextrose-based anabolic support. In addition to protein synthesis, amino acids have other synthetic and regulatory roles (methionine -\textgreater{} methylation of DNA, synthesis of creatine; leucine -\textgreater{} stimulator of insulin secretion; cysteine -\textgreater{} antioxidant; etc.) you may not otherwise think about.
\end{quote}

\hypertarget{later-onset}{%
\subsubsection{Later onset}\label{later-onset}}

\textbf{\emph{About 50\% of patients with IEMs present beyond the immediate neonatal period (even as adults!)}}

\hypertarget{history-7}{%
\paragraph{History}\label{history-7}}

\emph{Episodic illness} precipitated by mild intercurrent illness, fasting, or change of diet, specific dietary preferences (e.g., autovegetarianism seen in conditions predisposing to hyperammonemia), behavioral issues such as ADHD (partially treated PKU)

\hypertarget{presentation-92}{%
\paragraph{Presentation}\label{presentation-92}}

Can be classified into 2 patterns which may overlap:

\begin{itemize}
\tightlist
\item
  Acute, presenting in a metabolic crisis w/ emesis, lethargy, seizures, tachypnea

  \begin{itemize}
  \tightlist
  \item
    \textbf{Encephalopathy}

    \begin{itemize}
    \tightlist
    \item
      \textbf{Without focal findings:} look for predominant acidosis, hyperammonemia or hypoglycemia \& work up as outlined above
    \item
      \textbf{With focal findings:} homocystinuria with thromboembolic event, mitochondrial disorders with CVA, biotin-responsive basal ganglia disease, some OA (striatal necrosis inorganic acidemias); cerebral edema in UCDs
    \end{itemize}
  \item
    \textbf{Recurrent ataxia:} MSUD, OTC, pyruvate dehydrogenase (associated peripheral neuropathy)
  \item
    \textbf{Psychiatric symptoms:} UCD's, porphyrias, homocystinuria, cobalamin C disease, late-onset Tay Sachs
  \item
    \textbf{Dehydration} associated with:

    \begin{itemize}
    \tightlist
    \item
      \textbf{Polyuria:} RTA, nephrogenic Diabetes Insipidus
    \item
      \textbf{Diarrhea:} glucose or galactose malabsorption, acrodermatitis enteropathica (Zn deficiency), sucrase isomaltase deficiency, congenital chloride diarrhea
    \item
      \textbf{Ketoacidosis:} MMA, IVA, PA, DM
    \item
      \textbf{Salt losing:} CAH, hypoaldosteronism
    \end{itemize}
  \item
    \textbf{Reye syndrome-like:} UCD's and OA's, disorders of mitochondrial fatty acid oxidation and ketogenesis
  \end{itemize}
\item
  \textbf{Indolent:} FTT, myopathies, neurological sequelae (DD, ID, micro/microcephaly), dysmorphisms
\end{itemize}

\hypertarget{aminoacidopathies}{%
\subsection{Aminoacidopathies}\label{aminoacidopathies}}

\begin{quote}
\textbf{Bill's Pearls:} high-level approach to Aminoacidopathies

Amino acid concentrations that get excessively elevated can cause cerebral edema (e.g.~leucine in MSUD, methionine in homocystinuria). Avoid excessive fluid administration if you think these states are present. The key is to provide metabolic formula that has caloric value and a mixture of amino acids that don't include the toxic ones (i.e.~branched-chain-free formula in MSUD). The goal is to make the toxic amino acid the limiting reagent in protein synthesis and to provide enough calories to stimulate protein synthesis. You don't get the same effect with dextrose-containing fluids and end up giving more volume.
\end{quote}

\textbf{PowerPlan if relevant:} Metabolism MSUD Admit Orderset

\hypertarget{biochemical-defect}{%
\paragraph{Biochemical defect}\label{biochemical-defect}}

Defect in AA metabolism → toxic AA metabolites accumulate

\hypertarget{presentation-93}{%
\paragraph{Presentation}\label{presentation-93}}

\begin{itemize}
\tightlist
\item
  May present early (neonatal period) as catastrophic `intoxication'-like disease → feeding difficulty, lethargy, tachypnea, and poor perfusion → encephalopathy (e.g., MSUD)
\item
  May present later w/ chronic encephalopathy (e.g., PKU)
\item
  Often NO acidosis or hyperammonemia (vs organic acidemias and UCDs)
\end{itemize}

\hypertarget{workup-18}{%
\paragraph{Workup}\label{workup-18}}

\begin{itemize}
\tightlist
\item
  Definitive: quant plasma AAs + sequencing
\item
  May be suggested by NBS, labs w/ hypoglycemia, ketosis, liver dysfxn
\end{itemize}

\hypertarget{management-general-approach}{%
\paragraph{Management (general approach)}\label{management-general-approach}}

\begin{itemize}
\tightlist
\item
  Restrict culprit AA in diet, monitor plasma AAs carefully
\item
  \textbf{Avoid catabolism:} may be with dextrose-containing fluids and/or AA-excluding formulas (encourage new protein synthesis with toxic AA as limiting reagent)
\item
  Cofactor therapy in some cases
\end{itemize}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Phenylketonuria}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Phenylalanine hydroxylase (Phe → Tyr)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Phenylalanine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Neurotoxicity, intellectual deficits, microcephaly, GDD, eczema\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Avoid Phe, give special Phe-free diet, consider cofactor tx (sapropterin), enzyme substitution (adults)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Maple Syrup Urine Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Branched-chain alpha-keto acid dehydrogenase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
BCAAs: Leu, Ile, Val, Leu is neurotoxic, causes hypoNa\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Catabolic stress, high Leu intake → HA, confusion, halluc, lethargy, N/V → coma/death\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Stop all Leu, give Leu-free feeds, dex-containing IVF, AVOID hypotonic fluids (cerebral edema)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Homocystinuria}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Cystathionine β-synthase (Hcy → cystathionone)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Homocysteine (chronic toxicity), \textbf{Methionine (potentially acute cerebral edema)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Intellectual disability, tall stature, thrombosis (Hcy is thrombophilic), downward lens dislocation, osteoporosis\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Met-free formula, B6 (cofactor for cystathionine β-synthase) in responsive patients, betaine (Hcy → Met), risk of cerebral edema with rapid methionine correction\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Tyrosinemia}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Fumaryl- acetoacetase (fumaroaceto-acetate, → fumarate + acetoacetate)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Tyrosine (blood), Succinylacetone (urine)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Liver failure, RTA - due to accumulation of succinylacetone\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Nitisinone (blocks early step in Tyr metab - can't make succinylacetone), Tyr restriction\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{carbohydrate-metabolism-defects}{%
\subsection{Carbohydrate Metabolism Defects}\label{carbohydrate-metabolism-defects}}

\textbf{PowerPlan if relevant:} Galactosemia Admit Orderset

\hypertarget{biochemical-defect-1}{%
\paragraph{Biochemical defect}\label{biochemical-defect-1}}

Issues with glucose/fructose/galactose metabolism

\hypertarget{presentation-94}{%
\paragraph{Presentation}\label{presentation-94}}

\begin{itemize}
\tightlist
\item
  Timing depends on intro to culprit carb (\textbf{galactosemia early} d/t breastmilk, \textbf{fructose introduced later}) and from timing of spacing feeds (\textbf{longer fasting} = need to mobilize glycogen stores → \textbf{GSD becomes manifest})
\item
  Often p/w metabolic crises (lethargy, encephalopathy, HD instability); may have stigmata of toxic deposition (see chart below)
\end{itemize}

\hypertarget{workup-19}{%
\paragraph{Workup}\label{workup-19}}

\begin{itemize}
\tightlist
\item
  \textbf{NBS:} Galactosemia (NOT hereditary fructosuria or GSD)
\item
  Definitive with enzyme assays from blood (also done on cultured fibroblasts \& liver)
\item
  Suggestive labs: hypoglycemia, ketosis, metabolic acidosis, liver dysfunction; reducing substances in urine present in galactosemia + hereditary fructose intolerance
\end{itemize}

\hypertarget{management-general-approach-1}{%
\paragraph{Management (general approach)}\label{management-general-approach-1}}

\begin{itemize}
\tightlist
\item
  Dietary avoidance of the given carbohydrate
\item
  Some hepatic glycogen storage diseases are associated with hypoglycemia (I, III, IV, IX, 0). For sick children that need dextrose-containing fluids, the goal is to keep BG \textgreater{} 77 but below 110. In excess of that, glycogen starts to be stored and can worsen existing accumulation.
\end{itemize}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Classic Galactosemia}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Galactose-1- phosphate uridyl transferase (allows for transfer of Gal-1-P to Glu-1-P)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Gal-1-P, total galactose + urine reducing substances\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Hepatomegaly, jaundice, vomiting, cataracts, FTT, lethargy, proximal RTA (Fanconi syndrome), E Coli sepsis after starting galactose-containing feeds (e.g., breastmilk)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
No galactose - includes no lactose (milk / dairy)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Hereditary Fructose Intolerance}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Aldolase B (splits F-1-P into DHAP + glyceraldehyde)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
F-1-P - urine reducing substances\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Similar to classic galactosemia, but no cataracts; occurs w/ fructose-containing foods\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
No fructose from diet - includes no sucrose or sorbitol\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Glycogen Storage Disease (GSD) Type Ia (von Gierke)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glucose 6 phosphatase (G6P → glucose + Pi, last step of glycogen breakdown)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
G6P → lactate, triglycerides, and uric acid\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textasciitilde3-6 months: hypoglycemia 3-4 hrs after meal, lactic acidosis, hepatomegaly, hypertriglyceridemia, hyperuricemia, ``doll face,'' small size\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Frequent meals, Uncooked cornstarch 1.5-2.5 g/kg PO q4-6h, avoid sucrose/fructose/galactose, NaHCO3 for acidosis, allopurinol for hyperuricemia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{GSD Type IIa (Pompe)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Lysosomal acid α-glucosidase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glycogen - accumulates in skeletal and cardiac muscles\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Progressive hypotonia, macroglossia, loss of motor, respiratory, and cardiac functions (\textbf{cardiomyopathy}). Pilot optional test on NBS\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ERT (alglucosidase alfa), management of cardiomyopathy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{GSD Type IIIa \& IIIb (Cori)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Debranching enzyme\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glycogen - accumulates in liver and muscle\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Similar to Ia but may be milder; IIIb causes neutropenia\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Uncooked cornstarch + continuous feeds to maintain normoglycemia, high-protein diet\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{GSD Type V (McArdle)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Muscle phosphorylase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glycogen - accumulates in muscle\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Exercise intolerance / cramping, ``second wind'' phenomenon, myoglobinuria/ rhabdomyolysis\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Carbohydrate administration before exercise, high-protein diet\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{fatty-acid-oxidation-disorders}{%
\subsection{Fatty Acid Oxidation Disorders}\label{fatty-acid-oxidation-disorders}}

\textbf{PowerPlans if relevant:} Metabolism Fatty Acid Ox Disorder NOS Admit Orderset, LCFAOD Admit Orderset

\hypertarget{biochemical-defect-2}{%
\paragraph{Biochemical defect}\label{biochemical-defect-2}}

Mitochondrial FA oxidation (AKA β-oxidation) = main energy (FADH2 / NADH for \textbf{gluconeogenesis} and \textbf{ketogenesis}) for \textbf{heart, skeletal muscle, neurons} when Glucose is limited (starvation, exercise). Disorders occur d/t decreased carnitine uptake by cells (required for FA transport into the mitochondria), inhibiting entry of FAs into mitochondria, or by blocking β-oxidation. End result = energy-deficient state \textbf{without appropriate ketosis}.

\hypertarget{presentation-95}{%
\paragraph{Presentation}\label{presentation-95}}

Fasting-induced vomiting, lethargy, coma, and hypoglycemic seizures, occasional hepatomegaly (may be Reye's-like)

\hypertarget{workup-20}{%
\paragraph{Workup}\label{workup-20}}

Suggested by \textbf{hypoketotic hypoglycemia} +/- liver failure, acidosis \& hyperammonemia. Acylcarnitine profile with specific findings. Confirmation w/ DNA mutation analysis (less frequently enzyme testing in cultured skin fibroblasts)

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Medium-chain acyl-CoA DH deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
MCAD -- cannot degrade MC FAs to short-chain FAs and Acetyl CoA\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
C6, C8, and C10 acylcarnitines\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Illness + poor PO → glycogen depletion → HKHG → brain injury, seizures, \& death if untreated; excellent prognosis if treated. \textbf{On NBS in most states, but may present on DOL 2-3}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Avoid fasting during illnesses, give dex-containing IVF if unable to tolerate PO, carnitine supplementation if low carnitine, \textbf{AVOID MCT}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Long-chain / Very long-chain acyl-CoA DH deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
LCHAD/VLCAD\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{LCHAD/TFP:} 3-hydroxy-acyl-carnitines (C16-OH) \textbf{VLCAD:} unsat long-chain acylcarnitines (C14:1)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
More severe than MCAD -- rhabdo, CMP, liver failure, and HKHG even w/ rx. LCHAD may have peripheral neuropathy + retinopathy. On NBS in all states\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Dietary fat restriction, MCT oil supplementation, avoid fasting; give dex-containing IVF, Serial cardiac evaluations, check CK with illnesses\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Primary Carnitine Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Defective carnitine transporter (OCTN2) -- dec GI absorption / renal reabs.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Elevated urine carnitine, low blood carnitine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
CMP + recurrent HKHG, may progress to Reye-like picture. \textbf{Blood:} low free carnitine. \textbf{Urine:} elevated carnitine excretion\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
High-dose oral carnitine, avoidance of fasting, dex-containing IVF if unable to tolerate PO\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{lysosomal-diseases}{%
\subsection{Lysosomal Diseases}\label{lysosomal-diseases}}

\hypertarget{biochemical-defect-3}{%
\paragraph{Biochemical defect}\label{biochemical-defect-3}}

Deficiency in lysosomal enzyme → excess intracellular substrate (e.g., GAGs, MPS)

\hypertarget{presentation-96}{%
\paragraph{Presentation}\label{presentation-96}}

\begin{itemize}
\tightlist
\item
  Substrate build-up → HSM, coarse facies, short stature, skeletal abnormalities
\item
  If nervous system involvement → intellectual disability, cataracts, neuropathy
\end{itemize}

\hypertarget{workup-21}{%
\paragraph{Workup}\label{workup-21}}

\textbf{Enzyme assay} on samples of WBCs, serum, or skin fibroblasts

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Gaucher Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
β-glucosidase (glucocerebrosidase)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glucocerebroside\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Type 1:HSM, bone disease, anemia \& thrombocytopenia, absence of CNS disease Type 2\&3: Primarily neurologic with DD, regression, early death\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ERT, substrate reduction therapy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Tay-Sachs Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Hexosaminidase A\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
GM2 gangliosides\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
By age 1 - DD, exaggerated startle, sz, macular cherry-red spot\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Supportive\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Niemann-Pick Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Sphingomyelinase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Sphingomyelin\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Massive HSM, cherry red spot, interstitial lung disease; neuronopathic or non-neuronopathic\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
HSCT for non- neuronopathic\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Krabbe Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Galactocerebrosidase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Galactocerebroside\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Infantile-onset:By age 1 - irritability, rapid neurologic deterioration,early childhood death. Later-onset: variable\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Early HSCT\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Metachromatic Leukodystrophy}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Cerebroside sulfatase (arylsulfatase A)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Sulfatides\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
First years of life (late infantile form): DD/regression; Juvenile form with regression, of dev and beh, then gait; Peripheral neuropathy in adult form\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
HSCT for juvenile and adult MLD\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Fabry Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
α-galactosidase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Globotriaosyl- ceramide (GL-3)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
X-linked recessive. Acroparesthesias, pain crises, corneal opacities, fatigue, angiokeratomas\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ERT\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Hurler Syndrome (MPS I)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
α-L-iduronidase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glycosamino- glycans (GAGs): dermatan + heparan sulfate\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Coarse facies, DD, ID, corneal clouding, hearing loss, hernias, dysostosis multiplex\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ERT, HSCT\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Hunter Syndrome (MPS II)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Iduronate-2-sulfatase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
GAGs as above\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
X-linked recessive. Similar to MPSI r w/o corneal clouding.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ERT, HSCT\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\emph{ERT = enzyme-replacement therapy. HSCT = hematopoietic stem-cell transplant. Autosomal recessive unless otherwise specified}

\hypertarget{mitochondrial-disorders-primary-lactic-acidemias}{%
\subsection{Mitochondrial Disorders / Primary Lactic Acidemias}\label{mitochondrial-disorders-primary-lactic-acidemias}}

\begin{quote}
\textbf{Bill's Pearls:} high-level approach to Mitochondrial disorders

Mitochondrial diseases don't decompensate acutely like small molecule metabolic diseases. Therapy is focused on decreasing systemic stressors (treat infection, stop catabolism, correct dehydration, etc). Try to \textbf{keep the bicarbonate \textgreater{} 16}, otherwise acidemia will impair mitochondrial function. The lactate levels will be what they are -- just keep the bicarbonate up and don't give too much dextrose (D5 ok, D10 negotiable). \textbf{Don't give valproic acid or Lactated Ringers.} Lactate gets the attention but cardiac dysfunction in acute scenarios is the concern. Cardiac cells that have poor mitochondrial function typically hypertrophy, leading to hypertrophic cardiomyopathy and some preload dependence. You are never wrong to get an EKG and call cardiology. Correct dehydration to minimize perfusion-associated lactic acidemia.

If you think someone may have a mitochondrial disease, get a plasma amino acid level with a lactate. Look for elevated alanine as well, because of the high error associated with lactate due to blood draws. True metabolic acidemia should have an anion gap and acidic urine.
\end{quote}

\hypertarget{biochemical-defect-4}{%
\paragraph{Biochemical defect}\label{biochemical-defect-4}}

Disorders of \textbf{Krebs cycle} and \textbf{oxidative phosphorylation}; transmission via mitochondrial genes → defects vary / not all organs are affected equally

\hypertarget{presentation-97}{%
\paragraph{Presentation}\label{presentation-97}}

Indolent, progressive neurologic deterioration, +/- poor feeding, vomiting, CMP, myopathy, liver failure, seizures, strokes, blindness, deafness, and nephropathy

\hypertarget{workup-22}{%
\paragraph{Workup}\label{workup-22}}

\begin{itemize}
\tightlist
\item
  Definitive dx from enzyme assay or DNA testing
\item
  Labs often show \textbf{AG metabolic acidosis} and \textbf{primary lactic acidosis} +/- hypoglycemia w/ ketosis, liver dysfxn
\end{itemize}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Pyruvate Dehydrogenase Complex Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Pyruvate dehydrogenase (Pyruvate → Acetyl CoA + CO2)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Pyruvate → lactate\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Lactic acidosis, intellectual disability, hypotonia, seizures, exacerbated by ingestion of carbohydrates\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Supplement with carnitine, thiamine, and lipoic acid (cofactors for pyruvate DH complex), high fat / low carb diet or ketogenic diet\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Pyruvate Carboxylase Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Pyruvate carboxylase (pyruvate + CO2 → oxaloacetate)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Pyruvate → lactate\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
NH3 (as Asp cannot be formed from OAA) Severe lactic acidosis, hypothermia, hypotonia, hypoglycemia, hyperammonemia, lethargy, vomiting, often death as neonate or w/in 1 year for Type B; Types A \& C are milder\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
High carb and protein diet; Treat metabolic crisis with 10\% dex-containing IVF, avoid fasting, NaHCO3 for acidosis, possible liver transplant\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{organic-acidemias}{%
\subsection{Organic Acidemias}\label{organic-acidemias}}

\textbf{Powerplans if relevant:} Metabolism IVA, MMA, PA, Glutaric Acidemia Type I Admit Ordersets

\hypertarget{biochemical-defect-5}{%
\paragraph{Biochemical defect}\label{biochemical-defect-5}}

Defect in AA breakdown → accumulation of organic acid byproducts

\hypertarget{presentation-98}{%
\paragraph{Presentation}\label{presentation-98}}

Neonatal lethargy, poor perfusion, vomiting, coma, CVAs, death

\hypertarget{workup-23}{%
\paragraph{Workup}\label{workup-23}}

\begin{itemize}
\tightlist
\item
  \textbf{Definitive:} quant plasma AAs
\item
  Often on NBS (elevated C3 / C5 acylcarnitines)
\item
  Usually p/w severe high \textbf{AG metabolic acidosis}, +/- hyperammonemia, hypoglycemia, liver dysfunction, ketosis, and secondary carnitine deficiency
\end{itemize}

\hypertarget{management-general-approach-2}{%
\paragraph{Management (general approach)}\label{management-general-approach-2}}

Stop all protein intake, high-dose carnitine, promote anabolism with D10NS + IL +/- insulin, +/- NaHCO3 for severe acidosis, dialysis for life-threatening acidosis or hyperammonemia

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Methylmalonic acidemia}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
methylmalonyl-CoA mutase deficiency (MM-CoA → succinyl CoA)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Products of BCAAs (Ile, Val, Met) - MMA, methylcitrate, C3 acylcarnitine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Stressor (illness, excess protein intake) → metabolic crisis (high-AG metabolic acidosis, basal ganglia stroke, pancreatitis). Complications: renal dz, intellectual disability. Variable age of onset.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
As above, plus Vitamin B12, liver or liver/kidney transplantation, avoid Ile, Val, Met, Thr in diet\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Propionic acidemia}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
propionyl-CoA carboxylase deficiency (propionyl CoA → MM-CoA)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Products of BCAAs (Ile, Val, Met) - 3-OH propionic acid, methylcitrate, C3 acylcarnitine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Newborn period - profound metabolic acidosis w/ high AG and prominent ketosis → multiorgan dysfunction (cardiac, respiratory, pancytopenia, basal ganglia stroke, pancreatitis), hyperammonemia. Later - cardiomyopathy and dysrhythmias in early adulthood\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
As above, plus liver transplant, avoid Ile, Val, Met, Thr in diet. \textbf{Acutely,} anabolic support, increase carnitine to protect mito from organic acids. Consider bowel regimen (stool can harbor toxic intermediates).\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Isovaleric acidemia}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
isovaleryl-CoA dehydrogenase (isovaleryl-CoA → → acetoacetate and Ac-CoA)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Products of Leu metabolism (Isovaleric acid and metabolites), C5 acylcarnitine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Neonatal: severe lethargy and obtundation, +AG metabolic acidosis, hypoglycemia, ketonuria, hyperammonemia, odor of IVA in urine, pancreatitis. Infantile/late-onset: FTT, DD, seizures\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
As above, avoid Leu\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Glutaric acidemia type I (GA1)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Glutaryl CoA DH deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Products of Trp and Lys metab (plasma C5 dicarboxylic (C5DC) acylcarnitine)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Macrocephaly (risk of tearing of bridging veins → subdural hemorrhage), \textbf{metabolic basal ganglia stroke} (unlikely after 6y), isolated cerebral acidosis -- may not have metabolic acidosis/ketosis/hyperammonemia. \textbf{Catabolic stress, fever} → devastating neurologic injury (dystonia, movement disorders).\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
As above, restrict Trp and Lys in diet, aggressive sick day management. Start D10 at 1.5x mIVF regardless of appearance. If controlled during childhood, outcomes excellent.\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{peroxisomal-disorders}{%
\subsection{Peroxisomal Disorders}\label{peroxisomal-disorders}}

\hypertarget{biochemical-defect-6}{%
\paragraph{Biochemical defect}\label{biochemical-defect-6}}

Peroxisomes = site for β-ox of VLCFAs, H2O2 degradation, and pipecolic, phytanic, and pristanic acid metabolism, also of bile acid synthesis, plasmalogen formation (for membranes and myelin).

\hypertarget{presentation-99}{%
\paragraph{Presentation}\label{presentation-99}}

Dysmorphic facies (as below) alongside shortened proximal limbs, epiphyseal stippling, hypotonia, seizures, encephalopathy, cataracts, retinopathy, hepatomegaly, and cholestasis.

\hypertarget{workup-24}{%
\paragraph{Workup}\label{workup-24}}

Elevated levels of substrate in question (see below), enzyme assays

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Zellweger Syndrome\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Several peroxisomal genes; often PEX1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
VLCFAs and branched- chain FAs\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Early neuromotor arrest, seizures, ID, craniofacial anomalies (large fontanel, midface hypoplasia, short pf, incr. neck fat),chondrodysplasia punctata (calcification of cartilage), renal cysts, liver failure - cerebrohepatorenal syndrome, death w/in 1 yr\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Supportive care only; no disease-modifying rx\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Refsum Disease\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Defective phytanoyl-CoA -hydroxylase\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Phytanic acid\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Later onset (adolescence / adulthood) of ataxia, retinitis pigmentosa, ichthyosis, cataracts/night blindness, anosmia, and hearing loss\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Restrict phytanic acid intake (found in dairy, beef, lamb, seafood. Cardiac \& ophtho surveillance\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Adrenoleukodystrophy\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
ABCD1 gene - issues shuttling VLCFAs in to peroxisomes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
VLCFAs\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
X-linked recessive. Seizures, intellectual disability, neuromotor arrest, adrenal insufficiency, hypogonadism, beginning with behavioral changes around age 4-10.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Lorenzo's oil (special preparation of FAs)-NOT PROVEN. Treat adrenal disease. HSCT\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{urea-cycle-defects}{%
\subsection{Urea Cycle Defects}\label{urea-cycle-defects}}

\textbf{PowerPlans:} Several, including for known defects and unknown; search ``metabolism urea'' in PC for full list

\hypertarget{biochemical-defect-7}{%
\paragraph{Biochemical defect}\label{biochemical-defect-7}}

Deficiency in any of the 6 UC enzymes, which converting toxic nitrogenous metabolites from protein turnover to non-toxic urea for urinary excretion → NH3 accumulation.

\begin{figure}
\centering
\includegraphics{images/metab_urea_cycle.png}
\caption{Urea cycle diagram with assocated disorders in blue.}
\end{figure}

\hypertarget{presentation-100}{%
\paragraph{Presentation}\label{presentation-100}}

Interim healthy period → \textbf{catabolic stressor} (stress, infection, surgery, or starvation) → vomiting, feeding intolerance, tachypnea (due to central hyperventilation) → encephalopathy and coma, with potentially irreversible brain damage if untreated.

\hypertarget{workup-25}{%
\paragraph{Workup}\label{workup-25}}

\begin{itemize}
\tightlist
\item
  Labs w/ hyperammonemia and respiratory alkalosis → metabolic acidosis
\item
  Definitive: plasma/urine levels of UCD metabolites and confirm with enzyme testing
\end{itemize}

\hypertarget{management-general-approach-3}{%
\paragraph{Management (general approach)}\label{management-general-approach-3}}

\begin{quote}
\textbf{Bill's Pearls:} UCD management

Children often look better than their ammonia level. \emph{Start anabolic support when they get to the ED!} If they don't have access, then get it as fast as you can. If they are not vomiting, protein-free formula run continuously through a G-tube provides more calories than IV fluid and is faster to get going.
\end{quote}

\begin{itemize}
\tightlist
\item
  \textbf{Acutely:} immediate treatment of hyperammonemia (see full details in Metabolic crisis management section): Stop all protein intake (but no longer than 36-48h), give dex-containing IVF (10-25\% @ 1.5xM) and IL (1-3 g/kg/d) through central line, NH3 scavengers (Ammonul = Na benzoate and Na phenylacetate) usually with IV arginine, avoid hypoNa (would exacerbate cerebral edema), prepare for HD (likely if NH3 \textgreater{} 300 μmol/L)
\item
  \textbf{Long term:} Low-protein diet, avoid catabolism, include missing UC intermediates, liver transplant
\end{itemize}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Disorder\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Enzyme Blockade\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Accumulated Substrate(s)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Presentation\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Ornithine Transcarbamylase Deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
OTC (carbamoyl phosphate + ornithine → citrulline) - most common\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
NH3 → cerebral edema. Glutamine elevation. Low arginine and citrulline as cycle is blocked proximally. Elevated \textbf{orotic acid} in urine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
X-linked recessive. \textbf{Hyperammonemic crisis}, typically early on, p/w poor feeding, lethargy, tachypnea, hypothermia, irritability, vomiting, ataxia, seizures, hepatomegaly, coma. \textbf{NOT} always evident on NBS, may flag for low citrulline\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
As above, alongside: citrulline/ arginine, + carnitine, ammonia scavengers such as glycerol phenylbutyrate. \textbf{Consider ammonul for acute hyperammonemia}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Citrullinemia}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Arginosuccinate synthetase (citrulline + aspartate → argininosuccinate)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Same as OTC def but with elevated citrulline\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Similar to OTC def, but AR inheritance. All states include on NBS\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
As above, alongside: arginine, glycerol phenylbutyrate, NO citrulline\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Arginosuccinic aciduria}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Arginosuccinate lyase (arginosucc → fumarate + arginine)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Same as OTC def but with elevated citrulline and arginosuccinate\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Similar to citrullinemia. All states include on NBS\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Same as for citrullinemia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Carbamoyl phosphate synthetase (CPS) I deficiency \& NAGS deficiency}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
CPS I (NH3 + bicarb + Phos → CPS). NAGS is cofactor for CPSI\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Same as OTC def but without elevated orotic acid in the urine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Similar to OTC deficiency. NOT always evident on NBS, may flag for low citrulline\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Same as for OTC deficiency\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{glossary-1}{%
\subsection{Glossary}\label{glossary-1}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
Abbreviation\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
Term\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
BOHB/3OHB\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
3- (or beta-) Hydroxybutyrate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
3PGD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
3 Phosphoglycerate dehydrogenase deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
CAH\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Congenital adrenal hyperplasia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
CPS\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Carbamoyl phosphate synthetase\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
CPT-I\&II\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Carnitine palmitoyl transferase deficiency Type I and II\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
DH\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Dehydrogenase\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
FAOD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Fatty acid oxidation defects/disorders\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
FDP\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Fructose diphosphate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
GALT\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Galactose-1-phosphate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
GIR\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Glucose infusion rate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
GLUT1\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Glucose transporter protein type 1\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
GSD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Glycogen storage disease\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
HHH\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Hyperammonemia, hyperornithinemia, homocitrullinuria\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
HMGCoA\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
3-Hydroxy-3-methlyglutaryl-CoA\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
IEM\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Inborn error of metabolism\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
IVA\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Isovaleric acidemia/Isovaleryl-CoA DH deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
LCAD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Long-chain acyl-CoA DH deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
LCHAD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Long-chain hydroxyacyl-CoA DH deficiency / 3-Hydroxyacyl CoA DH deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
L/P\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Lactate/pyruvate ratio\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
MCADD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Medium-chain acyl-CoA DH deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
MCD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Multiple Carboxylase deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
MMA\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Methlymalonic acidemia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
MSUD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Maple syrup urine disease\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
OA\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Organic acidemia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
OTC\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Ornithine transcarbamylase\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
PA\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Propionic acidemia/Propionyl-CoA carboxylase deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
PC\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Pyruvate carboxylase\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
PDH\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Pyruvate DH\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
PKU\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Phenylketonuria\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
TEE\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Total energy expenditure\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
THAN\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Transient hyperammonemia of the Newborn\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
UCD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Urea Cycle Defect\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
VLCAD\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Very long-chain acyl-CoA DH deficiency\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{resources-1}{%
\subsection{Resources}\label{resources-1}}

\textbf{Information for patients and families:} \href{}{newenglandconsortium.org}, \href{}{https://www.newbornscreening.info/}\\
\textbf{Acute Illness Protocols:} \href{}{https://newenglandconsortium.org/for-professionals/acute-illness-protocols/}\\
\textbf{Newborn Screen Resources:} \href{}{https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT\_Sheets\_and\_Algorithms.aspx, http://genes-r-us.uthscsa.edu/resources.htm}\\
\textbf{Manifestations/Diagnosis/Treatment reviews} for most genetic/metabolic diseases: \href{}{https://www.ncbi.nlm.nih.gov/books/NBK1116/}

Major classification of IEMs and examples are adapted in part from Rice GM et al, Pediatrics in Review 2016;37.

\hypertarget{nephrology}{%
\section{Nephrology}\label{nephrology}}

\hypertarget{formulas}{%
\subsection{Formulas}\label{formulas}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.09\columnwidth}\raggedright
Formula Name\strut
\end{minipage} & \begin{minipage}[b]{0.34\columnwidth}\raggedright
Formula\strut
\end{minipage} & \begin{minipage}[b]{0.48\columnwidth}\raggedright
Clinical Use\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Modified Bedside Schwartz}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(eGFR=0.413 \times \frac{height_{(cm)}}{SCr}\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Used ages 1-18 to estimate GFR.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Insensible Fluid Loss}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(IFL_{(mL/day)}=300mL/m^{2}/day\) \(BSA_{(m^{2})}=\sqrt{\frac{ht_{(cm)}\times wt_{(kg)}}{3600}}\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Use for patients when replacing insensible fluid plus urine/stool losses.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Total Body Water}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(TBW_{males}=wt_{(kg)}\times 0.6\) \(TBW_{females}=wt_{(kg)}\times 0.5\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Use to calculate total body water.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Free Water Deficit}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(FWD_{(L)}=\left ( \frac{Current\: Na^{+}}{Desired\: Na^{+}} -1\right )\times TBW\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Calculate \textbf{water} to be replaced in \textbf{hypernatremic} dehydration.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Sodium Deficit}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(Na^{+} Deficit_{(mEq)}=(140-Na_{actual}^{+})\times TBW\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Calculate \textbf{Na+} to be replaced in \textbf{hyponatremic} dehydration.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Fractional Excretion Sodium}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(FENa=\frac{\left ( Urine\: Na^{^{+}}\times Plasma\: Cr \right )}{\left ( Plasma\: Na^{+}\times Urine\: Cr \right )}\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Use in oliguric \textbf{AKI} to determine \textbf{prerenal} (\textless1\%, sodium-avid) vs.~\textbf{intrinsic renal} (\textgreater{} 2\%, tubular dysfunction) etiology).\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Fractional Excretion of Urea}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(FEUrea=\frac{\left ( Urine\: Urea\: Nitrogen\times Plasma\:Cr \right )}{\left ( Plasma\: Urea\: Nitrogen\times Urine\: Cr \right )}\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Use in \textbf{AKI} if patient has recently been given \textbf{diuretics} (would alter Na+ excretion and therefore FENa), acute GN, or CKD; \textbf{prerenal} \textless35\%, \textbf{intrinsic renal} \textgreater{} 50\%.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Urine Protein/Cr Ratio}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(UPCR= \frac{Urine\: Protein\: Spot}{Urine\: Cr\: Spot}\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Normal \textless0.2. \textgreater{} 3.5 indicates nephrotic-range proteinuria.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Transtubular Potassium Gradient}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(TTKG= \left ( \frac{Urine\: K^{+}}{Plasma\: K^{+}} \right )/{\left ( \frac{Urine\: Osm}{Plasma\: Osm} \right )}\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Normal = 8-9. Can only use when urine osm \textgreater{} plasma osm and urine Na+ \textgreater{} 25 mmol/L. TTKG \textless{} 7 + \textbf{hyperkalemia} → aldo deficiency/resistance TTKG \textgreater{} 3 + \textbf{hypokalemia} → aldo ↑ vs renal K+ loss\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
\textbf{Tubular Reabsorption of Phosphate}\strut
\end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright
\(TRP_{\%}=\frac{1-\left ( Urine\: Phosphate \times Plasma\: Cr \right )}{\left ( Plasma\: Cr\times Urine\: Cr \right )}\times 100\)\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Normal 80-98\%. ↓ TRP can be seen in conditions with prox tubular dysfunction, such as Fanconi syndrome/Type 2 RTA\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbar{} \textbf{Urine Calcium/Cr Ratio} \textbar{} \(UCaCR=\frac{Urine\: Ca^{2+}Spot}{Urine\: Cr\: Spot}\) \textbar{} Normal:

0 - 6 months old: ≤ 0.8

7 - 11 months old: ≤ 0.6

≥ 1 year old: ≤ 0.2

Use to assess for hypercalciuria in patients with hematuria, stones, and/or hypercalcemia. \textbar{}
\textbar{} \textbf{Corrected Calcium} \textbar{} \(CorrCa^{2+}=\left ( 4-measured\:albumin \right )\times 0.8+measured\: Ca^{2+}\) \textbar{} Use to calculate calcium levels in low albumin states. Albumin = negatively charged, and therefore carries calcium. \textbar{}
\textbar{} \textbf{Calculated Serum Osmolality} \textbar{} \(CalcOsm=\left [ 2\times \left ( Na^{+}+K^{+} \right ) \right ]+\left ( \frac{Glucose}{18} \right )+\left (\frac{BUN}{2.8} \right )\) \textbar{} Use to calculate serum osmolality. \textbar{}
\textbar{} \textbf{Osmolar Gap} \textbar{} \(OG=Measured\: SOsm - Calculated\: SOsm\) \textbar{} Osmolar gap \textgreater{} 10 can be caused by toxic alcohols (ethanol, methanol, ethylene glycol, isopropyl alcohol), mannitol, and lorazepam infusions (which contain propylene glycol). \textbar{}

\hypertarget{fluid-management}{%
\subsection{Fluid Management}\label{fluid-management}}

\hypertarget{dehydration1}{%
\subsubsection[Dehydration]{\texorpdfstring{Dehydration\footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{Dehydration}}\label{dehydration1}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.06\columnwidth}\raggedright
Severity\strut
\end{minipage} & \begin{minipage}[b]{0.08\columnwidth}\raggedright
\% Volume Loss\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Vital Signs\strut
\end{minipage} & \begin{minipage}[b]{0.61\columnwidth}\raggedright
Physical Exam\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Mild}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
3-5\%\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\raggedright
Oliguria\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Moderate}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
6-9\%\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Inc HR, Orthostatic BP\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\raggedright
Decreased skin turgor, delayed cap refill, dry mucosa, sunken fontanelle, oliguria\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Severe}\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
≥10\%\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Inc HR, Dec BP\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\raggedright
Markedly decreased peripheral perfusion (cool, mottled extremities), lethargy/AMS, deep respirations, anuria\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{PowerPlans:} Gastroenteritis CPG Admit Plan, ED Gastroenteritis Pathway Plan

\textbf{Clinical Pathways:} Gastroenteritis Clinical Pathway

\textbf{Clinical Pearls:} estimate degree of dehydration by s/sx above to calc amt of fluid necessary to replace.

\begin{itemize}
\tightlist
\item
  Calculate fluid deficit: \(FD=Dry\: Weight-Current\: Weight\)
\item
  If dry weight unknown, estimate: \(Est.\,Dry\, Wt= \frac{Current\: Weight}{\left ( 1-\left ( p\times \frac{\% Dehydrated}{100} \right ) \right )}\), where p=0.6 for boys and 0.5 for girls (as \% of total weight is water is 60\% in boys and 50\% in girls).
\item
  Oral rehydration is preferred to IV rehydration when possible\\
\item
  If giving IV rehydration: 20cc/kg bolus of normal saline - consider D5NS if hypoglycemic or acidotic, rpt PRN until HDS, if ongoing IV rehydration necessary, start IVF @ maintenance (D5NS unless child is \textless1 mo, has renal disease, etc); for hypernatremic dehydration, give hypotonic fluids (e.g., D5 ½ NS) \textbf{after} volume resuscitation.
\end{itemize}

\#\#\#Maintenance Fluid Therapy
\textbar{} Fluid \textbar{} Dex \textbar{} Na+ \textbar{} Cl- \textbar{} K+ \textbar{} Ca2+ \textbar{} Buffer \textbar{} Osm \textbar{}
\textbar:-------------:\textbar:---------:\textbar:--------------:\textbar:--------------:\textbar:-------------:\textbar:---------------:\textbar:------------:\textbar:------:\textbar{}
\textbar{} \textbf{Unit} \textbar{} g/dL \textbar{} mEq/L \textbar{} mEq/L \textbar{} mEq/L \textbar{} mEq/L \textbar{} mEq/L \textbar{} mOsm/L \textbar{}
\textbar{} \textbf{Plasma} \textbar{} 0.07-0.11 \textbar{} 135-145 \textbar{} 95-105 \textbar{} 3.5-5 \textbar{} 4.4-5.2 \textbar{} 20-30 bicarb \textbar{} 308 \textbar{}
\textbar{} \textbf{NS (0.9\%)} \textbar{} 0 \textbar{} 154 \textbar{} 154 \textbar{} 0 \textbar{} 0 \textbar{} 0 \textbar{} 308 \textbar{}
\textbar{} \textbf{D5 NS} \textbar{} 5 \textbar{} 154 \textbar{} 154 \textbar{} 0 \textbar{} 0 \textbar{} 0 \textbar{} 308 \textbar{}
\textbar{} \textbf{D5 ½ NS} \textbar{} 5 \textbar{} 77 \textbar{} 77 \textbar{} 0 \textbar{} 0 \textbar{} 0 \textbar{} 15 \textbar{}
\textbar{} \textbf{D5 ¼ NS} \textbar{} 5 \textbar{} 34 \textbar{} 34 \textbar{} 0 \textbar{} 0 \textbar{} 0 \textbar{} 78 \textbar{}
\textbar{} \textbf{3\% Saline} \textbar{} 0 \textbar{} 513 \textbar{} 513 \textbar{} 0 \textbar{} 0 \textbar{} 0 \textbar{} 1026 \textbar{}
\textbar{} \textbf{D5 LR} \textbar{} 5 \textbar{} 130 \textbar{} 109 \textbar{} 4 \textbar{} 3 \textbar{} 28 lactate \textbar{} 284 \textbar{}

\#\#\#Holliday-Segar Method
Use for children \textgreater14 days old

\begin{longtable}[]{@{}lcc@{}}
\toprule
Body Weight & cc/kg/day & cc/kg/hr\tabularnewline
\midrule
\endhead
\textbf{First 10 kg} & 100 & 4\tabularnewline
\textbf{Second 10 kg} & 50 & 2\tabularnewline
\textbf{Each additional kg} & 20 & 1\tabularnewline
\bottomrule
\end{longtable}

\textbf{Insensible Fluid Loss:} \(IFL_{(mL/day)}=300mL/m^{2}/day\), with \(BSA_{(m^{2})}=\sqrt{\frac{ht_{(cm)}\times wt_{(kg)}}{3600}}\)

\textbf{Maintenance Electrolyte Requirements:} \textbf{Na+:} 2-4 mEq/kg/day / \textbf{K+:} 1-2 mEq/kg/day. Choice of fluid depends on age, serum sodium, and degree of dehydration.

\textbf{2018 AAP Clinical Practice Guideline:}\footnote{Jones, H. Guillain-Barre Syndrome: Perspectives w/ Infants and Children. Seminars in Pediatric Neurology June 2000.}

\begin{itemize}
\tightlist
\item
  \textbf{Bottom line:} when in doubt, use isotonic fluids + KCl and dextrose (e.g., D5NS + 20 mEq/L KCl)
\item
  \textbf{Exceptions:} neonates \textless28d or in NICU, CHF, renal disease, massive burns, hepatic disease, neurosurgical disorders, voluminous diarrhea, DI
\item
  \textbf{Why:} avoids iatrogenic hyponatremia (hypotonic fluids + non-osmotic stimuli to ADH release) without a notable increase in iatrogenic hypernatremia or hypertension.
\item
  \textbf{Note:} large amounts of NS → hyperchloremic non-gap metabolic acidosis. Keep this in mind when you see a persistent acidosis despite a normal anion gap when correcting patients in DKA!
\end{itemize}

\#\#Acid/Base
\#\#\#Simple Acid/Base Disorders
\textbar{} Disorder \textbar{} pH \textbar{} pCO2 \textbar{} HCO3 \textbar{}
\textbar-----------------------\textbar:-----:\textbar:---------------:\textbar-----------------\textbar{}
\textbar{} \textbf{Metabolic Acidosis} \textbar{} \textbf{\textless7.35} \textbar{} \textgreater45 \textbar{} \textbf{\textless22} \textbar{}
\textbar{} \textbf{Metabolic Alkalosis} \textbar{} \textbf{\textgreater7.45} \textbar{} \textless35 \textbar{} \textbf{\textgreater26} \textbar{}
\textbar{} \textbf{Respiratory Acidosis} \textbar{} \textbf{\textless7.35} \textbar{} \textbf{\textgreater45} \textbar{} \textless22 \textbar{}
\textbar{} \textbf{Respiratory Alkalosis} \textbar{} \textgreater7.45 \textbar{} \textbf{\textless35} \textbar{} \textgreater26 \textbar{}
\textbf{Bold} indicates primary disturbance -- non-bold indicates secondary response.

Note: lower serum bicarbonate levels (as low as 18 mmol/L) can be physiologically normal in neonates.

\begin{itemize}
\tightlist
\item
  \textbf{Acidemia} → pH \textless{} 7.35. \textbf{Acidosis} → process that makes pH ↓\\
\item
  \textbf{Alkalemia} → pH \textgreater{} 7.45. \textbf{Alkalosis} → process that makes pH ↑\\
\item
  In \textbf{respiratory} disorders, the \textbf{pH} moves in the same direction as the pCO2.\\
\item
  Always look at the pH! A high bicarb on a chem often represents a metabolic alkalosis, but could also be a compensation for chronic respiratory acidosis (e.g., in patients with chronic lung disease).
\end{itemize}

\#\#\#Metabolic Acidosis
\textbf{PowerPlans:} Metabolism Lactic or Metabolic Acidosis NOS Admit Plan

\textbf{Approach:} is there a concomitant respiratory acidosis / respiratory alkalosis?

Use Winter's Formula: \(Expected\: pCO_{2}=\left [ \left ( 1.5\times HCO_{3}^{-} \right ) + 8\pm 2\right ]\)

Calculate Anion Gap, \(AG = Na^{+}-\left ( Cl^{-} +HCO_{3}^-{}\right )\)

In healthy patients, \(Normal = 3\times albumin\pm 2\)
\textbf{Normal AG MAc:} GI loss (diarrhea, laxative, ureteroenteric fistula) vs renal loss (RTA (see chart), acetazolamide use, renal failure (may also have elevated AG), aggressive rehydration with NS.
Calculate urine AG, \(Urine\:AG=(UNa^{+}+UK^{+})-UCl^{-}\) (works b/c urine Cl- = proxy for NH4+ secretion)

\begin{itemize}
\tightlist
\item
  If positive → impaired renal acidification\\
\item
  If negative → GI loss of bicarb
\end{itemize}

\textbf{Increased AG MAc: MUDPILES}\\
\textbf{M}ethanol\\
\textbf{U}remia\\
\textbf{D}iabetic ketoacidosis/starvation ketoacidosis\\
\textbf{P}araldehyde\\
\textbf{I}nfection/\textbf{I}soniazid/\textbf{I}ron/\textbf{I}EM\\
\textbf{L}actic Acidosis\\
\textbf{E}thylene Glycol\\
\textbf{S}alicylates (cause primary metabolic acidosis and respiratory alkalosis)

\textbf{Not fitting? Use the ``delta gap'':} compares difference between measured and normal AG vs difference between normal bicarb and measured bicarb to answer the question: is each decrease in the bicarb accounted for by an increase in the AG? \[\Delta Gap = \frac{\left ( AG - 12 \right )}{\left ( 24-bicarb \right )}\]

If \textbf{yes}, then DGap = 0.8 to 2 → high AG metabolic acidosis (MAc) \textbf{alone}

If \textbf{no} and DGap \textless{} 0.4 → low/normal AG MAc \textbf{alone}

If \textbf{no} and DGap 0.4-0.8 → low/normal AG MAc \textbf{and} high AG MAc

If \textbf{no} and DGap \textgreater{} 2 → high AG MAc superimposed on chronic \textbf{metabolic alkalosis} or \textbf{respiratory acidosis} with metabolic compensation

\textbf{Management:} directed at underlying etiology; see Metabolism section for acute management.

\#\#\#\#Renal Tubular Acidosis: Hyperchloremic Metabolic Acidosis w/ +Urine AG**\\
\textbar{} \textbar{} \textbf{Proximal (Type 2)} \textbar{} \textbf{Distal (Type 1)} \textbar{} \textbf{Hyperkalemic (Type 4)} \textbar{}
\textbar-------------------------\textbar-------------------------------------------------------------------------------------------\textbar--------------------------------------------------------------------\textbar------------------------------------------------------------------\textbar{}
\textbar{} \textbf{Defect} \textbar{} Bicarb reabsorption \textbar{} H+ \textbar{} Inadequate aldosterone \textbar{}
\textbar{} \textbf{Potassium} \textbar{} Normal/Decreased \textbar{} Normal/Decreased \textbar{} \textbf{Increased} \textbar{}
\textbar{} \textbf{Urine pH} \textbar{} \textless5.5 \textbar{} \textgreater5.5 \textbar{} \textless5.5 \textbar{}
\textbar{} \textbf{Renal Stones} \textbar{} No \textbar{} \textbf{Yes} (high urine pH → CaPhos stones, low urine citrate) \textbar{} No \textbar{}
\textbar{} \textbf{Clinical Correlates} \textbar{} \textbf{Fanconi Syndrome} (generalized proximal tubular dysfunction → lose glucose, phos, AAs) \textbar{} Hereditary channelopathies (may be a/w sensorineural hearing loss) \textbar{} DM, primary adrenal insufficiency, use of ACEIs/aldo antagonists \textbar{}

\#\#\#Metabolic Alkalosis
\textbf{Chloride Responsive} (urine Cl- \textless{} 20 mEq/L)\textbf{:} loss of gastric secretions (HCl): vomiting, NG tube drainage, thiazide and loop diuretics (urine chloride varies based on when drug was given), CF

\textbf{Chloride Resistant} (urine Cl- \textgreater{} 20 mEq/L)\textbf{:} \textbf{w/ HTN:} primary hyperaldosteronism, CAH, renovascular HTN, Liddle's syndrome
\textbf{w/o HTN:} Bartter / Gitelman syndrome, severe K or Mg loss

\#\#\#Respiratory Acidosis
\textbf{DDx}\\

CNS depression

Nervous/Muscular disorders (Guillain-Barre, myasthenia gravis, botulism, muscular dystrophy)

Acute and chronic lung disease

\textbf{Workup/Management:} ABG/VBG, CXR, SaO2, escalate respiratory support as needed

\#\#\#Respiratory Alkalosis
\textbf{DDx}\\

Anxiety

Hypoxia

Pain

Salicylates

Urea cycle disorders (during metabolic crisis, hyperammonemia increases respiratory drive)

\#\#Hyponatremia\\
\textbf{Categorization}

\begin{itemize}
\tightlist
\item
  \textbf{Mild:} Na+ \textless{} 135 mEq/L
\item
  \textbf{Moderate:} Na+ \textless{} 130 mEq/L
\item
  \textbf{Severe:} Na+ \textless{} 120 mEq/L
\end{itemize}

\begin{longtable}[]{@{}lll@{}}
\toprule
\textbf{Hypovolemic} & \textbf{Evolemic} & \textbf{Hypervolemic}\tabularnewline
\midrule
\endhead
\bottomrule
\end{longtable}

\textbar{}

Nonrenal sodium losses: GI, skin, sequestration

Renal sodium losses: diuretics, cerebral salt wasting, mineralocorticoid/glucocorticoid deficiency

\textbar{}

SIADH

Psychogenic polydipsia

Reset osmostat

Drug-induced

Hypothyroidism

\textbar{}

Edematous states: nephrotic syndrome, CHF, cirrhosis

Renal failure (acute or chronic)

\textbar{}

\begin{figure}
\centering
\includegraphics{images/nephrology_hyponatremia-osmolality.jpg}
\caption{Serum Osmolality in Hyponatremia}
\end{figure}

\textbf{Presentation}

\begin{itemize}
\tightlist
\item
  Usually d/t underlying cause rather than symptoms from hyponatremia itself.
\item
  Sx occur when hyponatremia evolves acutely (\textless24h) \& include N/V/HA → seizures, coma, and respiratory arrest.
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  Chem 10, serum Osm (↓ in true hyponatremia. If ↑, look for hyperglycemia or other osms)
\item
  UA (proteinuria, hematuria, glucosuria), urine Osm. If euvolemic, nl response to hyponatremia = suppress ADH → urine is maximally dilute (osmolality \textless{} 100 mosmol/kg, SG ≤1.003).

  \begin{itemize}
  \tightlist
  \item
    Abnormally conc urine + euvolemic hypoNa = SIADH (whereas ↑ ADH i/s/o hypovolemia = appropriate ↑ in ADH)
  \item
    Urine Na+ (\textless20 = EABV depletion; \textgreater40 = SIADH, cerebral salt wasting, diuretic use, renal failure)
  \end{itemize}
\end{itemize}

\textbf{Management:} address underlying cause (volume if hypovolemic, fluid restriction if eu/hypervolemic), time course to match timing of onset (fast rx for onset \textless12h, slow rx for slow onset to prevent CPM).

\begin{itemize}
\tightlist
\item
  \textbf{Acute, symptomatic:} ICU admit, 3\% HTS to raise {[}Na+{]} by 3-5 mEq/L (give \textasciitilde TBW x 5 mEq/L x 2).
\item
  \textbf{Chronic, asymptomatic:} calculate Na+ Deficit (mEq) = (140 -- Na+actual) x TBW, where TBW = weight in kg x 0.6 for males, 0.5 for females. Then give IVF to account for missing Na+ content; should not exceed 0.5 mEq/L/hr rise in {[}Na+{]}.
\item
  \textbf{SIADH:} restrict free water intake to match insensible losses + UOP; use vaptans if severe.
\end{itemize}

\#\#Hypernatremia
\textbf{Definition:} Na+ \textgreater{} 145mEq/L

\textbf{Etiology:} \textbf{excessive water loss} (GI losses / Diuretics / Central or nephrogenic DI (see endocrine section) / Osmotic diuresis / Increased insensible losses / Impaired thirst mechanism) vs \textbf{excessive salt provision}

\textbf{Clinical Presentation:} lethargy, irritability, MS changes. Typically presents w/ sx of underlying cause.

\textbf{Exam:} check volume status, neurologic exam, mental status.

\textbf{Workup:} UA, chem 10, urine osm (appropriate response to hyperNa → ↑ ADH → concentrated urine. Inappropriately dilute urine i/s/o hyperNa → think DI), serum osm (Uosm \textless{} Sosm → think DI).

\textbf{Management}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  For hypernatremic dehydration, calculate Free Water Deficit(L) = \(\left ( \frac{Current\: Na^{+}}{Desired\: Na^{+}} -1\right )\)xTBW, where TBW = weight in kg x 0.6 for males, 0.5 for females.
\item
  Replace ½ of FWD w/in 24h, then remainder over next 1-2 days, and replace maintenance + ongoing losses. Avoid ↓ Na+ by \textgreater15 mEq/L over 24h (0.5 mEq/L/hr) due to risk of cerebral edema.
\end{enumerate}

\begin{itemize}
\tightlist
\item
  If due to DI, see endo section for management
\end{itemize}

\#\#Hypokalemia
\textbf{PowerPlan:} MSICU Intermittent IV Electrolyte Replacement Orderset

\textbf{Definition:} K+ \textless{} 3.5 mEq/L

\textbf{Etiology:} decreased K+ intake (malnutrition), increased K+ entry into cells (alkalosis → H+ for K+ / insulin / beta adrenergic activity - albuterol, pheo), increased GI losses (diarrhea, vomiting, laxative abuse, copious GT losses), renal losses (diuretics due to loops/thiazides but NOT aldo antagonists, mineralocorticoid excess -- primary hyperaldo, hyperreninemic states {[}p/w HTN, hyperNa, metabolic alkalosis{]}, Type I/II RTA, Gitelman/Bartter)

\textbf{Pathophysiology:} low K+ → hyperpolarization of myocytes → lack of inhibition of voltage-gated Na+ channels → ↑ Na+ entry into myocytes and ↑ excitability → cardiac arrhythmias

\textbf{Clinical Presentation (generally only K+ \textless{} 3):} muscle weakness, fatigue, constipation → ileus, tetany, rhabdo, respiratory muscle failure, EKG changes (ST depression → dec T wave amplitude → U waves)

\begin{figure}
\centering
\includegraphics{images/nephrology_EKG-hypokalemia.jpg}
\caption{EKG Changes in Hypokalemia}
\end{figure}

\textbf{Workup:} Chem 10, EKG (see above),\(TTKG= \left ( \frac{Urine\: K^{+}}{Plasma\: K^{+}} \right )/{\left ( \frac{Urine\: Osm}{Plasma\: Osm} \right )}\) (note: can only use when urine osm \textgreater300). TTKG \textgreater3 i/s/o hypoK suggests aldo excess.

\textbf{Management}

\begin{itemize}
\tightlist
\item
  \textbf{Mild to moderate (K+ = 3.0-3.5 mEq/L):} treat underlying d/o, give KCl 1 mEq/kg (max 20 mEq) PO q8-24h OR add KCl to IVF (max conc is 80 mEq/L via PIV).
\item
  \textbf{Severe (K+ \textless{} 2.5-3 mEq/L or symptomatic, EKG changes):} add KCl to IVF, give KCl 0.5-1 mEq/kg (max 30 mEq) IV x1 (only in ICU!), and should have EKG monitoring during infusion.
\item
  Also correct Mg2+ if low (25-50 mg/kg IV, max 2g/dose) as hypoMg prevents resolution of hypoK.
\end{itemize}

\#\#Hyperkalemia
\textbf{PowerPlan:} MICU/MSICU/NICU hyperkalemia Orderset

\textbf{Definition:} K+ \textgreater{} 5.5 mEq/L (up to 6.5 may be normal in neonates)

\textbf{Etiology:} ↑ K+ intake (TPN, IVF, formula), ↑ K+release from cells {[}acidosis (K+ efflux allows H+ influx to buffer acidosis), cell lysis (hemolysis, rhabdo, tumor lysis){]}, ↓ renal excretion {[}acute or chronic renal failure, hypoaldosteronism (adrenal insufficiency, hyporeninemic hypoAldo, ACE inhibitors -- look for hypoNa and metabolic acidosis), K+-sparing diuretics (spironolactone, epelrenone, amiloride, triamterene){]}, pseudohyperkalemia (hemolyzed blood sample)

\textbf{Clinical Presentation:} muscle weakness (LE \textgreater{} UE) → flaccid paralysis, arrhythmias (if K+ \textgreater{} 7). \textbf{EKG changes} (in order of appearance): tall peaked T wave, shortened QT → PR/QRS lengthening → ``sine wave'' QRS → VFib

\begin{figure}
\centering
\includegraphics{images/nephrology_EKG-hyperkalemia.jpg}
\caption{EKG Changes in Hyperkalemia}
\end{figure}

\textbf{Workup:} Chem 10 (ensure not hemolyzed -- free-flowing sample, order STAT), blood gas to assess acid/base status, EKG, TTKG (see above) -- low TTKG (\textless7) in setting of hyperkalemia may indicate aldo deficiency or resistance, plasma renin and aldosterone.

\textbf{Management:} if real and with EKG changes.

\begin{itemize}
\item
  \textbf{STOP} K+ supplementation, K+-containing IVF, and K+-sparing medications.
\item
  \textbf{Stabilize cardiac membrane}

  \begin{itemize}
  \tightlist
  \item
    Calcium gluconate 10\% @ 0.5 mL/kg (=100 mg/kg) IV over 5 min.
  \item
    Calcium chloride 20 mg/kg IV over 5-10 min if impending cardiac arrest.
  \end{itemize}
\item
  \textbf{Drive K+ into cells}

  \begin{itemize}
  \tightlist
  \item
    Insulin 0.1 U/kg, max 10U IV with glucose, infuse over 30 min:

    \begin{itemize}
    \tightlist
    \item
      \textless5 yo: D10 (100 mg/mL) @ 5 mL/kg
    \item
      ≥5 yo: D25 (250 mg/mL) @ 2-4 mL/kg IV (max 25g)
    \end{itemize}
  \item
    Albuterol nebs

    \begin{itemize}
    \item
      Neonates: 0.4 mg/2 mL NS
    \item
      \textless25 kg: 2.5 mg/2 mL NS
    \item
      25-50 kg: 5 mg/2 mL NS
    \item
      \begin{quote}
      50 kg: 10 mg/2-4 mL NS or 4-8 MDI puffs
      \end{quote}
    \end{itemize}
  \item
    Bicarb: 1 mEq/kg IV (max 50 mEq) over 10-15 min

    \begin{itemize}
    \tightlist
    \item
      \textless6 mo: 2 mL/kg of 4.2\% NaHCO3
    \item
      ≥6 mo: 1 mL/kg of 8.4\% NaHCO3
    \end{itemize}
  \item
    Intubate + hyperventilate (induce alkalosis)
  \end{itemize}
\item
  \textbf{Excrete total body K+}

  \begin{itemize}
  \tightlist
  \item
    Kayexalate 1 g/kg, max 50g PO/PR q4h PRN
  \item
    Furosemide 1-2 mg/kg IV (max 40 mg or 80 mg if renal insufficiency) q6h PRN
  \item
    Dialysis if emergent or if ongoing source of K+ release (tumor lysis, rhabdo)
  \end{itemize}
\end{itemize}

\#\#Proteinuria\\
\textbf{Definition}

\begin{itemize}
\tightlist
\item
  Excessive excretion of urinary protein
\item
  Dipstick: primarily detects albumin

  \begin{itemize}
  \tightlist
  \item
    Trace = 15-30 mg/dL
  \item
    1+ = 30-100 mg/dL
  \item
    2+ = 100-300 mg/dL
  \item
    3+ = 300-1000 mg/dL
  \item
    4+ = \textgreater1000 mg/dL
  \end{itemize}
\item
  If positive dip, perform \textbf{quantitative} analysis

  \begin{itemize}
  \tightlist
  \item
    \textbf{Spot UPCR:} nl \textless0.2 if ≤2 yo or \textless0.5 if \textless2 yo; \textgreater2 = nephrotic (see below section on nephrotic syndrome)
  \item
    \textbf{Urinary Protein Excretion 24h:} \textgreater100 mg/m2 per day = abnormal, ≥1000 mg/m2 per day = \textbf{nephrotic}
  \end{itemize}
\end{itemize}

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  \textbf{Glomerular} {[}inc filtration of macromolecules, esp albumin -- may be transient (fever, exercise, stress, seizures, resolves on rpt testing after stressor gone) vs orthostatic (present when standing and not when supine - first morning void) vs persistent (elevated on both supine/upright voids){]}
\item
  \textbf{Tubular} {[}inc excretion of low molecular weight proteins, esp β2 microglobulin, that are normally filtered in the glomerulus and reabsorbed in the proximal tubule -- may be d/t congenital disorders of proximal tubule (Fanconi syndrome, cystinosis, galactosemia, Lowe syndrome) or with acute tubular injury (ATN, AIN, pyelo){]}
\item
  \textbf{Overflow} {[}inc excretion of low molecular weight proteins d/t protein overproduction (multiple myeloma, myoglobin in rhabdomyolysis){]}.
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  If significant quantity, protein will be frothy; otherwise varies with cause.
\item
  If nephrotic, may have edema/HTN, may have stigmata of primary dx (oral ulcers, rash, and joint swelling in SLE; abdominal pain and palpable purpura in HSP; h/o recurrent UTIs with VUR, hepatitis and movement d/o in Wilson disease).
\end{itemize}

\textbf{Workup}

\begin{figure}
\centering
\includegraphics{images/nephrology_proteinuria-workup.jpg}
\caption{Proteinuria Workup}
\end{figure}

\#\#Hematuria\\
\textbf{Definition:} red blood cells in the urine

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  \textbf{Extraglomerular:} UTI, ureteral trauma, nephrolithiasis, cystitis (any UTI, adenovirus, cyclophosphamide), sickle cell disease or trait, malignancy (bladder CA, Wilms tumor)\\
\item
  \textbf{Glomerular:} glomerulonephritis (see GN section), benign familial hematuria / thin basement membrane disease
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  UA (+blood on dip \textbf{AND} +RBCs on micro)
\item
  If only +blood, think myoglobin vs hemoglobin
\item
  If red but neg blood/neg RBC, think beets, rifampin, nitrofurantoin, doxorubicin, chloroquine
\item
  If cola- or tea-colored urine, RBC casts, marked proteinuria, or dysmorphic RBCs, think GN
\item
  If blood clots, uniform RBCs, urethral bleeding, think extra-gl
\item
  If h/o trauma, do CTAP
\item
  If s/sx UTI, do UCx
\item
  If s/sx nephrolithiasis, do renal US +/- CTAP
\item
  If c/f GN, send chem 10, CBC w/diff + retic, C3/C4, albumin, ASLO titer, anti-DNase B, ANA, UPCR; consider renal biopsy if concomitant proteinuria/HTN and/or rising serum creatinine
\end{itemize}

\#\#Nephrotic Syndrome\\
\textbf{Definition:} syndrome characterized by presence of heavy proteinuria (albuminuria \textgreater3 g/24 hours), hypoalbuminemia (\textless3.0 g/dL), edema, and hyperlipidemia.

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  Minimal change disease (most common in children) -- see normal light microscopy but on EM there is diffuse foot process effacement
\item
  Focal Segmental Glomerulosclerosis
\item
  Membranous Nephropathy
\item
  Membranoproliferative GN (may be nephrotic + nephritic)
\item
  SLE (may be nephrotic + nephritic)
\item
  IgA/HSP (may be nephrotic + nephritic)
\item
  Post-infectious Glomerulonephritis (may be nephrotic + nephritic)
\end{itemize}

\textbf{Pathophysiology}

\begin{itemize}
\tightlist
\item
  Abnormalities in glomerular podocytes → increased filtration of proteins, \textbf{esp albumin}. Others include clotting inhibitors (Protein C, S, antithrombin III) → prothrombotic state and immunoglobulins → susceptibility to serious infections.
\item
  Increased Na+ retention and hypoalbuminemia → edema
\item
  Decreased oncotic pressure → inc hepatic lipoprotein synthesis → hypercholesterolemia
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  Edema, typically first appears in periorbital tissue/scrotum, then in dependent areas
\item
  HTN, HLD, increased risk of VTE
\item
  Can present with AKI
\item
  \textbf{Exam:} edema, hypertension, assess for extra-renal findings that may suggest a secondary cause for nephrotic syndrome (e.g.~infection)
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  Chem 10 / C3; see also section on proteinuria
\item
  UA + 24 hour urine collection with protein ≥1000 mg/m2/day OR spot UPCR \textgreater3.5
\item
  Consider renal biopsy for diagnosis (see below)
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  \textbf{Empiric steroids} for presumed minimal change disease (if persistent past 1-2 wk).

  \begin{itemize}
  \tightlist
  \item
    Prednisone 60 mg/m2/day (max 60 mg/day) for 4 weeks.
  \item
    Then prednisone 40 mg/m2/day QOD for 4 weeks w/ gradual taper, generally for minimum total 2-3 months.
  \item
    Consider biopsy if steroid resistant, steroid-dependent, or evidence of steroid toxicity.
  \end{itemize}
\item
  BP Control - \textbf{ACE inhibitors or ARBs} are preferred (decrease glomerular pressure → decreased protein filtration).

  \begin{itemize}
  \tightlist
  \item
    e.g., enalapril 0.08 mg/kg per day (maximum of 5 mg/day), can titrate to maximum dose of 0.6 mg/kg per day (maximum of 40 mg/day) for appropriate BP response
  \item
    Use with caution for GFR \textless{} 60 mL/min/1.73 m2.
  \item
    Re-check serum Cr, K+ 3-5 days after starting ACEI/ARB.
  \end{itemize}
\item
  Edema - \textbf{salt restriction} (\textless{} 2 mEq/kg/day) and \textbf{diuretics}.

  \begin{itemize}
  \tightlist
  \item
    If intravascular volume normal (FENa \textgreater2 \%) - furosemide 1-2 mg/kg/dose x2 doses.
  \item
    If intravascular volume low (FENa \textless{} 2\%) and edema is severe (anasarca, pleural effusions, ascites)

    \begin{itemize}
    \tightlist
    \item
      Albumin 25\% 1 gram/kg IV over 4 hours.
    \item
      Give 1 mg/kg IV lasix at the 2 hour point
    \item
      Give 1 mg/kg IV lasix after albumin infusion (4 hour point).
    \end{itemize}
  \end{itemize}
\item
  VTE

  \begin{itemize}
  \tightlist
  \item
    Consider prophylactic anticoagulation if high-risk (age \textgreater12, albumin \textless2, fibrinogen \textgreater6).
  \item
    Treat VTE if present with LMWH
  \end{itemize}
\item
  HLD - consider statin, especially if other ASCVD risk factors are present.
\end{itemize}

\#\#Nephritic Syndrome\\
\textbf{Definition:} any of several conditions leading to glomerular hematuria, proteinuria, and potential AKI with azotemia/oliguria, edema, and hypertension.

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  Post-infectious

  \begin{itemize}
  \tightlist
  \item
    \textbf{Group A β-hemolytic strep}, either after pharyngitis or impetigo
  \item
    Other infections: Staph aureus/epi, Pneumococcus, Mycoplasma, viral
  \end{itemize}
\item
  IgA Nephropathy (most common glomerulopathy worldwide)
\item
  SLE Nephritis
\item
  \textbf{Membranoproliferative GN:} can be idiopathic or secondary to HBV/HCV or rheumatologic disease
\item
  \textbf{Alport Syndrome:} XLR collagen IV mutations, a/w hearing loss, vision changes
\item
  \textbf{Goodpasture Syndrome:} autoAb to Type IV collagen in glomerular and alveolar basement membranes → hemoptysis
\item
  \textbf{Vasculitis:} HSP, granulomatosis with polyangiitis (lung/sinus/kidney), eosinophilic granulomatosis with polyangiitis (asthma/neuropathy/lung/kidney/skin), microscopic polyangiitis (lung/kidney)
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  Hypertension
\item
  Hematuria
\item
  Fluid retention/edema
\item
  Sequelae of underlying disease

  \begin{itemize}
  \tightlist
  \item
    \textbf{SLE:} rash, arthritis, oral ulcers
  \item
    \textbf{Vasculitides:} hemoptysis, skin ulcers
  \item
    \textbf{Alport:} sensorineural hearing loss, vision changes
  \end{itemize}
\item
  Ask about preceding sore throat (usually 2-3 weeks before onset of post strep GN) or current URI symptoms (which can be seen with IgAN).
\item
  Some patients may have rapid progression with development of acute renal failure over the course of several days. Any of the above etiologies can have a rapidly progressive course.\\
\item
  \textbf{Exam:} monitor BP, assess volume status. Look for signs of Lupus or other vasculitides such as rash, abdominal tenderness (HSP), joint swelling/tenderness.
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  UA: RBCs + proteinuria. Glomerular bleeding → dysmorphic RBCs and red cell casts.
\item
  Chem 10 / CBC w/ diff + retic / serum albumin / ASLO titer + anti-DNase B / ANA + anti-dsDNA
\item
  \textbf{C3, C4:} low C3 seen with post-infectious GN and C3 glomerulopathy; low C3/C4 in SLE; normal C3/C4 in IgAN, pauci-immune GNs (ANCA-associated vasculitis), and anti-GBM disease
\item
  \textbf{UPCR:} typically will see proteinuria, sometimes in nephrotic range (nephrotic range protein is UPCR \textgreater{} 3.5).
\item
  If rapidly progressive course or significant renal insufficiency on admission, send anti-GBM Ab and ANCA (for Goodpasture disease and GPA/MPA). Patients with rapidly progressive course should also have renal biopsy.
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  \textbf{Reasons for admission:} hypertension, acute renal failure, volume overload, or electrolyte abnormalities.
\item
  Hypertension typically responsive to diuretics.
\item
  Fluid and sodium restriction during acute phase.
\item
  Patients with RPGN may be treated with pulse dose steroids. *Patients with RPGN due to Goodpasture disease, SLE, or GPA/MPA may be treated with steroids, cyclophosphamide, and plasmapheresis.
\item
  Post-infectious GN is typically self-resolving.

  \begin{itemize}
  \tightlist
  \item
    Patients suspected to have post-infectious GN should have repeat complement studies sent in 8-12 weeks, at which time complement should return to normal.
  \item
    If still hypocomplementemic, consider other diagnoses such as C3 glomerulopathy or SLE.
  \end{itemize}
\end{itemize}

\#\#Acute Kidney Injury

\textbf{Definition:} acute decrease in GFR per KDIGO criteria.

\begin{figure}
\centering
\includegraphics{images/nephrology_AKI.jpg}
\caption{AKI Staging}
\end{figure}

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  \textbf{Pre-Renal:} decreased renal perfusion.

  \begin{itemize}
  \tightlist
  \item
    Decreased intravascular volume: dehydration, blood loss.
  \item
    Decreased effective circulating volume: shock, heart failure, cirrhosis.
  \end{itemize}
\item
  \textbf{Renal:} intrinsic renal parenchymal disease.

  \begin{itemize}
  \tightlist
  \item
    Glomerular disease: glomerulonephritis, nephrotic disorders.
  \item
    Vascular: vasculitis.
  \item
    Tubulointerstitial: ATN (ischemia/progression of pre-renal AKI, aminoglycosides, myoglobin, uric acid in tumor lysis syndrome), interstitial nephritis (NSAIDs, penicillins).
  \end{itemize}
\item
  \textbf{Post-Renal:} obstructive uropathy (posterior urethral valves, tumor, large stones, etc). Needs to be bilateral obstruction to develop renal failure in a patient with otherwise normal kidneys.
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  Fluid retention: edema, decreased urine output.
\item
  Hematuria with intrinsic kidney injury (glomerulonephritis, ATN).
\item
  Uremia: nausea/vomiting, GI bleeding, pericarditis, pruritus, mental status change.
\item
  \textbf{Exam:} look for hypertension and edema (periorbital and peripheral).
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  Urine Studies

  \begin{itemize}
  \tightlist
  \item
    UA

    \begin{itemize}
    \tightlist
    \item
      Hematuria, proteinuria, red cell casts suggests glomerulonephritis.
    \item
      Muddy brown casts suggests ATN.
    \item
      Urine eosinophils suggests acute interstitial nephritis (not a great test, may be positive even if only 1 eosinophil).
    \end{itemize}
  \item
    Urine electrolytes to calculate fractional excretion sodium (FENa).

    \begin{itemize}
    \tightlist
    \item
      \(FENa=\frac{\left ( Urine\: Na^{^{+}}\times Plasma\: Cr \right )}{\left ( Plasma\: Na^{+}\times Urine\: Cr \right )}\)
    \item
      FENa \textless{} 1\% suggests prerenal; FENa \textgreater{} 2\% suggests intrarenal.
    \end{itemize}
  \end{itemize}
\item
  Blood Labs: Chem 10, CBC w/ diff, consider CK if history suggestive of rhabdomyolysis.
\item
  Renal US to look for hydronephrosis, obstructive uropathy, renal scarring.
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  Correct associated electrolyte issues (hyperkalemia, hyponatremia, hypocalcemia, acidosis).
\item
  Manage hypertension (see section below).
\item
  Fluid management

  \begin{itemize}
  \tightlist
  \item
    Small NS bolus (5-10 cc/kg) if hypovolemic or in pre-renal failure.
  \item
    Reassess volume status and continue to give small boluses until patient is euvolemic.
  \item
    Replace insensible losses plus 1:1 urine/stool output.
  \item
    \(IFL_{(mL/day)}=300mL/m^{2}/day\)
  \item
    \(BSA_{(m^{2})}=\sqrt{\frac{ht_{(cm)}\times wt_{(kg)}}{3600}}\)
  \end{itemize}
\item
  Indications for dialysis: AEIOU

  \begin{itemize}
  \tightlist
  \item
    \textbf{A}cidosis
  \item
    \textbf{E}lectrolyte anomalies refractory to medical management (hyperK/phos)
  \item
    \textbf{I}ngestions (Li+, ASA)
  \item
    \textbf{O}verload
  \item
    \textbf{U}remia (pericarditis, encephalopathy)
  \end{itemize}
\end{itemize}

\#\#Chronic Kidney Disease

\textbf{Definition}

\begin{itemize}
\tightlist
\item
  Irreversible kidney damage and reduction in kidney function; may be progressive.
\item
  Requires 1 of 2 of the following (2012 KDIGO Clinical Practice Guideline):

  \begin{itemize}
  \tightlist
  \item
    For age ≥ 2 yo

    \begin{itemize}
    \tightlist
    \item
      GFR \textless{} 60 mL/1.73 m2 for \textgreater{} 3 mo
    \item
      GFR \textgreater{} 60 mL/1.73 m2 alongside evidence of structural kidney damage or other marker of abnormal renal function (proteinuria, albuminuria, renal tubular d/o).
    \end{itemize}
  \item
    For age \textless{} 2 yo → GFR \textless{} 1 std dev below mean = mod dysfunction, \textless{} 2 std dev = severe.
  \end{itemize}
\item
  Severity stratified by GFR from G1 (normal, ≥ 90) → G2 (60-89) → G3a (45-59) → G3b (30-44) → G4 (15-29) → G5 (\textless{} 15) = ESRD / dialysis-dependence.
\end{itemize}

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  Congenital causes (renal aplasia, reflux, PKD, obstructive uropathy) in \textasciitilde60\%.
\item
  Glomerular disease (FSGS, membranous nephropathy, MPGN, SLE nephritis, etc.).
\item
  Other: HUS, Alport syndrome, cystinosis, interstitial nephritis, tumors.
\end{itemize}

\textbf{Pathophysiology:} multiple possible insults leading to intraglomerular HTN and glomerular hypertrophy → nephron loss → hyperfiltration in remaining nephrons → further glomerular damage → glomerulosclerosis, proteinuria, fibrosis.

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  Edema + HTN
\item
  Proteinuria / hypoalbuminemia
\item
  Anemia (due to EPO deficiency)
\item
  Dyslipidemia / accelerated ASCVD
\item
  Vitamin D deficiency with secondary hyperparathyroidism
\item
  Electrolyte derangements: hyperkalemia, hyperphosphatemia, hypocalcemia, metabolic acidosis
\item
  Growth failure, delayed puberty, and intellectual disability
\item
  Complications of uremia: pericarditis, platelet dysfunction, encephalopathy
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  Chem 10
\item
  CBC w/diff + retic + iron studies
\item
  UA w/ UPCR
\item
  25-OH Vitamin D, PTH
\item
  Fasting lipid panel
\item
  If etiology uncertain: see sections on proteinuria/hematuria, consider renal U/S and bx.
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  Stage G1/G2

  \begin{itemize}
  \tightlist
  \item
    Monitor kidney function closely.
  \item
    Educate about nephrotoxin avoidance (NSAIDs, contrast, smoking, obesity, dehydration).
  \item
    BP control w/ ACEI/ARB based on guidelines from the ESCAPE Trial.\footnote{Shahrizaila, N, and Yuki, N. Bickerstaff brainstem encephalitis and Fisher Syndrome: anti-GQ1B antibody syndrome. Journal of Neurology, Neurosurgery and Psychiatry 84(5). 2013.}

    \begin{itemize}
    \tightlist
    \item
      Using ramipril (starting at 6 mg/m2/d and inc dose / adding other agents as needed).
    \item
      Targeting 50th-\%ile BP for age, sex, and weight vs 90th-\%ile slowed rate of progression to ESRD.
    \end{itemize}
  \end{itemize}
\item
  Stages G3 and above: as above and add the following.

  \begin{itemize}
  \tightlist
  \item
    Prepare for possibility of transplant, ideally prior to dialysis (HD vs peritoneal).
  \item
    Na+-restricted diet (2-3g/d) +/- diuretics (furosemide 0.5-2 mg/kg/d, HCTZ 1-3 mg/kg/d).
  \item
    Management of hyperkalemia (low K+ diet, diuretics), acidosis (sodium bicarb), hypocalcemia/hyperphosphatemia (Vitamin D, calcimimetics, phos binders).
  \item
    Rx anemia to goal Hgb 10-12 g/dL w/ EPO-stimulating agents (erythropoietin alfa, darbepoetin alfa).
  \item
    In pts with significant uremia, consider preoperative DDAVP to prevent bleeding.
  \end{itemize}
\end{itemize}

\#\#Hemolytic-Uremic Syndrome

\textbf{Definition}

\begin{itemize}
\tightlist
\item
  \textbf{Hemolytic Uremic Syndrome:} microangiopathic hemolytic anemia + AKI + thrombocytopenia
\item
  \textbf{Thrombotic Thrombocytopenic Purpura:} triad of HUS + fever + neurologic changes
\end{itemize}

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  Principally affects children under the age of five years.
\item
  90\% due to shiga toxin; of those 70\% due to \emph{enterohemorrhagic E. Coli}.
\item
  Occurs in 6-9\% of EHEC infections; usually begins 5-10 days after diarrhea onset.
\item
  Non-diarrheal (atypical) HUS associated can be due to S. pneumo infection or due to defects in the complement system (e.g., mutations in complement regulatory proteins).
\end{itemize}

\textbf{Pathophysiology}

\begin{itemize}
\tightlist
\item
  \textbf{HUS:} Shiga toxin binds to receptors in glomerular, colonic, and cerebral cells → promotes adhesion and aggregation of platelets onto endothelial cells → thrombocytopenia and RBC shearing (microangiopathic anemia); in kidney, glomerular damage.
\item
  \textbf{TTP:} due to deficiency or immune-mediated inhibition of ADAMTS13, a metalloproteinase responsible for breakdown of vWF. No vWF cleavage → coagulation occurs at a higher rate, particularly in microvasculature → platelet consumption → thrombocytopenia and microthrombi → microangiopathic hemolytic anemia.
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  Microangiopathic hemolytic anemia → jaundice, pallor, dark urine.
\item
  Thrombocytopenia → petechiae, bleeding.
\item
  Acute renal failure → HTN, edema.
\item
  Other systems

  \begin{itemize}
  \tightlist
  \item
    \textbf{Central nervous system:} seizures, coma, stroke
  \item
    \textbf{Cardiac:} dysfunction due to ischemia, uremia, fluid overload
  \item
    \textbf{Pancreas:} transient DM
  \item
    \textbf{Liver:} hepatomegaly, increased serum transaminases
  \item
    \textbf{Heme:} in addition to anemia and thrombocytopenia, leukocytosis is common in diarrhea-induced HUS; the prognosis is worse with increased white blood cell counts.
  \end{itemize}
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  \textbf{CBC w/diff + retic:} anemia, thrombocytopenia w/ appropriate reticulocytosis.
\item
  \textbf{Smear:} schistocytes
\item
  ↑ LDH, ↓ haptoglobin, Coombs negative (evidence of intravascular hemolysis).
\item
  \textbf{Chem 10:} evidence of acute kidney injury, elevated BUN/Cr
\item
  \textbf{LFTs:} elevation in transaminases, unconjugated hyperbilirubinemia
\item
  \textbf{UA:} possible proteinuria, hematuria.
\item
  Stool culture: causative pathogen
\item
  Head CT if any change in MS or abnormal neurologic exam.
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  Treatment mainly supportive; judicious fluid management (see section on AKI), correct electrolyte abnormalities, transfuse RBCs if needed (avoid platelets unless actively bleeding, as this may worsen the TMA process), manage hypertension.
\item
  If significant CNS involvement or if TTP is suspected, consider plasmapheresis.
\item
  For non-STx mediated (atypical) HUS, consider eculizumab (anti-C5 antibody; prevents activation of terminal complement pathway).
\item
  5-10\% mortality; 5-10\% progress to ESRD. Inc WBC, seizure, or CVA = poor prognostic factors.
\end{itemize}

\#\#Hypertension

\textbf{Definition}\footnote{Peragallo, J. Pediatric Myasthenia Gravis. Seminars in Pediatric Neurology. May 2017.}

\begin{longtable}[]{@{}ccc@{}}
\toprule
\begin{minipage}[b]{0.11\columnwidth}\centering
\strut
\end{minipage} & \begin{minipage}[b]{0.61\columnwidth}\centering
\textbf{Children 1-13 Years Old}\strut
\end{minipage} & \begin{minipage}[b]{0.19\columnwidth}\centering
\textbf{Children \textgreater{} 13 Years Old}\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.11\columnwidth}\centering
\textbf{Normal}\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\centering
\textless90th percentile\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\centering
\textless120/\textless80 mmHg\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.11\columnwidth}\centering
\textbf{Elevated BP}\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\centering
≥90th percentile to \textless95th percentile or 120/80 mmHg to \textless95th percentile (whichever is lower)\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\centering
120/\textless80 to 129/\textless80 mmHg\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.11\columnwidth}\centering
\textbf{Stage 1 HTN}\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\centering
≥95th percentile to \textless95th percentile +12 mmHg or 130/80 to 139/89 mmHg (whichever is lower)\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\centering
130/80 to 139/89 mmHg\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.11\columnwidth}\centering
\textbf{Stage 2 HTN}\strut
\end{minipage} & \begin{minipage}[t]{0.61\columnwidth}\centering
≥95th percentile + 12 mmHg or ≥140/90 mmHg (whichever is lower)\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\centering
≥140/90 mmHg\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

*Percentiles determined by gender, age, and height.

\textbf{Blood Pressure Levels for Boys}\footnote{Ayers, T. et al.~Acute Flaccid Myelitis in the United States: 2015-2017. Pediatrics. 2019;144(5) Epub 2019 Oct 7}

\begin{figure}
\centering
\includegraphics{images/nephrology_BP-boys.jpg}
\caption{BP Levels for Boys}
\end{figure}

\textbf{Blood Pressure Levels for Girls}\footnote{Thompson et al., Infant Botulism in the age of botulism immune globulin. Neurology. June 2005.}

\begin{figure}
\centering
\includegraphics{images/nephrology_BP-girls.jpg}
\caption{BP Levels for Girls}
\end{figure}

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  \textbf{Essential Hypertension}

  \begin{itemize}
  \tightlist
  \item
    Most common etiology in older children; increasing incidence with rise in obesity.
  \item
    More likely in children who are overweight, postpubertal, and/or have a family history of hypertension.
  \end{itemize}
\item
  \textbf{Secondary Hypertension}

  \begin{itemize}
  \tightlist
  \item
    Suspect in child \textless6, w/o family hx HTN, if acute rise in BP, or past hx suspicious of underlying etiology.
  \item
    \textbf{Renal Parenchymal Disease}

    \begin{itemize}
    \tightlist
    \item
      Glomerulonephritis, both acute and chronic
    \item
      Renal scarring from pyelonephritis, VUR → CKD.
    \end{itemize}
  \item
    \textbf{Renovascular}

    \begin{itemize}
    \tightlist
    \item
      Renal artery stenosis: fibromuscular dysplasia, Neurofibromatosis I, Williams Syndrome
    \item
      Thromboembolism (e.g., h/o UAC)
    \item
      Aortic coarctation
    \item
      Vasculitis: Takayasu's arteritis, polyarteritis nodosa
    \end{itemize}
  \item
    \textbf{Endocrine}

    \begin{itemize}
    \tightlist
    \item
      Hyperthyroidism
    \item
      Catecholamine excess: pheochromocytoma, neuroblastoma, exogenous catecholamines (cold medications, cocaine, amphetamines)
    \item
      Corticosteroid excess: exogenous or endogenous (Cushing's)
    \item
      Mineralocorticoid excess: congenital adrenal hyperplasia, primary hyperaldosteronism
    \end{itemize}
  \item
    \textbf{Neurologic:} intracranial hypertension, familial dysautonomia
  \end{itemize}
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  Depends on etiology; essential hypertension often asymptomatic and discovered on routine blood pressure screening.
\item
  Renal parenchymal disease: may present with hematuria, edema.
\item
  Catecholamine excess: headache, flushing, sweating, tachycardia.
\item
  Hyperthyroidism: sweating, diarrhea, tachycardia.
\item
  Hypertensive emergency can present with headache, altered mental status, chest pain, dyspnea (see section on hypertensive emergency).
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  \textbf{Phase 1: Confirmation}

  \begin{itemize}
  \tightlist
  \item
    Manual auscultatory measurement with appropriate-sized cuff on 3 separate occasions.

    \begin{itemize}
    \tightlist
    \item
      Bladder width: \textgreater{} 40\% of upper arm circumference.
    \item
      Bladder length: \textgreater{} 80\% of upper arm circumference.
    \end{itemize}
  \item
    Consider BP measurements at school, home, or ambulatory BP monitoring.
  \end{itemize}
\item
  \textbf{Phase 2: Screening Studies}

  \begin{itemize}
  \tightlist
  \item
    Urinalysis (microscopic if positive).
  \item
    Chem 10 + uric acid (if concern for oncologic etiology, can also be elevated in essential HTN).
  \item
    Renal ultrasound with doppler interrogation.
  \item
    If obese, add HgA1c and ALT.
  \end{itemize}
\item
  \textbf{Phase 3: Directed Testing}

  \begin{itemize}
  \tightlist
  \item
    Determine etiology (tests to consider based on history, PE, screening results).

    \begin{itemize}
    \tightlist
    \item
      TFTs
    \item
      Plasma/urine catecholamines and metanephrines
    \item
      Renin/aldosterone
    \item
      DMSA scan to identify renal scarring in the setting of severe VUR.
    \item
      Renal arteriography
    \end{itemize}
  \item
    Assess for end-organ damage.

    \begin{itemize}
    \tightlist
    \item
      Echocardiogram (?LVH)
    \item
      Dilated eye exam (?retinal changes)
    \end{itemize}
  \end{itemize}
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  For essential hypertension, can consider dietary/lifestyle modifications as first-line approach for patients with Stage 1 hypertension and no evidence of end-organ damage.
\item
  Pharmacologic therapy typically indicated for patients with Stage 2 hypertension, symptomatic hypertension, evidence of end-organ damage, or Stage 1 hypertension that does not improve after 4-6 months of lifestyle modifications.
\item
  Choice of pharmacologic agent depends on underlying etiology.

  \begin{itemize}
  \tightlist
  \item
    For renin-mediated hypertension (renal artery stenosis, renal scarring), ACE-inhibitor usually best choice (e.g., enalapril 0.08 mg/kg/day).
  \item
    For volume-related hypertension (e.g., glomerulonephritis) use diuretics (e.g., HCTZ 1-3 mg/kg once daily).
  \end{itemize}
\item
  General principle is to choose one medication and increase dose until reach maximum recommended dose, then add an additional agent until hypertension controlled.
\item
  \textbf{For treatment of hypertensive emergency, refer to hypertensive emergency section in critical care chapter.}
\end{itemize}

\#\#Urinary Tract Infections

\textbf{Definition}

\begin{itemize}
\tightlist
\item
  \textbf{Age \textless{} 2 mo:} ≥ 50,000 CFU/mL of a uropathogen OR 10,000-50,000 CFU/mL with pyuria on UA
\item
  \textbf{Age ≥ 2 mo:} significant bacteriuria (≥100,000 CFU/mL of single uropathogen from clean catch or ≥50,000 CFU/mL of uropathogen from cath sample) with associated inflammatory response (+LE/nitrite/WBC -- except if due to Enterococcus, Klebsiella, or PsA) and lower urinary tract symptoms (if appropriate age)
\item
  \textbf{Cystitis:} infection of urinary bladder
\item
  \textbf{Pyelonephritis:} infection of upper urinary tract (kidneys and ureters)
\end{itemize}

\textbf{Etiology}

\begin{itemize}
\tightlist
\item
  \textasciitilde90\% due to E coli; others include Enterococcus, Proteus, Pseudomonas, and Enterobacter
\item
  Adenovirus may cause acute infectious cystitis
\item
  \textbf{Risk factors}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Ages 2-23 months:} age \textless12 mo, max T ≥ 39 °C, nonblack race, female sex, uncircumcised male, no additional source of fever identified
  \item
    \textbf{Ages ≥ 2 years}

    \begin{itemize}
    \tightlist
    \item
      Female sex (shorter urethra, wetter periurethral environment)
    \item
      Lack of circumcision (in male infants)
    \item
      Sexual activity (receptive vaginal intercourse -- S saprophyticus; unprotected insertive anal intercourse)
    \item
      Urinary tract anomalies (bladder stones, constipation, urinary retention, posterior urethral valves, VUR)
    \item
      Bladder catheterization or instrumentation (predisposes to PsA, coag-neg Staph)
    \item
      Sickle cell disease
    \item
      DM or other immunosuppressive conditions
    \end{itemize}
  \end{itemize}
\end{itemize}

\textbf{Pathophysiology}

\begin{itemize}
\tightlist
\item
  \textbf{Newborns:} rare in first 6d life. May be due to hematogenous spread or ascending infection. Hematogenous spread more likely among preterm infants. Congenital anomalies of the kidney and urinary tract may predispose to UTI.
\item
  \textbf{Beyond newborn period:} colonization of periurethral area by uropathogens → attachment of pathogens to uroepithelium → inflammatory response. Inflammation of upper urinary tract (pyelonephritis) → renal scarring → HTN, ESRD.
\end{itemize}

\textbf{Clinical Presentation}

\begin{itemize}
\tightlist
\item
  \textbf{Age \textless{} 2 years:} fever may be sole manifestation, esp when ≥ 39 °C (102.2 °F).

  \begin{itemize}
  \tightlist
  \item
    Concomitant upper respiratory infection or AOM does not r/o UTI.
  \item
    May have concomitant poor feeding, irritability, or FTT.
  \item
    May cause conjugated hyperbilirubinemia.
  \end{itemize}
\item
  \textbf{Age ≥ 2 years}

  \begin{itemize}
  \tightlist
  \item
    Cystitis: dysuria, urinary frequency, hematuria, suprapubic pain and TTP
  \item
    Pyelonephritis: fever, flank/back pain, nausea/vomiting, headache
  \end{itemize}
\end{itemize}

\textbf{Workup}
\textbf{Don't Forget the UTI Clinical Pathway}

\begin{itemize}
\tightlist
\item
  \textbf{Age \textless{} 2 mo:} catheterized UA + urine culture

  \begin{itemize}
  \tightlist
  \item
    Obtain blood culture given risk of urosepsis.
  \item
    Strongly consider LP (1-3\% of infants with UTI have bacterial meningitis).
  \item
    Obtain renal/bladder U/S and consider VCUG if abnormal, if UTI is recurrent, or if pathogen other than E. Coli is identified.
  \item
    If ultrasound suggests renal damage - consider DMSA scan after resolution of acute illness.
  \end{itemize}
\item
  \textbf{Age 2 mo-2 years}

  \begin{itemize}
  \tightlist
  \item
    \emph{UTI Risk Score}

    \begin{itemize}
    \tightlist
    \item
      Two points if: temp ≥40oC, no alternative source of fever, female.
    \item
      One point if: temp Temp ≥39oC, male uncircumsized \textless12mo, male circumsized \textless6 mo, fever ≥2 days, sibling w/ VUR, prior UTI.
    \end{itemize}
  \item
    Low pre-test probability of UTI → consider starting with POCT UA on bagged urine sample. If normal, stop. If abnormal, obtain catheterized UA and send for culture. Do NOT send a bagged sample for culture.
  \item
    High pre-test probability of UTI (female w/ risk score ≥2, male w/ risk score ≥3) → obtain catheterized UA and send for culture.
  \end{itemize}
\item
  \textbf{Age ≥ 2 years:} clean catch UA → if +LE, nitrite, or WBC, send for culture. Consider empiric antibiotics for ≥1+ LE and nitrite, ≥1+ LE +/- nitrite, or ≥10 WBC/hpf.
\item
  Consider baseline creatinine if initiating nephrotoxic antibiotics .
\item
  Consider CRP and procalcitonin: CRP \textless2 mg/dL helps exclude pyelo, while procalcitonin \textgreater0.5 ng/mL can help confirm pyelo.
\end{itemize}

\textbf{Management}

\begin{itemize}
\tightlist
\item
  Neonate 0-1 month (consult reference for preterm neonates): \textbf{See BCH Clinical Pathway for Fever 0-1 month for additional recommendations.}

  \begin{itemize}
  \tightlist
  \item
    ≥35 wk GA and ≤7 days old

    \begin{itemize}
    \tightlist
    \item
      Ampicillin 50 mg/kg IV q8h
    \item
      Cefotaxime 50 mg/kg/dose q8h \textbf{OR} Gentamicin 4 mg/kg IV q24h
    \end{itemize}
  \item
    ≥35 wk GA and \textgreater7 days old

    \begin{itemize}
    \tightlist
    \item
      Ampicillin 50 mg/kg IV q6h
    \item
      Cefotaxime 50 mg/kg/dose q12h \textbf{OR} Gentamicin 5 mg/kg IV q24h
    \end{itemize}
  \end{itemize}
\item
  Infant/Child/Adolescent

  \begin{itemize}
  \tightlist
  \item
    \textbf{Duration:} 5-7 days if afebrile, 7-10 days if febrile.
  \item
    \textbf{1st line:} cephalexin 25 mg/kg/dose PO TID (max 500 mg/dose) vs ceftriaxone 50 mg/kg/dose IV q24h (max 2 g/dose).
  \item
    \textbf{2nd line:} TMP/SMX, amoxicillin-clavulanate, cefdinir, cefuroxime, ciprofloxacin (for adolescents with pyelo), nitrofurantoin (for adolescents with cystitis).
  \end{itemize}
\item
  If Grade III-V VUR is identified on VCUG, can consider prophylactic antibiotics, though the decrease in UTIs is exactly matched by an increase in MDROs as the etiology for UTI, when present.\footnote{Krupp et al.~International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal. April 2013.}
\end{itemize}

\#\#Nephrolithiasis

\textbf{Definition:} deposits of minerals within the kidney or the urinary tract.

\textbf{Risk Factors:} underlying risk factors are present in \textasciitilde75-85\% of children.

\begin{itemize}
\tightlist
\item
  PMHx or FHx of stone
\item
  Abnormal urinary system anatomy (ADPKD, UPJ obstruction)
\item
  Previous urological surgery
\item
  Metabolic disorder → solute excess (hypercalciuria, hyperoxaluria, hyperuricemia) or ↓ levels of inhibitors of stone formation (hypocitraturia, hypomagnesemia)
\item
  Chronic predisposing condition (IBD, CF, lymphoproliferative disorder, GSD, RTA)
\item
  Medications predisposing to stone formation (diuretics, steroids, topiramate, high dose vitamin C)
\item
  Recurrent UTIs
\end{itemize}

\textbf{Etiology:} majority of stones are CaOx, followed by CaPhos, struvite, cystine, and then uric acid.

\textbf{Clinical Presentation:} classic symptoms of abdominal/flank pain, hematuria, and dysuria

\begin{itemize}
\tightlist
\item
  Younger children tend to lack the classical symptoms.
\item
  If diagnosed with UTI and not getting better with abx, consider nephrolithiasis.
\item
  \textbf{Admission criteria:} Admit if unstable VS, inadequate pain control, poor hydration.
\end{itemize}

\textbf{Workup}

\begin{itemize}
\tightlist
\item
  Urine studies

  \begin{itemize}
  \tightlist
  \item
    Can do POCT UA, but consider formal if trying to clarify hematuria; UCx if c/f infection.
  \item
    Begin straining urine.
  \item
    Majority of urine/stone testing can wait until outpatient follow-up.
  \end{itemize}
\item
  Imaging

  \begin{itemize}
  \tightlist
  \item
    US preferred, but may miss small or ureteral stones.
  \item
    If no stone on US ± CT (may not need if normal anatomy and no other s/sx).
  \end{itemize}
\end{itemize}

\textbf{Management:} see Nephrolithiasis Clinical Pathway for additional recommendations.

\begin{itemize}
\tightlist
\item
  \textbf{Pain Control}
\item
  Hyperhydration
\item
  Diet: low Na+, but no Ca2+ restriction
\end{itemize}

\hypertarget{references-6}{%
\subsection{References}\label{references-6}}

\hypertarget{neurology}{%
\section{Neurology}\label{neurology}}

\hypertarget{neurologic-emergencies}{%
\subsection{Neurologic Emergencies}\label{neurologic-emergencies}}

\hypertarget{status-epilepticus}{%
\subsubsection{Status Epilepticus}\label{status-epilepticus}}

\hypertarget{powerplan}{%
\paragraph{PowerPlan}\label{powerplan}}

See new BCH Guidelines

\hypertarget{definition-46}{%
\paragraph{Definition}\label{definition-46}}

Seizure lasting \textgreater{} 5 min (or \textgreater{} 30 minutes, at which there may be long-term consequences), or two sequential seizures w/o return to baseline in between. Neurologic emergency. If seizure is refractory to multiple drugs, considered refractory SE.

\hypertarget{presentation-101}{%
\paragraph{Presentation}\label{presentation-101}}

May be generalized SE, focal SE, or non-convulsive (including absence, aura continua, aphasic)

\hypertarget{differential-15}{%
\paragraph{Differential}\label{differential-15}}

Epilepsy, electrolyte derangement, febrile status, meningitis/encephalitis, space occupying lesion, stroke, hypertensive emergency/PRES, PNES

\hypertarget{red-flags-2}{%
\paragraph{Red Flags}\label{red-flags-2}}

Refractory to treatment, focal neurologic deficits on examination

\hypertarget{work-up-46}{%
\paragraph{Work-up}\label{work-up-46}}

Initial labs include glucose, chem, UA/blood/urine cultures if febrile, urine tox screen, AED levels in patients taking AEDs, LP if concerns for CNS infections, imaging if examination is focal. Work up is considered following treatment.

\hypertarget{management-52}{%
\paragraph{Management}\label{management-52}}

ABC's, correct electrolyte disturbances, call relevant Neurology consult service, administer rescue meds as below, \textbf{consider activating Code Blue or anesthesia stat x5-5555}

\begin{itemize}
\tightlist
\item
  \textbf{First line} (0-5 min): IV lorazepam (Ativan) 0.05 - 0.1 mg/kg/dose (max 4 mg). If no access, diazepam (Diastat) PR: (0.5 mg/kg if \textless{} 5yo; 0.3 mg/kg if 6-11yo; 0.2 mg/kg if \textgreater{} 11yo)
\item
  \textbf{Second line} (5-15 min): Repeat benzos x1 at same dose if no response in 5 min

  \begin{itemize}
  \tightlist
  \item
    Fosphenytoin IV: 20 phenytoin equivalents/kg/ dose (max 1500 mg)
  \item
    Levetiracetam IV: 30 mg/kg (max 4500 mg) over 5-15 minutes. Dosing range 20-60 mg/kg.
  \end{itemize}
\item
  \textbf{Third line} (15-20 min): Phenobarbital 20/mg/kg IV push, monitor for resp. depression

  \begin{itemize}
  \tightlist
  \item
    Give Levetiracetam (60mg/kg IV) OR Fosphenytoin (20 mg PE/kg/dose), whichever was not previously given
  \item
    Consider repeat Fosphenytoin (10 mg PE/kg/dose IV) OR Valproic Acid (Depakote) (20 mg/kg IV)
  \end{itemize}
\end{itemize}

\hypertarget{complications-16}{%
\paragraph{Complications}\label{complications-16}}

Cardiac arrhythmia, cerebral edema, hypotension, rhabdomyolysis, dehydration, pneumonia

\hypertarget{increased-intracranial-pressure-icp}{%
\subsubsection{Increased Intracranial Pressure (ICP)}\label{increased-intracranial-pressure-icp}}

\emph{See Critical Care/ICP chapter}

\hypertarget{stroke1}{%
\subsubsection[Stroke]{\texorpdfstring{Stroke\footnote{Lehman, et al., Transient focal neurologic symptoms correspond to regional cerebral hypoperfusion by MRI: A stroke mimic in children. American Journal of Neuroradiology. July 2017.}}{Stroke}}\label{stroke1}}

\hypertarget{powerplans-order-sets-clinical-pathways-20}{%
\paragraph{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-20}}

\begin{itemize}
\tightlist
\item
  \textbf{PowerPlans \& Order Sets:} Neuroscience ICP Admit Plan; Neuro Stroke Plan
\item
  \textbf{Call for help!} \emph{Please call a \textbf{Code Stroke (x52170)} if symptom onset \textless{} 5 hrs prior!}
\item
  \textbf{Other resources:} See Neurology Card
\end{itemize}

\hypertarget{pathophysiology-41}{%
\paragraph{Pathophysiology}\label{pathophysiology-41}}

Acute-onset neurologic dysfunction due to impaired blood supply to the brain; ischemic or hemorrhagic

\hypertarget{presentation-102}{%
\paragraph{Presentation}\label{presentation-102}}

Any acute-onset focal neurologic finding including unilateral weakness or numbness, visual loss, aphasia, altered mental status, new-onset focal seizures

\hypertarget{differential-16}{%
\paragraph{Differential}\label{differential-16}}

Seizure, demyelinating process, Todd's paralysis following focal seizure, hemiplegic migraine

\hypertarget{red-flags-3}{%
\paragraph{Red Flags}\label{red-flags-3}}

\begin{itemize}
\tightlist
\item
  Risk factors include trauma, vasculitis/vasculopathy, infection, tumor/malignancy, prothrombotic state, leukocytosis and anemia
\item
  Risk factors for arterial ischemic stroke include Sickle Cell Disease and Cardiac Disease
\item
  Risk factors for venous stroke are IBD, auto-immune disorders, infections and dehydration
\end{itemize}

\hypertarget{work-up-47}{%
\paragraph{Work-up}\label{work-up-47}}

Brain MRI/MRA w/ stroke protocol (includes DWI/ADC, FLAIR, T2, T1, susceptibility sequences), +/- MRV. TTE to look for cardiac causes. Serum labs to look for coagulopathy. If newborn, add metabolic studies.

\hypertarget{management-53}{%
\paragraph{Management}\label{management-53}}

ABC's! Head of bed flat; IVF at maintenance, target SBP 50-90th percentile for age. Maintain euglycemia and normothermia, treat seizures, consider PICU admission and neurosurgical consult. Stroke in sickle cell is treated with exchange transfusion.

\hypertarget{complications-17}{%
\paragraph{Complications}\label{complications-17}}

Malignant edema which may lead to herniation, hemorrhagic conversion (consider STAT CT for change in exam)

\hypertarget{weakness}{%
\subsection{Weakness}\label{weakness}}

\hypertarget{guillain-barruxe9-syndorme-gbs2}{%
\subsubsection[Guillain-Barré Syndorme (GBS)]{\texorpdfstring{Guillain-Barré Syndorme (GBS)\footnote{Jones, H. Guillain-Barre Syndrome: Perspectives w/ Infants and Children. Seminars in Pediatric Neurology June 2000.}}{Guillain-Barré Syndorme (GBS)}}\label{guillain-barruxe9-syndorme-gbs2}}

\hypertarget{pathophysiology-42}{%
\paragraph{Pathophysiology}\label{pathophysiology-42}}

Monophasic demyelinating neuropathy. Antibody and complement-mediated injury to myelinated peripheral nerves. At least half of cases are preceded by viral infection (EBV, mycoplasma, c.~jejuni, CMV). Vaccines are also implicated.

\hypertarget{presentation-103}{%
\paragraph{Presentation}\label{presentation-103}}

Progressive motor weakness (ascending) \& areflexia +/- autonomic dysfunction. May also complain of pain. Children may refuse to walk.

\hypertarget{differential-17}{%
\paragraph{Differential}\label{differential-17}}

Spinal cord lesion (transverse myelitis, hematoma), acute flaccid myelitis, tick paralysis, toxic neuropathy

\hypertarget{red-flags-4}{%
\paragraph{Red Flags}\label{red-flags-4}}

Weakness of muscles of respiration can indicate need for intubation

\hypertarget{work-up-48}{%
\paragraph{Work-up}\label{work-up-48}}

CSF profile classically w/ albuminocytologic dissociation (elevated protein w/o leukocytosis). EMG is not helpful early in the disease course.

\hypertarget{management-54}{%
\paragraph{Management}\label{management-54}}

IVIG or plasmapheresis. Consult PT.

\hypertarget{miller-fisher-variant-of-guillain-barruxe93}{%
\subsubsection[Miller-Fisher variant of Guillain-Barré]{\texorpdfstring{Miller-Fisher variant of Guillain-Barré\footnote{Shahrizaila, N, and Yuki, N. Bickerstaff brainstem encephalitis and Fisher Syndrome: anti-GQ1B antibody syndrome. Journal of Neurology, Neurosurgery and Psychiatry 84(5). 2013.}}{Miller-Fisher variant of Guillain-Barré}}\label{miller-fisher-variant-of-guillain-barruxe93}}

\hypertarget{pathophysiology-43}{%
\paragraph{Pathophysiology}\label{pathophysiology-43}}

Antibody-mediated (anti-Gq1b) demyelination of the cranial nerves w/ or w/o peripheral nerve involvement

\hypertarget{presentation-104}{%
\paragraph{Presentation}\label{presentation-104}}

Defined by the presence of areflexia, ophthalmoplegia and ataxia; viral illness usually precedes symptoms. Sensorium remains intact.

\hypertarget{differential-18}{%
\paragraph{Differential}\label{differential-18}}

Guillain-Barré Syndrome, myasthenia gravis, spinal cord lesion, MS

\hypertarget{red-flags-5}{%
\paragraph{Red Flags}\label{red-flags-5}}

Weakness of muscles of respiration can indicate need for intubation

\hypertarget{work-up-49}{%
\paragraph{Work-up}\label{work-up-49}}

MRI of the brain and spine; LP if no space-occupying lesion. CSF profile similar to that of GBS w/ albuminocytologic dissociation (elevated protein w/o leukocytosis).

\hypertarget{management-55}{%
\paragraph{Management}\label{management-55}}

IVIG 2g/kg over 2-5 days

\hypertarget{myasthenia-gravis4}{%
\subsubsection[Myasthenia Gravis]{\texorpdfstring{Myasthenia Gravis\footnote{Peragallo, J. Pediatric Myasthenia Gravis. Seminars in Pediatric Neurology. May 2017.}}{Myasthenia Gravis}}\label{myasthenia-gravis4}}

\hypertarget{pathophysiology-44}{%
\paragraph{Pathophysiology}\label{pathophysiology-44}}

Antibody blockade of the post-synaptic ACh receptor at the neuromuscular junction

\hypertarget{presentation-105}{%
\paragraph{Presentation}\label{presentation-105}}

\begin{itemize}
\tightlist
\item
  Fatigable weakness (symptoms worse at the end of the day)
\item
  Diplopia and ptosis can be provoked by sustained upgaze, arm weakness can be provoked w/ repetitive arm pumps
\item
  Weakness tends to present in the muscles of the face, causing dysphagia, dysphonia, drooling, dysarthria (bulbar symptoms)
\item
  \textbf{Myasthenic Crisis:} Presents w/ inability to clear secretions or maintain oxygenation (precipitated by infection, surgery, stress, meds, etc)
\end{itemize}

\hypertarget{differential-19}{%
\paragraph{Differential}\label{differential-19}}

Botulism, Miller Fisher variant of GBS, brainstem lesion, thyroid ophthalmopathy

\hypertarget{red-flags-6}{%
\paragraph{Red Flags}\label{red-flags-6}}

Check how high the patient can count in a single breath, NIFs, check sustained up-gaze; evaluate neck flexion/extension (sensitive test for diaphragmatic strength) to assess need for intubation

\hypertarget{work-up-50}{%
\paragraph{Work-up}\label{work-up-50}}

Ice pack for eval of ptosis (should improve as cold slows acetylcholinesterase activity). Check for antibodies (anti-AChR, anti-MuSK). EMG (decrement in muscle potentials on repetitive nerve stim). CXR to screen for thymoma.

\hypertarget{management-56}{%
\paragraph{Management}\label{management-56}}

Avoidance of drugs which may exacerbate MG (see uptodate table). Monitor FVC/NIF and intubate for FVC \textless{} 15 mL/kg and NIF \textless{} -20. Suctioning, NG tube.

\hypertarget{management-57}{%
\paragraph{Management}\label{management-57}}

See below: IVIG (0.4 g/kg/d x 5d), plasmapheresis if severe

\hypertarget{complications-18}{%
\paragraph{Complications}\label{complications-18}}

Respiratory failure, pulmonary infections, death

\hypertarget{bells-palsy}{%
\subsubsection{Bell's Palsy}\label{bells-palsy}}

\hypertarget{powerplans-order-sets-clinical-pathways-21}{%
\paragraph{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-21}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathways:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=FACIALPALSY\&algVersion=1.6\&accessCode=null}{Facial Palsy}
\end{itemize}

\hypertarget{pathophysiology-45}{%
\paragraph{Pathophysiology}\label{pathophysiology-45}}

Acute paralysis of the peripheral facial nerve. Pathogenesis viral (most commonly HSV) but also may be post-viral or immune-mediated (VZV, Hepatitis, HIV, Lyme, EBV).

\hypertarget{presentation-106}{%
\paragraph{Presentation}\label{presentation-106}}

Weakness in the upper and lower face, pain, tingling in ipsilateral ear canal, taste changes, impaired lacrimation and hypersensitivity to sound

\hypertarget{differential-20}{%
\paragraph{Differential}\label{differential-20}}

Otitis media, trauma, tumor, TB, Ramsay Hunt syndrome, malignant hypertension, mastoiditis

\hypertarget{red-flags-7}{%
\paragraph{Red Flags}\label{red-flags-7}}

Signs of increased ICP, focal neurologic findings, other cranial neuropathies

\hypertarget{work-up-51}{%
\paragraph{Work-up}\label{work-up-51}}

Exclude other cause (i.e.~HTN, trauma, active herpetic lesions c/w RHS). Consider MRI, Lyme serologies if indicated by history/exam.

\hypertarget{management-58}{%
\paragraph{Management}\label{management-58}}

\begin{itemize}
\tightlist
\item
  \textbf{Watchful waiting:} Eye ointments/artificial tears to maintain hydration, eye patch or taping eyelid closed while sleeping, use of corticosteroids controversial (most kids have complete spontaneous recovery). Valacyclovir/acyclovir if HSV suspected, doxycycline if Lyme is suspected May-November. Consider MRI if other symptoms present.
\item
  \textbf{Empiric corticosteroids:} Prednisone 2 mg/kg once daily x 5 days w/ 5-day taper (max 60 mg/dose). Start w/i 3 days of symptom onset.
\end{itemize}

\hypertarget{complications-19}{%
\paragraph{Complications}\label{complications-19}}

Corneal ulcers if absent blink reflex/incomplete closure of palpebral fissure

\hypertarget{acute-flaccid-myelitis-afm5}{%
\subsubsection[Acute Flaccid Myelitis (AFM)]{\texorpdfstring{Acute Flaccid Myelitis (AFM)\footnote{Ayers, T. et al.~Acute Flaccid Myelitis in the United States: 2015-2017. Pediatrics. 2019;144(5) Epub 2019 Oct 7}}{Acute Flaccid Myelitis (AFM)}}\label{acute-flaccid-myelitis-afm5}}

\hypertarget{pathophysiology-46}{%
\paragraph{Pathophysiology}\label{pathophysiology-46}}

Inflammation of gray matter of spinal cord (anterior horn cells). Most commonly associated with enterovirus D68 or A71. Historically poliovirus. May also be caused by adenovirus, flavivirus and West Nile virus.

\hypertarget{presentation-107}{%
\paragraph{Presentation}\label{presentation-107}}

Limb weakness following non-specific viral symptoms (fever, cough, rhinorrhea, vomiting/diarrhea). Median onset \textasciitilde5 days (range 0-28 days). May have hyperacute presentation (rapid progression \textless6 hours). Quadriparesis at presentation in \textasciitilde1/3 of cases. May have UMN pattern due to involvement of lateral corticospinal tracts. May include bowel/bladder symptoms and/or cranial neuropathies.

\hypertarget{differential-21}{%
\paragraph{Differential}\label{differential-21}}

Spinal cord infarct or mass lesion, GBS, myasthenia, transverse myelitis/NMO

\hypertarget{red-flags-8}{%
\paragraph{Red Flags}\label{red-flags-8}}

Respiratory failure. Signs of brainstem encephalitis (Entero A71 - autonomic instability/shock, ataxia, cranial nerve involvement, AMS).

\hypertarget{work-up-52}{%
\paragraph{Work-up}\label{work-up-52}}

\begin{itemize}
\tightlist
\item
  MRI brain and spine w/wo contrast (Spinal gray matter T2 hyper-intensities, MRI may be normal \textless72 hrs)
\item
  CSF analysis (lymphocytic pleocytosis (mean \textasciitilde210), mild elevation of protein)

  \begin{itemize}
  \tightlist
  \item
    Note: Generally unable to detect viral RNA in CSF
  \end{itemize}
\item
  Nasopharyngeal and rectal swabs for viral PCR (or fecal)
\item
  Serologies for mimics (anti-MOG)
\end{itemize}

\hypertarget{management-59}{%
\paragraph{Management}\label{management-59}}

\begin{itemize}
\tightlist
\item
  Supportive care. \textasciitilde30\% require mechanical ventilation.
\item
  Immune therapies (glucocorticoids, IVIG, PLEX relatively contra-indicated given direct viral infection)
\end{itemize}

\hypertarget{complications-20}{%
\paragraph{Complications}\label{complications-20}}

Respiratory failure. Rare cases of A71 causing brainstem encephalitis with non-cardiogenic pulmonary edema and rapidly fatal cardiopulmonary failure.

\hypertarget{hypotonia}{%
\subsection{Hypotonia}\label{hypotonia}}

\hypertarget{approach-to-neonatal-hypotonia}{%
\subsubsection{Approach to Neonatal Hypotonia}\label{approach-to-neonatal-hypotonia}}

\hypertarget{pathophysiology-47}{%
\paragraph{Pathophysiology}\label{pathophysiology-47}}

Central (UMN) vs.~peripheral (LMN) injury or dysfunction leading to decreased tone, which is resistance to passive stretch of the muscle at joints, often but not always associated w/ weakness

\hypertarget{presentation-108}{%
\paragraph{Presentation}\label{presentation-108}}

Head lag, frog-legged positioning, slip-through on vertical suspension, U-shape on horizontal suspension. Failure to meet developmental milestones. Also with dysphagia, FTT.

\hypertarget{differential-22}{%
\paragraph{Differential}\label{differential-22}}

Central (HIE, TORCH, brain malformations, IEM, genetic disorders, mitochondrial disease, hemorrhage/stroke) vs.~peripheral (SMA, myasthenia gravis). Maternal drugs.

\hypertarget{red-flags-9}{%
\paragraph{Red Flags}\label{red-flags-9}}

Respiratory insufficiency/failure. Developmental regression.

\hypertarget{work-up-53}{%
\paragraph{Work-up}\label{work-up-53}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Reflexes are the most important examination maneuver (you can tap a finger to assess a baby's reflexes)

  \begin{itemize}
  \tightlist
  \item
    Areflexia indicates a peripheral process and need for non-urgent EMG
  \item
    Present reflexes indicate a central process
  \end{itemize}
\item
  Next is the presence of appendicular hypertonia, which is an increased resistance to passive stretch (and hyperreflexia) of the limbs despite the axial hypotonia (muscles of the neck and trunk), which can indicate perinatal injury and can be non-urgently assessed w/ MRI
\item
  Septic work-up, LFTs, ammonia, chemistry, CK, consider genetic work-up
\end{enumerate}

\hypertarget{management-60}{%
\paragraph{Management}\label{management-60}}

New therapies for SMA (nusinersen, zolgensma)! Otherwise, depends on etiology. Typically supportive, using EI for children under age 3 or the school for older children w/ emphasis on PT and OT, ST as needed for dysphagia.

\hypertarget{complications-21}{%
\paragraph{Complications}\label{complications-21}}

Dependent on the underlying cause but sometimes associated w/ cognitive dysfunction in addition to developmental delay

\hypertarget{infantile-botulism6}{%
\subsubsection[Infantile Botulism]{\texorpdfstring{Infantile Botulism\footnote{Thompson et al., Infant Botulism in the age of botulism immune globulin. Neurology. June 2005.}}{Infantile Botulism}}\label{infantile-botulism6}}

\hypertarget{pathophysiology-48}{%
\paragraph{Pathophysiology}\label{pathophysiology-48}}

\begin{itemize}
\tightlist
\item
  C. botulinum produces toxin that interferes w/ release of acetylcholine at NMJ (disrupts vesicle binding to the pre-synaptic membrane)
\item
  In infancy, C. botulinum colonizes intestinal tract in situ
\item
  Contamination of honey or corn syrup, dusty environments near construction/agricultural soil disruption are culprits
\item
  In adults, paralysis results from ingestion of the toxin
\end{itemize}

\hypertarget{presentation-109}{%
\paragraph{Presentation}\label{presentation-109}}

Descending paralysis, often starting w/ ophthalmoplegia (may involve pupillary response), followed by weak cry, dysphagia and progresses to weakness of respiratory muscles

\hypertarget{differential-23}{%
\paragraph{Differential}\label{differential-23}}

GBS Miller Fisher variant, hypermagnesemia, SMA, Myasthenia Gravis

\hypertarget{red-flags-10}{%
\paragraph{Red Flags}\label{red-flags-10}}

Weakness of muscles of respiration can indicate need for intubation

\hypertarget{work-up-54}{%
\paragraph{Work-up}\label{work-up-54}}

Isolation of organism in stool. EMG: short-duration, low-amplitude motor unit potentials.

\hypertarget{management-61}{%
\paragraph{Management}\label{management-61}}

\begin{itemize}
\tightlist
\item
  ICU care for severe presentation, may require ventilator support
\item
  Immune globulin
\item
  Avoid aminoglycosides (produce pre-synaptic neuromuscular blockage)
\item
  Treat w/ BIG prior to confirmation of stool/EMG if clinical suspicion is high
\end{itemize}

\hypertarget{complications-22}{%
\paragraph{Complications}\label{complications-22}}

Apnea, respiratory failure, sudden infant death

\hypertarget{neuroimmunology}{%
\subsection{Neuroimmunology}\label{neuroimmunology}}

\hypertarget{multiple-sclerosis-ms7}{%
\subsubsection[Multiple Sclerosis (MS)]{\texorpdfstring{Multiple Sclerosis (MS)\footnote{Krupp et al.~International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal. April 2013.}}{Multiple Sclerosis (MS)}}\label{multiple-sclerosis-ms7}}

\hypertarget{pathophysiology-49}{%
\paragraph{Pathophysiology}\label{pathophysiology-49}}

T lymphocytes attack oligodendrocytes, affecting myelin (autoimmune-mediated demyelination); known genetic (HLA subtypes) and environmental (smoking, latitude, vit D) risk factors

\hypertarget{presentation-110}{%
\paragraph{Presentation}\label{presentation-110}}

\begin{itemize}
\tightlist
\item
  Repeated episodes focal deficits (optic neuritis, weakness, numbness) separated in time
\item
  Imaging often shows lesions separated by space w/i the CNS
\end{itemize}

\hypertarget{differential-24}{%
\paragraph{Differential}\label{differential-24}}

ADEM (often a first presentation of MS- multiple lesions causing altered sensorium), NMO spectrum disorder (neuromyelitis optica), MOG-antibody associated demyelinating disease, malignancy, nutritional deficiency, leukodystrophy, mitochondrial disorder, CNS vasculitis, ophthalmologic disease

\hypertarget{red-flags-11}{%
\paragraph{Red Flags}\label{red-flags-11}}

\begin{itemize}
\tightlist
\item
  Presentation is broad and variable
\item
  Seizure (indicating gray matter involvement), fever should lead you to rethink the diagnosis
\item
  Weakness of muscles of respiration and/or mental status changes can indicate need for intubation
\end{itemize}

\hypertarget{work-up-55}{%
\paragraph{Work-up}\label{work-up-55}}

\begin{itemize}
\tightlist
\item
  Definitive diagnosis requires repeated episodes over time
\item
  LP reveals CSF w/ elevated protein count +/- presence of oligoclonal bands (must be compared w/ serum). MRI is imaging modality of choice.
\item
  The presence of 3+ white matter lesions on T2 imaging especially if perpendicular to the ventricles sensitive for diagnosis (Dawson's fingers)
\end{itemize}

\hypertarget{management-62}{%
\paragraph{Management}\label{management-62}}

Acute exacerbations require short-course of steroids. Load w/ methylprednisolone (30 mg/kg; maximum 1g), treat for 3-5 days. Neuroimmunology consult for disease-modifying drugs.

\hypertarget{acute-disseminated-encephalomyelitis-adem7}{%
\subsubsection[Acute Disseminated Encephalomyelitis (ADEM)]{\texorpdfstring{Acute Disseminated Encephalomyelitis (ADEM)\footnote{Krupp et al.~International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal. April 2013.}}{Acute Disseminated Encephalomyelitis (ADEM)}}\label{acute-disseminated-encephalomyelitis-adem7}}

\hypertarget{pathophysiology-50}{%
\paragraph{Pathophysiology}\label{pathophysiology-50}}

Central demyelinating disorder, presumed immune-mediated mechanism

\hypertarget{presentation-111}{%
\paragraph{Presentation}\label{presentation-111}}

Encephalopathy + lethargy, headache, vomiting, focal neurological symptoms

\hypertarget{differential-25}{%
\paragraph{Differential}\label{differential-25}}

Multiple Sclerosis, infectious/toxic/metabolic encephalitis, leukodystrophy

\hypertarget{red-flags-12}{%
\paragraph{Red Flags}\label{red-flags-12}}

Decreased level of arousal can indicate need for intubation for airway protection

\hypertarget{work-up-56}{%
\paragraph{Work-up}\label{work-up-56}}

MRI brain and spine w/ and w/o contrast (T2 weighted MRI reveals confluent increased signal intensity throughout white matter, specifically corpus callosum and periventricular region). LP (CSF can be normal or have elevated protein or WBC).

\hypertarget{management-63}{%
\paragraph{Management}\label{management-63}}

High dose IV methylprednisolone; IVIG and plasma exchange may help refractory cases

\hypertarget{complications-23}{%
\paragraph{Complications}\label{complications-23}}

\begin{itemize}
\tightlist
\item
  Typically a self-limiting, monophasic course
\item
  Multiple episodes raise concern for MS/MOG-associated demyelination
\end{itemize}

\hypertarget{transverse-myelitis8}{%
\subsubsection[Transverse Myelitis]{\texorpdfstring{Transverse Myelitis\footnote{Pidcock FS, et al.~Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007;68(18):1474.}}{Transverse Myelitis}}\label{transverse-myelitis8}}

\hypertarget{pathophysiology-51}{%
\paragraph{Pathophysiology}\label{pathophysiology-51}}

Combined demyelinating and inflammatory disorder. Wide variety of associations:

\begin{itemize}
\tightlist
\item
  May present as part of demyelinating disorder (MS, NMO)
\item
  Associated with various rheum conditions (SLE, RA, scleroderma, etc)
\item
  Idiopathic cases largely thought to be post-infectious (30-60\% preceded by viral illness)
\end{itemize}

\hypertarget{presentation-112}{%
\paragraph{Presentation}\label{presentation-112}}

Acute to subacute development (nadir 4 hrs to 21 days) of weakness (commonly UE), sensory deficit, autonomic disturbance. Although initially flaccid, spasticity often follows. Autonomic symptoms include urinary/fecal incontinence, urinary retention, sexual dysfunction.

\hypertarget{differential-26}{%
\paragraph{Differential}\label{differential-26}}

\begin{itemize}
\tightlist
\item
  \textbf{Non-inflammatory:} Compressive myelopathy (neoplasm, vertebral body compression fx, spondylosis, herniation); spinal infarct; nutritional deficiencies (B12, vitamin E, NO toxicity)
\item
  \textbf{Inflammatory:} Demyelinating disease syndrome (MS, ADEM, NMO); rheum disease (SLE, sarcoid, Sjogrens); infections (enterovirus, HIV, WNV, Lyme)
\end{itemize}

\hypertarget{red-flags-13}{%
\paragraph{Red Flags}\label{red-flags-13}}

Rapid onset of paraplegia/spinal shock

\hypertarget{work-up-57}{%
\paragraph{Work-up}\label{work-up-57}}

\begin{itemize}
\tightlist
\item
  Spinal MRI w/wo contrast (T2 hyperintensities; no mass lesion)
\item
  Brain MRI (r/o central lesions c/w MS)
\item
  CSF studies (basic + IgG index, oligoclonal bands, cytology, VLDR) abnormal in 50\% of cases

  \begin{itemize}
  \tightlist
  \item
    Expect lymphocytic pleocytosis (children \textgreater{} adults with mean \textasciitilde136/mm), elevated protein, elevated IgG index
  \end{itemize}
\item
  Serologies (AQP4, MOG, ANA, Ro/SSA, La/SSB)
\item
  Infectious studies (HIV, VZV, EBV, VLDR, WNV, enterovirus)
\item
  B12, MMA
\end{itemize}

\hypertarget{management-64}{%
\paragraph{Management}\label{management-64}}

High dose IV steroids (methylpred 30 mg/kg daily). PLEX if refractory disease or acute motor impairment. Relapsing disease may require long-term immunomodulation (mycophenolate or rituximab).

\hypertarget{complications-24}{%
\paragraph{Complications}\label{complications-24}}

Progression to multiple sclerosis (risk factors include brain MRI abnormalities, oligoclonal bands, mild or asymmetric disease)

\hypertarget{autoimmune-encephalitis-nmda-receptor-antibody-encephalopathy9}{%
\subsubsection[Autoimmune Encephalitis (NMDA Receptor Antibody Encephalopathy)]{\texorpdfstring{Autoimmune Encephalitis (NMDA Receptor Antibody Encephalopathy)\footnote{Dalmau, J. Clinical experience and laboratory investigations in patients w/ anti NMDAR encephalitis. Lancet Neurology. January 2011.}}{Autoimmune Encephalitis (NMDA Receptor Antibody Encephalopathy)}}\label{autoimmune-encephalitis-nmda-receptor-antibody-encephalopathy9}}

\hypertarget{pathophysiology-52}{%
\paragraph{Pathophysiology}\label{pathophysiology-52}}

\begin{itemize}
\tightlist
\item
  Antibodies bind to NR1 subunit of NMDAR and cause receptor endocytosis and subsequent neurologic dysfunction
\item
  Ovarian teratomas are an important cause in girls \textless{} 18 (31 \%); tumors rare in males
\item
  Overall, a rare disease
\end{itemize}

\hypertarget{presentation-113}{%
\paragraph{Presentation}\label{presentation-113}}

Acute (\textless3 mos) behavior and personality changes (including depression/anxiety/psychosis), seizures, insomnia, stereotyped movements and autonomic instability

\hypertarget{differential-27}{%
\paragraph{Differential}\label{differential-27}}

Viral encephalitis, neuroleptic malignant syndrome, psychosis, catatonia

\hypertarget{red-flags-14}{%
\paragraph{Red Flags}\label{red-flags-14}}

Autonomic instability

\hypertarget{work-up-58}{%
\paragraph{Work-up}\label{work-up-58}}

\begin{itemize}
\tightlist
\item
  MRI Brain typically w/ lesions
\item
  EEG can show slowing and delta brush
\item
  ELISA test of Ab against NR1 subunit of NMDA receptor (autoimmune encephalitis panel) is diagnostic
\item
  Look for tumor w/ US/MRI of abdomen/pelvis
\end{itemize}

\hypertarget{management-65}{%
\paragraph{Management}\label{management-65}}

\begin{itemize}
\tightlist
\item
  If applicable, tumor resection
\item
  Methylprednisolone 30mg/kg (max 1g) IV daily x5d, IVIG 2g/kg over 2 to 5 days and plasma exchange are all first line treatments
\end{itemize}

\hypertarget{complications-25}{%
\paragraph{Complications}\label{complications-25}}

Autonomic instability, seizures

\hypertarget{neuropsychiatric}{%
\subsection{Neuropsychiatric}\label{neuropsychiatric}}

\hypertarget{functional-neurologic-disorder10}{%
\subsubsection[Functional Neurologic Disorder]{\texorpdfstring{Functional Neurologic Disorder\footnote{Tremolizzo et al.~Positive signs of functional weakness. J Neurological Sciences. March 2014.}}{Functional Neurologic Disorder}}\label{functional-neurologic-disorder10}}

\hypertarget{powerplans-order-sets-clinical-pathways-22}{%
\paragraph{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-22}}

\begin{itemize}
\tightlist
\item
  \textbf{Other resources:} Refer patients to \textless www.neurosymptoms.org\textgreater{}
\end{itemize}

\hypertarget{pathophysiology-53}{%
\paragraph{Pathophysiology}\label{pathophysiology-53}}

Inorganic cause of neurologic symptoms, thought to be due to inappropriate signaling and heightened pain sensation as response to stress

\hypertarget{presentation-114}{%
\paragraph{Presentation}\label{presentation-114}}

\begin{itemize}
\tightlist
\item
  Can present w/ weakness or paralysis, nonepileptic seizures, sensory or somatic complaints
\item
  Often w/ comorbid anxiety or depression
\item
  \textbf{Inconsistencies on exam:} Distractibility, inconsistencies between confrontational testing and function, sensory symptoms in non-dermatomal distribution
\end{itemize}

\hypertarget{differential-28}{%
\paragraph{Differential}\label{differential-28}}

Stroke, GBS, transverse myelitis or other spinal disorder, seizures

\hypertarget{red-flags-15}{%
\paragraph{Red Flags}\label{red-flags-15}}

Sudden-onset weakness of one side, dermatomal distribution, spinal level of weakness, areflexia, altered mental status

\hypertarget{work-up-59}{%
\paragraph{Work-up}\label{work-up-59}}

\begin{itemize}
\tightlist
\item
  Thorough history and physical, including medical and psych, review prior labs or imaging, ask about psychological stressors
\item
  Depends on positive clinical findings rather than negative tests
\item
  Exam maneuvers

  \begin{itemize}
  \tightlist
  \item
    Hoover's sign: involuntary extension of weak leg when contralateral leg flexes against resistance \includegraphics{images/Hooversign.png}
  \item
    Hip abductor sign: hip abduction weakness in affected leg returns to normal during contralateral hip abduction against resistance of unaffected leg
  \item
    Drift without pronation sign: when asked to hold arms out with palms up and eyes closed, weak arm drifts without pronating (as would be seen with UMN lesions)
  \item
    Arm drop: weak arm held above face and released, will stay suspended or move to miss hitting face, can be tested during non-epileptiform seizures
  \item
    Midline splitting: complete sensory loss on one side, split exactly midline
  \end{itemize}
\end{itemize}

\hypertarget{management-66}{%
\paragraph{Management}\label{management-66}}

PT/OT, psychotherapy, pain management, supportive care, education

\hypertarget{headache}{%
\subsection{Headache}\label{headache}}

\hypertarget{migraine}{%
\subsubsection{Migraine}\label{migraine}}

\hypertarget{powerplans-order-sets-clinical-pathways-23}{%
\paragraph{PowerPlans, Order Sets \& Clinical Pathways}\label{powerplans-order-sets-clinical-pathways-23}}

\begin{itemize}
\tightlist
\item
  Clinical Pathway: \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=MIGRAINE\&algVersion=2.4\&accessCode=null}{Headache/Migraine, Emergent/Urgent}
\end{itemize}

\hypertarget{pathophysiology-54}{%
\paragraph{Pathophysiology}\label{pathophysiology-54}}

Cortical spreading depression: Neurons fire in a sequential manner across the surface of the brain (causing an aura). Associated w/ irritation and dysregulation of blood vessel tone of the overlying meninges, causing pain.

\hypertarget{presentation-115}{%
\paragraph{Presentation}\label{presentation-115}}

Unilateral throbbing headache (bilateral sometimes in young children), visual aura, photophobia, phonophobia, nausea, vomiting, relieved by rest

\hypertarget{differential-29}{%
\paragraph{Differential}\label{differential-29}}

Venous sinus thrombosis, concussion, tension type headache, intracranial mass lesion

\hypertarget{red-flags-16}{%
\paragraph{Red Flags}\label{red-flags-16}}

Any symptoms suggestive of increased ICP (i.e.~papilledema, nerve palsy, positional headache, morning emesis, encephalopathy, wake from sleep w/ headache), focal neurological deficits, change in character from typical headache, progressive worsening of headaches, neck stiffness

\hypertarget{work-up-60}{%
\paragraph{Work-up}\label{work-up-60}}

Clinical diagnosis, consider MRI for red-flag symptoms

\hypertarget{management-67}{%
\paragraph{Management}\label{management-67}}

\begin{itemize}
\tightlist
\item
  See treatment algorithm in \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=MIGRAINE\&algVersion=2.4\&accessCode=null}{Migraine Clinical Pathway} as above
\end{itemize}

\hypertarget{tension-headache}{%
\subsubsection{Tension Headache}\label{tension-headache}}

\emph{See Headache section of Neurology Reference Card}

\hypertarget{concussion-1}{%
\subsubsection{Concussion}\label{concussion-1}}

\emph{See Sports Medicine chapter}

\hypertarget{idiopathic-intracranial-hypertension-pseudotumor-cerebri}{%
\subsubsection{Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)}\label{idiopathic-intracranial-hypertension-pseudotumor-cerebri}}

\hypertarget{pathophysiology-55}{%
\paragraph{Pathophysiology}\label{pathophysiology-55}}

Syndrome of increased ICP due to impaired absorption at the arachnoid granulations. Risk factors: obesity, drugs (tetracyclines, retinoids, OCPs)

\hypertarget{presentation-116}{%
\paragraph{Presentation}\label{presentation-116}}

\begin{itemize}
\tightlist
\item
  Patients have frontal, positional HA worse upon awakening
\item
  Visual disturbances, visual loss, +/- dizziness
\item
  Examination reveals papilledema
\end{itemize}

\hypertarget{differential-30}{%
\paragraph{Differential}\label{differential-30}}

Venous sinus thrombosis, intracranial mass lesion, migraine headache, tension headache

\hypertarget{work-up-61}{%
\paragraph{Work-up}\label{work-up-61}}

MRI/MRV required in children w/ HA and papilledema to rule out mass/hydrocephalus, venous sinus thrombosis. LP w/ elevated opening pressure is diagnostic.

\hypertarget{management-68}{%
\paragraph{Management}\label{management-68}}

Acetazolamide 15-25 mg/kg/day (decreases rate of CSF production). Follow-up with Ophtho.

\hypertarget{complications-26}{%
\paragraph{Complications}\label{complications-26}}

Vision loss, optic neuropathy

\hypertarget{seizures-1}{%
\subsection{Seizures}\label{seizures-1}}

\hypertarget{febrile-seizure}{%
\subsubsection{Febrile Seizure}\label{febrile-seizure}}

\hypertarget{powerplans-order-sets-clinical-pathways-24}{%
\paragraph{PowerPlans, Order Sets \& Clinical Pathways:}\label{powerplans-order-sets-clinical-pathways-24}}

\begin{itemize}
\tightlist
\item
  \textbf{Clinical Pathway:} \href{https://bchfit.tch.harvard.edu/ebg-services/component/pdfAlgorithm?algCode=FEBSEIZE\&algVersion=2.1\&accessCode=null}{Seizure, Febrile}
\end{itemize}

\hypertarget{pathophysiology-56}{%
\paragraph{Pathophysiology}\label{pathophysiology-56}}

Decreased threshold for seizure due to fever and immaturity of the CNS, often familial

\hypertarget{presentation-117}{%
\paragraph{Presentation}\label{presentation-117}}

\begin{itemize}
\tightlist
\item
  \textbf{Simple:} \textless{} 15 min, generalized, occurred once in 24 hrs
\item
  \textbf{Complex:} \textgreater{} 15 min, focal, or occurred \emph{\textgreater{}} 2 times in a 24 hr period
\item
  Most commonly seen between 6mo and 6yo, w/ peak presentation between 12-24 mos
\end{itemize}

\hypertarget{differential-31}{%
\paragraph{Differential}\label{differential-31}}

Meningitis, encephalitis

\hypertarget{red-flags-17}{%
\paragraph{Red Flags}\label{red-flags-17}}

AMS, neck stiffness, lethargy, status epilepticus, focal deficits lead to consideration of meningitis/encephalitis

\hypertarget{work-up-62}{%
\paragraph{Work-up}\label{work-up-62}}

If examination is normal, no further work-up is required

\hypertarget{management-69}{%
\paragraph{Management}\label{management-69}}

Reassurance and anticipatory guidance. For complex febrile seizures \textgreater{} 15 minutes, prescribe rectal Diastat. Antipyretics not shown to decrease risk.

\hypertarget{complications-27}{%
\paragraph{Complications}\label{complications-27}}

30-50\% recurrence rate. Minimally increased risk of epilepsy compared w/ the average population, slightly greater for those w/ complex febrile seizures.

\hypertarget{first-time-unprovoked-seizure}{%
\subsubsection{First-time Unprovoked Seizure}\label{first-time-unprovoked-seizure}}

\hypertarget{pathophysiology-57}{%
\paragraph{Pathophysiology}\label{pathophysiology-57}}

Typically idiopathic (likely genetic), but sometimes symptomatic from underlying brain lesions

\hypertarget{presentation-118}{%
\paragraph{Presentation}\label{presentation-118}}

\begin{itemize}
\tightlist
\item
  \textbf{Focal:} Unilateral symptoms +/- AMS (dyscognitive vs.~cognitive)
\item
  \textbf{Generalized:} Bilateral tonic clonic movements (GTC), tonic, myoclonus, absence
\end{itemize}

\hypertarget{differential-32}{%
\paragraph{Differential}\label{differential-32}}

Meningitis, encephalitis, intracranial hematoma, focal lesion (i.e.~abscess, AVM, focal cortical dysplasia).

\hypertarget{red-flags-18}{%
\paragraph{Red Flags}\label{red-flags-18}}

AMS, neck stiffness, lethargy, focal deficits lead to consideration of meningitis/encephalitis

\hypertarget{work-up-63}{%
\paragraph{Work-up}\label{work-up-63}}

If examination is normal, no further work-up is required emergently. EEG is next step, as is neurology referral. If the seizure had focal onset or if the EEG shows focality (spikes arising from one portion of the brain), most neurologists opt to do an MRI of the brain w/o contrast.

\hypertarget{management-70}{%
\paragraph{Management}\label{management-70}}

Indication for AED therapy is 2 or more unprovoked seizures, or one unprovoked seizure w/ an abnormal EEG. Keppra is often our first line because of both focal and generalized coverage w/ favorable side-effect profile, but we avoid it in cases of children w/ behavioral issues. Neurology admission for patients not returning to baseline following seizure or for multiple seizures upon presentation requiring immediate treatment.

\hypertarget{complications-28}{%
\paragraph{Complications}\label{complications-28}}

Epilepsy for those who go on to have further unprovoked seizures. Rare complication of generalized epilepsy is \textbf{SUDEP} (sudden unexplained death in epilepsy patients).

\hypertarget{breakthrough-seizure-in-a-patient-w-epilepsy}{%
\subsubsection{Breakthrough Seizure (in a patient w/ epilepsy)}\label{breakthrough-seizure-in-a-patient-w-epilepsy}}

\hypertarget{pathophysiology-58}{%
\paragraph{Pathophysiology}\label{pathophysiology-58}}

Decreased threshold for seizure due to fever, lack of sleep, missed medication dose, alcohol use vs.~natural fluctuation of epilepsy (as is the natural history) such that seizures may become more frequent w/o provocation

\hypertarget{differential-33}{%
\paragraph{Differential}\label{differential-33}}

Evaluated potential underlying causes of increased seizure frequency

\hypertarget{red-flags-19}{%
\paragraph{Red Flags}\label{red-flags-19}}

AMS, prolonged seizures

\hypertarget{work-up-64}{%
\paragraph{Work-up}\label{work-up-64}}

Neurology consult for medication adjustment. Before calling, should know the following: Baseline seizure frequency and semiology (what the seizure looks like) vs.~current frequency and semiology, doses of all AEDs, most recent levels if available.

\hypertarget{management-71}{%
\paragraph{Management}\label{management-71}}

Typically small adjustments to AEDs including addition of AEDs when needed

\hypertarget{infantile-spasms}{%
\subsubsection{Infantile Spasms}\label{infantile-spasms}}

\hypertarget{pathophysiology-59}{%
\paragraph{Pathophysiology}\label{pathophysiology-59}}

Varied; can be associated w/ CNS malformations, genetic/metabolic abnormalities, trauma, infections, tuberous sclerosis and other neurocutaneous syndromes, trisomy 21 or may be idiopathic

\hypertarget{presentation-119}{%
\paragraph{Presentation}\label{presentation-119}}

\begin{itemize}
\tightlist
\item
  Spasms involving tonic flexion or extension of neck, trunk, and/or extremities lasting up to 10 sec, can occur in clusters, commonly followed by crying
\item
  Usually occur during daytime and while awake
\item
  Usually presents at \textless{} 1yo, peak incidence in 3-7mo
\end{itemize}

\hypertarget{differential-34}{%
\paragraph{Differential}\label{differential-34}}

Exaggerated startle, torticollis, reflux, colic, spasticity, benign myoclonus of infancy, myoclonic epilepsy

\hypertarget{work-up-65}{%
\paragraph{Work-up}\label{work-up-65}}

EEG: Hypsarrhythmia, MRI, genetic/metabolic labs

\hypertarget{management-72}{%
\paragraph{Management}\label{management-72}}

\begin{itemize}
\tightlist
\item
  ACTH is first-line, should monitor BP and chem10 while on ACTH
\item
  Vigabatrin
\end{itemize}

\hypertarget{complications-29}{%
\paragraph{Complications}\label{complications-29}}

Developmental regression, refractory seizures

\hypertarget{meningitis}{%
\subsection{Meningitis}\label{meningitis}}

\hypertarget{bacterial-meningitis-1}{%
\subsubsection{Bacterial Meningitis}\label{bacterial-meningitis-1}}

\emph{See ED and ID chapters}

\hypertarget{powerplans}{%
\paragraph{PowerPlans}\label{powerplans}}

Fever in infant \textless{} 30 days

\hypertarget{pathophysiology-60}{%
\paragraph{Pathophysiology}\label{pathophysiology-60}}

Bacterial infection of the meninges, caused by hematogenous spread or direct spread from sinuses or mastoids

\hypertarget{presentation-120}{%
\paragraph{Presentation}\label{presentation-120}}

\begin{itemize}
\tightlist
\item
  Fever, headache, vomiting, meningismus, seizures
\item
  Kernig Sign: Stretching of hamstring w/ knee extension + back pain
\item
  Brudzinski Sign: passive neck flexion, involuntary hip/knee flexion
\end{itemize}

\hypertarget{differential-35}{%
\paragraph{Differential}\label{differential-35}}

Viral meningitis/encephalitis, brain abscess, increased ICP, neoplasm, ADEM

\hypertarget{red-flags-20}{%
\paragraph{Red Flags}\label{red-flags-20}}

Focal neurological deficits, seizures, papilledema, risk factors for TB (poor clinical outcomes), petechiae on exam (Neisseria)

\hypertarget{work-up-66}{%
\paragraph{Work-up}\label{work-up-66}}

It's all about the LP. CSF: WBC count often \textgreater{} 1,000, glucose often \textless{} 40 or \textless{} half of serum value, protein \textgreater{} 250, cell count w/ \textgreater{} 50\% PMNs. Obtain imaging on comatose patients or those w/ focal neurologic deficits PRIOR to LP.

\hypertarget{management-73}{%
\paragraph{Management}\label{management-73}}

In addition to abx, dexamethasone used to reduce hearing loss in children 0.15mg/kg q6hr for 2-4 days. \emph{See ID chapter for meds/dosing.}

\hypertarget{complications-30}{%
\paragraph{Complications}\label{complications-30}}

Seizure, stroke, elevated intracranial pressure

\hypertarget{viral-meningitis-encephalitis}{%
\subsubsection{Viral Meningitis \& Encephalitis}\label{viral-meningitis-encephalitis}}

\hypertarget{pathophysiology-61}{%
\paragraph{Pathophysiology}\label{pathophysiology-61}}

Viral infection and inflammation of the meninges

\hypertarget{presentation-121}{%
\paragraph{Presentation}\label{presentation-121}}

Fever, headache, malaise, photophobia, altered mental status

\hypertarget{differential-36}{%
\paragraph{Differential}\label{differential-36}}

HSV (HSV-1 most common in children, HSV-2 most common in neonatal period acquired through maternal transmission), EBV, VZV, CMV (consider if immunocompromised), Eastern Equine Virus, Subacute sclerosis panencephalitis (if remote hx of measles infection), Lyme

\hypertarget{red-flags-21}{%
\paragraph{Red Flags}\label{red-flags-21}}

History of immunosuppression/transplant → consider less common organisms

\hypertarget{work-up-67}{%
\paragraph{Work-up}\label{work-up-67}}

\begin{itemize}
\tightlist
\item
  Consider MRI if focal neurologic deficits are present
\item
  LP should be performed (CSF profile w/ elevated protein and cells, lymphocytic pleocytosis)
\end{itemize}

\hypertarget{management-74}{%
\paragraph{Management}\label{management-74}}

\begin{itemize}
\tightlist
\item
  Largely supportive, w/ empiric treatment w/ antibiotics and acyclovir until cultures result
\item
  HSV → Acyclovir x 14-21 days (\textless35 wk conceptual age 40 mg/kg/d divided q12; \textgreater{} 35 wk conceptual age 60 mg/kg/d divided q8hr)
\item
  CMV → Ganciclovir
\end{itemize}

\hypertarget{complications-31}{%
\paragraph{Complications}\label{complications-31}}

Rarely associated w/ long-term issues; HSV may cause hemorrhage w/i temporal lobes, causing seizures

\hypertarget{references-7}{%
\subsection{References}\label{references-7}}

\includegraphics{images/neuro_ref-card-1.png}
\includegraphics{images/neuro_ref-card-2.png}

\hypertarget{newborn-nursery}{%
\section{Newborn Nursery}\label{newborn-nursery}}

\hypertarget{rotation-specific-entities}{%
\subsection{Rotation Specific Entities}\label{rotation-specific-entities}}

\textbf{BMC} Black binder and printouts on walls in work room include all clinical practice guidelines/approaches
\textbf{BWH} All clinical practice guidelines are available online via BWH PikeNotes

\hypertarget{gestational-age}{%
\subsection{Gestational Age}\label{gestational-age}}

\textbf{Early Preterm} * \textless34 0/7

\textbf{Late Preterm} ** 34 0/7 - 36 6/7

\textbf{Early Term} 37 0/7 - 38 6/7

\textbf{Full Term} 39 0/7 - 40 6/7

\textbf{Late Term} 41 0/7 - 41 6/7

\textbf{Postterm} 42 0/7+

*Use Fenton growth chart for late preterm. If between 37 0/7 and 37 6/7, chart on Fenton, Olsen and WHO and take better number

**``Great pretenders'' - risk of resp distress, apnea, temp dysregulation, poor feeding

\hypertarget{normal-infant-feeding}{%
\subsection{Normal Infant Feeding}\label{normal-infant-feeding}}

\begin{itemize}
\tightlist
\item
  All babies typically lose up to 2-3\% of BW/day, should not lose more than 10-12\% of BW before discharge. Babies born by c-section may lose more weight than vaginal births (Mom and therefore baby get IV fluids during delivery). Usually start gaining on DOL4. Baby should regain BW by 10-14 days and should gain 20-30g/day for first month, or 5 oz per week (``an ounce a day and time off for weekends'').
\item
  Babies usually awake for first 5-6 hrs and then sleepy for 24 hrs. Start waking up on DOL2 and are hungry (``all day cafe''). Sometimes if baby is not getting enough with feeds, may shut down and appear sleepy.
\end{itemize}

\hypertarget{breastfeeding}{%
\subsubsection{Breastfeeding}\label{breastfeeding}}

Newborns who are \textbf{breastfed need to eat every 2-3 hours}, on demand. If showing hunger cues, feed, even if just fed. No such thing as newborn ``using mother as a pacifier.'' Cluster feeding (at breast for several hours) happens on Day 2-3, as baby tries to get milk to come in. Mother may feel tired and frustrated. Reassure that this is NORMAL. Milk usually comes in around 3-5 days.

\hypertarget{breastfeeding-tips}{%
\paragraph{Breastfeeding Tips}\label{breastfeeding-tips}}

-Respond to \textbf{infant feeding cues} (early → late: stirring, turning head, mouth opening, hand in mouth, stretching, crying).

\begin{itemize}
\tightlist
\item
  \textbf{Infant latch}: Line up baby nose to nipple. Stroke baby lips with nipple. Aim nipple to roof of baby's mouth. Support baby's neck at the shoulders so head tips back and \textbf{bring baby onto breast (\emph{not} breast to baby).}
  \textgreater\textgreater{} - Signs of a good latch: lips flanged outward, \textbf{most of areola hidden} in mouth, nose free
\item
  Breast milk can sit out 8 hrs if freshly pumped, or 5 days in refrigerator. Can store 6-12 mos in freezer. Don't refreeze thawed breastmilk.
\item
  Mothers can hand express and/or pump to stimulate milk production. Holding baby skin to skin also stimulates because of hormone release. Hand expression is helpful especially for colostrum or if engorged. Can feed to baby via spoon or syringe.
\item
  For determining if mom's meds are safe during breastfeeding: \textbf{LactMed} (part of NIH ToxNet), \textbf{Hale's Medications \& Mother's Milk} (physical book in BMC workroom or HalesMeds.com. Physical book in BWH nursery)
\end{itemize}

\hypertarget{contraindications-to-breastfeeding}{%
\paragraph{Contraindications to breastfeeding}\label{contraindications-to-breastfeeding}}

Absolute: infant w/ galactosemia, mom w/ \textbf{HIV} or HTLV-1/2, mom actively using \textbf{illicit drugs, including marijuana or EtOH} (exception: moms in methadone program, see ``NAS''), HSV lesion on breast. OK to feed expressed milk: mom w/ varicella or active TB. HCV positive mom ok to breastfeed unless nipples cracked or bleeding.

\hypertarget{formula-feeding}{%
\subsubsection{Formula Feeding}\label{formula-feeding}}

\begin{itemize}
\item
  Formula fed babies eat \textbf{every 3-4 hours} (if sleeps \textgreater{} 4 hours, wake baby up). Infant stomach is size of a blueberry on DOL1 → lime at DOL7. Volume increases gradually over first several days. DOL1: 10-15 mL per feed, DOL2: 15-30 mL/feed; DOL3: 30-45 mL/feed, DOL4: 45-60 mL/feed. Give baby what last took and if not settled, feed more. Follow baby's cues.
\item
  Formula, in 60 mL bottles as supplied by hospital, needs to be consumed within 1 hour of starting feed and then discarded.
\end{itemize}

\hypertarget{tongue-ties}{%
\subsubsection{Tongue Ties}\label{tongue-ties}}

Type
Exam
Image
Mgmt
Normal

Tongue appears flat and broad
Tongue extends over bottom teeth
Can swipe finger under tongue uninterrupted
N/A
N/A
Type 4: Mild
Posterior tie on tongue, may be submucosal
N/A
Generally nothing
Type 3: Moderate
Tie is proximal to 50\% of length of tongue

Consider lactation consult
Type 2: Severe

Tie is distal to 50\% of length of tongue
May create a hump or cupping

Frenulectomy if interfering with feeding
Type 1: Complete
Tie extends to tip of tongue

Likely frenulectomy

\hypertarget{newborn-behavior}{%
\subsection{Newborn Behavior}\label{newborn-behavior}}

\textbf{Infant states}: newborn behavior related to state. There are 6 states, all normal. Infant's ability to self-regulate is related to ability to move fluidly from one state to next, affected by gestational age and perinatal stress.

Deep sleep -\textgreater{} light sleep -\textgreater{} drowsy -\textgreater{} active alert -\textgreater{} fussy -\textgreater{} full cry

\hypertarget{anticipatory-guidance-discharge-teaching}{%
\subsection{Anticipatory Guidance / Discharge Teaching}\label{anticipatory-guidance-discharge-teaching}}

\hypertarget{feeding}{%
\subsubsection{Feeding}\label{feeding}}

\textbf{feed on demand}, only breastmilk or formula, \textbf{8-12x in 24h - ``8 or more in 24.''} Wake up baby after 3-4h to feed.

\hypertarget{normal-voiding-stooling}{%
\subsubsection{Normal Voiding / Stooling}\label{normal-voiding-stooling}}

Should have \textbf{as many wet diapers as days of life}, up to 6-8 after 1 week of life. Should have \textbf{at least 2-3 stools/day.} Color may change, should be yellow, seedy.. Bloody or white stools would be concerning.

\hypertarget{cord-care}{%
\subsubsection{Cord Care}\label{cord-care}}

Keep \textbf{cord clean (sponge bath), dry, and uncovered by diaper}. Will fall off on its own in about 10 days.

\hypertarget{circumcision-care}{%
\subsubsection{Circumcision Care}\label{circumcision-care}}

Leave dressing on for 24h. Use petroleum jelly on penis with every diaper change. Written for tylenol x 2 doses in hospital but most babies do not need it and do fine with being skin to skin for comfort.

\hypertarget{safe-sleep}{%
\subsubsection{Safe Sleep}\label{safe-sleep}}

Baby should sleep on back in own crib with tight fitted sheet. NO loose blankets, stuffed animals, positioning aids. No propping on side. Swaddling is good. Tuck swaddle blanket under baby, or use velcro swaddler.

\hypertarget{tummy-time}{%
\subsubsection{Tummy Time}\label{tummy-time}}

Give baby time on tummy. As newborn, can lie on parents chest. Person holding baby should put baby down if feeling sleepy. Don't sleep with baby.

\hypertarget{consoling}{%
\subsubsection{Consoling}\label{consoling}}

Babies cry to communicate. Never shake the baby. Can put baby in crib or pass baby to other caretaker if frustrated. Giving baby hand to suck on and swaddling help with consoling.

\hypertarget{illness}{%
\subsubsection{Illness}\label{illness}}

\begin{itemize}
\tightlist
\item
  Visitors should wash hands before handling baby. Avoid crowds, passing baby among visitors, and people with colds, especially for first few months. Tell older sibs to touch baby's feet, not hands and face (newborns can't yet put their feet in mouths).
\item
  \textbf{Infant fever (taken rectally) is \textgreater{} 100.4 F:} Seek medical attention if baby seems ``off'': eating less than usual, making fewer wet diapers, fussy or lethargic.
\end{itemize}

\hypertarget{hyperbilirubinemia}{%
\subsection{Hyperbilirubinemia}\label{hyperbilirubinemia}}

\hypertarget{definition-47}{%
\subsubsection{Definition}\label{definition-47}}

Infants ≥ 35 wks GA: TB \textgreater{} 95th percentile (2004 AAP Guidelines/Bhutani nomograms)

\hypertarget{pathophysiology-62}{%
\subsubsection{Pathophysiology}\label{pathophysiology-62}}

↑ RBC turnover, ↓ clearance (UGT1A1 activity), ↑ enterohepatic recirculation. \textbf{Within first 24 hours of life = ALWAYS pathologic.}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.72\columnwidth}\raggedright
\textbf{Indirect}\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
\textbf{Direct - ALWAYS pathologic}\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.72\columnwidth}\raggedright
- \textbf{Breastfeeding jaundice}: first week of life due to insufficient feeding and dehydration - \textbf{Breast \emph{milk} jaundice}: persistent after first week of life, unknown mechanism, ?substance in milk blocks bilirubin breakdown - \textbf{ABO or Rh incompatibility}: suspect if set-up, previous child with hemolytic disease of the newborn, fetal hydrops, jaundice in the first 24 hours of life - Red cell membrane defects (spherocytosis and elliptocytosis) - G6PD deficiency - Sepsis - Decreased clearance -- Crigler-Najjar syndrome, Gilbert syndrome - Intestinal obstruction\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
- \textbf{Anatomic} (intestinal obstruction, cysts, tumors, biliary atresia) - \textbf{Infection/sepsis} - Metabolic - Gestational alloimmune liver disease (neonatal hemochromatosis)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{evaluation-6}{%
\subsubsection{Evaluation}\label{evaluation-6}}

\begin{itemize}
\item
  \textbf{Healthy infants}: Obtain routine transcutaneous bili (TcB) @ DOL2 and plot on \href{http://bilitool.org/}{bilitool.org}
  . If ABO/Coombs set-up, check TcB @ 12HOL and 24HOL.
  \textgreater\textgreater{} - Determine \textbf{follow-up frequency} based on \textbf{risk for developing severe hyperbili} (use risk zone, which is generated by nomogram + GA + presence of hyperbili risk factors {[}jaundice in first 24 hours, ABO incompatibility/positive direct Coombs, GA 35-36w, sibling required phototherapy, cephalohematoma, exclusive breastfeeding, East Asian race{]})
  \textgreater\textgreater{} - Determine \textbf{phototherapy threshold} based on \textbf{neurotoxicity risk} (use GA + presence of neurotoxicity risk factors {[}isoimmune hemolytic disease, G6PD, asphyxia, lethargy, temp instability, sepsis/acidosis, albumin \textless3.0)
  \textgreater\textgreater\textgreater{} - If above phototherapy threshold, check total serum bili (TSB). Once TSB is used, TcB may not be used again.
\item
  Consider checking CBC, retic, hemolysis labs (LDH, haptoglobin, smear), G6PD activity.
\end{itemize}

\hypertarget{management-75}{%
\subsubsection{Management}\label{management-75}}

Reconsider early discharge (before 72 HOL) if bili high intermediate risk. Phototherapy as per BiliTool curves. If near exchange levels: aggressive phototherapy, aggressive hydration (IV+PO). IVIG for isoimmune hemolytic disease. Call blood bank before exchange transfusion

\hypertarget{infant-of-a-diabetic-mother-idm}{%
\subsection{Infant of a Diabetic Mother (IDM)}\label{infant-of-a-diabetic-mother-idm}}

\hypertarget{increased-risks}{%
\subsubsection{Increased risks}\label{increased-risks}}

\textbf{LGA} (BW ≥ 4000g or ≥ 90th percentile for GA) → birth injury (shoulder dystocia, clavicular fracture), preterm birth, \textbf{RDS/TTN, hypoglycemia} (maternal hyperglycemia → infant hyperinsulinism → hypoglycemia; resolves in 2-4d), hypertrophic cardiomyopathy (of interventricular septum), \textbf{hyperbili, polycythemia} (Hct \textgreater{} 65\% → hyperviscosity → exchange transfusion if symptomatic)

\hypertarget{congenital-anomalies}{%
\subsubsection{Congenital anomalies}\label{congenital-anomalies}}

\textbf{Transposition of great arteries}, double outlet RV, VSD, truncus arteriosus, hypoplastic L heart syndrome, \textbf{small L colon syndrome} → functional lower bowel obstruction (contrast enema is diagnostic and curative)

\hypertarget{management-76}{%
\subsubsection{Management}\label{management-76}}

Obtain glucose at 2-4HOL, then pre-feed until glucoses stabilize. Consider checking Hct in first hours of life. Check Ca++/Mg if jittery or seizure

\hypertarget{hypoglycemia-2}{%
\subsubsection{Hypoglycemia}\label{hypoglycemia-2}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
**Glucose (mg/dl)\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
\textbf{\textless25}\strut
\end{minipage} & \begin{minipage}[b]{0.39\columnwidth}\raggedright
\textbf{25-39}\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
\textbf{\textgreater=40}\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
\textbf{Mgmt}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Admit to NICU} and give 2 cc/kg bolus of D10W followed by infusion of D10\strut
\end{minipage} & \begin{minipage}[t]{0.39\columnwidth}\raggedright
- Feed 10-15 mL colostrum / formula and re-check - \textbf{May give glucose gel 2x (with feed) in first 24 HOL before transferring to NICU}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
- Check 3 \textbf{pre-feed POC glucoses \textless= 3 hours apart;} if normal, routine care\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\begin{itemize}
\tightlist
\item
  Risk Factors: IDM, LGA, SGA, late preterm or post-term, \textless2500g, discordant twin, maternal medications (e.g., propranolol)
\item
  After 48 HOL, glucose levels should be \textgreater60
\item
  If hypoglycemia persists, send critical labs. Consider diazoxide if hyperinsulinism.
\end{itemize}

\hypertarget{neonatal-abstinence-syndrome-nas}{%
\subsection{Neonatal Abstinence Syndrome (NAS)}\label{neonatal-abstinence-syndrome-nas}}

\hypertarget{pathophysiology-63}{%
\subsubsection{Pathophysiology}\label{pathophysiology-63}}

Behavioral dysregulation seen 2/2 drug withdrawal in infants chronically exposed in utero to opiods (methadone, buprenorphine, morphine, oxycodone, hydromorphone, heroin) and other substances (nicotines, benzodiazepines, SSRIs). Skyrocketing incidence.

\hypertarget{presentation-122}{%
\subsubsection{Presentation}\label{presentation-122}}

\begin{itemize}
\tightlist
\item
  Irritability, hypertonia, tremors, poor sleep, poor feeding, vomiting, diarrhea, autonomic dysfunction (sweating, sneezing, tachypnea,fever), weight loss. Sx diminished in preterm infants 2/2 developmental immaturity of CNS.
\item
  Timing of withdrawal depends on half life: Heroin - \textless24 hours, Methadone or Buprenorphine: 24-72 hours.
\end{itemize}

\hypertarget{management-77}{%
\subsubsection{Management}\label{management-77}}

\begin{itemize}
\tightlist
\item
  \textbf{First line: Non-pharmacologic}
  \textgreater\textgreater{} - Parent rooming in, skin-to-skin, decreased stimulation, clustered care. BMC: Give mother NAS info packet on admission.
  \textgreater\textgreater{} - Consoling maneuvers: gentle hold (arms to midline), hand-to-mouth, voice of caregiver (especially parent), holding, swaddling, pacifier, feeding, skin-to-skin
  \textgreater\textgreater{} - Breastfeeding for eligible mothers on methadone or buprenorphine \textbf{(No relapses in the past 4 weeks, adequate prenatal care, treatment program)}
  \textgreater\textgreater{} - \textbf{24kcal/oz formula} if not breastfeeding
\item
  \textbf{Withdrawal (inability to eat/sleep/console, autonomic sx): Pharmacologic} (at BWH, transfer to NICU, at BMC, follow NAS protocol available on intraweb)
\item
  First-line opioid replacement therapy: methadone, morphine
\item
  Second line therapy: Clonidine, phenobarbital
\item
  60-70\% of infants exposed to opioids will need therapy, 40-50\% if using ESC scoring. Increased risk with methadone and polypharmacy.
\item
  Monitor for at least 5-7 days for infants exposed to methadone or buprenorphine
\end{itemize}

\hypertarget{newborn-id}{%
\subsection{Newborn ID}\label{newborn-id}}

\hypertarget{early-onset-sepsis}{%
\subsubsection{Early Onset Sepsis}\label{early-onset-sepsis}}

\hypertarget{pathophysiology-64}{%
\paragraph{Pathophysiology}\label{pathophysiology-64}}

GBS \textgreater\textgreater{} GNRs (especially E. coli, also Klebsiella), some Gram + (Listeria, enterococci, Group D Strep). Risk of GBS sepsis is 40x higher with heavy maternal colonization.

\hypertarget{sepsis-rfs}{%
\paragraph{Sepsis RFs}\label{sepsis-rfs}}

Preterm labor (\textless37w), maternal intrapartum fever \textgreater{} 100.4F or inadequately treated GBS, PROM (\textgreater18h), infant w/ tachycardia/tachypnea/respiratory distress/temp instability

\hypertarget{treatment-62}{%
\paragraph{Treatment}\label{treatment-62}}

\begin{itemize}
\tightlist
\item
  \textbf{BMC and BWH Algorithm}: Use \href{https://neonatalsepsiscalculator.kaiserpermanente.org/}{Kaiser Neonatal Sepsis calculator} to guide necessity of evaluation (full vs.~limited) and/or for antibiotics
\item
  \textbf{Empiric abx}: Ampicillin + Gentamicin x 48 hrs. Substitute cefotaxime/cefepime if suspect meningitis
\end{itemize}

\hypertarget{hepatitis-b}{%
\subsubsection{Hepatitis B}\label{hepatitis-b}}

\begin{itemize}
\tightlist
\item
  Up to 90\% of infants infected perinatally or in the first year of life will develop chronic HBV infection
\item
  OK for HepB+ moms to breastfeed
\end{itemize}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.06\columnwidth}\raggedright
\textbf{Maternal HBsAg}\strut
\end{minipage} & \begin{minipage}[b]{0.49\columnwidth}\raggedright
\textbf{BW\textgreater2000g}\strut
\end{minipage} & \begin{minipage}[b]{0.35\columnwidth}\raggedright
\textbf{BW\textless2000g}\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Positive}\strut
\end{minipage} & \begin{minipage}[t]{0.49\columnwidth}\raggedright
Vaccine + HBIG within 12h (concurrently, different anatomic sites)\strut
\end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright
Vaccine + HBIG within 12h (concurrently, different anatomic sites)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Unknown}\strut
\end{minipage} & \begin{minipage}[t]{0.49\columnwidth}\raggedright
- Test mother - HepB vaccine in first 12h - HBIG ASAP if mom positive\strut
\end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright
- Test mother - HepB vaccine in first 12h - HBIG ASAP if mom positive or if results not available within 12h\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
\textbf{Negative}\strut
\end{minipage} & \begin{minipage}[t]{0.49\columnwidth}\raggedright
- HepB vaccine at birth, within 24 hrs * if parents refuse, discuss again during nursery stay. If still refuses, at BMC must sign informed refusal form.\strut
\end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright
Delay 1st dose of HepB vaccine until 1 mo of age or hospital discharge, whichever is first\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{hiv-1}{%
\subsubsection{HIV}\label{hiv-1}}

\hypertarget{management-78}{%
\paragraph{Management}\label{management-78}}

Consult ID. Get maternal history, lab reports: If mom on ARV and infant low risk for acquiring HIV, testing on infant performed at 14 days, 21 days, 1-2 months, and 4-6 months. If mother not on ARVs or mom diagnosed during pregnancy, also test infant at birth.

\hypertarget{treatment-63}{%
\paragraph{Treatment}\label{treatment-63}}

\textbf{Post-exposure prophylaxis ASAP} (within 6 hours of delivery) with \textbf{zidovudine} (dosage based on GA at birth and weight) + \textbf{nevirapine if mother not on ARVs}

\hypertarget{hsv}{%
\subsubsection{HSV}\label{hsv}}

\hypertarget{pathophysiology-65}{%
\paragraph{Pathophysiology}\label{pathophysiology-65}}

HSV acquired intrauterine (rare), \textbf{perinatal} (85\% of infections; ↑ risk: \textbf{PROM}, fetal scalp monitor/forceps, vaginal delivery, primary infxn in mother -- but \textbf{majority of infants w/ HSV born to mothers without known hx of HSV})

\hypertarget{presentation-123}{%
\paragraph{Presentation}\label{presentation-123}}

\textbf{Fever or other nonspecific signs of sepsis, coalescing vesicles on erythematous base}, seizures/focality on neuro exam, hepatomegaly, ascites

\hypertarget{workup-26}{%
\paragraph{Workup}\label{workup-26}}

\begin{itemize}
\tightlist
\item
  \textbf{Asymptomatic}: Swab neonate from cleanest spot to least clean (same swab): conjunctivae, mouth, nasopharynx, rectum @ 24HOL for PCR and culture
\item
  \textbf{Symptomatic}: LP: CSF lymphocyte pleocytosis/elevated protein, consider \textbf{EEG, PCR and culture of unroofed vesicle}
\end{itemize}

\hypertarget{treatment-64}{%
\paragraph{Treatment}\label{treatment-64}}

IV Acyclovir 60 mg/kg per day divided q8h (initiate w/ any clinical suspicion; no need to start in asymptomatic infants) Duration depends on severity. Monitor renal function and ANC 2x/week.

\hypertarget{neonatology-nicu}{%
\section{Neonatology (NICU)}\label{neonatology-nicu}}

\includegraphics{images/nicu_nrp-reference-chart.png}

\includegraphics{images/nicu_nrp-equipment-checklist.png}

\hypertarget{apgar-scoring}{%
\subsection{APGAR Scoring}\label{apgar-scoring}}

\begin{longtable}[]{@{}llll@{}}
\toprule
& 0 & 1 & 2\tabularnewline
\midrule
\endhead
HR & \textless60 & 60-100 & \textgreater100\tabularnewline
Color & Blue throughout & Pink body \& blue extremities & All pink\tabularnewline
Respiratory effort & No effort & Weak cry, hypoventilation & Strong cry\tabularnewline
Tone & Limp & Some flexion w/o active movement & Active movement\tabularnewline
Reflex irritability & No response & Grimace & Cry/cough/sneeze\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{neonatal-respiratory-disorders-delivery-room-pathology}{%
\subsection{Neonatal Respiratory Disorders \& Delivery Room Pathology}\label{neonatal-respiratory-disorders-delivery-room-pathology}}

\begin{itemize}
\tightlist
\item
  Can be divided into:

  \begin{itemize}
  \tightlist
  \item
    Upper airway blockage (choanal atresia, pharyngeal airway malformation)
  \item
    Impaired lung function
  \end{itemize}
\end{itemize}

\hypertarget{choanal-atresia}{%
\subsubsection{Choanal Atresia}\label{choanal-atresia}}

\hypertarget{history-8}{%
\paragraph{History}\label{history-8}}

Pink when crying, cyanotic when quiet. Inability to pass NG tube in one or both sides

\hypertarget{management-79}{%
\paragraph{Management}\label{management-79}}

Oral airway, intubation

\hypertarget{pharyngeal-airway-malformation}{%
\subsubsection{Pharyngeal Airway Malformation}\label{pharyngeal-airway-malformation}}

\hypertarget{history-9}{%
\paragraph{History}\label{history-9}}

Persistent Retractions, poor aeration

\hypertarget{management-80}{%
\paragraph{Management}\label{management-80}}

Prone positioning, posterior nasopharyngeal tube

\hypertarget{congenital-diaphragmatic-hernia-cdh}{%
\subsubsection{Congenital Diaphragmatic Hernia (CDH)}\label{congenital-diaphragmatic-hernia-cdh}}

\hypertarget{history-10}{%
\paragraph{History}\label{history-10}}

Assymetric lung sounds, cyanosis with bradycardia, scaphoid abdomen.

\hypertarget{diagnosis-8}{%
\paragraph{Diagnosis}\label{diagnosis-8}}

Most likely on prenatal imaging in patients with prenatal care. Postnatally diagnosed with CXR

\hypertarget{management-81}{%
\paragraph{Management}\label{management-81}}

Intubation, \textbf{avoid positive pressure}! Place orogastric tube.

\hypertarget{pleural-effusion}{%
\subsubsection{Pleural Effusion}\label{pleural-effusion}}

\hypertarget{history-11}{%
\paragraph{History}\label{history-11}}

Diminished aeration with poor osygenation/ventilation

\hypertarget{management-82}{%
\paragraph{Management}\label{management-82}}

Intubation, needle thoracentesis +/- chest tube. Volume expansion if hemodynamically unstable. Fluid analysis to determine type and source of fluid.

\hypertarget{pneumothorax}{%
\subsubsection{Pneumothorax}\label{pneumothorax}}

\hypertarget{history-12}{%
\paragraph{History}\label{history-12}}

Persistent cyanosis, hypoxemia, +/- bradycardia associated with respiratory distress

\hypertarget{diagnosis-9}{%
\paragraph{Diagnosis}\label{diagnosis-9}}

CXR

\hypertarget{management-83}{%
\paragraph{Management}\label{management-83}}

Needle thoracentesis immediately, chest tube if recurrent

\hypertarget{meconium-aspiration}{%
\subsubsection{Meconium Aspiration}\label{meconium-aspiration}}

\hypertarget{history-13}{%
\paragraph{History}\label{history-13}}

Meconium stained fluid, respiratory distress and/or apnea if severe

\hypertarget{diagnosis-10}{%
\paragraph{Diagnosis}\label{diagnosis-10}}

CXR

\hypertarget{management-84}{%
\paragraph{Management}\label{management-84}}

Can deep suction upper airway. Tracheal suctioning not recommended. Intubation per NRP

\hypertarget{complications-32}{%
\paragraph{Complications}\label{complications-32}}

Can cause lung inflamation and direct surfactant inactivation and one of the causes of persistnet pulmonary hypertension, there is a range of severity but can be quite severe!

\hypertarget{persistent-pulmonay-hypertension-pphn}{%
\subsubsection{Persistent Pulmonay Hypertension (PPHN)}\label{persistent-pulmonay-hypertension-pphn}}

\hypertarget{history-14}{%
\paragraph{History}\label{history-14}}

Asphyxia, mecoumium aspiration, intrinsic lung disease

\hypertarget{clinical-manifestations-15}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-15}}

Hypoxemia, hypotension

\hypertarget{diagnostics}{%
\paragraph{Diagnostics}\label{diagnostics}}

CXR with decreased pulmonary vasculature. ECHO with increased R-\textgreater L shunting.

\hypertarget{management-85}{%
\paragraph{Management}\label{management-85}}

\begin{itemize}
\tightlist
\item
  Ultimate goal is to decrease the pulmonary vascular resistance and increase pulmonary blood flow.
\item
  Oxygenation Index (OI): Helpful numeric index evaluating oxygenation to direct management decisions

  \begin{itemize}
  \tightlist
  \item
    \textbf{OI = FiO2 x MAP / PaO2}
  \end{itemize}
\end{itemize}

\hypertarget{respiratory-distress-syndrome-rds}{%
\subsubsection{Respiratory Distress Syndrome (RDS)}\label{respiratory-distress-syndrome-rds}}

\hypertarget{etiology-25}{%
\paragraph{Etiology}\label{etiology-25}}

Surfactant deficiency, common in premature infants

\hypertarget{symtpoms}{%
\paragraph{Symtpoms}\label{symtpoms}}

Hypoxia with respiratory distress

\hypertarget{diagnostics-1}{%
\paragraph{Diagnostics}\label{diagnostics-1}}

CXR with ground glass opacities, low lung volumes, air bronchograms

\hypertarget{management-86}{%
\paragraph{Management}\label{management-86}}

\begin{itemize}
\tightlist
\item
  CPAP or if severe respiratory distress/apnea intubation
\item
  Surfactant administration if intubated. Can give 2 doses if still intubated 12 hrs after the 1st dose
\item
  Minimize barotrauma and FiO2
\end{itemize}

\hypertarget{transient-tachypnea-of-the-newborn-ttn}{%
\subsubsection{Transient Tachypnea of the Newborn (TTN)}\label{transient-tachypnea-of-the-newborn-ttn}}

\hypertarget{etiology-26}{%
\paragraph{Etiology}\label{etiology-26}}

Delayed retention of amniotic fluid

\hypertarget{history-15}{%
\paragraph{History}\label{history-15}}

Typically a term infant, higher risk with birth by C-section.

\hypertarget{clinical-manifestations-16}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-16}}

Tachypnea, respiratory distress, +/- hypoxemia

\hypertarget{diagnosis-11}{%
\paragraph{Diagnosis}\label{diagnosis-11}}

CXR with prominent vasculature and fluid in the fissures

\hypertarget{management-87}{%
\paragraph{Management}\label{management-87}}

Supportive care, usually improves in 4-6 hrs. If O2 needs or symptoms last longer than 24 hrs, question diagnosis.

\hypertarget{neonatal-cardiology}{%
\subsection{Neonatal Cardiology}\label{neonatal-cardiology}}

\emph{\textbf{NOTE:} See Cardiology chapter for full details.}

\hypertarget{blood-pressure-for-premature-infants}{%
\subsubsection{Blood Pressure for Premature Infants}\label{blood-pressure-for-premature-infants}}

\begin{itemize}
\tightlist
\item
  Can be controversial as there are no normatives in the literature, but rough rule of thumb:

  \begin{itemize}
  \tightlist
  \item
    First 1-2 DOL, MAP = GA (i.e.~24wk infant → goal MAP \textgreater24)

    \begin{itemize}
    \tightlist
    \item
      Some evidence that MAP should be \textgreater{} 30 mmHG even for ELBW
    \end{itemize}
  \item
    After first few DOL, goal MAP = GA + 5
  \item
    For infants w/ \textbf{PPHN}, goal MAP should be based on pulmonary blood flow and urine output, even if it requires higher MAPs than typical for GA (sometimes 40-50 mm Hg)
  \end{itemize}
\item
  Key is to monitor \textbf{urine output, pulses, perfusion, trends in BUN/Cr}
\end{itemize}

\hypertarget{patent-ductus-arteriosus-pda}{%
\subsubsection{Patent Ductus Arteriosus (PDA)}\label{patent-ductus-arteriosus-pda}}

\hypertarget{etiology-27}{%
\paragraph{Etiology}\label{etiology-27}}

Failure of ductal tissue to close in the premature infant. Affects about 60\% of infants \textless28 weeks.

\hypertarget{clinical-manifestations-17}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-17}}

\begin{itemize}
\tightlist
\item
  Continuous machine-like murmur
\item
  Hypotension, widened pulse pressure, hyperactive precorium
\item
  Worsening oxygenation and ventilation, secondary to pulmonary over-circulation
\item
  Metabolic acidosis
\end{itemize}

\hypertarget{diagnosis-12}{%
\paragraph{Diagnosis}\label{diagnosis-12}}

Echocardiogram

\hypertarget{management-88}{%
\paragraph{Management}\label{management-88}}

\begin{itemize}
\tightlist
\item
  \textbf{Medical therapy:} Indomethacin or ibuprofen or tylenol

  \begin{itemize}
  \tightlist
  \item
    Generally contraindicated if large IVH, severe oliguria, or NEC
  \end{itemize}
\item
  \textbf{Surgical ligation}
\item
  \textbf{Watch \& wait:} w/ symptomatic support (i.e.~ventilator management, pressors for MAP support)
\end{itemize}

\hypertarget{neonatal-hematology}{%
\subsection{Neonatal Hematology}\label{neonatal-hematology}}

\hypertarget{anemia}{%
\subsubsection{Anemia}\label{anemia}}

\hypertarget{definition-48}{%
\paragraph{Definition}\label{definition-48}}

Depends on gestation and chronologic age

\hypertarget{differential-37}{%
\paragraph{Differential}\label{differential-37}}

\begin{itemize}
\tightlist
\item
  \textbf{Iatrogenic:} Frequent blood draws, surgical/procedural blood loss
\item
  \textbf{Hemorrhagic:} Placental abruption, umblical cord disruption at delivery, head trauma (subcaleal, cephalohematoma), NEC, twin-twin transfusion, IVH
\item
  \textbf{Hemolytic:} Rh incompatability, ABO incompatability
\end{itemize}

\hypertarget{work-up-68}{%
\paragraph{Work-up}\label{work-up-68}}

\begin{itemize}
\tightlist
\item
  CBC, retic, type and Coombs, smear, bilirubin, HUS or head imaging if risk for IVH
\item
  At birth: Delivery history, PE, Kleinhauer-Betke on mother (determines if fetal blood is in maternal circulation) in addition to above
\end{itemize}

\hypertarget{management-89}{%
\paragraph{Management}\label{management-89}}

\begin{itemize}
\tightlist
\item
  \textbf{NOTE:} Transfusion criteria for term and premature infants does not have robust data and is controversial. It tends to be \textbf{\emph{facility dependent.}}
\item
  \textbf{Preterm:}

  \begin{itemize}
  \tightlist
  \item
    If intubated and acutely ill, Hct 35-40
  \item
    If ``feeding and growing,'' Hct \textgreater30 w/ good reticulocyte
  \end{itemize}
\item
  \textbf{Term:}

  \begin{itemize}
  \tightlist
  \item
    If acultely ill, consider transfusing to goal Hct \textgreater40
  \item
    If hemodynamically stable, goal Hct \textgreater25
  \end{itemize}
\end{itemize}

\hypertarget{polycythemia}{%
\subsubsection{Polycythemia}\label{polycythemia}}

\hypertarget{definition-49}{%
\paragraph{Definition}\label{definition-49}}

Hct \textgreater65

\hypertarget{differential-38}{%
\paragraph{Differential}\label{differential-38}}

Increased fetal production, placental insufficiency, thyrotoxicosis, gestational diabetes (GDM), genetic disorders (e.g.~Trisomy 21, Beckwith-Wiedemann), hypertransfusion, delayed cord clamping, twin-twin transfusion

\hypertarget{work-up-69}{%
\paragraph{Work-up}\label{work-up-69}}

\begin{itemize}
\tightlist
\item
  CBC, monitor for hypoglycemia, follow bili \& electrolytes
\item
  Monitor especially if there are neurologic symptoms or respiratory distress
\end{itemize}

\hypertarget{management-90}{%
\paragraph{Management}\label{management-90}}

Partial exchange transfusion w/ normal saline, ideally w/ UVC

\begin{itemize}
\tightlist
\item
  \textbf{Indications:} Hct \textgreater65 w/ symptoms, \textgreater70 and asymptomatic
\end{itemize}

\hypertarget{thrombocytopenia-1}{%
\subsubsection{Thrombocytopenia}\label{thrombocytopenia-1}}

\hypertarget{definition-50}{%
\paragraph{Definition}\label{definition-50}}

Plt \textless150

\hypertarget{differential-39}{%
\paragraph{Differential}\label{differential-39}}

\begin{itemize}
\tightlist
\item
  \textbf{Increased destruction/consumption:} Autoimmune, alloimmune (NAIT), infection/DIC/NEC, drug-induced/toxicity, hypersplenism, Kasabach-Merrit Syndrome, following transfusion
\item
  \textbf{Decreased production:} Thrombocytopenia-absent radius, Fanconi anemia, Trisomy 13, 18, 21
\item
  \textbf{Miscellaneous:} Asphyxia, pre-eclampsia, Type 2B Von-Willebrand
\end{itemize}

\hypertarget{work-up-70}{%
\paragraph{Work-up}\label{work-up-70}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} Repeat platelet count, coagulation studies
\item
  \textbf{Imaging:} Consider HUS
\item
  Exam for evidence of bleeding
\item
  Maternal history including maternal platelet count
\end{itemize}

\hypertarget{management-91}{%
\paragraph{Management}\label{management-91}}

Depends on etiology, symptoms, and upcoming needs (i.e.~procedures)

\begin{itemize}
\tightlist
\item
  \textbf{Platelet goals:}
\end{itemize}

\begin{longtable}[]{@{}lll@{}}
\toprule
GA & Symptomatic & Asymptomatic\tabularnewline
\midrule
\endhead
Term & \textgreater50-100k & \textgreater20-30k\tabularnewline
Pre-Term & \textgreater100k & \textgreater50k\tabularnewline
\bottomrule
\end{longtable}

\begin{itemize}
\tightlist
\item
  Management specific to \textbf{Neonatal Alloimmune Thrombocytopenia (NAIT):}

  \begin{itemize}
  \tightlist
  \item
    Goal plts \textgreater20-30k if no active bleeding (use antigen negative platelets to transfuse)
  \item
    Check HUS
  \item
    Consider steroids or IVIG
  \item
    Maternal platelet typing
  \end{itemize}
\end{itemize}

\hypertarget{neonatal-neurology}{%
\subsection{Neonatal Neurology}\label{neonatal-neurology}}

\hypertarget{interventricular-hemorrhage-ivh}{%
\subsubsection{Interventricular Hemorrhage (IVH)}\label{interventricular-hemorrhage-ivh}}

\hypertarget{pathophygiolosy}{%
\paragraph{Pathophygiolosy}\label{pathophygiolosy}}

Blood vessel/blood brain barrier development is premature leaving very delicate, fragile blood networks

\hypertarget{screening-2}{%
\paragraph{Screening}\label{screening-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Screening criteria (indications for HUS):} GA \textless32 wks, BW \textless1500g, low Hct, low plts, unstable BPs, prolonged hypotension, cardiopulmonary arrest, pneumothorax, asphyxia, pre/during ECMO

  \begin{itemize}
  \tightlist
  \item
    \textbf{Timing:} DOL 3, 7-10, 30, 60 (consider in first 24 HOL if very ill ELBW)
  \end{itemize}
\end{itemize}

\hypertarget{ivh-grading}{%
\paragraph{IVH Grading}\label{ivh-grading}}

\begin{itemize}
\tightlist
\item
  \textbf{Grade I:} Germinal matrix hemorrhage (GMH)
\item
  \textbf{Grade II:} Intraventricular hemorrhage \textbf{without} ventricular dilation
\item
  \textbf{Grade III:} Intraventricular hemorrage \textbf{with} ventricular dilation
\item
  \textbf{Grade IV:} Grade III + parenchymal hemorrhage
\end{itemize}

\hypertarget{therapeutic-cooling}{%
\subsubsection{Therapeutic Cooling}\label{therapeutic-cooling}}

\hypertarget{bwh-protocol}{%
\paragraph{BWH Protocol}\label{bwh-protocol}}

\textbf{\emph{NOTE:}} Protocols are \textbf{\emph{site-specific!}} This section reviews the \textbf{BWH} protocol. Access BMC info via the BMC Infonet.

\begin{itemize}
\tightlist
\item
  \textbf{Standard eligibility criteria:}

  \begin{itemize}
  \tightlist
  \item
    \emph{\textgreater{}} 34 wks gestation
  \item
    Any one of the following:

    \begin{itemize}
    \tightlist
    \item
      Sentinel event prior to delivery
    \item
      Apgar score \emph{\textless{}} 5 at 10 min
    \item
      Requires PPV, intubation, or CPR at 10 min
    \item
      pH \emph{\textless{}} 7.1 from cord or blood gas within 60 min of birth
    \item
      Abmormal base excess \emph{\textless{}} -10 meq/L from cord or blood gas within 60 min of birth
    \end{itemize}
  \item
    Any one of the following:

    \begin{itemize}
    \tightlist
    \item
      Neonatal encephalopathy score \emph{\textgreater{}} 4
    \item
      Seizure or clinical concern for seizure
    \end{itemize}
  \end{itemize}
\item
  \textbf{Exclusion criteria:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Absolute} contraindication: \textless34 wks gestation
  \item
    \textbf{Relative} contraindications: Severe IUGR, \textless1750g, severe congenital anomalies/genetic syndromes/known metabolic disorders, major intracranial hemorrhage, overwhelming sepsis, uncorrectable clinically significant coagulopathy
  \end{itemize}
\end{itemize}

\hypertarget{management-92}{%
\paragraph{Management}\label{management-92}}

\textbf{Site-specific} as encompassed in respective protocols, but below are some general guides:

\begin{itemize}
\tightlist
\item
  \textbf{Cardiovascular monitoring}
\item
  \textbf{Total fluid goal} of 60 ml/kg/day. Can do up to 10 mL/kg/day of eneteral feeding if clinically stable.

  \begin{itemize}
  \tightlist
  \item
    At BWH, infant will be on starter PN and then custom PN while cooled
  \end{itemize}
\item
  \textbf{Sedation:} Morphine 0.05 mg/kg loading dose, followed by 0.01 mg/kg/hr infusion. Can decrease to 0.005 mg/kg/hr after 12 hrs.
\item
  \textbf{Neuromonitoring}

  \begin{itemize}
  \tightlist
  \item
    EEG for 24 hrs, can be switched to aEEG if EEG w/o seizures
  \item
    HUS on admission
  \item
    MRI on DOL 4 after re-warming, and after DOL 10-21
  \item
    If leaving protocol early, consider MRI 24-48 hrs after rewarming
  \end{itemize}
\item
  \textbf{Seizures}

  \begin{itemize}
  \tightlist
  \item
    Drug of choice: Phenobarbital 20 mg/kg loading dose, w/ serum level 2-12 hrs
  \item
    2nd choice: Fosphenytoin 20 mg/kg
  \item
    3rd choice: Midazolam 0.05 mg/kg IV one time followed by 0.15 mg/kg/hr for 12 hours then taper over 24 hrs
  \end{itemize}
\item
  \textbf{Lab monitoring} (suggested)

  \begin{itemize}
  \tightlist
  \item
    \textbf{On admission:} Lactate, blood gas, CBC, PT/PTT/INR, fibrinogen, blood culture
  \item
    \textbf{At 12 hrs:} BMP, Mg, ALT, AST
  \end{itemize}
\end{itemize}

\hypertarget{neonatal-infectious-disease}{%
\subsection{Neonatal Infectious Disease}\label{neonatal-infectious-disease}}

\hypertarget{sepsis}{%
\subsubsection{Sepsis}\label{sepsis}}

\begin{itemize}
\tightlist
\item
  Use \href{https://neonatalsepsiscalculator.kaiserpermanente.org/}{Kaiser Early Onset Sepsis (EOS) risk calculator} for \textgreater{} 34 wks
\item
  Otherwise, use clinical illness in coordination w/ maternal fever, ROM, GBS status to help determine treatment
\end{itemize}

\hypertarget{torch-infections}{%
\subsubsection{TORCH infections}\label{torch-infections}}

\begin{itemize}
\tightlist
\item
  \textbf{When to be concerned:} IUGR/SGA (\textless10th\% for age), failed hearing screen, blueberry muffin rash, hepatosplenomegaly, unexplained direct hyperbilirubinemia
\item
  Infections and how to diagnose them:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Toxoplasmosis:} Newborn Screen (NBS)
  \item
    \textbf{Syphilis (other):} Maternal screen
  \item
    \textbf{Rubella:} Maternal screen
  \item
    \textbf{CMV:} Urine CMV shell or Buccal CMV PCR
  \item
    \textbf{HSV:} Maternal history or PCR/cultures from suspected lesions on baby. HSV PCR from blood/CSF.
  \end{itemize}
\end{itemize}

\hypertarget{vertical-transmission}{%
\subsubsection{Vertical Transmission}\label{vertical-transmission}}

\hypertarget{hep-b}{%
\paragraph{Hep B}\label{hep-b}}

See Newborn Nursery chapter

\hypertarget{hiv-2}{%
\paragraph{HIV}\label{hiv-2}}

Call ID consult w/ maternal labs and history to initiate treatment \textbf{AS SOON AS POSSIBLE!}

\hypertarget{neonatal-endocrinology}{%
\subsection{Neonatal Endocrinology}\label{neonatal-endocrinology}}

\hypertarget{hypoglycemia-3}{%
\subsubsection{Hypoglycemia}\label{hypoglycemia-3}}

\hypertarget{definition-51}{%
\paragraph{Definition}\label{definition-51}}

Goal glucose value depends on age:

\begin{itemize}
\item
  0-4 hours of life (HOL) = \textgreater40
\item
  4-24 HOL = \textgreater45
\item
  24-48 HOL = \textgreater50
\item
  \begin{quote}
  48 HOL = \textgreater60
  \end{quote}
\end{itemize}

\hypertarget{risk-factors-2}{%
\paragraph{Risk factors}\label{risk-factors-2}}

Infant of diabetic mother (IDM), birth weight \textless2500g, SGA (\textless10\%ile) or LGA (\textgreater90\%ile), preterm (\textless37w) or post-dates (\textgreater42w), 5-min Apgar \textless7, maternal meds (beta blocker, terbutaline given to mom w/i 48 hrs of delivery, respiratory distress \textgreater{} 1hr, family history of hypoglycemia, congenital syndrome or midline abnormalities

\hypertarget{management-93}{%
\paragraph{Management}\label{management-93}}

Depends on age and value:

\begin{itemize}
\tightlist
\item
  If mild for age, can feed
\item
  If severe for age, consider D10W 2 mL/kg bolus and/or maintenance D10W at 60 mL/kg/day
\end{itemize}

\hypertarget{neonatal-gastroenterology}{%
\subsection{Neonatal Gastroenterology}\label{neonatal-gastroenterology}}

\hypertarget{emesis-in-an-infant}{%
\subsubsection{Emesis in an Infant}\label{emesis-in-an-infant}}

\hypertarget{differential-40}{%
\paragraph{Differential}\label{differential-40}}

\textbf{Medical vs.~Surgical}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.44\columnwidth}\raggedright
Medical\strut
\end{minipage} & \begin{minipage}[b]{0.50\columnwidth}\raggedright
Surgical\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.44\columnwidth}\raggedright
- Anxiety, excitement- Celiac disease- CAH- Improper feeding- Inborn errors of metabolism- Infection (sepsis, UTI, meningitis)- Esophageal dysmotility- Excessive crying- Food allergies- Gastroenteritis- GERD- Ingestion of maternal blood/mucous- Kernicterus- Milk protein allergy- NEC- Overfeeding\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Annular pacreas- Appendicitis- Atresia, stenosis, webbing- Duplications- Esophageal atresia- Functional ileus- Hernias- Intussusception- Malrotation w midgut volvulus- Meconium ileus- Meconium plug syndrome- NEC w/ perforation- Pyloric stenosis- Testicular torsion- Tracheoesophageal fistula (TEF)- Tumors- Ulcers- Vascular rings\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{Bilious vs.~Non-Bilious}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.52\columnwidth}\raggedright
Bilious \textbf{OR} Non-Bilious\strut
\end{minipage} & \begin{minipage}[b]{0.42\columnwidth}\raggedright
Likely \textbf{NON}-Bilious\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.52\columnwidth}\raggedright
- Intestinal atresia- NEC- Meconium plug- Meconium ileus- Malrotation- Volvulus- Hirschsprung Disease\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
- Pyloric stenosis- Intussusception- Reflux\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{work-up-71}{%
\paragraph{Work-up}\label{work-up-71}}

\begin{itemize}
\tightlist
\item
  \textbf{Imaging:} Always start w/ KUB!

  \begin{itemize}
  \tightlist
  \item
    Ultrasound for anatomic, NEC or intussusception
  \item
    Consider contrast study

    \begin{itemize}
    \tightlist
    \item
      Upper if concern for malro/volvulus
    \item
      Lower in concern for jejunal/ileal atresia
    \end{itemize}
  \end{itemize}
\item
  Sepsis eval if concerned for NEC
\item
  Bowel rest
\item
  If concerned for surgical diagnosis, consult Surgery
\item
  Further \textbf{lab evaluation} depending on clinical presentation/suspected etiology: CBCd, chem10, blood gas, lactic acid, LFTs, amylase/lipase, BCx, UA/UCx, stool guaiac, consider metabolic/endocrine work-up
\end{itemize}

\hypertarget{acute-abdomen-in-the-neonate}{%
\subsubsection{Acute Abdomen in the Neonate}\label{acute-abdomen-in-the-neonate}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.31\columnwidth}\raggedright
``High'' Obstruction\strut
\end{minipage} & \begin{minipage}[b]{0.29\columnwidth}\raggedright
``Low'' Obstruction\strut
\end{minipage} & \begin{minipage}[b]{0.31\columnwidth}\raggedright
``Acquired'' Disease\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.31\columnwidth}\raggedright
- Esophageal atresia- Duodenal atriesia- Duodenal web- Annular pancreas- Malrotation- Jejunal atresia\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
- Ileal atresia- Meconium ileus- Meconium plug- Hirchsprung disease- Anal atresia\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
- NEC- Hypertrophic pyloric stenosis- Incarcerated inguinal hernia- Gastroenteritis- Sepsis- Perforated stress ulcer\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.31\columnwidth}\raggedright
\textbf{Main symptom:} Emesis\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
\textbf{Main symptom:} Constipation\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.31\columnwidth}\raggedright
\textbf{KUB:} No distal bowel gas\strut
\end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright
KUB: Dilated small bowel loops (proximal to obstruction) and microcolon (distal to obstruction)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{indirect-hyperbilirubinemia}{%
\subsubsection{Indirect Hyperbilirubinemia}\label{indirect-hyperbilirubinemia}}

\begin{itemize}
\tightlist
\item
  \textbf{ALL infants:} Juandice in the \textbf{first 24 HOL} should \textbf{ALWAYS} be considered pathologic and prompt an \textbf{immediate} serum bilirubin, both total \textbf{and} direct
\item
  Infants \textbf{\emph{\textgreater{}} 35 wks GA:} Use \href{http://bilitool.org/}{BiliTool}
\item
  \textbf{Premature infants} have light level (LL) and exchange transfusion levels based on gestational age (use corrected GA):
\end{itemize}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.37\columnwidth}\raggedright
Gestational Age (corrected)\strut
\end{minipage} & \begin{minipage}[b]{0.27\columnwidth}\raggedright
Phototherapy at TsB\strut
\end{minipage} & \begin{minipage}[b]{0.27\columnwidth}\raggedright
Exchange Transfusion at TsB\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.37\columnwidth}\raggedright
\textless28w 0/7\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
5\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
11\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.37\columnwidth}\raggedright
28w 0/7 to 29w 6/7\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
6\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
12\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.37\columnwidth}\raggedright
30w 0/7 to 31w 6/7\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
8\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
13\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.37\columnwidth}\raggedright
32w 0/7 to 33w 6/7\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
10\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
15\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.37\columnwidth}\raggedright
34w 0/7 to 34w 6/7\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
12\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
17\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\begin{itemize}
\tightlist
\item
  Other management if approaching \textbf{exchange transfusion:}

  \begin{itemize}
  \tightlist
  \item
    Aggressive phototherapy
  \item
    Aggressive hydration (IV + PO)
  \item
    IVIG if Coombs positive
  \item
    Consider steroids
  \item
    Prepare for exchange transfusion (call blood bank)
  \end{itemize}
\end{itemize}

\hypertarget{neonatal-entercolitis-nec}{%
\subsubsection{Neonatal Entercolitis (NEC)}\label{neonatal-entercolitis-nec}}

\hypertarget{etiology-28}{%
\paragraph{Etiology}\label{etiology-28}}

\begin{itemize}
\tightlist
\item
  Precise etiology unclear
\item
  Affects 10\% of premature infants, w/ increased incidence at lower gestational age
\item
  \textbf{Risk factors:} Prematurity, IUGR, preinatal asphyxia, PDA, shock/hypotension, umbilical arterial catheter (UAC), congenital heart disease
\end{itemize}

\hypertarget{clinical-manifestations-18}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-18}}

\begin{itemize}
\tightlist
\item
  Abdominal distension/discoloration/redness, feeding intolerance, heme positive stools (may be grossly bloody)
\item
  \textbf{Non-specific systemic symptoms,} including: lethargy, apnea, temperature instability, unexplained acidosis, hyperglycemia, poor perfusion
\item
  \textbf{Lab abnormalities:} Hyponatremia, hyperkalemia, metabolic acidosis, leukocytosis or leukopenia, thrombocytopenia
\end{itemize}

\hypertarget{work-up-72}{%
\paragraph{Work-up}\label{work-up-72}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} CBCd, blood culture, electrolytes
\item
  \textbf{Imaging:} KUB w/ left lateral decub
\end{itemize}

\hypertarget{management-94}{%
\paragraph{Management}\label{management-94}}

\begin{itemize}
\tightlist
\item
  Supportive care
\item
  Place replogle tube for decompression
\item
  Antibiotics, start IVF/TPN
\item
  Monitor labs and KUB serially
\item
  Surgery consult
\end{itemize}

\hypertarget{malrotation---mid-gut-volvulus}{%
\subsubsection{Malrotation (+/- Mid Gut Volvulus)}\label{malrotation---mid-gut-volvulus}}

\hypertarget{etiology-29}{%
\paragraph{Etiology}\label{etiology-29}}

\begin{itemize}
\tightlist
\item
  Developing bowel fails to undergo usual counterclockwise rotation during 4th-10th wk of embryogenesis
\item
  Peritoneal bands that usually attach bowel to central body axis are misplaced and compress duodenum, resulting in partial obstruction
\item
  Volvulus results in intestinal obstruction
\item
  Superior mesenteric artery may be compressed leading to ischemia
\end{itemize}

\hypertarget{clinical-manifestations-19}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-19}}

\begin{itemize}
\tightlist
\item
  Newborn \textless1mo w/ bilious emesis
\item
  Associated w/ diaphragmatic hernia, omphalocele, gastroschisis
\end{itemize}

\hypertarget{work-up-73}{%
\paragraph{Work-up}\label{work-up-73}}

\begin{itemize}
\tightlist
\item
  \textbf{KUB:} Usually unremarkable, may have signs of small bowel obstruction
\item
  \textbf{UGI:} Abnormal position of duodenal-jejunal junction. Volvulus appears as spirla corkscrew of duodenum.
\item
  \textbf{US:} May show volvulus in small bowel
\end{itemize}

\hypertarget{management-95}{%
\paragraph{Management}\label{management-95}}

Emergent surgical intervention

\begin{itemize}
\tightlist
\item
  \textbf{Modified Ladd's Procedure:}

  \begin{itemize}
  \tightlist
  \item
    Division of peritoneal bands around the duodenum
  \item
    Colon placed on the left w/ duodenum on the right, to broaden the mesentery
  \item
    Appendectomy preformed so no confusion w/ future abd pain
  \end{itemize}
\end{itemize}

\hypertarget{duodenal-atresia}{%
\subsubsection{Duodenal Atresia}\label{duodenal-atresia}}

\hypertarget{etiology-30}{%
\paragraph{Etiology}\label{etiology-30}}

Embryogenic. 1 in 5,000 live births. 25\% have Trisomy 21.

\hypertarget{clinical-manifestations-20}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-20}}

Bilious vomiting hours after birth w/o abdominal distention

\hypertarget{work-up-74}{%
\paragraph{Work-up}\label{work-up-74}}

KUB shows \textbf{double bubble sign} (gaseous distension of stomach and proximal duodenum)

\hypertarget{management-96}{%
\paragraph{Management}\label{management-96}}

\begin{itemize}
\tightlist
\item
  NPO w/ NG suction
\item
  Surgical consult for duodenoduodenostomy
\end{itemize}

\hypertarget{jujonoileal-atresia}{%
\subsubsection{Jujonoileal Atresia}\label{jujonoileal-atresia}}

\hypertarget{etiology-31}{%
\paragraph{Etiology}\label{etiology-31}}

\begin{itemize}
\tightlist
\item
  Mesenteric vascular accident during fetal life
\item
  1 in 3,000 live births
\end{itemize}

\hypertarget{clinical-manifestations-21}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-21}}

Bilious vomiting hours after birth w/ abdominal distension, failure to pass meconium; hyperbilirubinemia

\hypertarget{work-up-75}{%
\paragraph{Work-up}\label{work-up-75}}

KUB shows air-fluid levels

\hypertarget{management-97}{%
\paragraph{Management}\label{management-97}}

\begin{itemize}
\tightlist
\item
  NPO w/ NG suction
\item
  Surgical consult for resection and anastomosis
\end{itemize}

\hypertarget{meconium-ileus}{%
\subsubsection{Meconium ileus}\label{meconium-ileus}}

\hypertarget{etiology-32}{%
\paragraph{Etiology}\label{etiology-32}}

5\% of newborns with cystic fibrosis, and in 1 per 5,000 to 10,000 live births

\hypertarget{clinical-manifestations-22}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-22}}

Abdominal distension and vomiting hours after birth, failure to pass meconium

\hypertarget{work-up-76}{%
\paragraph{Work-up}\label{work-up-76}}

\begin{itemize}
\tightlist
\item
  KUB shows distension, air fluid levels
\item
  Contrast enema shows microcolon +/- inpacted meconium pellets
\end{itemize}

\hypertarget{management-98}{%
\paragraph{Management}\label{management-98}}

\begin{itemize}
\tightlist
\item
  NPO w/ NG suction
\item
  Water soluble contrast enema
\item
  Surgical enterostomy if needed
\end{itemize}

\hypertarget{oncology}{%
\section{Oncology}\label{oncology}}

\hypertarget{order-sets-powerplans}{%
\subsection{Order Sets \& PowerPlans}\label{order-sets-powerplans}}

\emph{Use these whenever possible!}

\begin{itemize}
\tightlist
\item
  Onc Admit Order Set
\item
  Onc New ALL Order Set (induction)
\item
  Onc Anti-Emetics
\item
  Onc Constipation Plan
\item
  Onc Sepsis (Fever \& Neutropenia) Plan
\item
  Onc Tumor Lysis Syndrome - one for allopurinol, one for rasburicase
\item
  Onc Platelets Plan
\item
  Onc pRBC Plan
\item
  Onc PJP Prophylaxis
\item
  Onc CVL Occlusion Plan
\item
  Onc / ICU Intermittent Electrolyte Replacement Plan
\end{itemize}

\hypertarget{common-pediatric-cancers}{%
\subsection{Common Pediatric Cancers}\label{common-pediatric-cancers}}

\hypertarget{hematologic-cancers}{%
\subsubsection{Hematologic Cancers}\label{hematologic-cancers}}

\hypertarget{b-all}{%
\paragraph{B-ALL}\label{b-all}}

\hypertarget{presentation-124}{%
\subparagraph{Presentation}\label{presentation-124}}

Non-specific/constitutional, bone pain, fever, malaise, lymphadenopathy, HSM, cytopenias, unilateral testicular enlargement

\hypertarget{epidemiology-3}{%
\subparagraph{Epidemiology}\label{epidemiology-3}}

\begin{itemize}
\tightlist
\item
  Peak incidence 2-5 yrs, M\textgreater F, 70-80\% ALL
\item
  Increased risk in Down syndrome (age \textgreater5 yr), NF 1, Bloom syndrome, and ataxia telangiectasia
\end{itemize}

\hypertarget{key-early-diagnostics}{%
\subparagraph{Key Early Diagnostics}\label{key-early-diagnostics}}

\begin{itemize}
\tightlist
\item
  BM Biopsy showing \textgreater25\% lymphoblasts (note \textless25\% + mediastinal mass = lymphoma)
\item
  Peripheral and BM Flow Cytometry (FC): determines type (B=CD19, CD20. T=CD2, CD3, CD5, CD7, CD4, CD8)
\item
  CNS Status via LP: \emph{CNS1} no blasts after cytospin. \emph{CNS2} WBC 1-5 blasts on cytospin. \emph{CNS3} ≥5 blasts or other sx of CNS involvement. For CNS2\&3, LP w IT done 2x/wk until blasts clear
\item
  FISH: ETV6/RUNX1, BCR/ABL1, KMT2A, intrachromosomal amplification of 21 (iAMP21)
\item
  Cytogenetics: assess for trisomies 4/10/17, hyperdiploid (favorable); hypodiploid (unfavorable)
\item
  Rapid Heme Panel: NGS sent on BM Bx. See below for favorable/adverse biology
\item
  ClonoSeq: NGS assay used to identify specific clone of leukemia cells. Will be used to assess Minimum Residual Disease (MRD) after Induction (can also be done by FC)
\end{itemize}

\hypertarget{risk-stratification-dfci-16-001}{%
\subparagraph{Risk Stratification (DFCI 16-001)}\label{risk-stratification-dfci-16-001}}

Age \& presenting WBC count historically used as they are proxies for biology -- as we learn more about specific biology of ALL, we will rely less on these imprecise measures.

\begin{itemize}
\tightlist
\item
  \textbf{Initial Low risk:} WBC \textless50K/uL, age \textless15 + CNS-1 or CNS-2 + no adverse biology. Often ETV6-RUNX1 (aka TEL/AML1) or hyperdiploid (51-65 chromosomes)
\item
  \textbf{Initial High Risk:} WBC ≥50K/uL or age ≥15 or CNS3 or iAMP21 or adverse biology. Receive 4 drug induction (+doxorubicin). If BCR-ABL1+ (Ph+ ALL), get dasatinib/TKI
\item
  \textbf{Initial Very High Risk:} Adverse biology by day 10 = KMT2A/MLL (FISH or RHP), t(17,19) (FISH), ≤40 chromosomes (cytogenetics), IKZF1 deletion (RHP). → 4 drug induction
\item
  Risk group is re-stratified at Day 32. \emph{Undetectable disease} (MRD \textless10-4) = best prognostic sign.
\end{itemize}

\hypertarget{standard-treatment}{%
\subparagraph{Standard Treatment}\label{standard-treatment}}

\begin{itemize}
\tightlist
\item
  Once reached MRD status, complete 2 more years of chemotherapy w/ oral dexamethasone, IV vincristine, 土 IV doxorubicin (HR or VHR), IV/IM asparaginase, oral 6-MP, IV methotrexate, IT MTX
\item
  Phases: steroid prophase → Induction → Consolidation → Continuation
\item
  Outcomes: Excellent 5 yr OS 92\%, EFS 86\% (DFCI 05-001)
\end{itemize}

\hypertarget{t-all}{%
\paragraph{T-ALL}\label{t-all}}

\hypertarget{presentation-125}{%
\subparagraph{Presentation}\label{presentation-125}}

Anterior mediastinal mass (airway compression, SVC syndrome), hyperleukocytosis, constitutional symptoms similar to B-ALL

\hypertarget{epidemiology-4}{%
\subparagraph{Epidemiology}\label{epidemiology-4}}

\begin{itemize}
\tightlist
\item
  Peak incidence 15-19 yrs (``T'' = teens), M\textgreater F, \textasciitilde15\% ALL
\item
  T-ALL and T-cell lymphoblastic lymphoma (NHL) distinguished by BM involvement (Leukemia if \textgreater25\% blasts in marrow)
\end{itemize}

\hypertarget{diagnostics-2}{%
\subparagraph{Diagnostics}\label{diagnostics-2}}

See details in B-ALL above

\hypertarget{risk-stratification}{%
\subparagraph{Risk Stratification}\label{risk-stratification}}

All T-ALL is \emph{Initial High Risk}

\hypertarget{treatment-65}{%
\subparagraph{Treatment}\label{treatment-65}}

All T-ALL gets 4 drug induction, otherwise similar chemo as B-ALL

\hypertarget{outcomesprognosis}{%
\subparagraph{Outcomes/Prognosis}\label{outcomesprognosis}}

Slightly worse than B-ALL, 5 yr OS 89\%, EFS 82\% (DFCI 05-001)

\hypertarget{aml}{%
\paragraph{AML}\label{aml}}

\hypertarget{presentation-126}{%
\subparagraph{Presentation}\label{presentation-126}}

\begin{itemize}
\tightlist
\item
  Non-specific/constitutional symptoms, cytopenias. Hyperleukocytosis (tumor lysis syndrome, DIC).
\item
  \textbf{Extramedullary symptoms:} HA, lethargy, AMS, CN palsy, myeloid sarcomas/ chloromas
\end{itemize}

\hypertarget{epidemiology-5}{%
\subparagraph{Epidemiology}\label{epidemiology-5}}

\begin{itemize}
\tightlist
\item
  AML accounts for \textasciitilde{} 20\% of all acute leukemias
\item
  \textbf{Down's Syndrome:} 150x risk of AML. 20\% of Transient Abnormal Myelopoiesis of DS (presents peri-natally with megakaryoblasts that self-resolve, usually due GATA1 mutation) becomes ML-DS by age 4
\item
  \textbf{Therapy-related AML:} secondary malignancy, typically assoc. with alkylating agents and topoisomerase inhibitors
\end{itemize}

\hypertarget{diagnostics-3}{%
\subparagraph{Diagnostics}\label{diagnostics-3}}

BM Bx, LP, FC (common AML markers CD13, CD15, CD34, CD117, MPO), FISH, cytogenetics, Rapid Heme NGS

\hypertarget{risk-stratification-1}{%
\subparagraph{Risk Stratification}\label{risk-stratification-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Favorable:} t(8;21)(q22;q22 = RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Mutated NPM1 without FLT3-ITD (normal karyotype), Mutated CEBPA (normal karyotype)

  \begin{itemize}
  \tightlist
  \item
    t(15,17)/PML-RARA: APML subtype, high risk of DIC, treat with All-trans-retinoic acid (ATRA) and arsenic (ATO). Excellent outcomes (OS \textgreater95\% Creutzig PBC 2017 and Spezza BJH 2020).
  \end{itemize}
\item
  \textbf{Intermediate:} sub-stratified based on response to induction therapy (MRD by FC)
\item
  \textbf{Adverse:} t(6;9)(p23;q34); DEK-NUP214, Monosomy 5 or del(5q); Monosomy 7; Complex karyotype; High allelic ratio FLT3-ITD
\end{itemize}

\hypertarget{treatment-66}{%
\subparagraph{Treatment}\label{treatment-66}}

\begin{itemize}
\tightlist
\item
  \textbf{High intensity induction chemo:} ADE (cytarabine, daunorubicin, etoposide) - All done inpatient
\item
  \textbf{Consolidation} (cytarabine based) \textbf{OR HCT if intermediate/high risk}
\end{itemize}

\hypertarget{outcomesprognosis-1}{%
\subparagraph{Outcomes/Prognosis}\label{outcomesprognosis-1}}

Poor. 3 yr OS \textasciitilde65\%, EFS \textasciitilde45\% (AAML1031)

\hypertarget{hodgkins-lymphoma}{%
\paragraph{Hodgkin's Lymphoma}\label{hodgkins-lymphoma}}

\hypertarget{presentation-127}{%
\subparagraph{Presentation}\label{presentation-127}}

Lymphadenopathy, constitutional B-symptoms, mediastinal mass effect, splenomegaly

\hypertarget{epidemiology-6}{%
\subparagraph{Epidemiology}\label{epidemiology-6}}

\begin{itemize}
\tightlist
\item
  \textbf{Bimodal:} Peak incidence late teenage years, most common childhood cancer in 15-19 yo; second peak in adults age \textgreater50
\item
  Association with EBV infection
\end{itemize}

\hypertarget{risk-stratigication-staging}{%
\subparagraph{Risk Stratigication \& Staging}\label{risk-stratigication-staging}}

\begin{itemize}
\tightlist
\item
  Risk stratification based on Ann Arbor staging with Cotswolds modifications for HL:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Stage I}: involvement of single lymph node (LN) region
  \item
    \textbf{Stage II}: involvement of ≥2 LN regions on same side of diaphragm
  \item
    \textbf{Stage III}: involves LN regions on both sides of the diaphragm
  \item
    \textbf{Stage IV}: Diffuse or disseminated involvement of one or more extranodal organs or tissue beyond that designated E (contiguous extranodal disease), with or without associated lymph node involvement.
  \item
    All cases are subclassified to indicate the \textbf{absence (A) or presence (B) of ``B symptoms''} (systemic symptoms of significant unexplained fever, night sweats, or unexplained weight loss exceeding 10\% of body weight during the six months prior to diagnosis)
  \end{itemize}
\item
  \emph{\textbf{High Risk disease = IIIB and IVB}}. Poor prognosis associated with higher stage, presence of B symptoms, presence of bulky disease, extranodal extension
\end{itemize}

\hypertarget{treatment-67}{%
\subparagraph{Treatment}\label{treatment-67}}

Combination chemotherapy (many different regimens) +/- Involved Field Radiation Therapy

\hypertarget{outcomesprognosis-2}{%
\subparagraph{Outcomes/Prognosis}\label{outcomesprognosis-2}}

Excellent. Low risk disease 5 yr EFS \textgreater90\%, high risk 5 yr EFS \textasciitilde85\%.

\hypertarget{non-hodgkins-lymphoma}{%
\paragraph{Non-Hodgkin's Lymphoma}\label{non-hodgkins-lymphoma}}

\hypertarget{presentation-128}{%
\subparagraph{Presentation}\label{presentation-128}}

Varies by location and type. Lymphadenopathy, mediastinal mass, palpable mass, intussusception, cranial nerve palsy.

\hypertarget{epidemiology-7}{%
\subparagraph{Epidemiology}\label{epidemiology-7}}

\begin{itemize}
\tightlist
\item
  Median age: 10 yrs, increase incidence with age
\item
  Increased risk in congenital and acquired immunodeficiency syndromes
\item
  Association with EBV infection
\end{itemize}

\hypertarget{notes-about-grouping-staging-or-potential-prognostic-features}{%
\subparagraph{Notes about Grouping, Staging, or Potential Prognostic Features}\label{notes-about-grouping-staging-or-potential-prognostic-features}}

\begin{itemize}
\tightlist
\item
  \textbf{Risk stratification} based on Murphy (St.~Jude's) staging system
\item
  \textbf{More common subtypes} include: \textbf{Burkitt lymphoma, diffuse large B cell lymphoma, lymphoblastic lymphoma} and \textbf{anaplastic large cell lymphoma}
\item
  \textbf{Post-transplant lymphoproliferative disease} frequently resembles non-Hodgkin lymphoma in a recipient of a solid organ transplant or stem cell transplant, and is also typically staged using Murphy (St.~Jude's) staging system
\end{itemize}

\hypertarget{musculoskeletal-tumors}{%
\subsubsection{Musculoskeletal Tumors}\label{musculoskeletal-tumors}}

\hypertarget{rhabdomyosarcoma}{%
\paragraph{Rhabdomyosarcoma}\label{rhabdomyosarcoma}}

\hypertarget{presentation-129}{%
\subparagraph{Presentation}\label{presentation-129}}

Always on Ddx, can occur anywhere. Most common head/neck/GU.

\begin{itemize}
\tightlist
\item
  \textbf{Head \& neck:} Orbital tumors (proptosis, ophthalmoplegia, parameningeal lesions.
\item
  \textbf{GU} (botryoid RMS): Hematuria, urinary obstruction, pelvic mass, constipation
\item
  \textbf{Extremities:} Painful mass +/- overlying erythema
\end{itemize}

\hypertarget{epidemiology-8}{%
\subparagraph{Epidemiology}\label{epidemiology-8}}

\begin{itemize}
\tightlist
\item
  Most common soft tissue tumor in childhood, majority of cases \textless6 yrs, M\textgreater F
\item
  Associated with neurofibromatosis, Li-Fraumeni (anaplastic RMS), Beckwith-Wiedemann, and Costello syndromes
\end{itemize}

\hypertarget{types-outcomesprognosis}{%
\subparagraph{Types \& Outcomes/Prognosis}\label{types-outcomesprognosis}}

Prognosis is based on histology, TNM stage, clinical group. Histologic subtypes:

\begin{itemize}
\tightlist
\item
  \textbf{Embryonal:} Intermediate prognosis (5 yr EFS 77\%)

  \begin{itemize}
  \tightlist
  \item
    \textbf{Botryoid:} Rare variant of embryonal RMS occuring in infants, favorable prognosis
  \end{itemize}
\item
  \textbf{Alveolar:} Poorer prognosis, most with PAX3- or PAX7-FOXO1 fusions (5 yr EFS 55-65\%)
\item
  \textbf{Anaplastic:} Rare variant associated with Li-Fraumeni syndrome
\end{itemize}

\hypertarget{treatment-68}{%
\subparagraph{Treatment}\label{treatment-68}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Surgical control of local disease
\item
  Radiation therapy
\item
  VAC Chemotherapy (Vincristine, actinomycin-d, cyclophosphamide)
\end{enumerate}

\hypertarget{osteosarcoma}{%
\paragraph{Osteosarcoma}\label{osteosarcoma}}

\hypertarget{presentation-130}{%
\subparagraph{Presentation}\label{presentation-130}}

\begin{itemize}
\tightlist
\item
  Localized bone pain, tender mass, pathological fracture
\item
  Predilection for long bone metaphysis (femur, tibia, humerus)
\item
  Typically metastasizes to lung
\end{itemize}

\hypertarget{epidemiology-9}{%
\subparagraph{Epidemiology}\label{epidemiology-9}}

\begin{itemize}
\tightlist
\item
  Peak incidence 13-16 yrs, M\textgreater F. Most common primary bone malignancy.
\item
  Associated with Li-Fraumeni, Rothmund-Thomson, Bloom and Werner syndromes
\end{itemize}

\hypertarget{risk-factors-3}{%
\subparagraph{Risk Factors}\label{risk-factors-3}}

High risk factors: Metastatic; axial primary site; \textless90\% tumor necrosis after initial chemotherapy

\hypertarget{treatment-69}{%
\subparagraph{Treatment}\label{treatment-69}}

``MAP'' = MTX + anthracycline (doxo) + cisplatin → surgical resection. Not radiosensitive.

\hypertarget{outcomesprognosis-3}{%
\subparagraph{Outcomes/Prognosis}\label{outcomesprognosis-3}}

Localized \textasciitilde60-70\% 3 year EFS. Metastatic / unresectable poor (10-30\% 2 yr OS).

\hypertarget{ewing-sarcoma}{%
\paragraph{Ewing Sarcoma}\label{ewing-sarcoma}}

\hypertarget{presentation-131}{%
\subparagraph{Presentation}\label{presentation-131}}

\begin{itemize}
\tightlist
\item
  Localized pain/swelling, tender soft tissue mass, pathological fractures
\item
  Predilection for axial skeleton, pelvis and diaphysis (midshaft) of long bones
\item
  Metastases to lung and bone/marrow
\end{itemize}

\hypertarget{epidemiology-10}{%
\subparagraph{Epidemiology}\label{epidemiology-10}}

\begin{itemize}
\tightlist
\item
  Peak incidence 10-15 yrs but wide age distribution, M\textgreater F, Caucasians\textgreater AA. 2nd most common primary bone malignancy.
\item
  Increased risk: Li-Fraumeni, MEN2. 95\% have EWS fusion (most commonly EWS-FLI1 / t(11,22), detected by FISH).
\end{itemize}

\hypertarget{treatment-70}{%
\subparagraph{Treatment}\label{treatment-70}}

Induction chemo (VDC/IE) 4-6 cycles → surgery. RT for metastatic disease (radiosensitive)

\hypertarget{outcomesprognosis-4}{%
\subparagraph{Outcomes/Prognosis}\label{outcomesprognosis-4}}

Localized 70-80\% 5 year OS. Metastatic poor (\textasciitilde30\% 5 year OS).

\hypertarget{nervous-system-tumors-managed-by-neuro-oncologists}{%
\subsubsection{Nervous System Tumors, managed by Neuro-Oncologists}\label{nervous-system-tumors-managed-by-neuro-oncologists}}

\hypertarget{medulloblastoma}{%
\paragraph{Medulloblastoma}\label{medulloblastoma}}

\hypertarget{presentation-132}{%
\subparagraph{Presentation}\label{presentation-132}}

Cerebellar mass, hydrocephalus, increased ICP. Midline tumors: gait ataxia or truncal instability; lateral cerebellar: limb discoordination. Dizziness, diplopia.

\hypertarget{epidemiology-11}{%
\subparagraph{Epidemiology}\label{epidemiology-11}}

\begin{itemize}
\tightlist
\item
  Peak incidence 5-9 yrs. Most common malignant brain tumor of childhood.
\item
  Associated with Gorlin syndrome, familial adenomatous polyposis
\end{itemize}

\hypertarget{risk-stratification-outcomesprognosis}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis}}

\begin{itemize}
\tightlist
\item
  \textbf{High-risk factors:} Age, extent of disease (modified Chang criteria), histopathologic subtype, and molecular subtype
\item
  Tumors with WNT signaling pathway mutations have the best prognosis (\textgreater95\% 5-year OS); ``group 3'' (MYC mutations) have the worst
\end{itemize}

\hypertarget{gliomas}{%
\paragraph{Gliomas}\label{gliomas}}

\hypertarget{presentation-133}{%
\subparagraph{Presentation}\label{presentation-133}}

Depending on location, size and rate of growth: Seizures, hemiparesis, ataxia, increased ICP, cranial neuropathies

\hypertarget{epidemiology-12}{%
\subparagraph{Epidemiology}\label{epidemiology-12}}

Associated with NF1, Li-Fraumeni, Tuberous Sclerosis, von Hippel-Lindau, familial adenomatous polyposis

\hypertarget{risk-stratification-outcomesprognosis-1}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-1}}

Several distinct entities based on histopathology:

\begin{itemize}
\tightlist
\item
  Low grade (WHO I/II) glioma excellent outcomes (85-95\% 5 y-yr OS)
\item
  Most common pilocytic astrocytoma
\item
  High grade (e.g.~Diffuse intrinsic pontine glioma) very poor (median survival 10-12 months)
\end{itemize}

\hypertarget{nervous-system-tumors-managed-by-non-neuro-oncologists}{%
\subsubsection{Nervous System Tumors, managed by Non-Neuro Oncologists}\label{nervous-system-tumors-managed-by-non-neuro-oncologists}}

\hypertarget{neuroblastoma}{%
\paragraph{Neuroblastoma}\label{neuroblastoma}}

\hypertarget{presentation-134}{%
\subparagraph{Presentation}\label{presentation-134}}

All a function of location. Adrenal/abdominal; thoracic (respiratory distress, Horner's syndrome, nerve root/spinal cord compression). Mets causing pain, proptosis/raccoon eyes. Paraneoplastic symptoms (catecholamine production).

\hypertarget{epidemiology-13}{%
\subparagraph{Epidemiology}\label{epidemiology-13}}

Median age of diagnosis 18 mos, increased incidence in Caucasian population

\hypertarget{risk-stratification-outcomesprognosis-2}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-2}}

\begin{itemize}
\tightlist
\item
  \textbf{High-risk features:} Age (\textless1yo 5yr EFS = 95\% vs \textgreater1yr = 65\%), MYCN amplification, metastatic, crossing the midline

  \begin{itemize}
  \tightlist
  \item
    \textbf{Exception:} ``MS'' (formerly 4S) disease (\textless1 yr, mets to skin, liver, \textless10\% BM only), very favorable
  \end{itemize}
\end{itemize}

\hypertarget{diagnostics-4}{%
\subparagraph{Diagnostics}\label{diagnostics-4}}

Urine VMA and HVA; CT/MRI, biopsy, MYCN amplification, 123I-MIBG or PET scan

\hypertarget{treatment-71}{%
\subparagraph{Treatment}\label{treatment-71}}

Varies based on stage (observation only vs very intense chemo) and new vs.~relapsed: Chemotherapy induction, surgical resection, auto-HCT consolidation, dinutuximab, 131I-MIBG

\hypertarget{retinoblastoma}{%
\paragraph{Retinoblastoma}\label{retinoblastoma}}

\hypertarget{presentation-135}{%
\subparagraph{Presentation}\label{presentation-135}}

Leukocoria (54\%), strabismus, nystagmus, red eye, decrease vision, iris heterochromia

\hypertarget{epidemiology-14}{%
\subparagraph{Epidemiology}\label{epidemiology-14}}

\begin{itemize}
\tightlist
\item
  Median age at diagnosis is 18 mos, later with unilateral disease. Majority present \textless5 yo
\item
  Germline mutations in RB1 (associated with sarcomas and melanoma)
\end{itemize}

\hypertarget{risk-stratification-outcomesprognosis-3}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-3}}

Poor prognosis: Delay in diagnosis \textgreater6 mos, h/o intraocular surgery, cataract, use of external beam radiotherapy, invasion of local anatomy, tumor anaplasia

\hypertarget{kidney-tumors}{%
\subsubsection{Kidney Tumors}\label{kidney-tumors}}

\hypertarget{wilms-tumor}{%
\paragraph{Wilm's Tumor}\label{wilms-tumor}}

\hypertarget{presentation-136}{%
\subparagraph{Presentation}\label{presentation-136}}

Abdominal mass, abd pain, hematuria, fever, HTN

\hypertarget{epidemiology-15}{%
\subparagraph{Epidemiology}\label{epidemiology-15}}

\begin{itemize}
\tightlist
\item
  Median age at diagnosis 4 yo, typically \textless15 yo
\item
  Bilateral disease 5-7\%; if bilateral, more likely to have associated syndrome: WAGR syndrome, Beckwith-Wiedemann, Denys-Drash, and Bloom syndrome
\end{itemize}

\hypertarget{risk-stratification-outcomesprognosis-4}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-4}}

\begin{itemize}
\tightlist
\item
  \textbf{High-risk features: }``Anaplastic'' histology, bilateral disease, metastatic disease
\item
  National Wilms Tumor Study (NWTS) staging system (post-resection and pre-chemo) - prognosis based on anatomic extent of the tumor
\end{itemize}

\hypertarget{liver-tumors}{%
\subsubsection{Liver Tumors}\label{liver-tumors}}

\hypertarget{hepatoblastoma}{%
\paragraph{Hepatoblastoma}\label{hepatoblastoma}}

\hypertarget{presentation-137}{%
\subparagraph{Presentation}\label{presentation-137}}

Asymptomatic abdominal mass, hemihyperplasia, sexual precocity (synthesis of ectopic gonadotropins), anorexia

\hypertarget{epidemiology-16}{%
\subparagraph{Epidemiology}\label{epidemiology-16}}

\begin{itemize}
\tightlist
\item
  Children \textless3 yrs
\item
  Associated with: Low birth weight (\textless1000 g), Beckwith Wiedmann syndrome, trisomy 18, trisomy 21, Acardia syndrome, Li-Fraumeni syndrome, and familial adenomatous polyposis
\end{itemize}

\hypertarget{risk-stratification-outcomesprognosis-5}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-5}}

Risk stratification based on: PRE-Treatment EXTent of disease (PRETEXT) group, histology, AFP level

\hypertarget{hepatocellular-carcinoma}{%
\paragraph{Hepatocellular Carcinoma}\label{hepatocellular-carcinoma}}

\hypertarget{presentation-138}{%
\subparagraph{Presentation}\label{presentation-138}}

Abdominal mass, anorexia, weight loss, jaundice

\hypertarget{epidemiology-17}{%
\subparagraph{Epidemiology}\label{epidemiology-17}}

\begin{itemize}
\tightlist
\item
  Peak incidence 15-19 yrs, rarely diagnosed \textless5 yrs
\item
  Increased risk in: Alagille syndrome, glycogen storage diseases, biliary atresia, infantile cholestasis, perinatally acquired HepB, tyrosinemia
\end{itemize}

\hypertarget{risk-stratification-outcomesprognisis}{%
\subparagraph{Risk Stratification \& Outcomes/Prognisis}\label{risk-stratification-outcomesprognisis}}

Risk stratification based on staging: Location, resectability, and response to any pre-surgical therapy

\hypertarget{germ-cell-tumors}{%
\subsubsection{Germ Cell Tumors}\label{germ-cell-tumors}}

\hypertarget{teratoma}{%
\paragraph{Teratoma}\label{teratoma}}

\hypertarget{presentation-139}{%
\subparagraph{Presentation}\label{presentation-139}}

\begin{itemize}
\tightlist
\item
  \textbf{Sacrococcygeal:} Prenatal diagnosis via U/S, or caudal mass at birth.
\item
  \textbf{Ovarian:} Abd mass, abd pain, distension, emesis, obstructive symptoms
\item
  \textbf{Testicular:} Testicular mass, +/- pain
\end{itemize}

\hypertarget{epidemiology-18}{%
\subparagraph{Epidemiology}\label{epidemiology-18}}

\begin{itemize}
\tightlist
\item
  \textbf{Sacrococcygeal:} Congenital
\item
  \textbf{Ovarian:} Increase incidence with age, peak incidence 15-19 yrs, can be bilateral
\item
  \textbf{Testicular:} More common \textless5 yrs
\end{itemize}

\hypertarget{risk-stratification-outcomesprognosis-6}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-6}}

Worse prognosis based on malignant transformation and anatomic extent of the tumor. Late presentation associated with worse prognosis (esp Sacrococcygeal)

\hypertarget{diagnostics-shared-among-all-gcts}{%
\subparagraph{Diagnostics (shared among all GCTs)}\label{diagnostics-shared-among-all-gcts}}

\begin{itemize}
\tightlist
\item
  \textbf{Biopsy}
\item
  \textbf{Imaging:} Primary site + Abdomen/Pelvis + chest for mets
\item
  \textbf{Tumor markers:} Establish baseline, use fall to monitor response to treatment

  \begin{itemize}
  \tightlist
  \item
    AFP: See Onc internal page for age-adjusted normal values. T1/2 7-days.
  \item
    B-HCG: T1/2 3.5 days
  \end{itemize}
\end{itemize}

\hypertarget{yolk-sac-tumor}{%
\paragraph{Yolk Sac Tumor}\label{yolk-sac-tumor}}

\hypertarget{presentation-140}{%
\subparagraph{Presentation}\label{presentation-140}}

\begin{itemize}
\tightlist
\item
  \textbf{Testis:} Painless testicular mass, torsion, elevated AFP
\item
  \textbf{Ovary:} Abd/pelvic mass, abd pain, torsion, ascites
\item
  \textbf{Intracranial:} See germinoma
\end{itemize}

\hypertarget{epidemiology-19}{%
\subparagraph{Epidemiology}\label{epidemiology-19}}

Prepubertal children, M=F, pure yolk sac tumors median age 1.5 yrs. Bimodal distribution in puberty.

\hypertarget{germinoma-neuro-onc}{%
\paragraph{Germinoma (Neuro-Onc)}\label{germinoma-neuro-onc}}

\hypertarget{presentation-141}{%
\subparagraph{Presentation}\label{presentation-141}}

Depends on location. Intracranial (increased ICP and cranial nerve compression); suprasellar regions (hypothalamic/pituitary dysfunctions, optic nerve compression), elevated B-HCG.

\hypertarget{epidemiology-20}{%
\subparagraph{Epidemiology}\label{epidemiology-20}}

Median age at diagnosis 10-12 yrs. Germinomas account for 60-65\% of all pediatric intracranial GCTs.

\hypertarget{risk-stratification-outcomesprognosis-7}{%
\subparagraph{Risk Stratification \& Outcomes/Prognosis}\label{risk-stratification-outcomesprognosis-7}}

Risk stratification based on histopathology

\hypertarget{common-chemotherapies}{%
\subsection{Common Chemotherapies}\label{common-chemotherapies}}

\begin{longtable}[]{@{}llllllll@{}}
\toprule
\begin{minipage}[b]{0.14\columnwidth}\raggedright
Class - Drugs\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Mechanism\strut
\end{minipage} & \begin{minipage}[b]{0.05\columnwidth}\raggedright
Used in\strut
\end{minipage} & \begin{minipage}[b]{0.10\columnwidth}\raggedright
Pharma/Metabolism/Excretion\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
Short-term side effects\strut
\end{minipage} & \begin{minipage}[b]{0.06\columnwidth}\raggedright
Long-term side effects\strut
\end{minipage} & \begin{minipage}[b]{0.18\columnwidth}\raggedright
Notes\strut
\end{minipage} & \begin{minipage}[b]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Alkylating agents} Cyclophosphamide Ifosfamide Melphalan Busulfan Procarbazine Dacarbazine Temozolomide\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Attaches an alkyl group to guanine in DNA; prevents replication and causes damage\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
NBL Sarcoma WT BTs Lymphoma\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Antagonized by MGMT enzymes; cyclophos via urine, ifos via liver\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
N/V/D Mucositis Myelosuppression Hemorrhagic cystitis SIADH IFOS-encephalopathy\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
Secondary malignancy Infertility (high doses)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Co treat w/ Mesna and hyper-hydration for cystitis IFOS-encephalopathy - methylene blue Biomarker: MGMT promoter methylation (gliomas)\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Platinum Analogues} Cisplatin Carboplatin Oxaliplatin\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
``Alkylating-like'' (no alkyl group); crosslinks w/ DNA, prevents replication and causes damage\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Sarcomas WT BTs GCTs Testicular\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Urine excretion\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
N/V/D Nephrotoxicity Electrolyte wasting (Mag, K)\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
Secondary neuropathy Ototoxicity\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Hyperhydration for renal protection\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Anti-folate agents} Methotrexate Pemetrexed\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Analog of folic acid, impairs DHFR, thus impairs DNA synthesis\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
ALL Lymphoma\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Hepatic metabolism, but urinary excretion. Elimination is person-specific\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Myelosuppression Mucositis Transaminitis Kidney failure Encephalopathy\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Hyperhydration Urine alkalinization Monitor serum levels Leucovorin Glucarpidase if unable to clear MTX\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Anti-metabolites} 6-Mercaptopurine Cytarabine (Ara-C)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Nucleoside analogue, incorporated into DNA and interrupts replication\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Leukemia Lymphoma IT for CNS disease\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Kidney (6MP) Liver (cytarabine)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Myelosuppression N/V/D Mucositis Bowel necrosis Fevers (AraC) Neurotoxicity Infections (esp strep viridans)\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
TPMT genotype (6MP) to guide dosing\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Topoisomerase inhibitors} \emph{Topo I inhibitors} Topotecan Irinotecan \emph{Topo II inhibitors} Etoposide (VP16)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Inhibits Topo I/II during S phase, preventing DNA replication\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Solid tumors\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Liver (etoposide) Urine (topotecan)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Metallic food taste Myelosuppression Hypotension Diarrhea (irinotecan)\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
Secondary malignancy\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Irinotecan-induced diarrhea Prophylaxis: Cefixime Acute onset: atropine \textgreater8h: loperamide UGT1A1 genotype (irinotecan)\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Anthracyclines} Doxorubicin Daunorubicin Idarubicin Mitoxantrone\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Antibiotic from Streptomyces bacteria; Intercalates between DNA/RNA hybrids in replication.\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Leukemia Sarcomas Lymphoma\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Myelosuppression Mucositis Skin reactions (hand-foot syndrome)\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
Heart failure (cumulative dose-dependent)\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Dexrazoxane may be used in limited cases for patients at highest risk of developing cardiotoxicity\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Asparaginase} PEG- Non-PEG (Erwinia)-\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Bacterial enzyme, converts asparagine to aspartic acid and ammonia. Inhibits protein synthesis\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
ALL AML\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
PEG half life 5-7 days, Non-PEG half life \textless24 hours\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Anaphylaxis Coagulopathy/Thrombosis Hyperammonemia Encephalopathy Hemorrhagic pancreatitis Transaminitis\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Vinca alkaloids} Vincristine Vinblastine Vinorelbine\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Inhibits mitotic M phase by preventing microtubule function\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
ALL Lymphoma Sarcoma CNS NBL WT\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Neurotoxicity Peripheral neuropathy SIADH Constipation Seizures Hypotension\strut
\end{minipage} & \begin{minipage}[t]{0.06\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Bowel regimen\strut
\end{minipage} & \begin{minipage}[t]{0.00\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{Legend}:
\emph{Diseases}: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BTs, brain tumors; NBL, neuroblastoma; WT, Wilms tumor
\emph{Side effects}: SIADH, syndrome of inappropriate ADH; N/V/D, nausea/vomiting, diarrhea
\emph{Genes}: DHFR, dihydrofolate reductase; MGMT, O-6-methylguanine-DNA methyltransferase; UGT1A1, UDP glucuronosyltransferase 1; TPMT, thiopurine S-methyltransferase
\emph{Other}: IT, intrathecal; PEG, polyethylene glycol

\hypertarget{common-targeted-therapies}{%
\subsection{Common Targeted Therapies}\label{common-targeted-therapies}}

\begin{longtable}[]{@{}lllllll@{}}
\toprule
\begin{minipage}[b]{0.06\columnwidth}\raggedright
Drug\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Mechanism\strut
\end{minipage} & \begin{minipage}[b]{0.10\columnwidth}\raggedright
Used in\strut
\end{minipage} & \begin{minipage}[b]{0.07\columnwidth}\raggedright
Pharma/Metabolism/Excretion\strut
\end{minipage} & \begin{minipage}[b]{0.19\columnwidth}\raggedright
Short-term side effects\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Long-term side effects\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Notes\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Imatinib\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Kinase inhibitor of BCR-ABL fusion, PDGFR and c-Kit\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Ph+ ALL GIST CML\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Nausea Diarrhea Myalgias\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Cardiac toxicity, delayed linear growth (pre-pubescent)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Genetic markers for use: -BCR-ABL fusion -PDGFR mutation\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Dasatinib\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Kinase Inhibitor of ABL, Src, c-Kit\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Ph+ ALL CML\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Myelosuppression Pleural effusion\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Pulmonary hypertension\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
BCR-ABL fusion\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Sorafenib\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Multi-kinase inhibitor (BRAF, VEGFR, PDGFR, FLT3\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
FLT 3+ AML RCC Liver tumors\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Hemorrhage Electrolyte wasting (low PO4, Ca, K) Myelosuppression Cardiac toxicity\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
FLT3 internal tandem duplication in AML\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Crizotinib\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Kinase Inhibitor of ALK, ROS1, and NTRK1\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Lymphoma NBL Others\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Nausea Vomiting Diarrhea\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Mutation or fusion of ALK, ROS1, NTRK1\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Entrectinib/Iarotrectinib\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Kinase inhibitor of NTRK1-3, Entrect. also ROS1 \& ALK\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
Infantile fibrosarcoma, high grade gliomas\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
Liver\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Parasthesias dizziness\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Weight gain\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
NTRK1, NTRK2, NTRk3, or ROS fusions\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Rituximab\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Monoclonal antibody against CD20 (B-cell lineage marker)\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
ALL Lymphomas\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Infusion reactions Pulmonary toxicity\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Reactivation of viruses\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Dinutuximab (ch14.18)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Monoclonal antibody against GD2 glycolipid\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
NBL\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Capillary leak syndrome Hypotension Neuropathic pain Hyper-sensitivity reactions\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
blinatumomab\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Bispecific T-cell engager (anti-CD3 and anti-CD19)\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
B-ALL (relapsed / HR)\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Cytokine release syndrome\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Requires continuous infusion\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.06\columnwidth}\raggedright
Inotuzumab ozogomicin\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Antibody drug conjugate against CD-22\strut
\end{minipage} & \begin{minipage}[t]{0.10\columnwidth}\raggedright
B-ALL (relapsed)\strut
\end{minipage} & \begin{minipage}[t]{0.07\columnwidth}\raggedright
-\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright
Hepatotoxicity, infection\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Increased risk of SoS after HCT\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{oncologic-emergencies}{%
\subsection{Oncologic Emergencies}\label{oncologic-emergencies}}

\hypertarget{tumor-lysis-syndrome-tls}{%
\subsubsection{Tumor Lysis Syndrome (TLS)}\label{tumor-lysis-syndrome-tls}}

\hypertarget{definition-52}{%
\paragraph{Definition}\label{definition-52}}

\begin{itemize}
\tightlist
\item
  Massive tumor cell lysis and the release of large amounts of intracellular contents (PKU Phosphate, potassium and uric acid) into systemic circulation
\item
  Most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas (particularly the Burkitt subtype) and ALL
\item
  Can also occur spontaneously and with other tumor types that have a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy
\end{itemize}

\hypertarget{pathogenesis-12}{%
\paragraph{Pathogenesis}\label{pathogenesis-12}}

\begin{itemize}
\tightlist
\item
  Rapid lysis of tumor cells → large amounts of intracellular contents (potassium, phosphate, and nucleic acids) → hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia
\item
  Purines are metabolized to hypoxanthine and xanthine, and then to uric acid via xanthine oxidase. Uric acid is poorly soluble in water leading to crystal precipitation and deposition in the renal tubules and AKI.
\item
  \textbf{Allopurinol} competitively inhibits xanthine oxidase, blocking the metabolism of hypoxanthine and xanthine to uric acid. Xanthine is less soluble than uric acid so allopurinol can exacerbate AKI.
\item
  Cancer cells have \textasciitilde4X higher Phos than normal cells. Hyperphosphatemia can lead to secondary hypocalcemia and renal calcium phosphate precipitation. Hypocalcemia may also cause cardiac arrhythmias.
\item
  Elevated uric acid and phosphate worsen the severity of AKI (increases precipitation of each other)
\end{itemize}

\hypertarget{clinical-manifestation}{%
\paragraph{Clinical Manifestation}\label{clinical-manifestation}}

\begin{itemize}
\tightlist
\item
  \textbf{Hyperuricemia:} Lethargy, nausea, and vomiting
\item
  \textbf{Hyperphosphatemia and hypocalcemia:} Anorexia, cramping, vomiting, spasm, tetany, seizures, altered consciousness, cardiac arrest
\item
  \textbf{Hyperkalemia:} Widened QRS; peaked T waves
\item
  \textbf{Acute Renal Failure:} 2/2 Uric acid and calcium phosphate deposition
\end{itemize}

\hypertarget{diagnostic-studies-10}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-10}}

\begin{itemize}
\tightlist
\item
  CBC, Chem 10, LFT's, LDH, Uric acid → Close attention to K, Ca, Phos, BUN/Cr and LDH
\item
  Obtain labs (chem 10, uric acid, LFTs) q4-8 hrs depending on severity
\item
  Urinalysis may show many uric acid crystals but can be normal due to lack of output from the obstructed nephrons
\item
  Monitor urine output closely
\end{itemize}

\hypertarget{treatment-72}{%
\paragraph{Treatment}\label{treatment-72}}

\begin{itemize}
\tightlist
\item
  \textbf{\emph{NOTE:}} Use Onc Tumor Lysis Syndrome Order Set in PowerChart (there is one for rasburicase and one for allopurinol)
\item
  \textbf{Hydration:} Goal of 3000 mL/m2/day, Consider D5W NS or D5W1/2NS, restrict potassium

  \begin{itemize}
  \tightlist
  \item
    Benefits unclear for alkalinization of urine (pH 7-8); can consider if appropriate
  \end{itemize}
\item
  \textbf{Hyperuricemia:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{1st line = Allopurinol:} \emph{Prevents further UA formation}. Competitively inhibits xanthine oxidase, blocking metabolism of hypoxanthine and xanthine to uric acid, does not reduce the preexisting serum uric acid. Do not use if risk of AKI.
  \item
    \textbf{Rasburicase:} \emph{Rapidly reduces existing UA}. Recombinant version of urate oxidase; leads to degradation of uric acid to allantoin (excreted renally). Consider if Uric acid \textgreater5 or unable to hyperhydrate

    \begin{itemize}
    \tightlist
    \item
      \emph{Test for G6PD first}. Contraindicated in patients with G6PD deficiency because hydrogen peroxide, a breakdown product, can cause methemoglobinemia and hemolytic anemia.
    \item
      Order ``Uric acid, post-rasburicase'' (in Order Set) to check levels
    \end{itemize}
  \end{itemize}
\item
  \textbf{Hyperkalemia:} Calcium gluconate to reduce risk of dysrhythmia. Insulin plus glucose or beta-agonists for quick control. Kayexalate for excretion.
\item
  \textbf{Hyperphosphatemia:} Hyperhydration
\item
  \textbf{Hypocalcemia:} IV calcium, careful to not worse calcium phosphate deposition if phos still high.
\end{itemize}

\hypertarget{fever-and-neutropenia}{%
\subsubsection{Fever and Neutropenia}\label{fever-and-neutropenia}}

\hypertarget{definition-53}{%
\paragraph{Definition}\label{definition-53}}

(Absolute neutrophil count (ANC) \textless500 cells/uL \textbf{OR} ANC expected to decrease to \textless500 cells/uL during the next 48 hours) \textbf{AND} fever \textgreater{} 38.5C once or \textgreater{} 38.0C twice (separated by ≥1 hour) in a 24 h period

\begin{itemize}
\tightlist
\item
  \textbf{``Functional neutropenia''} refers to patients whose hematologic malignancy results in qualitative defects (impaired phagocytosis and killing of pathogens) of circulating neutrophils (e.g.~prior to starting chemo)

  \begin{itemize}
  \tightlist
  \item
    These patients should also be considered to be at increased risk for infection, despite a ``normal'' neutrophil count
  \end{itemize}
\end{itemize}

\hypertarget{risk-stratification-2}{%
\paragraph{Risk Stratification}\label{risk-stratification-2}}

\begin{itemize}
\tightlist
\item
  \textbf{``High Risk'' Population:}

  \begin{itemize}
  \tightlist
  \item
    Patient with prolonged and profound neutropenia (ANC \textless100/mm3 for \textgreater7-10 days)

    \begin{itemize}
    \tightlist
    \item
      AML in all phases of therapy (except APML maintenance)
    \item
      ALL in all phases of therapy EXCEPT continuation
    \end{itemize}
  \item
    Patients with Down Syndrome with ANY oncologic diagnosis
  \item
    Patients with clinical features of severe infection (i.e.~septic shock, typhlitis)
  \end{itemize}
\item
  \textbf{``Standard Risk'' Population}

  \begin{itemize}
  \tightlist
  \item
    Solid tumor patients (most)
  \item
    ALL: Continuation phase of therapy only
  \item
    Patients with an anticipated duration of profound neutropenia lasting ≤ 7 days
  \end{itemize}
\end{itemize}

\hypertarget{pathogenesis-13}{%
\paragraph{Pathogenesis}\label{pathogenesis-13}}

Patients can have absolute or functional leukopenia (secondary to oncologic conditions and/or cytotoxic drugs). Impairs ability of host to defend against invasion by microorganisms.

\hypertarget{microbiology}{%
\paragraph{Microbiology}\label{microbiology}}

\begin{itemize}
\tightlist
\item
  \textbf{Gram-positive infections predominate}

  \begin{itemize}
  \tightlist
  \item
    Coagulase-negative staph, strep pneumo, staph aureus, strep viridans, B. Cereus
  \item
    Risk factor for S. Virdans bacteremia: high-dose IV cytarabine
  \end{itemize}
\item
  \textbf{Gram-negative infections are also common}

  \begin{itemize}
  \tightlist
  \item
    Pseudomonas aeruginosa, stenotrophomonas maltophilia, E. coli, Serratia, Klebsiella
  \end{itemize}
\end{itemize}

\hypertarget{clinical-manifestations-23}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-23}}

\begin{itemize}
\tightlist
\item
  \textbf{Fever:} Focal source of infection (skin/soft tissue/lungs/etc)
\item
  \textbf{Physical exam:} Thorough exam assessing for signs of infection including vitals, skin folds, line sites, oropharynx, perineum. Inflammation in neutropenic patients can be subtle.

  \begin{itemize}
  \tightlist
  \item
    *** \textbf{NO rectal exam or rectal temperatures} ***\\
  \end{itemize}
\item
  \textbf{Typhlitis (neutropenic enterocolitis):} Microbial infection leads to necrosis of layers of bowel wall. Cecum typically affected (possibly secondary to diminished vascularization), can also involve ascending color and terminal ileum.

  \begin{itemize}
  \tightlist
  \item
    \textbf{Signs/symptoms:} Abdominal pain (often RLQ), distention, cramping, nausea/vomiting, watery/bloody diarrhea, hematochezia. If peritoneal signs and shock, consider bowel wall perforation.
  \item
    \textbf{Work-up:} Plain film to r/o free air, Contrast CT, blood and stool cultures, and C. diff assay
  \item
    \textbf{Diagnosis:} CT with contrast demonstrating bowel wall thickening, mesenteric stranding, bowel dilatation, pneumatosis + fever + abdominal pain
  \end{itemize}
\end{itemize}

\hypertarget{diagnostic-studies-11}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-11}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} CBCd. LFT's, amylase and lipase if abdominal symptoms. Consider chemistries as clinically relevant (PN dependence, dehydration, etc).
\item
  \textbf{Cultures:}

  \begin{itemize}
  \tightlist
  \item
    Anaerobic and aerobic blood cultures should be obtained from each lumen of any indwelling catheters, and a peripheral vein. Obtained q24h for temperature \textgreater{} 38.5C from one lumen thereafter.
  \item
    Urinalysis and urine culture: Clean-catch urine or catheter specimen (if \textless{} 2 years, consider catheter specimen)
  \item
    Skin, sputum, throat swabs and cultures as indicated
  \item
    CSF usually not obtained for analysis or culture unless clinically warranted (seizure, change in mental status)
    \textbf{Imaging:} CXR in patients with respiratory symptoms. KUB with abdominal symptoms.
  \end{itemize}
\end{itemize}

\hypertarget{treatment-73}{%
\paragraph{Treatment}\label{treatment-73}}

\begin{itemize}
\tightlist
\item
  \textbf{\emph{NOTE:}} Use Onc Sepsis/F\&N Order Set
\item
  \textbf{Key Treatment Principles:}

  \begin{itemize}
  \tightlist
  \item
    Empiric antibiotic regimen must provide reliable coverage against Pseudomonas
  \item
    Antipseudomonal coverage must remain active until ANC count recovery (even if a gram positive organism is isolated)
  \item
    Vancomycin rule-out for 48 hours to provide empiric coverage for B. Cereus
  \end{itemize}
\item
  \textbf{Antibiotic Discontinuation Criteria}

  \begin{itemize}
  \tightlist
  \item
    ALL, AML (except Continuation phase), Advanced stage Burkitt/B-cell lymphoma

    \begin{itemize}
    \tightlist
    \item
      Blood cultures negative at 48 hrs
    \item
      Patient well-appearing
    \item
      ANC rising post-nadir: ANC \textgreater{} 200 x 2 days

      \begin{itemize}
      \tightlist
      \item
        \emph{Exception:} Febrile at time of new ALL dx, then cultures negative \citet{48-72} hours and afebrile since, can switch to prophylaxis (see below) w/o count recovery per 16-001
      \end{itemize}
    \end{itemize}
  \item
    All other diagnoses:

    \begin{itemize}
    \tightlist
    \item
      Blood culture negative at 48 hrs
    \item
      Afebrile x 24 hrs
    \item
      Patient well-appearing
    \item
      Counts rising post nadir and ANC \textgreater{} 200
    \item
      Discharge patient on oral Augmentin + Ciprofloxacin until ANC \textgreater{} 500. Use clindamycin for penicillin allergies.
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{high-risk-patient-w-fever}{%
\subparagraph{High-Risk Patient w/ Fever}\label{high-risk-patient-w-fever}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.48\columnwidth}\raggedright
Clinical Condition\strut
\end{minipage} & \begin{minipage}[b]{0.46\columnwidth}\raggedright
Empiric Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Hemodynamically stable\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Cefepime 50mg/kg/dose q8h (max 2000mg/dose) \textbf{AND} Vancomycin x48hrs- If \textbf{cephalosporin allergy:} Aztreonam 30mg/kg/dose q6h \textbf{AND} Vancomyci x48hrs\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
+ Abd or perirectal pain\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
ADD metronidazole 7.5mg/kg/dose q6h\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Hemodynamically UNSTABLE\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Meropenem 20mg/kg/dose q8h \textbf{AND} Vancomycin x48hrs\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Pts receiving cefepime prophylaxis at time of fever\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Meropenem 20mg/kg/dose q8h \textbf{AND} Vancomycin x48hrs\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Carbapenem allergy or anaphylactic PCN allergy\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Aztreonam 30mg/kg/dose q6h \textbf{AND} Vancomycin q8h x48hrs \textbf{AND} Tobramycin\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Fever lasting \emph{\textgreater{}} 5-7 days\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Consider Micafungin 3mg/kg/dose q24h- Obtain serum galactomannan \& BD-glucan PRIOR to initiation\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{standard-risk-patient-w-fever}{%
\subparagraph{Standard-Risk Patient w/ Fever}\label{standard-risk-patient-w-fever}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.48\columnwidth}\raggedright
Clinical Condition\strut
\end{minipage} & \begin{minipage}[b]{0.46\columnwidth}\raggedright
Empiric Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Hemodynamically stable\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Cefepime 50mg/kg/dose q8h- If \textbf{cephalosporin allergy:} Aztreonam 30mg/kg/dose q6h \textbf{AND} Clindamycin 10mg/kg/dose\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
+ Abd pain or perirectal pain\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
\textbf{ADD} Metronidazole 7.5mg/kg/dose q6h\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
+ Skin/soft tissue infection/mucositis\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
\textbf{ADD} Vancomycin\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Hemodynamically UNSTABLE\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Use High Risk Algorithm (above)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Fever lasting \emph{\textgreater{}} 72 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Discontinue clindamycin (if receiving) and \textbf{ADD} Vancomycin\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.48\columnwidth}\raggedright
Fever lasting \emph{\textgreater{}} 5-7 days\strut
\end{minipage} & \begin{minipage}[t]{0.46\columnwidth}\raggedright
Consider Micafungin 3mg/kg/dose q24h- Obtain serum galactomannan \& BD-glucan PRIOR to initiation\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{prophylaxis-1}{%
\paragraph{Prophylaxis}\label{prophylaxis-1}}

\hypertarget{antimicrobial}{%
\subparagraph{Antimicrobial}\label{antimicrobial}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.41\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
ALL\strut
\end{minipage} & \begin{minipage}[b]{0.20\columnwidth}\raggedright
AML\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.41\columnwidth}\raggedright
Agent of choice\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Levofloxacin\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
Cefepime\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.41\columnwidth}\raggedright
When to initiate\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
During induction in all afebrile pts\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
During induction 1 in all afebrile pts w/ ANC \textless1000 and falling\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.41\columnwidth}\raggedright
When to discontinue\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
ANC \emph{\textgreater{}} 200 post-nadir during induction\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
ANC \textgreater100 post-nadir and rising following each cycle of chemotherapy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.41\columnwidth}\raggedright
Dosing\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
- 6mos to 5yrs: 10mg/kg/dose IV/PO q12h- \textgreater5yrs: 10mg/kg/dose IV/PO q24h\strut
\end{minipage} & \begin{minipage}[t]{0.20\columnwidth}\raggedright
50mg/kg/dose IV q12h (all ages)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{antifungal}{%
\subparagraph{Antifungal}\label{antifungal}}

\begin{itemize}
\tightlist
\item
  \textbf{Patient population:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{AML:} All patients during all phase of therapy
  \item
    \textbf{ALL:} Patients receiving doxorubicin during induction per DF 16-001 + relapsed patients
  \end{itemize}
\item
  \textbf{Agents:} Micafungin, voriconazole
\end{itemize}

\hypertarget{pjp-prophylaxis}{%
\subparagraph{PJP Prophylaxis}\label{pjp-prophylaxis}}

\begin{itemize}
\tightlist
\item
  \textbf{Patient population:} All oncology patients. For ALL, start when in CR.
\item
  \textbf{Agents:} Bactrim (preferred, dosed 3 days/wk 5mg/kg up to 160mg PO), atovaquone, pentamidine
\end{itemize}

\hypertarget{antiviral}{%
\subparagraph{Antiviral}\label{antiviral}}

\begin{itemize}
\tightlist
\item
  \textbf{Patient population:} Generally reserved for patients with a h/o HSV infection during prior cycles
\item
  \textbf{Agents:} Valacyclovir
\end{itemize}

\hypertarget{anterior-mediastinal-mass-superior-vena-cava-syndrome}{%
\subsubsection{Anterior Mediastinal Mass \& Superior Vena Cava Syndrome}\label{anterior-mediastinal-mass-superior-vena-cava-syndrome}}

\hypertarget{pathogenesis-14}{%
\paragraph{Pathogenesis}\label{pathogenesis-14}}

Compression of mediastinal structures by an anterior mediastinal mass leading to upper body venous congestion and airway obstruction

\hypertarget{differential-41}{%
\paragraph{Differential}\label{differential-41}}

\textbf{For anterior mediastinal masses: ``4 T's''}

\begin{itemize}
\tightlist
\item
  Thyroid mass
\item
  Thymoma
\item
  Teratoma (malignant)
\item
  (Terrible) lymphoma/ T-ALL
\end{itemize}

\hypertarget{clinical-manifestations-24}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-24}}

\begin{itemize}
\tightlist
\item
  Cough/dyspnea/wheezing (40-70\% of pts). Arm, neck and/or facial swelling (\textgreater60\%) from decreased blood return, also predisposes to venous clot formation. Plethoric/ruddy facies (13-23\%). Also, dysphagia, orthopnea, hoarseness. Symptoms exacerbated when lying supine or valsalva.
\item
  Headache, anxiety, and altered mental status (secondary to CO2 retention)
\item
  Increased ICP, can cause life-threatening cerebral edema
\item
  Pleural effusion present in \textasciitilde40-60\%
\item
  Shock if cardiopulmonary compromise; pericardial effusion possible
\end{itemize}

\hypertarget{diagnostic-studies-12}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-12}}

\begin{itemize}
\tightlist
\item
  \textbf{Imaging:} CXR, thoracic and abdominal CT, echoc (if suspicion for cardiac compromise) and chest ultrasound with Doppler (if suspicion for SVC thrombosis)
\item
  \textbf{Labs:} CBC, tumor lysis labs, consider tumor marker evaluation, BM aspirate if peripheral blasts present
\item
  Diagnosis by least invasive method possible to avoid sedation (peripheral lymph node biopsy, bone marrow, pleurocentesis, pericardiocentesis)
\end{itemize}

\hypertarget{management-99}{%
\paragraph{Management}\label{management-99}}

\begin{itemize}
\tightlist
\item
  Anesthesia and ORL consult. Consider ICU transfer.
\item
  Immediate supportive care: O2, elevate HOB to 30 degrees
\item
  Empiric chemotherapy may be necessary based on specific circumstances
\item
  Therapy depends on most likely diagnosis, but radiation therapy, steroids, chemotherapy and diuretics are options to consider
\item
  Surgical resection of chemo/radio-resistant tumors (in rare cases)
\item
  Anticoagulation as appropriate if SVC syndrome is due to thrombus
\end{itemize}

\hypertarget{spinal-cord-compression}{%
\subsubsection{Spinal Cord Compression}\label{spinal-cord-compression}}

\hypertarget{pathogenesis-15}{%
\paragraph{Pathogenesis}\label{pathogenesis-15}}

\begin{itemize}
\tightlist
\item
  Epidural compression can result from perivertebral tumors extending through intervertebral foramen as well as bulky metastatic disease in vertebral bodies
\item
  Most common etiologies: Sarcoma, neuroblastoma, germ cell tumors, lymphoma and CNS metastases
\item
  Compression of venous plexus leads to cord edema, hemorrhage, and ischemia
\item
  Prognosis is based on duration of symptoms and time to diagnosis and treatment; in general survival for patients with spinal cord compression is \textless1 year
\item
  May occur at any spinal level (15\% cervical spine, 60\% thoracic spine, 25\% lumbosacral spine)
\end{itemize}

\hypertarget{clinical-manifestations-25}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-25}}

\begin{itemize}
\tightlist
\item
  \textbf{Focal back pain in a known oncology patient is considered spinal cord compression until proven otherwise!}
\item
  Back pain (80-90\% of patients), weakness (35-75\%), paresis, sensory abnormalities, paraplegia or quadriplegia, urinary and/or fecal incontinence, or constipation
\item
  Prolonged cord compression causes irreversible paralysis, sensory loss and sphincter incompetence
\end{itemize}

\hypertarget{physical-exam-22}{%
\paragraph{Physical Exam}\label{physical-exam-22}}

\begin{itemize}
\tightlist
\item
  Complete neurologic evaluation including rectal tone, with attention to level of deficit and sensory abnormalities
\item
  Pain is often aggravated by movement, straight-leg raise, neck flexion, recumbency or Valsalva maneuver
\end{itemize}

\hypertarget{diagnostic-studies-13}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-13}}

\begin{itemize}
\tightlist
\item
  MRI w/ + w/o gadolinium. Obtain emergently if back pain is associated w/ focal neurologic deficits or refusal/inability to walk
\item
  Following MRI, consider LP with cytology studies
\item
  Spine radiographs are generally not helpful (positive in 1/3rd of cases)
\end{itemize}

\hypertarget{treatment-74}{%
\paragraph{Treatment}\label{treatment-74}}

\textbf{Goal is rapid decompression of tumor}

\begin{itemize}
\tightlist
\item
  Dexamethasone load 1-2 mg/kg, then 0.25-- 0.5mg/kg IV q6hr (children) or 10mg IV bolus (adolescents/adults) followed by 6mg q6hr
\item
  Consult Neurosurgery to evaluate for surgical decompression and laminectomy
\item
  Consult Radiation Oncology to evaluate for emergent XRT
\item
  Chemotherapy may be helpful in select tumors if specific tumor type is known or highly suspected and is likely therapy-responsive (e.g.~lymphoma, neuroblastoma)
\item
  Surgical resection may be best option if tumor type unknown or if mass persists despite radiotherapy, steroids, and/or chemotherapy
\end{itemize}

\hypertarget{hyperleukocytosis-leukostasis}{%
\subsubsection{Hyperleukocytosis \& Leukostasis}\label{hyperleukocytosis-leukostasis}}

\hypertarget{definition-54}{%
\paragraph{Definition}\label{definition-54}}

Definition varies by disease. Occurs more commonly with AML (10-20\%) and very rarely in ALL.

\begin{itemize}
\tightlist
\item
  AML: WBC \textgreater100,000
\item
  ALL: WBC \textgreater300,000
\item
  Chronic phase CML: WBC \textgreater600,000
\end{itemize}

\hypertarget{pathogenesis-16}{%
\paragraph{Pathogenesis}\label{pathogenesis-16}}

\begin{itemize}
\tightlist
\item
  Increased blood viscosity as a direct complication of a large population of leukemic blasts that are less deformable than mature leukocytes
\item
  White blood cell plugs in the microvasculature causing symptoms of decreased tissue perfusion
\item
  This causes local hypoxia, and can lead to increased production of cytokines, resulting in endothelial damage
\end{itemize}

\hypertarget{clinical-manifestations-26}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-26}}

\begin{itemize}
\tightlist
\item
  \textbf{Neurological:}

  \begin{itemize}
  \tightlist
  \item
    Visual changes, headache, dizziness, tinnitus, gait instability, confusion, somnolence, and, occasionally, coma
  \item
    Increased risk of intracranial hemorrhage (persists for at least a week after the reduction of white cell count)
  \end{itemize}
\item
  \textbf{Pulmonary:}

  \begin{itemize}
  \tightlist
  \item
    Dyspnea, hypoxia, possible diffuse interstitial or alveolar infiltrates on imaging studies
  \item
    Occasionally, patients develop dyspnea and worsening hypoxemia following the initiation of chemotherapy due to the lysis of leukemic cells trapped in the lungs (eg, acute lysis pneumopathy)
  \item
    Note: Measured arterial pO2 can be falsely decreased in patients with hyperleukocytosis, since the WBCs in the test tube utilize oxygen. Pulse oximetry provides a more accurate assessment of O2 saturation in this setting
  \end{itemize}
\item
  \textbf{ID:} \textasciitilde80\% of patients with leukostasis are febrile, which may be due to inflammation associated with leukostasis or infection
  0 \textbf{Other:} Less common signs or symptoms include electrocardiographic signs of myocardial ischemia or right ventricular overload, worsening renal insufficiency, priapism, acute limb ischemia, or bowel infarction
\end{itemize}

\hypertarget{physical-exam-23}{%
\paragraph{Physical Exam}\label{physical-exam-23}}

Careful neurologic exam including fundoscopic exam

\hypertarget{diagnostic-studies-14}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-14}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} CBCd, tumor lysis labs (see above), coagulation panel

  \begin{itemize}
  \tightlist
  \item
    Measured arterial pO2 can be falsely decreased because WBCs in the test tube utilize oxygen. Pulse oximetry will be more accurate.
    0 \textbf{Imaging:} CXR and/or non-contrast head CT/MRI for neurologic abnormalities
  \end{itemize}
\end{itemize}

\hypertarget{treatment-75}{%
\paragraph{Treatment}\label{treatment-75}}

\begin{itemize}
\tightlist
\item
  \textbf{Supportive care:} This is the most important initial treatment

  \begin{itemize}
  \tightlist
  \item
    \textbf{Hyperhydration}
  \item
    Close monitoring for DIC (especially AML \& APML patients)
  \item
    Maintain platelets \textgreater20K given bleeding risk
  \item
    Judicious use of pRBC transfusion as this increases viscosity
  \end{itemize}
\item
  \textbf{Leukapheresis:} Variable implementation as a clear benefit for patient outcome is not established. Generally, may be considered as an option for WBC \textgreater100,000, more common in AML than ALL. - Contraindications may include hemodynamic instability (may be worsened by leukapheresis), patient unable to have central access, cardiovascular comorbidities
\item
  \textbf{Low dose-chemotherapy:} For cytoreduction purposes

  \begin{itemize}
  \tightlist
  \item
    Generally ``pre-induction'' therapy with cytarabine or hydroxyurea
  \item
    May rapidly lower WBC count and cause tumor lysis syndrome
  \end{itemize}
\end{itemize}

\hypertarget{increased-icp}{%
\subsubsection{Increased ICP}\label{increased-icp}}

\hypertarget{definition-55}{%
\paragraph{Definition}\label{definition-55}}

Normal ICP values vary w/ age but are generally 5-10 mmHg in infants and 10-15 mmHg in adolescents/adults. Symptoms generally when ICP \textgreater20 mmHg, though this can vary with age.

\hypertarget{pathogenesis-17}{%
\paragraph{Pathogenesis}\label{pathogenesis-17}}

Blockage of CSF flow, usually by compression of the third of fourth ventricle by an infratentorial tumor

\hypertarget{clinical-manifestations-27}{%
\paragraph{Clinical Manifestations}\label{clinical-manifestations-27}}

\begin{itemize}
\tightlist
\item
  \textbf{Infants:} Oersonality/behavior changes, head holding or banging, vomiting, lethargy, loss of milestones, seizures, increased head circumference, bulging fontanelle, distension of scalp veins, strabismus
\item
  \textbf{Older children:} Headache (classically in the morning and occipital), vomiting (often without nausea), diplopia, ataxia, hemiparesis, dizziness, lethargy, speech disturbances, neck stiffness and coma
\end{itemize}

\hypertarget{physical-exam-24}{%
\paragraph{Physical Exam}\label{physical-exam-24}}

\begin{itemize}
\tightlist
\item
  \textbf{Vital signs:} Classic Cushing's triad hypertension (systolic with widened pulse pressure), irregular respirations and bradycardia (late sign of increased ICP)
\item
  \textbf{Physical eam:} Complete neurologic exam with attention to mental status and cranial nerves
\item
  \textbf{Classic herniation syndromes:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Transtentorial:} Ipsilateral papillary dilation +/- contralateral hemiparesis
  \item
    \textbf{Foramen magnum:} Depressed LOC, Cushing's triad
  \end{itemize}
\end{itemize}

\hypertarget{diagnostic-studies-15}{%
\paragraph{Diagnostic Studies}\label{diagnostic-studies-15}}

\begin{itemize}
\tightlist
\item
  \textbf{Labs:} None needed. Do not obtain LP given risk of herniation!
\item
  \textbf{Imaging:} Emergent CT or MRI
\end{itemize}

\hypertarget{treatment-76}{%
\paragraph{Treatment}\label{treatment-76}}

\begin{itemize}
\tightlist
\item
  \textbf{\emph{NOTE:}} \emph{See Critical Care chapter for detailed management}
\item
  Goals are to maintain cerebral perfusion, control ICP and prevent herniation or seizures
\item
  Transfer to ICU; involve Neurosurgery
\item
  Neuroprotective measures: Elevate HOB 30 degrees, maintain normothermia \& normoglycemia, keep patient calm
\item
  3-5cc/kg bolus of 3\% hypertonic saline
\item
  0.5-1g/kg bolus of mannitol
\item
  Hyperventilation to reduce CO2 in severe cases
\item
  Intubation if concern for respiratory abnormalities
\end{itemize}

!\href{images/onc_card_1}{onc card 1}

!\href{images/onc_card_2}{onc\_card\_2}

\hypertarget{pain}{%
\section{Pain}\label{pain}}

\hypertarget{chronic-pain}{%
\subsection{Chronic Pain}\label{chronic-pain}}

\hypertarget{complex-regional-pain-syndrome-crps}{%
\subsubsection{Complex Regional Pain Syndrome (CRPS)}\label{complex-regional-pain-syndrome-crps}}

\hypertarget{management-100}{%
\paragraph{Management}\label{management-100}}

Aggressive physical therapy (desensitization is the mainstay, but can use a block to facilitate physical therapy), avoiding immobilization at all cost, cognitive behavioral therapy (CBT), medications (see below adjuncts)

\hypertarget{sickle-cell-disease}{%
\subsubsection{Sickle Cell Disease}\label{sickle-cell-disease}}

\hypertarget{management-101}{%
\paragraph{Management}\label{management-101}}

Can have \textbf{ACUTE} (acute chest, vaso occlusive episodes) and \textbf{CHRONIC} components

\begin{itemize}
\tightlist
\item
  Management of \textbf{ACUTE} episodes is \textbf{opiate} driven. See section below for common dosing strategies and delivery methods.

  \begin{itemize}
  \tightlist
  \item
    For opiate sparing in acute episodes, can add \textbf{ketamine} infusions and \textbf{regional blocks}

    \begin{itemize}
    \tightlist
    \item
      Max dose ketamine infusion is 6 mcg/kg/min, typically starts at 3 mcg/kg/min
    \item
      Side effects of ketamine infusions can be hallucinations at high doses
    \end{itemize}
  \end{itemize}
\item
  Management of \textbf{CHRONIC} episodes is driven by CBT, PT, avoidance of triggers of further acute episodes, and neuropathic pain medications to manage neuropathic pain components (such as gabapentin, duloxetine)
\end{itemize}

\hypertarget{adjunct-pain-medications-often-used-in-chronic-pain}{%
\subsubsection{Adjunct Pain Medications Often Used in Chronic Pain}\label{adjunct-pain-medications-often-used-in-chronic-pain}}

\begin{itemize}
\tightlist
\item
  Duloxetine (SSNRI directed towards neuropathic pain symptoms)
\item
  Magnesium
\item
  Lidocaine patches
\item
  Voltaren gel (NSAID gel to be used topically on area of pain)
\item
  Ketorolac
\item
  Gabapentin (neuropathic pain)
\item
  Clonidine
\item
  Baclofen (muscle relaxant)
\item
  Tizanidine (muscle relaxant)
\end{itemize}

\hypertarget{acute-pain}{%
\subsection{Acute Pain}\label{acute-pain}}

\hypertarget{post-surgical-pain}{%
\subsubsection{Post-Surgical Pain}\label{post-surgical-pain}}

\begin{itemize}
\tightlist
\item
  Opiates in form of PCA or rescue doses
\item
  Nerve blocks w/ catheters, typically for extremity surgeries:

  \begin{itemize}
  \tightlist
  \item
    Differentiate between \textbf{compressible} and \textbf{non-compressible} nerve blocks:

    \begin{itemize}
    \tightlist
    \item
      \textbf{Compressible:} Interscalene, TAP, intercostal, femoral, adductor canal, sciatic, popliteal fossa
    \item
      \textbf{Non-compressible:} Supraclavicular, retroclavicular, infraclavicular, paravertebral, lumbar plexus
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{acute-infectious-pain}{%
\subsubsection{Acute Infectious Pain}\label{acute-infectious-pain}}

\begin{itemize}
\tightlist
\item
  \textbf{Abdominal sources} (e.g.~appendicitis, acute cholecystitis): Pain is typically managed w/ combo of non-opiates (NSAIDs, acetaminophen) and opiates

  \begin{itemize}
  \tightlist
  \item
    Be wary of NSAID-induced \textbf{gastritis} and opiate-induced \textbf{constipation}
  \end{itemize}
\item
  \textbf{Soft tissue sources} (e.g.~necrotizing fasciitis, burns, cellulitis)
\end{itemize}

\hypertarget{acute-sickle-cell-pain}{%
\subsubsection{Acute Sickle Cell Pain}\label{acute-sickle-cell-pain}}

See above under Chronic Pain section

\hypertarget{cancer-pain-management}{%
\subsection{Cancer Pain Management}\label{cancer-pain-management}}

\hypertarget{patient-controlled-analgesia-pca}{%
\subsubsection{Patient-Controlled Analgesia (PCA)}\label{patient-controlled-analgesia-pca}}

NOTE: Use order sets!

\hypertarget{pca-notation}{%
\paragraph{PCA Notation}\label{pca-notation}}

\begin{itemize}
\tightlist
\item
  \textbf{PCA notation:} e.g.~morphine PCA for 15kg pt → 0.375mg/12min/0.225mg/hr/1.5mg/hr

  \begin{itemize}
  \tightlist
  \item
    This means \textbf{bolus dose} is 0.375mg, the patient or nurse can deliver it every 12 minutes maximum (\textbf{lock-out}), and the \textbf{continuous rate} is 0.225mg/hr, with a \textbf{max hourly rate} of 1.5mg/hr
  \end{itemize}
\end{itemize}

\hypertarget{pca-dosing}{%
\paragraph{PCA Dosing}\label{pca-dosing}}

\begin{itemize}
\tightlist
\item
  \textbf{Morphine PCA}

  \begin{itemize}
  \tightlist
  \item
    Standard bolus dose 0.025mg/kg (usual max 1.8mg)
  \item
    Usual lock-out of 7-12 minutes
  \item
    Usual continuous 0.015mg/kg/hr
  \item
    Max dose 1mg/hr (you don't need to have a continuous rate)
  \item
    Max hourly dose rate calculated as 0.1mg/kg
  \end{itemize}
\item
  \textbf{Hydromorphone PCA}

  \begin{itemize}
  \tightlist
  \item
    Standard bolus dosing 0.005mg/kg, usual max of 0.3mg
  \item
    Usual lock out 7-12 minutes
  \item
    Continuous 0.003mg/kg/hr (usual max 0.2mg/hr)
  \item
    Hourly dose limit 0.02mg/kg
  \end{itemize}
\item
  \textbf{Fentanyl PCA}

  \begin{itemize}
  \tightlist
  \item
    0.25mcg/kg (usual max 18mcg)
  \item
    Lock out 7-12 minutes
  \item
    Continuous dose 0.15mcg/kg/hr
  \item
    Hourly dose limit 1mcg/kg.
  \end{itemize}
\end{itemize}

\hypertarget{neuraxial-catheters-with-pump}{%
\subsubsection{Neuraxial Catheters with Pump}\label{neuraxial-catheters-with-pump}}

\hypertarget{intrathecal-vs.-epidural-catheters}{%
\paragraph{\texorpdfstring{\textbf{Intrathecal} vs.~\textbf{epidural} catheters:}{Intrathecal vs.~epidural catheters:}}\label{intrathecal-vs.-epidural-catheters}}

\begin{itemize}
\tightlist
\item
  \textbf{Intrathecal catheter:} The catheter sits beyond the pia mater, inside the same area as the spinal cord. Typically only used for end-of-life pain, often will cause a dense motor block. Narrow therapeutic index.
\item
  \textbf{Epidural catheter:} The catheter sits in the epidural space right above the dura mater. Used for post-operative pain (lumbar epidural for lower abdominal or pelvic procedures, thoracic epidural for thoracic or large abdominal procedures), as well as for cancer pain. Often able to achieve a strictly sensory block, though motor block common w/ lumbar epidurals.
\end{itemize}

\hypertarget{how-to-check-a-level}{%
\paragraph{How to check a level}\label{how-to-check-a-level}}

\begin{itemize}
\tightlist
\item
  \textbf{Ice:} Place ice on areas of different dermatomes below the block site; when the patient feels that the sensation is less cold compared to an area above the block or on the arm, you have the area of your block. Check bilaterally, as one-sided blocks can be common with epidurals.

  \begin{itemize}
  \tightlist
  \item
    Checking a level w/ ice will show you the earliest onset of a block, as temperature is blocked before pain.
  \end{itemize}
\item
  \textbf{Pinprick:} Using cocktail sword, blunt needle, or twisted up alcohol wipe wrapper, poke areas of different dermatomes below the level of the suspected block. Ask for any difference in sensation to a poke above the level of the block or on an arm.
\end{itemize}

\hypertarget{notation-for-patient--or-nurse-controlled-epidural-anesthesia}{%
\paragraph{Notation for patient- or nurse-controlled epidural anesthesia}\label{notation-for-patient--or-nurse-controlled-epidural-anesthesia}}

\begin{itemize}
\tightlist
\item
  e.g.~Bupivacaine 0.125\% running at 6/2/20/12

  \begin{itemize}
  \tightlist
  \item
    This means that the epidural is infusing 0.125\% bupivacaine at a \textbf{rate} of 6cc/hr, with a 2cc \textbf{bolus} that the patient can give themselves every 20min (also called a 20min \textbf{lock-out}), for a \textbf{total hourly dose max} of 12cc
  \end{itemize}
\end{itemize}

\hypertarget{common-neuraxial-questions-from-nursing}{%
\paragraph{Common neuraxial questions from nursing}\label{common-neuraxial-questions-from-nursing}}

\begin{itemize}
\tightlist
\item
  \textbf{Hypotension}

  \begin{itemize}
  \tightlist
  \item
    Due to blocked sympathetic activity causing vasodilation; or, if intrathecal catheter and level too high, due to inhibition of cardiac accelerator fibers and bradycardia paired with vasoplegia
  \item
    More common w/ intrathecal than epidural catheters, and more common w/ thoracic than lumbar epidurals
  \item
    \textbf{Steps to interrogate:} Pause the pump, check a level. If too high, keep the pump off. If appropriate, consider fluid bolus or decreasing rate of local anesthetic or concentration of local anesthetic.
  \end{itemize}
\item
  \textbf{Motor block}

  \begin{itemize}
  \tightlist
  \item
    Occurs more commonly w/ intrathecal catheters, or lumbar vs.~thoracic epidurals
  \item
    If occurring and not desired, call the Pain Service
  \end{itemize}
\item
  \textbf{Fluid under tegaderm covering catheter site}

  \begin{itemize}
  \tightlist
  \item
    Possibly due to catheter migration, can also be due to sweat
  \item
    \textbf{Steps to interrogate:} Check numbers on catheter to see if matches the procedure note; if the catheter has been displaced, contact the Pain Service. Also check to see if the patient still has a level, indicating a likely functioning block.
  \end{itemize}
\item
  \textbf{Catheter inadvertent removal}

  \begin{itemize}
  \tightlist
  \item
    Call post-operative Pain Service. Make note of whether patient is on anticoagulation and timing of last dose if so, they will want to know!
  \end{itemize}
\end{itemize}

\hypertarget{pediatric-advanced-care-team-pact-code-card}{%
\section{Pediatric Advanced Care Team (PACT) ``CODE CARD''}\label{pediatric-advanced-care-team-pact-code-card}}

\hypertarget{pediatric-palliative-care-ppc}{%
\subsection{Pediatric Palliative Care (PPC)}\label{pediatric-palliative-care-ppc}}

Physical, psychosocial, and spiritual support for children with life-threatening illnesses and their families. PPC focuses on comfort and quality of life, \emph{and may be provided alongside disease-directed treatment.}

\hypertarget{specialty-ppc-at-bch}{%
\subsection{Specialty PPC at BCH}\label{specialty-ppc-at-bch}}

\hypertarget{pact-teams}{%
\subsubsection{PACT Teams}\label{pact-teams}}

-\textbf{Team A:} NICU, CCS, Neurology, Metabolism, Genetics
-\textbf{Team B:} Oncology, Cardiology, Pulmonary, other solid organ transplant, Immunology
-Both staffed by an NP, social worker, fellow, and attending who provide interdisciplinary care alongside the primary care team

\hypertarget{requesting-a-pact-consult}{%
\subsubsection{Requesting a PACT Consult}\label{requesting-a-pact-consult}}

-Introduce the concept of PACT to the child and family (see below). If you are not sure how to best do this, ask PACT!
-Page PACT clinician on call; provide \textbf{reason for and urgency} of the referral, and the requesting \textbf{attending physician.}

\hypertarget{introducing-pact-to-families-sample-language}{%
\subsubsection{Introducing PACT to Families: Sample Language}\label{introducing-pact-to-families-sample-language}}

\emph{''To best meet these goals that we have been discussing, we believe it would be helpful to have PACT visit with your family. PACT is a team that works with us, and they specialize in optimizing your child's quality of life by helping to manage symptoms and by providing additional layer of support to your child and your family. They can also think with you about your child's care, and how it can best align with your goals and what is most important to you. PACT would work with your child's other teams to provide your child with the best care possible.''}

\hypertarget{primary-ppc-skills-for-all-clinicians}{%
\subsection{Primary PPC: Skills for All Clinicians}\label{primary-ppc-skills-for-all-clinicians}}

\hypertarget{promoting-child-wellbeing}{%
\subsubsection{PROMOTING CHILD WELLBEING}\label{promoting-child-wellbeing}}

\hypertarget{quality-of-life}{%
\paragraph{Quality of Life}\label{quality-of-life}}

-Integrated Therapies: massage therapy, guided imagery, Reiki, yoga, meditation
-Unit-based Child Life Specialists
-Pet Therapy: Center for Families: (617-355-6279)
-Make-A-Wish Foundation: (800)-722-WISH

\hypertarget{symptoms-non-pharmacologic-approaches}{%
\paragraph{Symptoms: Non-Pharmacologic Approaches}\label{symptoms-non-pharmacologic-approaches}}

-Limit non-essential painful procedures
-Address coincident depression and anxiety
-Fatigue: consider contributing factors (anemia, depression, drug effects), address sleep hygiene, encourage gentle exercise
-Dyspnea: consider suctioning, repositioning, loose clothing, a fan, limitation of IV fluids, breathing and relaxation exercises
-For nausea/vomiting: consider dietary modifications (bland or soft foods, adjust timing or volume of feeds), aromatherapy (peppermint, lavender), acupuncture or acupressure
\#\#\#\# Pain: Pharmacologic Approaches

\textbf{WHO Pain Ladder}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.19\columnwidth}\raggedright
Pain Level\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Drug Class\strut
\end{minipage} & \begin{minipage}[b]{0.42\columnwidth}\raggedright
Specific Agent\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.19\columnwidth}\raggedright
Step 1: mild to mod\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Non-opioid +/- adjuvant\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Acetaminophen or NSAID\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.19\columnwidth}\raggedright
Step 2: mod to severe\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Opioid +/- non-opioid +/- adjuvant\strut
\end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright
Morphine (usually the starting agent of choice)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{Standard Opioid Starting Doses and Intervals}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.12\columnwidth}\raggedright
Opioid\strut
\end{minipage} & \begin{minipage}[b]{0.26\columnwidth}\raggedright
Enteral (PO)\strut
\end{minipage} & \begin{minipage}[b]{0.54\columnwidth}\raggedright
Parenteral (IV)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Morphine\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
0.2-0.3 mg/kg (10-15 mg) Q3-4h\strut
\end{minipage} & \begin{minipage}[t]{0.54\columnwidth}\raggedright
0.1 mg/kg (5 mg) Q2-4h or 0.03 mg/kg/h (1.5 mg/h)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Oxycodone\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
0.1-0.2 mg/kg (5-10 mg) Q3-4h\strut
\end{minipage} & \begin{minipage}[t]{0.54\columnwidth}\raggedright
n/a\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Hydromorphone\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
0.04-0.08 mg/kg (2-4 mg) Q3-4h\strut
\end{minipage} & \begin{minipage}[t]{0.54\columnwidth}\raggedright
0.015-0.02 mg/kg (0.75-1 mg) Q2-4h or 0.0006 mg/kg/h (0.3 mg/h)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Fentanyl\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
n/a\strut
\end{minipage} & \begin{minipage}[t]{0.54\columnwidth}\raggedright
0.5-1 mcg/kg (25-50 mcg) Q60 min, or 0.5-1 mcg/kg/h (25-100 mcg/hr)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

**Doses in parenthesis are for children \textgreater50kg. For infants \textless6 mos, initial per-kg doses begins at 25\% of the above per-kg doses. All doses approximate; adjust according to clinical circumstances.*

\hypertarget{key-tips-prescribing-opioids}{%
\paragraph{KEY TIPS: Prescribing Opioids}\label{key-tips-prescribing-opioids}}

\begin{itemize}
\tightlist
\item
  Prescribe a bowel regimen that includes a stool softener AND laxative \emph{(``mush and push!'')}
\item
  When speaking with patients and families, use the term ``opioid'' (a medical term) rather than ``narcotic'' (a legal/regulatory term)
\item
  Reassure families that their child will not become a ``drug addict'' on the appropriate opioid regimen. Educate them on the difference between addiction and dependence
\item
  Increase opioid dose based on clinical response; the ``right dose'' is the dose that best controls pain with the fewest side effects.
\item
  Dose increases are based on a percentage of the current dose:
\item
  30\% increase for mild pain
\item
  50\% increase for moderate pain
\item
  75-100\% increase for severe pain
\item
  If discharging a patient with opioids, consider prescribing naloxone in the event opioid is misused and overdose occurs
\end{itemize}

\hypertarget{key-tips-breakthrough-pain-btp}{%
\paragraph{KEY TIPS: Breakthrough Pain (BTP)}\label{key-tips-breakthrough-pain-btp}}

\begin{itemize}
\tightlist
\item
  BTP is a transitory flare of moderate to severe pain that occurs on a background of otherwise adequately controlled pain.
\item
  BTP is different from end-of-dose failure (EDF). EDF is pain at the end of a dosing interval of an ATC analgesic.
\item
  For BTP: increase daily dose of opioid by 50-100\% of the total amount of breakthrough medication given in past 24 hrs.
\item
  Each subsequent dose of the breakthrough opioid should equal 10-15\% of the total daily opioid requirement.
\end{itemize}

\textbf{Equianalgesic Conversions}
\textbar{} Opioid \textbar{} PO (mg) \textbar{} IV/SQ (mg) \textbar{}
\textbar---------------\textbar---------\textbar---------------\textbar{}
\textbar{} Morphine \textbar{} 30 \textbar{} 10 \textbar{}
\textbar{} Oxycodone \textbar{} 20 \textbar{} n/a \textbar{}
\textbar{} Hydromorphone \textbar{} 7.5 \textbar{} 1.5 \textbar{}
\textbar{} Fentanyl \textbar{} n/a \textbar{} 0.1 (100 mcg) \textbar{}

\hypertarget{sample-opioid-calculations}{%
\paragraph{Sample Opioid Calculations}\label{sample-opioid-calculations}}

\textbf{\emph{Same Opioid, Changing the Route:}}

\emph{\textbf{Ex:} 90 mg q12hr SR morphine PO -\textgreater{} morphine IV infusion}
- Calculate 24 hr dose: 90 mg q12 * 2 = 180 mg PO/24 hrs
- Use PO to IV equianalgesic ratio: 30 mg PO = 10 mg IV
- Use ratios to calculate new dose: 180/x = 30/10; x= (180*10)/30 = 60 mg IV/24hr = 2.5 mg/hr IV infusion

\textbf{\emph{Changing the Opioid (Equianalgesic Conversion)}}
\emph{\textbf{Ex:} 90 mg q12hr SR morphine PO -\textgreater{} hydromorphone PO}
- Calculate 24 hr dose: 90 mg q12 * 2 = 180 mg PO/24 hrs
- Use equianalgesic ratio: 30 mg morphine PO = 7.5 mg hydromorphone PO
- Use ratios to calculate dose of new opioid: 180/x = 30/7.5; x = (180\emph{7.5)/30 = 45 mg hydromorphone PO/24 hr
\textbf{Reduce dose by 25-30\% to account for cross-tolerance:}
45 } 0.3 = 13.5; 45 mg-13.5mg=32 mg/24 hr (or about 5 mg q4hr)

\hypertarget{proper-use-of-naloxone}{%
\paragraph{Proper Use of Naloxone}\label{proper-use-of-naloxone}}

\begin{itemize}
\tightlist
\item
  Opioid antagonists can reverse opioid-induced respiratory depression; however, they also may reverse analgesic effects.
\item
  Naloxone should NOT be administered for a depressed RR but normal O2 saturation, or for a patient who is arousable.
\item
  In either of those cases, simply reduce the opioid dose, provide physical stimulation, and continue to monitor the patient closely.
\item
  If naloxone is needed: dilute 0.4 mg (1 ml) in 9 ml of NS, and give IV in 1-2 ml increments at 2-3 min intervals until response
\item
  If administered, be prepared for analgesia to be reversed
\end{itemize}

\hypertarget{adjuvant-agents}{%
\paragraph{Adjuvant Agents:}\label{adjuvant-agents}}

Primary purpose is typically not analgesic, yet they may relieve pain.

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.15\columnwidth}\raggedright
Adjuvants\strut
\end{minipage} & \begin{minipage}[b]{0.79\columnwidth}\raggedright
Comments\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.15\columnwidth}\raggedright
Tricyclics: \emph{Nortriptyline}\strut
\end{minipage} & \begin{minipage}[t]{0.79\columnwidth}\raggedright
May cause anticholinergic effects (amitriptyline \textgreater{} nortriptyline) constipation, dry mouth, postural hypotension. Can also prolong QT\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.15\columnwidth}\raggedright
Gabapentanoids: \emph{Gabapentin} \emph{Pregabalin}\strut
\end{minipage} & \begin{minipage}[t]{0.79\columnwidth}\raggedright
Titrate up gradually to prevent dizziness or drowsiness\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.15\columnwidth}\raggedright
α-agonist: \emph{Clonidine}\strut
\end{minipage} & \begin{minipage}[t]{0.79\columnwidth}\raggedright
Acts as an opioid sensitizer, can reduce withdrawal symptoms. May have synergistic sedative and respiratory effects with opioids\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.15\columnwidth}\raggedright
Antispasmodics: \emph{Baclofen} \emph{Diazepam}\strut
\end{minipage} & \begin{minipage}[t]{0.79\columnwidth}\raggedright
Baclofen may cause dizziness, drowsiness, constipation, confusion; rarely seizures or hallucinations Diazepam can cause drowsiness; relieves myoclonus (neurotoxicity) from opioids. synergistic sedative and respiratory effects with opioids\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.15\columnwidth}\raggedright
NSAIDS: \emph{Celecoxib}\strut
\end{minipage} & \begin{minipage}[t]{0.79\columnwidth}\raggedright
Celecoxib is a selective COX-2 inhibitor with little platelet inhibition (= less bleeding risk) than other NSAIDs\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{communicating-effectively}{%
\subsubsection{COMMUNICATING EFFECTIVELY}\label{communicating-effectively}}

\hypertarget{key-tips-language}{%
\paragraph{KEY TIPS: Language}\label{key-tips-language}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.38\columnwidth}\raggedright
Instead of Saying:\strut
\end{minipage} & \begin{minipage}[b]{0.56\columnwidth}\raggedright
Try Saying:\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.38\columnwidth}\raggedright
``Our hypoplast'' or ``CF-er''\strut
\end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright
``The child with hypoplastic left heart disease''; ``The young man living with CF''\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.38\columnwidth}\raggedright
``Your child failed the treatment plan''\strut
\end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright
``Our treatments were not successful in curing your child''\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.38\columnwidth}\raggedright
``I know how you feel'', or ``I know how difficult this situation is for you''\strut
\end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright
``I can only imagine how difficult this situation is for you''\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.38\columnwidth}\raggedright
``Do you want us to do everything''?\strut
\end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright
``What is your understanding of the decision to attempt life-sustaining interventions?''\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.38\columnwidth}\raggedright
``Are you ready to sign the Do Not Resuscitate (DNR) orders?''\strut
\end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright
Do you agree with the medical recommendation for a ``Do Not Attempt Resuscitation'' (DNAR) order for your child?\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.38\columnwidth}\raggedright
``We are going to withdraw support'' or ``We will be pulling the ventilator now''\strut
\end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright
``We will stop mechanical ventilation, but will continue to provide maximal efforts to manage your child's symptoms''\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{managing-emotion-nurse-mnemonic}{%
\paragraph{Managing Emotion (NURSE mnemonic)}\label{managing-emotion-nurse-mnemonic}}

One of the most important skills in difficult conversations. When emotion is running high, \emph{before moving forward with the conversation}, do the following:
\textbf{N}ame the emotion (``It sounds like you're really frustrated.'')
\textbf{U}nderstand the core message (``If I understand you correctly, you are worried that\ldots{}'')
\textbf{R}espect: (``I'm really impressed that you've taken care of Steven at home for so long.'')
\textbf{S}upport: (I will do my best to be sure that you have what you need.'')
\textbf{E}xplore: (``Could you say more about what you mean when you say that\ldots?'')

\hypertarget{discussing-goals-of-care}{%
\paragraph{Discussing Goals of Care}\label{discussing-goals-of-care}}

\begin{itemize}
\tightlist
\item
  Goals of care are different for everyone. The only way to understand a child/family's goals of care is to \textbf{\emph{ASK}}.
\item
  Goals of care may include: physical and psychological comfort; attending prom, graduation, or other important events; speaking; eating favorite foods; sleeping in own bed at home.
\item
  \textbf{Important questions to ask:} \emph{What do you expect in the future? What are the most important things that you are hoping for your child right now? What are you most worried about?}
\end{itemize}

\hypertarget{sharing-difficult-news}{%
\paragraph{Sharing Difficult News}\label{sharing-difficult-news}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Establish a shared agenda
\item
  Ask family about their current understanding of situation
\item
  Provide \emph{succinct} medical update
\item
  Forecast the medical possibilities; consider presenting worst, best, and most likely scenarios
\item
  As patient/family their goals and hopes in light of the information
\item
  Offer a medical recommendation based on the medical situation and the goals of care of the patient and family
\item
  Offer resources to help the family think through options (social worker, chaplaincy, Courageous Parents Network videos on the web).
\item
  Lay out the plan, including a time to meet again.
  9.Document discussion.
\end{enumerate}

\hypertarget{discussing-life-sustaining-therapies-lst}{%
\paragraph{Discussing Life-Sustaining Therapies (LST)}\label{discussing-life-sustaining-therapies-lst}}

\begin{itemize}
\tightlist
\item
  Avoid mechanical descriptions of CPR, such as ``starting the heart'' or ``putting on a breathing machine.''
\item
  Use neutral, non-judgmental language to describe options; for instance, avoid describing cardiac resuscitation in terms of broken ribs and painful electroshock.
\item
  Avoid saying, ``Do you want us to do everything?''
\item
  Many families believe CPR WILL restore their child to their baseline. It is helpful to describe it as an ATTEMPT to reverse death. Use of the word ``die'' also helps to clarify this.
\end{itemize}

\textbf{\emph{Talking About the Role of LST: Sample Language}}
\emph{We all share the hope that your child will live as long as possible. But that is usually not the only goal. We also want your child to live as well as he possibly can, and some of the treatments that we use to extend life may alter his quality of life in ways that may not be what you would wish for him. If the time comes when critical decisions need to be made, you will have more control over the situation if we all understand and agree about what is most important for you and your child. Talking about these possibilities does not mean that we are giving up -- we think of this strategy as hoping for the best, but planning for the worst. In case your child does not get better, what are you hoping for?}

\hypertarget{caring-for-a-child-facing-end-of-life}{%
\subsubsection{CARING FOR A CHILD FACING END OF LIFE}\label{caring-for-a-child-facing-end-of-life}}

\hypertarget{before-the-childs-death}{%
\paragraph{BEFORE the Child's Death:}\label{before-the-childs-death}}

\begin{itemize}
\tightlist
\item
  If there is a possibility that a child may die during your shift, introduce yourself to the child and family as soon as you arrive.
\item
  Familiarize yourself with the child's history by speaking with the child's nurse and/or other caregivers.
\item
  Involve chaplaincy, child life, and other supportive services based on family preferences.
\item
  Determine whether autopsy and organ donation have been discussed with the family. If not, address these issues with the family. If they agree, obtain informed consent.
\end{itemize}

\hypertarget{key-tips-organ-donation}{%
\paragraph{KEY TIPS: Organ Donation}\label{key-tips-organ-donation}}

\begin{itemize}
\tightlist
\item
  Donation is not limited to whole organs; families may choose to donate specific tissues, such as corneas, heart valves, pericardium, bone, veins, or skin.
\item
  Call the New England Organ Bank (NEOB) at 1-800-446-6362 to determine eligibility and discuss procurement logistics before donation is offered to the family.
\end{itemize}

\hypertarget{at-the-time-of-death}{%
\paragraph{AT the Time of Death:}\label{at-the-time-of-death}}

\begin{itemize}
\tightlist
\item
  If you did not know the child prior to death, familiarize yourself with the child's history before speaking with the family.
\item
  Consider asking the child's nurse to introduce you to the family and provide additional support.
  \textbf{\emph{In the Room:}}
\item
  Introduce yourself to the family, including your role and your relationship to the deceased child.
\item
  Express your sympathy, and allow the family to express their emotions before beginning.
\item
  Explain that you are going to examine their child. Reassure the family that they may stay if they wish.
  \textbf{\emph{Pronouncement:}}
\item
  Identify the patient by his or her hospital ID band.
\item
  Ensure that the patient does not rouse to verbal or tactile stimuli. \emph{Avoid painful and unnecessary stimuli.}
\item
  Listen and feel for the absence of heart sounds and of pulse.
\item
  Look and listen for the absence of spontaneous respirations.
\item
  Note the position of the pupils and the absence of pupillary light reflex.
\end{itemize}

\hypertarget{after-the-childs-death}{%
\paragraph{AFTER the Child's Death:}\label{after-the-childs-death}}

\begin{itemize}
\tightlist
\item
  \textbf{Autopsy and Organ Donation} (If not discussed prior)
\item
  \textbf{Notify the New England Organ Bank (NEOB)}: Massachusetts mandates that the NEOB be notified for all hospital deaths. Call \textbf{1-800-446-6362} within 1 hour of death to inform the NEOB of the family's wishes regarding donation.
\item
  \textbf{Notify Massachusetts Medical Examiner (ME)}: Call \textbf{1-617-267-6767}. This is legally mandated for all deaths of children \textless18 years, including anticipated home deaths +/- hospice.
\item
  Documentation: Date/time of death; presence of family at time of death; physical exam findings; date/time of physical assessment of patient; family and attending physician notified; family accepts/declines autopsy and/or organ donation; New England Organ Bank notified; Medical Examiner notified.
\item
  \textbf{Notify the attending physician} and other relevant clinicians
\item
  \textbf{Report of Death:} The physician who pronounced the patient must complete the ``Report of Death'' form and bring it to the Admitting Department (or the Emergency Dept during off-hours).
\item
  \textbf{Sign the Certificate:} Provide your pager number, so that you may be reached later to sign the typed Death Certificate.
\end{itemize}

\hypertarget{writing-a-condolence-note}{%
\paragraph{Writing a Condolence Note}\label{writing-a-condolence-note}}

\begin{itemize}
\tightlist
\item
  Name the deceased and acknowledge the loss.
\item
  Express your sympathy, using words that remind the bereaved that they are not alone in their feelings of sadness and loss.
\item
  Avoid statements such as \emph{I know how you feel}
\item
  Note those special qualities or characteristics that you appreciated about the person.
\item
  Recall a memory about the person, and capture what it was about the person in the story that you admired. Humor is ok -- funny stories are often appreciated.
\item
  Remind the bereaved of their personal strengths (patience, optimism, faith, resilience) that will help them to cope.
\item
  Offer help during this difficult time, and be specific about your offer. Never make an offer that you cannot fulfill.
\item
  End your letter with a phrase of sympathy: e.g.~``You are in my thoughts''
\end{itemize}

\textbf{\emph{Online PPC Resources}}
- PACT webpage on the BCH internal website
- Fast Facts: \url{https://www.mypcnow.org/fast-facts/}
- Vital Talk (communication): \url{https://www.vitaltalk.org}
- For confirming opioid calculations and conversions:GlobalRPH.com has a helpful opioid calculator

\textbf{\emph{Medical Disclaimer}}
The information contained on this reference card is provided as a supplemental resource and guide. This information is not a substitute for medical advice. Dana-Farber Cancer Institute, Inc.~does not assume any liability or responsibility for damage or injury (including death) to any person or property arising from any use of or reliance upon any information, ideas, or instructions through use of this reference card.

\emph{Created by Erica Kaye MD \& Christina Ullrich MD, MPH
Copyright 2011 Dana-Farber Cancer Institute, Inc.
Revised 30 April 2020 by Christina Ullrich, MD, MPH}

\hypertarget{primary-care}{%
\section{Primary Care}\label{primary-care}}

\hypertarget{developmental-milestones}{%
\subsection{Developmental Milestones}\label{developmental-milestones}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.02\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.18\columnwidth}\raggedright
Gross Motor\strut
\end{minipage} & \begin{minipage}[b]{0.18\columnwidth}\raggedright
Fine Motor\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Social Language/Self-Help\strut
\end{minipage} & \begin{minipage}[b]{0.26\columnwidth}\raggedright
Verbal Language\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.02\columnwidth}\raggedright
First Visit\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Reflexively moves arms and legs, Lifts head briefly when on stomach\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Keeps hands in fists\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Periods of wakefulness, Looks at parent when awake, Calms when picked up\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Cries with discomfort, Calms to parent's voice\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
2m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Lifts head and chest when on stomach, Keeps head steady when sitting\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Opens and shuts hands, Briefly brings hands together\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Smiles responsively, Makes sounds to show happiness/upset\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Makes cooing sounds\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
4m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Supports self on elbows and wrists when on stomach, Rolls from stomach to back, Pushes down on legs when feet on hard surface\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Keeps hands unfisted, Plays with fingers in midline, Grasps objects\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Laughs, Looks for caregiver when upset\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Turns to voices, Makes extended cooing sounds, Begins to babble\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
6m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Rolls from back to stomach, Sits briefly without support, Supports weight on legs while held ``standing''\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Passes toys between hands, Rakes small objects, Bangs small objects on surfaces\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Pats or smiles at own reflection, Looks when name is called, Knows familiar faces\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Babble, ``ga'', ``ma'', ``ba'', Responds to sounds by making sounds\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
9m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Sits well without support, Pulls to stand, Crawls\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Picks up food to eat, Picks up small objects with 3 fingers and thumb, Lets go of objects intentionally, Bangs objects together\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Uses basic gestures (wave bye), Looks for dropped objects, Turns when name is called, Plays Peek-a-boo, May be afraid of strangers\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Says ``Dada'' ``Mama'' nonspecifically, Copies sound that parent makes, Looks around when hearing things like ``where's your bottle?''\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
12m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Cruising, May take first independent steps, Stands without support\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Uses 2-finger pincer grip, Picks up food to eat, Drops objects in a cup, Uses index finger to point\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Looks for hidden objects, Imitates new gestures, May be shy or nervous with strangers, Cries when parents leave\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Uses ``Dada'' ``Mama'' specifically, Uses 1 other word, Makes sounds with changes in tone, Follows directions with gestures\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
15m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Squats to pick up objects, Crawls up a few steps, Runs\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Makes marks with crayon, Drops objects in and takes objects out of container\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Imitates scribbling, Points to ask for something\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Uses 3 words other than names, Follows directions without a gesture\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
18m\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Walks up steps with 2 feet per step, Sits in small chair, Carries toy while walking\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Scribbles spontaneously, Drinks from a cup, Eats with a spoon\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Engages with others for play, Helps dress and undress self, Points to pictures in book, Uses words to ask for help\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Identifies at least 2 body parts, Names at least 5 familiar objects\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
2y\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Jumps on 2 feet, Kicks a ball, Begins to run, Walks up and down stairs holding on\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Stacks objects, Turns book pages, Draws lines and circles, Uses hands to turn objects (i.e.~door)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Plays alongside other kids, Takes off some clothing, Shows defiant behavior and more independence, Copies others\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Uses 50 words, combines two to four words in short phrases, 50\% understandable speech, Follows 2-step command, Names 5 body parts, Repeats words overheard in conversation (careful!)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
3y\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Pedals a tricycle, Jumps forward, Climbs on and off chair/couch, Runs well\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Draws a circle, Draws a person with head and 1 body part, Cuts with child scissors\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Puts on coat, jacket by themselves, Eats independently, Enters bathroom and urinates independently, Imaginative play, shares\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
3 word sentences, 75\% of words are understandable to strangers, Tells a story from a book, Understands simple prepositions, Carries on conversation with 2-3 sentences\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
4y\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Skips on 1 foot, Climbs stairs, alternating feet without support\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Draws simple cross, Draws person with 3 body parts, Unbuttons/buttons, Grasps pencil with thumb and fingers\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Enters bathroom and has bowel movement independently, Brushes teeth, Dresses and undresses self, Well-developed imaginative play, Cooperates with others\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Tells stories, words 100\% intelligible to strangers, Follows simple rules in game, Draws recognizable pictures\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.02\columnwidth}\raggedright
5y/6y\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Balances on 1 foot, hops, skips\strut
\end{minipage} & \begin{minipage}[t]{0.18\columnwidth}\raggedright
Can draw person with 6 body parts, Copies squares and triangles, Prints some letters/numbers, Can tie a knot\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Follows simple directions, Dresses with minimal assistance, Aware of gender, Wants to please friends, wants to be like friends\strut
\end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright
Counts to 10, Names 4 or more colors, Speaks very clearly, Tells a simple story using full sentences\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\emph{Milestones from Bright Futures and CDC}
Early Intervention is responsible for assessing developmental delays and providing appropriate support in children birth through 2 years and 9 months. The Public School System is responsible for assessing deficits and providing appropriate support after 2.9 years. Their initial assessment is called a ``TEAM evaluation''. An IEP is developed after the TEAM evaluation.

\hypertarget{red-flags-22}{%
\subsection{Red Flags}\label{red-flags-22}}

\textbf{REGRESSION} (loss of skills) \& \textbf{PARENTAL CONCERN} are red flags at any age
- Asymmetry
- Idiosyncratic speech, disordered sequence of development
- Poor intelligibility for age
- Abnormal tone or movement patterns at any age, spasticity, hypotonia, absent DTRs
- Persistent primitive reflexes
- Lack of developmentally appropriate response to visual stimuli
- Immature play (like younger child)
- Stereotypic play; lack of pretend
- School failure (either for specific subjects like reading or math, or generalized)
- Always check vision and hearing if any concerns -- can be assessed as young as newborn
- Emotional dysregulation
- Abnormal attachment patterns (over-clingy, indiscriminate)
- Using one hand exclusively at any age
- Problems w/ feeding and/or swallowing

Age-Specific:
- Poor head control at \textbf{5 mos}
- Limited social smiling and shared enjoyment by \textbf{6 mos}
- Parent suspects hearing loss, babbling stops at \textbf{\textgreater6 mos}, lack of response to sound (check hearing!)
- Lack of transfer at \textbf{7 mos}
- Not sitting independently w/ hands-free at \textbf{8 mos}
- Not rolling back-front, not taking weight well through the legs when held at \textbf{9 mos}
- Limited gestures like pointing response to name, joint attention by \textbf{12 mos}
- No single words by \textbf{15 mos}
- Not walking by \textbf{18 mos}
- Limited social imitative play by \textbf{18 mos} (e.g.~imitating housework)
- No combos by \textbf{24 mos}
- Limited pretend play (e.g.~feeding doll) by \textbf{24 mos}
- Stutter past \textbf{3 ½ yrs} (or earlier if anxiety/mannerisms)
- Delayed self care (ADLs) at \textbf{4 yrs}
- Delayed printing at school entry
- No friends at school age

\hypertarget{newborn-visit}{%
\subsection{Newborn Visit}\label{newborn-visit}}

\hypertarget{hpi}{%
\subsubsection{HPI}\label{hpi}}

\hypertarget{birthpregnancy-history}{%
\paragraph{BIRTH/PREGNANCY HISTORY}\label{birthpregnancy-history}}

G/Ps, prenatal labs
Gestational age, birth method, GBS status, whether sepsis r/o required at birth

\hypertarget{inouts}{%
\paragraph{IN/OUTs}\label{inouts}}

Feeding (8-12/24 hrs): breastfed vs.~formula vs.~mixed- go over feeding cues (rooting, hands to mouth, fussing)
No more than around 4 hours w/o feeding.
Stool: transitioning from meconium (black, sticky) -\textgreater{} green -\textgreater{} yellow and seedy
Urine: multiple times per day (\# of voids = days of life up until DOL 6, then \textgreater6/day)

\hypertarget{sleep}{%
\paragraph{SLEEP}\label{sleep}}

Supine, in own separate space on flat, firm mattress w/o pillows, blankets, or stuffed animals.
Discuss dangers of co-sleeping
Room sharing recommended for first 6 months
Discuss harm reduction (no alcohol/smoking, consider bringing bassinet into bed) if family is going to cosleep

\hypertarget{development}{%
\paragraph{DEVELOPMENT}\label{development}}

See chart above

\hypertarget{social}{%
\paragraph{SOCIAL}\label{social}}

Who lives at home, who is involved w/ care
Screen for postpartum depression/baby blues
Assess mood of primary caretaker, can be exhausting and difficult time

\hypertarget{exam}{%
\subsubsection{Exam}\label{exam}}

Full exam including red reflex, Ortolani and Barlow maneuvers, umbilical exam
Weight check: \% of birth weight (should regain BW by 10-14 days)
Check for dysmorphic features

\hypertarget{ap}{%
\subsubsection{A/P}\label{ap}}

\hypertarget{immunizationssupplements}{%
\paragraph{Immunizations/Supplements}\label{immunizationssupplements}}

Has child received Hep B in nursery? If no, give today.
Vitamin D (400 IU daily) if exclusively breastfeeding or taking \textless32 oz of formula.

\hypertarget{anticipatory-guidance-1}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-1}}

\begin{itemize}
\tightlist
\item
  When to call: jaundice, temperature \textgreater100.4F, decreased feeding, decreased urine
\item
  Development: Impossible to spoil an infant, intermittent tummy time when supervised
\item
  Sleep: Safe sleep as above
\item
  Nutrition:

  \begin{itemize}
  \tightlist
  \item
    If formula fed, go over how to properly mix formula, should take about 3-4 oz every 3-4 hours
  \item
    If breastfeeding, go over safe storage of breastmilk
  \item
    Breastmilk rule of 4's - can be left at room temperature (77 F or colder) for 4 hours, refrigerator (40 F) for 4 days or freezer (\textless0F) for up to 6 months (best) to 12 months (acceptable)
  \end{itemize}
\item
  Safety: Rear facing car seat, avoid smoke, avoid hot liquids while holding baby, umbilical stump care
\item
  Caregiver: Normalize caregiver feelings, offer community supports, can introduce idea of planning ahead re day care but may be too early and overwhelming at this stage for some families
\end{itemize}

\hypertarget{follow-up}{%
\paragraph{Follow Up}\label{follow-up}}

\begin{itemize}
\tightlist
\item
  Determine if infant needs weight check
\item
  1 month visit
\end{itemize}

\hypertarget{month-wcc}{%
\subsection{2 Month WCC}\label{month-wcc}}

\hypertarget{hpi-1}{%
\subsubsection{HPI}\label{hpi-1}}

\hypertarget{inouts-1}{%
\paragraph{IN/OUTs}\label{inouts-1}}

Feeding (8-12/24 hrs): breastfed vs.~formula vs.~mixed
Stool: yellow and seedy
Urine: multiple times per day

\hypertarget{sleep-1}{%
\paragraph{SLEEP}\label{sleep-1}}

Supine, in crib w/o pillows, blankets, or stuffed animals.
Discuss co-sleeping

\hypertarget{development-1}{%
\paragraph{DEVELOPMENT}\label{development-1}}

See chart above

\hypertarget{social-1}{%
\paragraph{SOCIAL}\label{social-1}}

Mother's mood: screen for postpartum depression, plan for childcare, caretaker's mood and supports

\hypertarget{exam-1}{%
\subsubsection{Exam}\label{exam-1}}

Full exam including red reflex, Ortolani and Barlow maneuvers
Weight, length, height: head circumference, growing along curve

\hypertarget{ap-1}{%
\subsubsection{A/P}\label{ap-1}}

\hypertarget{immunizationssupplements-1}{%
\paragraph{Immunizations/Supplements}\label{immunizationssupplements-1}}

\begin{itemize}
\tightlist
\item
  Vaccines: Hep B \#2, Hib \#1, DTaP \#1, IPV \#1 , PCV \#1, Rotavirus \#1 (NOTE: CHPCC gives HepB \# 2 @ 1 month)
\item
  Vitamin D (400 IU daily) if exclusively breastfeeding (should start at newborn visit)
\end{itemize}

\hypertarget{anticipatory-guidance-2}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-2}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Risk of falling once learn to roll, unswaddle arms at night once rolling, develop a plan for fussy periods
\item
  Sleep: safe sleep, place in crib before fully asleep
\item
  Nutrition: If formula feeding, should take about 3-6 oz 5-8 times per day, wait to introduce solids until 4-6 months, no water or cow's milk
\item
  Safety: Rear facing car seat, avoid smoke, hand on baby at all times while on high surfaces
\item
  Caregiver: Go over caregiver supports, family planning, daycare options
\item
  Dental: Avoid putting to bed w/ bottle
\end{itemize}

\hypertarget{follow-up-1}{%
\paragraph{Follow Up}\label{follow-up-1}}

4 month CPE

\hypertarget{month-wcc-1}{%
\subsection{4 Month WCC}\label{month-wcc-1}}

\hypertarget{hpi-2}{%
\subsubsection{HPI}\label{hpi-2}}

\hypertarget{inouts-2}{%
\paragraph{IN/OUTs}\label{inouts-2}}

Feeding Q4-5 hours. breastfed vs.~formula vs.~mixed
Assess if started any purees/table foods
Stool: yellow and seedy
Urine: multiple times per day
Assess family history of severe food allergy/eczema

\hypertarget{sleep-2}{%
\paragraph{SLEEP}\label{sleep-2}}

Supine, in crib w/o pillows, blankets, or stuffed animals

\hypertarget{development-2}{%
\paragraph{DEVELOPMENT}\label{development-2}}

See chart above

\hypertarget{social-2}{%
\paragraph{SOCIAL}\label{social-2}}

Who lives at home; Mother's mood: screen for postpartum depression, childcare plans

\hypertarget{exam-2}{%
\subsubsection{Exam}\label{exam-2}}

Full exam including red reflex, Ortolani and Barlow maneuvers
Weight, length, height: head circumference, growing along curve

\hypertarget{ap-2}{%
\subsubsection{A/P}\label{ap-2}}

\hypertarget{vaccinessupplements}{%
\paragraph{Vaccines/Supplements}\label{vaccinessupplements}}

Vaccines: Hib \#2, DTaP \#2, IPV \#2, PCV \#2, Rotavirus \#2
Poly-Vi-Sol + IRON if \textgreater{} 50\% breastfed or taking \textless32 oz formula per day

\hypertarget{anticipatory-guidance-3}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-3}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Provide safe opportunities to explore, continue tummy time, calming strategies for fussy periods, unswaddle arms at night once rolling, begin to learn baby's temperament
\item
  Sleep: Place in crib before completely asleep, back to sleep, decrease overnight feeds
\item
  Nutrition: If formula feeding should take about 4-6 oz 4-6 times per day, introduce solids (1 at a time), introduce peanut (peanut butter in baby oatmeal is good option), discuss dietary sources of iron (iron fortified cereal, pureed meat, dark leafy greens), discuss choking hazards
\item
  Safety: Start baby proofing, keep small objects away from baby, keep one hand on baby, rear facing car seat
\item
  Caregiver: Go over caregiver supports, family planning, daycare options
\item
  Dental: Avoid putting to bed with bottle
\end{itemize}

\hypertarget{follow-up-2}{%
\paragraph{Follow Up}\label{follow-up-2}}

6 month CPE

\hypertarget{month-wcc-2}{%
\subsection{6 Month WCC}\label{month-wcc-2}}

\hypertarget{hpi-3}{%
\subsubsection{HPI}\label{hpi-3}}

\hypertarget{inouts-3}{%
\paragraph{IN/OUTs}\label{inouts-3}}

Feeding Q4-5 Hours, breastfed vs.~formula vs.~mixed
Ask if started solids (if so, stool might be less frequent, firm/hard, constipation)
Stool: yellow and seedy
Urine: multiple times per day

\hypertarget{sleep-3}{%
\paragraph{SLEEP}\label{sleep-3}}

Supine, in crib w/o pillows, blankets, or stuffed animals

\hypertarget{development-3}{%
\paragraph{DEVELOPMENT}\label{development-3}}

See chart above

\hypertarget{social-3}{%
\paragraph{SOCIAL}\label{social-3}}

Who lives at home; Mother's mood: screen for postpartum depression, childcare plans

\hypertarget{exam-3}{%
\subsubsection{Exam}\label{exam-3}}

Full exam including red reflex, Ortolani and Barlow maneuvers
Teeth?
Weight, length, height: growing along curve

\hypertarget{ap-3}{%
\subsubsection{A/P}\label{ap-3}}

\hypertarget{vaccinessupplements-1}{%
\paragraph{Vaccines/Supplements}\label{vaccinessupplements-1}}

Vaccines: Hep B \#3, Hib \#3, DTaP \#3, IPV \#3 , PCV \#3, Rotavirus \#3
Eligible for flu vaccine (need two to complete series, separated by 1 month)
Continue Poly-Vi-Sol + IRON if \textgreater{} 50\% breastfed or taking \textless32 oz formula per day

\hypertarget{anticipatory-guidance-4}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-4}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Engage in reciprocal play, read to baby
\item
  Sleep: Safe sleep, put baby to sleep awake but drowsy, try to eliminate night time feeds
\item
  Nutrition: If formula feeding, should take about 6-8 oz 3-5 times per day, continue to work on solid food introduction (1 at a time), ensure baby has had peanut, go over dietary sources of iron (iron fortified cereal, pureed meat, dark leafy greens), discuss choking hazards, delay cow's milk until1 year old, okay to offer small amounts of water
\item
  Safety: Baby proof home, keep small objects away, give poison control number (1-800-222-1222), rear facing car seat, avoid baby walkers, don't leave baby alone in the tub
\item
  Caregiver: Use trusted child care providers
\item
  Dental: Brushing/wiping down teeth to build habits
\end{itemize}

\hypertarget{follow-up-3}{%
\paragraph{Follow Up}\label{follow-up-3}}

9 month CPE

\hypertarget{month-wcc-3}{%
\subsection{9 Month WCC}\label{month-wcc-3}}

\hypertarget{hpi-4}{%
\subsubsection{HPI}\label{hpi-4}}

\hypertarget{inouts-4}{%
\paragraph{IN/OUTs}\label{inouts-4}}

Feeding Q4-5 hours. breastfed vs.~formula vs.~mixed
Solids, no overnight feeds
Stool: might be less frequent since starting solids, ask if stool if firm/hard and if pt having abdominal distention (these are signs of constipation)
Urine: multiple times per day

\hypertarget{development-4}{%
\paragraph{DEVELOPMENT}\label{development-4}}

See chart above

\hypertarget{exam-4}{%
\subsubsection{Exam}\label{exam-4}}

Full exam
Weight, length, height: growing along curve (head circum)

\hypertarget{ap-4}{%
\subsubsection{A/P}\label{ap-4}}

\hypertarget{vaccinessupplementsscreenings}{%
\paragraph{Vaccines/Supplements/Screenings}\label{vaccinessupplementsscreenings}}

Vaccines: check that have received 3 of: Hep B, Hib, DTaP, IPV, PCV, Rotavirus
Eligible for flu vaccine (needs 2 to complete series)
CBC and lead screening
Continue Poly-Vi-Sol + IRON if \textgreater{} 50\% breastfed or taking \textless32 oz formula per day

\hypertarget{anticipatory-guidance-5}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-5}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Develop daily routine, allow for safe exploration, discuss separation anxiety, read/talk/sing together, avoid screens if possible, focus on positive reinforcement/redirection for discipline, start to learn baby's temperament
\item
  Sleep: Eliminate overnight feeds, develop bedtime routine
\item
  Nutrition: If formula feeding should take about 7-8 oz 3-4 times per day, increase table food to 3 meals and 2-3 snacks, start to introduce more textures, avoid juice, avoid cow's milk until 1, encourage starting to wean from bottle to cup, discuss choking hazards
\item
  Safety: Rear facing car seat until age 2 or highest weight allowed by manufacturer , keep small objects away, avoid baby walkers, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs
\item
  Dental: Brush teeth, avoid bottle in bed
\end{itemize}

\hypertarget{follow-up-4}{%
\paragraph{Follow Up}\label{follow-up-4}}

12 month CPE , 1st dental visit at 1 year old or w/i 6 months of 1st tooth eruption

\hypertarget{month-wcc-4}{%
\subsection{12 Month WCC}\label{month-wcc-4}}

\hypertarget{hpi-5}{%
\subsubsection{HPI}\label{hpi-5}}

\hypertarget{inouts-5}{%
\paragraph{IN/OUTs}\label{inouts-5}}

Goals to have social meals, eat w/ family if feasible, 3 meals and 2-3 snacks spaced evenly.
Transition from formula to whole milk
Solids, no overnight feeds
Stool: might be less frequent since starting solids, ask if stool if firm/hard and if pt having abdominal distention (these are signs of constipation)
Urine: multiple times per day

\hypertarget{development-5}{%
\paragraph{DEVELOPMENT}\label{development-5}}

See chart above

\hypertarget{exam-5}{%
\subsubsection{Exam}\label{exam-5}}

Full exam - ensure testes are descended bilaterally
Weight, length, height: growing along curve (head circum)

\hypertarget{ap-5}{%
\subsubsection{A/P}\label{ap-5}}

\hypertarget{vaccinessupplementsscreenings-1}{%
\paragraph{Vaccines/Supplements/Screenings}\label{vaccinessupplementsscreenings-1}}

Vaccines: PCV\#4, MMR\#1, VZV\#1
Eligible for flu vaccine (needs 2 to complete series)
CBC/lead screening if not done at 9 months
Ensure ferrous sulfate started if evidence of iron deficiency anemia

\hypertarget{anticipatory-guidance-6}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-6}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Develop daily routine, focus on positive reinforcement/redirection for discipline, limit screen time, read/sing/talk together, options for developmentally appropriate play
\item
  Sleep: Continue 1 nap a day, nightly bedtime routine, try to introduce a comfort object (blanket, stuffed animal) to help with any nighttime awakenings
\item
  Nutrition: Should be transitioned to cow's milk (limit 16-24 oz per day), transition to cup from bottle, 3 meals with 2-3 snacks per day, trust a toddler to know how much to eat, continue to introduce textures, discuss choking hazards
\item
  Safety: Rear facing car seat until age 2 or highest weight allowed by manufacturer , childproof home, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs, discuss gun safety
\item
  Dental: Make first dental appointment, brush teeth twice a day with plain water, no bottle in bed
\end{itemize}

\hypertarget{follow-up-5}{%
\paragraph{Follow Up}\label{follow-up-5}}

15 month CPE, 1st dental visit at 1 year old or w/i 6 months of 1st tooth eruption

\hypertarget{month-wcc-5}{%
\subsection{15 Month WCC}\label{month-wcc-5}}

\hypertarget{hpi-6}{%
\subsubsection{HPI}\label{hpi-6}}

\hypertarget{inouts-6}{%
\paragraph{IN/OUTs}\label{inouts-6}}

Eat w/ family, 3 meals and 2-3 snacks spaced evenly.
Drinks whole milk
Solids, no overnight feeds
Stool: might be less frequent since starting solids, ask if stool if firm/hard and if pt having abdominal distention (these are signs of constipation)
Urine: multiple times per day

\hypertarget{development-6}{%
\paragraph{DEVELOPMENT}\label{development-6}}

See chart above

\hypertarget{exam-6}{%
\subsubsection{Exam}\label{exam-6}}

Full exam including red reflexes and dental exam
Weight, length, height: growing along curve (head circum)

\hypertarget{ap-6}{%
\subsubsection{A/P}\label{ap-6}}

\hypertarget{vaccines}{%
\paragraph{Vaccines}\label{vaccines}}

HepA\#1, DTap\#4, Hib\#4, flu if hasn't had

\hypertarget{anticipatory-guidance-7}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-7}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Try to allow child to choose between 2 options, stranger anxiety is normal at this age, read/sing/talk together, focus on positive reinforcement/redirection for discipline, limit screen time
\item
  Sleep: Maintain consistent bedtime routine, try to introduce a comfort object (blanket, stuffed animal) to help with any nighttime awakenings, should still take 1 daily nap
\item
  Nutrition: Should be transitioned to cow's milk (limit 16-24 oz per day), fully transition to cups from bottles, 3 meals with 2-3 snacks per day, trust a toddler to know how much to eat, continue to introduce textures, discuss choking hazards
\item
  Safety: Rear facing car seat until age 2 or highest weight allowed by manufacturer , childproof home, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs, discuss gun safety
\item
  Dental: Ensure they have had first dental visit, twice daily brushing, no bottle in bed
\end{itemize}

\hypertarget{follow-up-6}{%
\paragraph{Follow up}\label{follow-up-6}}

18 month CPE, 1st dental visit at 1 year old or w/i 6 months of 1st tooth eruption

\hypertarget{month-wcc-6}{%
\subsection{18 Month WCC}\label{month-wcc-6}}

\hypertarget{hpi-7}{%
\subsubsection{HPI}\label{hpi-7}}

\hypertarget{inouts-7}{%
\paragraph{IN/OUTs}\label{inouts-7}}

Eat w/ family, 3 meals and 2-3 snacks spaced evenly. Drinks whole milk
Starts developing preferences, important to introduce healthy foods multiple times
Stool: might be less frequent since starting solids, ask if stool if firm/hard and if pt having abdominal distention (these are signs of constipation)
Urine: multiple times per day

\hypertarget{development-7}{%
\paragraph{DEVELOPMENT}\label{development-7}}

See chart above

\hypertarget{exam-7}{%
\subsubsection{Exam}\label{exam-7}}

Full exam including red reflexes and dental exam
Weight, length, height: growing along curve (head circum)

\hypertarget{ap-7}{%
\subsubsection{A/P}\label{ap-7}}

\hypertarget{vaccinesscreenings}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings}}

Vaccines: Catchup and flu
MCHAT for Autism

\hypertarget{anticipatory-guidance-8}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-8}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Reinforce limits and appropriate behavior, focus on positive praise, allow child to choose between 2 options when possible, limit screen time, talk/read frequently with your child in simple words to help with language
\item
  Sleep: Maintain consistent bedtime routine, try to introduce a comfort object (blanket, stuffed animal) to help with any nighttime awakenings, should still take 1 daily nap
\item
  Nutrition: Ensure no more than 16-24 oz cow's milk daily, ensure no more bottle, trust a toddler to know when they are full, try to have family meal times, often have to offer a new food several times
\item
  Safety: Rear facing car seat until age 2 or highest weight allowed by manufacturer , childproof home, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs, discuss gun safety, install stair/window gates now that child is walking/climbing
\item
  Dental: Ensure they have had first dental visit, twice daily brushing, no bottle in bed
\end{itemize}

\hypertarget{follow-up-7}{%
\paragraph{Follow up}\label{follow-up-7}}

2 year CPE, 1st dental visit at 1 year old or w/i 6 months of 1st tooth eruption

\hypertarget{year-old-wcc}{%
\subsection{2 Year Old WCC}\label{year-old-wcc}}

\hypertarget{hpi-8}{%
\subsubsection{HPI}\label{hpi-8}}

\hypertarget{inouts-8}{%
\paragraph{IN/OUTs}\label{inouts-8}}

Eat w/ family, 3 meals and 2-3 snacks spaced evenly. Transition to 1-2\% milk.
Starts developing preferences, important to introduce healthy foods multiple times
Beginning of awareness of urges to urinate and stool, discomfort in diaper, interested in toileting

\hypertarget{development-8}{%
\paragraph{DEVELOPMENT}\label{development-8}}

See chart above

\hypertarget{exam-8}{%
\subsubsection{Exam}\label{exam-8}}

Full exam
Weight, height: growing along curve (head circum)
Observe coordination, language (expressive and receptive), socialization

\hypertarget{ap-8}{%
\subsubsection{A/P}\label{ap-8}}

\hypertarget{vaccinesscreenings-1}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings-1}}

Vaccines: HepA\#2 and flu
CBC and lead
MCHAT for autism screening

\hypertarget{anticipatory-guidance-9}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-9}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Help child recognize emotions, encourage play with other children, start looking for signs of toilet training readiness, limit screen time to 1-2 hr/day, establish a routine and stick to it, clear/consistent limits and a lot of positive praise, read together daily, can start thinking about preschool enrollment around 2.5
\item
  Sleep: Maintain consistent bedtime routine, try to introduce a comfort object (blanket, stuffed animal) to help with any nighttime awakenings, if awakening at night, provide quick reassurance and return to bed
\item
  Nutrition: Ensure no more than 16-24 oz cow's milk daily, ensure no more bottle, trust a toddler to know when they are full, try to have family meal times, often have to offer a new food several times
\item
  Safety: Rear facing car seat until age 2 or highest weight allowed by manufacturer, childproof home, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs, discuss gun safety, install stair/window gates now that child is walking/climbing, wear helmets on bikes/scooters, teach street safety
\item
  Dental: Brush teeth twice daily
\end{itemize}

\hypertarget{follow-up-8}{%
\paragraph{Follow up}\label{follow-up-8}}

2.5-3 year CPE, 1st dental visit at 1 year old or w/i 6 months of 1st tooth eruption

\hypertarget{year-old-wcc-1}{%
\subsection{3 Year Old WCC}\label{year-old-wcc-1}}

\hypertarget{hpi-9}{%
\subsubsection{HPI}\label{hpi-9}}

\hypertarget{inouts-9}{%
\paragraph{IN/OUTs}\label{inouts-9}}

Eat w/ family, 3 meals and 2-3 snacks spaced evenly. 1-2\% milk.
Starts developing preferences, important to introduce healthy foods multiple times
Beginning of awareness of urges to urinate and stool, discomfort in diaper, interested in toileting

\hypertarget{development-9}{%
\paragraph{DEVELOPMENT}\label{development-9}}

See chart above

\hypertarget{exam-9}{%
\subsubsection{Exam}\label{exam-9}}

Full exam
Weight, height: growing along curve
Observe language and socialization

\hypertarget{ap-9}{%
\subsubsection{A/P}\label{ap-9}}

\hypertarget{vaccinesscreenings-2}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings-2}}

Vaccines: MMRV and flu
CBC and lead
Begin BP screening

\hypertarget{anticipatory-guidance-10}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-10}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Encourage child to talk about feelings/experiences, encourage age appropriate imaginative/interactive play, continue to read together and allow child to ``tell'' the story, limit screen time to 1-2 hrs/day
\item
  Sleep: Maintain consistent bedtime routine, try to introduce a comfort object (blanket, stuffed animal) to help with any nighttime awakenings, if awakening at night, provide quick reassurance and return to bed
\item
  Nutrition: Ensure no more than 16-24 oz cow's milk daily, trust a toddler to know when they are full, try to have family meal times, often have to offer a new food several times, limit juice
\item
  Safety: Forward facing car seat, switch to booster when child is at the highest weight allowed by carseat, teach street safety, discuss gun safety, wear helmets on bikes/scooters, can discuss protective factors of family/child resilience, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs
\item
  Dental: Brush teeth twice daily
\end{itemize}

\hypertarget{follow-up-9}{%
\paragraph{Follow up}\label{follow-up-9}}

yearly CPE, yearly dental visit

\hypertarget{year-old-wcc-2}{%
\subsection{4 Year Old WCC}\label{year-old-wcc-2}}

\hypertarget{hpi-10}{%
\subsubsection{HPI}\label{hpi-10}}

\hypertarget{inouts-10}{%
\paragraph{IN/OUTs}\label{inouts-10}}

Eat w/ family, 3 meals and 2-3 snacks spaced evenly. 1-2\% milk.
Starts developing preferences, important to introduce healthy foods multiple times
Should be toilet trained

\hypertarget{development-10}{%
\paragraph{DEVELOPMENT}\label{development-10}}

See chart above

\hypertarget{exam-10}{%
\subsubsection{Exam}\label{exam-10}}

Full exam
Weight, height: growing along curve
Observe language and socialization

\hypertarget{ap-10}{%
\subsubsection{A/P}\label{ap-10}}

\hypertarget{vaccinesscreenings-3}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings-3}}

Vaccines: DTAP, IPV and flu
CBC and lead
Hearing and vision screening

\hypertarget{anticipatory-guidance-11}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-11}}

\begin{itemize}
\tightlist
\item
  When to call: Temperature, decreased feeding, decreased wakefulness
\item
  Development: Encourage child to talk about feelings/experiences, make opportunities for daily play, continue to read together and allow child to ``tell'' the story, limit screen time to 1-2 hrs/day, ask about plans for kindergarten
\item
  Sleep: Maintain consistent bedtime routine, try to introduce a comfort object (blanket, stuffed animal) to help with any nighttime awakenings, if awakening at night, provide quick reassurance and return to bed, might eliminate daytime naps
\item
  Nutrition: Ensure no more than 16-24 oz cow's milk daily, try to have family meal times, limit juice
\item
  Safety: Forward facing car seat, switch to booster when child is at the highest weight allowed by carseat, teach street safety, discuss gun safety, wear helmets on bikes/scooters, can discuss protective factors of family/child resilience, poison control number (1-800-222-1222), be within arm's reach near water/pools/bathtubs, discuss rules for safety with adults (no secrets, safe touching)
\item
  Dental: Brush teeth twice daily w/ pea-sized amount of toothpaste
\end{itemize}

\hypertarget{follow-up-10}{%
\paragraph{Follow up}\label{follow-up-10}}

yearly CPE, yearly dental visit

\hypertarget{school-age-5-10}{%
\subsection{School Age (\textasciitilde5-10)}\label{school-age-5-10}}

\hypertarget{hpi-11}{%
\subsubsection{HPI}\label{hpi-11}}

\hypertarget{inouts-11}{%
\paragraph{IN/OUTs}\label{inouts-11}}

Emphasize healthy eating and continue to introduce healthy foods even if child does not like. Limit calorie containing beverages.
Typically toilet training; screen for enuresis/encopresis

\hypertarget{development-11}{%
\paragraph{DEVELOPMENT}\label{development-11}}

Assess school readiness (language understanding and fluency, communication of feelings). Provide opportunities for socialization and structured learning experiences like early childhood programs or pre-school.
School readiness includes SDH, think about organizations that could help your family navigate school system, particularly if there are any special needs

\hypertarget{exam-11}{%
\subsubsection{Exam}\label{exam-11}}

Full exam including back exam for scoliosis
Weight, height: growing along curve

\hypertarget{ap-11}{%
\subsubsection{A/P}\label{ap-11}}

\hypertarget{vaccinesscreenings-4}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings-4}}

9y Vaccines: HPV and flu (second HPV in 6mo or at next WCC visit)
BP screening yearly
Hearing and vision screening at 5y
Obesity screening
LIpid screening once between 9-11

\hypertarget{anticipatory-guidance-12}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-12}}

\begin{itemize}
\tightlist
\item
  Discuss 5-2-1-0 rule for nutrition: 5 servings of fruits/veggies, 2 hours or less of screen time daily, 1 hour of physical activity and 0 sugary beverages
\item
  Safety: emphasize accident prevention including drowning prevention and water safety/firearm safety, teach child how to be safe with other adults (safe touching, no secrets), always wear a seatbelt, always wear helmets on bikes/scooters, discuss street safety
\item
  Address SDH and protective factors of family/child resilience
\end{itemize}

\hypertarget{follow-up-11}{%
\paragraph{Follow up}\label{follow-up-11}}

Yearly CPE, twice yearly dental visit

\hypertarget{middle-school-11-13}{%
\subsection{Middle School (\textasciitilde11-13)}\label{middle-school-11-13}}

\hypertarget{hpi-12}{%
\subsubsection{HPI}\label{hpi-12}}

\hypertarget{inouts-12}{%
\paragraph{IN/OUTs}\label{inouts-12}}

Emphasize healthy eating and continue to introduce healthy foods even if child does not like. Limit calorie containing beverages. Allow child to choose between healthy options and be involved in food preparation.

\hypertarget{development-12}{%
\paragraph{DEVELOPMENT}\label{development-12}}

Evaluate for school challenges. Discuss bullying, peer group, after school activities.

\hypertarget{exam-12}{%
\subsubsection{Exam}\label{exam-12}}

Full exam
Weight, height: growing along curve

\hypertarget{ap-12}{%
\subsubsection{A/P}\label{ap-12}}

\hypertarget{vaccinesscreenings-5}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings-5}}

11y Vaccines: TDap\#1, MCV\#1 and flu
BP screening
Lipid screening once between 9-11
Obesity screening

\hypertarget{anticipatory-guidance-13}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-13}}

\begin{itemize}
\tightlist
\item
  Talk to child alone or discuss that this will happen at next visit.
\item
  Discuss 5-2-1-0 rule for nutrition: 5 servings of fruits/veggies, 2 hours or less of screen time daily, 1 hour of physical activity and 0 sugary beverages
\item
  Discuss puberty and sexuality and gender identity.
\item
  Discuss drugs, tobacco products, and alcohol
\item
  Discuss mental health, mood, and how to seek help
\item
  Firearm and fire safety.
\item
  Always wear seatbelt and helmet
\item
  Consistent limit setting and encourage positive behaviors
\item
  Address SDH and protective factors of family/child resilience
\end{itemize}

\hypertarget{follow-up-12}{%
\paragraph{Follow up}\label{follow-up-12}}

Yearly CPE, Twice yearly dental visit

\hypertarget{adolescence-13-18}{%
\subsection{Adolescence (\textasciitilde13-18)}\label{adolescence-13-18}}

\hypertarget{hpi-13}{%
\subsubsection{HPI}\label{hpi-13}}

\hypertarget{inouts-13}{%
\paragraph{IN/OUTs}\label{inouts-13}}

Emphasize healthy eating and healthy choices. Discuss what child purchases and chooses for his or herself.

\hypertarget{development-13}{%
\paragraph{DEVELOPMENT}\label{development-13}}

Evaluate for school challenges. Discuss bullying, peer group, after school activities. Discuss college preparation and resources for college assistance.

\hypertarget{exam-13}{%
\subsubsection{Exam}\label{exam-13}}

Full exam
Weight, height: growing along curve

\hypertarget{ap-13}{%
\subsubsection{A/P}\label{ap-13}}

\hypertarget{vaccinesscreenings-6}{%
\paragraph{Vaccines/Screenings}\label{vaccinesscreenings-6}}

16y Vaccines: MCV\#2 and flu
BP screening
Obesity screening
Yearly GC/CT in sexually active females

\hypertarget{anticipatory-guidance-14}{%
\paragraph{Anticipatory Guidance}\label{anticipatory-guidance-14}}

\begin{itemize}
\tightlist
\item
  Talk to child alone
\item
  Discuss 5-2-1-0 rule for nutrition: 5 servings of fruits/veggies, 2 hours or less of screen time daily, 1 hour of physical activity and 0 sugary beverages
\item
  Assess satisfaction with current weight and risk factors for eating disorders
\item
  Continue to discuss sexuality and gender identity. Discuss safe sexual practices.
\item
  Discuss drugs, tobacco products, and alcohol.
\item
  Discuss mental health, mood, and how to seek help. Assess for suicide risk.
\item
  Firearm safety
\item
  Consistent limit setting and encourage positive behaviors
  = Always wear seatbelt and helmet
\item
  Address SDH and protective factors of family/child resilience
\end{itemize}

\hypertarget{follow-up-13}{%
\paragraph{Follow up}\label{follow-up-13}}

Yearly CPE, Twice yearly dental visit

\hypertarget{vaccine-schedule-birth-to-18-years}{%
\subsection{Vaccine Schedule (Birth to 18 years)}\label{vaccine-schedule-birth-to-18-years}}

\begin{figure}
\centering
\includegraphics{images/vaccine_schedule.png}
\caption{vaccine\_schedule\_birth\_to\_18}
\end{figure}

Recommended Child and Adolescent Immunization Schedule by Medical Indication:
\url{https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf}

\hypertarget{chpcc-vaccine-schedule}{%
\subsection{CHPCC Vaccine Schedule}\label{chpcc-vaccine-schedule}}

\begin{figure}
\centering
\includegraphics{images/CHPCC_vaccine_schedule.jpg}
\caption{CHPCC\_vaccine\_schedule}
\end{figure}

\begin{itemize}
\tightlist
\item
  PENTACEL = HiB + DTaP + IPV. PEDIARIX = HepB + DTap + IPV. KINRIX = DTaP + IPV
  ** MMR + VZV (separate) given @ 12m, combined MMRV @ 3 y/o
  \textbf{\emph{Children 6m - 9y who have never had flu vaccine require 2 doses, 4 weeks apart.
  }}*If HPV course started before 15th birthday, only need two doses. Each dose should be 6-12m apart.
\end{itemize}

\hypertarget{chpcc-screening-schedule}{%
\subsection{CHPCC Screening Schedule}\label{chpcc-screening-schedule}}

\begin{figure}
\centering
\includegraphics{images/CHPCC_screening_schedule.png}
\caption{CHPCC\_screening\_schedule}
\end{figure}

\hypertarget{bmc-clinic-screening-questionnaire-schedule}{%
\subsection{BMC Clinic Screening Questionnaire Schedule}\label{bmc-clinic-screening-questionnaire-schedule}}

\begin{figure}
\centering
\includegraphics{images/Primary_care_BMC_clinic_screening.png}
\caption{BMC\_clinic\_screening}
\end{figure}

\hypertarget{autism-management-in-primary-care-clinic-chop-ebg}{%
\subsection{Autism Management in Primary Care Clinic (**CHOP EBG)}\label{autism-management-in-primary-care-clinic-chop-ebg}}

\hypertarget{who-to-screen}{%
\subsubsection{Who to Screen}\label{who-to-screen}}

All children at 18 mo and 24 or 30 mo
Any child over 12 mo with concerns
Risk factors for ASD: sibling w/ ASD, unusual social responses, genetic disorder

\hypertarget{how-to-screen}{%
\subsubsection{How to Screen}\label{how-to-screen}}

PEDS questionnaire @ every visit
Do you have any concerns about your child's development or behavior?''
MCHAT-R or MCHAT-R/F (modified checklist for autism in toddlers) @ 18mo, 24mo

\hypertarget{developmental-red-flags}{%
\subsubsection{Developmental Red Flags}\label{developmental-red-flags}}

Diminished, atypical, or no babbling by 12 months
Diminished, atypical, or no gesturing (e.g., pointing, waving bye-bye) by 12 months
Lack of response to name by 12 months
No single words by 16 months
Diminished, atypical, or no two-word spontaneous phrases (excluding echolalia or repetitive speech) by 24 months
Loss of any language or social skill at any age
Lack of joint attention

\hypertarget{positive-screening---what-now}{%
\subsubsection{Positive screening - what now?}\label{positive-screening---what-now}}

Formal audiology testing
EI referral (\textless5 years old), EI services end at 2 years and 9 months
DBP or ASK clinic referral for all
Other specialty referrals as needed

\hypertarget{follow-up-14}{%
\subsubsection{Follow up}\label{follow-up-14}}

1 month after positive screening w/ primary provider for continuity
Ensure EI referral was placed, answer family questions, make sure school is involved for children \textgreater{} 2.9 years

\hypertarget{adhd}{%
\subsection{ADHD}\label{adhd}}

\hypertarget{ebgs}{%
\subsubsection{EBGs}\label{ebgs}}

ADHD, adolescents; ADHD, pre-school and school-age

\hypertarget{adhd-definition}{%
\subsubsection{ADHD Definition}\label{adhd-definition}}

Persistent and pervasive inattention, hyperactivity, and/or impulsivity affecting cognitive, academic, behavioral, emotional, and social functioning in more than one setting.

\hypertarget{how-to-screen-1}{%
\subsubsection{How to Screen}\label{how-to-screen-1}}

PSC-17, attention score \textgreater/= 7 should prompt further assessment for ADHD
Age \textgreater/= 4 years: Vanderbilt Assessment Scales (Diagnostic) (print from internet)
- To be filled out by parent and teacher
- Obtain detailed information from teacher, including report cards, IEP

\hypertarget{common-coexisting-disorders}{%
\subsubsection{Common Coexisting Disorders}\label{common-coexisting-disorders}}

Learning disabilities
Tic disorders
Anxiety
Depression
OCD
ODD
Substance abuse

\hypertarget{additional-evaluation-prn}{%
\subsubsection{Additional Evaluation PRN}\label{additional-evaluation-prn}}

\begin{itemize}
\tightlist
\item
  PT/OT for motor deficits
\item
  Speech/language eval if needed
\item
  Labs/imaging if risk factors for alternate organic diagnosis:

  \begin{itemize}
  \tightlist
  \item
    Blood lead levels, TSH, neuroimaging, EEG
  \end{itemize}
\end{itemize}

\hypertarget{considerations-prior-to-initiating-pharmacotherapy}{%
\subsubsection{Considerations Prior to Initiating Pharmacotherapy}\label{considerations-prior-to-initiating-pharmacotherapy}}

\begin{itemize}
\tightlist
\item
  Age: If \textless6, start with short acting and ensure they are also in behavioral therapy
\item
  Make sure to document baseline height, weight, BP, HR and allergies
\item
  Make sure to ask about personal hx of substance use, can consider nonstimulant or vyvanse (prodrug, thus lower abuse potential) if hx of SUD
\item
  Take a thorough history including personal hx of cardiac disease, epilepsy, tics or comorbid psychiatric conditions and family hx of cardiac disease or sudden cardiac death

  \begin{itemize}
  \tightlist
  \item
    If any concerning cardiac personal or family hx: obtain ekg and consider discussion with cardiology prior to starting stimulant medications
  \end{itemize}
\item
  Consider subspecialty consultation if age \textless6, significant psychiatric comorbidities, cardiac concerns, hx of epilepsy or tourette syndrome
  *See medication chart below for more information about common ADHD medications
\end{itemize}

\hypertarget{follow-up-15}{%
\subsubsection{Follow Up}\label{follow-up-15}}

See patient for dose titration follow up every 1-2 weeks
- Uptitrate dose until symptom remission, max FDA approved dose or patient experience treatment limiting side effects
- If patient is experiencing significant side effects or not having symptom remission can switch drug class (ie methylphenidate to amphetamine)
- If patient is well controlled in the AM and experiencing relapse of symptoms in afternoon, can consider adding in afternoon short acting medication
- Make sure to document height, weight, BP and HR at each follow up visit
Repeat vanderbilt forms once patient at stable dose of medication
- All children with ADHD qualify for a 504 - have provide a diagnosis letter to school
See patient in clinic every 3-6 months once at stable dose of medication with tolerable side effects

\hypertarget{general-prescribing-principles}{%
\subsubsection{General Prescribing Principles}\label{general-prescribing-principles}}

\begin{itemize}
\tightlist
\item
  In children 6 years and older, long-acting formulations are first line (improved compliance, lower abuse potential
\item
  In children \textless6 years, short-acting formulations are first line. In this age group, medication should always be used in conjunction with therapy.
\item
  Increase dose until either 1) symptoms are in remission, 2) patient encounters dose-limiting side effects, or 3) maximum daily dose is reached
\item
  Before switching medication class 1) maximize dose, 2) optimize dosing schedule, and 3) manage side effects
\end{itemize}

\hypertarget{stimulants}{%
\subsubsection{Stimulants}\label{stimulants}}

\hypertarget{methylphenidates}{%
\paragraph{Methylphenidates}\label{methylphenidates}}

\emph{First Line}
\textbar{} Drug Name \textbar{} Starting Dose \& Titration \textbar{} Duration of Action \textbar{} Notes \textbar{}
\textbar------------------\textbar----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\textbar--------------------\textbar------------------------------------------------------------------------------------------------\textbar{}
\textbar{} Ritalin \textbar{} Start with 5 mg 1-2 times per day and increase by 5 mg per week until good control achieved. May need additional reduced dose in the afternoon. Max daily dose: 60 mg \textbar{} 3-4 hrs \textbar{} Oral solution or chewable tablets \textbar{}
\textbar{} Ritalin SR or LA \textbar{} Start with 20 mg in the morning and increase by 20 mg per week until good control achieved. May need second dose or regular Ritalin dose in the afternoon. Max daily dose: 60 mg \textbar{} 4-8 hrs \textbar{} Capsules can be opened and sprinkled. Offers steady release of medication throughout the day \textbar{}
\textbar{} Focalin \textbar{} Start with 2.5 mg per day and increase by 2.5-5 mg per week until good control achieved. Max daily dose: 40 mg \textbar{} 3-4 hrs \textbar{} Focalin is twice as potent as other methylphenidates, so halve dose when converting to Focalin \textbar{}
\textbar{} Focalin XR \textbar{} Start with 5 mg per day and increase by 5 mg per week until good control achieved. Max daily dose: 30 mg \textbar{} 8-12 hrs \textbar{} Capsules can be opened and sprinkled \textbar{}
\textbar{} Concerta \textbar{} Start at 18 mg each morning and increase by 18 mg each week until good control achieved. Max daily dose: 72 mg \textbar{} 8-12 hrs \textbar{} Not ideal for children who cannot swallow pills \textbar{}

\hypertarget{amphetamines}{%
\paragraph{Amphetamines}\label{amphetamines}}

\emph{Second Line} due to higher incidence of side effects

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.05\columnwidth}\raggedright
Drug Name\strut
\end{minipage} & \begin{minipage}[b]{0.50\columnwidth}\raggedright
Starting Dose \& Titration\strut
\end{minipage} & \begin{minipage}[b]{0.08\columnwidth}\raggedright
Duration of Action\strut
\end{minipage} & \begin{minipage}[b]{0.25\columnwidth}\raggedright
Notes\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Adderall\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Start with 5 mg 1-2 times per day and increase by 5 mg per week until good control achieved. Max daily dose: 40 mg\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
4-6 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Adderall XR\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Start with 10 mg in the morning and increase by 10 mg per week until good control is achieved. Max daily dose: 40 mg\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
8-12 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Capsules can be opened and sprinkled\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.05\columnwidth}\raggedright
Vyvanse\strut
\end{minipage} & \begin{minipage}[t]{0.50\columnwidth}\raggedright
Start with 30 mg in the morning and increase by 10-20 mg per week until good control achieved. Max daily dose: 70 mg\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
10-12 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright
Capsules can be opened and sprinkled. Low abuse potential.\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\emph{Stimulant Side Effects: Anorexia/weight loss, insomnia, irritability, headache, stomachache, increased BP/HR, tics (rare)}

\hypertarget{non-stimulants}{%
\paragraph{Non-Stimulants}\label{non-stimulants}}

\emph{Third Line}
\#\#\#\#\# Norepinephrine Reuptake Inhibitors
\textbar{} Drug Name \textbar{} Starting Dose \& Titration \textbar{} Duration of Action \textbar{} Notes \textbar{}
\textbar-------------------------\textbar-------------------------------------------------------------------------------------------------------------------------------------------------------------\textbar--------------------\textbar--------------------------------\textbar{}
\textbar{} Atomoxetine (Strattera) \textbar{} Start with 0.5 mg/kg/day and increase after at least three days to target dose of 1.2-1.4 mg/kg/day. Max daily dose: 1.4 mg/kg or 100 mg, whichever is less \textbar{} 24 hrs \textbar{} Takes 4-6 weeks to see effects \textbar{}

\emph{NRI side effects: Nausea, GI upset, insomnia, sedation, decreased appetite}

\hypertarget{alpha-agonists}{%
\subparagraph{Alpha Agonists}\label{alpha-agonists}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.10\columnwidth}\raggedright
Drug Name\strut
\end{minipage} & \begin{minipage}[b]{0.55\columnwidth}\raggedright
Starting Dose \& Titration\strut
\end{minipage} & \begin{minipage}[b]{0.08\columnwidth}\raggedright
Duration of Action\strut
\end{minipage} & \begin{minipage}[b]{0.15\columnwidth}\raggedright
Notes\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.10\columnwidth}\raggedright
Clonidine ER (Kapvay)\strut
\end{minipage} & \begin{minipage}[t]{0.55\columnwidth}\raggedright
Start with 0.1 mg at bedtime and increase by 0.1 mg per week until good control achieved. Max daily dose: 0.4 mg\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
12-24 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
Helpful for use as sleep aid as well\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.10\columnwidth}\raggedright
Guanfacine ER (Intuniv)\strut
\end{minipage} & \begin{minipage}[t]{0.55\columnwidth}\raggedright
Start with 1 mg per day and increase by 1 mg per week until good control achieved, target dose 0.05-0.12 mg/kg/day. Max daily dose: 7 mg\strut
\end{minipage} & \begin{minipage}[t]{0.08\columnwidth}\raggedright
12-24 hrs\strut
\end{minipage} & \begin{minipage}[t]{0.15\columnwidth}\raggedright
First line in Tourette's\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\emph{Alpha agonist side effects: hypotension, sedation, lightheadedness, dry mouth}

\hypertarget{anxiety-1}{%
\subsection{Anxiety}\label{anxiety-1}}

\hypertarget{types-of-anxiety-disorders}{%
\subsubsection{Types of Anxiety Disorders}\label{types-of-anxiety-disorders}}

Selective mutism, separation anxiety disorder, phobias, OCD, social anxiety disorder, generalized anxiety disorder, panic disorder
- Important to screen in patients with ADHD and to screen for ADHD in those with anxiety--often linked

\hypertarget{how-to-screen-2}{%
\subsubsection{How to Screen}\label{how-to-screen-2}}

PSC-17 (Pediatric Symptom Checklist): 4 year olds +
- Looks at psychosocial functioning, externalization and internalization
SDQb (Strengths and Difficulties Questionnaire): 3 year olds +
- Sensitivity: 63\% to 94\% for emotional symptoms
= Specificity: 88\% to 98\% conduct problems
- Separate scale assesses impact of symptoms on global functioning
ASQ-SE (Ages and stages questionnaire---social emotional): 6-60 months
- Screens for social-emotional communicative, motor, problem- problems
- Sensitivity: 71\% to 85\%
- Specificity: 90\% to 98\%

\hypertarget{positive-screening}{%
\subsubsection{Positive Screening}\label{positive-screening}}

Obtain detailed hx re: symptoms, freq, duration, severity, degree of distress or interference
Consider SW involvement as needed
Behavioral Health/Psych referral

\hypertarget{initial-treatment-school-aged}{%
\subsubsection{Initial treatment (school aged)}\label{initial-treatment-school-aged}}

CBT
Fluoxetine 10 mg daily - can uptitrate to 20 mg daily
\textbf{What if symptoms persist?} (school age): SSRI treatment in consult w/ psych, see medication table below for further recommendations

\hypertarget{depression}{%
\subsection{Depression}\label{depression}}

\hypertarget{background}{%
\subsubsection{Background}\label{background}}

Extremely significant cause of morbidity/mortality in children, \textgreater⅓ children experience a psychiatric disorder by childhood

Cormorbidity with ADHD very common, important to screen for both

Many types but most often will see:
1. Unipolar major depression (MDD): at least 2 weeks of depression plus 4 neurovegetative symptoms, no hx of mania
2. Persistent depressive disorder (Dysthmia): depression for \textgreater2 years and at least 2 other symptoms (or MDD that persists for 2 years+)

\hypertarget{neurovegetative-symptoms-sigecaps}{%
\subsubsection{Neurovegetative Symptoms (SIGECAPS)}\label{neurovegetative-symptoms-sigecaps}}

\textbf{S}leep disruption
\textbf{I}nterest deficit
\textbf{G}uilty Feelings
\textbf{E}nergy deficit
\textbf{C}oncentration deficit
\textbf{A}ppetite disorder
\textbf{P}sychomotor Changes
\textbf{S}uicidality

\hypertarget{how-to-screen-3}{%
\subsubsection{How to Screen}\label{how-to-screen-3}}

Always screen for history of mania or bipolar symptoms (25-30\% of Bipolar Disorder starts with depressive episode)
- Use PSC internalizing scale for anxiety/depression
- PHQ-9
*Important to consider referral to psychiatrist for severe symptoms, significant comorbidities and for children \textless12

\hypertarget{therapy}{%
\subsubsection{Therapy}\label{therapy}}

Should always be concurrent with starting medications (or offered), particularly in younger children. See tables below re medication management

\hypertarget{follow-up-16}{%
\subsubsection{Follow Up}\label{follow-up-16}}

Follow up 2 wks after initiation and then 2-4 wks after, monitoring closely
Most symptom improvement in 6-8 wks with some mild effects seen at 2 wks

\hypertarget{medication-management-anxiety-and-depression}{%
\subsection{Medication Management: Anxiety and Depression}\label{medication-management-anxiety-and-depression}}

\hypertarget{side-effectsprecautions-with-ssri-use-see-chart-below-for-medication-recs}{%
\subsubsection{Side Effects/Precautions with SSRI use (see chart below for medication recs)}\label{side-effectsprecautions-with-ssri-use-see-chart-below-for-medication-recs}}

Black box warning:
- Increase in suicidality/self harm after dose initiation or increase in dose
- Important to monitor closely during any initiation or changes
- Often suicidality exists prior to starting medication and important to assess prior and during medication management
SSRI Activation Syndrome/Induced Mania
- Irritability, restlessness, agitation, impulsivity, hyperactivity, manic symptoms, psychosis
- Often emerges with initiation of SSRI or dose increase
- Risk higher in younger children and those at risk for bipolar disorder
QTc prolongation/cardiac events seen in escitalopram and citalopram in particular, consider closer monitoring or avoiding in patients with cardiac history
Avoid Wellbutrin in patients with eating disorders or seizure history
- Important to do good diet history prior to initiation given common disordered eating, particularly in adolescents
Serotonin syndrome
Most common mild side effects: GI, HA, sleep disturbances

\hypertarget{anxiety-2}{%
\subsubsection{Anxiety}\label{anxiety-2}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.12\columnwidth}\raggedright
SSRI\strut
\end{minipage} & \begin{minipage}[b]{0.31\columnwidth}\raggedright
Range\strut
\end{minipage} & \begin{minipage}[b]{0.48\columnwidth}\raggedright
Notes\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Sertraline (Zoloft)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
50-200 mg\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
FDA approved pediatric OCD age 6+ (POTS), often requires high doses for OCD\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Fluvoxamine (Luvox)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
100-300 mg\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
FDA approved pediatric OCD ages 8+, BID dosing, monitor for drug/drug interactions\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Fluoxetine (Prozac)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
20-40 mg\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
FDA approved pediatrics OCD 7+, long half-life, behavioral activation\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Escitalopram (Lexapro)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
20-40 mg\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
FDA-approved pediatric depression, dose related QTc prolongation; lower side effect profile\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
Citalopram (Celexa)\strut
\end{minipage} & \begin{minipage}[t]{0.31\columnwidth}\raggedright
20-40 mg *Do not exceed 40 mg daily given QTc prolongation\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Dose related QTc prolonging; lower side effect profile\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{depression-1}{%
\subsubsection{Depression}\label{depression-1}}

First line: SSRI
\textbar{} SSRI \textbar{} Range \textbar{} Notes \textbar{}
\textbar------------------------\textbar----------\textbar-------------------------------------------------------------------------------------------------------------------\textbar{}
\textbar{} Fluoxetine (Prozac) \textbar{} 20-40 mg \textbar{} FDA approved pediatric depression age 8+, most consistent evidence, long half-life, assoc w behavioral activation \textbar{}
\textbar{} Escitalopram (Lexapro) \textbar{} 20-40 mg \textbar{} FDA approved for adolescent depression 12+, well tolerated \textbar{}
\textbar{} Sertraline (Zoloft) \textbar{} 5-200 mg \textbar{} FDA approved pediatrics OCD 7+ \textbar{}
\textbar{} Citalopram (Celexa) \textbar{} 20-40 mg \textbar{} QTc prolongation concern but lower side effects otherwise; do not exceed 40mg daily \textbar{}

Second line: another SSRI
-Try increasing dose of first before switching to a second
-Switch to second SSRI if one is not working or side effects bothersome with first attempt

Third line: Refer to specialist; medications include venlafaxine, bupropion, mirtazapine, duloxetine
-Should be done in conjunction with a specialist

\hypertarget{bmc-primary-care-clinic-resources}{%
\subsection{BMC Primary Care Clinic Resources}\label{bmc-primary-care-clinic-resources}}

\hypertarget{asthma-education}{%
\subsubsection{Asthma Education}\label{asthma-education}}

\textbf{WHAT}: 5-10 minute check in w/ patients to review triggers, spacer teaching, med teaching, Asthma Action Plan,, screening for in home asthma services such as Breathe Easy
\textbf{WHEN}: Monday-Friday 9am-5pm. Appropriate for any patient w/ asthma here for WCE, urgent visit, etc.
\textbf{HOW}: Reachable via pager 8818p

\hypertarget{reach-out-and-read-ror}{%
\subsubsection{Reach out and Read (ROR)}\label{reach-out-and-read-ror}}

\textbf{WHAT}: Program to promote early literacy
\textbf{WHO}: Age child 6 months -- 5 years
\textbf{HOW}: Kids ages 6 months -- 5 years receive a book at every well child visit.
\textbf{WHERE}: The ROR books are located in the little office next to the nursing office in the main primary care clinic hallway -- they are next to a bunch of stickers too!!

\hypertarget{lactation-resources}{%
\subsubsection{Lactation Resources}\label{lactation-resources}}

\textbf{WHAT}: We have lactation consults (both in the clinic and in the newborn nursery) who can often help mom's during the newborn visits.
\textbf{WHO}: Any mom who is breastfeeding or attempting to breastfeed, especially those who have babies who aren't gaining good weight. Also appropriate to call them if moms have questions about pumping, latch, nipple pain, etc.
\textbf{WHEN}: Anytime during PC clinic
\textbf{HOW}: You can page the Child Life Specialist who is usually in clinic and can come work w/ moms! You can also page a lactation consultant from the newborn nursery but it is very likely that they will be too busy to come during your visit.

\hypertarget{food-pantry}{%
\subsubsection{Food Pantry}\label{food-pantry}}

\textbf{WHAT}: Provides food resources (including fresh fruits and vegetables) to patients w/ food insecurity, chronic illness, etc.
\textbf{WHO}: Anyone who gets a referral; immigration status DOES NOT matter and you don't need to document income when you refer, you just need to place the referral
\textbf{WHEN}: Open Monday -- Friday; 10:00 AM -- 4:00 PM; pts can go 2x monthly
\textbf{HOW}: Write a prescription for your patient in EPIC (they MUST have a Rx)

\hypertarget{street-cred}{%
\subsubsection{Street Cred}\label{street-cred}}

\textbf{WHAT}: Organization started by BCRP alum Lucy Marcil to help families get the maximum amount on their tax returns
\textbf{WHO}: For all pts w/ income \textless54,000
\textbf{HOW}: Refer patients to street cred (use .STREETCRED in the EMR)
\href{mailto:info@mystreetcred.org}{\nolinkurl{info@mystreetcred.org}}
(617) 414-5946

\hypertarget{child-witness-to-violence-project}{%
\subsubsection{Child Witness to Violence Project}\label{child-witness-to-violence-project}}

\textbf{WHAT}: Provides social support and counseling for young (\textless{} 8y) children who have witnessed domestic violence. Run under the auspices of the DBP clinic.
\textbf{WHERE}: Counseling happens at BMC but there is no documentation left in the chart. This can be tricky because you will not know if your patients are receiving services based on chart review alone.
\textbf{HOW}: Call (617) 414-7425

\hypertarget{bmc-pediatrics-specialty-outpatient-clinics}{%
\subsection{BMC Pediatrics Specialty Outpatient Clinics}\label{bmc-pediatrics-specialty-outpatient-clinics}}

\hypertarget{ccp-clinic}{%
\subsubsection{CCP Clinic}\label{ccp-clinic}}

\textbf{WHAT}: Primary care home for patients w/ complex medical problems including NICU grads, patients w/ complex genetic disorders, etc.
\textbf{WHO}: All patients w/ multiple medical problems and/or exceptionally complex social situations AND their siblings
\textbf{HOW}: Talk to Dr.~Jack Maypole (BCRP alum!)

\hypertarget{grow-clinic}{%
\subsubsection{GROW Clinic}\label{grow-clinic}}

\textbf{WHAT}: BMC based clinic for kids w/ FTT, provides comprehensive wrap around services including social work and home visits performed by a dietician. Not a PCP
\textbf{WHO}: For FTT kiddos (I think only less than age 5)
\textbf{HOW}: Talk to the Grow clinic patient navigator (refer in EPIC)

\hypertarget{baby-steps-clinic}{%
\subsubsection{Baby Steps Clinic}\label{baby-steps-clinic}}

\textbf{WHAT}: Provides coordination of care for babies who are preterm or have had complicated newborn courses; NOT primary care. Comprehensive team including pediatrician, nutritionist, OT, dieticians and close communication w/ neuro and GI
\textbf{WHO}: For any baby who had a tough newborn course, is having difficulty gaining weight or other challenges. (All preterm)
\textbf{HOW}: This is usually done when the baby leaves the nursery but if you think a baby would benefit from this clinic as well you can place a referral in EPIC

\hypertarget{sofar-clinic}{%
\subsection{SoFAR Clinic}\label{sofar-clinic}}

\textbf{WHAT}: Primary Care Clinic for moms w/ a history of substance use and their babies (babies w/ a history of NAS) or exposure
\textbf{WHO}: Babies born to moms who struggled w/ substance use during pregnancy and their siblings. Moms get care too--Dyadic approach!
\textbf{HOW}: Usually referred to the clinic from the newborn nursery but this can also be done on the outpatient side. Reach out to SoFar clinic SW to schedule an intake for the family.

\hypertarget{teen-and-tot-clinic}{%
\subsubsection{Teen and Tot Clinic}\label{teen-and-tot-clinic}}

\textbf{WHAT}: Primary Care Clinic for teen moms and their babies -- teen girls can get prenatal care in a centering group by midwife. Teen girls and children are seen together during primary care visits. The clinic also has a patient navigators and is run by Dr.~Pierre-Joseph
\textbf{WHO}: Teen moms and their babies/pregnant teens who have elected to become parents
\textbf{HOW}: Page Adrian Stevenson (teen and tot patient navigator) or talk to Dr.~Adolphe or Dr.~Pierre-Joseph to transfer maternal/newborn care to teen and tot. Adrian will talk to the mom and do an intake

\hypertarget{iep-clinic}{%
\subsubsection{IEP Clinic}\label{iep-clinic}}

\textbf{WHAT}: Clinic that is run by BMC preceptor Dr.~Adolphe that bridges primary care w/ DBP, Helps w/ ADHD, ASD, learning/intellectual disorders. Appropriate for kids w/ IEP who aren't making progress or accessing the curriculum well or if parents have questions about the IEP.
\textbf{WHEN}: Usually takes patients \textasciitilde{} 1 month to get in (for now)\ldots{} if you need help sooner or in the meantime, reach out to Dr.~Adolphe directly.
\textbf{HOW}: Place a referral in EPIC

\hypertarget{family-planning-services}{%
\subsubsection{Family Planning Services}\label{family-planning-services}}

Birth control counseling, STD testing, options counseling, for patients of ANY AGE, same-day birth control available page Teakia Brown

\hypertarget{pain-clinic}{%
\subsubsection{Pain Clinic}\label{pain-clinic}}

For kids with chronic pain (including functional), MD, acupuncturist, psychologist, PT

\hypertarget{catalyst-clinic}{%
\subsubsection{CATALYST Clinic}\label{catalyst-clinic}}

Teens with substance use disorder

\hypertarget{menstrual-disorders-clinic}{%
\subsubsection{Menstrual Disorders Clinic}\label{menstrual-disorders-clinic}}

Joint Adolescent/Heme Clinic

\hypertarget{lead-clinic}{%
\subsubsection{Lead Clinic}\label{lead-clinic}}

Sean Palfrey, for kids with elevated lead

\hypertarget{catch-clinic}{%
\subsubsection{CATCH Clinic}\label{catch-clinic}}

For gender affirming care

\hypertarget{embedded-child-psychiatrist}{%
\subsubsection{Embedded Child Psychiatrist}\label{embedded-child-psychiatrist}}

Andrea Spencer available for ``curbside consults'' and ``co-management of patients with behavioral health concerns''-- page directly or refer to Integrated Behavioral health

\hypertarget{bmc-indications-for-social-work-consult}{%
\subsection{BMC Indications for Social Work Consult}\label{bmc-indications-for-social-work-consult}}

Child Abuse
Neglect
Domestic Violence
Sexual assault
Mental health (depression, anxiety, psychosis, PTSD, etc.)
Thoughts of suicidal ideation/homicidal ideation
Substance abuse
Family bereavement
Newly diagnosed chronic or fatal illness
Witnessing/part of community violence
Family distress or dysfunction
Bullying

Liz Renzella \#3433, 4-7756
Jill Baker \#2610, 4-7799

\hypertarget{bmc-clinic-tips}{%
\subsection{BMC Clinic Tips}\label{bmc-clinic-tips}}

Always review medications, allergies, etc by going to the A/P section of epic and clicking ``mark all as reviewed''
You can delete a note by clicking the ``X'' by the ``sign note'' or ``pend note'' drop down
When ordering immunizations, use the order sets, which are present under ``A/P'' order section
- Simply check off the box and sign the orders
Huddle w/ your nurse and CA prior to clinic to discuss patients that may be late, clinic flow goals, complex patients, anticipated orders
You know a patient is roomed when their vitals populate into your note
To promote continuity, staple your card to the after visit summary
\textbf{You must import the flowsheets for the developmental screens into your note \& indicate positive or negative}
\textbf{You must send your notes to your preceptor w/i 48 hours for signing and billing}

\hypertarget{chpcc-co-located-specialty-clinics}{%
\subsection{CHPCC Co-Located ``Specialty'' Clinics}\label{chpcc-co-located-specialty-clinics}}

Refer patients with a PowerChart Order

\hypertarget{asthma-clinic}{%
\subsubsection{Asthma Clinic}\label{asthma-clinic}}

In-depth education or intervisit care, including home visits, for asthma patients requiring more frequent visits and/or asthma patients with more severe disease

\hypertarget{advocating-success-for-kids-ask}{%
\subsubsection{Advocating Success for Kids (ASK)}\label{advocating-success-for-kids-ask}}

A multidisciplinary team (developmental medicine, educational specialist, social worker, and primary care) assists children who are having academic difficulties, such as from ADHD or a learning disability, who are not making adequate progress despite having an IEP, and also conducts evaluations for autism spectrum disorder and other developmental delays

\hypertarget{rainbow}{%
\subsubsection{Rainbow}\label{rainbow}}

A multidisciplinary team to coordinate care for our clinic's medically complex children. Owing to their medical complexity, patients with a ``Rainbow'' distinction get longer patient visits, intervisit monitoring, and additional nursing, social work, and case management support.

\hypertarget{rash}{%
\subsubsection{RASH}\label{rash}}

Have your patients' skin concerns addressed quickly, in a primary care setting, by pediatricians. This is generally far faster than a referral to dermatology.

\hypertarget{young-parents-program-ypp}{%
\subsubsection{Young Parents Program (YPP)}\label{young-parents-program-ypp}}

A teen-tot clinic that provides primary care for adolescent parents and their children. Dedicated YPP staff provide longitudinal supports.

\hypertarget{chpcc-contacts}{%
\subsection{CHPCC Contacts}\label{chpcc-contacts}}

Fax: 617-730-0505
Charge RN: 84706
Front Desk: 58944
SW Pager: 0170
Child Life: 84708
Dental Clinic: 5654
Lactation: 56445
Newborn Pager (for scheduling visits): 5222
Navigator: 5931
YPP: 7718

\hypertarget{psychiatry}{%
\section{Psychiatry}\label{psychiatry}}

\hypertarget{consulting-psych}{%
\subsection{Consulting Psych}\label{consulting-psych}}

\begin{itemize}
\tightlist
\item
  Place ``Psychiatry Consult'' order in PowerChart. Will allow you to select an indication (including Agitation plan, Psychiatric Disposition, etc). What you write in Order Comments = what Psych uses to prioritize urgency and assign consult. Must obtain patient/guardian consent prior to placing consult.
\item
  If patient seen in ER by Psych SW and officially boarding for inpatient LOC, as of Sept 2020 this is a new option to select on consult order
\item
  Reasons to page Psych on-call on nights/wknd: Severe agitation, active SI w/ plan/intent, psychosis, behavior interfering w/ essential medical care
\end{itemize}

\hypertarget{ap-template-for-patients-awaiting-inpatient-psych-placement}{%
\subsection{A/P Template for Patients Awaiting Inpatient Psych Placement}\label{ap-template-for-patients-awaiting-inpatient-psych-placement}}

\textbf{Use the Behavioral Healthy Safety Plan order set!}

Assessment: \_ is a \_ y/o M/F w/ PMH \_\_ who presents w/ concerning \_\_ SI that makes him/her unsafe for discharge home. S/He has been medically cleared and is awaiting placement at an inpatient psychiatric facility. We will continue to provide a safe environment and follow along w/ Psychiatry.

Plan:

-- Medical clearance
- Utox, urine HCG
- EKG (document baseline QTc)

-- Behavioral plan
- Supervision: 1:1 sitter vs.~security, safety tray, safety check prior to any room changes
- Activity level: Start w/ confined to room (Psych will decide when out-of-room privileges are ok, e.g.~supervised walks around unit or visit to playroom at RN's discretion
- Electronics: Start w/ no phone or internet (Psych will decide if/when permitted and w/ what level of supervision/restrictions)

-- Agitation plan, per Psychiatry on {[}date{]}
- Mild agitation: Utilize behavioral strategies
- Moderate agitation: Ativan OR Haldol , ALWAYS WITH Benadryl . Call BRT to help prevent further escalation to severe agitation.
- Severe agitation: Olanzapine PO/IM (Zydis ODT for PO) OR Haldol PO/IM , ALWAYS WITH Benadryl PO/IM PRN. Call 5-5555 to activate Behavioral Rapid Response (summons Psych, BRT, Security). Call on-call Psych if requires IM or if not responding within 20-30min or if need further guidance.
- If administering antipsychotics, daily EKG to monitor QTc (target \textless{} 450)
- PO's should be ordered as PRNs, IM must be one-time in the moment and can only be ordered by PGY2 or higher

-- Dispo: pending placement to inpatient psych when available bed identified

\textbf{Note: dosing for agitation meds is written as \_\_ mg q\_ NTE \_\_ from all sources in 24hrs. Dosing recommendations per table below:}

\hypertarget{agitation-1}{%
\subsection{Agitation}\label{agitation-1}}

\hypertarget{identifying-agitation}{%
\subsubsection{Identifying Agitation}\label{identifying-agitation}}

Mild: Pacing, worrying, agitated but cooperative
Moderate: Swearing, threatening, yelling, screaming, clenching fists, pacing, superficial self-injury, request for meds
Severe: Imminent risk of harm to self or others, aggression to others/self, destruction of property

\hypertarget{non-pharm-management}{%
\subsubsection{Non-Pharm Management}\label{non-pharm-management}}

BRT is your best friend!

\hypertarget{prevention}{%
\paragraph{Prevention}\label{prevention}}

Identifying triggers:
- Stimuli that trigger upsetting feelings or problematic behaviors (precipitant to behavior)
- Environmental or emotional

Patients at risk: ASD, developmental delay, trauma
Think about the 4 functions of any behavior: Attention, escape, sensory, tangibles/access

\hypertarget{ways-to-respond}{%
\paragraph{Ways to respond}\label{ways-to-respond}}

Recognize and respond to initial signs of agitation or inappropriate behavior w/ redirection. Avoid using the word ``no.''
Avoid non-specific comments such as ``behave'' or ``calm down''

Ignore behavior that is disruptive, but not harmful. Make a blank non-smiling face, avoid eye contact and turn away. As soon as the child stops the unwanted behavior, smile and make eye contact.
Give the child a space - somewhere calm and safe - where they can go when they feel overwhelmed.
Do not simply react; try to understand the reasons behind the behavior.

\hypertarget{managing-the-situation}{%
\paragraph{Managing the situation}\label{managing-the-situation}}

Managing the situation
Start by asking ``what do you want?''
Try the SAVE mnemonic: Support ''Let's work together\ldots'', Acknowledge ``I see this has been hard for you.'', Validate ''I'd probably be reacting the same way if I was in your shoes.'', Emotion naming ''You seem upset.'' or similar communication efforts when talking with the patient.

Strategies will differ based on degree of agitation:
\textbf{Mild}
Listen, validate, problem-solve
Stay w/ the patient, have them sit w/ you
Maintain calm demeanor
Eliminate distractions
Empathic listening
Utilize supportive eye and verbal communication, gestures, posture, and facial expressions
Utilize preferred activities (eg music)

\textbf{Moderate}
Redirect, problem-solve
Allow individual to vent
Validate feelings

\textbf{Severe}
Direct, clear communication
Call 5-5555 to activate Behavioral Rapid Response (summons Psych, BRT, Security)
Maintain safe distance (4ft); intervene if danger is imminent
Interrupt individual's focus
Body language techniques
Positive verbal command
Throwing/dropping an object
Moving as an escape technique
Medications (PO vs.~IM), potential need for restraint.

\hypertarget{restraints}{%
\subsubsection{Restraints}\label{restraints}}

Ordering restraints for violent or self-destructive/injurious behavior:
- \textbf{CANNOT} be written PRN! Appropriate restraint order must be placed immediately upon initiation of restraint.
- Ordering clinician must perform face-to-face within 1hr
- Order cannot be written by an intern, must be junior/senior resident

\hypertarget{pharmacologic-management}{%
\subsubsection{Pharmacologic Management}\label{pharmacologic-management}}

See A/P Template section above, as well as Rapid Reference chapter

Psychiatry will determine an appropriately tailored pharmacologic agitation plan, but these guidelines are a good starting place if you don't yet have a formal plan in place:

\hypertarget{medication-recommendations---moderate-agitation}{%
\paragraph{Medication Recommendations - Moderate Agitation}\label{medication-recommendations---moderate-agitation}}

Parenteral medication orders for agitation may not be ordered PRN. Place 1 time orders at the time the medication is needed.

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.58\columnwidth}\raggedright
Parameter\strut
\end{minipage} & \begin{minipage}[b]{0.16\columnwidth}\raggedright
Child (weighing 25-50 kg)\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Adolescent (weighing \textgreater{} 50 kg)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.58\columnwidth}\raggedright
Preferred Agent(s)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
Diphenhydramine or Lorazepam\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Diphenhydramine or Lorazepam\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.58\columnwidth}\raggedright
\textbf{Administration Route} For escalating patients who refuse PO and for whom there is significant concern for imminent and serious risk of harm to self or others, please progress to severe agitation IM plan below. IM medications usually require physical holds or restraints and should only be involuntarily administered if there is significant risk of harm\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
PO\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
PO\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.58\columnwidth}\raggedright
Initial Dosing\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
Diphenhydramine 25 mg or Lorazepam 0.5 - 1 mg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Diphenhydramine 50 mg or Lorazepam 1- 2 mg\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.58\columnwidth}\raggedright
Repeat dosing (60 minutes after initial dose if ineffective)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
Diphenhydramine 25 mg or Lorazepam 0.5 - 1 mg\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Diphenhydramine 25 mg or Lorazepam 1 -- 2 mg\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.58\columnwidth}\raggedright
Subsequent Frequency\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
Q4 -- 6 hours Not to exceed 100 mg of diphenhydramine or 2 mg of lorazepam in 24 hours\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Q4 -- 6 hours Not to exceed 150 mg of diphenhydramine or 4 mg of lorazepam in 24 hours\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

PO's should be ordered as PRNs, IM must be one-time in the moment and can only be ordered by PGY2 or higher
Prescribers to use discretion and order lower or higher doses as appropriate.

\hypertarget{medication-recommendations---severe-agitation}{%
\paragraph{Medication Recommendations - Severe Agitation}\label{medication-recommendations---severe-agitation}}

Parenteral medication orders for agitation may not be ordered PRN. Place 1 time orders at the time the medication is needed.

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.14\columnwidth}\raggedright
Parameter\strut
\end{minipage} & \begin{minipage}[b]{0.33\columnwidth}\raggedright
Child (weighing 25-50 kg)\strut
\end{minipage} & \begin{minipage}[b]{0.45\columnwidth}\raggedright
Adolescent (weighing \textgreater{} 50 kg)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.14\columnwidth}\raggedright
Preferred Agent(s)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Olanzapine* (ODT for PO) or Haloperidol and Diphenhydramine** or Lorazepam\strut
\end{minipage} & \begin{minipage}[t]{0.45\columnwidth}\raggedright
Olanzapine* (ODT for PO) or Haloperidol and Diphenhydramine** and/or Lorazepam\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
Administration Route\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
PO or IM\strut
\end{minipage} & \begin{minipage}[t]{0.45\columnwidth}\raggedright
PO or IM\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
Initial Dosing\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Olanzapine 2.5 mg or Haloperidol 2 mg and Diphenhydramine 25 mg or Lorazepam 0.5-1 mg\strut
\end{minipage} & \begin{minipage}[t]{0.45\columnwidth}\raggedright
Olanzapine 5 mg (can use 7.5mg for patients weighing \textgreater{} 70kg) or Haloperidol 5 mg and Diphenhydramine 50 mg and/or Lorazepam 1-2 mg (can use Haloperidol, Diphenhydramine and Lorazepam combined for patients weighing \textgreater{} 70kg)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
Repeat dosing (45 minutes after initial dose if ineffective***)\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Olanzapine 2.5 mg or Haloperidol 1 mg and Diphenhydramine 25 mg or Lorazepam 0.5-1 mg\strut
\end{minipage} & \begin{minipage}[t]{0.45\columnwidth}\raggedright
Olanzapine 5 mg or Haloperidol 2.5 mg and Diphenhydramine 25 mg and/or Lorazepam 1-2 mg\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
Subsequent Frequency\strut
\end{minipage} & \begin{minipage}[t]{0.33\columnwidth}\raggedright
Q4hr Do not exceed: Olanzapine 10 mg in 24 hours Haloperidol 5 mg in 24 hours Diphenhydramine 100 mg in 24 hours Lorazepam 3 mg in 24 hours \strut
\end{minipage} & \begin{minipage}[t]{0.45\columnwidth}\raggedright
Q4hr Do not exceed: Olanzapine 15 mg in 24 hours Haloperidol 10 mg in 24 hours Diphenhydramine 150 mg in 24 hours Lorazepam 6 mg in 24 hours\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\begin{itemize}
\tightlist
\item
  \textbf{Do NOT use IM olanzapine within 4 hours of IM/IV lorazepam due to risk of cardiopulmonary depression.}
  ODT = orally disintegrating tablet.
  ** Use of diphenhydramine with haloperidol is preferred to haloperidol alone to avoid risk of acute dystonic reactions. The use of haloperidol in combination with Fluoxetine (Prozac) or Citalopram (Celexa) can significantly increase the risk of QT prolongation and should only be used if benefits outweigh the risks.\\
  Consult formulary for complete information.
  *** If pharmaceutical interventions are not effective, patients at risk for self-harm or harming others may require physical restraints, turning off the lights and an urgent psychiatry evaluation.
\end{itemize}

\textbf{The use of haloperidol in combination with Fluoxetine (Prozac) or Citalopram (Celexa) can significantly increase the risk of QT prolongation and should only be used if benefits outweigh the risks. }

\hypertarget{medications-that-cause-psychiatric-side-effects}{%
\subsection{Medications That Cause Psychiatric Side Effects}\label{medications-that-cause-psychiatric-side-effects}}

\hypertarget{selected-meds}{%
\subsubsection{Selected Meds}\label{selected-meds}}

Steroids: Aggressiveness/agitation, mania, depression, anxiety, psychosis
Procainamide, quinidine: Confusion, delirium
Albuterol: Anxiety, confusion
Isoniazid: Psychosis
Tetracycline: Depression
Nifedipine, verapamil: Depression
Cimetidine: Depression, confusion, psychosis

\hypertarget{psychosis}{%
\subsubsection{Psychosis}\label{psychosis}}

Sympathomimetics, analgesics, antibiotics (e.g.~isoniazid, antimalarials), anticholinergics, anticonvulsants, antihistamines, corticosteroids, antiparkinsonian agents.

\hypertarget{agitationconfusiondelirium}{%
\subsubsection{Agitation/Confusion/Delirium}\label{agitationconfusiondelirium}}

Benzos, antipsychotics, anticholinergics, antihistamines, antidepressants, antiarrhythmics, antineoplastics, corticosteroids, NSAIDs, antiasthmatics, antibiotics, antihypertensives, antiparkinsonian agents, thyroid hormones

\hypertarget{depression-2}{%
\subsubsection{Depression}\label{depression-2}}

Antihypertensives, antiparkinsonian agents, corticosteroids, calcium channel blockers, NSAIDs, antibiotics, peptic ulcer drugs.

\hypertarget{anxiety-3}{%
\subsubsection{Anxiety}\label{anxiety-3}}

Sympathomimetics, antiasthmatics, antiparkinsonian agents, hypoglycemic agents, NSAIDs, thyroid hormones.

\hypertarget{sedationpoor-concentration}{%
\subsubsection{Sedation/Poor concentration}\label{sedationpoor-concentration}}

Antianxiety agents/hypnotics, anticholinergics, antibiotics, antihistamines.

\hypertarget{capacity-assessment}{%
\subsection{Capacity Assessment}\label{capacity-assessment}}

Capacity vs competency: Capacity is a one-time assessment by a clinician. Competency is a legal decision based on accumulated evidence that requires court hearing/proceeding.

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.18\columnwidth}\raggedright
Patient (18yo+)/family must\ldots{}\strut
\end{minipage} & \begin{minipage}[b]{0.76\columnwidth}\raggedright
Assessment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Communicate a clear and stable choice\strut
\end{minipage} & \begin{minipage}[t]{0.76\columnwidth}\raggedright
Ask patient to indicate a choice. Frequent reversals may indicate lack of capacity.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Understand relevant information\strut
\end{minipage} & \begin{minipage}[t]{0.76\columnwidth}\raggedright
Ask patient to explain their understanding of the information given by physician (diagnosis, prognosis, proposed intervention, risks/benefits of intervention and alternatives, including no intervention)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Appreciate the situation and its consequences\strut
\end{minipage} & \begin{minipage}[t]{0.76\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Manage the information in a rational manner\strut
\end{minipage} & \begin{minipage}[t]{0.76\columnwidth}\raggedright
Does patient weigh risks/benefits logically?\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Is there true imminent risk?\strut
\end{minipage} & \begin{minipage}[t]{0.76\columnwidth}\raggedright
EX: patient indicating they are suicidal but meet all 4 criteria above.\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{depression-anxiety}{%
\subsection{Depression \& Anxiety}\label{depression-anxiety}}

\hypertarget{diagnosis-13}{%
\subsubsection{Diagnosis}\label{diagnosis-13}}

Major Depressive Episode: \textbf{2 wks of}: Depressed mood (or irritability, which is more common in children) OR anhedonia, PLUS 4+ of remaining SIGECAPs (\textbf{S}leep change, \textbf{I}nterest loss, \textbf{G}uilt/worthlessness, \textbf{E}nergy loss/fatigue, \textbf{C}ognition/concentration, \textbf{A}ppetite change, \textbf{P}sychomotor change, \textbf{S}I)
- Ddx: Hypoactive type (wax/wane, acute-onset, possibly 2/2 underlying medical illness or iatrogenic), adjustment disorder (needs psychotherapy only), delirium

\hypertarget{management-102}{%
\subsubsection{Management}\label{management-102}}

According to TADS and CAMS (2 large RCTs w/ govt oversight), combination therapy of SSRI + CBT is superior to monotherapy w/ either! CBT or SSRI is superior to placebo.
No SSRI-associated suicidal events in either study, but when initiating SSRI it is important to monitor carefully (wks 1-4: weekly; wks 5-12: every other week) for any signs of ↑ suicidality
- \textbf{NEVER} prescribe paroxetine (Paxil) to adolescents (black box warning for suicide)

\textbf{SSRIs are 1st line}: Help ⅔ of pts in first trial over \textbf{4-8 wks}. ⅔ of nonresponders respond to 2nd trial.
- \textbf{Sertraline (Zoloft)} and \textbf{Fluoxetine (Prozac)} are most commonly used, least SE (used in TADS, CAMS).
- Mild serotonergic side-effects (hyperhidrosis, nausea, headache, tremulousness, diarrhea) can happen w/ SSRI/SNRI initiation and/or uptitration, usually goes away in 2-3 days

\hypertarget{suicide}{%
\subsection{Suicide}\label{suicide}}

\begin{itemize}
\tightlist
\item
  If you don't directly ask about suicide, you won't hear about it. NEVER assume! You don't have to be depressed to be suicidal.
\item
  \textasciitilde4\% of patients coming in to ED (for all complaints) are suicidal.
\item
  Adolescents more likely to kill selves by firearm; children by strangulation
\end{itemize}

\textbf{ASQ: Adolescent Suicide Screening Tool}
In the past few weeks, have you wished you were dead?
In the past few weeks, have you felt that you or your family would be better off if you were dead?
- Yes to 1 or 2 (passive SI): Counsel, supportive listening, referrals
In the past week, have you been having thoughts about killing yourself?
Have you ever tried to kill yourself?
Are you having thoughts of killing yourself right now?
- Yes to 3 or 5 (active SI): Immediate consult from ER/floor/outpt mental health clinician

\hypertarget{antidepressants}{%
\subsection{Antidepressants}\label{antidepressants}}

\hypertarget{selective-serotonin-reuptake-inhibitors-ssris}{%
\subsubsection{Selective Serotonin Reuptake Inhibitors (SSRIs)}\label{selective-serotonin-reuptake-inhibitors-ssris}}

\hypertarget{mechanism-of-action}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action}}

5-HT-specific reuptake inhibitor

\hypertarget{use}{%
\paragraph{Use}\label{use}}

Depression, Gen.~anxiety disorder, Panic disorder, OCD, bulimia, social anxiety disorder, PTSD, premature ejaculation, premenstrual dysphoric disorder
- It normally takes \textbf{4--8 weeks} for antidepressants to have full effect.
\textbf{Fluoxetine} (Prozac), \textbf{Paroxetine} (Paxil), \textbf{Sertraline} (Zoloft), \textbf{Citalopram} (Celexa), \textbf{Escitalopram}\\
(\emph{Fl} ashbacks \emph{par} alyze \emph{se} nior \emph{cit} izens)
Paroxetine → short half-life → discontinuation syndrome (flu-like sxs, dizzy, diaphoretic, ``electric shock,'' + depression). Do not use in adolescents due to black box warning for suicide.
Fluoxetine → long half-life → no need to taper/good for poor compliance, P450 inhibitor, can ↑antipsychotics → ↑SEs
Citalopram/Escitalopram → Dose dependent QTc prolongation (usually minimal)

\hypertarget{side-effects}{%
\paragraph{Side Effects}\label{side-effects}}

GI distress, SIADH, sexual dysfunction (anorgasmia, ↓ libido), insomnia, anorexia, ↑ suicidality in adolescents , QTc prolongation, mildly ↓ Na (i.e.~128)

Serotonin syndrome: 2 meds that ↑ serotonin (MAOis, SNRIs, TCAs, Opoids, Tramadol, Linezolid) → ↑↑ serotonin in brain. (ex: triptan/SSRIs)

\textbf{3 A's}: neuromuscular \textbf{A}ctivity (clonus, hyperreflexia, hypertonia, tremor, seizure), \textbf{A}utonomic stim (hyperthermia, diaphoresis, diarrhea), and \textbf{A}gitation.
Tx: cyproheptadine (5-HT2 receptor antagonist) or benzodiazepines

\hypertarget{serotonin-norepinephrine-reuptake-inhibitors-snris}{%
\subsubsection{Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)}\label{serotonin-norepinephrine-reuptake-inhibitors-snris}}

\hypertarget{mechanism-of-action-1}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-1}}

Inhibit 5-HT and NE reuptake

\hypertarget{use-1}{%
\paragraph{Use}\label{use-1}}

Depression, general anxiety disorder, diabetic neuropathy.
\textbf{Venlafaxine} → also indicated for social anxiety disorder, panic disorder, PTSD, OCD, menopausal depression (b/c of NE effects)
\textbf{Duloxetine} → also used for neuropathy (vs.~Amitriptyline is better in suicidal patient who might overdose)

\hypertarget{examples}{%
\paragraph{Examples}\label{examples}}

Venlafaxine (Effexor), Duloxetine (Cymbalta), desvenlafaxine, levomilnacipran, milnacipran.

\hypertarget{side-effects-1}{%
\paragraph{Side Effects}\label{side-effects-1}}

↑ BP most common; also stimulant effects, sedation, nausea

\hypertarget{tricyclic-antidepressants-tcas}{%
\subsubsection{Tricyclic Antidepressants (TCAs)}\label{tricyclic-antidepressants-tcas}}

\hypertarget{mechanism-of-action-2}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-2}}

Block reuptake of NE and 5-HT. (-triptyline, -pramine --doxepin)

\hypertarget{use-2}{%
\paragraph{Use}\label{use-2}}

Major depression, OCD (clomipramine), peripheral neuropathy, chronic pain, migraine prophylaxis.

\hypertarget{examples-1}{%
\paragraph{Examples}\label{examples-1}}

3° amines: -Amitriptyline (pain/migraines), Imipramine (enuresis), clomipramine (OCD), doxepin
2° amines: -Nortriptyline, amoxapine, desipramine (ADHD)

\hypertarget{side-effects-2}{%
\paragraph{Side Effects}\label{side-effects-2}}

Tri-C's: CNS toxicity (Convulsions/Coma), Cardiotoxicity (arrhythmia -Na+ channel inhib, ↑QT int), antiCholinergic (urinary retention);
Sedation, α1-blocking effects (postural hypotension), anticholinergic SEs (tachycardia, urinary retention, dry mouth)
3° TCAs (amitriptyline) have more anticholinergic effects than 2° TCAs (nortriptyline).
QRS duration \textgreater100 msec → assoc. w. ↑risk of arrhythmias and/or seizures =indication for Tx: NaHCO3-stabilizes myocardium, alkalinize urine
Confusion/hallucinations in elderly due to anticholinergic side effects (use nortriptyline)

\hypertarget{monoamine-oxidase-inhibitors-maois}{%
\subsubsection{Monoamine Oxidase Inhibitors (MAOIs)}\label{monoamine-oxidase-inhibitors-maois}}

Note: Rarely used anymore

\hypertarget{mechanism-of-action-3}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-3}}

Nonselective MAO inhibition → ↑ levels of amine neurotransmitters (NE, 5-HT,dopamine)

\hypertarget{use-3}{%
\paragraph{Use}\label{use-3}}

Atypical depression (hypersomnia, ↑ appetite, heavy extremities, ↑ sensitivity to interpersonal rejection)
Anxiety
- Selegiline → only antidepressant that comes in dermal patch form (good for patient that cannot tolerate PO)

\hypertarget{examples-2}{%
\paragraph{Examples}\label{examples-2}}

Phenelzine, Isocarboxazid, Tranylcypromine, (MAO Takes Pride In Shanghai), Selegiline (selective MAO-B inhibitor -- Parkinson's, Transdermal).

\hypertarget{side-effects-3}{%
\paragraph{Side Effects}\label{side-effects-3}}

\textbf{Hypertensive crisis} (tyramine (cheese, wine)) → ↑↑ BP, HA, sweating, N/V, photophobia, autonomic instability, stroke/death Tx: Nitroprusside, Phentolamine
\textbf{Serotonin Syndrome}: MAOIs are contraindicated in combo w/ SSRIs, TCAs, Tramadol, Linezolid, St.~John's wort, meperidine, dextromethorphan
- Wait 2 weeks after stopping MAO inhibitors before starting serotonergic drugs or stopping dietary restrictions.
Linezolid is a weak MAOI, and warrants avoidance of norepi and serotonergic drugs (big problem in CF patients w/ depression), otherwise risk hypertensive urgency and/or serotonin syndrome, respectively

\hypertarget{norepinephrine-dopamine-reuptake-inhibitors-ndris}{%
\subsubsection{Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)}\label{norepinephrine-dopamine-reuptake-inhibitors-ndris}}

\hypertarget{mechanism-of-action-4}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-4}}

↑ norepinephrine and Dopamine via unknown mechanism

\hypertarget{use-4}{%
\paragraph{Use}\label{use-4}}

MDD w/ sexual side effects from SSRI's, MDD w/ wt gain/hypersomnia (bupropion is PRO penis, not Bulemic). Smoking cessation.

\hypertarget{examples-3}{%
\paragraph{Examples}\label{examples-3}}

Bupropion (Wellbutrin)

\hypertarget{side-effects-4}{%
\paragraph{Side Effects}\label{side-effects-4}}

Seizures (in anorexic/bulimic or hx seizures), stimulant effects (tachycardia, insomnia), headache
No sexual side effects

\hypertarget{alpha2-adrenergic-receptor-antagonists}{%
\subsubsection{Alpha2-Adrenergic Receptor Antagonists}\label{alpha2-adrenergic-receptor-antagonists}}

\hypertarget{mechanism-of-action-5}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-5}}

α2-antagonist (↑release of NE and 5-HT), potent 5-HT2 /5-HT3 receptor antagonist and H1 antagonist (sleepy/appetite effects)

\hypertarget{use-5}{%
\paragraph{Use}\label{use-5}}

Major depression (especially in patient w/ weight loss and/or insomnia) → EX: cancer patient w/ N/V, ↓appetite, + MDD

\hypertarget{examples-4}{%
\paragraph{Examples}\label{examples-4}}

Mirtazapine (Remeron)

\hypertarget{side-effects-5}{%
\paragraph{Side Effects}\label{side-effects-5}}

Sedation (desirable in depressed patients w/ insomnia), ↑appetite, wt gain (may be desirable in elderly/anorexic), dry mouth.

\hypertarget{notes}{%
\paragraph{Notes}\label{notes}}

Adrenergics like guanfacine and clonidine are very useful in hyperactive ADHD and sometimes PTSD/irritability in general. Mirtazapine/Remeron is a multi-receptor drug and most of its psychotropic effect is from 5-HT activity, actually.

\hypertarget{serotonin-receptor-antagonists-and-agonists}{%
\subsubsection{Serotonin Receptor Antagonists and Agonists}\label{serotonin-receptor-antagonists-and-agonists}}

\hypertarget{mechanism-of-action-6}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-6}}

Primarily blocks 5-HT2, α1-adrenergic, and H1 receptors; also weakly inhibits 5-HT reuptake.

\hypertarget{use-6}{%
\paragraph{Use}\label{use-6}}

Insomnia (high doses are needed for antidepressant effects)

\hypertarget{examples-5}{%
\paragraph{Examples}\label{examples-5}}

Trazodone (Desyrel) and Nefazodone (Serzone)

\hypertarget{side-effects-6}{%
\paragraph{Side Effects}\label{side-effects-6}}

Sedation, nausea, priapism, postural hypotension. Called traZZZoBONE → b/c sedative and male-specific side effects.

\hypertarget{nicotinic-ach-receptor-partial-agonist}{%
\subsubsection{Nicotinic ACh Receptor Partial Agonist}\label{nicotinic-ach-receptor-partial-agonist}}

\hypertarget{use-7}{%
\paragraph{Use}\label{use-7}}

Smoking cessation

\hypertarget{examples-6}{%
\paragraph{Examples}\label{examples-6}}

Varenicline (Chantix)

\hypertarget{side-effects-7}{%
\paragraph{Side Effects}\label{side-effects-7}}

Sleep disturbance, mood changes, suicidality, cardiovascular events

\hypertarget{antipsychotics}{%
\subsection{Antipsychotics}\label{antipsychotics}}

\hypertarget{typical-antipsychotics-1st-generation}{%
\subsubsection{Typical Antipsychotics (1st Generation)}\label{typical-antipsychotics-1st-generation}}

\hypertarget{mechanism-of-action-7}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-7}}

Block D2 receptors (↑{[}cAMP{]}) → Low/High Potency can cause QT prolongation(450 = number you are looking for)

\hypertarget{use-8}{%
\paragraph{Use}\label{use-8}}

Schizophrenia (helps positive sx, little effect on neg sx), psychosis, bipolar disorder, delirium, Tourette syndrome, Huntington disease, OCD

\hypertarget{low-potency}{%
\paragraph{Low Potency}\label{low-potency}}

Chlorpromazine,(Corneal deposition), Thioridazine(reTinal deposition) → \textbf{C}heating \textbf{T}hieves are \textbf{LOW}
- Blocks HAM -- Histamine (sedation), α1 (orthostatic hypoTN), Muscarinic (dry mouth, constipation)

\hypertarget{high-potency}{%
\paragraph{High Potency}\label{high-potency}}

Trifluoperazine, Fluphenazine, Haloperidol → Try to Fly High
- Libido, osteoporosis, amenorrhea, gynecomastia Tuberoinfundibular: block dopa → ↑ prolactin→ ↓GnRH → ↓ FSH/LH\\
- Extrapyramidal symptoms - Nigrostriatal: ACTH/dopamine in balance → block dopamine → ↑ACTH

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.09\columnwidth}\raggedright
ADAPT\strut
\end{minipage} & \begin{minipage}[b]{0.05\columnwidth}\raggedright
Time\strut
\end{minipage} & \begin{minipage}[b]{0.27\columnwidth}\raggedright
Extrapyramidal Symptoms\strut
\end{minipage} & \begin{minipage}[b]{0.48\columnwidth}\raggedright
Management\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.09\columnwidth}\raggedright
Acute Dystonia\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Hrs-days\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Muscle spasm, torticollis, stiffness, oculogyric crisis\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
IM: (1) Benztropine (2) Diphenhydramine (antihistamine and anticholinergic effects) (3) Lorazepam\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
Akathisia\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Days -mos\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Restlessness, ↑risk for suicide\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
Propranolol\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
Parkinsonism\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Days- mos\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Bradykinesia, tremor, rigidity, mask-like facies,\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
1. Benztropine (NOT L-dopa b/c ↑ dopamine → ↑ psychosis) 2. Trihexyphenidyl, maybe amantadine\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.09\columnwidth}\raggedright
Tardive dyskinesia\strut
\end{minipage} & \begin{minipage}[t]{0.05\columnwidth}\raggedright
Mos-yrs\strut
\end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright
Repetitive orofacial movements - dopamine hypersensitivity\strut
\end{minipage} & \begin{minipage}[t]{0.48\columnwidth}\raggedright
1. STOP antipsychotic (may worsen when first stop) 2. START atypical -\textgreater{} Quetiapine or Clozapine\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

Neuroleptic malignant syndrome: Fever (\textgreater103), Rigidity, ↑ CPK → rhabdo, AKI
- Due to dopamine dysregulation. Caused by: typical/atypical antipsychotics, antiemetics, antiparkinson med withdrawal, infection, surgery
- FEVER: Fever, Encephalopathy (AMS), Vitals unstable, ↑ Enzymes, Rigidity (lead pipe), leukocytosis
- Compare to Serotonin Syndrome → NMS (↑↑Rigidity), SS (↑DTRs/clonus, GI sxs)
- Tx; (1) STOP drug (most important intervention) (2) Hydrate, cooling blankets
If no response to stopping drug →(3) Dantrolene (inhibition of Ca2+ release)/ Bromocriptine/Amantadine (4) ECT

\hypertarget{notes-1}{%
\paragraph{Notes}\label{notes-1}}

IV and IM carry more risk of QTc and torsades than PO
Our hospital has policy that only can get IV haloperidol while on telemetry (ICUs and 8E)

\hypertarget{atypical-antipsychotics-2nd-generation}{%
\subsubsection{Atypical Antipsychotics (2nd Generation)}\label{atypical-antipsychotics-2nd-generation}}

\hypertarget{mechanism-of-action-8}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-8}}

Blocking D2 receptor AND serotonin 2A receptor blockade

\hypertarget{use-9}{%
\paragraph{Use}\label{use-9}}

Schizophrenia (better neg sx coverage than typicals), bipolar disorder, OCD, anxiety disorder, depression, mania, Tourette syndrome

\hypertarget{side-effects-8}{%
\paragraph{Side Effects}\label{side-effects-8}}

ALL SE's: Metabolic side effects → sleepy and fat, → W/u: EKG, Lipids, BMI
- Olanzapine → Obesity (metabolic syndrome)
- Risperidone → ↑prolactin (↓dopamine activity in tuberoinfundibular pathway→ gynecomastia, galactorrhea, amenorrhea)
- Quetiapine → best for movement disorders (ex: Parkinson's)
- Ziprasidone → starts w/ Z worst for the qTC, ↓metabolic effects
- Aripiprazole → light and ``ari'' → doesn't put you to sleep/lead to weight gain; partial agonist at D2
- Clozapine → D4 blockade is primary effect, must watch closely → monitor WBC and ANC
-- 3 good: best efficacy (if nothing else working), ↓ risk of suicide in schizophrenia (lithium only other), good for Lewy Body Dementia
-- 6 bad (1) Agranulocytosis (CBCd before/wkly for 1st 6 mo→ ANC \textless1500 → Tx: STOP. (2) Myocarditis (EKG, troponins, etc) (3) ↓ Seizure threshold (most common) (4) Wt gain (worse than olanzapine) (5) Sedation (6) Sialorrhea
Others in this class not already mentioned above: Asenapine, Iloperidone, Lurasidone, Paliperidone

\hypertarget{mood-stabilizers}{%
\subsection{Mood Stabilizers}\label{mood-stabilizers}}

\hypertarget{lithium}{%
\subsubsection{Lithium}\label{lithium}}

\hypertarget{mechanism-of-action-9}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-9}}

Not established; possibly related to inhibition of phosphoinositol cascade → inositol = buzzword

\hypertarget{use-10}{%
\paragraph{Use}\label{use-10}}

Mood stabilizer for bipolar disorder; blocks relapse and acute manic events.
- Drug of choice in acute mania and as prophylaxis for both manic/depressive episodes in bipolar \& schizoaffective disorders.
- It is also used in cyclothymic disorder and unipolar depression
- Excellent at low doses for anti-suicidality
\emph{Contraindications}: chronic kidney disease, heart disease, hyponatremia or diuretic use
\emph{Therapeutic range}: 0.8-1.2 mEq/L

\hypertarget{side-effects-9}{%
\paragraph{Side Effects}\label{side-effects-9}}

Lithium SEs: Movement (tremor), Nephrogenic Diabetes Insipidus HypOthyroidism, Pregnancy problems (Ebstein anomaly) (LMNOP). Skin problems (acne, psoriasis).
- Prior to starting: ECG, BUN, creatinine, Ca2+, u/s,, thyroid function tests, CBC, and a pregnancy test
Almost exclusively excreted by kidneys; most is reabsorbed at PCT w/ Na+
- ↑ Li+ levels: NSAIDs, Aspirin, Thiazides, ACEi/ARBs, Metronidazole, Dehydration, Salt depr, Sweating (salt loss), ↓renal fxn
- ↓ Li+ levels: K+ sparing diuretics, Theophylline, CCB/Furosemide may ↑/↓
\textbf{Acute Lithium toxicity}: tremor, diarrhea, vomiting, weakness, polyuria, polydipsia, ataxia, cognitive impairment
\textbf{Chronic Lithium toxicity}: nephrogenic diabetes insipidus, thyroid dysfunction, hyperparathyroidism

\hypertarget{valproic-acid-depakote}{%
\subsubsection{Valproic Acid (Depakote)}\label{valproic-acid-depakote}}

\hypertarget{mechanism-of-action-10}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-10}}

↑ Na+ channel inactivation, ↑ GABA concentration by inhibiting GABA transaminase

\hypertarget{use-11}{%
\paragraph{Use}\label{use-11}}

Bipolar (acute mania, mixed features, rapid cycling), Migraine prophylaxis, Myoclonic seizures

\hypertarget{side-effects-10}{%
\paragraph{Side Effects}\label{side-effects-10}}

Hepatotoxicity (measure LFTs)/↑ ammonia, Hemorrhagic Pancreatitis, ↓ plts, neural tube defects, tremor, wt gain/PCOS, hair loss

\hypertarget{carbamazepine-tegretol}{%
\subsubsection{Carbamazepine (Tegretol)}\label{carbamazepine-tegretol}}

\hypertarget{mechanism-of-action-11}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-11}}

Blocks Na+ channels

\hypertarget{use-12}{%
\paragraph{Use}\label{use-12}}

Bipolar (esp.~mania w/ mixed features and rapid-cycling), Antiepileptic, Trigeminal neuralgia

\hypertarget{side-effects-11}{%
\paragraph{Side Effects}\label{side-effects-11}}

cyt P-450 inducer (↓ Warfarin effects → bleed, ↓ OCP effects → pregnancy), blood dyscrasias (agranulocytosis (↓ ANC), aplastic anemia), liver toxicity, teratogenesis, SIADH, Stevens-Johnson syndrome, Diplopia, ataxia

\hypertarget{buspirone-buspar}{%
\subsubsection{Buspirone (BuSpar)}\label{buspirone-buspar}}

\hypertarget{mechanism-of-action-12}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-12}}

Stimulates 5-HT1A receptors

\hypertarget{use-13}{%
\paragraph{Use}\label{use-13}}

Generalized anxiety disorder

\hypertarget{side-effects-12}{%
\paragraph{Side Effects}\label{side-effects-12}}

Does not cause sedation, addiction, or tolerance.
Takes 1--2 wks to take effect. Does not interact w/ alcohol (vs barbiturates, benzodiazepines)

\hypertarget{benzodiazepines}{%
\subsubsection{Benzodiazepines}\label{benzodiazepines}}

\hypertarget{mechanism-of-action-13}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-13}}

Facilitate GABA-A action by ↑ freq of Cl− channel opening. ↓ REM sleep.
``Frenzodiazepines'' ↑ frequency. Benzos, barbs, and alcohol all bind the GABA-A receptor, which is a ligand-gated Cl− channel.
Most have long half-lives/active metabolites (except: Alprazolam, Triazolam, Oxazepam, Midazolam→ short acting, ↑ addictive potential)

\hypertarget{use-14}{%
\paragraph{Use}\label{use-14}}

Anxiety, akathisia, spasticity, status epilepticus (Lorazepam, diazepam), eclampsia, detoxification (esp.~alcohol withdrawal/DTs), night terrors, sleepwalking, general anesthetic (amnesia, muscle relaxation), hypnotic (insomnia)

\hypertarget{examples-7}{%
\paragraph{Examples}\label{examples-7}}

Diazepam (Valium), Clonazepam (Klonopin), Lorazepam (Ativan), temazepam, oxazepam (safer for impaired liver), midazolam (Versed), triazolam, chlordiazepoxide (long-acting, used to treat EtOH withdrawal, but not in liver failure), Alprazolam (Xanex).

\hypertarget{side-effects-13}{%
\paragraph{Side Effects}\label{side-effects-13}}

Dependence, Additive CNS depression effects w/ alcohol (drowsiness, impaired intellect, motor coordination, amnesia)
- Less risk of respiratory depression and coma than in barbiturates.

Overdose tx: Flumazenil (competitive antagonist at GABA benzodiazepine receptor)
- Can precipitate seizures by causing acute benzodiazepine withdrawal → withdrawal can be life threatening

\hypertarget{barbiturates}{%
\subsubsection{Barbiturates}\label{barbiturates}}

\hypertarget{mechanism-of-action-14}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-14}}

Facilitate GABA-A action by ↑ duration of Cl− channel opening → ↓ neuron firing (barbiturates → ↑ duration).
Contraindicated in porphyria.

\hypertarget{use-15}{%
\paragraph{Use}\label{use-15}}

Sedative for anxiety, seizures, insomnia, induction of anesthesia (thiopental).

\hypertarget{examples-8}{%
\paragraph{Examples}\label{examples-8}}

Phenobarbital, pentobarbital, thiopental, secobarbital

\hypertarget{side-effects-14}{%
\paragraph{Side Effects}\label{side-effects-14}}

Respiratory/cardiovascular depression (can be fatal); CNS depression (exacerbated by alcohol use); dependence
- Drug interactions (induces cytochrome P-450)

Overdose Tx: supportive (assist respiration and maintain BP)

\hypertarget{non-benzodiazepine-hypnotics}{%
\subsubsection{Non-Benzodiazepine Hypnotics}\label{non-benzodiazepine-hypnotics}}

\hypertarget{mechanism-of-action-15}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-15}}

Act via the BZ1 subtype of the GABA receptor. Effects reversed by flumazenil.
Sleep cycle less affected as compared w/ benzodiazepine hypnotics

\hypertarget{use-16}{%
\paragraph{Use}\label{use-16}}

Insomnia. Should be used short-term (weeks-months), although ↓ risk of dependence compared to benzos as sleep aid.

\hypertarget{examples-9}{%
\paragraph{Examples}\label{examples-9}}

Zolpidem (Ambien), Zaleplon (Sonata), esZopiclone (Lunesta). ``All ZZZs put you to sleep.''

\hypertarget{side-effects-15}{%
\paragraph{Side Effects}\label{side-effects-15}}

Sleep-walking, ataxia, headaches, confusion. Short duration because of rapid metabolism by liver enzymes.
Unlike older sedative-hypnotics, cause only modest day-after psychomotor depression and few amnestic effects.

\hypertarget{other-psychotropic-medications}{%
\subsection{Other Psychotropic Medications}\label{other-psychotropic-medications}}

\hypertarget{stimulants-1}{%
\subsubsection{Stimulants}\label{stimulants-1}}

\hypertarget{mechanism-of-action-16}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-16}}

↑ catecholamines in the synaptic cleft, especially norepinephrine and dopamine

\hypertarget{use-17}{%
\paragraph{Use}\label{use-17}}

ADHD, narcolepsy (modafinil), appetite control

\hypertarget{examples-10}{%
\paragraph{Examples}\label{examples-10}}

Methylphenidate (Ritalin, Concerta), Dextroamphetamine (Adderall), methamphetamine, Modafinil (Provigil). Atomoxetine (Strattera) is not technically a stimulant, in its own class.

\hypertarget{side-effects-16}{%
\paragraph{Side Effects}\label{side-effects-16}}

Hypertension, weight loss, insomnia, exacerbation of tics, ↓ seizure threshold

\hypertarget{acetylcholinesterase-inhibitors}{%
\subsubsection{Acetylcholinesterase Inhibitors}\label{acetylcholinesterase-inhibitors}}

\hypertarget{mechanism-of-action-17}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-17}}

Inhibits AChE → ↑ ACh in synaptic cleft

\hypertarget{use-18}{%
\paragraph{Use}\label{use-18}}

Mild-moderate dementias (neurocognitive disorders) → ex: Alzheimer's (Donepezil/Rivastigmine)

\hypertarget{examples-11}{%
\paragraph{Examples}\label{examples-11}}

Donepezil (Aricept), Galantamine (Razadyne), Rivastigmine (Exelon)

\hypertarget{nmda-glutamate-receptor-antagonist}{%
\subsubsection{NMDA (Glutamate) Receptor Antagonist}\label{nmda-glutamate-receptor-antagonist}}

\hypertarget{mechanism-of-action-18}{%
\paragraph{Mechanism of Action}\label{mechanism-of-action-18}}

Antagonist at NMDA (glutamate) receptor

\hypertarget{use-19}{%
\paragraph{Use}\label{use-19}}

ADHD, narcolepsy (modafinil), appetite control

\hypertarget{examples-12}{%
\paragraph{Examples}\label{examples-12}}

Memantine (Nemenda)

\hypertarget{electroconvulsive-therapy-ect}{%
\subsection{Electroconvulsive Therapy (ECT)}\label{electroconvulsive-therapy-ect}}

\hypertarget{definition-56}{%
\subsubsection{Definition}\label{definition-56}}

Small electric current to produce generalized seizure for 20-30 seconds under general anesthesia

\hypertarget{indications-6}{%
\subsubsection{Indications}\label{indications-6}}

Used in: Unipolar/bipolar depression, catatonia, bipolar mania. For: Treatment resistance, psychotic features, emergent conditions (pregnancy, refusal to eat/drink, imminent risk for suicide), pharmacotherapy contraindicated due to comorbid illness/poor tolerability, hx of ECT response.

\hypertarget{safety-1}{%
\subsubsection{Safety}\label{safety-1}}

No absolute contraindications
Increased risk: severe cardiovascular disease, recent MI, space-occupying brain lesion, recent stroke, unstable aneurysm

\hypertarget{side-effects-17}{%
\subsubsection{Side Effects}\label{side-effects-17}}

Most common: amnesia (anterograde or retrograde; anterograde resolves rapidly, retrograde persists) -- rare w/ unilateral ECT and many experts think repeated general anesthesia may be major contributor

\hypertarget{psychotherapy}{%
\subsection{Psychotherapy}\label{psychotherapy}}

\begin{longtable}[]{@{}cccc@{}}
\toprule
\begin{minipage}[b]{0.10\columnwidth}\centering
Modality\strut
\end{minipage} & \begin{minipage}[b]{0.04\columnwidth}\centering
Duration\strut
\end{minipage} & \begin{minipage}[b]{0.37\columnwidth}\centering
Patient\strut
\end{minipage} & \begin{minipage}[b]{0.37\columnwidth}\centering
Focus\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.10\columnwidth}\centering
Cognitive behavioral therapy (CBT)\strut
\end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\centering
Time limited\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Anxiety, mood, personality, somatic symptom, eating disorder Maladaptive thoughts, avoidance behavior, ability to participate in homework\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Combines cognitive/behavioral tech Challenges maladaptive thoughts Targets avoidance w/ behavioral techniques (relaxation, exposure)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.10\columnwidth}\centering
Dialectical behavioral therapy (DBT)\strut
\end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\centering
Varies\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Borderline personality disorder; self-injury\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Improves emotion regulation, mindful awareness, distress tolerance Manages self-harm\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.10\columnwidth}\centering
Interpersonal psychotherapy\strut
\end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\centering
Time limited\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Depressed w/ relationship conflicts\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Links current relationships conflicts to depressive symptoms\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.10\columnwidth}\centering
Supportive psychotherapy\strut
\end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\centering
Ongoing\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Lower functioning; in crisis, psychotic\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Therapist as guide Reinforces coping skills / builds adaptive defenses\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.10\columnwidth}\centering
Motivational interviewing\strut
\end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\centering
Varies\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Substance use disorder\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Addresses ambivalence and enhances motivation to change Nonjudgmental; acknowledge resistance\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.10\columnwidth}\centering
Biofeedback\strut
\end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\centering
Varies\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Prominent physical symptoms; pain disorders\strut
\end{minipage} & \begin{minipage}[t]{0.37\columnwidth}\centering
Improves awareness and control over physiological reactions Lowers stress levels, integrates mind/body\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{pulmonology}{%
\section{Pulmonology}\label{pulmonology}}

\hypertarget{asthma-edinpatient-ebg}{%
\subsection{Asthma -- ED/Inpatient: EBG}\label{asthma-edinpatient-ebg}}

\hypertarget{history-to-elicit}{%
\subsubsection{History to Elicit}\label{history-to-elicit}}

Time of onset, causes/triggers, symptom severity, prior treatments before presentation, last time of medications, last dose of oral steroids and past requirements for oral steroid doses
\#\#\# Exam
* Tachypnea, hypoxia, altered mental status, accessory muscle use, URI symptoms, wheezing, prolonged expiratory phase, eczema, rash, signs of pneumonia/pneumothorax
* Red flags: dehydration, cyanosis/pallor, decreased aeration, AMS, admission w/i 1 year, ICU admission w/i 3 years, PCP/ED visit w/i 72 hours

\hypertarget{etiology-33}{%
\subsubsection{Etiology}\label{etiology-33}}

Trigger → Production of IgE antibodies, overstimulation of mast cells/eosinophils → Inflammation, airway smooth muscle constriction, mucus production, edema → hyper-responsiveness of airway, obstruction, air-trapping → airway remodeling

\hypertarget{work-up-77}{%
\subsubsection{Work-up}\label{work-up-77}}

\begin{itemize}
\tightlist
\item
  Assess severity w/ amount of dyspnea, RR, retractions, inspiratory vs.~expiratory wheezes, and SpO2 (determines the HASS score).
\item
  Not routinely recommended: CXR (unless prolonged fever, asymmetry post-albuterol, severe symptoms, hypoxemia, aspiration concern), viral testing, blood gas (if respiratory failure is suspected)
\end{itemize}

\hypertarget{order-sets}{%
\subsubsection{Order Sets}\label{order-sets}}

``Asthma admit plan'' (includes albuterol, Unineb, etc orders)

\hypertarget{treatment-77}{%
\subsubsection{Treatment}\label{treatment-77}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
Drug\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
Use\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Albuterol}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-For mild-severe exacerbation MDI or nebulizer, base frequency on severity -For MDI must use an aerochamber. In general, use w/ face mask (\textless6 mos = small orange facemask, 6 mos-6 yrs = medium yellow facemask, \textgreater6 years = large blue facemask)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{UniNeb}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
For moderate-severe exacerbation 3 albuterol + 3 ipratropium over 1 hr\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Systemic Corticosteroids}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
For moderate-severe exacerbation Dexamethasone Prednisone, prednisolone, or methylprednisolone\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Epinephrine}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
For severe exacerbation Administer by EpiPen if able\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Magnesium Sulfate}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
For severe exacerbation Administer w/ 20 cc/kg bolus of normal saline before dose to decrease risk of hypotension\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Terbutaline}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
For severe exacerbation\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Heliox} (80\% He + 20\% O2)\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
For severe exacerbation Contraindications: Requiring FiO2 \textgreater0.6 to maintain SpO2 \textgreater92\%, Need for PPV, PTX, pneumopericardium, pneumoperitoneum\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\emph{During flu season, also empirically treat for flu as patients with asthma are at high risk
\#\#\# Discharge Criteria
} HASS \textless7
* Pulse ox \textgreater94\%
* None or mild tachypnea
* Normal mental status
* None or minimal WOB
* Good aeration
* Mild expiratory wheeze only or clear
* Access to necessary medications, devices, and appropriate follow up

\hypertarget{asthma-outpatient-ebg}{%
\subsection{Asthma -- Outpatient: EBG}\label{asthma-outpatient-ebg}}

\hypertarget{history-to-elicit-1}{%
\subsubsection{History to Elicit}\label{history-to-elicit-1}}

Symptoms, nocturnal awakening, missed school, hospitalizations (ED, ICU, ETT), triggers, controllers, albuterol use, adherence, atopic history, vaccines, requirement for oral steroid courses.

Many of these factors go into the Asthma Predictive Index (wheezing episodes per year, asthma family history, eczema, allergic rhinitis, wheezing apart from colds, peripheral eosinophila \textgreater=4\%)

\hypertarget{presentation-142}{%
\subsubsection{Presentation}\label{presentation-142}}

SOB, coughing, wheezing, chest tightness

Exam: Tachypnea, hypoxia, altered mental status, accessory muscle use, URI symptoms, wheezing, prolonged expiration, eczema, rash

\hypertarget{etiology-34}{%
\subsubsection{Etiology}\label{etiology-34}}

Trigger → Production of IgE antibodies, overstimulation of mast cells/eosinophils → Inflammation, airway smooth muscle constriction, mucus production, edema → hyper-responsiveness of airway, obstruction, air-trapping → airway remodeling

\hypertarget{workup-27}{%
\subsubsection{Workup}\label{workup-27}}

PFTs +/- provocation test, other testing as suggested by differential diagnosis (immune work-up, GERD evaluation, allergy testing, sweat test, etc.)

\hypertarget{severity-classification}{%
\subsubsection{Severity Classification}\label{severity-classification}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
Variable\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Intermittent\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Mild\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Moderate\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Severe\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Symptom frequency\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
≤2 d/wk\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textgreater2 d/wk\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Daily\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Throughout day\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Nighttime awakenings\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
0-4 yr: 0 ≥5 yr: ≤2/mo\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
0-4 yr: 1-2/mo ≥5 yr: 3-4/mo\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
0-4 yr: 3-4/mo ≥5 yr: ≥1/wk\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
0-4 yr: \textgreater1/wk ≥5 yr: \textgreater7/wk\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Interference w/ activity\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
None\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Minor\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Some\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Extreme\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
SABA use\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
≤2 d/wk\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
0-4 yr: \textgreater2d/wk ≥5 yr: \textgreater2/wk\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Daily\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Throughout day\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
FEV1\% predicted\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textgreater80\%\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textgreater80\%\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
60-80\%\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\textless60\%\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Step 1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Step 2\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Step 3\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Step 3\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{stepwise-approach-to-asthma-treatment}{%
\subsubsection{Stepwise Approach to Asthma Treatment}\label{stepwise-approach-to-asthma-treatment}}

\begin{longtable}[]{@{}lllllll@{}}
\toprule
\begin{minipage}[b]{0.12\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Step 1\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Step 2\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Step 3\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Step 4\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Step 5\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Step 6\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.12\columnwidth}\raggedright
0-4\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
SABA PRN\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Low dose ICS\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Medium dose ICS\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Medium dose ICS + (LABA OR montelukast)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High dose ICS + (LABA OR montelukast)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High dose ICS + (LABA or montelukast) + PO steroids\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
5-11\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
SABA PRN\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Low dose ICS\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Low dose ICS + LABA or LTRA OR Medium dose ICS\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Medium dose ICS + LABA\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High dose ICS + LABA\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High dose ICS + LABA + PO steroids\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textgreater12\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
SABA PRN\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Low dose ICS\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Low dose ICS + LABA OR Medium dose ICS\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Medium dose ICS + LABA\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High dose ICS + LABA\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
High dose ICS + LABA + PO steroids\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{bronchiolitis-ebg}{%
\subsection{Bronchiolitis: EBG}\label{bronchiolitis-ebg}}

\hypertarget{presentation-143}{%
\subsubsection{Presentation}\label{presentation-143}}

URI symptoms → cough, wheezing/rales, increased WOB, peak symptoms 4-7 days of illness

Exam: rhinorrhea, cough, tachypnea, retractions, nasal flaring, grunting, crackles, wheezing

\hypertarget{differential-42}{%
\subsubsection{Differential}\label{differential-42}}

Viral URI, asthma exacerbation, PNA, croup

Red Flags: apnea, respiratory failure, pneumothorax, bacterial PNA superinfection, dehydration

\hypertarget{workup-28}{%
\subsubsection{Workup}\label{workup-28}}

Assess severity (mental/hydration/respiratory status); no routine indication for labs or CXR but consider if concern for bacterial superinfection

\hypertarget{treatment-78}{%
\subsubsection{Treatment}\label{treatment-78}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
Location\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Outpatient}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Supportive w/ bulb suction, hydration, tylenol/motrin\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Inpatient}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Absolute admission criteria: Apnea prior to admission \textless37 weeks GA and age \textless48 weeks post-conception Age \textless1 month RA sat persistent \textless92\% RR persistent \textgreater70 for \textless12 months and \textgreater60 for \textgreater20 months Severe retractions Unable to feed Wall suction, IVF, chest PT, supp O2 to maintain SpO2 \textgreater90\%, spot check SpO2HFNC - see ICP section for Bronchiolitis Pathway\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{ICU}(if hypoxia respiratory failure)\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Wall suction, IVF, chest PT, supp O2 to maintain SpO2 \textgreater90\%, CPAP/BiPAP, consider albuterol, HTS, rac epi though little evidence to support benefits of therapy, NPO for aspiration risk\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{prevention-1}{%
\subsubsection{Prevention}\label{prevention-1}}

Palivizumab for 1st 1-2 years of life depending on indication. Indications may include HD significant congenital heart disease, CLD of prematurity (\textless32 weeks + supp O2 for 1st 28 days of life or BPD in children \textless2 years who required medical therapy within 6 months of RSV season, born at \textless29 weeks gestation, anatomic pulmonary disorders, immunocompromised

\hypertarget{approach-to-cough}{%
\subsection{Approach to Cough}\label{approach-to-cough}}

\hypertarget{definition-57}{%
\subsubsection{Definition}\label{definition-57}}

Acute (less then 4 weeks) or chronic (\textgreater4 weeks)

\hypertarget{history-to-elicit-2}{%
\subsubsection{History to Elicit}\label{history-to-elicit-2}}

\begin{itemize}
\tightlist
\item
  Age and circumstances of onset
\item
  Nature of cough (dry vs.~wet)
\item
  Triggers
\item
  Associated symptoms (particularly wheezing or allergy symptoms)
\item
  History of atopy/eczema
\item
  History of recurrent infections
\item
  History of travel
\item
  Timing (night/day vs daytime only)
\end{itemize}

\hypertarget{exam-14}{%
\subsubsection{Exam}\label{exam-14}}

Look for increased work of breathing, wheezing, atopy, boggy turbinates, conjunctivitis, dysmorphisms, cardiac abnormalities

\hypertarget{differential-diagnosis-2}{%
\subsubsection{Differential Diagnosis}\label{differential-diagnosis-2}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
DDx\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Infant\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Chlamydia, viral (RSV, CMV, rubella), bacterial (pertussis), pneumocystis jiroveci, tracheoesophageal fistula, vascular ring, airway malformation (bronchogenic cyst, CPAM), pulmonary sequestration, CF, reactive airway disease/asthma, reflux, aspiration, interstitial lung disease, PCD, immunodeficiency, toxic exposures\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
Preschool to School age\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Inhaled FB, mycoplasma, bacterial (pertussis), reactive airway disease/asthma, CF, bronchiectasis, PCD, viral, passive smoke inhalation, reflux, aspiration, interstitial lung disease, allergic rhinitis, sinusitis, croup, hypersensitivity pneumonitis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
School age to Adolescence\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Reactive airway disease/asthma, infectious, CF, psychogenic/habit cough, cigarette smoking, interstitial lung disease, reflux, aspiration, smoking, allergic rhinitis\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\includegraphics{images/pulm_cough.png}

\hypertarget{cystic-fibrosis-ebg}{%
\subsection{Cystic Fibrosis: EBG}\label{cystic-fibrosis-ebg}}

\hypertarget{clinical-manifestations-28}{%
\subsubsection{Clinical Manifestations}\label{clinical-manifestations-28}}

\begin{itemize}
\tightlist
\item
  Pulmonary: Chronic airway disease w/ infection (H flu, S. aureus, P aeruginosa, Burkholderia, Steno, MRSA, atypical), bronchiectasis, air trapping, hypoxemia, hypercarbia
\item
  Sinus: Sinus infections, nasal polyposis
\item
  GI: Meconium ileus, constipation, distal intestinal obstructive syndrome, deficiencies in A, D, E, K, biliary disease
\item
  Endocrine: CF related diabetes, osteoporosis from vitamin D deficiency
\item
  MSK: Hypertrophic osteoarthropathy
\item
  Reproduction: Congenital absence of vas deferens
\item
  Renal: Nephrolithiasis due to chronic metabolic acidosis
\item
  Hematologic: Recurrent venous thrombosis due to chronic inflammatory state
\end{itemize}

\hypertarget{diagnosis-14}{%
\subsubsection{Diagnosis}\label{diagnosis-14}}

\begin{itemize}
\tightlist
\item
  Diagnostic Criteria: CF in 1+ organ system AND evidence of CFTR dysfunction through either elevated sweat chloride, two disease causing mutations, or abnormal nasal transepithelial potential difference
\item
  Sweat Test: \textless=29 normal, 30-59 intermediate, \textgreater=60 abnormal
\item
  Newborn Screen: Massachuesetts NBS measures immunoreactive trypsinogen (IRT) by radioimmunoassay or enzyme-linked immunoassay. If elevated, then DNA is run to look for CFTR mutations.
\item
  CFTR Genetic Analysis
\end{itemize}

\hypertarget{pulmonary-exacerbations}{%
\subsubsection{Pulmonary Exacerbations}\label{pulmonary-exacerbations}}

Symptoms: Increased cough, change in sputum color/quantity, decreased appetite, weight loss, tachypnea

\hypertarget{chronic-pulmonary-treatment}{%
\subsubsection{Chronic Pulmonary Treatment}\label{chronic-pulmonary-treatment}}

\begin{itemize}
\tightlist
\item
  Agents to increase mucus clearance: Albuterol → Inhaled hypertonic saline → Pulmozyme → Chest PT (baseline in 2x per day and during illness increased to 3-4x)
\item
  Anti-inflammatory therapy: Consider azithromycin
\item
  Persistent Pseudomonas Colonization: Inhaled tobramycin and aztreonam
\item
  Vaccines: pneumococcal, yearly influenza
\item
  Supplemental O2: If intermittent or chronic hypoxemia
\item
  Nutritional support: pancreatic enzymes, replacement of fat-soluble vitamins, nutritional counseling
\item
  CFTR modulators:
  * Ivacaftor ``Kalydeco'' (CFTR potentiator for C551D mutation)
  * Lumacaftor/Ivacaftor ``Orkambi'' (CFTR potentiator + corrects the F508del mutation and increases amount of functional CFTR at surface)
  * Tezacaftor/Ivacaftor ``Symdeko'' (CFTR modulator for F508del mutation)
  * Elexacaftor/Ivacaftor/Tezacaftor ``Trikafta'' (CFTR potentiator + corrects F508del mutation)
\item
  Annual Screening: OGTT if \textgreater12, audiogram
\end{itemize}

\hypertarget{treatment-cf-exacerbations}{%
\subsubsection{Treatment CF Exacerbations}\label{treatment-cf-exacerbations}}

\begin{itemize}
\tightlist
\item
  Home meds
\item
  Antibiotics
\item
  Pulmonary clearance regimen
\item
  Bowel regimen
\end{itemize}

\hypertarget{admission-labs}{%
\subsubsection{Admission Labs}\label{admission-labs}}

\begin{itemize}
\tightlist
\item
  Use ``Pulmonary Cystic Fibrosis CPG admit order set'': CBC w/ diff, coags, electrolytes, LFTs, CRP, IgE, IgG, C3, C4, UA

  \begin{itemize}
  \tightlist
  \item
    Vitamin levels if not done within 6 months (25OH Vit D, PTH, Vit A, Vit E)
  \item
    Urine HcG for women \textgreater13
  \item
    Urine specific gravity if starting nephrotoxic IV agent; if \textgreater1.012, give 20 cc/kg NS bolus prior to starting
  \end{itemize}
\end{itemize}

\hypertarget{lab-monitoring}{%
\subsubsection{Lab monitoring:}\label{lab-monitoring}}

\begin{itemize}
\tightlist
\item
  Qweek (CBC diff, LFTs, CRP), Qmon/Thurs (BUN/Cr, Abx trough)
\end{itemize}

\hypertarget{antibiotics-1}{%
\subsubsection{Antibiotics:}\label{antibiotics-1}}

\begin{itemize}
\tightlist
\item
  Tailor antibiotic regimen based on previous sputum cultures and antibiotic regimens to provide optimal coverage

  \begin{itemize}
  \tightlist
  \item
    Pseudomonas aeruginosa: aztreonam, cefepime, ceftazidime, ciprofloxacin, colistimethate, meropenem/imipenem, piperacillin/tazobactam, tobramycin, amikacin, ceftazidime, colistin

    \begin{itemize}
    \tightlist
    \item
      Inhaled options: tobramycin, aztreonam, amikacin
    \end{itemize}
  \item
    MRSA: vancomycin, linezolid, ceftaroline, bactrim, minocycline, doxycycline, clindamycin

    \begin{itemize}
    \tightlist
    \item
      Inhaled option: vancomycin
    \end{itemize}
  \item
    MSSA: augmentin, unasyn, cefepime
  \item
    Stenotrophomonas maltophilia: bactrim, minocycline, levofloxacin
  \item
    Haemophilus influenzae: augmentin, azithromycin, ceftriaxone, cefuroxime, cefotaxime, ciprofloxacin, levofloxacin, moxifloxacin, doxycycline, bactrim, unasyn
  \item
    Achromobacter: meropenem, zosyn, bactrim, ceftazidime, cefepime, colistimethate, tobramycin
  \item
    Burkolderia cepacia complex: meropenem, ceftazidime, minocycline, doxycycline, zosyn, bactrim
  \end{itemize}
\end{itemize}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.22\columnwidth}\raggedright
Class\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Antibiotic\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Side Effects\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Monitoring\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Amino-glycoside\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Tobramycin\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
OtotoxicityNephrotoxicityPhototoxicity\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Peak/trough w/ 2nd dose, goal peak is 20-40, tough \textless{} 1 (IV only)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Amino-glycoside\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Amikacin\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
OtotoxicityNephrotoxicityPhototoxicity\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
PeakAFB= 20-30PSA or Short term dosing=40-60Trough \textless{} 2.5\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
B lactams\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
MeropenemImipenem\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
TransaminitisGI intolerance\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
B lactams\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Ceftaroline (5th generation cephalosporin)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Oxazolidinones\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Linezolid\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Serotonin syndrome (w/ concurrent SSRI, avoid aged chees, meat, red wine, fava beans)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Sulfonamide\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Trimethoprim- Sulfamex-thoxasole (TMP- SMX, or Bactrim)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Photosensitivity, SJS\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Polycationic\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Polymyxin E (Colistin)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Pulmonary toxicity (respiratory failure following inhalation, bronchoconstriction, Nephrotoxicity)Paraesthesias\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Glycopeptide\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Vancomycin\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Nephrotoxicity, red man syndrome, eosinophilia, DRESS\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
No peak, goal trough 15-20 (for continuous vanc: q24 until goal level 20-30)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Tetracycline\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Tigecycline**Minocycline\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Photosensitivity, pancreatitis, hepatotoxicity, acute, intracranial hypertension, renal failure, photosensitivity\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{pulmonary-clearance}{%
\subsubsection{Pulmonary Clearance:}\label{pulmonary-clearance}}

Order: Bronchodilator → Hypertonic saline → Pulmozyme → Chest PT → Inhaled steroid and/or inhaled antibiotic

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Bronchodilators = albuterol, levalbuterol, ipratropium, duoneb
\item
  Hypertonic saline = 7\% usually BID
\item
  Pulmozyme = 2.5 neb daily or BID (occasionally also 5 mg neb Qday)
\item
  Chest PT = TID to QID
\end{enumerate}

\hypertarget{bowel-regimen}{%
\subsubsection{Bowel Regimen}\label{bowel-regimen}}

Prevention of distal intestinal obstruction syndrome
Options:

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Miralax
\item
  Dulcolax (oral or PR)
\item
  Lactulose
\item
  Mucomyst enema
\item
  SMOG enema
\end{enumerate}

\hypertarget{hemoptysis-cf}{%
\subsection{Hemoptysis (CF)}\label{hemoptysis-cf}}

\hypertarget{definition-58}{%
\subsubsection{Definition}\label{definition-58}}

Acute bleeding \textgreater240 cc in 24 hours or recurrent bleeding of \textgreater100 cc daily for several days

\hypertarget{management-103}{%
\subsubsection{Management}\label{management-103}}

\begin{itemize}
\tightlist
\item
  Call for help
\item
  Assess site of bleeding on auscultation and place patient with that side down
\item
  Interventions: attempt to identify bleeding source, hemostasis interventions, chest CT, bronchial artery embolization, tranexamic acid, ECMO
\item
  ORL and GI consult to help evaluate for hematemesis vs.~hemoptysis
\item
  Treatment is all guided by the volume of hemoptysis

  \begin{itemize}
  \tightlist
  \item
    \textbf{Scant}: anything from blood-streaked mucous to a teaspoon (5 mL)

    \begin{itemize}
    \tightlist
    \item
      Consider stopping NSAIDS, but guidelines recommend continuing the rest of the pulmonary clearance regimen!
    \item
      Ensure vitamin K replete
    \end{itemize}
  \item
    \textbf{Mild/moderate}: approximately between an ounce and half a cup

    \begin{itemize}
    \tightlist
    \item
      Here's where you might consider decreasing pulmonary clearance regimen, weighing the risks of bleeding with the need to remove the inspissated mucous causing the problem
    \item
      Hypertonic saline is more caustic/irritating than dornase alfa
    \item
      If your patient is bleeding so much that you're considering holding their BIPAP to avoid destabilizing a clot, they should be in a higher level of care
    \item
      Consider tranexamic acid (inhaled or IV) to stabilize clot
    \item
      Bronchoalveolar embolization of the bleeding arteries by interventional radiology is the gold standard treatment
    \end{itemize}
  \item
    \textbf{Massive}: more than a cup
    * Bleeding lung down to the bed to maximize gas exchange in the other lung
    * ICU stat or code blue
  \end{itemize}
\end{itemize}

\hypertarget{clinically-stable-patient-with-hemoptysis}{%
\subsubsection{Clinically stable patient with hemoptysis}\label{clinically-stable-patient-with-hemoptysis}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.22\columnwidth}\raggedright
Volume\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Scant\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Mild/moderate\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Massive\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.22\columnwidth}\raggedright
NSAIDS\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
No consensus\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Stop\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Stop\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Chest PT\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Do not stop\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
No consensus\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Stop\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Hypertonic saline\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Do not stop\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
No consensus\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Stop\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Dornase alfa\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Do not stop\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
No consensus\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Stop\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
BIPAP\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Do not stop\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
No consensus\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Stop\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Other considerations\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Vitamin K repletionLocation of pain?\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Tranexamic AcidIR embolization\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Bleeding lung downICU stat\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

Source: Cystic Fibrosis Pulmonary Guidelines: Pulmonary Complications: Hemoptysis, 2010 (consensus-based, national guidelines)

\hypertarget{pneumothorax-1}{%
\subsection{Pneumothorax}\label{pneumothorax-1}}

\hypertarget{types}{%
\subsubsection{Types}\label{types}}

Spontaneous, traumatic, tension
\#\#\# Presentation
Chest pain, SOB, no symptoms, decreased breath sounds, hypoxia, if tension (hypotension, tachycardia, JVD)
\#\#\# Workup
CXR (If concern for tension physiology, skip CXR and go straight to management)
\#\#\# Management
* ABCs, supplemental O2 if hypoxia
* Unstable: chest tube placement
* Tension: needle decompression 2nd ICS at MCL
* Stable/Small: observation
* Stable/Large: chest tube or pigtail catheter, VATS w/ pleurodesis if continued air leak (typically after 72 hours)

\hypertarget{pneumonia-ebg}{%
\subsection{Pneumonia: EBG}\label{pneumonia-ebg}}

\hypertarget{presentation-144}{%
\subsubsection{Presentation}\label{presentation-144}}

Fever, cough, dyspnea, pleuritic pain, respiratory distress
\#\#\# Etiology
* Neonatal: GBS, E. coli, K. pneumoniae, HSV
* Infants: viral, S. pneumoniae, C. trachomatis
* Pre-school age: viral, S. pneumoniae, S. pyogenes, S. aureus, B. pertussis
* School-aged: M. pneumoniae, C. pneumoniae, S. pneumoniae, S. aureus

\hypertarget{differential-43}{%
\subsubsection{Differential}\label{differential-43}}

Asthma, pleural effusion/empyema, FB aspiration
\#\#\# Workup
CXR, RVP, ESR/CRP, procalcitonin (although WBC, ANC, CRP, and procal do not correlate with illness severity)

\hypertarget{when-to-hospitalize}{%
\subsubsection{When to Hospitalize}\label{when-to-hospitalize}}

Moderate-severe respiratory distress, SpO2 \textless90\%, infants \textless6 mos, concern for virulent pathogen (MRSA), unable to tolerate PO intake
\#\#\# Treatment
* Outpatient: amoxicillin
* Inpatient: ampicillin
* Alternatives: add azithromycin if concern for atypicals, vancomycin if concern for s. aureus
* Duration: 10 days, 2-4 weeks if parapneumonic effusion

\hypertarget{pleural-effusions}{%
\subsection{Pleural Effusions}\label{pleural-effusions}}

\hypertarget{presentation-145}{%
\subsubsection{Presentation}\label{presentation-145}}

\begin{itemize}
\tightlist
\item
  Pain w/ inspiration, hypoxemia, hypercarbia
\item
  Exam: decreased breath sounds, dullness to percussion
\end{itemize}

\hypertarget{differential-44}{%
\subsubsection{Differential}\label{differential-44}}

\begin{itemize}
\tightlist
\item
  Transudative: Decreased plasma oncotic pressure (nephrotic syndrome, cirrhosis, hypoalbuminemia) OR increased capillary hydrostatic pressure (HF, cirrhosis)
\item
  Exudative: Increased capillary permeability (parapneumonic effusions, TB, AI disease, malignancy)
\item
  Chylothorax: Secondary to lymphatic abnormalities
\end{itemize}

\hypertarget{workup-29}{%
\subsubsection{Workup}\label{workup-29}}

\begin{itemize}
\tightlist
\item
  Imaging: CXR, US, CT
\item
  Diagnostic thoracentesis (consider if \textgreater10 mm fluid from lung to chest wall, need for definitive diagnosis, respiratory compromise)

  \begin{itemize}
  \tightlist
  \item
    Light's Criteria: Exudative if 1+ of (1) Pleural fluid protein:serum protein ratio ≥0.5, (2) Pleural fluid LDH:Serum LDH ratio \textgreater0.6, (3) Pleural fluid LDH \textgreater66\% ULN of normal serum LDH
  \end{itemize}
\end{itemize}

\hypertarget{treatment-79}{%
\subsubsection{Treatment}\label{treatment-79}}

\begin{itemize}
\tightlist
\item
  Transudative: address underlying problem
\item
  Chylothorax: Drainage, restrict to medium chain TGs as main source of dietary fat
\item
  Parapneumonic effusions (pleural fluid + pneumonia, abscess or bronchiectasis)

  \begin{itemize}
  \tightlist
  \item
    Uncomplicated: Antibiotics
  \item
    Complicated: Antibiotics + drainage +/- fibrinolytics +/- VATS
  \end{itemize}
\item
  Consider chest tube if: persistent fever, toxic appearing, large effusion, complicated pleural effusion or empyema
\end{itemize}

\hypertarget{obstructive-sleep-apnea}{%
\subsection{Obstructive Sleep Apnea}\label{obstructive-sleep-apnea}}

\hypertarget{presentation-146}{%
\subsubsection{Presentation}\label{presentation-146}}

\begin{itemize}
\tightlist
\item
  Snoring (\textgreater3 nights/wk), labored/obstructive breathing, daytime sleepiness, learning difficulties, FTT
\item
  Exam: tonsillar hypertrophy, adenoidal faces, micrognathia, HTN, overweight
\end{itemize}

\hypertarget{differential-45}{%
\subsubsection{Differential}\label{differential-45}}

Central sleep apnea, narcolepsy
\#\#\# Workup
Polysomnography to assess severity via apnea-hypopnea index (AHI) → \textgreater5 AHI warrants treatment
\#\#\# Treatment
CPAP, adenotonsillectomy if adenotonsillar hypertrophy, topical intranasal steroids or montelukast

\hypertarget{tuberculosis}{%
\subsection{Tuberculosis}\label{tuberculosis}}

\hypertarget{symptoms}{%
\subsubsection{Symptoms}\label{symptoms}}

Most common presentation in children is pulmonary disease +/- intrathoracic adenopathy. Other sxs include:

\begin{itemize}
\tightlist
\item
  Pulm: Chronic cough \textgreater3 wks w/ weight loss, fever, diaphoresis, miliary TB
\item
  CNS: Meningitis, communicating hydrocephalus, stroke, increased ICP
\item
  Abd: Ascites, abdominal pain, jaundice, chronic diarrhea
\item
  MSK: Joint effusion, Pott's disease
\item
  Derm: Warty/papulonecrotis lesions, erythema nodosum
\item
  Renal: Sterile pyuria, hematuria
\item
  Ocular: Iritis, neuritis, conjunctivitis
\end{itemize}

\hypertarget{workup-30}{%
\subsubsection{Workup}\label{workup-30}}

\begin{itemize}
\tightlist
\item
  Bacteriologic Diagnosis

  \begin{itemize}
  \tightlist
  \item
    Infants: 3 early morning gastric aspirates for AFB, Cx, PCR
  \item
    Children/Adolescents: 3 sputum for AFB, Cx, PCR
  \item
    PCR: Xpert MTB/RIF detects M. tuberculosis and rifampin resistance
  \end{itemize}
\item
  Clinical Diagnosis

  \begin{itemize}
  \tightlist
  \item
    Recent close contact w/ known infectious case + positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA) + suggestive findings on CXR or exam
  \end{itemize}
\end{itemize}

\hypertarget{treatment-80}{%
\subsubsection{Treatment}\label{treatment-80}}

\begin{itemize}
\tightlist
\item
  General: Rifampin, INH, pyrazinamide, ethambutol (RIPE) 2 mo → rifampin and INH (RI) for 4 mos
\item
  TB Meningitis: RIP + streptomycin (SM) 2 mo → RI for 7-10 mo
\item
  Osteoarticular: RIPE 2 mo → RI 7-10 mos
\item
  Relapse: RIPE + SM 2 mo → RIPE 1 mo → RIE 5 mo
\end{itemize}

\hypertarget{pulmonary-function-tests}{%
\subsection{Pulmonary Function Tests}\label{pulmonary-function-tests}}

\begin{itemize}
\item
  Indications:

  \begin{enumerate}
  \def\labelenumi{\arabic{enumi}.}
  \tightlist
  \item
    Determine the nature of an unknown disease process
  \item
    Study progression of known disease (asthma, CF)
  \item
    Evaluate effect of therapy
  \item
    Establish a baseline in pts whose lung function is affected by a disease
  \end{enumerate}
\item
  Difficult to reliably obtain in children \textless6
\item
  Reference values depend on age, height, gender, race
\end{itemize}

\hypertarget{definitions-2}{%
\subsubsection{Definitions}\label{definitions-2}}

\hypertarget{forced-vital-capacity-fvc}{%
\paragraph{Forced vital capacity (FVC)}\label{forced-vital-capacity-fvc}}

Measures total amount of air you can exhale w/ force after you inhale as deeply as possible

\hypertarget{forced-expiratory-volume-1-fev1}{%
\paragraph{Forced expiratory volume 1 (FEV1)}\label{forced-expiratory-volume-1-fev1}}

Measures the amount of air you can exhale w/ force in one breath. The amount of air you exhale measured at 1 second
\#\#\#\# Forced expiratory flow 25\% to 75\%
This measures the air flow over the middle half of the FVC
\#\#\#\# Peak expiratory flow (PEF):
The maximum flow rate obtained during a forced exhalation. It is usually measured at the same time as your forced vital capacity (FVC)
\#\#\#\# Total lung capacity (TLC)
This measures the total volume of air in your lungs after you inhale as deeply as possible
\#\#\#\# Functional residual capacity (FRC)
This measures the amount of air in your lungs at the end of a normal exhaled breath
\#\#\#\# Expiratory reserve volume (ERV)
This measures the difference between the amount of air in your lungs after a normal exhale (FRC) and the amount after you exhale w/ force (RV)

\hypertarget{obstructive-vs.-restrictive-lung-disease}{%
\subsection{Obstructive vs.~Restrictive Lung Disease}\label{obstructive-vs.-restrictive-lung-disease}}

\begin{longtable}[]{@{}lll@{}}
\toprule
\begin{minipage}[b]{0.30\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Obstructive\strut
\end{minipage} & \begin{minipage}[b]{0.30\columnwidth}\raggedright
Restrictive\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Definition}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
The airways are narrowed, usually causing an increase in the time it takes to empty the lungs. Affect flow.\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Either a loss of lung tissue, a decrease in the lungs' ability to expand, or a decrease in the lungs' ability to transfer oxygen to the blood. Affect volume.\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{FVC}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Decreased\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Decreased\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{FEV1}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Decreased\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Decreased\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{FEV1/FVC}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Decreased\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Normal or increased\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{TLC}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Normal\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Decreased\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Differential Diagnosis}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Asthma, bronchiectasis, bronchiolitis obliterans, cystic fibrosis, alpha 1 antitrypsin deficiency\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
Chest wall: ankylosing spondylitis, kyphosis, obesity, scoliosisDrugs: amiodarone, methotrexate, nitrofurantoinInterstitial lung disease: pneumonia, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, sarcoidosis, exposures (asbestos, beryllium) Neuromuscular disorders: Guillain-Barre syndrome, muscular dystrophy, myasthenia gravis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Extent of Defect}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\% of predicted FEV1: Normal \textgreater80\%, Mild \textasciitilde80\%, Moderate 60-80\%, Severe \textless60\% FEF 25-75: Decreased\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\% of predicted TLC: Normal \textgreater80\%, Mild 70-80\%, Moderate 60-70\%, Severe \textless60\%\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.30\columnwidth}\raggedright
\textbf{Pattern}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/pulm_obstructive.jpg}\strut
\end{minipage} & \begin{minipage}[t]{0.30\columnwidth}\raggedright
\includegraphics{images/pulm_restrictive.jpg}\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{bronchodilatorbronchoprovocation-testing-in-asthma}{%
\subsection{Bronchodilator/Bronchoprovocation Testing in Asthma}\label{bronchodilatorbronchoprovocation-testing-in-asthma}}

\begin{itemize}
\tightlist
\item
  Response to bronchodilator: significant if FEV1 improved by \textgreater12-15\%
\item
  Exercise challenge: 12-15\% decrease in FEV1 is indicative of airway responsiveness
\item
  Cold air challenge: 12-15\% decrease in FEV1 is indicative of airway responsiveness
\end{itemize}

\hypertarget{evali-e-cigarette-and-vaping-associated-lung-injury}{%
\subsection{EVALI (E-Cigarette and Vaping Associated Lung Injury)}\label{evali-e-cigarette-and-vaping-associated-lung-injury}}

\hypertarget{presentation-147}{%
\subsubsection{Presentation}\label{presentation-147}}

\begin{itemize}
\tightlist
\item
  Shortness of breath, cough, chest pain, pleuritic chest pain, hemoptysis, fever, chills.
\item
  Commonly also includes GI symptoms such as nausea, vomiting, diarrhea, abdominal pain.
\item
  Can have hypoxemia, tachycardia, and tachypnea.
\end{itemize}

\hypertarget{etiologypathophysiology}{%
\subsubsection{Etiology/Pathophysiology}\label{etiologypathophysiology}}

\begin{itemize}
\tightlist
\item
  Acute lung injury with pathologic findings of acute fibrinous pneumonitis, diffuse alveolar damage, eosinophilic pneumonia, or organizing pneumonia.
\item
  No infectious etiology identified. Majority related to THC or vitamin E acetate in vaping compound but exact cause is unknown.
\end{itemize}

\hypertarget{differential-46}{%
\subsubsection{Differential}\label{differential-46}}

\begin{itemize}
\tightlist
\item
  Community-acquired pneumonia
\item
  Acute eosinophilic pneumonia
\item
  Organizing pneumonia
\item
  Lipoid pneumonia
\item
  Diffuse alveolar hemorrhage
\item
  Hypersensitivity pneumonitis
\item
  Respiratory bronchiolitis interstitial lung disease
\item
  Giant cell pneumonitis
\end{itemize}

\hypertarget{proposed-criteria-for-diagnosis}{%
\subsubsection{Proposed Criteria for Diagnosis}\label{proposed-criteria-for-diagnosis}}

\begin{itemize}
\tightlist
\item
  Clinical symptoms as above (pneumonia-like syndrome, dyspnea, hypoxemia)
\item
  Use of e-cigarette in the past 90 days
\item
  Exclusion of lung infection or plausible alternate diagnosis
\item
  Lung opacities on CXR or CT
\end{itemize}

\hypertarget{workup-31}{%
\subsubsection{Workup}\label{workup-31}}

\begin{itemize}
\tightlist
\item
  CXR +/- CT
\item
  CBC with diff
\item
  Influenza PCR or rapid test
\item
  Respiratory viral panel
\item
  Sputum culture +/- blood culture
\item
  Urine antigen test for Legionella and Strep pneumo
\item
  Testing for HIV-related opportunistic infections if indicated by history
\item
  Consider bronchoscopy and bronchoalveolar lavage
\end{itemize}

\hypertarget{consults}{%
\subsubsection{Consults}\label{consults}}

\begin{itemize}
\tightlist
\item
  Pulmonary
\item
  Infectious Diseases
\end{itemize}

\hypertarget{treatment-81}{%
\subsubsection{Treatment}\label{treatment-81}}

\begin{itemize}
\tightlist
\item
  Empiric antibiotics for CAP
\item
  Systemic glucocorticoids (with guidance of pulmonary team)
\item
  Supportive care
\end{itemize}

\hypertarget{rheumatology}{%
\section{Rheumatology}\label{rheumatology}}

\hypertarget{pediatric-approach-to-rheumatic-disease}{%
\subsection{Pediatric approach to rheumatic disease}\label{pediatric-approach-to-rheumatic-disease}}

\begin{itemize}
\tightlist
\item
  Rheumatology is a field of many unknowns, however, it occurs when chronic inflammation affects the MSK system, blood vessels, and other tissues, presenting with periods of exacerbation and remission
\item
  History is essential: constitutional sx, joint/muscle sx (limp, stiffness, regressing milestones, problems walking/with stairs/dressing), pain, rashes, ulcers, chest pain
\item
  Physical exam: focus on eyes, skin, muscle, joints

  \begin{itemize}
  \tightlist
  \item
    For arthritides see below
  \end{itemize}
\item
  Vaccinations: A few guidelines, but contact Rheumatology for guidance

  \begin{itemize}
  \tightlist
  \item
    Varicella, live virus/bacteria vaccines: contraindicated in children taking high dose steroids and biologics
  \item
    IVIG: children should wait anywhere from 8-11 months after the last dose for immunizations.
    PPSV23 and PCV13 should be given to children on immunosuppressants
  \item
    Most importantly, consider the whole picture when arriving at a diagnosis. Presentation, personal/family history, labs must all be taken into account. Autoantibody testing is helpful, however, it is not always diagnostic.
  \end{itemize}
\end{itemize}

\hypertarget{inflammatory-markers-and-autoantibodies}{%
\subsection{Inflammatory markers and autoantibodies}\label{inflammatory-markers-and-autoantibodies}}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
Marker\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
Description\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{CRP}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-Acute phase reactant, produced by liver in response to pathogens/inflammation/tissue damage. -Level rises \textasciitilde{} 4-6 hours after injury/infection, peak at \textasciitilde24-72 hours, then falls after appropriate treatment -CRP can be normal in SLE, JDM/PM, scleroderma, and Sjorgen's\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{ESR}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-Acute phase reactant, non-specific marker of inflammation -Rate at which RBCs settle through plasma to form sediment at the bottom of a tube -Slower rise and slower fall compared to CRP -May be elevated due to anemia or hypergammaglobulinemia -May fall quickly in DIC or other conditions that consume or decrease production of fibrinogen\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{ANA}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-Autoantibodies directed against antigens predominantly found in the nucleus -Conditions associated w/ (+) ANA: ---\emph{Autoimmune}: SLE, MCTD, Sjogren's, Juvenile Ssc, JIA, JDM, autoimmune hepatitis, Graves', Hashimoto's ---\emph{ID}: EBV, HIV, TB, SBE ---\emph{Systemic inflam.}: lymphoproliferative disorders, interstitial pulmonary fibrosis, asbestosis -Medications associated w/ (+) ANA and drug-induced lupus (+anti-histone Ab): ---Procainamide (90\%), Hydralazine (65\%), Anti-TNF agents (especially infliximab), INH, Quinidine, Phenytoin, Sulfasalazine, Minocycline, Lithium, chlorpromazine -Titers do not correlate w/ disease severity -Can be found in 10-15\% of healthy children, most of whom do not develop autoimmune disease\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{ANCA}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-Ab targeting antigens in cytoplasmic granules of neutrophils; highly sensitive for vasculitides that have predominant pulmonary and renal involvement -Not used on its own for screening patients, as they can be found in non-vasculitides -\textbf{Cytoplasmic (c-ANCA)}: antibody to proteinase-3 \& positive in about 90\% of patients w/ Granulomatosis w/ Polyangiitis (formerly Wegener's granulomatosis) -\textbf{Perinuclear (p-ANCA)}: antibody to myeloperoxidase \& associated w/ microscopic polyangiitis, Churg-Strauss, Ulcerative colitis -Titers often do not correlate w/ disease severity\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{RF}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-IgM autoantibody that reacts to Fc portion of IgG antibodies-Present in 2-7\% of children w/ JIA -Useful for predicting erosive disease in polyarticular JIA -Higher titers can be seen in Sjogren's Syndrome, MCTD, GPA-Also seen in infections: Chagas, SBE, Hep C, EBV -Circulating immune complexes may give false positive RF results\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{dsDNA}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-IgG, directed toward ds-DNA -High specificity for SLE -Rising levels associated with flares\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{SSA/Ro SSB/LA}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-Sjogren's syndrome-Cutaneous lupus -Neonatal lupus/congenital heart block-La less common and usually not found w/o Ro\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{CCP (ACPA)}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-High specificity, low sensitivity for JIA-Adults: 70-80\% of RA, predicts erosive disease\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Sm (Smith)}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-High specificity, 30\% of juvenile SLE, 60\% of adult SLE-Remains positive when SLE in remission\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{RNP}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-\textgreater95\% MCTD-SLE\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Scl-70}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-Systemic sclerosis-Assoc. w/ pulmonary fibrosis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Jo-1}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
-20\% of DM/PM-Associated w/ ILD-Mechanic hands-Most frequent Ab in antisynthetase syndrome\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{childhood-vasculitides}{%
\subsection{Childhood Vasculitides}\label{childhood-vasculitides}}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright
*Most Common\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Symptoms/Signs\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Biopsy/Labs\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\emph{\textbf{Large Vessel}}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Takayasu's arteritis}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
FemalesHigher in Asian pop Adol.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Pulseless DiseaseBlood pressure dif \textgreater10 between limbsBruit over aorta, carotids\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Granulomatous inflammation of the aortaelevated ESR/CRP\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
SteroidsAntiplatelet drugsSurgery\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\emph{\textbf{Medium Vessel}}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Polyarteritis nodosa}*\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Middle childhood\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Livedo reticularis, skin nodules, myalgia, HTN, renal involvement\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Transmural fibrinoid necrosisUrinalysis: proteinuria/hematuria\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
SteroidsCyclophosphamide/azathioprineanti-TNF biologics\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Kawasaki Disease}*\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Young children (higher in Asian pop.)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
CRASH: Conjunctivitis, Rash, Adenitis, Strawberry tongue, Hand/foot swellingCoronary artery aneurysms\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Complete: clinical Incomplete: clinical + labs (see below)Cardiac echo\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
IVIGAspirinSteroids\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\emph{\textbf{Small Vessel}}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Microscopic polyangiitis}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
9-12 yo\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
HTN, hematuriaHemoptysisPurpura, ulcers\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
p-ANCANo granulomasNecrotizing glomerulonephritis\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
SteroidsCyclophosRituximab\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Granulomatosis w/ Polyangiitis (Wegener's)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Young adults (20s)F\textgreater M\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Hemoptysis/alveolar hemorrhageChronic sinusitis, otitis, mastoiditis\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
c-ANCANecrotizing granulomas in upper/lower airway, focal segmental necrotizing GNUrinalysis: proteinuria/hematuria CXR: nodules\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
MTXSteroidsRTX/CYCPheresis (severe)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Eosinophilic granulomatosis w/ polyangiitis (Churg-Strauss)}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
12yoF\textgreater M\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Asthma, allergic rhinitis,sinusitisPeriph. NeuropathyCardiomyopathy\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
p-ANCAEosinophiliaExtravascular necrotizing granulomas\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
SteroidsCyclophosMepolizumab\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Henoch-Schonlein Purpura (HSP)}*\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Most common vasculitis in children3-15yoM\textgreater F\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Palpable purpuraArthritis/arthralgiasAbdominal painRenal disease (IgA nephro)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
IgA mediatedUrinalysisRenal/skin biopsyAbd U/S: intussusception\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
SupportiveNSAIDsHydrationSteroids\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright
\textbf{Behcet disease}\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Age of onset varies\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Aphthous stomatitisGenital ulcerationUveitis, erythema nodosum, purpura, acneiform lesions, pathergyDVT, arterial aneurysm\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Associated with HLA-B51Involves arterial and venous system, occlusive vasculitisElevated ESR/CRP\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright
Ulcers: sucralfate/GCs/infliximabUveitis: azathioprine/GCsGCs, DMARDs, Biologics\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{henoch-schonlein-purpura-iga-vasculitis}{%
\subsection{Henoch-Schonlein Purpura (IgA vasculitis)}\label{henoch-schonlein-purpura-iga-vasculitis}}

\textbf{Etiology}:

\begin{itemize}
\tightlist
\item
  No clear etiology
\item
  Frequently preceded by upper respiratory infections (esp streptococcus, staphylococcus, and parainfluenza) or immunizations
\end{itemize}

\textbf{Pathophysiology}:

\begin{itemize}
\tightlist
\item
  Deposition of IgA-containing immune complexes in vessel walls of affected organs and in kidney mesangium activates alternative complement pathway (w/ deposition of C3)
\item
  HSP nephritis and IgA nephropathy are histologically identical
\end{itemize}

\textbf{Clinical Manifestations}:

\begin{itemize}
\tightlist
\item
  Palpable purpura: symmetric, lower limb predominance

  \begin{itemize}
  \tightlist
  \item
    Present in all cases, but may not be presenting symptom
  \end{itemize}
\item
  Arthralgias/arthritis: oligoarticular, large lower extremity joints (knees, hips, ankles)

  \begin{itemize}
  \tightlist
  \item
    Occurs in ¾ of cases
  \end{itemize}
\item
  Abdominal pain: diffuse pain, colicky, worse after meals, often w/ nausea or vomiting

  \begin{itemize}
  \tightlist
  \item
    Occurs in 2/3 of cases
  \item
    3-4\% of HSP patients develop intussusception
  \end{itemize}
\item
  Renal disease: hematuria is most common, but proteinuria/hypertension may be seen

  \begin{itemize}
  \tightlist
  \item
    Occurs is 20-50\% of cases
  \item
    Usually delayed 1-2 weeks after onset
  \item
    \textless15\% children have long-term kidney damage, \textless1\% develop renal failure
  \end{itemize}
\end{itemize}

\textbf{Diagnosis}:

\begin{itemize}
\tightlist
\item
  Palpable purpura (w/o thrombocytopenia or coagulopathy), and ≥1 of the following:

  \begin{itemize}
  \tightlist
  \item
    Abdominal pain
  \item
    Arthritis/arthralgias
  \item
    Biopsy w/ leukocytoclastic vasculitis (skin) or glomerulonephritis w/ IgA deposition (renal)
  \end{itemize}
\item
  Urinalysis (screen for renal involvement), CBC (Plt normal to elevated), IgA level (NOT helpful)
\item
  Abdominal ultrasound if c/f intussusception
\end{itemize}

\textbf{Treatment}:

\begin{itemize}
\tightlist
\item
  Self-limited, supportive care
\item
  Mild/moderate pain: naproxen
\item
  F/u with PCP for weekly/biweekly urinalysis and BP checks for 1-2months
\item
  Severe pain: steroids reduce sx but do not change clinical course, requires taper (4-8wks)
\item
  Severe renal involvement: proteinuria/hematuria, requires closer follow-up and steroids
\end{itemize}

\hypertarget{kawasaki-disease}{%
\subsection{Kawasaki Disease}\label{kawasaki-disease}}

\textbf{Epidemiology}:

\begin{itemize}
\tightlist
\item
  Acute, self-limited systemic vasculitis of medium-sized arteries in infants/children
\item
  Average age of onset \textasciitilde{} 2 years w/ 80\% occurring in those \textless{} 4 years old
\item
  Incidence in US: 17-18/100,000, M:F = 1.6:1
\item
  Incidence doubled for Asian Americans, highest incidence in Japan
\item
  Increased rates in winter \& spring
\end{itemize}

\textbf{Pathophysiology}:

\begin{itemize}
\tightlist
\item
  May be related to infectious triggers
\item
  Vasculitis begins as a neutrophilic infiltrate; plasma cells producing IgA in vessel walls
\end{itemize}

\textbf{Clinical Manifestations}:

\begin{itemize}
\tightlist
\item
  Classical criteria = fever ≥ 5 days w/ ≥ 4/5 classical criteria, w/o alternative diagnosis

  \begin{itemize}
  \tightlist
  \item
    \emph{Conjunctivitis}: Bilateral bulbar conjunctival injection (non-exudative \& limb sparing)
  \item
    \emph{Rash}: Polymorphous rash (maculopapular, diffuse erythroderma, or erythema multiforme-like)
  \item
    \emph{Adenopathy}: Cervical lymphadenopathy (≥1 lymph node, \textgreater{} 1.5 cm in diameter), usually unilateral
  \item
    \emph{Serositis}: Injected/fissured lips, injected pharynx, or strawberry tongue.
  \item
    \emph{Hand/Feet}: Erythema of palms/soles, edema of hands/feet (acute), periungual desquamation (convalescent)
  \end{itemize}
\end{itemize}

\hypertarget{complete-kd}{%
\paragraph{\texorpdfstring{\textbf{Complete KD}:}{Complete KD:}}\label{complete-kd}}

\begin{itemize}
\tightlist
\item
  Fever ≥ 5 days and ≥ 4 principal clinical features OR fever ≥ 4 days and 5 clinical features
\end{itemize}

\hypertarget{incomplete-atypical-kd}{%
\paragraph{\texorpdfstring{\textbf{Incomplete (Atypical) KD}:}{Incomplete (Atypical) KD:}}\label{incomplete-atypical-kd}}

\begin{itemize}
\tightlist
\item
  2 possible diagnostic criteria:

  \begin{itemize}
  \item
    \begin{enumerate}
    \def\labelenumi{\alph{enumi})}
    \tightlist
    \item
      0 or 1 clinical criteria in a child \textless6 months old and fever \textgreater7 days PLUS positive echo
    \end{enumerate}
  \item
    \begin{enumerate}
    \def\labelenumi{\alph{enumi})}
    \setcounter{enumi}{1}
    \tightlist
    \item
      Fever ≥ 4 days + 2-3 clinical criteria + elevated ESR/CRP + ≥ 3 supplemental labs OR positive echo
    \end{enumerate}
  \item
    Supplemental labs:

    \begin{itemize}
    \tightlist
    \item
      Anemia for age
    \item
      ALT \textgreater{} 50 units/L
    \item
      Platelet count \textgreater{} 450,000 after 7th day of fever
    \item
      WBC \textgreater{} 15,000/mm3
    \item
      UA w/ \textgreater{} 10 WBC per hpf (sterile pyuria)
    \item
      Albumin \textless{} 3.0 g/dL
    \end{itemize}
  \end{itemize}
\end{itemize}

\textbf{Other clinical findings}

\begin{itemize}
\tightlist
\item
  Neuro: Irritability, hearing loss, facial nerve palsy
\item
  Cardiac: Coronary artery aneurysms, depressed myocardial function, pericardial effusion, prolonged PR interval.

  \begin{itemize}
  \tightlist
  \item
    \emph{Risk factors for CA aneurysms include}: male, \textless1 y/o, prolonged fever, elevated CRP, low platelets, low albumin levels on diagnosis
  \end{itemize}
\item
  GI: Pain, vomiting/diarrhea, hepatitis, acute acalculous distention of the gallbladder
\item
  MSK: Arthritis, arthralgias (pleocytosis of synovial fluid)
\item
  GU: Urethritis/meatitis, hydrocele
\end{itemize}

\textbf{Studies}

\begin{itemize}
\tightlist
\item
  Echocardiogram w/i 24 hours (abnormal echo= coronary artery Z score ≥ 2.5)
\end{itemize}

\textbf{Treatments}

\begin{itemize}
\tightlist
\item
  IVIG (2g/kg) infused over 12 hours→ repeat, if febrile, 36 hours after first infusion.
\item
  Aspirin: medium dose (30-50 mg/kg/d divided QID) until afebrile x 48 hours. Then low dose (3-5 mg/kg/d). (consider starting w/ low dose for age ≤ 6 mo)
\item
  Corticosteroids: trials indicate that steroids may be effective as primary/rescue therapy.
\item
  Repeat echo post-treatment, either before or after discharge, to observe improvement
\item
  Patients w/ severe CA dilation may need long-term anticoagulation therapy
\item
  Under study: infliximab, cyclosporine, other immunomodulatory agents
\end{itemize}

\hypertarget{polyarteritis-nodosa}{%
\subsection{Polyarteritis Nodosa}\label{polyarteritis-nodosa}}

\textbf{Etiology}:

\begin{itemize}
\tightlist
\item
  Focal, segmental, fibrinoid necrosis of walls of medium/small arteries leading to aneurysms
\item
  Rarely caused by loss-of-function mutation in adenosine deaminase 2
\end{itemize}

\textbf{Cutaneous PAN}:

\begin{itemize}
\tightlist
\item
  Nodular, painful, non-purpuric lesions, +/- livedo reticularis, w/o systemic involvement (as in sPAN)
\item
  Ass. w/ fever, elevated acute phase reactants, myalgia, arthralgia, non-erosive arthritis
\item
  Biopsy: necrotizing non-granulomatous vasculitis
\item
  Labs: ANCA neg, may see + ASO (up to ⅓ of cases are triggered by a strep infection)
\end{itemize}

\textbf{Systemic PAN}:

\begin{itemize}
\tightlist
\item
  EULAR/PRINTO/PRES Criteria: biopsy for histopathology (necrotizing vasculitis) OR angiography (aneurysms, stenosis, occlusions), AND ≥ 1 of:

  \begin{itemize}
  \tightlist
  \item
    Skin: livedo reticularis, tender subcutaneous nodules, superficial/deep skin infarctions
  \item
    Rheum: Myalgia or muscle tenderness
  \item
    Cardio: HTN
  \item
    Neuro: Peripheral neuropathy, sensory or motor mononeuritis multiplex
  \item
    Renal: proteinuria, hematuria, RBC casts, GFR \textless50\% normal for age
  \end{itemize}
\item
  Labs: ANCA negative
\end{itemize}

\textbf{Laboratory Studies}:

\begin{itemize}
\tightlist
\item
  ANCA, ANA, C3/4, CRP, ESR
\item
  Urinalysis, Cr
\item
  Consider other causes: infectious, thrombotic, other autoimmune diseases
\end{itemize}

\textbf{Complications}:

\begin{itemize}
\tightlist
\item
  Acute: organ failure (cardiac, pulmonary, renal), thrombi, hemorrhage, infection
\item
  Chronic: HTN, ischemic cardiomyopathy, CKD, mesenteric arteritis, hearing loss, orchitis
\end{itemize}

\textbf{Treatment}:

\begin{itemize}
\tightlist
\item
  Mild (normal renal function, no significant/life-threatening complications): Steroids, may add Azathioprine or MTX
\item
  Moderate to severe (ex: kidney involvement, proteinuria, neuro/cardiac/GI complications): Steroids + Cyclophosphamide, with eventual switch from Cyclophosphamide to Azathioprine or MTX, TNF inhibitors useful as well, especially in cutaneous PAN and DADA2
\item
  Pheresis considered in organ threatening disease
\item
  HTN: ACE Inhibitor
\end{itemize}

\hypertarget{connective-tissue-disorders}{%
\subsection{Connective Tissue Disorders}\label{connective-tissue-disorders}}

\hypertarget{sle}{%
\subsubsection{\texorpdfstring{\emph{SLE}}{SLE}}\label{sle}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Rash (malar, discoid), photosensitivity, serositis, nephritis, oral/nasal ulcers, seizure, psychosis, arthritis
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  Cytopenias (+)
\item
  anti-RNP (30\%)
\item
  +anti-dsDNA (40-60\%, assoc w SLE activity and lupus nephritis)
\item
  +anti-Smith (30\%, w/ high specificity, remains + in remission)
\item
  +anti-SS-A (Ro, 40\%)
\item
  +anti-SS-B (La, 10-15\%, more specific than Ro)
\item
  Low C3/C4
\end{itemize}

\hypertarget{juvenile-polymyositis}{%
\subsubsection{\texorpdfstring{\emph{Juvenile Polymyositis}}{Juvenile Polymyositis}}\label{juvenile-polymyositis}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Proximal muscle weakness (symmetric) +/- tenderness
\item
  Makes up 3-6\% of childhood idiopathic inflammatory myopathies
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  CK
\item
  Aldolase
\item
  LDH
\item
  AST and ALT (rarely nl unless ``burnt out'')
\item
  (+)anti-Jo-1 (20\%, a/w ILD, mechanic hands)
\item
  (+)anti-mi2 (5-7\%, a/w acute onset, shawl sign, good prognosis)
\end{itemize}

\hypertarget{juvenile-dermatomyositis}{%
\subsubsection{\texorpdfstring{\emph{Juvenile Dermatomyositis}}{Juvenile Dermatomyositis}}\label{juvenile-dermatomyositis}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Proximal muscle weakness (symmetric) +/- tenderness
\item
  Rash (heliotrope on upper eyelids, shawl sign on back, V-sign on chest)
\item
  Nailfold capillary changes (dilation, tortuosity)
\item
  Gottron's papules or scaly eruption over extensor surfaces such as knuckles (pathognomonic)
\item
  Skin ulcerations - indicate worse prognosis
\item
  Most common idiopathic inflammatory myopathy of childhood (85\% of all such myopathies)
\end{itemize}

\textbf{Other}:

\begin{itemize}
\tightlist
\item
  ILD in 10\%, upper esophageal involvement (dysphagia) in 25\%; may cause life-threatening aspiration
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  (+)anti-Jo-1 (20\%, a/w ILD, mechanic hands)
\item
  (+)anti-Mi2 (5-7\%, a/w acute onset, shawl sign, good prognosis)
\item
  (+)anti-MDA5 (ILD, poor prognosis)
\end{itemize}

\hypertarget{sjogrens}{%
\subsubsection{\texorpdfstring{\emph{Sjogren's}}{Sjogren's}}\label{sjogrens}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Sicca sx (dry mouth/eyes)
\item
  Vasculitis
\item
  Interstitial nephritis
\item
  Neuropathy; 5\% lifetime risk of NHL
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  (+)ANA
\item
  (+)anti-SS-A (Ro, 70\%)
\item
  (+)anti-SS-B (La, 50-70\%, more specific)
\item
  (+)RF
\end{itemize}

\hypertarget{scleroderma}{%
\subsubsection{\texorpdfstring{\emph{Scleroderma}}{Scleroderma}}\label{scleroderma}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Skin tightening \& thickening prox to forearms
\item
  Nail fold capillary dilatation \& dropout
\item
  ILD \& later stages PAH
\item
  GI dysmotility
\item
  Renal crisis (tx w/ ACE-I)
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  (+)anti-Scl 70 (30\%)
\item
  (+)anti-centromere (15\%)
\end{itemize}

\hypertarget{crest}{%
\subsubsection{\texorpdfstring{\emph{CREST}}{CREST}}\label{crest}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Calcinosis
\item
  Raynaud's phenomenon
\item
  Esophageal dysmotility
\item
  Sclerodactyly
\item
  Telangiectasias
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  (+)anti-centromere (60\%), associated with PAH
\item
  (+)anti-Scl 70 (15\%)
\end{itemize}

\hypertarget{mixed-connective-tissue-disease}{%
\subsubsection{\texorpdfstring{\emph{Mixed Connective Tissue Disease}}{Mixed Connective Tissue Disease}}\label{mixed-connective-tissue-disease}}

\textbf{Clinical}:

\begin{itemize}
\tightlist
\item
  Overlapping features of SLE
\item
  Polymyositis
\item
  Systemic sclerosis
\item
  Raynaud phenomenon
\item
  Swollen fingers
\item
  Arthritis
\item
  Inflam myopathy
\item
  Pleuritic
\item
  Pulm fibrosis, etc.
\end{itemize}

\textbf{Lab markers}:

\begin{itemize}
\tightlist
\item
  Anti-U1-RNP (Ribonucleoprotein) should be positive
\end{itemize}

\textbf{Treatment}:

\begin{itemize}
\tightlist
\item
  NSAIDs
\item
  Corticosteroids
\item
  ACE-I
\item
  Supportive measures
\end{itemize}

\hypertarget{systemic-lupus-erythematosus}{%
\subsection{Systemic Lupus Erythematosus}\label{systemic-lupus-erythematosus}}

\textbf{Definition}:

\begin{itemize}
\tightlist
\item
  Multiorgan system autoimmune disorder with markedly variable presentations/course
\end{itemize}

\textbf{Epidemiology}:

\begin{itemize}
\tightlist
\item
  F\textgreater M
\item
  Most often after age 8 yo
\item
  Median age of onset for juvenile SLE 12-13 yo
\item
  More common in people of Asian, African, and Hispanic race/ethnicity vs Caucasian
\end{itemize}

\textbf{Other presenting symptoms}:

\begin{itemize}
\tightlist
\item
  Constitutional: Fever, Weight loss, Anorexia
\item
  Physical exam: Raynaud's, LAD, HSM, HTN
\end{itemize}

\textbf{Neonatal Lupus Erythematosus (NLE)}:

\begin{itemize}
\tightlist
\item
  1-2\% of Infants born to mothers w/ anti-Ro and/or anti-La antibodies (transplacental)
\item
  Auto-Ab interfere w/ development of cardiac conduction system → permanent AV block -Flat/erythematous, annular, photosensitive rash that spontaneously resolves \textasciitilde6 mo of age (as maternal Abs dissipate)
\item
  No increased risk of autoimmune diseases later in life
\end{itemize}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.47\columnwidth}\raggedright
SLICC Criteria (Not validated in children/adolescents)\strut
\end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright
4+ criteria, including 1+ clinical and 1+ immunologic (serial or simultaneously), w/o alternative explanation OR SLE nephritis with +ANA/+dsDNA\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Acute cutaneous lupus}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Malar rash, bullous, TEN variant, photosensitive rash\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Chronic cutaneous lupus}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Discoid, hypertrophic/verrucous, panniculitis, mucosal, chilblains, erythema timidus\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Non-scarring alopecia}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Diffuse thinning or hair fragility with visible broken hairs\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Oral/Nasal Ulcers}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Palate, buccal, tongue, or nasal\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Joint Disease}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Synovitis in 2+ joints (swelling/effusion) OR 2+ joint tenderness + \textgreater30m AM stiffness\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Serositis}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Pleurisy or pericardial pain ≥1d, pleural or pericardial effusion, pleural or pericardial rub, pericarditis on TTE\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Renal}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
≥ 500 mg protein/day or RBC casts\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Neuro}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Seizures, psychosis, mononeuritis multiplex, myelitis, peripheral/cranial neuropathy\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Hemolytic anemia}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Autoimmune (direct Coombs+), thrombotic MAHA (TTP, HUS)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Leuko/lymphopenia}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Leukopenia \textless4000/mm\^{}3, lymphopenia \textless1000/mm\^{}3\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Thrombocytopenia}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
\textless100,000/mm\^{}3, including ITP, TTP\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Immuno}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
ANA (+) , Anti-dsDNA (+) or \textgreater twofold reference range on ELISA\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Low complement}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Low C3, C4, or CH50\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Direct Coombs test}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Positive in absence of hemolytic anemia\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.47\columnwidth}\raggedright
\textbf{Antiphospholipid}\strut
\end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright
Lupus anticoagulant, RPR (false positive), anticardiolipin Ab, or beta 2-glycoprotein I\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{Treatment}:

\begin{itemize}
\tightlist
\item
  Initial: Hydroxychloroquine (\textless{} max 5 mh/kg/d, need regular ophtho evals for visual field testing and color vision) + glucocorticoids (IV or PO depending on severity)
\item
  Mild: No renal/organ involvement→hydroxychloroquine, NSAIDS - arthralgia, Dapsone - derm, MT - arthritis. Can use LD prednisone (\textless0.35 mg/kg/d), but if needs \textgreater3 mo consider second-line agent (ex: MMF)
\item
  Mod: Renal/organ involvement → consider MMF, azathioprine, rituximab, systemic steroids
\item
  Severe: Substantial renal/neuro disease → cyclophosphamide
\item
  Flares:Steroids + MMF, or cyclophosphamide if already on MMF/azathioprine
\end{itemize}

\hypertarget{inflammatory-myopathies}{%
\subsection{Inflammatory Myopathies}\label{inflammatory-myopathies}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.22\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Polymyositis\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Dermatomyositis\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Inclusion Body Myositis\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Path}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
CD8+ T cells\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
CD4+ T Cells\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Inflam/neurodegen\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Clinical}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Symmetric proximal muscle weakness (shoulders)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Symmetric proximal muscle weaknessGottron papules, heliotrope (periorbital) rash,``shawl+face 'rash,``mechanics hands''\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Distal \textgreater\textgreater{} Proximal muscle weakness (Extremely rare in children)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Labs}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Increased CK, ANA (+)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Increased CK, ANA (+)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Increased CK, ANA (+)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Anti-MI-2/MJ\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Anti-Jo-1 (Anti-tRNA-synthetase)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Anti-cN1A\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Bx: Endomysial inflam\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Bx: Perimysial inflam/atrophy (myopathic), Von Willebrand Factor Ag\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Bx: Basophilic rimmed vacuoles, ragged-red fibers\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Assoc.}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Autoimmune (Crohn's, Vasculitis, Sarcoidosis, MG)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Lipodystrophy, Calcinosis, ILD, GI bleedJuvenile DM NOT assoc. w/ malignancy like adults\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
-\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Treatment}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Steroids (prednisone) followed by long-term immunosuppression (MTX, cyclosporine)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Steroids (prednisone) followed by long-term immunosuppression (MTX, cyclosporine)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Not steroid responsive\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{sjogren-syndrome}{%
\subsection{Sjogren Syndrome}\label{sjogren-syndrome}}

\textbf{Pathophysiology}:

\begin{itemize}
\tightlist
\item
  Inflammatory autoimmune disorder of exocrine glands (salivary/lacrimal glands)
\end{itemize}

\textbf{Exocrine features}:

\begin{itemize}
\tightlist
\item
  Keratoconjunctivitis sicca → dry mouth, salivary hypertrophy, Xerosis of skin
\item
  Xerophthalmia (dry eyes, conjunctivitis, sensation of sand in eyes)
\item
  Xerostomia (dry mouth, dysphagia, enlarged parotid glands, dental caries)
\end{itemize}

\textbf{Extraglandular features}:

\begin{itemize}
\tightlist
\item
  Arthritis/arthralgias, Raynaud phenomenon, Cutaneous vasculitis, ILD
\end{itemize}

\textbf{Lab tests}:

\begin{itemize}
\tightlist
\item
  Anti-SSA (Anti-Ro) Abs and Anti-SSB (Anti-La) Abs
\item
  Schirmer Test -- objective signs of decreased lacrimation
\item
  Salivary gland biopsy w/ focal lymphocytic sialadenitis
\end{itemize}

\textbf{Treatment}:

\begin{itemize}
\tightlist
\item
  Dry eyes: Artificial tears, cyclosporine drops
\item
  Dry mouth: Muscarinic agonists -- pilocarpine, cevimeline
\item
  Arthritis: Hydroxychloroquine or methotrexate
\end{itemize}

\hypertarget{pediatric-arthritides-approach-to-joint-disease}{%
\subsection{Pediatric arthritides: Approach to Joint Disease}\label{pediatric-arthritides-approach-to-joint-disease}}

\textbf{Questions to consider}:

\begin{itemize}
\tightlist
\item
  Which joint(s) is/are affected?
\item
  For how long? Persistent vs.~intermittent?
\item
  Is there morning stiffness?
\item
  Has the distribution changed over time?
\item
  Does anything make joint pain better or worse (e.g.~movement or prolonged inactivity)?
\item
  What are associated symptoms (fever, rash, weight loss, etc.)?
\item
  Family history of arthritis or autoimmune disease?
\item
  Any exposures (camping, sexual activity, viral illness, etc.)?
\end{itemize}

\textbf{Differential for joint pain}

\begin{itemize}
\tightlist
\item
  \textbf{\emph{Trauma/Overuse}}: LCP, SCFE, patellar tendonitis, patellofemoral syndrome (sports med!)
\item
  \textbf{\emph{Infection}}:

  \begin{itemize}
  \tightlist
  \item
    Septic arthritis (red, hot, angry, WBC \textgreater50K on joint tap)
  \item
    Lyme Disease (may or may not have seen tick or noticed other Lyme symptoms)
  \item
    Endocarditis (persistent fever and positive cultures)
  \item
    Rheumatic Fever (h/o strep throat)
  \item
    Transient Synovitis (h/o recent URI)
  \end{itemize}
\item
  \textbf{\emph{Inflammatory/Autoimmune}}:

  \begin{itemize}
  \tightlist
  \item
    Lupus
  \item
    JIA
  \item
    sJIA
  \end{itemize}
\end{itemize}

\hypertarget{juvenile-idiopathic-arthritis}{%
\subsection{Juvenile Idiopathic Arthritis}\label{juvenile-idiopathic-arthritis}}

\begin{itemize}
\tightlist
\item
  International League Against Rheumatism (ILAR) → 6 sub-categories+ ``undifferentiated'' category (not shown)
\item
  Controversy as to whether juvenile and adult inflammatory arthritides should be considered distinct from each other based on genetic and clinical parallels
\end{itemize}

\textbf{Definitions}:

\begin{itemize}
\tightlist
\item
  \textbf{\emph{JIA}}: Clinical diagnosis based on having objective signs of arthritis in ≥1 joint for ≥ 6 weeks in a child \textless{} 16 after other types of childhood arthritis have been excluded
\item
  \textbf{\emph{Oligoarticular}}: up to 4 joints affected in first 6 months after diagnosis. Can be ``persistent'' or ``extended'', based on whether stays limited past the 6 month mark
\item
  \textbf{\emph{Polyarticular}}: affects more than 5 joints in first
\end{itemize}

\begin{longtable}[]{@{}lllllll@{}}
\toprule
\begin{minipage}[b]{0.12\columnwidth}\raggedright
Subtype\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Age\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
F: M\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
\% JIA\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Pattern\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Extra-articular/Notable Features\strut
\end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright
Treatment\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Systemic}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
1-5\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
1:1\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
5-15\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Polyarticular (U/L ext, neck, hips)\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Recurrent fever and evanescent rash; organ dysfxn; MAS, *note uveitis rare in this population\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
NSAIDS, MTX, IL-1 inhibitor, IL-6 inhibitor\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Oligo}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
2-4\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
5:1\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
30-50\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Knee, ankle, wrist, elbow\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
\textless5 joints\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Uveitis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Poly RF(-)}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
2-4\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
8-12\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
3:1\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
10-30\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Symmetric; small joints (e.g.~hands)\textgreater5 joints\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Uveitis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Poly RF(+)}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
9-12\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
3:1\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
\textless10\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Symmetric; small joints (e.g.~hands) \textgreater5 joints\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Rheumatoid nodules, *note uveitis rare in this population\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
NSAIDS, MTX, anti-TNF\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Psoriatic}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
2-4\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
9-11\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
2:1\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
5-10\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Knees, ankles, tenosynovitis of digits ``sausage''\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Uveitis, Psoriasis or FmHx, Dactylitis, Nail Changes\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Enthesitis-related}\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
9-12\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
1:3\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
5-10\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
Sacroiliac/axial\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
IBD, HLA-B27 positivity\strut
\end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright
NSAIDS, steroids, sulfasalazine, anti-TNF\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{systemic-jia-stills-disease}{%
\subsection{Systemic JIA (Still's disease)}\label{systemic-jia-stills-disease}}

\begin{itemize}
\tightlist
\item
  Complex pathogenesis: autoimmune (genetic risk factor in MHC complex) vs.~autoinflammatory (F=M, cyclic fevers, response to IL1 inhibitors)

  \begin{itemize}
  \tightlist
  \item
    Fever and rash may precede chronic arthritis
  \item
    Early disease is mediated by inflammatory cytokines IL-1, IL-6 etc
  \item
    Macrophage activation syndrome is a complication associated with sJIA
  \item
    ILAR classification: Arthritis in ≥1 joint with or preceded by fever for ≥2 weeks that manifests as a daily or ``quotidian'' in timing for at least 3 days + one or more of the following:

    \begin{itemize}
    \tightlist
    \item
      Evanescent erythematous rash (i.e.~comes and goes, often worse with fever)
    \item
      Lymphadenopathy
    \item
      Hepato/splenomegaly
    \item
      Serositis
    \end{itemize}
  \end{itemize}
\end{itemize}

\textbf{Treatment}:

\begin{itemize}
\tightlist
\item
  Cytokine inhibitors can attenuate disease progression (ie.anakinra and canakinumab)
\item
  For patients that develop chronic arthritis, co-stimulatory blockade of T-cells has anecdotally provided benefit (e.g.~abatacept)
\end{itemize}

\hypertarget{macrophage-activation-syndrome-mas}{%
\subsection{Macrophage Activation Syndrome (MAS)}\label{macrophage-activation-syndrome-mas}}

\begin{itemize}
\tightlist
\item
  A secondary form of hemophagocytic lymphohistiocytosis (HLH)
\item
  Dysregulation of the immune system with ineffective cytotoxic T and NK cell response leading to cytokine storm and over activation of macrophages
\item
  Can occur with most systemic/rheumatic disorders (ie KD, SLE) OR in the setting of viral illnesses such as EBV
\item
  Incidence is much higher in sJIA (\textasciitilde10-20\%)
\item
  PRINTO diagnostic criteria for MAS in SJIA:

  \begin{itemize}
  \tightlist
  \item
    Fever and serum ferritin \textgreater{} 684ng/mL + any two of the following:

    \begin{itemize}
    \tightlist
    \item
      Platelet count ≤ 181*109/L
    \item
      AST (\textgreater48U/L)
    \item
      Triglycerides \textgreater{} 156mg/dl
    \item
      Fibrinogen ≤ 360 mg/dl
    \end{itemize}
  \end{itemize}
\end{itemize}

\textbf{Workup and Treatment}

\begin{itemize}
\tightlist
\item
  BCH EBG available → Page 1 = workup (not shown); Page 2 = Treatment (below)
\item
  Multidisciplinary treatment of patient including Rheum and Immunology
  !\href{MAS.png}{MAS}
\end{itemize}

\hypertarget{fever-of-unknown-origin}{%
\subsection{Fever of Unknown Origin}\label{fever-of-unknown-origin}}

\begin{itemize}
\tightlist
\item
  Age \textgreater3 months
\item
  Parent report of fever measured at \textgreater38 C daily for \textgreater=7 days
\item
  No source identified during prior workup
\item
  BCH EBG available
\end{itemize}

\textbf{Initial Workup}:

\begin{itemize}
\tightlist
\item
  Chem 10, LFTs, Ferritin
\item
  IgG level
\item
  LDH, Uric acid
\item
  UA, Urine culture
\item
  Blood culture
\item
  EBV, CMV
\item
  Viral respiratory testing, CXR
\item
  Additional possible testing on individual basis: HIV, PPD/T-spot, Bartonella IgG and IgM, peripheral blood smear, echocardiogram
\end{itemize}

\textbf{Consults}:

\begin{itemize}
\tightlist
\item
  Infectious Disease
\item
  Rheumatology (if \textgreater=1 met):

  \begin{itemize}
  \tightlist
  \item
    Age \textless12 months with ESR \textgreater=40 mm/hr or CRP \textgreater3 mg/kL
  \item
    Ferritin \textgreater=500
  \item
    IgG level \textgreater=2000 mg/dL
  \item
    Joint symptoms
  \item
    Rash (especially malar, heliotrope, or livedo reticularis)
  \item
    Serositis
  \item
    Inflammatory eye disease
  \item
    1st degree relative with rheumatologic disease
  \end{itemize}
\item
  GI

  \begin{itemize}
  \tightlist
  \item
    Poor growth
  \item
    Prominent GI symptoms
  \item
    Anemia
  \item
    Elevated inflammatory markers
  \end{itemize}
\item
  Immunology

  \begin{itemize}
  \tightlist
  \item
    Recurrent and/or opportunistic infections
  \item
    Failure to thrive
  \end{itemize}
\item
  Oncology

  \begin{itemize}
  \tightlist
  \item
    Abnormal CBC (cytopenias, blasts)
  \item
    Elevated LDH and/or uric acid
  \end{itemize}
\end{itemize}

\hypertarget{autoinflammatory-diseases}{%
\subsection{Autoinflammatory Diseases}\label{autoinflammatory-diseases}}

\textbf{Autoimmune vs.~Autoinflammatory}

\begin{itemize}
\tightlist
\item
  In broad strokes, autoinflammatory conditions are thought to be due to disruptions in innate immunity, whereas autoimmune conditions are due to disruptions in immune tolerance/adaptive immunity
\item
  Autoinflammatory conditions often have mutations in genes related to the inflammatory cascade leading to uncontrolled inflammation with high levels of pro-inflammatory cytokines, fevers + rashes, and a similar incidence in males and females; biologics that block IL-1 and IL-6 can be helpful
\item
  Autoimmune conditions may have auto-antigens and auto-reactive T-cells and B-cells; fever is not a core feature, although may be present; usually F\textgreater M; drugs that inhibit T-cells and B-cells are more useful (e.g.~calcineurin inhibitors, MTX, rituximab)
\item
  These divisions are not black and white, and most diseases are thought to lie on the spectrum and/or develop in immune pathophysiology over time (see sJIA)
\end{itemize}

\textbf{Diagnosis}

\begin{itemize}
\tightlist
\item
  Careful H\&P (r/o malignancy, infection, cyclic neutropenia) → may confirm w/targeted genetic testing
\end{itemize}

\textbf{Categories}

\begin{itemize}
\tightlist
\item
  Includes both periodic fever syndromes as well as non-periodic fever syndromes
\end{itemize}

\hypertarget{periodic-fever-syndromes}{%
\subsubsection{Periodic Fever Syndromes}\label{periodic-fever-syndromes}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.14\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
FMF (Familial Mediterranean Fever)\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
TRAPS (TNF Rec.-associated Periodic Syndrome)\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
HIDS (Hyper IgD Syndrome a.k.a. Mevalonate kinase deficiency (MDK))\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
MWS (Muckle Wells Syndrome)\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, cervical adenitis)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Inherit}.\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
AR\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
AD\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
AR\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
AD\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Sporadic\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Protein Defect}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Pyrin\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
TNF receptor\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Mevalonate kinase\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Cryopryrin\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Unknown\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Ethnicity}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Jewish, Turkish, Italian, Arab\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Any\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Dutch, French\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Northern European\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Any\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Flare Duration}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
1-3 days\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
\textgreater7-14 days\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
3-7 days\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
2-3 days\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
3-4 days\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Interval Between Events}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Variable\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Variable (days- wks)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Fixed (4-8 wks)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Variable URI trigger\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Fixed (2-8 wks)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Age of Onset}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
School age\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
School age\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Infancy\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
School age\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Early childhood\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Clinical}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
SerositisPeritonitisRenal amyloidosis (if untreated)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Eye stuff (periorbital edema/pain, conjunctivitis)Limb painAbdominal painAmyloidosisRash\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
LADAbdominal painDiarrheaArthralgiasVomitingOral UlcersDevelopmental Delay (with complete enzyme deficiency)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Sensorineural hearing lossRecurrent hivesAmyloidosis\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Multiple fever spikes per a daySore throatMouth soresCervical LAD\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.14\columnwidth}\raggedright
\textbf{Treatment}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
ColchicineIL-1 inhibitor (if resistant to colchicine)\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
SteroidsEtanerceptSome evidence for IL-1 inhibitors\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
NSAIDS/GCs/IL-1 inhibitor during attacksIL-1 blockade or etanercept for maintenance\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
IL-1 Inhibitor\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
SteroidsTonsillectomy\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{autoinflammatory-disorders-without-periodic-fever}{%
\subsubsection{Autoinflammatory Disorders without Periodic Fever}\label{autoinflammatory-disorders-without-periodic-fever}}

\begin{itemize}
\tightlist
\item
  Chronic recurrent multifocal osteomyelitis (CRMO)

  \begin{itemize}
  \tightlist
  \item
    Multifocal, non-infectious osteomyelitis, diagnosed with whole body MRI
  \item
    Pts may only be symptomatic in one location, making dx difficult
  \item
    Red flags for CRMO (vs.~infectious OM) include: clavicular lesions, bilateral/symmetric lesions, concurrent spondylarthritis/IBD/psoriasis/palmoplantar pustulosis, or OM that never had positive cultures and is persistently unresponsive to antibiotics
  \end{itemize}
\item
  Deficiency of the interleukin-1 receptor antagonist (DIRA)
\item
  Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA)
\item
  Juvenile systemic granulomatosis (Blau Syndrome)
\item
  Chronic atypical neutrophilic dermatitis w/ lipodystrophy and elevated temperature (CANDLE)
\end{itemize}

\hypertarget{common-rheumatology-medications}{%
\subsection{Common Rheumatology Medications}\label{common-rheumatology-medications}}

\begin{longtable}[]{@{}llll@{}}
\toprule
\begin{minipage}[b]{0.22\columnwidth}\raggedright
Medication\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Indication\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
MOA\strut
\end{minipage} & \begin{minipage}[b]{0.22\columnwidth}\raggedright
Side Effects\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Glucocorticoids}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JIA, JRA, SLE, vasculitides\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Activate the glucocorticoid receptor, decrease chemo/cytokine production, multiple genomic and nongenomic mechanisms\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Cushing syndrome, growth suppression, osteoporosis, avascular necrosis, lymphopenia, psychosis, cataracts, myopathy, diabetesIV methylprednisolone: hyper or hypotension, bradycardia, hyperglycemia, acute psychosis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Hydroxychloroquine} (Disease modifying antirheumatic drug/DMARD)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JDM, SLE, Sjogren's\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Alters pH of lysosomes, decreasing immune recognition of autoantigens\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Retinopathy, N/V, hemolytic anemia in G6PD deficiency\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Methotrexate} (DMARD)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JIA, RA,JDM, vasculitis, SLE\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Dihydrofolate reductase inhibitor, give with folic acid\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Hepatotoxicity, Pancytopenias, GI discomfort, Stomatitis\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Sulfasalazine} (DMARD)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JIA, RA, IBD\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Interferes with enzymes that produce leukotrienes, prostaglandins\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Maculopapular rash on sun exposed area, Stomatitis, SJS, not given in G6PD def\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Leflunomide} (DMARD)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JIA, RA, Psor. arthritis\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Pyrimidine synthesis inhibitor\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Hepatotoxicity, GI upset\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Cyclophosphamide}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Vasculitis, scleroderma, lupus nephritis\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Alkylating agent\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Cytopenia, Hemorrhagic cystitis, Pulmonary fibrosis, Skin/bladder cancer (adults)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Azathioprine}\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
DM/PM, SLE, vasculitis\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Antimetabolite\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
GI upset, myelotoxicity\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Abatacept, Rituximab, Tocilizumab} (Biologics)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JIA, uveitis, RA\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Non-TNF inhibitorsAbatacept (hIgG1+CTLR4, prevents APCs from activating T-cells)Rituximab (anti-CD20,promotes B cell death)Tocilizumab (anti-IL6)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Infection (TB), infusion reaction, GI upset/perforation\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{Adalimumab, Etanercept, Infliximab} (Biologics)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
JIA, RA, Psoriatic arthritis, AS psoriasis, IBD, vasculitis (TA, DADA2)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
TNF inhibitors\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Infection (TB, fungal), lymphoma, MS\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
\textbf{IVIG} (biologic)\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
KD\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Prepared from pooled human plasma, neutralize autoantibodies/cytokines/complement\strut
\end{minipage} & \begin{minipage}[t]{0.22\columnwidth}\raggedright
Anaphylactoid reaction, thromboembolism, aseptic meningitis, renal failure, hemolysis, do not give to IgA deficient pts\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{sports-medicine}{%
\section{Sports Medicine}\label{sports-medicine}}

\hypertarget{general-approach-to-the-msk-exam}{%
\subsection{General Approach to the MSK Exam}\label{general-approach-to-the-msk-exam}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  \textbf{History}

  \begin{itemize}
  \tightlist
  \item
    Mechanism, chronicity, exposures, associated symptoms
  \item
    \textbf{Red flags:} B symptoms, major trauma
  \end{itemize}
\item
  \textbf{Inspection:} Compare to contralateral side. Make sure to EXPOSE for best exam.

  \begin{itemize}
  \tightlist
  \item
    Look for asymmetry, atrophy, deformity, ecchymosis, erythema, scars
  \item
    \textbf{Red flags:} Erythema (sign of infxn), deformity concerning for major trauma
  \end{itemize}
\item
  \textbf{Palpation}

  \begin{itemize}
  \tightlist
  \item
    Feel for anatomic points of interest
  \item
    \textbf{Red flags:} Warmth (sign of infxn), diminished sensation (sign of neurologic deficit)
  \end{itemize}
\item
  \textbf{Range of motion (ROM):} Active first, then passive

  \begin{itemize}
  \tightlist
  \item
    Look for pain w/ motion, limited ROM (and distinguish whether due to pain, effusion, mechanical problem)
  \end{itemize}
\item
  Strength

  \begin{itemize}
  \tightlist
  \item
    Graded from 0-5 out of 5:

    \begin{itemize}
    \tightlist
    \item
      5/5 = full strength
    \item
      4/5 = movement against some resistance
    \item
      3/5 = movement against gravity
    \item
      2/5 = movement but not against gravity
    \item
      1/5 = muscle flicker
    \item
      0/5 = no contraction
    \end{itemize}
  \item
    \textbf{Red flags:} Diminished strength if not due to pain (sign of neurologic deficit)
  \end{itemize}
\item
  \textbf{Special testing} is joint specific - see relevant sections below
\end{enumerate}

\hypertarget{fractures}{%
\subsection{Fractures}\label{fractures}}

\hypertarget{salter-harris-classification-for-physeal-fractures}{%
\subsubsection{Salter-Harris Classification for Physeal Fractures}\label{salter-harris-classification-for-physeal-fractures}}

\begin{longtable}[]{@{}llllll@{}}
\toprule
\begin{minipage}[b]{0.22\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
Type I\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Type II\strut
\end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright
Type III\strut
\end{minipage} & \begin{minipage}[b]{0.13\columnwidth}\raggedright
Type IV\strut
\end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright
Type V\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Lesion\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
\includegraphics{images/sports_salter-harris-type-i.png}\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
\includegraphics{images/sports_salter-harris-type-ii.png}\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
\includegraphics{images/sports_salter-harris-type-iii.png}\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
\includegraphics{images/sports_salter-harris-type-iv.png}\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
\includegraphics{images/sports_salter-harris-type-v.png}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Details\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Often involves growth plate\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
\textbf{Most common!} Growth plate + metaphysis\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Growth plate + epiphysis + joint space\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Metaphysis + growth plate + epiphysis + joint space\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Compression of growth plate\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Implications\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Good prognosis\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Good prognosis\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
Threatens growth and articular integrity\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Threatens growth and articular integrity\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
Very high risk for growth arrest\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.22\columnwidth}\raggedright
Management\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- \textbf{Dx:} Usually clinical dx (XR negative unless displaced); contralateral XR may be useful - Immobilization (cast vs.~splint) for \emph{\textgreater{}} 3 wks\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
Immobilization (cast vs.~splint) for \emph{\textgreater{}} 3 wks\strut
\end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright
- Immediate Ortho consult - Likely reduction (anatomic vs.~surgical)\strut
\end{minipage} & \begin{minipage}[t]{0.13\columnwidth}\raggedright
- Immediate Ortho consult - Likely reduction (anatomic vs.~surgical)\strut
\end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright
- Immediate Ortho consult - Likely reduction (anatomic vs.~surgical)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{pre-participation-physical}{%
\subsection{Pre-Participation Physical}\label{pre-participation-physical}}

\hypertarget{history-16}{%
\paragraph{History}\label{history-16}}

\begin{itemize}
\tightlist
\item
  \textbf{Goal:} Elucidate conditions that might preclude or limit sports participation
\item
  Cardiac history
\item
  Dyspnea on exertion → consider exercise induced asthma or vocal cord dysfunction
\item
  History of head trauma
\item
  History of ``burners'' or ``stingers'' (from transient brachial plexus compression/stretching) → if recurrent, may need C-spine XR
\item
  Disordered eating (esp/ in sports w/ weight requirements)
\item
  Substance abuse
\item
  \textbf{Family history:} Sudden death, congenital heart disease, arrhythmias, Marfan syndrome
\end{itemize}

\hypertarget{physical-exam-25}{%
\paragraph{Physical Exam}\label{physical-exam-25}}

Special attention to \textbf{CV}, \textbf{resp}, and \textbf{MSK} (assess ROM, symmetry, stability)

\hypertarget{cardiac-testing}{%
\paragraph{Cardiac Testing}\label{cardiac-testing}}

\begin{itemize}
\tightlist
\item
  e.g.~EKG, echo, exercise testing
\item
  ONLY if clinically indicated, though highly controversial and recommendations worldwide differ. Current AHA/AAP PPE guidelines currently \textbf{do not recommend} global EKG/echo.
\end{itemize}

\hypertarget{clearance}{%
\paragraph{Clearance}\label{clearance}}

\begin{itemize}
\tightlist
\item
  Increased risk of injury?
\item
  Would treatment make athlete safe to participate?
\item
  Can limited participation be allowed while treatment is undergone?
\item
  Limitations for some or all sports?
\end{itemize}

\hypertarget{upper-extremity-elbow-forearm-wrist}{%
\subsection{Upper Extremity: Elbow, Forearm \& Wrist}\label{upper-extremity-elbow-forearm-wrist}}

\hypertarget{anatomy-1}{%
\subsubsection{Anatomy}\label{anatomy-1}}

\includegraphics{images/sports_anatomy-elbow-forearm-wrist.png}

\hypertarget{exam-pearls}{%
\subsubsection{Exam Pearls}\label{exam-pearls}}

\begin{itemize}
\tightlist
\item
  Rapid elbow/forearm neurovascular exam:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Brachial artery:} Brachial + radial pulses, perfusion check
  \item
    \textbf{Median nerve:} Sensation over palmar side of digits 1-3
  \item
    \textbf{Anterior interosseous nerve} (motor-only branch of median nerve): ``OK'' sign 👌, grip strength
  \item
    \textbf{Radial nerve:} Wrist extension, thumbs-up sign 👍
  \item
    \textbf{Ulnar nerve:} Spread fingers against resistance
  \end{itemize}
\end{itemize}

\hypertarget{supracondylar-fracture}{%
\subsubsection{Supracondylar Fracture}\label{supracondylar-fracture}}

\hypertarget{descriptionmechanism}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism}}

Usually fall on outstretched hand (FOOSH) with elbow hyperextension

\includegraphics{images/sports_nursemaids-elbow.png}

\hypertarget{diagnosis-15}{%
\paragraph{Diagnosis}\label{diagnosis-15}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Gross deformity, limited active elbow motion
\item
  \textbf{Imaging:} AP + lateral XR. Findings may be subtle (posterior fat pad sign on lateral film)
\end{itemize}

\hypertarget{management-104}{%
\paragraph{Management}\label{management-104}}

\begin{itemize}
\tightlist
\item
  Ortho consult
\item
  Usually surgical fixation for displaced fractures
\end{itemize}

\hypertarget{nursemaids-elbow-subluxation-of-radial-head}{%
\subsubsection{Nursemaid's Elbow (Subluxation of Radial Head)}\label{nursemaids-elbow-subluxation-of-radial-head}}

\hypertarget{descriptionmechanism-1}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-1}}

Traction on arm with extended elbow (e.g.~swinging child through the air)

\hypertarget{diagnosis-16}{%
\paragraph{Diagnosis}\label{diagnosis-16}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} No deformity, elbow held in passive pronation with slight flexion, refusing to use arm
\item
  \textbf{Imaging:} Unnecessary unless suspect fracture based on H\&P, or if reduction unsuccessful
\end{itemize}

\hypertarget{management-105}{%
\paragraph{Management}\label{management-105}}

Stabilize elbow w/ one hand → supinate forearm and flex elbow (will usually feel/hear click)

\hypertarget{distal-radius-fracture}{%
\subsubsection{Distal Radius Fracture}\label{distal-radius-fracture}}

\hypertarget{descriptionmechanism-2}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-2}}

\begin{itemize}
\tightlist
\item
  FOOSH
\item
  \textbf{Most common pediatric fracture}
\end{itemize}

\hypertarget{diagnosis-17}{%
\paragraph{Diagnosis}\label{diagnosis-17}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Pain, ecchymosis, swelling
\item
  \textbf{Imaging:} AP + lateral XR of wrist and forearm; consider AP + lateral of elbow if tender or if diaphyseal fractures present
\end{itemize}

\hypertarget{management-106}{%
\paragraph{Management}\label{management-106}}

\begin{itemize}
\tightlist
\item
  Ortho consult
\item
  Depending on severity, may require anything from immobilization to ORIF
\end{itemize}

\hypertarget{upper-extremity-shoulder}{%
\subsection{Upper Extremity: Shoulder}\label{upper-extremity-shoulder}}

\hypertarget{anatomy-2}{%
\subsubsection{Anatomy}\label{anatomy-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Rotator cuff} muscles (mnemonic: \textbf{SITS} → \textbf{AEEI})

  \begin{itemize}
  \tightlist
  \item
    \textbf{S}upraspinatus → \textbf{A}bduction
  \item
    \textbf{I}nfraspinatus and \textbf{T}eres Minor → \textbf{E}xternal rotation x2
  \item
    \textbf{S}ubscapularis → \textbf{I}nternal rotation
  \end{itemize}
\end{itemize}

\includegraphics{images/sports_anatomy-shoulder.png}

\hypertarget{exam-pearls-special-tests}{%
\subsubsection{Exam Pearls \& Special Tests}\label{exam-pearls-special-tests}}

\begin{itemize}
\tightlist
\item
  \textbf{Empty can test:} Strength in internal rotation/thumb down position. Tests \textbf{supraspinatus}.
\item
  \textbf{Scarf test:} Pain w/ cross arm adduction. Tests \textbf{AC joint}.
\item
  \textbf{Lift-off test:} Strength in lifting dorsum of hand off back. Tests \textbf{subscapularis}.
\item
  \textbf{Impingement test:} Pain w/ passive internal rotation/forward flexion. Tests \textbf{subacromial impingement}.
\end{itemize}

\includegraphics{images/sports_special-tests-shoulder.png}

\hypertarget{common-associations}{%
\paragraph{Common Associations}\label{common-associations}}

\begin{itemize}
\tightlist
\item
  \textbf{Scapular winging} i/s/o recent trauma or viral illness → likely serratus anterior or trapezius dysfunction
\item
  Inability to passively/actively rotate affected arm externally s/p seizure → likely posterior shoulder dislocation
\item
  \textbf{Supraspinatus/infraspinatus wasting} → likely rotator cuff tear or suprascapular nerve entrapment
\item
  Decreased cervical ROM w/ pain radiating below elbow → likely cervical disc disease
\item
  Shoulder pain in a throwing athlete w/ anterior glenohumeral joint pain/impingement → likely glenohumeral joint instability
\item
  Pain or ``clunking'' sound w/ overhead motion → likely labral disorder
\end{itemize}

\hypertarget{proximal-humeral-fracture}{%
\subsubsection{Proximal Humeral Fracture}\label{proximal-humeral-fracture}}

\hypertarget{descriptionmechanism-3}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-3}}

\begin{itemize}
\tightlist
\item
  FOOSH
\item
  Direct blow to lateral shoulder
\end{itemize}

\hypertarget{signs-symptoms-1}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-1}}

History of trauma, severe shoulder pain, pain w/ arm movement

\hypertarget{diagnosis-18}{%
\paragraph{Diagnosis}\label{diagnosis-18}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} tenderness, swelling, shoulder asymmetry, arm shortened and held in extension
\item
  \textbf{Imaging:} AP + axillary XR of humerus

  \begin{itemize}
  \tightlist
  \item
    Also get scapular ``Y'' view if concerned for shoulder injury
  \item
    Suspect Salter-Harris I if negative XR + tenderness at physis
  \end{itemize}
\end{itemize}

\hypertarget{management-107}{%
\paragraph{Management}\label{management-107}}

\begin{itemize}
\tightlist
\item
  Immobilization
\item
  Likely Ortho consult, esp.~if more severe (a/w shoulder dislocation, neurovascular compromise, etc.)
\end{itemize}

\hypertarget{dislocation}{%
\subsubsection{Dislocation}\label{dislocation}}

\hypertarget{descriptionmechanism-4}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-4}}

\begin{itemize}
\tightlist
\item
  Majority of dislocations are \textbf{anterior}
\item
  Blow to abducted/externally rotated/extended arm
\item
  FOOSH
\item
  Forceful forward swinging of arm
\end{itemize}

\hypertarget{diagnosis-19}{%
\paragraph{Diagnosis}\label{diagnosis-19}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Arm abducted and externally rotated w/ resistance to all movement, loss of rounded appearance of shoulder. Evaluate for sensory loss over lateral deltoid (2/2 axillary nerve dysfunction).
\item
  \textbf{Imaging:} AP + scapular ``Y'' + axillary XR to confirm dx and exclude fractures (can be repeated post-reduction if unsure of success)
\end{itemize}

\hypertarget{management-108}{%
\paragraph{Management}\label{management-108}}

Reduction (variety of techniques exist) → immobilization and referral to Sports Med/Ortho for prevention of recurrent dislocation

\hypertarget{rotator-cuff-injury}{%
\subsubsection{Rotator Cuff Injury}\label{rotator-cuff-injury}}

\hypertarget{descriptionmechanism-5}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-5}}

\begin{itemize}
\tightlist
\item
  Includes \textbf{impingement} (inflammation \& pinching of rotator cuff tendons) and rotator cuff \textbf{tears}

  \begin{itemize}
  \tightlist
  \item
    Impingement very common, tears very uncommon in youth athletes
  \end{itemize}
\item
  Overuse or acute injury, usually involving throwing or overhead activities
\end{itemize}

\hypertarget{signs-symptoms-2}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-2}}

Pain in upper arm, worse w/ overhead activity or lying on affected side

\hypertarget{diagnosis-20}{%
\paragraph{Diagnosis}\label{diagnosis-20}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Pain/weakness w/ testing of rotator cuff muscles; positive empty can, lift off, Hawkins, and/or impingement tests (see above)
\item
  \textbf{Imaging:} XR only if bony pathology suspected; MRI best
\end{itemize}

\hypertarget{management-109}{%
\paragraph{Management}\label{management-109}}

\begin{itemize}
\tightlist
\item
  Can start w/ conservative management (NSAIDs, PT)
\item
  Chronic, symptomatic tears → consider surgical intervention
\end{itemize}

\hypertarget{little-leage-shoulder-proximal-humeral-epiphysiolysis}{%
\subsubsection{Little Leage Shoulder (Proximal Humeral Epiphysiolysis)}\label{little-leage-shoulder-proximal-humeral-epiphysiolysis}}

\hypertarget{descriptionmechanism-6}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-6}}

\begin{itemize}
\tightlist
\item
  Overuse injury from throwing causing microfractures in humeral epiphysis
\item
  Most common in \textbf{11-16yo} athletes
\end{itemize}

\hypertarget{signs-symptoms-3}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-3}}

Progressive shoulder pain w/ throwing, localized to proximal humerus, usually lateral

\hypertarget{diagnosis-21}{%
\paragraph{Diagnosis}\label{diagnosis-21}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} TTP at proximal lateral humerus over deltoid
\item
  \textbf{Imaging:} AP XR of both arms in external and internal rotation; can get MRI if dx unclear
\end{itemize}

\hypertarget{management-110}{%
\paragraph{Management}\label{management-110}}

\begin{itemize}
\tightlist
\item
  Rest x3 mos (minimum) + PT, then gradual progression to throwing
\item
  Can still bat and play positions that do not require a lot of throwing
\end{itemize}

\hypertarget{acromioclavicular-ac-joint-injury}{%
\subsubsection{Acromioclavicular (AC) Joint Injury}\label{acromioclavicular-ac-joint-injury}}

\hypertarget{descriptionmechanism-7}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-7}}

\begin{itemize}
\tightlist
\item
  Ranges from sprain of AC ligaments to full ligamentous rupture w/ clavicular displacement
\item
  Usually fall onto or direct blow to shoulder
\end{itemize}

\hypertarget{diagnosis-22}{%
\paragraph{Diagnosis}\label{diagnosis-22}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Tenderness, swelling, asymmetry at AC joint, prominent distal clavicle; + scarf test
\item
  \textbf{Imaging:} XR (abnormal in more severe injury, may be normal if joint space not widened)
\end{itemize}

\hypertarget{management-111}{%
\paragraph{Management}\label{management-111}}

\begin{itemize}
\tightlist
\item
  Less severe injury (no separation of joint capsule) → sling 1-2 wks, ice, NSAIDs → early motion as able, including flexion/extension at elbow
\item
  More severe injury → likely surgical intervention
\end{itemize}

\hypertarget{clavicular-fracture}{%
\subsubsection{Clavicular Fracture}\label{clavicular-fracture}}

\hypertarget{descriptionmechanism-8}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-8}}

Classified by location: most common is \textbf{midshaft fracture} \textgreater{} distal third \textgreater{} proximal third

\hypertarget{diagnosis-23}{%
\paragraph{Diagnosis}\label{diagnosis-23}}

\begin{itemize}
\tightlist
\item
  Exam: Arm held adducted close to body, often supported w/ opposite hand; point tenderness, crepitus

  \begin{itemize}
  \tightlist
  \item
    \textbf{Neurovascular} and \textbf{respiratory} exam \textbf{crucial} due to risk of brachial plexus and lung injury
  \end{itemize}
\item
  Imaging: XR
\end{itemize}

\hypertarget{management-112}{%
\paragraph{Management}\label{management-112}}

\begin{itemize}
\tightlist
\item
  Most heal well w/ sling, but indications for surgery are controversial
\item
  Any sign of neurovascular compromise → acute reduction needed
\end{itemize}

\hypertarget{lower-extremity-hip}{%
\subsection{Lower Extremity: Hip}\label{lower-extremity-hip}}

\hypertarget{anatomy-3}{%
\subsubsection{Anatomy}\label{anatomy-3}}

\includegraphics{images/sports_anatomy-hip.png}

\hypertarget{exam-pearls-special-tests-1}{%
\subsubsection{Exam Pearls \& Special Tests}\label{exam-pearls-special-tests-1}}

\begin{itemize}
\tightlist
\item
  Hip pain can refer to groin, thigh, or knee, or can present as limp/refusal to walk w/o complaint of pain

  \begin{itemize}
  \tightlist
  \item
    Pain from intra-articular pathology often localizes to groin
  \end{itemize}
\item
  \textbf{Barlow/Ortolani:} Remember to apply gentle anterior pressure to the trochanter during abduction (Ortolani test)
\item
  \textbf{Trendelenburg test:} Positive when patient stands on one leg and the contralateral hip drops, indicative of gluteals/hip abductor weakness
\item
  \textbf{FABER} (Flexion, Abduction, External Rotation): Test for hip or SI joint pathology
\item
  \textbf{FADIR} (Flexion, Adduction, Internal Rotation): Test for hip impingement
\item
  \textbf{Log roll test:} Patient on back w/ leg fully extended and relaxed, examiner passively rotates leg and hip internally and externally. Pain should yield high suspicion for intra-articular pathology.
\end{itemize}

\includegraphics{images/sports_special-tests-trendelenburg.png}

\hypertarget{legg-calve-parthes-disease}{%
\subsubsection{Legg-Calve-Parthes Disease}\label{legg-calve-parthes-disease}}

\hypertarget{descriptionmechanism-9}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-9}}

\begin{itemize}
\tightlist
\item
  Avascular necrosis (AVN) of the hip
\item
  Most common age \textbf{5-7yo, M \textgreater{} F,} bilateral in 10-20\%
\end{itemize}

\hypertarget{signs-symptoms-4}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-4}}

Activity-related hip pain and/or limp (acute or chronic)

\hypertarget{diagnosis-24}{%
\paragraph{Diagnosis}\label{diagnosis-24}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Trendelenburg gait, decreased hip abduction and internal rotation
\item
  \textbf{Imaging:} XR often normal early in course, bone scan or MRI more suggestive of dx
\end{itemize}

\hypertarget{management-113}{%
\paragraph{Management}\label{management-113}}

\begin{itemize}
\tightlist
\item
  Non-weight bearing and restoration of motion (crutches), NSAIDS, PT, aquatherapy
\item
  Severe cases may require spica casting or surgery
\end{itemize}

\hypertarget{slipped-capital-femoral-epiphysis-scfe}{%
\subsubsection{Slipped Capital Femoral Epiphysis (SCFE)}\label{slipped-capital-femoral-epiphysis-scfe}}

\hypertarget{descriptionmechanism-10}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-10}}

\begin{itemize}
\tightlist
\item
  Displacement of the capital femoral epiphysis from the femoral neck through the physeal plate
\item
  Commonly ages \textbf{10-16yo, M \textgreater{} F,} bilateral in 20-40\%
\end{itemize}

\hypertarget{signs-symptoms-5}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-5}}

Groin pain, knee pain, limp

\hypertarget{diagnosis-25}{%
\paragraph{Diagnosis}\label{diagnosis-25}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Decreased hip ROM, hip externally rotated at rest, leg length discrepancy
\item
  \textbf{Imaging:} AP + frog leg lateral hip XR. Look for ``ice cream scoop falling off the cone, S-sign (frog leg) + Klein's Line (AP) for subtle cases.
\end{itemize}

\includegraphics{images/sports_scfe.png}

\hypertarget{developmental-dysplasia-of-the-hip-ddh}{%
\subsubsection{Developmental Dysplasia of the Hip (DDH)}\label{developmental-dysplasia-of-the-hip-ddh}}

\hypertarget{descriptionmechanism-11}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-11}}

\begin{itemize}
\tightlist
\item
  Abnormal development of shallow acetabulum causing hip joint instability
\item
  \textbf{F \textgreater{} M}
\end{itemize}

\hypertarget{diagnosis-26}{%
\paragraph{Diagnosis}\label{diagnosis-26}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Positive Barlow/Ortolani (only reliable in ages \textbf{\textless3mo}). Limitation of hip abduction or positive Galeazzi (asymmetric knee heights when hips \& knees flexed) in ages \textbf{\textgreater3mo}.
\item
  \textbf{Imaging:} US until age 4-6mos, AP XR pelvis w/ hip in 20-30 degree flexion after age 4-6mos
\end{itemize}

\hypertarget{management-114}{%
\paragraph{Management}\label{management-114}}

\begin{itemize}
\tightlist
\item
  Ortho referral
\item
  Depending on age at diagnosis/referral and severity, may be treated w/ anything from observation to harness to operative management
\end{itemize}

\hypertarget{femoroacetabular-impingement-fai}{%
\subsubsection{Femoroacetabular Impingement (FAI)}\label{femoroacetabular-impingement-fai}}

\hypertarget{descriptionmechanism-12}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-12}}

\begin{itemize}
\tightlist
\item
  Trapping of femoral neck against anterior acetabulum
\item
  Acetabular overcoverage (Pincer impingement) vs decreased head-neck offset (CAM impingement) vs both
\item
  Common in athletes
\item
  Difficult to differentiate from hip flexor tendinitis
\end{itemize}

\includegraphics{images/sports_fai.png}

\hypertarget{diagnosis-27}{%
\paragraph{Diagnosis}\label{diagnosis-27}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Pain on hip flexion passively or against resistance, impact/running, deep flexion; pain is usually anterior or into groin.
\item
  \textbf{Imaging:} XR AP Pelvis and Dunn laterals bilaterally

  \begin{itemize}
  \tightlist
  \item
    Can have skeletal setup and still not be their pain cause
  \end{itemize}
\end{itemize}

\hypertarget{management-115}{%
\paragraph{Management}\label{management-115}}

Safe to start with PT unless having mechanical/catch/lock symptoms or difficulty weight bearing (in which case, refer to Sports Med/Ortho)

\hypertarget{lower-extremity-knee}{%
\subsection{Lower Extremity: Knee}\label{lower-extremity-knee}}

\hypertarget{anatomy-4}{%
\subsubsection{Anatomy}\label{anatomy-4}}

\includegraphics{images/sports_anatomy-knee.png}

\hypertarget{exam-pearls-special-tests-2}{%
\subsubsection{Exam Pearls \& Special Tests}\label{exam-pearls-special-tests-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Ober test:} Positive if superior leg doesn't drop towards table when released. Tests \textbf{IT band}.
\item
  \textbf{Anterior drawer test:} Anterior translation (keep foot stabilized) compared to contralateral knee. Tests \textbf{ACL}.
\item
  \textbf{Valgus/varus stress test:} Laxity/pain w/ valgus/varus at 0° and 30°. Tests \textbf{MCL/LCL} (respectively).
\item
  \textbf{McMurray test:} Pain/click w/ knee extension w/ tibia internally/externally rotated. Tests \textbf{lateral/medial meniscus} (respectively).
\end{itemize}

\includegraphics{images/sports_special-tests-knee.png}

\hypertarget{osgood-schlatter-disease}{%
\subsubsection{Osgood-Schlatter Disease}\label{osgood-schlatter-disease}}

\hypertarget{descriptionmechanism-13}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-13}}

\begin{itemize}
\tightlist
\item
  Traction apophysitis of tibial tubercle at patellar tendon insertion
\item
  Often children who play jumping sports and/or are undergoing rapid growth spurt
\item
  Corollary process at inferior patellar pole = \textbf{Sinding-Larsen-Johansson Syndrome}
\end{itemize}

\hypertarget{signs-symptoms-6}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-6}}

\begin{itemize}
\tightlist
\item
  Gradually worsening anterior knee pain, exacerbated by kneeling, jumping, stairs, walking uphill
\item
  Can be asymmetric or bilateral
\item
  Pain relieved by rest
\end{itemize}

\hypertarget{diagnosis-28}{%
\paragraph{Diagnosis}\label{diagnosis-28}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Prominence of and TTP at the tibial tubercle, pain w/ resisted knee extension or squatting
\item
  \textbf{Imaging:} Not routinely indicated unless to rule out other dx
\end{itemize}

\hypertarget{management-116}{%
\paragraph{Management}\label{management-116}}

\begin{itemize}
\tightlist
\item
  Usually conservative: Pain management, PT for strengthening
\item
  Continuation of activity, as long as not prolonged squatting/kneeling (e.g.~playing)
\end{itemize}

\hypertarget{patellofemoral-pain-syndrome-pfps}{%
\subsubsection{Patellofemoral Pain Syndrome (PFPS)}\label{patellofemoral-pain-syndrome-pfps}}

\hypertarget{descriptionmechanism-14}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-14}}

Abnormal tracking of patella causes anterior knee pain w/o intra-articular pathology

\hypertarget{signs-symptoms-7}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-7}}

\begin{itemize}
\tightlist
\item
  Anterior knee pain worsened w/ prolonged sitting (theater sign) or descending stairs
\item
  Pain w/ running/impact activity (aka Runner's knee)
\end{itemize}

\hypertarget{diagnosis-29}{%
\paragraph{Diagnosis}\label{diagnosis-29}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Positive J-sign (lateral patellar tracking during terminal knee extension), positive patella mobility test (medial glide \textless{} ¼ or \textgreater{} ¾ patella width suggesting hypo- or hypermobility)
\item
  \textbf{Imaging:} Not routinely indicated unless to exclude other dx
\end{itemize}

\hypertarget{management-117}{%
\paragraph{Management}\label{management-117}}

\begin{itemize}
\tightlist
\item
  Conservative treatment, PT for strengthening
\item
  Avoid long-term NSAID use
\end{itemize}

\hypertarget{anterior-cruciate-ligament-acl-injuries}{%
\subsubsection{Anterior Cruciate Ligament (ACL) Injuries}\label{anterior-cruciate-ligament-acl-injuries}}

\hypertarget{descriptionmechanism-15}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-15}}

\begin{itemize}
\tightlist
\item
  Cutting/pivoting motion causing valgus stress on knee, can be due to direct blow causing hyperextension/valgus deformation
\item
  Medial meniscus and MCL often injured at same time (\textbf{Unhappy Triad})
\end{itemize}

\hypertarget{signs-symptoms-8}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-8}}

``Pop'' at time of injury, swelling, feeling of knee ``giving out''

\hypertarget{diagnosis-30}{%
\paragraph{Diagnosis}\label{diagnosis-30}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Joint effusion, positive anterior drawer test
\item
  \textbf{Imaging:} MRI \textgreater{} XR, but can get XR to evaluate for associated injury/fracture
\end{itemize}

\hypertarget{management-118}{%
\paragraph{Management}\label{management-118}}

\begin{itemize}
\tightlist
\item
  Ortho/Sports Med referral
\item
  Operative management in majority of cases, ideally w/ period of pre-operative rehabilitation to optimize outcomes
\end{itemize}

\hypertarget{meniscus-injuries}{%
\subsubsection{Meniscus Injuries}\label{meniscus-injuries}}

\hypertarget{descriptionmechanism-16}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-16}}

\begin{itemize}
\tightlist
\item
  Direction change w/ knee rotation, planted foot, and flexed knee
\item
  Commonly in sports w/ lots of deceleration and direction change
\end{itemize}

\hypertarget{signs-symptoms-9}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-9}}

\begin{itemize}
\tightlist
\item
  Often insidious onset of pain/swelling in 24h after injury
\item
  Pain worse w/ twisting/pivoting
\item
  Can have locking/popping/catching sensation
\end{itemize}

\hypertarget{diagnosis-31}{%
\paragraph{Diagnosis}\label{diagnosis-31}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Joint line tenderness, inability to fully extend/squat/kneel, positive McMurray test
\item
  \textbf{Imaging:} MRI \textgreater{} XR (plain films often negative)
\end{itemize}

\hypertarget{management-119}{%
\paragraph{Management}\label{management-119}}

\begin{itemize}
\tightlist
\item
  Ortho/Sports Med referral
\item
  Management varies from conservative to operative (usually arthroscopic)
\end{itemize}

\hypertarget{iliotibial-it-band-syndrome}{%
\subsubsection{Iliotibial (IT) Band Syndrome}\label{iliotibial-it-band-syndrome}}

\hypertarget{descriptionmechanism-17}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-17}}

Tight IT band sliding over lateral femoral epicondyle

\hypertarget{signs-symptoms-10}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-10}}

Diffuse lateral knee pain, worsened w/ activity or w/ prolonged sitting w/ knee in flexed position

\hypertarget{diagnosis-32}{%
\paragraph{Diagnosis}\label{diagnosis-32}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} TTP in lateral knee, positive Ober test
\item
  \textbf{Imaging:} Not routinely indicated
\end{itemize}

\hypertarget{management-120}{%
\paragraph{Management}\label{management-120}}

\begin{itemize}
\tightlist
\item
  Activity modification
\item
  NSAIDs
\item
  Stretching/strengthening regimen
\end{itemize}

\hypertarget{osteochondritis-dissecans}{%
\subsubsection{Osteochondritis Dissecans}\label{osteochondritis-dissecans}}

\hypertarget{descriptionmechanism-18}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-18}}

\begin{itemize}
\tightlist
\item
  Acquired subchondral bone lesion which can progress to involve cartilage causing separation from underlying bone; most common in knee
\item
  Mechanism unknown; proposed to be due to repetitive trauma vs.~inflammation
\item
  Can lead to \textbf{osteoarthritis} if not recognized/treated
\end{itemize}

\hypertarget{signs-symptoms-11}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-11}}

\begin{itemize}
\tightlist
\item
  May be incidental finding on imaging vs.~non-specific activity related knee pain
\item
  May have swelling or symptoms of catching/locking if lesions are unstable
\end{itemize}

\hypertarget{diagnosis-33}{%
\paragraph{Diagnosis}\label{diagnosis-33}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} No specific findings
\item
  \textbf{Imaging:} 4-view XR (AP, lateral, sunrise, tunnel) of knee, MRI to further delineate known OCD lesion and determine management (or if XR negative but high clinical suspicion)
\end{itemize}

\hypertarget{management-121}{%
\paragraph{Management}\label{management-121}}

\begin{itemize}
\tightlist
\item
  Referral to Ortho/Sports Med
\item
  May be treated conservatively (non-weight-bearing or activity limitation) vs.~operatively (if lesions are unstable or unresponsive to conservative treatment)
\end{itemize}

\hypertarget{lower-extremity-anklefoot}{%
\subsection{Lower Extremity: Ankle/Foot}\label{lower-extremity-anklefoot}}

\hypertarget{anatomy-5}{%
\subsubsection{Anatomy}\label{anatomy-5}}

\includegraphics{images/sports_anatomy-ankle.png}

\hypertarget{exam-pearls-special-tests-3}{%
\subsubsection{Exam Pearls \& Special Tests}\label{exam-pearls-special-tests-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Mid-calf squeeze:} Positive if generates pain in ankle. Tests \textbf{tibiofibular syndesmosis}.
\item
  \textbf{Anterior drawer test:} Anterior translation comapred to contralateral ankle. Tests \textbf{ATFL}.
\item
  \textbf{Talar tilt:} Range of inversion compared to contralateral ankle. Tests \textbf{CFL}.
\item
  \textbf{Ottawa ankle rules} (when to get XR of ankle/foot, validated for \textgreater18yo):

  \begin{itemize}
  \tightlist
  \item
    \textbf{Ankle:} Pain in malleolar zone + EITHER of:

    \begin{itemize}
    \tightlist
    \item
      Bony tenderness at posterior edge of lateral/medial malleolus
    \item
      Inability to bear weight both immediately after injury + at time of exam
    \end{itemize}
  \item
    \textbf{Foot:} Pain in midfoot zone + EITHER of:

    \begin{itemize}
    \tightlist
    \item
      Bony tenderness at base of 5th metatarsal or navicular bone
    \item
      Inability to bear weight both immediately after injury + at time of exam
    \end{itemize}
  \end{itemize}
\end{itemize}

\includegraphics{images/sports_special-tests-ottawa-ankle-rules.png}
\includegraphics{images/sports_special-tests-ankle.png}

\hypertarget{ankle-sprain}{%
\subsubsection{Ankle Sprain}\label{ankle-sprain}}

\hypertarget{descriptionmechanism-19}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-19}}

\begin{itemize}
\tightlist
\item
  Ligamentous stretching/tearing
\item
  \textbf{Lateral:} Inversion of plantar-flexed foot; injuries \textbf{ATFL} most commonly
\item
  \textbf{Medial:} Eversion or abduction/ external
\end{itemize}

\hypertarget{signs-symptoms-12}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-12}}

Pain, swelling (diffuse or localized), +/- inability to bear weight

\hypertarget{diagnosis-34}{%
\paragraph{Diagnosis}\label{diagnosis-34}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Swelling, TTP, positive anterior drawer/talar tilt (lateral sprain), positive mid-calf squeeze (high sprain), squeeze test for syndesmotic injury
\item
  \textbf{Imaging:} Not routinely indicated unless concern for fracture (see Ottawa rules above) or clinical uncertainty
\end{itemize}

\hypertarget{management-122}{%
\paragraph{Management}\label{management-122}}

\begin{itemize}
\tightlist
\item
  Short period of complete immobilization (longer depending on severity), supportive device (lace-up brace or elastic bandage)
\item
  ROM/strength exercises (can be w/ formal PT, esp.~in case of recurrent ankle sprains) are critical to restoring function and proprioception
\item
  For HIGH ankle sprains, consult Ortho/Sports Med (may need acute surgical stabilization if severe)
\end{itemize}

\hypertarget{severs-disease}{%
\subsubsection{Sever's Disease}\label{severs-disease}}

\hypertarget{descriptionmechanism-20}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-20}}

\begin{itemize}
\tightlist
\item
  Traction apophysitis of calcaneal growth plate at site of Achilles insertion; often children who play sports w/ jumping/heel striking and/or are undergoing rapid growth spurt
\item
  Essentially Osgood-Schlatter at the calcaneus
\end{itemize}

\hypertarget{signs-symptoms-13}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-13}}

Chronic heel pain w/ insidious onset, worse w/ activity or wearing non-supportive footwear

\hypertarget{diagnosis-35}{%
\paragraph{Diagnosis}\label{diagnosis-35}}

\begin{itemize}
\tightlist
\item
  Exam: TTP at calcaneal apophysis or w/ ``calcaneal compression test''
\item
  Imaging: Not routinely indicated unless diagnosis unclear or to rule out fracture
\end{itemize}

\hypertarget{management-123}{%
\paragraph{Management}\label{management-123}}

Painful activity → gradual return to play, use of heel cup for support, ice and stretching

\hypertarget{spiraloblique-fracture}{%
\subsubsection{Spiral/Oblique Fracture}\label{spiraloblique-fracture}}

\hypertarget{descriptionmechanism-21}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-21}}

\begin{itemize}
\tightlist
\item
  \textbf{``Toddler's fracture''} in 9mo-3yo
\item
  Rotation around fixed foot → distal tibial fracture; often minimal trauma in toddlers, higher impact injury in older children
\item
  \textasciitilde30\% of tibial fractures have associated fibular fracture
\item
  Spiral fractures in \textbf{NON-ambulatory} child → concern for \textbf{NAT}
\end{itemize}

\hypertarget{signs-symptoms-14}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-14}}

Limp, refusal to bear weight

\hypertarget{diagnosis-36}{%
\paragraph{Diagnosis}\label{diagnosis-36}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Point tenderness over distal ⅓ of tibia
\item
  \textbf{Imaging:} AP + lateral XR of the tibia and fibula; fractures may be occult (not seen on imaging)
\end{itemize}

\hypertarget{management-124}{%
\paragraph{Management}\label{management-124}}

\begin{itemize}
\tightlist
\item
  Immobilization in long leg posterior splint/cast
\item
  Ortho referral
\end{itemize}

\hypertarget{congenital-clubfoot}{%
\subsubsection{Congenital Clubfoot}\label{congenital-clubfoot}}

\hypertarget{descriptionmechanism-22}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-22}}

\begin{itemize}
\tightlist
\item
  Idiopathic vs.~due to intrinsic (e.g.~neurologic) or extrinsic (e.g.~fibroids) factors
\item
  1:1000 live births, \textbf{M \textgreater{} F}
\end{itemize}

\hypertarget{diagnosis-37}{%
\paragraph{Diagnosis}\label{diagnosis-37}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Fixed (e.g.~not correctable) deformity of the foot w/ plantar flexion and inversion + rotation, calf atrophy
\item
  \textbf{Imaging:} Usually dx on prenatal US, XR minimally useful initially
\end{itemize}

\hypertarget{management-125}{%
\paragraph{Management}\label{management-125}}

\begin{itemize}
\tightlist
\item
  Ortho referral (usually done in nursery prior to d/c)
\item
  Serial casting → Achilles tenotomy → bracing
\end{itemize}

\hypertarget{spine}{%
\subsection{Spine}\label{spine}}

\hypertarget{anatomy-6}{%
\subsubsection{Anatomy}\label{anatomy-6}}

\includegraphics{images/sports_anatomy-spine.png}

\hypertarget{exam-pearls-special-tests-4}{%
\subsubsection{Exam Pearls \& Special Tests}\label{exam-pearls-special-tests-4}}

\begin{itemize}
\tightlist
\item
  \textbf{Straight leg raise:} Patient lying supine → flex at hip w/ knee straight (best if cervical spine flexed and ankle dorsiflexed) → assess for sciatic pain (sign of herniated disc)
\end{itemize}

\includegraphics{images/sports_special-tests-straight-leg-raise.png}

\hypertarget{scoliosis}{%
\subsubsection{Scoliosis}\label{scoliosis}}

\hypertarget{descriptionmechanism-23}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-23}}

\begin{itemize}
\tightlist
\item
  Lateral curvature of the spine \emph{\textgreater{}} 10°
\item
  Idiopathic (80\%) vs.~congenital vs.~neuromuscular
\end{itemize}

\hypertarget{diagnosis-38}{%
\paragraph{Diagnosis}\label{diagnosis-38}}

\begin{itemize}
\tightlist
\item
  \textbf{Exam:} Adam's forward bend test + inclinometer. Shoulder/torso asymmetry, rib prominence, paraspinal muscle prominence.
\item
  \textbf{Imaging:} XR w/ Cobb Angle \emph{\textgreater{}} 10°
\end{itemize}

\includegraphics{images/sports_scoliosis.png}

\hypertarget{management-126}{%
\paragraph{Management}\label{management-126}}

\begin{itemize}
\item
  \emph{\textless{}} 25° → observation
\item
  25-45° + skeletal immaturity → bracing
\item
  \begin{quote}
  45° → consider surgical intervention
  \end{quote}
\end{itemize}

\hypertarget{spondylolysis-spondylolisthesis}{%
\subsubsection{Spondylolysis \& Spondylolisthesis}\label{spondylolysis-spondylolisthesis}}

\hypertarget{descriptionmechanism-24}{%
\paragraph{Description/Mechanism}\label{descriptionmechanism-24}}

\begin{itemize}
\tightlist
\item
  \textbf{Spondylolysis:} Bony defect in pars interarticularis (usually L4 and L5)
\item
  \textbf{Spondylolisthesis:} Displacement of vertebral body relative to inferior vertebral body
\item
  Caused by repetitive microtrauma
\item
  \textbf{Most common causes of back pain in children \textgreater10yo}; often in athletes engaged in sports w/ repetitive extension, flexion, and rotation
\end{itemize}

\includegraphics{images/sports_spondylolysis-spondylolisthesis.png}

\hypertarget{signs-symptoms-15}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-15}}

\begin{itemize}
\tightlist
\item
  Low back pain that worsens w/ activity, improves w/ rest
\item
  \textbf{Spondylolisthesis:} May have radicular or cauda equina symptoms
\end{itemize}

\hypertarget{diagnosis-39}{%
\paragraph{Diagnosis}\label{diagnosis-39}}

\begin{itemize}
\tightlist
\item
  \textbf{Imaging:}

  \begin{itemize}
  \tightlist
  \item
    MRI is now study of choice
  \item
    XR: Poorly sensitive and do not assess acuity, but might be required prior to MRI

    \begin{itemize}
    \tightlist
    \item
      Standing AP, lateral, oblique views: Visualize defect
    \item
      Flexion and extension views: Assess stability
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{management-127}{%
\paragraph{Management}\label{management-127}}

\begin{itemize}
\tightlist
\item
  \textbf{Spondylolysis} and \textbf{low-grade spondylolisthesis} → conservative (rest from sports for \emph{\textgreater{}} 3 mos, NSAIDs, PT, back bracing)
\item
  \textbf{Higher-grade spondylolisthesis} (or failure of conservative management) → consider surgical intervention
\end{itemize}

\hypertarget{spondyloarthropathies}{%
\subsubsection{Spondyloarthropathies}\label{spondyloarthropathies}}

\hypertarget{signs-symptoms-16}{%
\paragraph{Signs \& Symptoms}\label{signs-symptoms-16}}

\begin{itemize}
\tightlist
\item
  Insidious onset
\item
  Often misdiagnosed w/ recurrent strains/sprains
\item
  Pain worse at night, improves w/ activity
\end{itemize}

\hypertarget{head-1}{%
\subsection{Head}\label{head-1}}

\hypertarget{mild-traumatic-brain-injury-tbi-concussion}{%
\subsubsection{Mild Traumatic Brain Injury (TBI) (Concussion)}\label{mild-traumatic-brain-injury-tbi-concussion}}

Including Graduated Return-to-Sport Program

*\textbf{See }ED chapter** for Mild TBI section*

\hypertarget{toxicology}{%
\section{Toxicology}\label{toxicology}}

\hypertarget{key-resources}{%
\subsection{Key Resources}\label{key-resources}}

\begin{itemize}
\tightlist
\item
  Poison Control: \textbf{1-800-222-1222}
\item
  BCH Toxicology Fellow/Attending (on call 24/7)
\item
  BCH Chemistry Fellow (daytime hours, can help interpret labs and select specialized testing)
\item
  Hazmat Team: Boston Fire Department
\item
  MSDS: Material Safety Data Sheets
\item
  www.maripoisoncenter.com
\item
  www.aapcc.org
\end{itemize}

\hypertarget{approach-to-poisoned-patient}{%
\subsection{Approach to Poisoned Patient}\label{approach-to-poisoned-patient}}

\hypertarget{stabilization}{%
\subsubsection{Stabilization}\label{stabilization}}

Airway, Breathing, Circulation, Disability, Drugs/D-Stick, Decontamination

\hypertarget{physical-exam-26}{%
\subsubsection{Physical Exam}\label{physical-exam-26}}

\textbf{Vital signs}
\textbf{Neuro}: MS, tone, clonus, abnormal movements
\textbf{Eyes}: pupils, EOM, nystagmus
\textbf{Mouth}: corrosive lesions, odors
\textbf{CV}: rate, rhythm, perfusion
\textbf{Resp}: rate, depth of respirations, air entry, wheeze
\textbf{GI}: motility (?bowel sounds), corrosive effects (i.e.~vomiting)
\textbf{Skin}: color, bullae, burn, sweat, track marks

\hypertarget{history-17}{%
\subsubsection{History}\label{history-17}}

\begin{itemize}
\tightlist
\item
  \textbf{AMPLE}: \textbf{A}llergies, \textbf{M}eds/Toxins (everyone in home), \textbf{P}ast medical history, \textbf{L}ast meal, \textbf{E}vents
\item
  \textbf{Known toxin}: amount, time since ingestion, early sx, home tx
\item
  \textbf{Concern for poisoning}: h/o pica or ingestions, meds in home, recent illnesses, visitors/events
\end{itemize}

\hypertarget{basic-labs}{%
\subsubsection{Basic Labs}\label{basic-labs}}

Consider ABG, co-oximetry, CBC, D-stick, EKG, Chem, LFTs, serum OSM, UA, urine/serum tox

\hypertarget{tox-screens}{%
\subsubsection{Tox Screens}\label{tox-screens}}

\begin{itemize}
\tightlist
\item
  Substances included, limits of detection vary hospital to hospital
\item
  Urine drug screens rarely inform acute management decisions
\item
  \textbf{Urine tox screens}: detect amphetamines, MDMA, barbiturates, benzos, cocaine, opioids, +/- THC

  \begin{itemize}
  \tightlist
  \item
    Qualitative (+/-)
  \item
    Does not detect synthetic cathinones (i.e.~``bath salts''); false + and false - (esp benzos, synthetic opioids) common
  \item
    ADHD drugs: adderall → positive amphetamine
  \end{itemize}
\item
  Urine THC - must order separately at BMC
\item
  Expanded opioid panel, urine (BMC): detects buprenorphine, oxycodone, methadone, fentanyl
\item
  \textbf{Extended tox screen}: GC/MS, urine better than serum, send out test
\item
  \textbf{Meconium tox}: amphetamines, THC, cocaine, opiates, PCP
\item
  \textbf{Serum tox}: APAP, ASA, EtOH (quantitative),TCAs (qualitative)
  \textbf{Specific drug levels}: can request agents not on tox screens (digoxin, lithium, AEDs, iron, etc.)
\end{itemize}

\hypertarget{management-128}{%
\subsubsection{Management}\label{management-128}}

\begin{itemize}
\tightlist
\item
  Can I decontaminate?
\item
  Can I enhance the elimination of the toxin? (www.extrip-workgroup.org)
\item
  Is there an antidote?
\item
  How can I provide the best, targeted supportive care?
\end{itemize}

\hypertarget{toxidromes}{%
\subsection{Toxidromes}\label{toxidromes}}

\begin{figure}
\centering
\includegraphics{images/toxidromes_table.jpg}
\caption{toxidromes\_table}
\end{figure}

\hypertarget{differential-diagnosis-non-exhaustive}{%
\subsection{Differential Diagnosis (non-exhaustive)}\label{differential-diagnosis-non-exhaustive}}

\hypertarget{temperature}{%
\subsubsection{Temperature}\label{temperature}}

\textbf{Hyperthermia: NASA}
- NMS, nicotine
- Antihistamines, alcohol withdrawal, anesthetics
- Salicylates, sympathomimetics, serotonin syndrome
- Anti: -cholinergics, -depressants, -psychotics

\textbf{Hypothermia: COOLS}
- Carbon monoxide
- Opioids
- Oral hypoglycemics
- Liquor
- Sedative-hypnotics

\hypertarget{heart-rate}{%
\subsubsection{Heart Rate}\label{heart-rate}}

\textbf{Tachycardia: FAST}
- Free base or other forms of cocaine
- Anticholinergics, antihistamines, antipsychotics, amphetamines
- Sympathomimetics
- Theophylline, TCAs, thyroid hormones

\textbf{Bradycardia: PACED}
- Propranolol (beta-blockers), poppies (opioids), physostigmine
- Anticholinesterase drugs, antiarrhythmics
- Clonidine, calcium channel blockers
- Ethanol or other alcohols
- Digoxin, digitalis

\hypertarget{blood-pressure}{%
\subsubsection{Blood Pressure}\label{blood-pressure}}

\textbf{Hypertension: CT SCAN}
- Cocaine
- Thyroid supplements
- Sympathomimetics
- Caffeine
- Anticholinergics, amphetamines
- Nicotine

\textbf{Hypotension: CRASH}
- Clonidine, calcium channel blockers
- Rodenticides (containing arsenic, cyanide)
- Antidepressants, aminophylline, antihypertensives
- Sedative-hypnotics
- Heroin (opioids)

\hypertarget{respiratory-rate}{%
\subsubsection{Respiratory Rate}\label{respiratory-rate}}

\textbf{Tachypnea: PANT}
- PCP
- Aspirin and other salicylates, acute lung injury (hydrocarbons, vaping)
- Noncardiogenic pulmonary edema
- Toxin-induced metabolic acidosis

\textbf{Hypopnea: SLOW}
- Sedative-hypnotics (benzodiazepines, barbiturates)
- Liquor
- Opioids
- Weed

\hypertarget{blood-glucose}{%
\subsubsection{Blood Glucose}\label{blood-glucose}}

\textbf{Hyperglycemia: CAPT ABC}
- Corticosteroids
- Antibiotics (quinolones)
- Protease inhibitors
- Thiazides
- Atypical antipsychotics
- Beta-agonists
- Corticosteroids
\textbf{Hypoglycemia: HOBBIES}
- Hypoglycemics (oral)
- Other (quinine, unripe ackee fruit)
- Beta-blockers
- Insulin
- Ethanol
- Salicylates (late)

\hypertarget{acetaminophen-overdose}{%
\subsection{Acetaminophen Overdose}\label{acetaminophen-overdose}}

\hypertarget{toxic-dose}{%
\subsubsection{Toxic Dose}\label{toxic-dose}}

200 mg/kg (7.5-10 g in older pts) as a single acute overdose

\hypertarget{pathophysiology-66}{%
\subsubsection{Pathophysiology}\label{pathophysiology-66}}

Saturation of glucuronidation/sulfate conjugation pathway → ↑ metabolism via P450 pathway and depletion of glutathione → build up of toxic NAPQI → hepatotoxicity +/- renal toxicity

\hypertarget{symptoms-1}{%
\subsubsection{Symptoms}\label{symptoms-1}}

See chart below

\hypertarget{evaluation-7}{%
\subsubsection{Evaluation}\label{evaluation-7}}

Acetaminophen levels (at ≥ 4 hours post-ingestion, LFTs, coags, electrolytes, BUN/Cr, UA w/ tox screen (serum and urine), urine pregnancy for females

\hypertarget{management-129}{%
\subsubsection{Management}\label{management-129}}

\begin{itemize}
\tightlist
\item
  Activated charcoal if w/i 1-2 hrs of ingestion and no contraindications (unprotected airway and decreased LOC)
\item
  Goal: Initiate NAC ≤ 8 hours of ingestion (or ASAP if \textgreater8 hours post-ingestion)
\item
  APAP level → apply NOMOGRAM → estimate risk of hepatotoxicity
\item
  KEY POINT: NOMOGRAM can ONLY be used for: single acute ingestion, known time of ingestion, ingestion w/i 24hrs of presentation. Also, caution if coingestants that may affect GI motility

  \begin{itemize}
  \tightlist
  \item
    Risk of hepatotoxicity → give N-acetylcysteine
  \item
    IV: loading dose of 150mg/kg over 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours; check APAP levels, LFTs, coags 2 hours before 16h infusion is scheduled to end
  \item
    PO/NG: Loading dose 140mg/kg then 70mg/kg 14hrs x24 hours
  \item
    Guidelines for stopping NAC: clinically well, improving LFTs, normalizing coags, APAP level \textless10 (if patient does not meet guidelines, continue NAC (100mg/kg IV over 16 hours) until they meet criteria.
  \end{itemize}
\item
  King's College Criteria for Liver Transplant:

  \begin{itemize}
  \tightlist
  \item
    pH \textless{} 7.3 or
  \item
    INR \textgreater{} 6.5 AND serum creatinine \textgreater{} 3.4mg/dL AND grade III - IV encephalopathy
  \item
    West Haven Criteria for encephalopathy:

    \begin{itemize}
    \tightlist
    \item
      I: Changes in behavior with minimal change in level of consciousness
    \item
      II: Gross disorientation, drowsiness, possible asterixis, behavior changes
    \item
      III: Marked confusion, incoherent speech, sleepy but arousable to voice
    \item
      IV: Comatose, unresponsive to pain, decorticate/decerebrate positioning
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{rule-of-150}{%
\subsubsection{Rule of 150}\label{rule-of-150}}

\begin{itemize}
\tightlist
\item
  Potentially toxic dose: 150mg/kg
\item
  Treatment line: 150mcg/mL at 4 hours
\item
  Loading dose of NAC 150mg/kg over one hour
\end{itemize}

\textbf{Acute APAP Toxicity: 4 stages}
\textbar{} \textbar{} \textbf{Symptoms} \textbar{} \textbf{Labs} \textbar{}
\textbar---------------------------\textbar-----------------------------------------------------------------------------------------------------------------------------------------------------------------\textbar-------------------------------------------------\textbar{}
\textbar{} \textbf{Stage 1}: 0-24 hours \textbar{} N/V, diaphoresis, malaise May be asymptomatic \textbar{} Labs, PE generally normal \textbar{}
\textbar{} \textbf{Stage 2}: 24-72 hours \textbar{} Initial symptoms resolve RUQ pain, liver enlargement/tenderness \textbar{} AST/ALT, ↑ PT/INR, renal dysfunction, ↑ amylase \textbar{}
\textbar{} \textbf{Stage 3}: 72-96 hours \textbar{} N/V, diaphoresis return - Jaundice, hepatic encephalopathy, hyperammonemia, bleeding, hypoglycemia, lactic acidosis - Renal failure, multi organ failure, death \textbar{} LFTs peak \textbar{}
\textbar{} \textbf{Stage 4}: 4-14 days \textbar{} Recovery phase Slow normalization of symptoms and lab values (Symptoms typically normalize well before transaminases do) \textbar{} Slow normalization \textbar{}

\hypertarget{aspirin-overdose}{%
\subsection{Aspirin Overdose}\label{aspirin-overdose}}

\hypertarget{toxic-dose-1}{%
\subsubsection{Toxic Dose}\label{toxic-dose-1}}

150 mg/kg

\hypertarget{pathophysiology-67}{%
\subsubsection{Pathophysiology}\label{pathophysiology-67}}

\begin{itemize}
\tightlist
\item
  Stimulates medullary respiratory center → ↑RR, hyperpnea, respiratory alkalosis
\item
  Inhibits Kreb's cycle enzymes → lactic acidosis, ketoacidosis
\item
  Inhibits platelet function + vitamin-K dependent clotting factors → coagulopathy
\end{itemize}

\hypertarget{symptoms-2}{%
\subsubsection{Symptoms}\label{symptoms-2}}

\begin{itemize}
\tightlist
\item
  Mild toxicity: GI upset, tinnitus and tachypnea
\item
  Moderate toxicity: fever, diaphoresis, tachycardia, agitation, confusion
\item
  Severe toxicity: coma, pulmonary edema, seizures
\end{itemize}

\hypertarget{evaluation-8}{%
\subsubsection{Evaluation}\label{evaluation-8}}

Serum salicylate level (normal \textless30 mg/dL), ABG (primary respiratory alkalosis, primary anion-gap met acidosis), glucose (elevated - early, low - late), Electrolytes (hyper/hyponatremia, hypokalemia) +/- LFTs, CBC, coags, UA, serum/urine tox screen. Resulting acidosis and electrolyte changes MAY demonstrate EKG changes (ex. widened QRS, AV block, arrhythmias)

\hypertarget{management-130}{%
\subsubsection{Management}\label{management-130}}

\begin{itemize}
\tightlist
\item
  GI decontamination: activated charcoal (consider repeat dose, prone to bezoar formation)
\item
  Aggressive fluid resuscitation (lots of insensible losses)
\item
  Urine alkalinization: goal URINE pH = 8, goal SERUM pH 7.45-7.55 to enhance ion trapping; can use D5 W150 mEq/L Na-bicarb
\item
  Potassium repletion
\item
  Follow salicylate levels q1-2 hours
\item
  Hemodialysis (ASA level \textgreater90-100mg/dL (acute overdose), \textgreater60 mg/dL (chronic overdose), severe acidosis or electrolyte disturbances, renal failure, pulm edema, neurologic symptoms, deterioration despite interventions)
\end{itemize}

\hypertarget{beta-blocker-overdose}{%
\subsection{Beta-Blocker Overdose}\label{beta-blocker-overdose}}

\hypertarget{toxic-dose-2}{%
\subsubsection{Toxic Dose}\label{toxic-dose-2}}

``One pill can kill'' in toddlers

\hypertarget{pathophysiology-68}{%
\subsubsection{Pathophysiology}\label{pathophysiology-68}}

adrenergic antagonist → ↓ sympathetic outflow

\hypertarget{symptoms-3}{%
\subsubsection{Symptoms}\label{symptoms-3}}

Bradycardia, hypotension, bronchospasm, coma, seizures, hypoglycemia

\hypertarget{evaluation-9}{%
\subsubsection{Evaluation}\label{evaluation-9}}

DS (hypoglycemia), EKG (brady, AV block, accelerated junctional rhythm), serum/urine tox (in cases of suspected intentional ingestions)

\hypertarget{management-131}{%
\subsubsection{Management}\label{management-131}}

\begin{itemize}
\tightlist
\item
  GI decontamination: activated charcoal (consider whole bowel irrigation) if indicated and no contraindications
\item
  Glucagon bolus: 0.15 mg/kg then infusion of 0.05-0.1 mg/kg/hr (for symptomatic bradycardia)
\item
  Fluids +/- pressors for hypotension
\item
  Hyperinsulinemia/euglycemia (HIE) therapy: sometimes used in severe BB OD
\end{itemize}

\hypertarget{calcium-channel-blocker-overdose}{%
\subsection{Calcium Channel Blocker Overdose}\label{calcium-channel-blocker-overdose}}

\hypertarget{toxic-dose-3}{%
\subsubsection{Toxic Dose}\label{toxic-dose-3}}

``One pill can kill'' in toddlers; individual drug selectivity for cardioactive vs vasoactive effects lost in significant overdose

\hypertarget{pathophysiology-69}{%
\subsubsection{Pathophysiology}\label{pathophysiology-69}}

Block L-type Ca channel blockers (affect myocyte contractility, SA nodal AP initiation)

\hypertarget{symptoms-4}{%
\subsubsection{Symptoms}\label{symptoms-4}}

Bradycardia, hypotension, coma, seizures, dihydropyridine CCBs (amlodipine, nifedipine, etc) can present w/ TACHYcardia and relative hypotension, HYPERglycemia

\hypertarget{evaluation-10}{%
\subsubsection{Evaluation}\label{evaluation-10}}

DS (hyperglycemia), EKG (bradycardia, AV block, accelerated junctional rhythm, wide QRS, ST changes), serum/urine tox (in cases of suspected intentional ingestions)

\hypertarget{management-132}{%
\subsubsection{Management}\label{management-132}}

\begin{itemize}
\tightlist
\item
  GI decontamination: activated charcoal (consider whole bowel irrigation) if indicated and no contraindications
\item
  IV calcium chloride or calcium gluconate
\item
  HIE (hyperinsulinemia/euglycemia) therapy: 1 unit/kg bolus of regular insulin then 0.5-1+unit/kg/hr infusion
\item
  Intralipid 20\%: 1.5ml/kg during 2-3 mins, followed by 0.25 ml/kg/min IV x 30-60 min (consult Tox)
\end{itemize}

\hypertarget{antidepressants-ssris-and-snris}{%
\subsection{Antidepressants: SSRIs and SNRIs}\label{antidepressants-ssris-and-snris}}

\hypertarget{toxicity}{%
\subsubsection{Toxicity}\label{toxicity}}

\begin{itemize}
\tightlist
\item
  SSRIs: less toxic than MAOIs or TCAs; most fatalities due to co-ingestion
\item
  SNRIs: greater toxicity than SSRIs (but less than MAOIs or TCAs)
\end{itemize}

\hypertarget{pathophysiology-70}{%
\subsubsection{Pathophysiology}\label{pathophysiology-70}}

Inhibit serotonin +/- norepinephrine reuptake (primarily in CNS)

\hypertarget{symptoms-5}{%
\subsubsection{Symptoms}\label{symptoms-5}}

\begin{itemize}
\tightlist
\item
  Vomiting, CNS depression, tachycardia
\item
  Serotonin syndrome: altered mental status, neuromuscular hyperexcitability (clonus, rigidity, hyperreflexia), autonomic instability (hyperthermia, tachy, HTN) → can lead to rhabdo, seizures, renal failure, DIC
\end{itemize}

\hypertarget{evaluation-11}{%
\subsubsection{Evaluation}\label{evaluation-11}}

Electrolytes, serum/tox screen, EKG (↑QTc, rare ↑ QRS w/ some SNRIs); levels not helpful

\hypertarget{management-133}{%
\subsubsection{Management}\label{management-133}}

\begin{itemize}
\tightlist
\item
  Decontamination and supportive care
\item
  Benzos and/or serotonin antagonists (cyproheptadine) for serotonin syndrome, consider cooling and paralysis for severe serotonin syndrome
\end{itemize}

\hypertarget{antidepressants-tcas}{%
\subsection{Antidepressants: TCAs}\label{antidepressants-tcas}}

\hypertarget{toxic-dose-4}{%
\subsubsection{Toxic Dose}\label{toxic-dose-4}}

``One pill can kill'' in toddlers

\hypertarget{pathophysiology-71}{%
\subsubsection{Pathophysiology}\label{pathophysiology-71}}

Peripheral and central anticholinergic, peripheral alpha-1 adrenergic blockade, inhibits CNS NE and serotonin reuptake, blocks cardiac fast Na channels, blocks GABA receptors

\hypertarget{symptoms-6}{%
\subsubsection{Symptoms}\label{symptoms-6}}

\begin{itemize}
\tightlist
\item
  Anticholinergic toxidrome (see toxidrome chart)
\item
  Neurotoxicity (seizures, coma)
\item
  Cardiovascular toxicity (arrhythmias, refractory hypotension, widened QRS)
\end{itemize}

\hypertarget{evaluation-12}{%
\subsubsection{Evaluation}\label{evaluation-12}}

Electrolytes, CK, D-stick, urinalysis, tox screens, TCA level not useful (other than to confirm ingestion), EKG (prolonged QRS (\textgreater100ms a/w seizure, dysrhythmias), sinus tach, vent arrhythmias, lead aVR prominent R waves)

\hypertarget{management-134}{%
\subsubsection{Management}\label{management-134}}

\begin{itemize}
\tightlist
\item
  Gastric decontamination, close monitoring, EKGs
\item
  NaHCO3 titrated to serum pH 7.45-7.55 (indicated for QRS \textgreater{} 100ms w/ other signs of TCA toxicity, vent. arrhythmias, CV collapse, seizures). Mechanism: increase pH -\textgreater{} increase non-ionized TCA = cannot bind sodium channels. Also increases gradient across cardiac cell membranes -\textgreater{} attenuates TCA-induced blockade of rapid sodium channels.
\item
  Supportive care (treat refractory hypotension w/ alpha-agonist pressors)
\item
  For severe TCA overdoses, consider intralipid
\end{itemize}

\hypertarget{antidepressants-buproprion}{%
\subsection{Antidepressants: Buproprion}\label{antidepressants-buproprion}}

\hypertarget{toxic-dose-5}{%
\subsubsection{Toxic Dose}\label{toxic-dose-5}}

``One pill can kill'' in toddlers

\hypertarget{pathophysiology-72}{%
\subsubsection{Pathophysiology}\label{pathophysiology-72}}

Dopamine and NE reuptake inhibitor w/ some serotonin reuptake blockade; contraindicated in eating disorder patients given ↑ seizures

\hypertarget{symptoms-7}{%
\subsubsection{Symptoms}\label{symptoms-7}}

Seizures, agitation, HTN, tachycardia, arrhythmias

\hypertarget{evaluation-13}{%
\subsubsection{Evaluation}\label{evaluation-13}}

Levels not helpful, electrolytes, EKG (QRS and QTc prolongation). May cause +amphetamine screen

\hypertarget{management-135}{%
\subsubsection{Management}\label{management-135}}

Supportive care, benzos for seizures, admit for \textgreater24 hours to monitor for late onset seizures if ingested Wellbutrin SR, ↑ QRS treated w/ IV sodium bicarb (though may not be as effective)

\hypertarget{iron}{%
\subsection{Iron}\label{iron}}

\hypertarget{toxic-dose-6}{%
\subsubsection{Toxic Dose}\label{toxic-dose-6}}

\begin{itemize}
\item
  \textless{} 20mg/kg \textbf{elemental iron} usually asymptomatic
\item
  20-60 mg/kg: variable response
\item
  \begin{quote}
  60 mg/kg: greatest risk of serious toxicity (death reported at 60-300+ mg/kg)
  \end{quote}
\end{itemize}

\hypertarget{pathophysiology-73}{%
\subsubsection{Pathophysiology}\label{pathophysiology-73}}

Direct caustic effect on GI mucosa → hemorrhagic necrosis; multisystem toxicity 2/2 mitochondrial poison; iron absorbed at duodenum/jejunum

\hypertarget{symptoms-8}{%
\subsubsection{Symptoms}\label{symptoms-8}}

\emph{If no significant GI symptoms w/i first 6 hrs after overdose, very low likelihood of significant toxicity}

\begin{longtable}[]{@{}ll@{}}
\toprule
\begin{minipage}[b]{0.12\columnwidth}\raggedright
\textbf{Phase I (30min -- 6h)}\strut
\end{minipage} & \begin{minipage}[b]{0.82\columnwidth}\raggedright
\textbf{GI sx}: vomiting, diarrhea, GI bleeding\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Phase II (6h -- 24h)}\strut
\end{minipage} & \begin{minipage}[t]{0.82\columnwidth}\raggedright
Latent period: apparent improvement\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Phase III (4h-4days)}\strut
\end{minipage} & \begin{minipage}[t]{0.82\columnwidth}\raggedright
\textbf{Hepatotoxicity}: hepatocellular injury, AG metabolic acidosis (↑ lactic acid), coma, seizures, multi-organ failure, shock \textbf{Labs}: ↑ bili, ↑ LFTs, ↑ glucose, ↑ PT/INR, ↑ BUN\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.12\columnwidth}\raggedright
\textbf{Phase IV (2-8 wks)}\strut
\end{minipage} & \begin{minipage}[t]{0.82\columnwidth}\raggedright
\textbf{Late effects}: possible bowel obstruction secondary to strictures\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{evaluation-14}{%
\subsubsection{Evaluation}\label{evaluation-14}}

KUB (radio-opaque pills), Fe level, VBG/ABG, lytes, BUN/Cr, glucose, LFTs, PT/INR, CK

\hypertarget{management-136}{%
\subsubsection{Management}\label{management-136}}

Support ABC's, replace fluid/blood losses, GI decontamination, IV deferoxamine (severe sx, iron level \textgreater{} 500 mcg/d w/ clinical symptoms, sig AG met acidosis)

\hypertarget{lead}{%
\subsection{Lead}\label{lead}}

\hypertarget{toxic-dose-7}{%
\subsubsection{Toxic Dose}\label{toxic-dose-7}}

No safe lead level exists

\hypertarget{pathophysiology-74}{%
\subsubsection{Pathophysiology}\label{pathophysiology-74}}

Interferes w/ interactions of divalent cations and sulfhydryl groups leading to widespread physiologic effects and clinical toxicity

\hypertarget{symptoms-9}{%
\subsubsection{Symptoms}\label{symptoms-9}}

\begin{itemize}
\tightlist
\item
  Lower levels: Abdominal pain, constipation, anorexia, vomiting, developmental delays, aggression, hyperactivity
\item
  Higher levels: drowsiness, clumsiness, ataxia
\item
  Severe levels: decreased consciousness, coma, seizures, death (usually 2/2 cerebral edema)
\end{itemize}

\hypertarget{evaluation-15}{%
\subsubsection{Evaluation}\label{evaluation-15}}

Lead levels, CBC (microcytic anemia + basophilic stippling of RBC), FEP (free erythrocyte protoporphyrin), BUN/Cr, AST/ALT, x-ray (radiopaque flecks)

\hypertarget{management-137}{%
\subsubsection{Management}\label{management-137}}

\begin{itemize}
\tightlist
\item
  CDC Child Lead Poisoning Program: \url{https://www.cdc.gov/nceh/lead/default.htm}
\item
  See also BCH lead poisoning EBG
\item
  Prevention is key: screening and lead levels at WCC (9-12 mo, 2 years)
\item
  Gastric decontamination: whole bowel irrigation
\item
  Chelation therapy (depending on lead levels)
\item
  \textbf{Seminal Article}: CDC. Managing elevated blood lead levels among young children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention, Atlanta: CDC; 2002
\item
  BCH has a separate Environmental Health clinic and service that can assist w/ management
\end{itemize}

\hypertarget{drugs-of-abuse}{%
\subsection{Drugs of Abuse}\label{drugs-of-abuse}}

\hypertarget{ethanol}{%
\subsubsection{Ethanol}\label{ethanol}}

\hypertarget{hxpe}{%
\paragraph{Hx/PE}\label{hxpe}}

Euphoria, loss of coordination, ataxia, slurred speech, nystagmus, nausea, vomiting, hypoglycemia (especially in young children), seizures, coma, respiratory depression

\hypertarget{dx}{%
\paragraph{Dx}\label{dx}}

Blood ethanol level, D-stick

\hypertarget{management-138}{%
\paragraph{Management}\label{management-138}}

Supportive; secure airway if unresponsive, no gag reflex

\hypertarget{marijuana}{%
\subsubsection{Marijuana}\label{marijuana}}

\hypertarget{hxpe-1}{%
\paragraph{Hx/PE}\label{hxpe-1}}

Pupils unchanged, injected conjunctiva, tachycardia, increased appetite, euphoria, anxiety, time-space distortions, panic reaction, psychotic reaction; can cause ataxia and significant sedation in toddlers. Ask about routes of exposure (smoking, vaping, dabbing, edibles, etc.); edibles particularly problematic in young children.

\hypertarget{dx-1}{%
\paragraph{Dx}\label{dx-1}}

Urine drug screen (note, synthetic cannabinoids not detected on standard urine toxicology screens

\hypertarget{management-139}{%
\paragraph{Management}\label{management-139}}

Supportive care, can treat w/ anxiolytics if needed. Some young children may require airway protection due to degree of sedation.

\hypertarget{stimulants-amphetamines-cocaine-ecstasymdma-bath-salts}{%
\subsubsection{Stimulants (Amphetamines, Cocaine, Ecstasy/MDMA, ``Bath Salts'')}\label{stimulants-amphetamines-cocaine-ecstasymdma-bath-salts}}

\hypertarget{hxpe-2}{%
\paragraph{Hx/PE}\label{hxpe-2}}

Tachycardia, hyperthermia, mydriasis, diaphoresis, restlessness, tremors, panic, agitations, psychosis, seizures

\hypertarget{dx-2}{%
\paragraph{Dx}\label{dx-2}}

Urine drug screen; EKG (cocaine may cause QRS widening); troponin if chest pain; CK if concern for rhabdo; electrolytes (hyponatremia w/ MDMA)

\hypertarget{management-140}{%
\paragraph{Management}\label{management-140}}

Supportive care including fluids, avoid beta blockers in HTN due to unrestrained alpha-agonism, benzos for agitation, HTN, and tachycardia

\hypertarget{opioids}{%
\subsubsection{Opioids}\label{opioids}}

\hypertarget{hxpe-3}{%
\paragraph{Hx/PE}\label{hxpe-3}}

Respiratory depression (hallmark), miosis, CNS depression, hypotension, hypothermia, pulmonary edema

\hypertarget{dx-3}{%
\paragraph{Dx}\label{dx-3}}

Urine drug screen (extended screen available at BMC, typically done as send-out at BCH); EKG (methadone can cause QTc prolongation)

\hypertarget{management-141}{%
\paragraph{Management}\label{management-141}}

Naloxone for severe respiratory/CNS depression, titrate dosing to severity of presentation (may precipitate withdrawal in chronic users); otherwise supportive

\hypertarget{notes-2}{%
\paragraph{Notes}\label{notes-2}}

Opioids are one of the ``one pill can kill'' medications in toddlers

\end{document}
